"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01468558","Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole",,"Completed","Has Results","Healthy","Drug: MAP0004|Drug: IV DHE|Drug: Ketoconazole","Cmax of Dihydroergotamine After MAP0004, MAP0004 Co-administered With Ketoconazole, and IV DHE Administration|AUC(0-48) of Dihydroergotamine After MAP0004, MAP0004 Co-administered With Ketoconazole, and IV DHE Administration","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAP0004-CL-P104","July 2010","August 2010","August 2010","November 9, 2011","October 22, 2013","January 9, 2014","Simbec Research Limited, Merthyr Tydfil, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01468558"
2,"NCT01199965","Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers",,"Completed","Has Results","Healthy Subjects","Drug: MAP0004|Drug: IV DHE","Cmax of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers Versus Non-smokers|AUC(0-48) of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers and Non-smokers","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAP0004-CL-P203","January 2010","April 2010","April 2010","September 13, 2010","October 22, 2013","January 9, 2014","Simbec Research Limited, Merthyr Tydfil, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01199965"
3,"NCT01191723","QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo",,"Completed","Has Results","Healthy","Drug: MAP0004|Drug: Inhaler Placebo|Drug: Moxifloxacin|Drug: Placebo Capsule","Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 Minutes|Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours|Change From Baseline in QTcF for MAP0004 3.0mg and Placebo at 30 Minutes|Change From Baseline in QTcF for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours|Change From Baseline in Heart Rate for MAP0004 3.0mg, Placebo, and Moxifloxacin at 30 Minutes and 2 Hours","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","18 Years to 45 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAP0004-CL-P103","August 2010","September 2010","September 2010","August 31, 2010","October 22, 2013","January 9, 2014","Cetero Research, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01191723"
4,"NCT01089062","Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure",,"Completed","Has Results","Healthy","Drug: MAP0004|Drug: IV Placebo (Saline)|Drug: Placebo Inhaler|Drug: IV Dihydroergotamine Mesylate (DHE)","AUC(0-2hrs) of Pulmonary Arterial Systolic Pressure (PASP) Over Time Post 1st Dose|Percent of Subjects With an Increase in PASP Greater Than 10mmHg From Baseline to 2 Hours From the First Dose|Maximum Change in PASP From Baseline to the Two Hour Period Following the First Dose|AUC(0-4hrs) of Pulmonary Arterial Systolic Pressure (PASP) From the Start of the First Dose to Two Hours After the Second Dose|Change in Blood Pressure From Baseline After the Two 2-hour Post Dosing Periods|Change From Baseline in QTc Interval at 14 Minutes After the 1st and 2nd Dose","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAP0004-CL-P102","March 2010","September 2010","December 2010","March 18, 2010","October 22, 2013","January 9, 2014","Duke Clinical Research Unit, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01089062"
5,"NCT00995904","Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma",,"Completed","Has Results","Asthma","Drug: 84ug MAP0020|Drug: 42ug MAP0020|Drug: 21ug MAP0020","Cmax of Budesonide After Administration of MAP0020|AUC(0-inf) of Budesonide After Administration of MAP0020|Half-life (t1/2) of Budesonide After Administration of MAP0020","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","4 Years to 11 Years   (Child)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAP0020-CL-P201","September 2009","November 2009","November 2009","October 15, 2009","November 20, 2013","January 9, 2014","West Coast Clinical Trials LLC, Cypress, California, United States|Sylvana Research Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00995904"
6,"NCT00697801","Study of MAP0010 in Asthmatic Children and Adolescents",,"Completed","Has Results","Asthma","Drug: MAP0010 low dose|Drug: MAP0010 high dose|Drug: Placebo","Change From Baseline in Daytime Composite Symptom Score|Change From Baseline in Nighttime Composite Symptom Score|Change From Baseline in FEV1% Predicted","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","1 Year to 18 Years   (Child, Adult)","Phase 2","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MAP0010-CL-P201","July 2006","December 2006","December 2006","June 16, 2008","October 23, 2013","January 9, 2014","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00697801"
7,"NCT00697697","A Study of 2 Doses of MAP0010 in Asthmatic Children",,"Terminated","Has Results","Asthma","Drug: 0.135mg MAP0010|Drug: 0.25mg MAP0010","Number of Patients With Treatment Emergent Adverse Events Related to Study Drug|Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","12 Months to 8 Years   (Child)","Phase 3","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MAP0010-CL-P301X","April 2008","August 2009","December 2009","June 16, 2008","October 23, 2013","January 9, 2014",,,"https://ClinicalTrials.gov/show/NCT00697697"
8,"NCT00623636","Phase 3 Study of MAP0004 in Adult Migraineurs","FREEDOM301","Completed","Has Results","Migraine Disorders","Drug: MAP0004|Drug: Placebo","Number of Subjects With Pain Relief at 2 Hours From Time of First Dose|Number of Subjects Photophobia Free at 2 Hours From Time of First Dose|Number of Subjects Phonophobia Free at 2 Hours From Time of First Dose|Number of Subjects Nausea Free at 2 Hours From Time of First Dose|Number of Subjects With Sustained Pain Relief From 2 to 24 Hours|Number of Subjects Whose Time to Pain Relief Occurred Within 2 Hours|Number of Subjects With Pain Relief at 4 Hours|Number of Subjects With Pain Relief at 10 Minutes","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","902","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAP0004 CL P301","July 2008","December 2010","January 2011","February 26, 2008","October 29, 2013","January 9, 2014","Swedish Pain and Headache Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00623636"
9,"NCT00569192","A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children",,"Completed","Has Results","Asthma","Drug: 0.135mg MAP0010|Drug: 0.25mg MAP0010|Drug: Placebo","Change From Baseline in Daytime Composite Symptom Score|Change From Baseline in Nighttime Composite Symptom Score|Change From Baseline in FEV1% Predicted|Change From Baseline in PEF|Change From Baseline in Daytime Individual Symptom Scores|Change From Baseline in Nighttime Individual Symptom Scores","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","12 Months to 8 Years   (Child)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MAP0010-CL-P301","December 2007","September 2008","January 2009","December 7, 2007","October 23, 2013","January 9, 2014",,,"https://ClinicalTrials.gov/show/NCT00569192"
10,"NCT00554970","A Study of 2 Doses of MAP0010 in Adult Asthmatics","P202","Completed","Has Results","Asthma","Drug: MAP0010 low dose|Drug: MAP0010 high dose|Drug: Budesonide inhalation suspension 0.25mg|Drug: Budesonide inhalation suspension 0.5mg","Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg|Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg|AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg|AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg|Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg|Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","All","18 Years to 45 Years   (Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAP0010-CL-P202","November 2007","January 2008","March 2008","November 7, 2007","October 23, 2013","January 9, 2014","West Coast Clinical Trials Phase 2-4, LLC, Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT00554970"
11,"NCT00627679","Safety and Blood Level Study of Unit Dose Budesonide","UDB P101","Completed","Has Results","Asthma","Drug: Budesonide Inhalation Suspension|Drug: MAP0010 low dose|Drug: MAP0010 intermediate dose|Drug: MAP0010 high dose","Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010|Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010|AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010|AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010|Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan|Q-Pharm Pty Limited","All","18 Years to 50 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAP0010-CL-P101","December 2005","December 2005","May 2006","March 3, 2008","October 23, 2013","January 9, 2014","Q-Pharm Pty Limited, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT00627679"
12,"NCT04206293","A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers",,"Active, not recruiting","No Results Available","Healthy Adults|Skin Enhancement","Device: Hyaluronic acid (HA) intradermal injection in the forearm","Change from Baseline in Skin Hydration|Change from Baseline in Skin Elasticity|Change from Baseline in Skin Thickness and Density|Change from Baseline in Skin Roughness, Density, and Vascularity|Change from Baseline in Skin Brightness|Change from Baseline in Skin Color|Change from Baseline in Skin Melanin Content|Histological and Genomic Analysis","Allergan","All","30 Years to 50 Years   (Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CMO-MA-FAS-0617","October 29, 2019","January 31, 2020","January 31, 2020","December 20, 2019",,"December 20, 2019","EuroFins Dermscan Poland, Gdansk, Poland",,"https://ClinicalTrials.gov/show/NCT04206293"
13,"NCT04179474","Safety, Tolerability & Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine",,"Recruiting","No Results Available","Migraine","Drug: Ubrogepant|Drug: Erenumab|Drug: Galcanezumab","Area under the plasma concentration versus time curve from time 0 to time t (AUC0-t) ) for ubrogepant|Area under the plasma concentration versus time curve from time 0 infinity (AUC0-∞) for ubrogepant|Maximum plasma drug concentration (Cmax)|Time of maximum plasma drug concentration (Tmax) for ubrogepant|Terminal elimination rate constant (λz) for ubrogepant|Terminal elimination half-life (T½) for ubrogepant|Apparent total body clearance of drug from plasma after extravascular administration (CL/F) for ubrogepant|Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) for ubrogepant|The percentage of participants who have potentially clinically significant (PCS) post baseline vital sign values|The percentage of participants who have PCS post baseline clinical laboratory values|The percentage of participants who have PCS post baseline physical exam values|The percentage of participants who have PCS post baseline electrocardiogram (ECG) values|The incidence of adverse events (safety and tolerability)","Allergan","All","18 Years to 50 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3110-108-002","September 26, 2019","December 24, 2019","December 24, 2019","November 27, 2019",,"November 27, 2019","QPS, Springfield, Missouri, United States|Spaulding, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04179474"
14,"NCT04166058","Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C",,"Recruiting","No Results Available","Irritable Bowel Syndrome With Constipation|Functional Constipation","Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers):","Incidence of Treatment Emergent Adverse Events.","Allergan|Ironwood Pharmaceuticals, Inc.","All","6 Years to 18 Years   (Child, Adult)","Phase 3","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LIN-MD-66","November 19, 2019","February 28, 2023","February 28, 2023","November 18, 2019",,"November 29, 2019","HealthStar Research, Hot Springs, Arkansas, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Children's Hospital of Orange County, Orange, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Prohealth Research Center, Doral, Florida, United States|Amedica Research Institute, Inc, Hialeah, Florida, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Biotech Pharmaceuticals Group LLC, Miami, Florida, United States|South Miami Medical & Research Group, Inc., Miami, Florida, United States|Advanced Research for Health Improvement,LLC, Naples, Florida, United States|Childrens Center for Digestive Health Care, Atlanta, Georgia, United States|SleepCare Research Institute, Inc., Stockbridge, Georgia, United States|Private Practice - Dr. Michael W. Simon, Nicholasville, Kentucky, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Virgo Carter Pediatrics, Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Gastroenterology PA, Minneapolis, Minnesota, United States|Gastrointestinal Associates and Endoscopy Center, Flowood, Mississippi, United States|Private Practice - Dr. Craig Spiegel, Bridgeton, Missouri, United States|Biomedical Research Alliance of New York/ Montefiore Medical Center, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Columbia University Medical Center and Morgan Stanley Children's Hospital of New York, New York, New York, United States|UNC Physicians Network (Capitol Pediatrics & Adolescent Center), Raleigh, North Carolina, United States|University of Oklahoma Health Sciences Center/Children's Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Research, Summerville, South Carolina, United States|The Jackson Clinic, P.A., Jackson, Tennessee, United States|Cook Childrens Health Care System, Fort Worth, Texas, United States|Capital Area Primary Care, PLLC dba San Gabriel Clinical Research, Georgetown, Texas, United States|Valley Institute of Research, Harlingen, Texas, United States|Discovery MM Services, Inc., Houston, Texas, United States|Vilo Research Group, Houston, Texas, United States|Cullen Research, Houston, Texas, United States|Pioneer Research Solutions Inc, Houston, Texas, United States|Discovery MM Services, Inc, Missouri City, Texas, United States|AIM Trials, LLC, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Ace Clinical Research, Sugar Land, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medical Center-1-Sevlievo EOOD, Sevlievo, Gabrovo, Bulgaria|MBAL Sv.Ivan Rilski Kozlodui, Kiril I Metodiy, Bulgaria|University Hospital Plovdiv, Plovdiv, Bulgaria|Multi-Profile Hospital for Active Treatment - Ruse JSC MHAT-Ruse, Ruse, Bulgaria|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria|UMHAT Sveta Marina, Varna, Bulgaria|London Health Sciences Centre, London, Ontario, Canada|Stollery Children's Hospital, Edmonton, Canada|Kindergastroenterologie, Uni-Kinderklinik Leipzig, Leipzig, Saxony-Anhalt, Germany|Klinikum Kassel GmbH, Kassel, Germany|Svabhegy Pediatric Clinic, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacious Intezet, Sopron, Hungary|Rambam Health Care Campus, Ruth Rappaport Children's Hospital, Haifa, Israel|Hadassah University Hospital, Jerusalem, Israel|The Baruch Padeh Medical Center Poriya, Lower Galilee, Israel|Sheba medical center, Tel Hashomer, Israel|Azienda Ospedaliera Sant' Andrea, Naples, Italy|IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy|Academisch Medisch Centrum Universiteit Van Amsterdam, Amsterdam, Netherlands|Maasstad Hospital Rotterdam, Rotterdam, Netherlands|Isala Zwolle, Zwolle, Netherlands|Szpital Uniwersytecki ""r. A. Jurasza"", Bydgoszcz, Poland|Klinika Pediatrii Gastroenterologii Hepatologii Zywienia Dzieci Szpiatl, Gdansk, Poland|Wojew dzki Specjalistyczny Szpital Dzieciecy, Olsztyn, Poland|Korczowski Bartosz, Gabinet Lekarski, Rzeszów, Poland|Centrum Zdrowia MDM, Warsaw, Poland|University Children's Hospital, Belgrade, Serbia|University Children's Hospital - Tirsova, Belgrad, Serbia|Institute for Child and Youth Health Care of Vojvodina, Novi Sad, Serbia|Hospital Regional Universitario de Malaga, Malaga, Spain|MMI ""Regional children's clinical hospital"", Chernivtsi, Chernivets'ka Oblast', Ukraine|State Institution ""Dnipropetrovsk medical academy"", Dnipro, Ukraine|Kharkiv National Medical University, Kharkiv, Ukraine|Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Barts Health NHS Trust - The Royal London Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|William Harvey Hospital, Willesborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04166058"
15,"NCT04157686","MT10109L in the Long-term, Open-label Treatment of Glabellar Lines and Lateral Canthal Lines",,"Enrolling by invitation","No Results Available","Glabellar Lines|Lateral Canthal Lines","Drug: MT10109L","Number of participants who experienced an adverse event|Mean change from baseline in pulse rate (beats per minute)|Mean change from baseline in blood pressure (mm Hg)|Mean change from baseline in respiratory rate (breaths per minute)|Number of participants with binding and neutralizing antibodies","Allergan","All","19 Years and older   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT10109L-004|2014-005303-24","October 23, 2019","January 31, 2023","February 13, 2023","November 8, 2019",,"December 3, 2019","Advanced Research Associates, Glendale, Arizona, United States|Investigate MD, Scottsdale, Arizona, United States|Eye Research Foundation, Newport Beach, California, United States|Art of Skin MD, Solana Beach, California, United States|Susan H. Weinkle, MD, Bradenton, Florida, United States|Skin Research Institute LLC, Coral Gables, Florida, United States|Coleman Dermatologic Surgery Center, Metairie, Louisiana, United States|Etre, Cosmetic Dermatology and Laser Center, New Orleans, Louisiana, United States|Maryland Laser, Skin, & Vein Institute, Hunt Valley, Maryland, United States|Laser Skin Surgery Center of New York, New York, New York, United States|SkinSearch of Rochester, Inc., Rochester, New York, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Aventiv Research, Inc., Dublin, Ohio, United States|Westlake Dermatology & Cosmetic Surgery, Austin, Texas, United States|Bellaire Dermatology Associates, Bellaire, Texas, United States|SkinDC, Arlington, Virginia, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, United States|Centre de la fontaine, Loverval, Hainaut, Belgium|Medical Skin Care, Sint-Truiden, Limburg, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|CHU Liege, Liege, Belgium|Dr. Jean Carruthers Cosmetic Surgery, Inc., Vancouver, British Columbia, Canada|Dr. Shannon Humphrey Inc., Vancouver, British Columbia, Canada|Maryland Laser, Skin, & Vein Institute, Vancouver, British Columbia, Canada|Nectar Research Group Inc., Vancouver, British Columbia, Canada|Dermetics, Burlington, Ontario, Canada|Nectar Research Group Inc., Richmond Hill, Ontario, Canada|Sweat Clinics of Canada, Toronto, Ontario, Canada|Bertucci MedSpa Inc., Woodbridge, Ontario, Canada|Hautok und Hautok-cosmetics, Munich, Bavaria, Germany|Studienzentrum Theatiner46, Munich, Bavaria, Germany|Rosenpark-Research, Darmstadt, Hessen, Germany|DRK-Kliniken Nordhessen, Kassel, Hessen, Germany|Privatpraxis Dr. Hilton & Partner, Düsseldorf, NRW, Germany|Rzany&Hund, Privatpraxis, Berlin, Germany|Hautzentrum Köln, Cologne, Germany|Medicorum Praxis für Dermatologie und Ästhetik, Oberursel, Germany|CentroDerm GmbH, Wuppertal, Germany|Kazan State Medical University, Kazan, Tatarstan Republic, Russian Federation|Medical Centre Capital-Zdorovie, Moscow, Russian Federation|Moscow scientific-practical centre of dermatovenerology and cosmetology, Moscow, Russian Federation|I.I Mechnikov North-Western State Medical University, Saint-Petersburg, Russian Federation|Expert Aesthetics Ltd, Alderley Edge, Cheshire, United Kingdom|Bermuda Practice, Basingstoke, Hampshire, United Kingdom|Waverley Medical Practice, Coatbridge, North Lanarkshire, United Kingdom|Medizen Clinic, Sutton Coldfield, West Midlands, United Kingdom|The Bosham Clinic, Chichester, West Sussex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04157686"
16,"NCT04142450","CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Descent (XinCOOL)",,"Recruiting","No Results Available","Body Fat Disorder","Device: CoolSculpting® System","Correct identification of baseline versus 12-week treatment images of the upper arms by at least two out of three blinded, independent reviewers.|Correct identification of baseline versus 12-week treatment images of the inner thighs by at least two out of three blinded, independent reviewers.|Participant response of 'satisfied' or 'very satisfied' for question 1 (overall satisfaction) on the CoolSculpting upper arms participant questionnaire at the 12-week visit.|Participant response of 'satisfied' or 'very satisfied' for question 1 (overall satisfaction) on the CoolSculpting inner thighs participant questionnaire at the 12-week visit.|Mean fat layer reduction using caliper measurements at 12-weeks compared to baseline for upper arms.|Mean fat layer reduction using caliper measurements at 12-weeks compared to baseline for inner thighs.","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MED-MA-PLS-0633","October 27, 2019","March 1, 2020","March 1, 2020","October 29, 2019",,"November 14, 2019","Vancouver Laser and Skin Care Clinic, Vancouver, British Columbia, Canada|Project Skin MD, Vancouver, British Columbia, Canada|Pacific Derm, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04142450"
17,"NCT04124705","A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants","ARCH","Recruiting","No Results Available","Hypothyroidism|Thyroid Disease|Euthyroid|Thyroid Gland|Thyroid Hormones","Drug: Armour® Thyroid|Drug: Synthetic T4","The percent of participants who are Sustained Thyroid-Stimulating Hormone (TSH) Responders|The percent of participants who are Titration TSH Responders","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3014-201-002","October 11, 2019","July 28, 2021","July 28, 2021","October 11, 2019",,"December 20, 2019","Central Research Associates, Birmingham, Alabama, United States|Atria Research, Little Rock, Arkansas, United States|Marin Endocrine Care and Research, Greenbrae, California, United States|Diabetes/Lipid Management & Research Center, Huntington Beach, California, United States|Center of Excellence in Diabetes and Endocrinology, Sacramento, California, United States|Care Access Research, Santa Clarita, California, United States|San Fernando Valley Health Institute, Van Nuys, California, United States|Creekside Endocrine Associates, Denver, Colorado, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Physicians Research Associates, Lawrenceville, Georgia, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|NYC Health + Hospitals/ Queens, Jamaica, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States|OnSite Clinical Solutions, Charlotte, North Carolina, United States|Physicia's East Endocrinology, Greenville, North Carolina, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Academy of Diabetes, Thyroid and Endocrine, El Paso, Texas, United States|Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States|Multicare Institute for Research and Innovation, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04124705"
18,"NCT04110145","Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation",,"Recruiting","No Results Available","Functional Constipation","Drug: Linaclotide|Drug: Placebo","Change from baseline in 4-week overall spontaneous bowel movement (SBM) frequency rate (SBMs/week) during the Study Intervention Period of each cohort|Change from baseline in 4-week stool consistency reported by the caregiver during the Study Intervention Period of each cohort|Change from baseline in 4-week straining reported by the caregiver during the Study Intervention Period of each cohort|Proportion of days with fecal incontinence during the Study Intervention Period (for participants who have acquired toileting skills during the daytime and nighttime or acquired toileting skills during daytime only) within each cohort","Allergan|Ironwood Pharmaceuticals, Inc.","All","2 Years to 5 Years   (Child)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LIN-MD-67","October 14, 2019","February 28, 2023","February 28, 2023","October 1, 2019",,"January 18, 2020","Central Research Associates, Inc, Birmingham, Alabama, United States|HealthStar Research, Hot Springs, Arkansas, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Prohealth Research Center, Doral, Florida, United States|South Miami Medical & Research Group, Inc., Miami, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|SleepCare Research Institute, Inc., Stockbridge, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Gastroenterology PA, Minneapolis, Minnesota, United States|David M. Headley, MD, P.A., Port Gibson, Mississippi, United States|Private Practice - Dr. Craig Spiegel, Bridgeton, Missouri, United States|Foundation Pediatrics Med Clinical Research Partners, LLC, East Orange, New Jersey, United States|Biomedical Research Alliance of NY-Montefiore Medical Center, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Oklahoma Health Sciences Center/Children's Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Research, Summerville, South Carolina, United States|Cook Childrens Health Care System, Fort Worth, Texas, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Marshall Health, Huntington, West Virginia, United States|Virgo Carter Pediatrics, Morgantown, West Virginia, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04110145"
19,"NCT04096326","AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines",,"Recruiting","No Results Available","Glabellar Lines","Drug: AGN-151586|Drug: Placebo","Efficacy: To compare the efficacy between placebo and a range of doses of AGN-151586 for the treatment of GL (Glabellar Lines) in participants with moderate to severe GL|Safety: To compare the safety between placebo and a range of doses of AGN-151586 for the treatment of GL in participants with moderate to severe GL","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2034-201-008","September 26, 2019","June 22, 2020","June 22, 2020","September 19, 2019",,"December 19, 2019","Center for Dermatology Clinical Research, Inc., Fremont, California, United States|Ava T. Shamban MD, INC, Santa Monica, California, United States|Baumann Cosmetic and Research Institute, Miami, Florida, United States|Laser & Skin Surgery Center of Indiana, Indianapolis, Indiana, United States|WDC Cosmetic and Research, PLLC, Wilmington, North Carolina, United States|KGL LLC, Broomall, Pennsylvania, United States|DermResearch, Inc., Austin, Texas, United States|Suzanne Bruce and Associates; The Center for Skin Research, Houston, Texas, United States|Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04096326"
20,"NCT04073303","BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence",,"Recruiting","No Results Available","Masseter Muscle Prominence","Biological: Botulinum Toxin Type A|Other: Placebo","Proportion of responders that show change in masseter muscle prominence (MMP)|Incidence of Adverse Events (AEs)|Change from baseline in vital sign values (blood pressure, respiratory rate, and pulse rate)|Proportion of responders who achieve a clinical target on a MMP scale|Proportion of responders who achieve improvement using a self-assessment scale|Proportion of responders that show improvement in MMP|Change from baseline in lower facial width|Duration of treatment effect","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1789-301-008","August 29, 2019","March 12, 2020","March 12, 2020","August 29, 2019",,"December 23, 2019","Institute for Skin Advancement, Calgary, Alberta, Canada|Carruthers & Humphrey Clinical Research, Vancouver, British Columbia, Canada|Pacific Dermaesthetics, Vancouver, British Columbia, Canada|Project Skin MD, LTD, Vancouver, British Columbia, Canada|The Centre for Dermatology & Cosmetic Surgery, Richmond Hill, Ontario, Canada|Peking University First Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|Shanghai Ninth People's Hospital, Shanghai, Shanghai, China|The First Affiliated Hospital of XI'AN Jiaotong University, Xi'An, Shanxi, China|The Fourth Military Medical University Tangdu hospital, Xi'An, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04073303"
21,"NCT04030962","A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease",,"Not yet recruiting","No Results Available","Dry Eye Disease|Dry Eye Syndrome","Drug: AGN-242428|Drug: AGN-231868|Other: AGN-242428 Vehicle|Other: AGN-231868 Vehicle","The incidence of adverse events (safety and tolerability)|Area under the plasma concentration versus time curve from time 0 to time of the last measurable concentration (AUC0-tlast) after a single dose administration|Area under the tear concentration versus time curve from time 0 to time of the last measurable concentration (AUC0-tlast) after a single dose administration|Maximum plasma drug concentration (Cmax) after a single dose administration|Maximum tear drug concentration (Cmax) after a single dose administration|Time of maximum plasma drug concentration (Tmax) after a single dose administration|Time of maximum tear drug concentration(Tmax) after a single dose administration|Terminal elimination half-life (t1/2) after a single dose administration|Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval (AUC0-τ) following repeat dose administration|Area under the tear concentration versus time curve from time 0 to the end of the dosing interval (AUC0-τ) following repeat dose administration|Maximum plasma drug concentration (Cmax) following repeat dose administration|Maximum tear drug concentration (Cmax) following repeat dose administration|Time of maximum plasma drug concentration (Tmax) following repeat dose administration|Time of maximum tear drug concentration (Tmax) following repeat dose administration|Minimum plasma drug concentration at steady state (Cmin,ss) following repeat dose administration|Minimum tear drug concentration at steady state (Cmin,ss) following repeat dose administration|Terminal elimination half-life of the study drugs (t1/2) following repeat dose administration|Accumulation index of drug concentration (AI) following repeat dose administration|Drop Tolerability Questionnaire Score|Number of patients experiencing one or more adverse events (AEs) during the 15 day treatment period|Potentially clinically significant (PCS) clinical laboratory values|Vital sign values (blood pressure, pulse rate, weight, respiration rate, and temperature)|Electrocardiogram (ECG) heart rate|ECG PR interval|ECG QRS duration|ECG QT interval|ECG QTc|Change from baseline in intraocular pressure (IOP)|Change from baseline in best-corrected visual acuity (BCVA)|Change from baseline in slit-lamp biomicroscopy|Change from baseline in dilated fundus examination","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2012-201-005","March 2, 2020","June 1, 2020","June 1, 2020","July 24, 2019",,"October 16, 2019","Andover Eye Associates, Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04030962"
22,"NCT04026113","Linaclotide Safety and Efficacy, Functional Constipation, in Pediatric Participants 6 to 17 Years of Age",,"Recruiting","No Results Available","Functional Constipation","Drug: Linaclotide 72 μg|Drug: Placebo","Change from baseline in 12-week SBM (spontaneous bowel movement) frequency rate (SBMs/week) during the study intervention period|Change from baseline in 12-week stool consistency during the study intervention period","Allergan|Ironwood Pharmaceuticals, Inc.","All","6 Years to 17 Years   (Child)","Phase 3","326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LIN-MD-64","October 1, 2019","January 31, 2022","January 31, 2022","July 19, 2019",,"October 3, 2019","HealthStar Research, Hot Springs, Arkansas, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Biotech Pharmaceuticals Group LLC, Miami, Florida, United States|South Miami Medical & Research Group, Inc., Miami, Florida, United States|Advanced Research for Health Improvement,LLC, Naples, Florida, United States|Childrens Center for Digestive Health Care, Atlanta, Georgia, United States|SleepCare Research Institute, Inc., Stockbridge, Georgia, United States|Private Practice - Dr. Michael W. Simon, Nicholasville, Kentucky, United States|Private Practice - Dr. Michael W. Simon, Nicholasville, Kentucky, United States|LSU Health Science Center - Shreveport, Shreveport, Louisiana, United States|Virgo Carter Pediatrics, Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Gastroenterology PA, Minneapolis, Minnesota, United States|Gastrointestinal Associates and Endoscopy Center, Flowood, Mississippi, United States|Private Practice - Dr. Craig Spiegel, Bridgeton, Missouri, United States|Advantage Clinical Trials, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center/Children's Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center/Children's Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Research, Summerville, South Carolina, United States|The Jackson Clinic, P.A., Jackson, Tennessee, United States|Cook Childrens Health Care System, Fort Worth, Texas, United States|Discovery MM Services, Inc., Houston, Texas, United States|Discovery MM Services, Inc, Missouri City, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medical Center-1-Sevlievo EOOD, Sevlievo, Gabrovo, Bulgaria|MBAL Sv.Ivan Rilski Kozlodui, Kiril I Metodii, Bulgaria|Multi-Profile Hospital for Active Treatment - Ruse JSC MHAT-Ruse, Ruse, Bulgaria|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria|University Hospital Plovdiv, Tsentar, Bulgaria|UMHAT Sveta Marina, Varna, Bulgaria|Stollery Children's Hospital, Edmonton, Alberta, Canada|Victoria Hospital - London Health Sciences Centre/Lawson Health Research Institute, London, Ontario, Canada|Svabhegy Pediatric Clinic, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacious Intezet, Sopron, Hungary|Azienda Ospedaliera Sant' Andrea, Naples, Italy|IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy|Academisch Medisch Centrum Universiteit Van Amsterdam, Amsterdam, Netherlands|Isala Zwolle, Zwolle, Netherlands|Klinika Pediatrii Gastroenterologii Hepatologii Zywienia Dzieci Szpiatl, Gdansk, Poland|Korczowski Bartosz, Gabinet Lekarski, RzeszÃ³w, Poland|Centrum Zdrowia MDM, Warsaw, Poland|Hospital San Joan de Deu, Barcelona, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain",,"https://ClinicalTrials.gov/show/NCT04026113"
23,"NCT03961815","Open-label Extension Study of Brazikumab in Crohn's Disease",,"Enrolling by invitation","No Results Available","Crohn's Disease","Drug: Brazikumab","To assess the safety of long-term treatment with Brazikumab in patients with Crohn's disease (CD) based on the number of patients who experience one or more Treatment Emergent Adverse Events (TEAE)|Percentage of participants with potentially clinically significant vital sign measurements|Percentage of participants with potentially clinically significant laboratory values|Percentage of participants with potentially clinically significant electrocardiograms","Allergan","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3150-303-008","January 31, 2020","April 28, 2024","April 28, 2024","May 23, 2019",,"January 9, 2020","Gastro Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03961815"
24,"NCT03953807","A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated",,"Recruiting","No Results Available","Diabetic Macular Edema","Drug: Dexamethasone Intravitreal Implant","Mean change in best corrected visual acuity (BCVA) 2 months (± 2 weeks) after the last injection|Mean change in Central Retinal Thickness (CRT) 2 months (± 2 weeks) after the last injection received|Mean retreatment interval in months|Area under the curve (AUC) for CRT|AUC for BCVA|Mean change in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25)|Proportion of patients with 2nd injection|Proportion of patients with 3rd injection|Mean number of injections administered|Time to 3rd injection|Time to 2nd injection","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-MA-EYE-0603|2018-004785-33","September 5, 2019","May 31, 2021","May 31, 2021","May 17, 2019",,"November 18, 2019","CHUC - Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal|Hospital de Santo André - Centro Hospitalar de Leiria, Leiria, Portugal|IRL - Instituto de Retina e Diabetes Ocular de Lisboa, Lisboa, Portugal|Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria, Lisboa, Portugal|Hospital de So Joo EPE, Porto, Portugal|Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal|Centro de Oftalmología Barraquer, Barcelona, Spain|Instituto Clínic de Oftalmología (ICOF), Barcelona, Spain|IMO, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital Clínico San Carlos, Madrid, Spain|Oftalvist Moncloa, Madrid, Spain|Vissum Madrid, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda Ophthalmology, Madrid, Spain|Hospital Universitari Son Espases, Palma, Spain|Clnica Universitaria de Navarra, Pamplona, Spain|Instituto Oftalmológico Gomez Ulla, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Seville, Spain|Hospital General Universitario, Valencia, Spain|Hospital Arnau Vilanova, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Universitario de Araba, Vitoria, Spain|Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain|Miguel Servet University Hospital Ophthalmology Department, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT03953807"
25,"NCT03939312","Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine",,"Enrolling by invitation","No Results Available","Episodic Migraine","Drug: Atogepant 60 mg","Percentage of Participants with at Least 1 Treatment Emergent Adverse Event|Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Urinalysis) as assessed by the Investigator|Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as assessed by the Investigator|Percentage of Participants with Clinically Significant Vital Sign Measurements as assessed by the Investigator|Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation and Behaviour using 5-Point Scales","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3101-309-002","May 6, 2019","November 10, 2020","November 10, 2020","May 6, 2019",,"January 13, 2020","Alea Research, Phoenix, Arizona, United States|Orange Grove Family Practice, Tucson, Arizona, United States|Principals Research Group, Hot Springs, Arkansas, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Med Center Medical Clinic, Carmichael, California, United States|Neuro Pain Medical Center, Fresno, California, United States|California Headache and Balance Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Paradigm Clinical Research Centers, Inc, La Mesa, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Long Beach Clinical Trials Services, Long Beach, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Newport Beach Clinical Research Associates, Newport Beach, California, United States|Rancho Cucamonga Clinical Trials, Rancho Cucamonga, California, United States|George J. Rederich, M.D. Inc., Redondo Beach, California, United States|Optimus Medical Group, San Francisco, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Aventura Neurological Associates, Aventura, Florida, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Sarkis Clinical Trials- Gainesville, Gainesville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Atlanta, Georgia, United States|Neurotrials Research, Atlanta, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Diamond Headache Clinic Ltd, Chicago, Illinois, United States|JWM Neurology, Indianapolis, Indiana, United States|Deaconess Clinic - Gateway Health Center, Newburgh, Indiana, United States|PMG Research, Inc. d/b/a PMG Research of McFarland Clinic, Ames, Iowa, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|College Park Family Care Center, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, LLC - An AMR Company, Wichita, Kansas, United States|Heartland Research Associates, LLC - An AMR Company, Wichita, Kansas, United States|Otrimed, Edgewood, Kentucky, United States|DelRicht Research, New Orleans, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|John R. Graham Headache Center Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|The Headache Center, Ridgeland, Mississippi, United States|Radiant Research, Inc., Saint Louis, Missouri, United States|StudyMetrix Research, Saint Peters, Missouri, United States|Clinvest Research LLC, Springfield, Missouri, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurosciences Research Center, Amherst, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Wilmington Health, PLLC, Wilmington, North Carolina, United States|Piedmont Medical Research of Winston-Salem, Winston-Salem, North Carolina, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Patient Priority Clinical Sites, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Ohio Clinical Research, LLC, Lyndhurst, Ohio, United States|OK Clinical Research, LLC, Edmond, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Jacob Murphy, Uniontown, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Ocean State Clinical Research Partners, Lincoln, Rhode Island, United States|Primary Care Associates/Synexus Clinical, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Hillcrest Family Practice, Simpsonville, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Psychiatry & Psychotherapy Partners Austin, Austin, Texas, United States|Synexus-US, Dallas, Texas, United States|Ventavia Research Group, Fort Worth, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Protenium Clinical Research, Hurst, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States|Synexus-US, Salt Lake City, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|J. Lewis Research, Inc., South Jordan, Utah, United States|Health Research of Hampton Roads, Newport News, Virginia, United States|National Clinical Research, Inc, Richmond, Virginia, United States|Sentara Neruology Specialists, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Eastside Therapeutic Resource and Core Clinical Research, Everett, Washington, United States|The Polyclinic, Seattle, Washington, United States|Puget Sound Neurology, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03939312"
26,"NCT03924323","A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder",,"Recruiting","No Results Available","Anxiety Disorders|Generalized Anxiety Disorder","Drug: Escitalopram|Other: Placebo","Change in Pediatric Anxiety Rating Scale (PARS) severity score|Response rate on the PARS|Remission rate on the PARS|Change on the Clinical Global Impression of Severity (CGI-S)|Change on the Children's Global Assessment Scale (CGAS)","Allergan","All","7 Years to 17 Years   (Child)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SCT-MD-60","May 31, 2019","July 2, 2021","July 2, 2021","April 23, 2019",,"November 1, 2019","Harmonex, Dothan, Alabama, United States|Woodland International Research Group, LLC, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|ATP Clinical Research Inc, Costa Mesa, California, United States|Sun Valley Research Center, Inc., Imperial, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., North Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|APG Research LLC, Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Meridien Research, Inc., Winter Park, Florida, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR Baber Research Inc, Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Alivation Research, Lincoln, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Quest Therapeutics of Avon Lake, Avon Lake, Ohio, United States|UC Health, LLC, Cincinnati, Ohio, United States|Midwest Clinical Research Center, LLC, Dayton, Ohio, United States|CincyScience, West Chester, Ohio, United States|SP Research, PLLC, Oklahoma City, Oklahoma, United States|Central States Research, LLC, Tulsa, Oklahoma, United States|Coastal Carloina Research Center, Mount Pleasant, South Carolina, United States|Houston Clinical Trials LLC, Bellaire, Texas, United States|AIM Trials LLC, Plano, Texas, United States|Focus CRC Inc, South Ogden, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Core Clinical Research, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03924323"
27,"NCT03915067","BOTOX for the Treatment of Platysma Prominence",,"Active, not recruiting","No Results Available","Platysma Prominence","Drug: BOTOX High Dose|Drug: BOTOX Low Dose|Drug: Placebo","Achievement of improvement as rated by investigator using the clinician platysma scale|To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on incidence of adverse events|To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on change from baseline in pulse rate|To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on change from baseline in systolic and diastolic blood pressure (BP)|To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on change from baseline in respiration rate|Achievement of improvement as rated by participant using the participant platysma scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1936-201-008","April 23, 2019","April 13, 2020","April 13, 2020","April 16, 2019",,"January 10, 2020","Skincare & Laser Physicians of Beverly Hills, Los Angeles, California, United States|Skin Research Institute LLC, Coral Gables, Florida, United States|DeNova Research dba Arano, LLC, Chicago, Illinois, United States|Maryland Laser Skin and Vein, Hunt Valley, Maryland, United States|The Center for Dermatology, Cosmetics, & Laser Surgery, Mount Kisco, New York, United States|The Practice of Brian S. Biesman, MD, Nashville, Tennessee, United States|Dallas Plastic Surgery Institute, Dallas, Texas, United States|Dr. Shannon Humphrey Inc., Vancouver, British Columbia, Canada|Pacific Derm, Vancouver, British Columbia, Canada|Dermetics, Burlington, Ontario, Canada|Sweat Clinics of Canada, Toronto, Ontario, Canada|Bertucci MedSpa, Woodbridge, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03915067"
28,"NCT03909100","International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Invasive Fat Reduction in Abdomen and/or Flanks (iCOOL)",,"Active, not recruiting","No Results Available","Body Fat Disorder","Device: CoolSculpting® System","Proportion of subjects with ""satisfied"" or ""very satisfied"" on CSQ Item #1|Proportion of subjects by number of treatment cycles who received 1 or 2 treatments with ""satisfied"" or ""very satisfied"" on CSQ item #1|Proportion of subjects by BMI categories with ""Satisfied"" or ""Very Satisfied"" on CSQ Item #1|Change in volume of fat from baseline|Frequency of AEs including SAEs|Frequency of ADEs including SADEs","Allergan","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","112","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-MA-PLS-0602","September 4, 2019","February 21, 2020","February 21, 2020","April 9, 2019",,"November 29, 2019","Sandhurt Plastic Surgery, Bendigo, Victoria, Australia|Academy Face and Body, Subiaco, Western Australia, Australia|Vancouver Laser & Skin Care Centre, Vancouver, British Columbia, Canada|Halley Medical Aesthetics, Singapore, Singapore|Dr Benjamin Yim Clinical Aesthetics and Laser Centre, Singapore, Singapore|Revere Riverside Ltd, Northwood, Middlesex, United Kingdom|Revere Clinics, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03909100"
29,"NCT03908307","Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China","YANGTZE","Recruiting","No Results Available","Macular Edema|Retinal Vein Occlusion","Drug: OZURDEX","Mean change in visual acuity from Baseline|Proportion of patients with a BCVA improvement of 15 letters or more compared to Baseline|BCVA average change from Baseline in area under the curve (AUC) analysis|Mean change from Baseline in BCVA|Mean change from Baseline in Central Retinal Thickness (CRT)|Mean change from Baseline in the National Eye Institute (NEI) Visual Function Questionnaire (VFQ)-25|Mean number of OZURDEX injections|Mean retreatment interval in months|Proportion of patients with 2nd injection|Proportion of patients with 3rd injection|Time to 2nd injection|Time to 3rd injection|Correlation between the change of BCVA and extent of leak by fluorescein angiography (FA)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-MA-EYE-0575","July 27, 2019","March 31, 2021","March 31, 2021","April 9, 2019",,"September 4, 2019","Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, Guangdong, China|The First Xiangya Hospital of Central South University, Changsha, Hunan, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Beijing Tong Ren Hospital, Beijing, China|Peking Union medical college hospital, Beijing, China|Eye & ENT Hospital of Fudan University, Shanghai, China|Shanghai General Hospital, Shanghai, China|Tianjin Eye Hospital, Tianjin, China|XiAn No.4 Hospital, Xian, China",,"https://ClinicalTrials.gov/show/NCT03908307"
30,"NCT03891446","Long-term Safety and Efficacy Extension Trial of Bimatoprost SR",,"Enrolling by invitation","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost SR","Duration of effect of Bimatoprost SR|Number of patients experiencing a treatment emergent adverse event.","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1698-302-007|2018-003597-26","March 27, 2019","April 30, 2023","April 30, 2023","March 27, 2019",,"November 22, 2019","Trinity Research Group, Dothan, Alabama, United States|Arizona Eye Center Phoenix, Phoenix, Arizona, United States|Arizona Glaucoma Specialists, Phoenix, Arizona, United States|M&M Eye Institute, Prescott, Arizona, United States|Walman Eye Center, Sun City, Arizona, United States|Lugene Eye Institute, Glendale, California, United States|Lakeside Vision Center, Irvine, California, United States|Hamilton Glaucoma Center, Shiley Eye Center UCSD, La Jolla, California, United States|Eye Research Foundation, Newport Beach, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Shasta Eye Medical Group, Inc, Redding, California, United States|Pacific Eye Associates, San Francisco, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Specialty Retina Center, Coral Springs, Florida, United States|Nature Coast Clinical Research - Crystal River, Crystal River, Florida, United States|Bruce Segal MD PA, Delray Beach, Florida, United States|Eye Associates of Fort Myers, Fort Myers, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|The Eye Institute for Medicine and Surgery, Melbourne, Florida, United States|MedEye Associates, South Miami, Florida, United States|International Research Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Chicago Eye Specialists, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|The Eye Care Institute, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Clinical Eye Research of Boston, LLC, Winchester, Massachusetts, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Rutgers, The State University of New Jersey, New Jersey Medi, Newark, New Jersey, United States|Vision Research Center Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Ophthalmic Consultants Long Island, Lynbrook, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Rochester Ophthalmological Group PC, Rochester, New York, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|Albemarle Clinical Trials, LLC, Elizabeth City, North Carolina, United States|James D. Branch, Winston-Salem, North Carolina, United States|Bergstrom Eye Research, LLC, Fargo, North Dakota, United States|Legacy Devers Eye Institute, Portland, Oregon, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Carolinas Center for Sight, PC, Florence, South Carolina, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Advancing Vision Research, LLC, Nashville, Tennessee, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|Houston Eye Associates, Houston, Texas, United States|DCT-Shah Research, LLC dba Discovery Clinical Trials, Mission, Texas, United States|Plano Office, Plano, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|Piedmont Eye Center, Lynchburg, Virginia, United States|Vistar Eye Center, Roanoke, Virginia, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|The Eye Centers of Racine & Kenosha, Racine, Wisconsin, United States|Clinica Privada de Ojos, Mar del Plata, Buenos Aires Province, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires Province, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Oftalmologia Global, Rosario, Santa Fe, Argentina|Consultorio Oftalmologico Dr. Fabian Lerner, Buenos Aires, Argentina|University of Graz, Graz, Austria|University Hospitals Leuven, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|Universidade Federal de Goias, Goiania, Goias, Brazil|Nova Campinas Oftalmologia, Campinas, Sao Paulo, Brazil|Hospital Oftalmologico Medicina dos Olhos, Osasco, Sao Paulo, Brazil|Clinica Privada de Ojos, Campo Grande, Brazil|Hospital de Olhos de Mato Grosso Do Sul, Campo Grande, Brazil|Hospital Sao Paulo, Sao Paulo, Brazil|Dalhousie University, Halifax, Nova Scotia, Canada|St Joseph's Healthcare, Hamilton, Ontario, Canada|Ophthalmic Consultant Centres, Mississauga, Ontario, Canada|Montreal Glaucoma Institute, Montreal, Quebec, Canada|Clinica de Oftalmologia Sandiego S.A., Medellin, Antioquia, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Santander, Colombia|Fundacion Oftalmologica Nacional, Bogota, Colombia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|OFTEX s.r.o., Pardubice, Czechia|Glostrup Hospital, Glostrup, Denmark|Menoufia University Hospital, Shibin Al Kawm, Al Minufiyah, Egypt|Bostan Diagnostic Eye Center, Cairo, Egypt|Ain Shams University Hospital, Cairo, Egypt|CHU de NICE, Nice, Alpes-Maritimes, France|CHU de Bordeaux Hopital Pellegrin, Bordeaux, Gironde, France|Centre Opthalmologie Pole Vision, Ecully, France|CHU de Limoges - Service d'Ophthalmologie, Limoges, France|CHU de NICE, Nice, France|CHU Purpan, Toulouse Cedex 9, France|Charite-Universtitaetsmedizin Berlin, Berlin, Germany|Internationale Innovative Ophthalmochirurgie, Dusseldorf, Germany|Universitatsaugenklinik Magdeburg, Magdeburg, Germany|Universitatsklinikum Munster, Munster, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Bnai Zion M. C., Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Italy|Azienda Sanitaria Locale (ASL) Chieti, Chieti, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genoa, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milan, Italy|U.O. Oculistica Dipartimento di Medicina e Chirurgia. Univ., Parma, Italy|Azienda Ospedaliero Universitaria di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy|Universita Degli Studi di Pisa - Ospedale di Cisanello Pisa, Pisa, Italy|University of Udine - Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Samsung Medical Center, Sungkyunkwan University, Seoul, Korea, Republic of|University of Ulsan, Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Capital Eye Specialist - Wellington, Te Aro, Wellington N, New Zealand|Centro Oftalmologico Macula Diagnostico and Tratamiento, Lima, Peru|Asian Eye Institute, Makati City, Philippines|Peregrine Eye and Laser Institute, Makati City, Philippines|OFTALMIKA Sp. z o.o., Bydgoszcz, Poland|Optimum Profesorskie Centrum Okulistyki, Gdansk, Poland|Klinkita Diagnostyki i Mikrochirugii Jaskry, Lublin, Poland|Centrum Diagnostyki i Mikrochirurgii Oka LENS, Olsztyn, Poland|Clinical Ophthalmology Hospital n.a. V.P. Vihodtsev, Omsk, Russian Federation|Samara State Medical University, Samara, Russian Federation|St. Petersburg State Medical University, St. Petersburg, Russian Federation|Singapore National Eye Centre, Singapore, Singapore|Pretoria Eye Institute - Private Practice, Pretoria, South Africa|Dr Lynette Venter, Westdene, South Africa|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey|Marmara University Hospital, Istanbul, Turkey|Huntingdon Glaucoma Diagnostic & Research Centre, Huntingdon, Cambridgeshire, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom|Addenbrookes Hospital, Huntingdon, United Kingdom|Moorfield Eye Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03891446"
31,"NCT03889444","Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)",,"Completed","No Results Available","Diabetic Macular Edema",,"Time to OZURDEX® Re-Injection|Change in Best Corrected Visual Acuity (BCVA) 7 to 12 Weeks Following each Injection|Change from Baseline in (BCVA) 7 to 12 Weeks Following each Ozurdex implant Injection|Change in Central Retinal Thickness by Optical Coherence Tomography (OCT) 7 to 12 Weeks Following each Injection|Change From Baseline in Central Retinal Thickness by (OCT) 7 to 12 Weeks Following each Ozurdex implant Injection|Percentage of participants who experienced Adverse events of special interest (AESIs)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"142","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","CMO-MA-EYE-0564","January 15, 2019","June 7, 2019","June 7, 2019","March 26, 2019",,"June 27, 2019","Clinical Trials Registry Team, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03889444"
32,"NCT03872479","Single Ascending Dose Study in Participants With LCA10",,"Recruiting","No Results Available","Blindness|Leber Congenital Amaurosis 10|Vision Disorders|Eye Diseases|Eye Diseases, Hereditary|Eye Disorders Congenital|Retinal Disease|Retinal Degeneration","Drug: AGN-151587","Frequency of Adverse Events related to AGN-151587|Number of participants experiencing procedural related adverse events|Incidence of dose limiting toxicities|Maximum tolerated dose as determined by occurrence of dose limiting toxicities|Change from baseline in Mobility course score|Change from baseline in LogMAR measurement of BCVA|Change from baseline in pupillary response|Change from baseline in dark adapted visual sensitivity using Full field light sensitivity threshold (FST)|Change from baseline in macula thickness|Change from baseline in contrast sensitivity|Change from baseline in macular sensitivity as measured by microperimetry|Change from baseline in color vision score using the Farnsworth 15 score|Change from baseline in QOL score for Age <8 years using the Children's Visual Function Questionnaire|Change from baseline in QOL score for Age 8 to <18 years using the Impact of Vision Impairment for Children|Change from baseline in QOL score for Age >18 years if BCVA is worse than 1.0 logMAR in both eyes using the Impact of Vision Impairment for Very Low Vision|Change from baseline in QOL score for Age >18 years if BCVA is 1.0 logMAR or better in both eyes using the Impact of Vision Impairment|Change from baseline in visual field using kinetic perimetry|Change from baseline in Patient Global Impressions of Change score|Change from baseline in gaze tracking","Allergan|Editas Medicine, Inc.","All","3 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1991-201-008","September 26, 2019","March 22, 2024","March 22, 2024","March 13, 2019",,"November 22, 2019","Bascom Palmer Eye Institute, Miami, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|W.K. Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States|Casey Eye Institute - OSHU, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03872479"
33,"NCT03868254","Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)",,"Completed","No Results Available","Glaucoma","Device: XEN Group","Change from baseline (medicated) in mean Intraocular pressure (IOP)|Change from baseline in the number of topical IOP-lowering medications 3 years after implantation|Change from baseline (medicated) in mean (IOP)|Change from baseline in the number of topical IOP-lowering medications 4 years after implantation|Proportion of eyes achieving at least 20% IOP reductions on same or lower number of topical IOP-lowering medications|Proportion of eyes achieving at least 20% IOP reductions while taking no topical IOP-lowering medications|Percentage of participants experiencing adverse events of special interest (AESIs)","Allergan","All","Child, Adult, Older Adult",,"174","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","CMO-MA-EYE-0590","April 5, 2019","October 25, 2019","October 25, 2019","March 11, 2019",,"December 2, 2019","Clinical Trials Registry Team, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03868254"
34,"NCT03861936","BOTOX Treatment of Masseter Muscle Prominence",,"Recruiting","No Results Available","Masseter Muscle Prominence","Biological: Botulinum toxin type A|Drug: Normal saline","Proportion of responders who achieve MMPS Grade ≤ 3 at Day 90, per investigator assessments of Masseter Muscle Prominence (MMP) using the Masseter Muscle Prominence Scale (MMPS)|Incidence of Adverse Events|Proportion of patients who experience an abnormal pulse rate|Proportion of patients who experience an abnormal respiratory rate|Proportion of patients who experience an abnormal blood pressure|Proportion of responders who achieve MMPS-P Grade ≤ 3 at Day 90, per participant assessments of MMP using the Participant Masseter Muscle Prominence Scale (MMPS-P)|Proportion of responders who achieve ≥ 2-grade improvement from baseline at Day 90, per investigator using the MMPS|Proportion of responders who achieve ≥ 2-grade improvement from baseline at Day 90, per participant using the MMPS-P|Proportion of responders who achieve Participant Self-Assessment of Change in MMP (PSAC) PSAC Grade ≥ 2 (at least moderately improved from baseline) at Day 90, per participant using the PSAC|Change from baseline in lower facial volume (cm3) at Day 90","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1789-202-008","May 16, 2019","April 14, 2020","July 30, 2020","March 5, 2019",,"July 10, 2019","Total Skin & Beauty Dermatology Center, PC, Birmingham, Alabama, United States|Westside Aesthetics, Los Angeles, California, United States|Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States|Cosmetic Laser Dermatology, San Diego, California, United States|Baumann Cosmetic and Research Institute, Miami, Florida, United States|DeNova Research, Chicago, Illinois, United States|Etre, Cosmetic Dermatology and Laser Center, New Orleans, Louisiana, United States|Saint Louis University Dermatology, Saint Louis, Missouri, United States|Skin Specialists, PC, Omaha, Nebraska, United States|Nashville Centre for Laser and Facial Surgery, Nashville, Tennessee, United States|DermResearch, Inc., Austin, Texas, United States|Bellaire Dermatology Associates, Bellaire, Texas, United States|Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States|Advanced Clinical Research Gateway Aesthetic Institute & Laser Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03861936"
35,"NCT03857542","A Phase 3 Efficacy Study of AGN-190584 in Participants With Presbyopia",,"Active, not recruiting","No Results Available","Presbyopia","Drug: AGN-190584|Other: Vehicle","Change in baseline visual acuity","Allergan","All","40 Years to 55 Years   (Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1883-302-013","March 1, 2019","February 19, 2020","February 19, 2020","February 28, 2019",,"November 12, 2019","Eye Center South, Dothan, Alabama, United States|M&M Eye Institute, Prescott, Arizona, United States|Walman Eye Center, Sun City, Arizona, United States|Milton M. Hom, OD, FAAO, Azusa, California, United States|Global Research Management, Glendale, California, United States|Foothill Eye Institute, Glendora, California, United States|Lakeside Vision Center, Irvine, California, United States|Advanced Vision Care, Los Angeles, California, United States|North Valley Eye Medical Group, Inc., Mission Hills, California, United States|Retina Institute of California, Palm Desert, California, United States|California Eye Specialists, Pasadena, California, United States|Corneal Consultants of Colorado, Littleton, Colorado, United States|South Florida Vision Center, Fort Lauderdale, Florida, United States|Bowden Eye Associates, Jacksonville, Florida, United States|Citrus Surgery Center, Lecanto, Florida, United States|Mid Florida Eye Center, Mount Dora, Florida, United States|Central Florida Eye Institute, Ocala, Florida, United States|Newsom Eye & Laser Center, Sebring, Florida, United States|Clayton Eye Center, Morrow, Georgia, United States|The Midwest Center for Sight, Des Plaines, Illinois, United States|Jacksoneye, Lake Villa, Illinois, United States|Kannarr Eye Care, Pittsburg, Kansas, United States|Heart of America Eyecare, Shawnee Mission, Kansas, United States|Cincinnati Eye Institute, Edgewood, Kentucky, United States|Solomon Eye Physicians & Surgeons, Bowie, Maryland, United States|Chu Laser Eye Institute, Bloomington, Minnesota, United States|Silverstein Eye Centers, Kansas City, Missouri, United States|Moyes Eye Center, Kansas City, Missouri, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Amel Youssef, OD, Las Vegas, Nevada, United States|Debry Medical Services PC, Las Vegas, Nevada, United States|Eye Associates of New mexico, Albuquerque, New Mexico, United States|Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States|Dry Eye Clinic, Tannersville, Pennsylvania, United States|Bucci Laser Vision, Wilkes-Barre, Pennsylvania, United States|Waring Vision Institute, Mount Pleasant, South Carolina, United States|University Eye Surgeons, Maryville, Tennessee, United States|Total Eye Care, PA, Memphis, Tennessee, United States|Keystone Research ltd. at Texan Eye, Austin, Texas, United States|The Cataract and Glaucoma Center, El Paso, Texas, United States|Texas Eye & Laser Ctr, Hurst, Texas, United States|Lake Travis Eye & Laser Center, Lakeway, Texas, United States|Country Hills Eye Center, Ogden, Utah, United States|Vision Consultants and Surgeons, Falls Church, Virginia, United States|See Clearly Vision, McLean, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03857542"
36,"NCT03855137","Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine",,"Recruiting","No Results Available","Chronic Migraine","Drug: Atogepant 30 mg|Drug: Atogepant 60 mg|Drug: Placebo","Change from baseline in mean monthly migraine days across the treatment period|Change from baseline in mean monthly headache days across the 12-week treatment period|Change from baseline in mean monthly acute medication use days across the 12-week treatment period|Proportion of participants with at least a 50% reduction in mean monthly migraine days across the 12-week treatment period|Change from baseline in MSQ v2.1 Role Function-Restrictive domain score at Week 12|Change from baseline in mean AIM-D monthly functioning and activity impairment score across the 12-week treatment period","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3101-303-002","March 11, 2019","August 31, 2021","August 31, 2021","February 26, 2019",,"December 4, 2019","Barrow Neurological Institute, Phoenix, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|California Headache and Balance Center, Fresno, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|GW Medical Faculty Associates, Washington, District of Columbia, United States|Palm Beach Medical Group, West Palm Beach, Florida, United States|Ochsner Clinic Foundation, Covington, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|The Headache Center, Ridgeland, Mississippi, United States|Nevada Headache Institute, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical Center, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|Headache Wellness Center, Greensboro, North Carolina, United States|Raleigh Neurology Associates, P.A, Raleigh, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Texas Neurology, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|MedStar Georgetown Neurology, McLean, Virginia, United States|Sentara Family Medicine Physicians, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Puget Sound Neurology, Tacoma, Washington, United States|CHAMP Clinic, Calgary, Alberta, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|Ottawa Headache Centre Research Inc, Ottawa, Ontario, Canada|Centre de Traitement Neurologique, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03855137"
37,"NCT03852810","Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma","XENPRO","Recruiting","No Results Available","Glaucoma",,"To evaluate and compare the visual function and local eye symptoms in patients receiving surgical intervention via XEN (Xen gel stent) or trabeculectomy.|To evaluate and compare the treatment satisfaction and expectations in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate and compare work productivity in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate and compare the visual acuity recovery time in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate and compare the refractive change from baseline in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate and compare the IOP (Intraocular Pressure) change from baseline in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate and compare new onset ocular hypotensive medication use in patients receiving surgical intervention via XEN and trabeculectomy.|To present glaucoma procedure-related adverse events in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate glaucoma related healthcare resource utilization (HRU) by the mean number of physician office visits|To present post-operative medical management in patients receiving surgical intervention via XEN and trabeculectomy.|To evaluate glaucoma related healthcare resource utilization (HRU) by medication use|To present post-operative surgical management in patients receiving surgical intervention via XEN and trabeculectomy","Allergan","All","18 Years and older   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","P-2016-6380","February 25, 2019","December 31, 2020","December 31, 2020","February 25, 2019",,"July 5, 2019","Dalhousie University, Halifax, Nova Scotia, Canada|Galen Eye Center, Kingston, Ontario, Canada|Prism Eye Institute, Mississauga, Ontario, Canada|Toronto Ophthalmic Research Innovation Centre, Inc, Toronto, Ontario, Canada|Universitat Augenklinik, Mainz, Germany|Ludwig-Maximilians-Universität München, Munich, Germany|University of Tübingen, Tübingen, Germany|Addenbrooke's Hospital, Cambridge, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Southend University Hospital, Southend-on-sea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03852810"
38,"NCT03850782","Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension",,"Recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost (SR)","Retreatment or rescue administered for IOP|Number of patients experiencing a treatment emergent adverse event.","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1698-301-007|2018-002574-52","February 28, 2019","July 17, 2023","July 17, 2023","February 22, 2019",,"October 15, 2019","Walman Eye Center, Sun City, Arizona, United States|Atlantis Eyecare, Huntington Beach, California, United States|Lakeside Vision Center, Irvine, California, United States|Southern Califonria Kaiser Permanente, West Los Angeles, Los Angeles, California, United States|Global Research Foundation, Los Angeles, California, United States|Tayani Institute / American Institute of Research, Mission Viejo, California, United States|Eye Research Foundation, Newport Beach, California, United States|Byers Eye Institute, Stanford, Palo Alto, California, United States|Foothill Eye Institute, Pasadena, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Danbury Eye Physicians and Surgeons PC, Danbury, Connecticut, United States|Bruce Segal, MD, Delray Beach, Florida, United States|International Research Center, Tampa, Florida, United States|Specialty Retina Center, Weston, Florida, United States|Thomas Eye Group, P.C., Sandy Springs, Georgia, United States|Indiana University - Glick Eye Institute, Indianapolis, Indiana, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Clinical Eye Research of Boston, LLC, Winchester, Massachusetts, United States|Kellogg Eye Center, Ann Arbor, Michigan, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Silverstein Eye Center, Kansas City, Missouri, United States|Moyes Eye Center, Kansas City, Missouri, United States|Clinical Research Center of Nevada LLC, Las Vegas, Nevada, United States|Alterman, Modi & Wolter, Poughkeepsie, New York, United States|The Ohio State University, Columbus, Ohio, United States|AMA Eyes Research Institute, Marysville, Ohio, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|Drs. Fine, Hoffman and Sims, LLC, Eugene, Oregon, United States|Vantage EyeCare, LLC, Bala-Cynwyd, Pennsylvania, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Vance Thompson Vision, Sioux Falls, South Dakota, United States|Eye Specialty Group, Memphis, Tennessee, United States|Nashville Vision Associates, Nashville, Tennessee, United States|Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States|Keystone Eye Research, Austin, Texas, United States|Medical Center Opthalmology Associates - Keystone Medical Research, LTD, San Antonio, Texas, United States|Southern Utah Medical Research, Saint George, Utah, United States|Southern Utah Medical Research, Saint George, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03850782"
39,"NCT03842566","Evaluation of Age-Related Skin Changes",,"Completed","No Results Available","Age-related Skin Changes",,"Age-related changes in fine lines on the cheek|Age-related changes in skin hydration on the cheek|Age-related changes in skin barrier function on the cheek|Age-related changes in skin radiance on the cheek|Age-related changes in skin color on the cheek|Age-related changes in skin melanin on the cheek|Age-related changes in skin elasticity on the cheek and thigh|Age-related changes in skin thickness on the cheek and thigh|Age-related changes in skin topography on the cheek and thigh|Age-related changes in skin density on the cheek and thigh|Reproducibility and repeatability of the skin hydration measurement on the cheek|Reproducibility and repeatability of the skin barrier function measurement on the cheek|Reproducibility and repeatability of the skin radiance measurement on the cheek|Reproducibility and repeatability of the skin color measurement on the cheek|Reproducibility and repeatability of the skin melanin changes on the cheek|Reproducibility and repeatability of the changes in skin elasticity on the cheek and thigh|Reproducibility and repeatability of the changes in skin thickness and density on the cheek and thigh|Reproducibility and repeatability of the changes in skin topography on the cheek","Allergan","Female","18 Years to 80 Years   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2019-602-000","April 18, 2019","July 12, 2019","July 12, 2019","February 15, 2019",,"July 17, 2019","Dermscan-Pharmascan, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT03842566"
40,"NCT03827564","Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease",,"Recruiting","No Results Available","Dry Eye Syndromes","Device: Intranasal Tear Neurostimulator (ITN) [TrueTear®]","Mean change in goblet cell degranulation post-intranasal use of the ITN at the Application visit compared to without use of the ITN at the Screening visit","Allergan","All","22 Years and older   (Adult, Older Adult)","Not Applicable","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1919-802-019","June 24, 2019","December 31, 2019","December 31, 2019","February 1, 2019",,"July 30, 2019","Baylor College of Medicine - Department of Ophthalmology, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03827564"
41,"NCT03817502","Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia",,"Recruiting","No Results Available","Schizophrenia","Drug: Cariprazine|Drug: Placebo","Change from baseline in PANSS total score at Week 6","Allergan","All","13 Years to 17 Years   (Child)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RGH-MD-20|2018-004006-26","June 6, 2019","December 17, 2022","December 17, 2022","January 25, 2019",,"August 9, 2019","ProScience Research Group, Culver City, California, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States|Manhattan Behavioral Medicine PLLC, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03817502"
42,"NCT03804268","Phase 3 Efficacy Study of AGN-190584 in Participants With Presbyopia",,"Recruiting","No Results Available","Presbyopia","Drug: AGN-190584|Drug: Vehicle","Proportion of participants gaining 3 lines or more in mesopic, high contrast, binocular DCNVA (distance-corrected near visual acuity)|Proportion of participants gaining 3 lines or more in mesopic, high contrast, binocular DCNVA","Allergan","All","40 Years to 55 Years   (Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1883-301-013","December 21, 2018","March 31, 2020","March 31, 2020","January 15, 2019",,"October 10, 2019","Arizona Eye Center, Chandler, Arizona, United States|Schwartz Laser Eye Center, Scottsdale, Arizona, United States|Assil Eye Institute, Beverly Hills, California, United States|Scripps Clinic, La Jolla, California, United States|American Institute of Research, Los Angeles, California, United States|Eye Research Foundation, Newport Beach, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Grutzmacher & Lewis, A Medical Corporation DBA Sacramento Eye Consultants, Sacramento, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Miramar Eye Specialists, Ventura, California, United States|Haas Vision Center, Colorado Springs, Colorado, United States|Danbury Eye Physicians and Surgeons P.C., Danbury, Connecticut, United States|The Eye Associates, Bradenton, Florida, United States|Bruce Segal, MD, Delray Beach, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Florida Eye Associates, Melbourne, Florida, United States|USF Eye Institute, Tampa, Florida, United States|Chicago Cornea Consultants LTD, Hoffman Estates, Illinois, United States|Price Vision Group, Indianapolis, Indiana, United States|Sabates Eye Centers, Leawood, Kansas, United States|The Eye Care Institute, Louisville, Kentucky, United States|Seidenberg Protzko Eye Associates, Havre De Grace, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Tauber Eye Center, Kansas City, Missouri, United States|NV Eye Surgery, Las Vegas, Nevada, United States|Alterman, Modi & Wolter, Poughkeepsie, New York, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|EyeCare Professionals DWA Insight Research Clinic, LLC, Powell, Ohio, United States|Devers Eye Institute, Portland, Oregon, United States|Scott & Christie and Associates, PC, Cranberry, Pennsylvania, United States|UPMC Montefiore Hospital, Pittsburgh, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Vance Thompson Vision, Sioux Falls, South Dakota, United States|Southern College of Optometry, Memphis, Tennessee, United States|Nashville Vision Associates, Nashville, Tennessee, United States|Hill Country Eye Center, Cedar Park, Texas, United States|Key-Whitman Eye Center, Dallas, Texas, United States|PNV Clinical Research LLC, San Antonio, Texas, United States|R and R Eye Research, LLC, San Antonio, Texas, United States|Hoopes, Durrie, Rivera Research, Draper, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03804268"
43,"NCT03796728","This Study Will Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation","LIPS","Active, not recruiting","No Results Available","Lip Augmentation","Device: Juvéderm® VOLIFT™ with Lidocaine","Number of patients with a one point improvement with the 5-point Lip Fullness scale (LFS2) at 30 days post last treatment|To quantify the Investigators' and subject's assessment of aesthetic improvement of the subject's lips using a Lip Fullness scale|To quantify the subject's assessment of aesthetic improvement of their lips using a FACE-Q assessment|To quantify the Investigators' and subject's assessment of aesthetic improvement of their lips using the Global Aesthetic Improvement Scale|To quantify the subject's assessment of natural look and feel|To quantify the Investigators' assessment of smoothness|To quantify the Investigators' assessment of the dynamic lip lines upon animation","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CMO-MA-FAS-0512","December 31, 2018","May 26, 2020","May 26, 2020","January 8, 2019",,"December 9, 2019","Clínica Secret Beauty, Lisboa, Portugal|Clinica Milenio, Lisbon, Portugal|Medical and Cosmetic Clinic, Edinburgh, United Kingdom|MediZen Ltd, Sutton Coldfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03796728"
44,"NCT03795922","MT10109L in the Treatment of Glabellar Lines",,"Recruiting","No Results Available","Glabellar Lines","Drug: MT10109L|Drug: Placebo","The proportion of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) according to investigator and participant assessments of GL severity at maximum frown at Day 30|The duration of GL treatment in participants who achieved a rating of ≥ 2-grade improvement from baseline in GL severity at maximum frown at Day 30 according to investigator assessments using the FWS|The proportion of responders for investigator assessments of GL severity at maximum frown using the FWS|The proportion of participants reporting mostly satisfied/very satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) follow-up version Item 5 for GL|The proportion of responders for investigator assessments of GL severity at rest using the FWS|Number of patients who experienced an adverse event|Mean change from baseline in vital signs|Mean change from baseline in Electrocardiogram (ECG) parameters|Number of participants with binding and neutralizing antibodies","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT10109L-001|2018-004384-31","December 24, 2018","February 1, 2020","January 1, 2021","January 8, 2019",,"December 24, 2019","Investigate MD, Scottsdale, Arizona, United States|Art of Skin MD, Solana Beach, California, United States|Susan H. Weinkle, MD, Bradenton, Florida, United States|Etre, Cosmetic Dermatology and Laser Center, New Orleans, Louisiana, United States|Dermatology and Laser Surgery Center of New York, New York, New York, United States|SkinSearch of Rochester, Inc., Rochester, New York, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Aventiv Research, Inc., Dublin, Ohio, United States|Westlake Dermatology & Cosmetic Surgery, Austin, Texas, United States|Centre de la Fontaine, Loverval, Hainaut, Belgium|Medical Skin Care, Sint-Truiden, Limburg, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|CHU Liege, Liege, Belgium|Kazan State Medical University, Kazan, Tatarstan Republic, Russian Federation|Medical Centre Capital-Zdorovie, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03795922"
45,"NCT03786380","Diabetic Gastroparesis Study 05",,"Enrolling by invitation","No Results Available","Gastroparesis","Drug: Relamorelin 10 μg","Proportion of adverse events in participants|Proportion of abnormal clinical laboratory values|Proportion of abnormal vital signs|Propotion of abnormal electrocardiograms","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3071-305-020|2019‐000406‐30","December 20, 2018","September 30, 2024","September 30, 2024","December 26, 2018",,"December 18, 2019","North Alabama Research Center, LLC, Athens, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Adobe Clinical Research LLC, Tucson, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|HCP Clinical Research LLC, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|GW Research Inc, Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Diagnamics Inc., Encinitas, California, United States|Valley View Wellness and Medical Center - VVCRD Clinical Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Angel City Research Inc., Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|Stanford Hospital, Palo Alto, California, United States|TriWest Research Associates, Poway, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Upland Clinical Research, Upland, California, United States|New Hope Research Development, Whittier, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Denver Esophageal and Stomach Center, Englewood, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|Visionary Investigators Network, Aventura, Florida, United States|Gastro Florida, Clearwater, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research LLC, Cooper City, Florida, United States|American Research Institute, Inc, Cutler Bay, Florida, United States|Top Medical Research, Cutler Bay, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Cfagi Llc, Maitland, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|University of South Florida, Tampa, Florida, United States|Gastro Florida, Tampa, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, Buford, Georgia, United States|Summit Clinical Research, LLC., Carnesville, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|North Shore University Health System, Evanston, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|Tri-State Gastroenterology, Crestview Hills, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, Bastrop, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Delta Research Partners - Administration, Monroe, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Coastal Research Associates, Inc., South Weymouth, Massachusetts, United States|Boston VA Healthcare System, West Roxbury, Massachusetts, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Aa Mrc, Llc, Flint, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Troy Gastroenterology, PC dba Center for Digestive Health, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Montana Medical Research, Missoula, Montana, United States|Diabetes and Endocrine Associates, P.C., Omaha, Nebraska, United States|Heartland Clinical Research, Inc, Omaha, Nebraska, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Test Center 3, Brick, New Jersey, United States|AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Test Center 2, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Concord, North Carolina, United States|Carolina Digestive Health Associates, PA, Davidson, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|The MetroHealth System MHS, Cleveland, Ohio, United States|Digestive Disease & Surgery Institute, Cleveland, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Clinical Inquest Center Ltd., Dayton, Ohio, United States|Family Practice Center of Wadsworth, Inc. DBA New Venture Medical Research, Wadsworth, Ohio, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Jacob Murphy, Uniontown, Pennsylvania, United States|Partners in Clinical Research, LLC, Cumberland, Rhode Island, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Clinsearch, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Avant Research Associates,LLC, Austin, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Texas Tech University Health Sciences, Center Division of Gastroenterology, El Paso, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|Digestive Center of South Texas, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|SAGACT PLLC., San Antonio Gastroenterology Associates, PA, San Antonio, Texas, United States|Texas Digestive Disease Consultants, Southlake, Texas, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Consultorios Asociados de Endocrinologia e Investigación Cl, C.a.b.a., Buenos Aires Province, Argentina|CIAD Morón, Caba, Buenos Aires Province, Argentina|CIPREC, Ciudad Autonoma deBuenos Aires, Buenos Aires Province, Argentina|Instituto de Investigaciones Clínicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de hematología y medicina clínica ""Dr. Rubén Dávoli"", Rosario, Santa Fe, Argentina|Sanatorio Guemes, Caba, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Nepean Hospital, Kingswood, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordination, Saint Stefan, Steiermark, Austria|Medizinische Universitaet Innsbruck, Innsbruck, Tirol, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria|Privatklinik Wehrle-Diakonissen, Salzburg, Austria|Oö. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|Krankenanstalt Rudolfstiftung Wien, Vienna, Austria|KH Hietzing, Vienna, Austria|AZ Sint Lucas Brugge, Brugge, Antwerpen, Belgium|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerpen, Belgium|Hôpitaux Iris Sud - Joseph Bracops, Brussels, Belgium|UZ Brussel, Jette, Belgium|CHC - Clinique Saint-Joseph, Liège, Belgium|Hospital Universitário Walter Cantídio, Fortaleza, Ceara, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Parana, Brazil|Hospital Universitário João de Barros Barreto - UFPA, Belém, Para, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo- RS, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital São Lucas da PUC-RS, Porto Alegre, Rio Grande Do Sul, Brazil|NOOVA, Florianópolis, Santa Catarina, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Instituto de Pesquisa Clínica em Campinas, Campinas, Sao Paulo, Brazil|Universidade de Sao Paulo (USP) - Hospital das Clinicas da F, Cerqueira Cesar - Sao Paulo, Sao Paulo, Brazil|CPQuali Pesquisa Clínica Ltda, São Paulo, Sao Paulo, Brazil|Instituto de Estudos e Pesquisas Clínicas do Ceará - IEP/CE - Oncology, Fortaleza, Brazil|MHAT Yuliya Vrevska Byala, Byala, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Eastern Health, St. John's, Newfoundland and Labrador, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Etobicoke, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - CHUM, Montreal, Quebec, Canada|The Bailey Clinic, Red Deer, Canada|Toronto Digestive Disease Associates, Vaughan, Canada|Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlántico, Colombia|Fundación BIOS, Barranquilla, Atlántico, Colombia|Endocare Ltda., Bogota, Cundinamarca, Colombia|Healthy Medical Center, Zipaquirá, Cundinamarca, Colombia|Medplus Medicina Prepagada, Bogotá, Distrito Capltal, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Distrito Capltal, Colombia|Clinica Meta, Villavicencio, Meta, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Gastroenheden, Hvidovre hospital, Hvidovre, Kobenhavn, Denmark|Aalborg University Hospital, Aalborg, Denmark|Steno Diabetes Center Copenhagen, Hellerup, Denmark|Nordsjaellands Hospital, Hilleroed, Denmark|MEA KFA, Aarhus, Århus, Denmark|CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, Gironde, France|Hôpital Louis-Mourier, Colombes, France|Corbeil Essonnes, Corbeil Essonnes, France|Service d'hépato-gastroentérologie - 7°D, Grenoble, France|Hospices Civils de Lyon - Hôpital Edouard Herrriot, Lyon, France|CHU Nantes, Nantes, France|CHU de Poitiers, Poitiers, France|Hopital Charles Nicolle, Rouen Cedex, France|CHRU Nancy, Vandoeuvre-lès-Nancy, France|Centre de Recherche Clinique, Venissieux, France|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-Württemberg, Germany|Praxis Dr. Etzrodt-Walter und Kollegen, Ulm, Baden-Württemberg, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg-Western Pomerania, Germany|Diabetologische Schwerpunktpraxis, Bad Berleburg, North Rhine-Westphalia, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Studienzentrum Schwittay, Böhlen, Germany|Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|Clinical Research Hamburg GmbH, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|KRH Klinikum Siloah, Hannover, Germany|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Coromed SMO, Pecs, Pécs, Hungary|First Department of Medicine, University of Szeged, Szeged, Szaged, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Semmelweis University, Budapest, Hungary|Stra¡zshegy Medicina, Budapest, Hungary|Hetenyi Geza Hospital, Szolnok, Hungary|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Res, Ahmedabad, Gujarat, India|Zydus Hospital, Ahmedabad, Gujarat, India|Surat Institute of Digestive Sciences Hospitals, Surat, Gujarat, India|Lifecare Clinic and Research Centre - Internal Med/Diabetolo, Bangalore, Karnataka, India|Diacon Hospital and research Center, Bengaluru, Karnataka, India|Victoria Hospital Bangalore Medical College and Research Ins, Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre, Mangalore, Karnataka, India|Chopda Medicare & Research Centre Pvt.Ltd, Magnum Heart Institute, Nashik, Maharashtra, India|Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|University Hospital, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|S.P.Medical College & Group of Hospitals Bikaner, Bikaner, Rajasthan, India|S.R. Kalla Memorial Gastro and General Hospital, Jaipur, Rajasthan, India|Sir Ganga Ram Hospital (SGRH), Jaipur, Rajasthan, India|Eternal Hospital, Unit of Eternal Heart Care Centre and Research Institute Pvt. Ltd., Jaipur, Rajasthan, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India|M V Hospital & Research Centre, Lucknow, Uttar Pradesh, India|IPGME&R and SSKM Hospital, Kolkata, West Bengal, India|M. S. Ramaiah medical College and Hospitals - Gastroenterolo, Bangalore, India|Kumudini Devi Diabetes Research Center, Hyderabad, India|Bhatia Hospital, Mumbai, India|Soroka University Medical Center, Beer Sheva, Israel|Bnai Zion M.C., Haifa, Israel|E. Wolfson Medical Center, Holon, Israel|Digestive Diseases Institute, Jerusalem, Israel|Gastroenterology Institute, Petach Tikva, Israel|Endocrinology & Diabetes Center, Safed, Israel|Gastroenterology Institute, Tel Aviv, Israel|IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy|Clinical Institute Beato Matteo, Vigevano, Pavia, Italy|Policlinico Gemelli, Divisione di Endocrinologia e Malattie del Metabolismo, Rome, Rome Roma, Italy|Ospedale Cardinal Massaia, Asti, Italy|University of Bari, Bari, Italy|Azienda Ospedaliera Rilievo Nazionale Alta Specialita (ARNAS) Garibaldi, Catania, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Universita degli Studi di Napoli Federico II, Napoli, Italy|Azienda Opsedaliera di Padova, Padova, Italy|IRCCS S.Matteo Hospital Foundation, University of Pavia, Pavia, Italy|University of Pisa - Cisanello Hospital, Pisa, Italy|Gruppo Humanitas - Humanitas Research Hospital, Rozzano, Italy|Universita' Di Salerno- Aou Ruggi D'aragona, Salerno, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Polana-D, Daugavpils, Latvia|Ogorelova Jelena GP, Kraslava, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Clinicos Asociados BOCM SC, Mexico, Distrito Federal, Mexico|Clinica OMEGA, Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion, Mexico, Distrito Federal, Mexico|Medical and Nutritional Trials, México DF, Distrito Federal, Mexico|Centro de Investigacion Morales Vargas - CIMOVA, León, Guanajuato, Mexico|Centro de Diabetes de Pachuca, Pachuca, Hidalgo, Mexico|Unidad de Investigación Clínica Cardiometabolica de Occidente, Guadalajara, Jalisco, Mexico|Consultorio Medico, Guadalajara, Jalisco, Mexico|Unidad de Investigación clínica y atención Médica HEPA S.C., Guadalajara, Jalisco, Mexico|Instituto de Diabetes Obesidad y Nutrición SC, Cuautla, Morelos, Mexico|Accelerium Clinical Research, Monterrey, Nuevo Leon, Mexico|Centro Medico Christus Muguerza Sur, Monterrey, Nuevo Leon, Mexico|Investigación Médica Sonora, S.C., Hermosillo, Sonora, Mexico|Centro Especializado en Investigación Clínica S.C., Boca del Rio, Veracruz, Mexico|Centro de Desarrollo Biomédico, Mérida, Yucatan, Mexico|Practice Dr Gerardo Gonzalez, Acapulco, Mexico|Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigación, Durango, Mexico|CIADEN (Centro de Investigación y Atención de Diabetes, Endocrinología y Nutrición), Durango, Mexico|Sociedad de Metabolismo y Corazón, S.C., Veracruz, Mexico|Perpetual Succor Hospital, Cebu City, Philippines|West Visayas State University Medical Center, IloIlo City, Philippines|Ospital ng Makati, Makati City, Philippines|Manila Doctors Hospital, Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan, Philippines|NZOZ Vita - Diabetica Malgorzata Buraczyk, Diabetes Clinic,, Ystok, Bia, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Warazawa, Poland|Szpital Uniwestytetu Medycznego w Bialymstoku, Bialystok, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland|Vitamed, Bydgoszcz, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Silmedic Sp z o o, Katowice, Poland|CenterMed Krakow Ltd, Krakow, Poland|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Poland|Centrum Medyczne Medyk, Lublin, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Oddzial Gastroenterologii Mazowieckie Centrum Rehabilitacji Stocer sp. Z o.o., Pruszków, Poland|Endoskopia SP. Z O.O., Sopot, Poland|Powiatowe Centrum Medyczne w Wołowie, Wołów, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wrocław, Poland|Zamość, Zamość, Poland|Sana Medical Center, Bucharest, Romania|National Institute of Endocrinology, Bucharest, Romania|AMES Research Center SRL, Calarasi, Romania|ClinTrial Medical Center, Pulmonology Department, Dobrosloveni Resca, Olt County, Romania|Polisano-Clinic, Sibiu, Romania|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Novosibirskaya Oblast, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Sankt-Peterburg, Russian Federation|Millitary-medical Academy, department of hospital therapy, Saint-Petersburg, Sankt-Peterburg, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Leningrad Region, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|MUZ City Clinical Hospital 9, Saratov, Russian Federation|Saratov City Clinical Hospital 12, Saratov, Russian Federation|King Fahad Specialist Hospital - Dammam, Dammam, Saudi Arabia|Hayyal Jamia Hospital, Jeddah, Saudi Arabia|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|FARMOVS, Bloemfontein, Free State, South Africa|Soweto CTC, Johannesburg, Gauteng, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clincal Reaserch Centre, Pretoria, Gauteng, South Africa|Endocare Research, Paarl, Western Cape, South Africa|Moriana Clinical Research, Brandfort, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|Syenxus Watermeyer Dedicated Research, Val De Grace, South Africa|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Principe de Asturias, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|State Institution Ukrainian State Research Institute, Dnipro, Dnipropetrovs'ka Oblast, Ukraine|""Kryvyi Rih City Hospital #3"" of Dnipropetrovsk Regional Council, Dnipro, Dnipropetrovs'ka Oblast, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ivano-Frankivs'ka Oblast', Ukraine|Kyiv city clinical endocrinology center, department of general endocrine pathology and metabolism, c. Kyiv, Kyiv, Kyïv, Ukraine|DRRI-Vinnytsia National Pirogov Memorial Medical University, Vinnytsya, Vinnyts'ka Oblast', Ukraine|Municipal Institution Lutsk City Clinical Hospital, Lutsk, Volyos'ka Oblast', Ukraine|Municipal nonprofit entity ""Chernigiv city hospital #2"" of Chernigiv municipal council, therapeutic department, Chernihiv, Ukraine|Regional municipal institution ""Chernivtsi's regional clinical hospital"", gastroenterological department, Higher state educational establishment of Ukraine ""Bukovinian state medical university"", department of internal medicine and infectious diseases, c.C, Chernivtsi, Ukraine|Regional Public Organization Chernivtsi Regional Endocrinology Center, Chernivtsi, Ukraine|SU Clinic of medical academy of SI Dnepropetrovsk medical cacadamy of MoH of Ukraine, Dnipro, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Municipal nonprofit entity ""City clinical hospital #2 n.a. Prof.O.O.Shalimov"" of Kharkiv municipal council, department of endocrinology, Kharkiv, Ukraine|""State Institution ""National Institute of Therapy named after. L.T. Maloi NAMNU"" / Government Institution ""L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine"", Department of the study of diseases of the digestive, Kharkiv, Ukraine|Clinical Endocrinology of SI V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine, Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Limited Liability Company ""Medical and Diagnostic Center ""ADONIS Plus"", outpatient department, c. Kyiv, Kyiv, Ukraine|Kyiv Railway Clinical Hospital #2 of Branch Healthcare Center of the PJSC Ukranian Railway, Endocrynology Department, Kyiv, Ukraine|Medical Center Universal Clinic OberigMedical Center Universal Clinic Oberig / Medical Center ""Universal Clininc ""Oberig"" of LLC ""Capital"", Gastroenterological Center, c. Kyiv, Kyiv, Ukraine|Polyclinic of medical services and rehabilitation department of State Joint-Stock Holding Company Artem, day-patient unit, Kyiv, Ukraine|Institute of Endocrinology and Metabolism im. V. P. Komisarenka NAMS Ukraine, Kyiv, Ukraine|City Hospital #1, department of endocrinology, c. Mykolayiv, Mykolaiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Communal Institution ""Odesa Regional Clinical Hospital"", Out-patient department, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Municipal Institution of Sumy Regional Council Sumy Regional Clinical Hospital, Sumy, Ukraine|Ternopil University Hospital, Regional Center for Gastroenterology with Hepatology, Department of Gastroenterology, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Center Pulse, Vinnytsia, Ukraine|Medical Center of the Limited Liability Company ""Health Clinic"", Medical Clinical Research Center, Department of Gastroenterology, Hepatology and Endocrinology, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|Municipal nonprofit entity ""Vinnytsia's city clinical hospital #1"", gastroenterological department, Vinnytsia National Pirogov Memorial Medical University, department of propedeutics of internal medicine, c. Vinnytsia, Vinnytsia, Ukraine|6th City Clinical Hospital, c. Zaporizhzhia, Zaporizhzhia, Ukraine|""Municipal Institution """"City Hospital #7"""", polyclinic department, c. Zaporizhzhia"", Zaporizhzhia, Ukraine|Municipal Institution-Zaporizhzhia Regional Clinical Hospital, Zaporizhzhia, Ukraine|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Kaman Court, Blackpool, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|Western General Hospital Edinburgh, Edinburgh, United Kingdom|MAC Clinical Research, Monarch House, Leeds, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|Wingate Institute, London, United Kingdom|University College London Hospita, London, United Kingdom|MAC Clinical Research Manchester, Manchester, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|Biomedical Research Centre, Nottingham, United Kingdom|MAC Clinical Research, GAC House, Stockton-on-Tees, United Kingdom|St George's Hospital, Tooting, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03786380"
46,"NCT03785145","MT10109L in the Treatment of Lateral Canthal Lines",,"Recruiting","No Results Available","Lateral Canthal Lines","Drug: MT10109L|Drug: Placebo","The proportion of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale with Photonumeric Guide (FWS) according to investigator and participant assessments of LCL severity at maximum smile at Day 30|The duration of LCL treatment in participants who achieved a rating of ≥ 2 grade improvement from baseline in LCL severity at maximum smile at Day 30 according to investigator assessments using the FWS|The proportion of responders for investigator assessments of LCL severity at maximum smile using the FWS|The proportion of participants reporting mostly satisfied/very satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) follow-up version Item 5 for LCL|The proportion of responders for investigator assessments of LCL severity at rest using the FWS|Number of patients who experienced an adverse event|Mean change from baseline in vital signs|Mean change from baseline in Electrocardiogram (ECG) parameters|Number of participants with binding and neutralizing antibodies","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT10109L-002|2014-005279-10","December 20, 2018","February 1, 2020","January 9, 2021","December 24, 2018",,"December 24, 2019","Advanced Research Associates, Glendale, Arizona, United States|Eye Research Foundation, Newport Beach, California, United States|Skin Research Institute LLC, Coral Gables, Florida, United States|Coleman Dermatologic Surgery Center, Metairie, Louisiana, United States|Maryland Laser, Skin, & Vein Institute, Hunt Valley, Maryland, United States|Laser Skin Surgery Center of New York, New York, New York, United States|Bellaire Dermatology Associates, Bellaire, Texas, United States|SkinDC, Arlington, Virginia, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, United States|Moscow scientific-practical centre of dermatovenerology and cosmetology, Moscow, Russian Federation|I.I Mechnikov North-Western State Medical University, Saint-Petersburg, Russian Federation|Expert Aesthetics Ltd, Alderley Edge, Cheshire, United Kingdom|Waverley Medical Practice, Coatbridge, North Lanarkshire, United Kingdom|Medizen Clinic, Sutton Coldfield, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03785145"
47,"NCT03779841","Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open-chest Cardiac Surgery (NOVA)",,"Recruiting","No Results Available","Post-Operative Atrial Fibrillation","Drug: AGN-151607|Drug: Placebo","Percentage of participants with at least 1 continuous atrial fibrillation (AF) episode ≥ 30 seconds during the first 30 days post-surgery.|Percentage of time spent in AF (AF burden) during the first 30 days post-surgery|Percentage of participants with at least 1 event of symptomatic AF during the first 30 days post-surgery|Time to first occurrence of AF during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 2 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 5 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 30 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 1 hour during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 4 hours during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 24 hours during the first 30 days post-surgery","Allergan","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1925-201-008|2017-004399-68","March 1, 2019","October 15, 2020","October 14, 2021","December 19, 2018",,"December 20, 2019","Medstar Heart and Vascular Institute, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|The University of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Medical Center Heart and Vascular Research Organization, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor Scott & White Research Institute The Heart Hospital Plano, Plano, Texas, United States|University of Utah Division of Cardiothoracic Surgery, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Allgemeines Krankenhaus Wien Universitätsklinik für Chirurgie Klinische Abteilung für Herzchirurgie, Vienna, Austria|London Health Sciences Centre, University Hospital, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec Universié Laval, Laval, Quebec, Canada|Montreal Heart University, Montreal, Quebec, Canada|CHUM, Montreal, Quebec, Canada|CIUSS North of Montreal Island Sacré-Cœur Hospital Montreal, Montreal, Quebec, Canada|Asklepios Klinik Harburg-Hamburg, Hamburg, Germany|Leipzig Heart Institute, Leipzig, Germany|Asst degli Spegali Civili di Brescia, Brescia, Italy|Amsterdam UMC, Amsterdam, Noord Holland, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Utrecht, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Karolinska University Hospital, Solna, Stockholm, Sweden|Orebro University Hospital, Orebro, Sweden|Derriford Hospital, Plymouth, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03779841"
48,"NCT03777059","To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine",,"Recruiting","No Results Available","Episodic Migraine","Drug: Atogepant 30 mg|Drug: Atogepant 60 mg|Drug: Placebo|Drug: Atogepant 10 mg","Change from baseline in mean monthly migraine days across the 12-week treatment period|Change from baseline in mean monthly headache days across the 12-week treatment period.|Change from baseline in mean monthly acute medication use days across the 12-week treatment period.|Proportion of participants with at least a 50% reduction in mean monthly migraine days across the 12-week treatment period.|Change from baseline in mean monthly performance of daily activities domain score of the AIM-D across the 12-week treatment period.|Change from baseline in mean monthly physical impairment domain score of the AIM-D across the 12-week treatment period.","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","872","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","3101-301-002","December 14, 2018","February 5, 2020","February 5, 2020","December 17, 2018",,"December 5, 2019","Synexus Clinical Research US, Inc., Chandler, Arizona, United States|Alea Research Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Orange Grove Family Practice, Tucson, Arizona, United States|Principals Research Group, Hot Springs, Arkansas, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Med Center Medical Clinic, Carmichael, California, United States|Triwest Research Associates, El Cajon, California, United States|Neuro Pain Medical Center, Fresno, California, United States|California Headache and Balance Center, Fresno, California, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|NervePro Research Bruce Cleeremans, Irvine, California, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Long Beach Clinical Trials Services, Long Beach, California, United States|Keck Medicine of USC, Los Angeles, California, United States|Keck Medicine of USC, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Newport Beach Clinical Research Associates, Newport Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|Stanford, Palo Alto, California, United States|Stanford, Palo Alto, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Desert Valley Research, Redlands, California, United States|George J. Rederich, M.D. Inc., Redondo Beach, California, United States|Paradigm Clinical Research Centers, Inc, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Delta Waves, Inc., Colorado Springs, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Aventura Neurological Associates, Aventura, Florida, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Sarkis Clinical Trials- Gainesville, Gainesville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Well Pharma Medical Research, Corp., Miami, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Atlanta, Georgia, United States|Synexus Clinical Research US, Inc., Atlanta, Georgia, United States|Neurotrials Research, Atlanta, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Diamond Headache Clinic Ltd, Chicago, Illinois, United States|Clinical Investigation Specialists, Gurnee, Illinois, United States|JWM Neurology, Indianapolis, Indiana, United States|Deaconess Clinic - Gateway Health Center, Newburgh, Indiana, United States|PMG Research, Inc. d/b/a PMG Research of McFarland Clinic, Ames, Iowa, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|College Park Family Care Center, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, LLC - An AMR Company, Wichita, Kansas, United States|Heartland Research Associates, LLC - An AMR Company, Wichita, Kansas, United States|Otrimed, Edgewood, Kentucky, United States|Ochsner Clinic Foundation, Covington, Louisiana, United States|DelRicht Research, New Orleans, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Mid-Atlantic Permanente Medical Group, PC, Largo, Maryland, United States|John R. Graham Headache Center Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Synexus Usa, Bay Saint Louis, Mississippi, United States|The Headache Center, Ridgeland, Mississippi, United States|StudyMetrix Research, Saint Peters, Missouri, United States|Clinvest Research LLC., Springfield, Missouri, United States|Synexus Clinical Research US, Inc., Omaha, Nebraska, United States|Nevada Headache Institute, Las Vegas, Nevada, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Clinical Trials, Albuquerque, New Mexico, United States|Dent Neurologic Institute, Amherst, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Northwell Health, Great Neck, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Inc, Greensboro, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Wilmington Health, PLLC, Wilmington, North Carolina, United States|Piedmont Medical Research of Winston-Salem, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Patient Priority Clinical Sites, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Family Physicians Associates, Lyndhurst, Ohio, United States|OK Clinical Research, LLC, Edmond, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Jacob Murphy, Uniontown, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Partners, Lincoln, Rhode Island, United States|Primary Care Associates/Synexus Clinical, Anderson, South Carolina, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Hillcrest Family Practice, Simpsonville, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|CNS Healthcare - Memphis, Memphis, Tennessee, United States|Psychiatry & Psychotherapy Partners Austin, Austin, Texas, United States|Tekton Research, Austin, Texas, United States|Synexus-US, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Ventavia Research Group, Fort Worth, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Protenium Clinical Research, Hurst, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Synexus-US, Murray, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|J. Lewis Research, Inc., South Jordan, Utah, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Health Research of Hampton Roads, Inc., Newport News, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|National Clinical Research, Inc, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Sentara Family Medicine Physicians, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Eastside Therapeutic Resource and Core Clinical Research, Everett, Washington, United States|The Polyclinic, Seattle, Washington, United States|Puget Sound Neurology, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03777059"
49,"NCT03767400","Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.",,"Completed","No Results Available","Skin Care","Device: Skin Imaging|Other: Facial Cleanser","VivoSight software measurements of Epidermal Thickness|VivoSight software measurements of surface roughness|VivoSight software measurements of redness|VivoSight software measurements of attenuation coefficient|Overall Photodamage Score at Day 1|Overall Appearance of Fine Lines/Wrinkles Cheek Areas|Post-study Dynamic Optical Coherence Tomography (D-OCT) Image Analysis of Epidermal Thickness|Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Epidermis|Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Superficial Dermis|Post-study D-OCT Image Analysis of Collagen Fibers|Post-study D-OCT Image Analysis of Integrity of Collagen|Post-study D-OCT Image Analysis of Score of Vessels|Post-study D-OCT Image Analysis of Vascularity Quantification with Thresholds|Blinded Independent Physician Assessor Grading of the D-OCT Images of Stratum Corneum Reflectivity|Blinded Independent Physician Assessor Grading of the D-OCT images of Upper Dermal Reflectivity|Blinded Independent Physician Assessor Grading of the D-OCT Images of Dermoepidermal Contrast|Blinded Independent Physician Assessor Grading of the D-OCT images of Vessel Density|Antera 3D Images|VISIA-CR Images","Allergan","Female","18 Years to 75 Years   (Adult, Older Adult)",,"99","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SCRIC18-OCT-01","December 7, 2018","May 31, 2019","July 30, 2019","December 6, 2018",,"October 31, 2019","Skinmedica Clinical Research and Innovation Center, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03767400"
50,"NCT03759288","An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease",,"Recruiting","No Results Available","Crohn's Disease|IBD","Drug: Brazikumab low dose|Drug: Brazikumab high dose|Drug: Humira®|Drug: Placebo","Stage 1. Percentage of participants with endoscopic response and clinical remission at Week 12|Stage 2. Percentage of participants with endoscopic response and clinical remission at Week 52|Stage 1. Percentage of participants with endoscopic response and clinical remission at both Weeks 12 and 52|Stage 1. Percentage of participants with endoscopic remission and clinical remission at Week 52|Stage 1. Percentage of participants with endoscopic response at Week 12 and endoscopic remission at Week 52 and clinical remission at both Weeks 12 and 52|Stage 2. Percentage of participants with endoscopic response and clinical remission at both Weeks 12 and 52|Stage 2. Percentage of participants with endoscopic remission and clinical remission at Week 52|Stage 2. Percentage of participants with corticosteriod-free endoscopic remission and clinical remission at Week 52","Allergan","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","1140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3150-301-008","December 7, 2018","December 4, 2022","December 4, 2022","November 29, 2018",,"January 18, 2020","Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Ventura Gastroenterolgy Medical Group, Camarillo, California, United States|eStudySite, Chula Vista, California, United States|Om Research LLC, Lancaster, California, United States|Clinical Trials Research, Lincoln, California, United States|United Medical Doctors, Los Alamitos, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|Clinical Trials Specialist, Los Angeles, California, United States|ACRC Studies, Poway, California, United States|Breakthrough Clinical Trials, LLC, San Bernardino, California, United States|Clinical Applications Laboratories, Inc, San Diego, California, United States|Lomita Family Medical Group, Inc, San Diego, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Plasma Med Research, Boca Raton, Florida, United States|Gastroenterology Consultants of Clearwater, Clearwater, Florida, United States|Top Medical Research, Cutler Bay, Florida, United States|Wellness Clinical Research, Hialeah, Florida, United States|SIH Research, Kissimmee, Florida, United States|C&R Research Services USA, Lake Worth, Florida, United States|Auzmer Research, Lakeland, Florida, United States|Sanchez Clinical Research, Inc, Miami, Florida, United States|Medical Professional Clinical Research Center, INC., Miami, Florida, United States|Advanced Research, Inc, New Port Richey, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Advanced Research Institute, Inc., Saint Petersburg, Florida, United States|Guardian Angel Research Center, Tampa, Florida, United States|Gastro Florida, Tampa, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Atlanta Gastroenterology Specialists, Suwanee, Georgia, United States|Northwest Gastroenterology Group, Arlington Heights, Illinois, United States|Illinois Gastroenterology Group, LLC, Gurnee, Illinois, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|Aquaint Research, New Albany, Indiana, United States|Ideal Health, Shawnee Mission, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Capital Research, Rockville, Maryland, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Gen 1 Research - National Diabetes and Obesity Research Institute, Biloxi, Mississippi, United States|Jubilee Clinical Research, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Trialspark, Astoria, New York, United States|Trialspark, Inc., Brooklyn, New York, United States|Trialspark, Inc., Brooklyn, New York, United States|Manhattan Medical Research, New York, New York, United States|Manhattan Medical Research, New York, New York, United States|Trialspark, New York, New York, United States|Lucas Research, Morehead City, North Carolina, United States|Great Lakes Medical Research, LLC, Beachwood, Ohio, United States|Clinical Inquest Center, Springfield, Ohio, United States|Central Sooner Research, Norman, Oklahoma, United States|Digestive Disease Specialists (DDSI), Oklahoma City, Oklahoma, United States|Fontier Clinical Research, LLC, Uniontown, Pennsylvania, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|PharmaTex Research, Amarillo, Texas, United States|Mesa Research, Austin, Texas, United States|ClinRX Research Joseph INC, Carrollton, Texas, United States|Vilo Research Group, Houston, Texas, United States|Sensible Healthcare, Houston, Texas, United States|DCT-McAllen Primary Care DBA Discovery Clinical Trials, McAllen, Texas, United States|DCT-AACT DBA Discovery Clinical Trials, Pflugerville, Texas, United States|Gastroenterology of San Antonio, San Antonio, Texas, United States|DCT Stone Oak DBA Discovery Clinical Trials, San Antonio, Texas, United States|Advanced Research Institute, South Ogden, Utah, United States|Clinical Research Partners, Richmond, Virginia, United States|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Fundación de Investigación de Diego, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03759288"
51,"NCT03739203","The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Cariprazine|Drug: Placebo","Total score change from baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3111-302-001","November 10, 2018","July 9, 2021","July 9, 2021","November 13, 2018",,"November 1, 2019","Harmonex, Dothan, Alabama, United States|Woodland International Research Group, Little Rock, Arkansas, United States|California Pharmaceutical Research Institute, Anaheim, California, United States|Global Clinical Trials, Costa Mesa, California, United States|Collaborative Neuro Science, Garden Grove, California, United States|Behavioral Research Specialist, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|North County Clinical Research, Oceanside, California, United States|Excell Research, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Psykeria Research Institute LLC, Palm Bay, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|Institute for Behavior Medicine, LCC, Smyrna, Georgia, United States|AMR Conventions Limited, Naperville, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Phoenix Medical Research, Leawood, Kansas, United States|Neuroscientific Insights LLC, Rockville, Maryland, United States|Boston Clinical Trails, Boston, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|The Coastal Research Associates, Inc, South Weymouth, Massachusetts, United States|Center For Emotional Fitness, Cherry Hill, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Clinical Trials of America, Hickory, North Carolina, United States|Quest Therapeutics of Avon Lake, Avon Lake, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|North Star Medical Research, Middleburg Heights, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Keystone Clinical Studies, Norristown, Pennsylvania, United States|AIM Trials, Plano, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03739203"
52,"NCT03738215","Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Cariprazine|Drug: Placebo","Total score change from baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3111-301-001","November 9, 2018","July 9, 2021","July 9, 2021","November 13, 2018",,"November 1, 2019","Alea Research, Phoenix, Arizona, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|ATP Clinical Research, Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Omega Clinical Trials, La Habra, California, United States|Synergy Clinical Research, National City, California, United States|Viking Clinical Research Ltd, Temecula, California, United States|Collaborative Neuro Science Network, Torrance, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Medicine and Research Centre, Marietta, Georgia, United States|Advanced Clinical Research, Boise, Idaho, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Pillar Clinical Research, LLC, Lincolnwood, Illinois, United States|Neuroscience Research Institute, Winfield, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Dr. Gary J. Booker, Shreveport, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|CBH Health, Gaithersburg, Maryland, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Finger Lakes Clinical Research, Rochester, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|CTI Clinical Trial and Consulting, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, Bellaire, Texas, United States|FutureSearch Trials of Dallas LP, Dallas, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Pillar Clinical Research, Richardson, Texas, United States|Core Clinical Research, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03738215"
53,"NCT03732833","MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines",,"Recruiting","No Results Available","Lateral Canthal Lines, Glabellar Lines","Drug: MT10109L|Drug: Placebo","The proportion of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) according to investigator and participant assessments of LCL severity at maximum smile at Day 30|The duration of LCL treatment in participants who achieved a rating of ≥ 2-grade improvement from baseline in LCL severity at maximum smile at Day 30 according to investigator assessments using the FWS|The proportion of responders for investigator assessments of LCL severity at maximum smile using the FWS|The proportion of participants reporting mostly satisfied/very satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) follow-up version Item 5 for LCL|The proportion of responders for investigator assessments of LCL severity at rest using the FWS|Number of patients who experienced an adverse event|Mean change from baseline in vital signs|Mean change from baseline in Electrocardiogram (ECG) parameters|Mean change from baseline in lab parameters|Number of participants with binding and neutralizing antibodies","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT10109L-006|2014-005302-38","November 5, 2018","February 1, 2020","January 1, 2021","November 7, 2018",,"December 24, 2019","Investigate MD, Scottsdale, Arizona, United States|Art of Skin MD, Solana Beach, California, United States|Susan H. Weinkle, MD, Bradenton, Florida, United States|Etre, Cosmetic Dermatology and Laser Center, New Orleans, Louisiana, United States|Dermatology and Laser Surgery Center of New York, New York, New York, United States|SkinSearch of Rochester, Inc., Rochester, New York, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Wilmington Dermatology Center, Wilmington, North Carolina, United States|Aventiv Research, Inc., Dublin, Ohio, United States|Westlake Dermatology & Cosmetic Surgery, Austin, Texas, United States|DermResearch, Inc., Austin, Texas, United States|Dr. Jean Carruthers Cosmetic Surgery, Inc., Vancouver, British Columbia, Canada|Pacific Derm, Vancouver, British Columbia, Canada|Dermetics, Burlington, Ontario, Canada|Nectar Research Group Inc., Richmond Hill, Ontario, Canada|Hautok und Hautok-cosmetics, Munich, Bavaria, Germany|Rosenpark-Research, Darmstadt, Hessen, Germany|Hautzentrum Köln, Cologne, Germany|Medicorum Praxis für Dermatologie und Ästhetik, Oberursel, Germany",,"https://ClinicalTrials.gov/show/NCT03732833"
54,"NCT03721016","MT10109L in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines",,"Recruiting","No Results Available","Glabellar Lines, Lateral Canthal Lines","Drug: MT10109L|Drug: Placebo","The proportion of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) according to investigator and participant assessments of GL severity at maximum frown at Day 30|The duration of GL treatment in participants who achieved a rating of ≥ 2-grade improvement from baseline in GL severity at maximum frown at Day 30 according to investigator assessments using the FWS|The proportion of responders for investigator assessments of GL severity at maximum frown using the FWS|The proportion of participants reporting mostly satisfied/very satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) follow-up version Item 5 for GL|The proportion of responders for investigator assessments of GL severity at rest using the FWS|Number of patients who experienced an adverse event|Mean change from baseline in vital signs|Mean change from baseline in Electrocardiogram (ECG) parameters|Mean change from baseline in lab parameters|Number of participants with binding and neutralizing antibodies","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT10109L-005|2014-005301-21","October 26, 2018","February 1, 2020","January 1, 2021","October 26, 2018",,"December 24, 2019","Advanced Research Associates, Glendale, Arizona, United States|Eye Research Foundation, Newport Beach, California, United States|Skin Research Institute LLC, Coral Gables, Florida, United States|Coleman Dermatologic Surgery Center, Metairie, Louisiana, United States|Maryland Laser, Skin, & Vein Institute, Hunt Valley, Maryland, United States|Laser Skin Surgery Center of New York, New York, New York, United States|Bellaire Dermatology Associates, Bellaire, Texas, United States|SkinDC, Arlington, Virginia, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, United States|Carruthers & Humphrey Clinical Research, Vancouver, British Columbia, Canada|Project Skin MD, Vancouver, British Columbia, Canada|Sweat Clinics of Canada, Toronto, Ontario, Canada|Bertucci MedSpa Inc., Woodbridge, Ontario, Canada|Studienzentrum Theatiner46, Munich, Bavaria, Germany|DRK-Kliniken Nordhessen, Kassel, Hessen, Germany|Privatpraxis Dr. Hilton & Partner, Düsseldorf, NRW, Germany|Bermuda Practice, Basingstoke, Hampshire, United Kingdom|The Bosham Clinic, Chichester, West Sussex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03721016"
55,"NCT03712449","A Study to Evaluate Subject Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment",,"Recruiting","No Results Available","Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality","Device: JUVÉDERM®|Drug: BOTOX Cosmetic®|Drug: BELKYRA®|Other: SkinMedica","Change from baseline before treatment in the Rasch-transformed score of the FACE-Q Satisfaction with facial appearance overall scale.|Mean change from baseline in subject's assessment of expectations of life in Rasch-transformed score of the FACE-Q expectation scale aging appraisal|The mean change from baseline in subject's assessment of age-related facial appearance in Rasch-transformed score of the FACE-Q|Mean change from baseline in subject's assessment of psychological well-being in Rasch-transformed score of the FACE-Q psychological function scale|Mean change from baseline in subject's assessment of social function in the Rasch-transformed score of the FACE-Q social function scale.|Mean change subject's assessment of overall satisfaction with skin in Rasch-transformed score of FACE-Q satisfaction with skin|Change from baseline in responders achieving a younger category in subject's assessment of age-related facial appearance measured by self-perception of age","Allergan","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-MA-FAS-0579","January 22, 2019","August 30, 2020","August 30, 2020","October 19, 2018",,"April 4, 2019","Carruthers & Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada|Project Skin MD Vancouver, Vancouver, British Columbia, Canada|Pacific Derm, Vancouver, British Columbia, Canada|Dermetics, Burlington, Ontario, Canada|Dr Nowell Solish, Toronto, Ontario, Canada|Bertucci MedSpa, Woodbridge, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03712449"
56,"NCT03712137","Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition",,"Active, not recruiting","No Results Available","Jawline Definition","Device: VOLUX XC|Other: No-treatment control","Percentage of subjects who show ≥ 1-point jawline improvement from baseline on the Allergan Loss ofJawline Definition Scale (ALJDS)|Percentage of Participants who note ""Improved"" or ""Much Improved"" in jawline area as Assessed by the Evaluating Investigator using the Global Aesthetic Improvement Scale (GAIS)|Percentage of Participants who note ""Improved"" or ""Much Improved"" in jawline area as Assessed by the Participant using the GAIS|Change from baseline for FACE-Q™ Satisfaction with lower face and jawline score","Allergan","All","22 Years and older   (Adult, Older Adult)","Phase 3","227","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","V25L-002","November 12, 2018","February 10, 2020","February 12, 2021","October 19, 2018",,"October 7, 2019","Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States|Westside Aesthetics, Los Angeles, California, United States|Artemedica, Santa Rosa, California, United States|Center for Dermatology and Dermatologic Surgery, Washington, District of Columbia, United States|Susan H Weinkle, MD, Bradenton, Florida, United States|Hevia Cosmetic Dermatology, Coral Gables, Florida, United States|Skin Research Institute LLC, Coral Gables, Florida, United States|Baumann Cosmetic and Research Institute, Miami, Florida, United States|DeNova Research dba Arano, LLC, Chicago, Illinois, United States|Callender Center for Clinical Research, Glenn Dale, Maryland, United States|MDLSV, Hunt Valley, Maryland, United States|Williams Center, Latham, New York, United States|The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco, New York, United States|Center aesthetic and dermatology, New York, New York, United States|Laser & Skin Surgery Center of New York, New York, New York, United States|Aesthetic Solutions, PA., Chapel Hill, North Carolina, United States|Bellaire Dermatology Associates, Bellaire, Texas, United States|Suzanne Bruce and Associates, P.A., The Center for Skin Research, Houston, Texas, United States|SkinDC, Arlington, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03712137"
57,"NCT03700320","To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine",,"Active, not recruiting","No Results Available","Episodic Migraine","Drug: Atogepant 60 mg|Drug: Standard of Care (SOC) Migraine Prevention Medication","Percentage of Participants with at Least 1 Treatment Emergent Adverse Event|Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Urinalysis) as assessed by the Investigator|Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as assessed by the Investigator|Percentage of Participants with Clinically Significant Vital Sign Measurements as assessed by the Investigator|Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation and Behaviour using 5-Point Scales","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3101-302-002","October 8, 2018","June 22, 2020","November 9, 2020","October 9, 2018",,"March 25, 2019","Simon Williamson Clinic, Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Birmingham, Alabama, United States|East Valley Family Physicians, Chandler, Arizona, United States|Desert Clinical Research, Mesa, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Anaheim Clinical Trials, Anaheim, California, United States|Hope Clinical Reseach, Canoga Park, California, United States|Pharmacology Research Institute, Encino, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|Synergy Clinical Research Centers, Lemon Grove, California, United States|Southland Neurologic, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Research Partners, Oakland, California, United States|Excell Research, Inc., Oceanside, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Medical Center for Clinical Research, San Diego, California, United States|California Research Foundation, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Cassidy Medical Group, Vista, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Delta Waves Sleep Disorders And Research Center, Colorado Springs, Colorado, United States|Advanced Neurology of Colorado, Fort Collins, Colorado, United States|MD Clinical, Hallandale Beach, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Well Pharma Medical Research, Corp., Miami, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Compass Research dba Bioclinica Research, Orlando, Florida, United States|Aspire Health Partners, Orlando, Florida, United States|Infinity Clinical Research, Sunrise, Florida, United States|Meridien Research, Tampa, Florida, United States|Palm Beach Medical Group, West Palm Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Radiant Research - Atlanta, Atlanta, Georgia, United States|Atlanta Center for Clinical Research, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Kansas City Bone & Joint Clinic, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Kentucky Pediatric Research, Bardstown, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|Community Clinical Research Network, Marlborough, Massachusetts, United States|Michigan Headache & Neurological Institute, Ann Arbor, Michigan, United States|Beyer Research, Kalamazoo, Michigan, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|ClinVest, Springfield, Missouri, United States|Meridian Clinical Research Norfolk, Norfolk, Nebraska, United States|Quality Clinical Research, Omaha, Nebraska, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Clinical Research Advantage, Inc., Omaha, Nebraska, United States|Altea Research, Las Vegas, Nevada, United States|Advocare Berlin Medical Associates, Berlin, New Jersey, United States|Amici Clinical Research, Martinsville, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Clinical Trials, Albuquerque, New Mexico, United States|Dent Neurologic Institute, Amherst, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Central New York Clinical Research, Manlius, New York, United States|Clinilabs, New York, New York, United States|Rochester Clinical Research, Rochester, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Plains Medical Clinic, Fargo, North Dakota, United States|Radiant Akron, Akron, Ohio, United States|Radiant Research Cincinnati, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio Clinical Research, LLC, Lyndhurst, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Oregon Center for Clinical Investigations, Salem, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Clinical Research of Philadelphia, Philadelphia, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Radiant Research, Anderson, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Volunteer Research Group, Knoxville, Tennessee, United States|CNS Healthcare - Memphis, Memphis, Tennessee, United States|Trinity Clinical Research, Tullahoma, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Tekton Research, Austin, Texas, United States|DiscoveResearch, Bryan, Texas, United States|FutureSearch Trials, Dallas, Texas, United States|Earle Research, Houston, Texas, United States|Research Trials WorldWide, Humble, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Foothill Family Draper Clinic, Draper, Utah, United States|Advanced Research Institute, Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|North Seattle Women's Group, Seattle, Washington, United States|SSM Dean Health Research, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03700320"
58,"NCT03691415","Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea",,"Recruiting","No Results Available","Submental Fullness","Drug: BELKYRA Inj.","Change from baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)|Change from baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CMO-EPI-FAS-0537|EUPAS23762","September 7, 2018","September 30, 2022","June 30, 2023","October 1, 2018",,"January 17, 2019","Oracle-Dermatology, Daejeon, Korea, Republic of|Koeunme & S-line clinic, Hwaseong-si, Korea, Republic of|Yeonse Medi-Noble clinic, Seoul, Korea, Republic of|Maylin- Clinic, Seoul, Korea, Republic of|Goldenview plastic surgery, Seoul, Korea, Republic of|MH- Clinic, Seoul, Korea, Republic of|(Apgujeong) Oracle-Dermatology, Seoul, Korea, Republic of|Dream-Dermatology, Seoul, Korea, Republic of|ID-Dermatology, Seoul, Korea, Republic of|Nana Plastic surgery, Seoul, Korea, Republic of|Regen- Clinic, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03691415"
59,"NCT03682471","Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)",,"Completed","No Results Available","Subcutaneous Fat","Drug: Deoxycholic acid Injection|Drug: Placebo","Percentage of Participants Maintaining Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were CR-SMFRS 1-Grade Responders at both LTFU Baseline and at 24-Month Visit|Percentage of Participants with Maintenance of Response as Assessed by the Subject Satisfaction Rating Scale (SSRS) During the 24 Months of Follow up, i.e. % of Participants who were SSRS Responders at both LTFU Baseline and at 24-Month Visit|Percentage of Participants Maintaining Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 2-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were CR-SMFRS 2-Grade Responders at both LTFU Baseline and at 24-Month Visit|Patient-Reported Submental Fat Impact Scale (PR-SMFIS)|Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were Composite SMFRS 1-Grade Responders at both LTFU Baseline and at 24-Month Visit|Percentage of Participants with at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants with Treatment-emergent Adverse Events Associated with the Treatment Area (Drug-related)|Percentage of Participants with Treatment-emergent Adverse Events of Special Interest (AESIs)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"201","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1403740|16045|2011-005026-21","February 14, 2012","December 13, 2013","December 13, 2013","September 24, 2018",,"September 24, 2018","Licca Clinical Research Institute, Augsburg, Germany|Campus Charité Mitte, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany|Ruhruniversität Bochum - St. Josef Hospital, Bochum, Germany|Klinikum Darmstadt, Darmstadt, Germany|Krankenhaus Dresden- Friedrichstadt Klinik für Dermatologie und Allergologie, Dresden, Germany|Dr. Beatrice Gerlach, Dresden, Germany|Klinikum der Johann-Wolfgang Goethe-Universität - Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany|Hautarztpraxis Cutanis, Freiburg, Germany|Praxis Dr. Walker and Dr. Biwer, Ludwigshafen, Germany|Universitätsklinik Schleswig Holstein, Campus Luebeck, Klinik f. Dermatologie, Lübeck, Germany|Gemeinschaftsprax is für Dermatologie, Mahlow, Germany|Ludwig- Maximilians- Universität München, Klinik für Dermatologie und Allergologie, München, Germany|Germania Campus PraxisKlinik, Münster, Germany|Praxis Dr. Graefe, Northeim, Germany|Haut- und Laserzentrum Potsdam, Potsdam, Germany|Klinik für Dermatologie und Allergologie Klinikum Vest GmbH Recklinghausen, Recklinghausen, Germany|Hautzentrum am Starnberger See GmbH, Starnberg, Germany|Dermatologische Privatpraxis, Wuppertal, Germany",,"https://ClinicalTrials.gov/show/NCT03682471"
60,"NCT03654885","XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)","GPS","Recruiting","No Results Available","Glaucoma","Device: XEN group|Procedure: Trabeculectomy","Percentage of subjects achieving at least 20% mean Intraocular pressure (IOP) change from baseline on the same or fewer number of IOP-lowering medications|Change from baseline (medicated) in mean Intraocular pressure (IOP)|Change from baseline (medicated)in mean number of topical IOP-lowering medications|Proportion of eyes achieving specific IOP targets (≤18 mmHg, ≤17 mmHg, ≤16 mmHg, ≤15 mmHg, ≤14 mmHg, ≤13 mmHg, ≤12 mmHg|Proportion of eyes achieving at least 20% IOP reductions and specific IOP targets on same or lower number of topical IOP-lowering medications|proportion of eyes achieving at least 20% reduction of needling rates, number of needlings per eye, outcomes post needling, antifibrotics, including mean IOP and number of medications measured","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-US-EYE-0600","October 1, 2018","September 30, 2020","March 31, 2021","August 31, 2018",,"April 4, 2019","Vold Vision, Fayetteville, Arkansas, United States|UCSD- Shiley Eye Center, La Jolla, California, United States|Sacramento Eye Consultants, Sacramento, California, United States|UC Health, Aurora, Colorado, United States|Howard University Hospital, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Pinnacle Eye Center, Melbourne, Florida, United States|Your Eye Specialists, Plantation, Florida, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|Georgia Eye Partners, Atlanta, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Jenkins Eye Care, Honolulu, Hawaii, United States|Illinois Eye Center, Peoria, Illinois, United States|Stiles Eyecare Excellence Glaucoma Institute, Overland Park, Kansas, United States|Advanced Glaucoma Speicialists, Reading, Massachusetts, United States|Kellogg Eye Center, Ann Arbor, Michigan, United States|Glaucoma Center of Michigan, Southfield, Michigan, United States|Univesity of Missouri, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Glaucoma Associates ot the Captiol Region, Slingerlands, New York, United States|Carolina Eye Associates, Southern Pines, North Carolina, United States|Eye Care Associates, Poland, Ohio, United States|Ludwick Eye Center, Chambersburg, Pennsylvania, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hamilton Eye Institute, Memphis, Tennessee, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|El Paso Eye Surgeons, PA, El Paso, Texas, United States|Houston Eye Associates HEA - Gramercy Location, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|SSM Health, Madison, Wisconsin, United States|Unity Point Health Meriter, Madison, Wisconsin, United States|Eye Center of Racine and Kenosha, Racine, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03654885"
61,"NCT03616821","An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]",,"Recruiting","No Results Available","Colitis|Ulcerative|IBD","Drug: Brazikumab|Drug: Vedolizumab|Drug: Placebo","Clinical remission based on modified Mayo score (mMS)|Sustained clinical remission based on mMS|Corticosteroid-free (CS-free) clinical remission based on mMS|Maximum serum concentration of brazikumab (Cmax)|Presence of antibrazikumab antibodies|Area under the serum concentration time curve (AUC) of brazikumab","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","3151-201-008|2018-001605-93","August 7, 2018","August 30, 2020","February 16, 2022","August 6, 2018",,"January 18, 2020","Arizona Arthritis & Rheumatology Research, Scottsdale, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Clinical Trials Specialist, Inc., Beverly Hills, California, United States|Ventura Gastroenterolgy Medical Group, Camarillo, California, United States|eStudySite, Chula Vista, California, United States|VVCRD Clinical Research, Garden Grove, California, United States|Om Research LLC, Lancaster, California, United States|Clinical Trials Research, Lincoln, California, United States|United Medical Doctors, Los Alamitos, California, United States|Gastroinestinal Biosciences, Los Angeles, California, United States|ACRC Studies, Poway, California, United States|Breakthrough Clinical Trials, LLC, San Bernardino, California, United States|Clincal Applications Laboratories, Inc., San Diego, California, United States|Lomita Family Medical Group, Inc, San Diego, California, United States|Ritchken & First MD's, San Diego, California, United States|Care Access Research, San Pablo, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Plasma Med Research, Boca Raton, Florida, United States|Gastroenterology Consultants of Clearwater, Clearwater, Florida, United States|American Research Institute, Cutler Bay, Florida, United States|Top Medical Research, Inc, Cutler Bay, Florida, United States|Wellness Clinical Research, Hialeah, Florida, United States|SIH Research, Kissimmee, Florida, United States|C&R Research Services, Lake Worth, Florida, United States|Auzmer Research, Lakeland, Florida, United States|Sanchez Clinical Research, Inc, Miami, Florida, United States|Medical Professional Clinical Research, Miami, Florida, United States|Valencia Medial & Research Center, Miami, Florida, United States|Advanced Research, Inc, New Port Richey, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Advanced Research Institute Inc, Saint Petersburg, Florida, United States|Guardian Angel Research Center, Tampa, Florida, United States|Gastro Florida, Tampa, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Atlanta Gastroenterology Specialists, Suwanee, Georgia, United States|Northwest Gastroenterology Group, Arlington, Illinois, United States|Illinois Gastroenterology Group, Gurnee, Illinois, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|Qualmedica Research, LLC, Evansville, Indiana, United States|Ideal Health, Shawnee Mission, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Capital Research, Rockville, Maryland, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Gen 1 Research - National Diabetes and Obesity Research Institute, Biloxi, Mississippi, United States|Jubilee Clinical Research, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Trialspark, Inc., Astoria, New York, United States|Trialspark, Inc., Brooklyn, New York, United States|Trialspark, Inc., Brooklyn, New York, United States|Trialspark, Inc., New York, New York, United States|Manhattan Medical Research Practice PLLC, New York, New York, United States|Trialspark, Inc., New York, New York, United States|Lucas Research, Morehead City, North Carolina, United States|Great Lakes Medical Research, Beachwood, Ohio, United States|Consultants for Clinical Research, Inc., Cincinnati, Ohio, United States|Clinical Inquest Center, Springfield, Ohio, United States|Central Sooner Research, Norman, Oklahoma, United States|Digestive Disease Specialists (DDSI), Oklahoma City, Oklahoma, United States|Fontier Clinical Research, LLC, Uniontown, Pennsylvania, United States|PharmaTex Research, Amarillo, Texas, United States|Mesa Research, Austin, Texas, United States|ClinRX Research Joseph INC, Carrollton, Texas, United States|Vilo Research Group, Houston, Texas, United States|Centex Studies, Inc. - Houston, Houston, Texas, United States|Discovery Clinical Trials, McAllen, Texas, United States|DCT-AACT DBA Discovery Clinical Trials, Pflugerville, Texas, United States|Gastroenterology of San Antonio, San Antonio, Texas, United States|Discovery Clinical Trials, San Antonio, Texas, United States|Advanced Research Institute, South Ogden, Utah, United States|Clinical Research Partners, Richmond, Virginia, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|GI Research Institute (G.I.R.I.), Vancouver, British Columbia, Canada|Barrie Endoscopy, Barrie, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Toronto Western Hospital/University Health Network, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Fundacion de Investigation de Diego, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03616821"
62,"NCT03594721","Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light Exposure",,"Completed","No Results Available","Blue Light Damage","Other: Marvel AM","Photographs for detection of changes in the treatment areas.|Chromamemter instrument will be used to assess the change of color on the skin.|Punch biopsies will be taken from the 3 different areas on the lower back to evaluate histological changes.","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKM18-MARV-HEV","August 6, 2018","August 30, 2018","August 30, 2018","July 20, 2018",,"September 7, 2018","McDaniel Institute of Anti Aging Research, Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03594721"
63,"NCT03586427","AGN-241751 in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: AGN-241751|Other: Placebo","Change from baseline in Montgomery-Asberg Depression Rating Scale(MADRS) total score","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","251","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3125-201-002","June 13, 2018","July 22, 2019","August 21, 2019","July 13, 2018",,"August 29, 2019","Health Initiatives Research PLLC, Fayetteville, Arkansas, United States|Synexus US - Cerritos, Cerritos, California, United States|Wake Research - Pharmacology Research Institute, Encino, California, United States|Wake Research - Pharmacology Research Institute, Newport Beach, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|North County Clinical Research, Inc., Oceanside, California, United States|Collaborative Neuroscience Network, Torrance, California, United States|Elite Clinical Trials, Inc., Wildomar, California, United States|Synexus US - Atlanta, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Pillar Clinical Research, Lincolnwood, Illinois, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Neurobehavioral Research, Inc, Cedarhurst, New York, United States|Synexus US - Queens, Jamaica, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Clinical Neuroscience Solutions, Inc - Memphis, TN, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03586427"
64,"NCT03569475","Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Fluoxetine|Drug: Placebo","Change from baseline in Children's Depression Rating Scale- Revised (CDRS-R)|Change from baseline in Clinical Global Impression-Severity (CGI-S) scale","Allergan","All","7 Years to 17 Years   (Child)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-14","July 6, 2018","May 19, 2021","May 19, 2021","June 26, 2018",,"December 9, 2019","Woodland International Research Group, Little Rock, Arkansas, United States|Care Access Research, Beverly Hills, Beverly Hills, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Alliance Research, Long Beach, California, United States|Excell Research, Inc, Oceanside, California, United States|Orange County Neuropsychiatric Research Center, LLC, Orange, California, United States|Stanford University, Palo Alto, California, United States|Elite Clinical Trials, Inc., Wildomar, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Children's National Health System, Washington, District of Columbia, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Zynak Clinical, Lauderdale Lakes, Florida, United States|Columbus Clinical Services, LLC, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|University of South Florida Board of Trustee, Tampa, Florida, United States|Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|INOVA clinical trials and research center, Tyrone, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Joliet Center Clinical Research, Joliet, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR Conventions Limited, Naperville, Illinois, United States|AMR-Baber Research, Inc., Naperville, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|KU Wichita Center for Clinical Research, Wichita, Kansas, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|Millennium Center for Clinical Research, Creve Coeur, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, Bellaire, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|Mech Healthcare Associates, Frisco, Texas, United States|Biopharma Informatic, LLC, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Northpointe Psychiatry, Lewisville, Texas, United States|Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States|AIM Trials, Plano, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Eastside Therapeutic Resource dba Core Clinical Research, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03569475"
65,"NCT03559972","Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections",,"Completed","No Results Available","Facial Photodamage","Other: on-label facial injection","Change from Baseline in Clinical grading of the full face on the Griffith's modified 10-point scale","Allergan","Female","30 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKM18-HULK-INJ","June 4, 2018","December 3, 2018","December 3, 2018","June 18, 2018",,"January 30, 2019","Cosmetic Laser Dermatology, San Diego, California, United States|Suzanne Bruce and Associates, PA, The Center for Skin Research, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03559972"
66,"NCT03539549","Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)",,"Completed","No Results Available","Macular Degeneration","Drug: Abicipar pegol","Change from Baseline in Best Corrected Visual Acuity ( BCVA) in the study eye using Early-Treatment Diabetic Retinopathy study (ETDRS) Scale|Percentage of Participants with Change from Baseline in Full Ophthalmic Exam Findings [i.e. Slit Lamp Exam, Intraocular Pressure (IOP) Measurements, Funduscopic Exam]|Changes from Baseline in General Physical Condition as Measured through General Physical Exam|Percentage of Participants with Changes from Baseline in Vital Signs (Blood Pressure, Pulse Rate, ECG)|Percentage of Participants with Change from Baseline in Clinically Relevant Laboratory Values (Serum Chemistry, Hematology, Urinalysis)|Percentage of Participants with anti-abicipar antibiodies measured in serum|Change from Baseline in Central Retinal Thickness (CRT) in the Study eye|Percentage of Patients with Best Corrected Visual Acuity (BCVA) Change from Baseline ≤15 Letters in the Study Eye|Change from Baseline in BCVA in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1771-201-008","May 23, 2018","February 27, 2019","March 20, 2019","May 29, 2018",,"January 14, 2020","Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States|Retina Associates Southwest, PC, Tucson, Arizona, United States|Northwest Arkansas Retina Associates, P.A., Springdale, Arkansas, United States|Win Retina, Arcadia, California, United States|Retina Consultants of Orange County, Fullerton, California, United States|Mark B. Kislinger, MD, Inc., Glendora, California, United States|Atlantis Retina Institute (Atlantis Eyecare), Huntington Beach, California, United States|South Coast Retina Center, Long Beach, California, United States|N. California Retina Vitreous Associates Medical Group, INC., Mountain View, California, United States|California Eye Specialists Medical Group, Inc, Pasadena, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Retinal Consultants Medical Group, Inc., Sacramento, California, United States|Colorado Retina Associates, Golden, Colorado, United States|Retina Specialty Institute, Pensacola, Florida, United States|Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Georgia Retina, P.C., Marietta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|Raj K. Maturi, MD, PC, Indianapolis, Indiana, United States|Sabates Eye Center, Leawood, Kansas, United States|Sierra Eye Associates, Reno, Nevada, United States|Capital Region Retina, PLLC, Albany, New York, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Pennsylvania Retina Specialists, P.C., Camp Hill, Pennsylvania, United States|Charleston Neuroscience Institute, Ladson, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Retina Research Institute of Texas, Abilene, Texas, United States|Texas Retina Associates, Arlington, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Texan Eye, Austin, Texas, United States|Retinal Consultants of Houston, Houston, Texas, United States|Premiere Retina Specialists, Midland, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States|Strategic Clinical Research Group, LLC, Willow Park, Texas, United States|Retina Institute of Virginia, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03539549"
67,"NCT03519204","Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults",,"Completed","Has Results","Lip Enhancement","Device: JUVÉDERM® VOLBELLA® XC with Lidocaine|Other: No-treatment Control","Percentage of Participants With a ≥1-point Increase (Improvement) on the Evaluating Investigator's (EI's) Assessed 5-point Lip Fullness Scale (LFS)|Percentage of Participants With a ≥1-point Increase (Improvement) Based on the Participant's Assessed 5-point LFS|Change From Baseline in Overall Lip Volume|Percentage Change From Baseline in Lip Surface Area|Procedural Pain Score|Number of Participants With Injection Site Responses (ISRs)|Number of Participants With Treatment-emergent Adverse Events (TEAEs)","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","VOLBELLA-005","January 28, 2016","March 30, 2018","March 30, 2018","May 8, 2018","June 21, 2019","August 6, 2019","General Hospital of Southern Theatre Command, Guangzhou, Guangdong, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|China-Japan Friendship Hospital, Beijing, China|Peking University Third Hospital, Beijing, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03519204/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03519204/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03519204"
68,"NCT03441581","3030-401-002 ELX BAM Study",,"Active, not recruiting","No Results Available","Irritable Bowel Syndrome With Diarrhea","Drug: Eluxadoline","Change from baseline in average Bristol Stool Form Scale (BSFS) score over 4 weeks of treatment period|Percentage of Participants with Treatment Emergent Adverse Events|Percentage of participants who experienced clinically significant change in Laboratory Tests|Percentage of Participants who experienced clinically significant change in Vital Signs|Percentage of Participants with Change from Baseline in General Physical Condition as Measured through General Physical Exam|Change from baseline in the 4-week average of daily bowel movement frequency during the treatment period|Change from baseline in the 4-week average of daily worst abdominal pain scores during the treatment period|Change from baseline in the 4-week average of daily bloating scores during the treatment period|Change from baseline in the 4-week average of urgency-free days in a week during the treatment period|Proportion of participants with any fecal incontinence during the treatment period|Change from baseline in IBS-QOL score at the end of the treatment period|Change from baseline in serum 7αC4 levels at the end of the treatment period|Cmax: Maximum Plasma concentration|Cmin: Minimum Plasma Concentration|AUCtau: Area under the plasma concentration-time curve during the dosing interval|Tmax: Time to Cmax|t1/2: Half-Life|CL: Apparent clearance for eluxadoline|V: Apparent volume of distribution for eluxadoline","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3030-401-002","February 23, 2018","March 31, 2020","March 31, 2020","February 22, 2018",,"December 9, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03441581"
69,"NCT03438266","A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula",,"Completed","Has Results","Age-related Volume Deficit in the Mid-face","Device: JUVÉDERM VOLUMA® XC injectable gel with cannula|Device: JUVÉDERM VOLUMA® XC injectable gel with needle","Change From Baseline in Mid-Face Volume Deficit Scale (MFVDS) Score|Percentage of Participants With at Least a 1-Point Improvement (Decrease From Baseline) in MFVDS Score|Change From Baseline in FACE-Q Satisfaction With Cheeks Questionnaire Score|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","Allergan","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1650-801-008","February 5, 2018","May 29, 2018","August 2, 2018","February 19, 2018","August 5, 2019","August 5, 2019","Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States|Art of Skin MD, Solana Beach, California, United States|Baumann Cosmetic and Research Institute, Miami, Florida, United States|Saint Louis University Dermatology, Saint Louis, Missouri, United States|Skin Laser & Surgery Specialists of NY/NJ, Hackensack, New Jersey, United States|Rhoda S. Narins, MD, PC, White Plains, New York, United States|Aesthetic Solutions, PA, Chapel Hill, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03438266/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03438266/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03438266"
70,"NCT03430986","Safety and Effectiveness of VOLUMA With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults.",,"Completed","No Results Available","Nose Enhancement","Device: VOLUMA With Lidocaine|Other: No-treatment control","Volume change from baseline in the nose area|Percentage of Participants who note ""Improved"" or ""Much Improved"" as Assessed by the Evaluating Investigator using the Global Aesthetic Improvement Scale (GAIS)|Percentage of Participants who note ""Improved"" or ""Much Improved"" as Assessed by the Participant using the GAIS|Percentage of participants who note ""Satisfied"" or ""Very Satisfied"" with treatment outcome on the Nose Satisfaction Scale (NSS)|Number of Participants with Adverse Events (AEs)","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1894-701-008","February 2, 2018","December 4, 2019","December 4, 2019","February 13, 2018",,"December 23, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Beijing, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, Shanghai, China|Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Beijing, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT03430986"
71,"NCT03429556","Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty",,"Terminated","Has Results","Abdominoplasty","Biological: Botulinum Neurotoxin Serotype E|Drug: Placebo","Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)|Participants Overall Assessment of Pain Using the NPRS After Discharge|Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)|Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories|Number of Doses of Rescue Medications Used","Allergan","All","23 Years to 55 Years   (Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EB001-ABD201","May 8, 2018","July 10, 2018","July 10, 2018","February 12, 2018","August 5, 2019","August 5, 2019","Huntington Ambulatory Surgery Center, Pasadena, California, United States|Lotus Clinical Research, LLC, Pasadena, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03429556/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03429556/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03429556"
72,"NCT03426345","Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02",,"Recruiting","No Results Available","Gastroparesis|Diabetes Mellitus","Drug: Relamorelin|Drug: Placebo","Percentage of patients meeting the diabetic gastroparesis symptom responder criterion during the 12 weeks of treatment|Percentage of patients meeting the vomiting symptom responder criterion in each of the last 6 of the 12 weeks of treatment|Percentage of Patients Meeting the Nausea Responder Criterion|Percentage of Patients Meeting the Abdominal Pain Responder Criterion|Percentage of Patients Meeting the Bloating Responder Criterion|Percentage of Patients Meeting the Postprandial Fullness Responder Criterion|Number of Patients who experienced one or more Treatment Emergent Adverse Event (TEAE)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RLM-MD-02|2017-002177-20","February 20, 2018","January 18, 2020","January 18, 2020","February 8, 2018",,"December 18, 2019","North Alabama Research Center, LLC, Athens, Alabama, United States|Synexus Clinical Research US - Simon Williamson Clinic, Birmingham, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Adobe Clinical Research LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastorenterology, North Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|HCP Clinical Research LLC, Anaheim, California, United States|GW Research Inc, Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Diagnamics Inc., Encinitas, California, United States|Fresno Clinical Research Center, Fresno, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Angel City Research Inc., Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|United Medical Doctors, Murrieta, California, United States|Stanford Hospital, Palo Alto, California, United States|TriWest Research Associates, Poway, California, United States|Optimal Research California, San Diego, California, United States|Care Access Research, San Pablo, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|New Hope Research Development, Whittier, California, United States|Synexus / Synexus Clinical Research US, Inc. - Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Synexus Clinical Research US, Inc. - Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Visionary Investigators Network, Aventura, Florida, United States|Leonard J. Dunn, MD, Clearwater, Florida, United States|ALL Medical Research LLC, Cooper City, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|UF Health Jacksonville - Gastroenterology Emerson, Jacksonville, Florida, United States|Panax Clinical Research, LLC., Miami Lakes, Florida, United States|Sanchez Clinical Research, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Synexus, Pinellas Park, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, Buford, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Synexus Clinical Research US, Inc., Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|American Research, LLC, Jeffersonville, Indiana, United States|Gastroenterology of Southern Indiana, New Albany, Indiana, United States|Integrated Clinical Trial Services Inc, West Des Moines, Iowa, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|Tri-State Gastroenterology, Crestview Hills, Kentucky, United States|Delta Research Partners, LLC, Bastrop, Louisiana, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Clinical Trials of SWLA, LLC / Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Trialspark - Sood, Bowie, Maryland, United States|Clinvax: Capital Diabetes and Endocrine Associates/BLT Netwrok LLC, Camp Springs, Maryland, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Rockville Internal Medicine, Rockville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Coastal Research Associates, Inc., South Weymouth, Massachusetts, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Aa Mrc, Llc, Flint, Michigan, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Diabetes and Endocrine Associates, PC, Omaha, Nebraska, United States|Heartland Clinical Research, Inc, Omaha, Nebraska, United States|USMA Clinical Research, LLC, Elizabeth, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Trialspark - Silverman, Forest Hills, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Queens Hospital Center, Jamaica, New York, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|Winthrop-University Hospital, Mineola, New York, United States|Carolina Digestive Health Associates, PA, Davidson, North Carolina, United States|Vidant Multispeciality Clinic - Kinston, Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|Dayton Gasteroenterology,Inc., Beavercreek, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|The MetroHealth System MHS, Cleveland, Ohio, United States|Digestive Disease & Surgery Institute, Cleveland, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Clinical Inquest Center Ltd., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Partners in Clinical Research, LLC, Cumberland, Rhode Island, United States|Care Access Research, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Texas Tech University Health Sciences, Center Division of Gastroenterology, El Paso, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Memorial Hermann Southeast Medical Plaza 1, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Digestive Center of South Texas, San Antonio, Texas, United States|Sagact PLLC., San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Digestive & Liver Disease Center of San Antonio, PLLC, San Antonio, Texas, United States|Digestive & Liver Disease, San Antonio, Texas, United States|Texas Digestive Disease Consultantsc, Southlake, Texas, United States|Gastrointestinal and Liver disease consultants, Sugar Land, Texas, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|Centro de Investigaciones Medicas Mar del Plata SRL, Mar del Plata, Buenos Aires, Argentina|CIPREC, Buenos Aires, Capital Federal, Argentina|Consultorios Asociados de Endocrinologia e Investigacion Cl, Buenos Aires, Ciudad Autonoma De Buenos Aire, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de Hematologia y Medicina Clinica Dr. Ruben Davoli, Rosario, Santa Fe, Argentina|Centro Modelo de Cardiologia, San Miguel de Tucuman, Tucuman, Argentina|Hospital Sirio Libanes, Buenos Aires, Argentina|Sanatorio Guemes, Caba, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Instituto de Investigaciones Clinicas Cba, Córdoba, Argentina|ILAIM, Córdoba, Argentina|CIAD Moron, Moron, Argentina|Ordination, Sankt Stefan ob Stainz, Styria, Austria|Medizinische Universitat Innsbruck, Innsbruck, Tirol, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria|Privatklinik Wehrle-Diakonissen, Salzburg, Austria|Oo. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|Krankenanstalt Rudolfstiftung Wien, Vienna, Austria|KH Hietzing, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|AZ Sint Lucas Brugge, Brugge, West-Vlaanderen, Belgium|Hopitaux Iris Sud - Joseph Bracops, Brussels, Belgium|Hospital Universitario Walter Cantidio, Fortaleza, Ceara, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, ParanÃ¡, Brazil|Hospital Universitario Joao de Barros Barreto, Belem, Para, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre/ Nucleo de Pesquisa Clinica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, Rio Grande Do Sul, Brazil|NOOVA, Florianópolis, Santa Catarina, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clinica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica em Campinas, Campinas, Sao Paulo, Brazil|Instituto de Estudos E Persquisas Clinica Do Ceara IEP/CE - Oncology, Fortaleza, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, Brazil|Universidade de Sao Paulo (USP) - Hospital das Clinicas da F, Sao Paulo, Brazil|Instituto de Pesquisa ClÍnica e Medicina AvanCada Ltda, SÃo Paulo, Brazil|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Eastern Health, St. John's, Newfoundland and Labrador, Canada|Medical Clinic, Bridgewater, Nova Scotia, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - CHUM, Montreal, Quebec, Canada|IPS Rodrigo Botero SAS, Medellin, Antioquia, Colombia|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundacion Bios, Barranquilla, Atlantico, Colombia|Healthy Medical Center, Zipaquira, Cundinamarca, Colombia|Medplus Mp, Bogota, Distrito Capital De Bogotá, Colombia|Endocare Ltda., Bogota, Distrito Capital De Bogotá, Colombia|Asociación Colombiana de Diabetes, Teusaquillo, Distrito Capital De Bogotá, Colombia|Clinica Meta, Villavicencio, Meta, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|Gentofte Hospital/ Steno Diabetes Center Copenhagen, Hellerup, Copenhagen, Denmark|Gastroenheden, Hvidovre hospital, Hvidovre, Copenhagen, Denmark|Endocrinology, Aalborg University Hospital, Aalborg, Denmark|MEA KFA, Aarhus, Denmark|Nordsjaellands Hospital, Hillerød, Denmark|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-SWÃƒÂ¼rttemberg, Germany|Praxis Dr. Etzrodt-Walter und Kollegen, Ulm, Baden-württemberg, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg Vorpommern, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Diabetologische Schwerpunktpraxis, Bad Berleburg, Germany|Clinical Research Unit, Giessen, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Klinikum Region Hannover/KRH Siloah, Hannover, Germany|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Hetenyi Geza Hospital, Szolnok, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Semmelweis University, Budapest, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|Coromed SMO, Pecs, Hungary|Szegedi Tudomanyegyetem, Szeged, Hungary|Polana-D, LLC, Daugavpils, Latvia|Kraslava Hospital, Kraslava, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Clinicos Asociados BOCM SC, Benito Juarez, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion, Tlalpan, Distrito Federal, Mexico|Centro de Investigacion Morales Vargas - CIMOVA, León, Guanajuato, Mexico|CIADEN (Centro de Investigación y Atención de Diabetes, Endocrinología y Nutrición), Durango, Guillermina, Mexico|Centro de Diabetes de Pachuca, Pachuca, Hidalgo, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, Guadalajara, Jalisco, Mexico|Consultorio Medico, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C., Guadalajara, Jalisco, Mexico|Mentrials Sa de Cv, Distrito Federal, Mexico DF, Mexico|Clinica Omega (CAIFRC OMEGA S.C.), Mexico, Mexico DF, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Mexico Distrito Federal, Mexico|Instituto de Diabetes Obesidad y Nutricion SC, Cuautla, Morelos, Mexico|Accelerium Clinical Research, Monterrey, Nuevo Leon, Mexico|Oncologico Potosino, San Luis Potosi, San Luis Potosí, Mexico|Investigacion Medica Sonora, S.C., Hermosillo, Sonora, Mexico|Clínica de Mérida, Mérida, Yucatán, Mexico|Practice Dr Gerardo Gonzalez, Acapulco, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|Centro Medico Christus Muguerza Sur, Nuevo Leon, Mexico|Centro Especializado en Investigacion Clinica S.C., Veracruz, Mexico|Sociedad de Metabolismo y Corazon, S.C., Veracruz, Mexico|ClinTrial Medical Center, Pulmonology Department, Dobrosloveni, Oltenia, Romania|Sana Medical Center, Bucharest, Romania|National Institute of Endocrinology, Bucharest, Romania|AMES Research Center SRL, Calarasi, Romania|Polisano-Clinic, Sibiu, Romania|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|GUZ Â""Saratov City Clinical Hospital 9, Saratov, Saratov Region, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny Novgorod, Volga, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Millitary-medical Academy, department of hospital therapy, Saint-Petersburg, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Russian Federation|Saratov City Clinical Hospital 12, Saratov, Russian Federation|FARMOVS, Bloemfontein, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clincal Reaserch Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Silverton, Gauteng, South Africa|Soweto CTC, Soweto, Gauteng, South Africa|Endocare, Paarl, Western Cape, South Africa|Moriana Clinical Research, Brandfort, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|SU"" Clinic of medical academy"" of SI ""Dnepropetrovsk medical cacadamy of MoH of Ukraine"", Dnipro, Ukraine|Queens Medical Centre, Nottingham, East Midland, United Kingdom|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|St George's Hospital, Tooting, London, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Blackpool, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|Wingate Institute of Neurogastroenterology and Barts Health Trust and the Royal London Hospital, London, United Kingdom|University College London Hospita, London, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|MAC Clinical Research, GAC House, Stockton-on-Tees, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03426345"
73,"NCT03425721","Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers",,"Recruiting","No Results Available","Dermal Nodule","Other: No Intervention","Histological Sampling|Microbiological Sampling","Allergan","All","18 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CMO-US-FAS-0486","November 21, 2017","January 1, 2020","January 1, 2020","February 8, 2018",,"June 5, 2019","Skin Care and Laser Physicians (SCLP) of Beverly Hills, West Hollywood, California, United States|Assure Surgical, P.C., New York, New York, United States|Integrated Specialist Healthcare, Miranda, New South Wales, Australia|Dermatology Insitute of Victoria, South Yarra, Victoria, Australia|Aalst Dermatology Clinic, Aalst, Belgium|Carruthers and Humphrey Cosmetic Medicine, Vancouver, British Columbia, Canada|Nowell Solish, Toronto, Ontario, Canada|Klinik Für Dermatologie Und Allergologie Der Ruhr-Universität Bochum St. Josef Hospital, Bochum, Germany|Hautzentrum Koeln, Cologne, Germany|Skin Concept, Muenchen, Germany|Servizio Ambulatoriale di Medicina, Rome, Italy|Erasmus MC, Rotterdam, Netherlands|Knysna Advanced Medical Centre, Knysna, South Africa",,"https://ClinicalTrials.gov/show/NCT03425721"
74,"NCT03425253","Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour","JAWLINE","Active, not recruiting","No Results Available","Contour","Drug: BELKYRA®|Device: Juvéderm® VOLUMA™ with Lidocaine","Percentage of subjects who show ≥ 1-point jawline improvement from baseline on the Allergan Loss ofJawline Definition Scale (ALJDS)|Change from baseline to last BELKYRA® treatment on ALJDS|Change from baseline to final study visit for FACE-Q™ Satisfaction with lower face and jawline score|Change from baseline to final study visit for FACE-Q™ Appraisal of Neck|Change from baseline to final study visit for FACE-Q™ Appraisal of Area under Chin|Change from baseline to final study visit for CR (Clinician-Reported) Submental Fat Rating Scale (SMFRS)|Change from baseline to final study visit for PR (Patient-Reported) Submental Fat Rating Scale (SMFRS)|Change from baseline to final study visit for Submental Skin Laxity Grade (SMSLG) score|Change from baseline to final study visit in jawline definition based on Independent Reviewer assessment using the ALJDS and photographic images","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-MA-FAS-0513","February 2, 2018","December 5, 2019","December 5, 2019","February 7, 2018",,"November 29, 2019","Darlinghurst Dermatology, Darlinghurst, New South Wales, Australia|Living Art, East Melbourne, Victoria, Australia|Dermatology Institute of Victoria, South Yarra, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03425253"
75,"NCT03420781","A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03",,"Enrolling by invitation","No Results Available","Gastroparesis|Diabetes Mellitus","Drug: Relamorelin|Drug: Placebo","Change from Baseline to Week 12 of this study in the weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)|Percentage of patients meeting the vomiting symptom responder criterion in each of the last 6 weeks of the first 12 week Treatment Period|Nausea Week 12 Responder|Abdominal Pain Week 12 Responder|Bloating Week 12 Responder|Postprandial Fullness Week 12 Responder|DGSSS at Week 40|Vomiting Frequency at Week 40|Vomiting Week-40 Responder|DGSSS at Week 46|Number of Vomiting Episodes at Week 46|Number of Patients who experienced one or more Treatment Emergent Adverse Event (TEAE)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","960","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RLM-MD-03","January 24, 2018","December 6, 2020","December 6, 2020","February 5, 2018",,"December 9, 2019","Pinnacle Research Group, Anniston, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|Simon Williamson Clinic, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Avant Research Associates, Huntsville, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Del Sol Research Management, LLC, Chandler, Arizona, United States|Synexus Clinical Research US, Inc., Fountain Hills, Arizona, United States|Central Arizona Medical Associates, Mesa, Arizona, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Adobe Clinical Research LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|CHI St. Vincent's Gastroenterology: John Tyler Baber, MD, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|GW Research Inc, Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Citrus Valley Gastroenterology Clinic, Covina, California, United States|Diagnamics Inc., Encinitas, California, United States|Fresno Clinical Research Center, Fresno, California, United States|Valley View Wellness and Medical Center - VVCRD Clinical Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Angel City Research Inc., Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|United Medical Doctors, Murrieta, California, United States|Stanford Hospital, Palo Alto, California, United States|TriWest Research Associates, Poway, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|Optimal Research California, San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Care Access Research, San Pablo, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Synexus Clinical Research, US, Santa Rosa, Santa Rosa, California, United States|Upland Clinical Research, Upland, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|New Hope Research Development, Whittier, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Synexus, Colorado Springs, Colorado, United States|Denver Esophageal and Stomach Center, Englewood, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|TrialSpark, Inc., Washington, District of Columbia, United States|Visionary Investigators Network, Aventura, Florida, United States|Gastro Florida, Clearwater, Florida, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research LLC, Cooper City, Florida, United States|American Research Institute, Inc, Cutler Bay, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Hometown Urgent Care and Research, Inverness, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Cfagi Llc, Maitland, Florida, United States|Panax Clinical Research, LLC., Miami Lakes, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|Sanchez Clinical Research, Inc., Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Top Medical Research, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Gulf Region Clinical Research Institute, Pensacola, Florida, United States|Synexus, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Gastro Florida, Tampa, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, Buford, Georgia, United States|Summit Clinical Research, LLC., Carnesville, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Northwest Clinical Trials, Inc., Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Synexus Clinical Research US, Inc ., Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|Gastroenterology of Southern Indiana, New Albany, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|Tri-State Gastroenterology, Crestview Hills, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, Bastrop, Louisiana, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Trialspark - Silverman, Bowie, Maryland, United States|Clinvax: Capital Diabetes and Endocrine Associates/BLT Netwrok LLC, Camp Springs, Maryland, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Frederick Gastroenterology Associates, PA an Elligo Health Research Site, Frederick, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Coastal Research Associates, Inc., South Weymouth, Massachusetts, United States|Boston VA Healthcare System, West Roxbury, Massachusetts, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Aa Mrc, Llc, Flint, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Troy Gastroenterology, PC dba Center for Digestive Health, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|Minnesota Gastroenterology, P.A., Coon Rapids, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|National Diabetes and Obesity Research Institute - Gen1 Research, Biloxi, Mississippi, United States|Synexus Clinical Research US, Inc., Saint Louis, Missouri, United States|Montana Medical Research, Missoula, Montana, United States|Diabetes and Endocrine Associates, P.C., Omaha, Nebraska, United States|Heartland Clinical Research, Inc`, Omaha, Nebraska, United States|Synexus Clinical Research, Henderson, Nevada, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Clinical Research of South Nevada - CROSN, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology, Brick, New Jersey, United States|Synexus Clinical Research US, Inc., Bridgeton, New Jersey, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|CHEAR Center LLC, Bronx, New York, United States|Trialspark - Silverman, Forest Hills, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Queens Hospital Center, Jamaica, New York, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare-Charlotte, Charlotte, North Carolina, United States|Carolina Digestive Health Associates, PA, Concord, North Carolina, United States|Carolina Digestive Health Associates, PA, Davidson, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Kinston Medical Specialists, P.A., Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Trial Management Associates, LLC, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc., Cincinnati, Ohio, United States|The MetroHealth System MHS, Cleveland, Ohio, United States|Digestive Disease & Surgery Institute, Cleveland, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Clinical Inquest Center Ltd., Dayton, Ohio, United States|Premier Clinical Research d.b.a. STAT Research, Franklin, Ohio, United States|Family Practice Center of Wadsworth, Inc. DBA New Venture Medical Research, Wadsworth, Ohio, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Partners in Clinical Research, LLC, Cumberland, Rhode Island, United States|Care Access Research, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Medical Research South, Charleston, South Carolina, United States|Carolina Medical Research, Clinton, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Synexus Clinical Research, Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastroenterology Centers of the Midsouth, Germantown, Tennessee, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Avant Research Associates,LLC, Austin, Texas, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Texas Tech University Health Sciences, Center Division of Gastroenterology, El Paso, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|DHAT Research Institute, Garland, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|SAGACT PLLC., San Antonio Gastroenterology Associates, PA, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Digestive & Liver Disease Center of San Antonio, PLLC, San Antonio, Texas, United States|Gastrointestinal and Liver disease consultants, Sugar Land, Texas, United States|Synexus Clinical Research US, Inc., Layton, Utah, United States|Synexus Clinical Research US, Inc., Murray, Utah, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Gastroenterology Consultants of Southwest Virginia, Inc., Roanoke, Virginia, United States|Cardinal Internal Medicine Associates, PC, Woodbridge, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|CIMEL, Lanús, Buenos Aires Province, Argentina|DIM Clinica Privada, Ramos Mejia, Buenos Aires Province, Argentina|Centro de Investigaciones Medicas Mar del Plata SRL, Mar del Plata, Buenos Aires, Argentina|CIAD Moron, Moron, Buenos Aires, Argentina|Consultorios Asociados de Endocrinologia e Investigacion Cl, Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de Hematologia y Medicina Clinica Dr. Ruben Davoli, Rosario, Santa Fe, Argentina|Centro Modelo de Cardiologia, San Miguel de Tucuman, Tucuman, Argentina|Hospital Sirio Libanes, Buenos Aires, Argentina|Sanatorio Guemes, Caba, Argentina|CIPREC, Ciudad Autonoma de Buenos Aires, Argentina|ILAIM, Cordoba, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Instituto de Investigaciones Clinicas Cba, Córdoba, Argentina|Nepean Hospital, Kingswood, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordination, Sankt Stefan ob Stainz, Styria, Austria|Medizinische Universitat Innsbruck, Innsbruck, Tirol, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch`, Vorarlberg, Austria|Klinikum Klagenfurt am WÃ¶rthersee, Klagenfurt, Austria|Privatklinik Wehrle-Diakonissen, Salzburg, Austria|Oö. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|AZ Sint Lucas Brugge, Brugge, West-Vlaanderen, Belgium|Hopitaux Iris Sud - Joseph Bracops, Brussels, Belgium|CHC - Clinique Saint-Joseph, Liege, Belgium|Instituto de Estudos e Pesquisas Clinicas do Ceara IEP/CE - Oncology, Fortaleza, Ceara, Brazil|Hospital Universitário Walter Cantídio, Fortaleza, Ceara, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Parana, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, Rio Grande Do Sul, Brazil|NOOVA, Florianópolis, Santa Catarina, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clinica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica de Campinas, Campinas, Sao Paulo, Brazil|Hospital Universitário João de Barros Barreto, Belém, Brazil|Instituto de Pesquisa ClÍnica e Medicina AvanCada Ltda, Sao Paulo, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, Brazil|Hospital de Clínicas da FMUSP - Centro de Pesquisas Clínicas, Sao Paulo, Brazil|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|MHAT Dr. Tota Venkova AD, Gabrovo, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|Sliven, MHAT ""Hadzhi Dimitar"", Sliven, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|Acibadem City Clinic Oncology Center, Sofia, Bulgaria|Medical centre Synexus Sofia EOOD, Sofia, Bulgaria|Medical Center Synexus Sofia, Stara Zagora, Bulgaria|MHAT Dobrich AD, Targovishte, Bulgaria|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Eastern Health, St. John's, Newfoundland and Labrador, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Etobicoke, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - CHUM, Montreal, Quebec, Canada|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|IPS Rodrigo Botero SAS, Medellín, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundacion BIOS, Barranquilla, Atlantico, Colombia|Endocare Ltda., Bogotá, Cundinamarca, Colombia|Healthy Medical Center, Zipaquira, Cundinamarca, Colombia|Medplus Medicina Prepagada, Bogota, Distrito Capital De Bogota, Colombia|Asociación Colombiana de Diabetes, Teusaquillo, Distrito Capital De Bogotá, Colombia|Clinica Meta, Villavicencio, Meta, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Gentofte Hospital, Hellerup, Copenhagen, Denmark|Gastroenheden, Hvidovre hospital, Hvidovre, Copenhagen, Denmark|Aalborg University Hospital, Aalborg, Denmark|CHU de Bordeaux - HÃ´pital Haut-LÃ©vÃªque, Pessac, Gironde, France|CHRU Nancy, Vandœuvre-lès-Nancy, Grand Est, France|Hopital Louis Mourier, Colombes, France|Corbeil Essonnes, Corbeil Essonnes cedex, France|Grenoble, Grenoble, France|Hospices Civils de Lyon - Hôpital Edouard Herrriot, Lyon Cedex 03, France|CHU Nantes, Nantes Cedex 1, France|Hopital Charles Nicolle, Rouen Cedex, France|Centre de Recherche Clinique, Venissieux, France|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-Wuertemberg, Germany|Praxis Dr. Etzrodt-Walter und Kollegen, Ulm, Baden-WÃ¼rttemberg, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg Vorpommern, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Diabetologische Schwerpunktpraxis, Bad Berleburg, Germany|Clinical Research Unit/ UniversitÃ¤tsklinikum Giessen und Marburg GmbH, Giessen, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|CRH Clinic Siloah, Hannover, Germany|Diabetesinstitut Heidelberg c/o St. Josefskrankenhaus, Heidelberg, Germany|SMO.MD GmbH, Magdeburg, Germany|First Department of Medicine, University of Szeged, Szeged, CsonfrÃ¡d, Hungary|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Hetenyi Geza Hospital, Szolnok, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Synexus Budapest DRS, Budapest, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|SYNEXUS Magyarorszag Kft Debrecen A.S., Debrecen, Hungary|Synexus Magyarország kft. Gyula DRS, Gyula, Hungary|BKS Research Kft Synexus AS, Hatvan, Hungary|Medifarma-98, Nyíregyháza, Hungary|Clinfan Szolgáltató Kft, Szekszard, Hungary|Synexus Magyarorszag Kft, Zalaegerszeg, Hungary|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Andhra Pradesh, India|Anu Hospitals, Vijayawada, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology, Ahmedabad, Gujarat, India|Zydus Hospital, Ahmedabad, Gujarat, India|Apollo Hospitals International Limited - Diabetologist, Ahmedabad, Gujarat, India|Victoria Hospital Bangalore Medical College and Research Institute, Bangalore, Karnataka, India|Lifecare Clinic and Research Centre - Internal Med/Diabetology, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre, Mangalore, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|Chopda Medicare & Research Centre Pvt.Ltd, Magnum Heart Institute, Nashik, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|SP Medical College, Bikaner, Rajasthan, India|S R Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Diabetic Thyroid and Endocrine Centre, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|M.V. Hospital for Diabetes & Diabetes Research Centre, Chennai, Tamil Nadu, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India|Kumudini Devi Diabetes Research Center, Hyderabad, Telangana, India|M V Hospital & Research Centre, Lucknow, Uttar Prandesh, India|Sir Ganga Ram Hospital, New Delhi, India|Soroka University Medical Center, Beer Sheba, Israel|Bnei-Zion MC, Haifa, Israel|E. Wolfson Medical Center, Holon, Israel|Digestive Diseases Institute, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Holy Family Hospital, Nazareth, Israel|Gastroenterology Institute, Petach Tikva, Israel|Endocrinology & Diabetes Center, Safed, Israel|Gastroenterology Institute, Tel Aviv, Israel|Humanitas Research Hospital, Rozzano, Lombardy, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy|Azienda Ospedaliera Rilievo Nazionale Alta Specialita (ARNAS) Garibaldi, Catania, Sicily, Italy|Ospedale Cardinal Massaia, Asti, Italy|University of Bari, Bari, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|AO Universitaria San Martino - IRCCS, Genova, Italy|Federico II University of Naples, Napoli, Italy|Azienda Ospedaliera di Padova, Padua, Italy|IRCCS S.Matteo Hospital Foundation, University of Pavia, Pavia, Italy|University of Pisa - Cisanello Hospital, Pisa, Italy|Policlinico Gemelli, Divisione di Endocrinologia e Malattie del Metabolismo, Rome, Italy|Universita' Di Salerno- Aou Ruggi D'aragona, Salerno, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Clinical Institute Beato Matteo, Vigevano, Italy|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ogorelova Jelena GP, Kraslava, Kraslavas Nov., Latvia|Polana-D, LLC, Daugavpils, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Riga Health Centre, Riga, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Clinicos Asociados BOCM SC, Mexico City, Ciudad De Mexico, Mexico|Mentrials SA DE CV, Mexico City, Distrito Federal, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Distrito Federal, Mexico|Morales Vargas Centro de Investigacion SC, León, Guanajuato, Mexico|Centro de Investigación y Atención de Diabetes - Endocrinología y Nutrición, Durango, Guillermina, Mexico|Centro de Diabetes de Pachuca, Pachuca, Hidalgo, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, S.C., Guadalajara, Jalisco, Mexico|Consultorio Medico, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C., Guadalajara, Jalisco, Mexico|Clinica Omega (CAIFRC OMEGA S.C.), Mexico City, Mexico DF, Mexico|Not yet Instituto de Diabetes Obesidad y Nutricion SC, Cuautla, Morelos, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Tlalpan, Mexico|Centro Especializado en Investigacion Clinica S.C., Boca del Rio, Veracruz, Mexico|Centro de Desarrollo Biomedico S.C.P., Mérida, Yucatán, Mexico|Practice Dr Gerardo Gonzalez, Acapulco, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|Investigación Médica Sonora, S.C., Hermosillo, Mexico|Centro Medico Christus Muguerza Sur, Nuevo Leon, Mexico|Oncologico Potosino, San Luis Potosi, Mexico|Sociedad de Metabolismo y Corazon, S.C., Veracruz, Mexico|West Visayas State University Medical Center, IloIlo City, IloIlo, Philippines|St. Luke's Medical Center, Quezon City, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Manila Doctors Hospital, Ermita, Manila, Metropolitan Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metropolitan Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Lesser Poland, Poland|Zamość, Zamość, Lublin, Poland|CenterMed Krakow Ltd, Krakow, Malopolska, Poland|Oddzial Gastroenterologii Mazowieckie Centrum Rehabilitacji Stocer sp. Z o.o., Pruszków, Masovian, Poland|University Hospital Białystok, Białystok, Podlaskie, Poland|NZOZ Vita - Diabetica Malgorzata Buraczyk, Diabetes Clinic, Bialystok, Podlaski, Poland|Endoskopia Sp. Z O.O., Sopot, Pomorskie, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Warmia-Mazury, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Silmedic Sp z o o, Katowice, Poland|DRS Katowice, Katowice, Poland|Synexus Polska Sp. z o.o. Oddzial w Lodzi, Lodz, Poland|Instytut Medycyny Wsi im. Witolda Chodzki w Lublinie, Lublin, Poland|Synexus Polska Sp. z o.o.Oddzial w Poznaniu, Poznan, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Powiatowe Centrum Medyczne w Wolowie Sp. z o.o., Wołów, Poland|DRS Wroclaw, Wroclaw, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|ClinTrial Medical Center, Pulmonology Department, Dobrosloveni, Oltenia, Romania|Sana Medical Center, Bucharest, Romania|Cabinet Medical De Nutritie Si Boli Metabolice Dr. Nicoleta, Bucharest, Romania|University Emergency Militare Central Dr.Carol Davila, Bucharest, Romania|National Institute of Endocrinology, Bucharest, Romania|Societatea Civila Medicala, Bucharest, Romania|AMES Research Center SRL, Calarasi, Romania|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny Novgorod, Volga, Russian Federation|State Budgetary Healthcare Institution Of Arkhangelsk Region Suvorova 1, Arkhangelsk, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Millitary-medical Academy, department of hospital therapy, Saint-Petersburg, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Russian Federation|Saratov City Clinical Hospital 9, Saratov, Russian Federation|Saratov City Clinical Hospital 12, Saratov, Russian Federation|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|FARMOVS, Bloemfontein, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clincal Reaserch Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Pretoria, Gauteng, South Africa|Soweto CTC, Soweto, Gauteng, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|Jakaranda Hospital, Pretoria, South Africa|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital Universitario la Paz, Madrid, Spain|Hospital Universitario Principe de Asturias, Madrid, Spain|Hospital Universitario De Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|City Hospital 3, Kryvyi Rih, Dnipropetrovsk, Ukraine|Limited Liability Company ""Medical Center ""Salutem"", Vinnitsa, Vinnyts'ka Oblast', Ukraine|Chernihiv City Hospital No 2 of Chernihiv City Council, Chernihiv, Ukraine|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Regional Public Organization ""Chernivtsi Regional Endocrinology Center"", Chernivtsi, Ukraine|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Ukraine|SU"" Clinic of medical academy"" of SI ""Dnepropetrovsk medical cacadamy of MoH of Ukraine"", Dnipro, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Kharkiv City Clinical Hospital 2 named of Prof. O.O. Shalimov, Kharkiv, Ukraine|GI ""L.T. Maloi National institute of therapy NAMS of Ukraine"", Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Kyiv municipal clinical endocrinological center, Kyiv, Ukraine|Medical and Diagnostic Center ADONIS, Kyiv, Ukraine|Medical Center of Edelweiss Medics LLC, Kyiv, Ukraine|Medical Center of Medbud-Clinic LLC, Kyiv, Ukraine|Kyiv Railway Clinical Hospital No-2 of Branch of Healthcare Center of the PJSC Ukrainian Railway , Endocrynology Department, Kyiv, Ukraine|Medical Center Universal Clinic Oberig, Kyiv, Ukraine|Administration of Medical Service and Rehabilitation of State Joint-Stock Holding Company Artem, Kyiv, Ukraine|Institute of Endocrinology and Metabolism im. V. P. Komisarenka NAMS Ukraine, Kyiv, Ukraine|Mykolayiv City Hospital 1, Mykolaiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Odesa regional clinical hospital, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Municipal Institution of Sumy Regional Council Sumy Regional Clinical Hospital, Sumy, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Medica Clinical Investigational Center of Medical Center Health Clinic, LLC, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|City Clinical Hospital N 1, Vinnytsia, Ukraine|Scientific and Research Institute of Invalid Rehabilitation of MOH of Ukraine on the base of Pirogov National Medical University, Vinnytsya, Ukraine|Municipal Institution 6th City Clinical Hospital, Dept of Gastroenterology, Zaporizhzhia, Ukraine|Municipal Institution City Hospital No. 7, Zaporizhzhia, Ukraine|Communal or Municipal Institution ""Zaporizhzhia Regional Clinical Hospital"" of the Zaporizhzhia Regional Council, Regional Center for the Diagnosis, Treatment and Prophylaxis or Prevention of Gastroenterologic Diseases, Zaporizhzhya, Ukraine|Queens Medical Centre, Nottingham, East Midland, United Kingdom|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Blackpool, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|Synexus Lancashire Dedicated Research Centre, Chorley, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Synexus Hexham Dedicated Research Centre, Hardwick, United Kingdom|Synexus North Tees Clinical Research Centre, Hardwick, United Kingdom|Synexus Merseyside Dedicated Research Centre, Liverpool, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|Wingate Institute of Neurogastroenterology and Barts Health Trust and the Royal London Hospital, London, United Kingdom|University College London Hospita, London, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|MAC Clinical Research, GAC House, Stockton-on-Tees, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03420781"
76,"NCT03400202","Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles",,"Completed","No Results Available","Periorbital Hyperpigmentation","Device: Skin imaging|Other: Facial cleanser","Dark Circles Severity Scale Score|Classification Type of Dark Circles Score|Subject Questionnaire on Dark Circles, Medical History, and Lifestyle Habits","Allergan","All","25 Years to 50 Years   (Adult)",,"44","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SCRIC17-PHYEYE-01","February 2, 2018","November 7, 2018","November 7, 2018","January 17, 2018",,"January 23, 2019","SkinMedica Clinical Research and Innovation Center, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03400202"
77,"NCT03396042","Natural History Study of CEP290-Related Retinal Degeneration",,"Recruiting","No Results Available","Blindness|Leber Congenital Amaurosis 10|Vision Disorders|Eye Diseases|Eye Diseases, Hereditary|Eye Disorders Congenital|Retinal Disease|Retinal Degeneration",,"Characterize CEP290-related retinal degeneration","Allergan|Editas Medicine, Inc.","All","3 Years to 99 Years   (Child, Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EDIT-NHS01","December 17, 2017","December 31, 2020","December 31, 2020","January 10, 2018",,"August 30, 2019","Bascom Palmer Eye Institute, Miami, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|W.K. Kellogg Eye Center, Ann Arbor, Michigan, United States|Casey Eye Institute - OHSU, Portland, Oregon, United States|Universite Pierre et Marie Curie, Paris, France|Universitaetsklinikum Giessen and Marburg GmbH, Giessen, Germany|Radboud Universitair Medisch Centrum, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03396042"
78,"NCT03383146","A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04",,"Recruiting","No Results Available","Gastroparesis|Diabetes Mellitus","Drug: Relamorelin|Drug: Placebo","Change from Baseline to Week 12 in the weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)|Change from Baseline to Week 52 in weekly average DGSSS|Number of participants with adverse events (AEs)|Number of clinically significant (CS) clinical laboratory values|Vital sign values (heart rate, blood pressure, respiratory rate, and temperature)|Electrocardiogram (ECG) Heart Rate|ECG PR Interval|ECG QRS Interval|ECG QT Interval|ECG QTc Interval|Change from Baseline in hemoglobin A1c (HbA1c) levels|Change from Baseline in anti-relamorelin antibodies","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RLM-MD-04|2017-002144-33","December 19, 2017","July 28, 2021","July 28, 2021","December 26, 2017",,"November 26, 2019","Pinnacle Research Group, Anniston, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|Simon Williamson Clinic, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Avant Research Associates, Huntsville, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Del Sol Research Management, LLC, Chandler, Arizona, United States|Synexus Clinical Research US, Inc., Fountain Hills, Arizona, United States|Central Arizona Medical Associates, Mesa, Arizona, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Adobe Clinical Research LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|CHI St. Vincent's Gastroenterology: John Tyler Baber, MD, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|HCP Clinical Research LLC, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|GW Research Inc, Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Citrus Valley Gastroenterology Clinic, Covina, California, United States|TriWest Research Associates, El Cajon, California, United States|Diagnamics Inc., Encinitas, California, United States|Fresno Clinical Research Center, Fresno, California, United States|Valley View Wellness and Medical Center - VVCRD Clinical Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Angel City Research Inc., Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|United Medical Doctors, Murrieta, California, United States|Stanford Hospital, Palo Alto, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Care Access Research, San Pablo, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Synexus Clinical Research, US, Santa Rosa, Santa Rosa, California, United States|Upland Clinical Research, Upland, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|New Hope Research Development, Whittier, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Synexus, Colorado Springs, Colorado, United States|Denver Esophageal and Stomach Center, Englewood, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|TrialSpark, Inc., Washington, District of Columbia, United States|Visionary Investigators Network, Aventura, Florida, United States|Gastro Florida, Clearwater, Florida, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|American Research Institute, Inc, Cutler Bay, Florida, United States|Top Medical Research, Inc., Cutler Bay, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|UF Health Jacksonville - Gastroenterology Emerson, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Cfagi Llc, Maitland, Florida, United States|Panax Clinical Research, LLC., Miami Lakes, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|Sanchez Clinical Research, Inc., Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Gulf Region Clinical Research Institute, Pensacola, Florida, United States|Synexus, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Gastro Florida, Tampa, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, Buford, Georgia, United States|Summit Clinical Research, LLC., Carnesville, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Synexus Clinical Research US, Inc, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|Gastroenterology of Southern Indiana, New Albany, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Integrated Clinical Trial Services Inc, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|St. Elizabeth Healthcare â€"" Clinical Research Institute, Erlanger, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Trialspark - Silverman, Bowie, Maryland, United States|Clinvax: Capital Diabetes and Endocrine Associates/BLT Netwrok LLC, Camp Springs, Maryland, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Frederick Gastroenterology Associates, PA an Elligo Health Research Site, Frederick, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Coastal Research Associates, Inc., South Weymouth, Massachusetts, United States|Boston VA Healthcare System, West Roxbury, Massachusetts, United States|Biocon Clinical Research, LLC, Caro, Michigan, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Aa Mrc, Llc, Flint, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Troy Gastroenterology, PC dba Center for Digestive Health, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|Minnesota Gastroenterology, P.A ., Coon Rapids, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|National Diabetes and Obesity Research Institute - Gen 1 Research, Biloxi, Mississippi, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Montana Medical Research, Missoula, Montana, United States|Diabetes and Endocrine Associates, PC, Omaha, Nebraska, United States|Heartland Clinical Research, Inc, Omaha, Nebraska, United States|Synexus Clinical Research, Henderson, Nevada, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Clinical Research of South Nevada - CROSN, Las Vegas, Nevada, United States|Advanced Biomedical Research of America ABRA`, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology LLC, Brick, New Jersey, United States|Synexus Clinical Research US, Inc., Bridgeton, New Jersey, United States|AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey, United States|USMA Clinical Research, LLC, Elizabeth, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|CHEAR Center LLC, Bronx, New York, United States|Trialspark - Silverman, Forest Hills, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Queens Hospital Center, Jamaica, New York, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare-Charlotte, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Concord, North Carolina, United States|Carolina Digestive Health Associates, PA, Davidson, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Kinston Medical Specialists, P.A., Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|The MetroHealth System MHS, Cleveland, Ohio, United States|Digestive Disease & Surgery Institute, Cleveland, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Clinical Inquest Center Ltd., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Premier Clinical Research d.b.a. STAT Research, Franklin, Ohio, United States|Family Practice Center of Wadsworth, Inc., Wadsworth, Ohio, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Partners in Clinical Research, LLC, Cumberland, Rhode Island, United States|Care Access Research, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Medical Research South, Charleston, South Carolina, United States|Carolina Medical Research, Clinton, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Synexus Clinical Research, Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastroenterology Centers of the Midsouth, Germantown, Tennessee, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Avant Research Associates,LLC, Austin, Texas, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Methodist Health System Clinical Research Institute, Dallas, Texas, United States|Synexus Clinical Research US, Inc., Dallas, Texas, United States|Texas Tech University Health Sciences, Center Division of Gastroenterology, El Paso, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|Digestive Center of South Texas, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|SAGACT PLLC., San Antonio Gastroenterology Associates, PA, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Digestive & Liver Disease Center of San Antonio, PLLC, San Antonio, Texas, United States|Texas Digestive Disease Consultants, Southlake, Texas, United States|Gastrointestinal and Liver disease consultants, Sugar Land, Texas, United States|Synexus Clinical Research US, Inc., Layton, Utah, United States|Synexus Clinical Research US, Inc., Murray, Utah, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Gastroenterology Consultants of Southwest Virginia, Inc., Roanoke, Virginia, United States|Cardinal Internal Medicine, Woodbridge, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Consultorios Asociados de Endocrinologia e InvestigaciÃ³n Cl, Buenos Aires, Buenos Aires Province, Argentina|Centro de Investigaciones Medicas Mar del Plata SRL, Mar del Plata, Buenos Aires, Argentina|CIPREC, Buenos Aires, Ciudad Autonoma deBuenos Aires, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de Hematologia y Medicina Clinica Dr. Ruben Davoli, Rosario, Santa Fe, Argentina|Centro Modelo de Cardiologia, San Miguel de Tucuman, Tucuman, Argentina|DIM Clinica Privada, Buenos Aires, Argentina|CIMEL, Buenos Aires, Argentina|Hospital Sirio Libanes, Buenos Aires, Argentina|Sanatorio Guemes, Caba, Argentina|CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegian, Cordoba, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Instituto Privado de Investigaciones Clinicas de Cordoba, Córdoba, Argentina|CIAD Moron, Moron, Argentina|Nepean Hospital, Kingswood, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordination, Sankt Stefan ob Stainz, Styria, Austria|Medizinische Universitat Innsbruck, Innsbruck, Tirol, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Klinikum Klagenfurt am WÃ¶rthersee, Klagenfurt, Austria|Privatklinik wehlre-Diakonissen, Salzburg, Austria|Landeskrankenhaus Steyr, Steyr, Austria|Krankenanstalt Rudolfstiftung Wien, Vienna, Austria|KH Hietzing, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|AZ Sint Lucas Brugge, Brugge, West-Vlaanderen, Belgium|CHC - Clinique Saint-Joseph, Liège, Belgium|Hospital Universitário Walter Cantídio, Fortaleza, Ceara, Brazil|NOOVA, Florianópolis, Distrito Capital De Bogotá, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Parana, Brazil|Hospital Universitário João de Barros Barreto - UFPA, Belem, Para, Brazil|Hospital Sao Vicente de Paulo, Campinas, Rio Grande Do Sul, Brazil|Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clínica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica em Campinas, Campinas, Sao Paulo, Brazil|Instituto de Estudos e Pesquisas Clinicas do Ceara IEP/CE - Oncology, Fortaleza, Brazil|Instituto de Pesquisa ClÍnica e Medicina AvanCada Ltda, Sao Paulo, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de SÃ£o Paulo, Sao Paulo, Brazil|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|MHAT Dobrich AD, Targovishte, Turgovishte, Bulgaria|MHAT Ivan Rilski - 2003, Dupnitsa, Bulgaria|MHAT Dr. Tota Venkova AD, Gabrovo, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|MHAT Hadji Dimitar, Sliven, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|Acibadem City Clinic Oncology Center, Sofia, Bulgaria|Medical centre Synexus Sofia EOOD, Sofia, Bulgaria|Medical Center Synexus Sofia, Stara Zagora, Bulgaria|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Patient research centre, St. John's, Newfoundland and Labrador, Canada|Medical Clinic, Bridgewater, Nova Scotia, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Etobicoke, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - CHUM, Montreal, Quebec, Canada|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S., Medellín, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundacion BIOS, Barranquilla, Atlantico, Colombia|Asociación Colombiana de Diabetes, Bogotá, Cundinamarca, Colombia|Healthy Medical Center, Zipaquira, Cundinamarca, Colombia|Endocare Ltda., Bogotá, Distrito Capital De Bogotá, Colombia|Medplus Medicina Prepagada, Bogotá, Distrito Capital, Colombia|Clinica Meta, Villavicencio, Meta, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|Gentofte Hospital, Hellerup, Copenhagen, Denmark|Gastroenheden, Hvidovre hospital, Hvidovre, Copenhagen, Denmark|Aalborg University Hospital, Aalborg, Denmark|MEA KFA, Aarhus, Denmark|CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, Gironde, France|CHRU Nancy, Vandœuvre-lès-Nancy, Grand Est, France|Corbeil Essonnes, Corbeil Essonnes cedex, France|Grenoble, Grenoble, France|Hospices Civils de Lyon - HÃ´pital Edouard Herrriot, LYON Cedex 03, France|CHU Nantes, Nantes Cedex 1, France|CHU de Poitiers, Poitiers, France|Hopital Charles Nicolle, Rouen Cedex, France|Centre de Recherche Clinique, Venissieux, France|Hopital Louis Mourier, Service d'Hepato Gastro-enterologie, Colombes, Île-de-France, France|Praxis Dr. Etzrodt-Walter und Kollegen, Ulm, Baden Wurttemberg, Germany|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-Wurttemberg, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg Vorpommern, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Diabetologische Schwerpunktpraxis, Bad Berleburg, Germany|Diabetespraxis Prenzlauer, Berlin, Germany|Emovis GmbH, Berlin, Germany|Synexus Clinical Research GmbH, Frankfurt am MAin, Germany|Clinical Research Unit, Giessen, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Klinikum Region Hannover/KRH Siloah, Hannover, Germany|Diabetesinstitut Heidelberg c/o St. Josefskrankenhaus, Heidelberg, Germany|DRS Leipzig, Leipzig, Germany|SMO.MD GmbH, Magdeburg, Germany|Klinikum Bogenhausen, Munich, Germany|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Hetenyi Geza Hospital, Szolnok, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Synexus Budapest DRS, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|SYNEXUS Magyarorszag Kft Debrecen A.S., Debrecen, Hungary|Synexus Magyarország kft. Gyula DRS, Gyula, Hungary|BKS Research Kft Synexus AS, Hatvan, Hungary|Medifarma-98, Nyiregyhaza, Hungary|Coromed SMO, Pecs, Hungary|First Department of Medicine, University of Szeged, Szeged, Hungary|Clinfan Szolgáltató Kft, Szekszard, Hungary|Synexus Magyarorszag Kft, Zalaegerszeg, Hungary|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Andhra Pradesh, India|Anu Hospitals, Vijayawada, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology, Ahmedabad, Gujarat, India|Zydus Hospital, Ahmedabad, Gujarat, India|Apollo Hospitals International Limited - Diabetologist, Ahmedabad, Gujarat, India|Surat Institute of Digestive Sciences Hospitals, Surat, Gujarat, India|Lifecare Clinic and Research Centre - Internal Med/Diabetology, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Victoria Hospital Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Mysore Medical College & Research Institute, Mysore, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|Chopda Medicare & Research Centre Pvt.Ltd, Magnum Heart Institute, Nashik, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|S.P.Medical College & Group of Hospitals Bikaner, Bikaner, Rajasthan, India|S R Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Diabetic Thyroid and Endocrine Centre, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|M.V. Hospital for Diabetes & Diabetes Research Centre, Chennai, Tamil Nadu, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India|Kumudini Devi Diabetes Research Center, Hyderabad, Telangana, India|M V Hospital & Research Centre, Lucknow, Uttar Pradesh, India|M.V Hospital and Research Centre, Lucknow, Uttar Pradesh, India|IPGME&R and SSKM Hospital, Kolkata, West Bengal, India|M. S. Ramaiah Medical College and Hospitals, Bangalore, India|Sir Ganga Ram Hospital (SGRH), Delhi, India|Vinaya Hospital & Research Centre, Mangalore, India|Gastroenterology Institute, Tel Aviv`, Tel Aviv, Israel|Soroka University Medical Center, Beer Sheba, Israel|Bnei-Zion MC, Haifa, Israel|The E. Wolfson Medical Center, Holon, Israel|Digestive Diseases Institute, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Holy Family Hospital, Nazareth, Israel|Gastroenterology Institute, Petach Tikva, Israel|Endocrinology & Diabetes Center, Safed, Israel|Gruppo Humanitas - Humanitas Research Hospital, Rozzano, Lombardy, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy|Clinical Institute Beato Matteo, Vigevano, Pavia, Italy|University of Pisa - Cisanello Hospital, Pisa, PI, Italy|Azienda Ospedaliera Rilievo Nazionale Alta Specialita (ARNAS) Garibaldi, Catania, Sicily, Italy|Ospedale Cardinal Massaia, Asti, Italy|University of Bari, Bari, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Federico II University of Naples, Napoli, Italy|Azienda Ospedale-UniversitÃ Padova, Padova, Italy|IRCCS S.Matteo Hospital Foundation, University of Pavia, Pavia, Italy|Policlinico Gemelli, Divisione di Endocrinologia e Malattie del Metabolismo, Rome, Italy|Universita' Di Salerno- Aou Ruggi D'aragona, Salerno, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ogorelova Jelena GP, Kraslava, Kraslavas Nov., Latvia|Polana-D, LLC, Daugavpils, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Riga Health Centre, Riga, Latvia|Siguldas Hospital, Sigulda, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Clinicos Asociados BOCM SC, Mexico, Distrito Federal, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion, Mexico, Distrito Federal, Mexico|Centro de Investigacion Morales Vargas - CIMOVA, León, Guanajuato, Mexico|CIADEN (Centro de Investigación y Atención de Diabetes, Endocrinología y Nutrición), Durango, Guillermina, Mexico|Centro de Diabetes de Pachuca, Pachuca, Hidalgo, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, Guadalajara, Jalisco, Mexico|Consultorio particular, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C/, Guadalajara, Jalisco, Mexico|Medical and Nutritional Trials, Distrito Federal, Mexico DF, Mexico|Clinica Omega (CAIFRC OMEGA S.C.), Mexico, Mexico DF, Mexico|Instituto de Diabetes Obesidad y Nutricion SC, Cuautla, Morelos, Mexico|Centro Medico Christus Muguerza Sur, Monterrey, Nuevo Leon, Mexico|Accelerium Clinical Research, Monterrey, Nuevo Leon, Mexico|Oncologico Potosino, San Luis Potosi, San Luis Potosí, Mexico|Clínica de Mérida, Mérida, Yucatán, Mexico|Practice Dr Gerardo Gonzalez, Acapulco, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|Investigacion Medica Sonora, S.C., Hermosillo, Mexico|Sociedad de Metabolismo y Corazon S.C., Veracruz, Mexico|Centro Especializado en Investigacion Clinica S.C., Veracruz, Mexico|West Visayas State University Medical Center, IloIlo City, IloIlo, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Manila Doctors Hospital, Ermita, Manila, Metropolitan Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metropolitan Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Powiatowe Centrum Medyczne w Wolowie Sp. z o.o., Wołów, Brzeg Dolny, Poland|Synexus Polska Sp.z o.o., Pomorskie, Gdansk, Poland|Vitamed Galaj i Cichomski sp.j., Bydgoszcz, Kuj-pom, Poland|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Lesser Poland, Poland|Zamość, Zamość, Lublin, Poland|CenterMed Krakow Ltd, Krakow, Malopolska, Poland|Oddzial Gastroenterologii Mazowieckie Centrum Rehabilitacji Stocer sp. Z o.o., Pruszków, Masovian, Poland|University Hospital BiaÃ…â€šystok, Białystok, Podlaskie, Poland|Diabetmed-SMO, Bialystok, Podlaski, Poland|Endoskopia Sp. Z O.O., Sopot, Pomorskie, Poland|Synexus Polska Sp. z o.o.Oddzial w Poznaniu, Poznan, Poznañ, Poland|Provincial Specialist Hospital in Olsztyn, Olsztyn, Warmia-Mazury, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Synexus Polska sp.z.o.o oddzial Czestochowa, Czestochowa, Poland|Silmedic Sp z o o, Katowice, Poland|DRS Katowice, Katowice, Poland|Synexus Polska Sp. z o.o. Oddzial w Lodzi, Lodz, Poland|Instytut Medycyny Wsi im. Witolda Chodzki w Lublinie, Lublin, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|DRS Wroclaw, Wroclaw, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|ClinTrial Medical Center, Pulmonology Department, Dobrosloveni, Oltenia, Romania|Sana Medical Center, Bucharest, Romania|Cabinet Medical De Nutritie Si Boli Metabolice Dr. Nicoleta, Bucharest, Romania|University Emergency Militare Central Dr.Carol Davila, Bucharest, Romania|National Institute of Endocrinology, Bucharest, Romania|Societatea Civila Medicala, Bucharest, Romania|AMES Research Center SRL, Calarasi, Romania|Polisano-Clinic, Sibiu, Romania|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|MUZ City Clinical Hospital 9, Saratov, Saratov Region, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny Novgorod, Volga, Russian Federation|State Budgetary Healthcare Institution Of Arkhangelsk Region Suvorova 1, Arkhangelsk, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Millitary-medical Academy, department of hospital therapy, Saint-Petersburg, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Russian Federation|Saratov City Clinical Hospital, Saratov, Russian Federation|King Fahad Specialist Hospital - Dammam, Dammam, Ash Sharqiyah, Saudi Arabia|Hayyal Jamia Hospital, Jeddah, Saudi Arabia|National University Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|FARMOVS, Bloemfontein, Free State, South Africa|Soweto CTC, Johannesburg, Gauteng, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clincal Reaserch Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Pretoria, Val De Grace, South Africa|Endocare, Paarl, Western Cape, South Africa|Moriana Clinical Research, Brandfort, South Africa|TREAD Research, Cape Town, South Africa|Jakaranda Hospital, Pretoria, South Africa|Synexus Helderberg Clinical Research Centre, Somerset West, South Africa|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital Universitario la Paz, Madrid, Spain|Hospital Universitario Principe de Asturias, Madrid, Spain|Hospital Universitario De Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|City Hospital 3, Dnipropetrovsk, Dnipropetrovsk Region, Ukraine|Odesa regional clinical hospital, Odesa, Odesa Region, Ukraine|Limited Liability Company ""Medical Center ""Salutem"", Vinnitsa, Vinnyts'ka Oblast', Ukraine|Municipal Institution Lutsk City Clinical Hospital, Lutsk, Volyns'ka Oblast, Ukraine|Municipal Institution City Hospital No. 7, Zaporizhzhia, Zaporizhzhia Region, Ukraine|Chernihiv City Hospital No 2 of Chernihiv City Council, Chernihiv, Ukraine|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Regional Public Organization ""Chernivtsi Regional Endocrinology Center"", Chernivtsi, Ukraine|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Ukraine|SU"" Clinic of medical academy"" of SI ""Dnepropetrovsk medical cacadamy of MoH of Ukraine"", Dnipro, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Kharkiv City Clinical Hospital 2 named of Prof. O.O. Shalimov, Kharkiv, Ukraine|GI ""L.T. Maloi National institute of therapy NAMS of Ukraine"", Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Kyiv municipal clinical endocrinological center, Kyiv, Ukraine|Medical and Diagnostic Center ADONIS, Kyiv, Ukraine|Medical Center of Edelweiss Medics LLC, Kyiv, Ukraine|Medical Center of Medbud-Clinic LLC, Kyiv, Ukraine|Kyiv Railway Clinical Hospital No-2 of Branch of Healthcare Center of the PJSC Ukrainian Railway , Endocrynology Department, Kyiv, Ukraine|Medical Center Universal Clinic Oberig, Kyiv, Ukraine|Administration of Medical Service and Rehabilitation of State Joint-Stock Holding Company Artem, Kyiv, Ukraine|Institute of Endocrinology and Metabolism im. V. P. Komisarenka NAMS Ukraine, Kyiv, Ukraine|Mykolayiv City Hospital 1, Mykolaiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Municipal Institution of Sumy Regional Council Sumy Regional Clinical Hospital, Sumy, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Medica Clinical Investigational Center of Medical Center Health Clinic, LLC, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|City Clinical Hospital N 1, Vinnytsia, Ukraine|Scientific and Research Institute of Invalid Rehabilitation of MOH of Ukraine on the base of Pirogov National Medical University, Vinnytsya, Ukraine|Municipal Institution 6th City Clinical Hospital, Dept of Gastroenterology, Zaporizhzhia, Ukraine|Communal Institution Zaporizhzhia, Zaporizhzhya, Ukraine|Queens Medical Centre, Nottingham, East Midland, United Kingdom|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|St George's Hospital, Tooting, London, United Kingdom|MAC Clinical Research, Liverpool, Merseyside, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Blackpool, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|Synexus Lancashire Dedicated Research Centre, Chorley, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Synexus Hexham Dedicated Research Centre, Hardwick, United Kingdom|Synexus North Tees Clinical Research Centre, Hardwick, United Kingdom|Synexus Merseyside Dedicated Research Centre, Liverpool, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|Wingate Institute, London, United Kingdom|University College London Hospita, London, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|MAC Clinical Research, GAC House, Stockton-on-Tees, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03383146"
79,"NCT03376841","Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites",,"Completed","No Results Available","Hepatic Impairment","Drug: Cenicriviroc","Area under the plasma concentration versus time curve (AUC) from time 0 to time t (AUC0-t)|AUC from time 0 to infinity (AUC0-∞)|Maximum plasma drug concentration (Cmax)|Time of maximum plasma drug concentration (Tmax)|Terminal elimination rate constant|Terminal elimination half-life (T½)|Total body clearance of drug from plasma (CL/F for CVC only)|Volume of distribution during the terminal phase (Vz/F for CVC only)","Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3152-102-002","June 6, 2017","November 24, 2017","December 17, 2017","December 19, 2017",,"January 11, 2018","Clinical Pharmacology of Miami, Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03376841"
80,"NCT03362931","Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma",,"Recruiting","No Results Available","Glaucoma, Angle-Closure","Device: XEN45","Percentage of patients achieving at least a 20% reduction from baseline Hour 0 IOP while on the same number or fewer IOP lowering medications|Change from baseline the number of concomitant IOP-lowering medications","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1924-701-007","July 19, 2018","June 12, 2020","June 12, 2020","December 5, 2017",,"March 21, 2019","Melbourne Eye Specialists, Fitzroy, Melbourne, Australia|St Vincent's private Hospital Melbourne, Fitzroy, Melbourne, Australia|Marsden Eye Specialist, Parramatta, New South Wales, Australia|East Sydney Private Hospital, Woolloomooloo, New South Wales, Australia|Eye Surgery Associates, Melbourne, Australia|Vermont Private Hospital, Melbourne, Australia|Eye Associates, Sydney, Australia|Institut de l'oeil des Laurentides, Borisbriand, Canada|Opthalmology Clinic Bellevue, Montreal, Canada|Hong Kong Eye Hospital, Kowloon, Hong Kong|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|Singapore Eye Research Institute, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Buddhist Tzu Chi General Hospital, Hualien, Taiwan|Kaohsiung Medical University, Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|The essex County Hospital, Colchester, Essex, United Kingdom|Royal Surrey (London), Guildford, Surrey, United Kingdom|Queen Victoria Hospital, East Grinstead, West Sussex, United Kingdom|Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom|Manchester Royal Eye Hospital, Edinburgh, United Kingdom|Frimley Park Hospital, Frimley, United Kingdom|Western Eye Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03362931"
81,"NCT03339128","Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children.",,"Recruiting","No Results Available","Irritable Bowel Syndrome","Drug: Eluxadoline|Drug: Placebo","Change from baseline in stool consistency averaged over the 4-week Treatment Period|Change from baseline in stool consistency for daily daytime and nighttime stool consistency scores|Change from baseline for daytime, nighttime, and 24-hour abdominal pain scores|Change from baseline for daytime, nighttime, and 24-hour bowel movement frequency|Change from baseline for daytime, nighttime, and 24 hour urgency-free days|Change from baseline for daytime, nighttime, and 24 hour number of fecal incontinence-free days","Allergan","All","12 Years to 17 Years   (Child)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3030-202-002|2017-003770-14","November 15, 2017","January 25, 2021","February 8, 2021","November 13, 2017",,"May 24, 2019","University Of Arizona, Tucson, Arizona, United States|Applied Research of Arkansas, Little Rock, Arkansas, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|VVCRD Clinical Research, Garden Grove, California, United States|University of California, San Francisco, San Francisco, California, United States|Wellness Clinical Research, LLC, Hialeah, Florida, United States|Clinical Neuroscience Solutions Inc dba CNS Healthcare, Jacksonville, Florida, United States|Sunrise Research Institute, Miami, Florida, United States|Florida Research Center, Inc, Miami, Florida, United States|Nemours Children's Clinic, Orlando, Orlando, Florida, United States|Children's Center for Digestive Health Care, Atlanta, Georgia, United States|Sleep Care Research Institute/Global Research Associates, Stockbridge, Georgia, United States|Center for Children's Digestive Health, Park Ridge, Illinois, United States|Unity Point Health Pediatric Gastroenterology, Peoria, Illinois, United States|MBAL Sv. Ivan Rilski Kozlodui, Indianapolis, Indiana, United States|Michael W. Simon, MD, PSC, Nicholasville, Kentucky, United States|Willis-Knighton Physician Network, Shreveport, Louisiana, United States|Certified Research Consultants Virgo-Carter Pediatrics, Silver Spring, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Celen Medical Group, Corp, Marlton, New Jersey, United States|Ubmd Ddnc, Buffalo, New York, United States|UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|St. Christopher's Hospital for Children - Drexel University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians Inc., Pittsburgh, Pennsylvania, United States|Coastal Pediatrics Associates, Mount Pleasant, South Carolina, United States|Cook Children's Digestive Health, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Envision Clinical Research, LLC, Laredo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Multicare Health Institute for Research and Innovation, Tacoma, Washington, United States|Korczowski Bartosz, Gabinet Lekarski, Kozlodui, Bulgaria|Edmonton Clinic Health Academy (ECHA), Edmonton, Alberta, Canada|Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada|Mentahaz Maganorvosi Kozpont, Székesfehérvár, Hungary|Specjalistyczny Gabinet Naurologiczny Marta Banach, Krakow, Poland|Korczowski Bartosz, Gabinet Lekarski, Rzeszow, Poland|The Children's Memorial Health Institute, Warsaw, Poland|Hospital Universitario Dr. Peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03339128"
82,"NCT03335852","Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD","PINE","Completed","No Results Available","Macular Degeneration","Drug: Abicipar pegol","Peak Serum Concentration (CMax) for Free and VEGF-Bound Abicipar|Serum Concentration Immediately before Next Dose (Ctrough) for Free and VEGF-Bound Abicipar|Time to Cmax (Tmax) for Free and VEGF-Bound Abicipar|Terminal Elimination Half-Life (t1/2) for Free and VEGF-Bound Abicipar|Area Under the Serum Concentration-Time Curve from Zero to the End of the Dosing Interval ""tau"" (AUC0-tau) for Free and VEGF-Bound Abicipar|Area Under the Serum Concentration-Time Curve from Zero to Infinity (AUC0-inf) for Free and VEGF-Bound Abicipar|Serum Levels of Anti-abicipar Antibodies|Percentage of Participants with Treatment Emergent Adverse Events|Best Corrected Visual Acuity using an Eye Chart|Percentage of Participants with Change from Baseline in Full Ophthalmic Exam Findings [i.e. Slit Lamp Exam, Intraocular Pressure (IOP) Measurements, Funduscopic Exam]|Changes from Baseline in General Physical Condition as Measured through General Physical Exam|Percentage of Participants with Changes from Baseline in Vital Signs (Blood Pressure, Pulse Rate, ECG)|Percentage of Participants with Change from Baseline in Clinically Relevant Laboratory Values (Serum Chemistry, Hematology, Urinalysis)","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1771-101-008","November 28, 2017","October 8, 2018","October 8, 2018","November 8, 2017",,"November 1, 2018","Kimura Eye and Internal Medicine Hospital, Kure, Hiroshima, Japan|Musashi Dream Clinic, Tennouji-ku, Osaka, Japan|Takeuchi Eye Clinic, Taito-ku, Tokyo, Japan|Souseikai Hakata Clinic, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan",,"https://ClinicalTrials.gov/show/NCT03335852"
83,"NCT03325673","Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control",,"Completed","Has Results","Dry Eye Syndromes","Device: TrueTear|Device: TrueTear Sham Control","Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score in the Study Eye|Comfort Rating Score in the Study Eye|Comfortable Wear Time (CWT) in the Study Eye|Total Wear Time (Total WT) in the Study Eye","Allergan","All","22 Years and older   (Adult, Older Adult)","Not Applicable","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OCUN-024","November 22, 2017","November 29, 2018","November 29, 2018","October 30, 2017","December 6, 2019","December 18, 2019","Centre for Contact Lens Research School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03325673/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03325673"
84,"NCT03320850","BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence","APOLLO","Recruiting","No Results Available","Urinary Incontinence|Overactive Bladder With Urinary Incontinence","Drug: OnabotulinumtoxinA and Hydrogel admixture|Drug: Placebo and Hydrogel admixture","Change from baseline at Week 12 (Stage 2) in the average number of urinary incontinence episodes per day|Change from baseline at Week 12 (Stage 2) in the average number of micturition episodes per day|Change from baseline at Week 12 (Stage 2) in the average volume voided per micturition","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","335","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1839-201-021","October 4, 2017","October 27, 2019","April 12, 2020","October 25, 2017",,"April 25, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Coastal Clinical Research, Inc., an AMR company, Mobile, Alabama, United States|Urological Assoc. of South AZ, Tucson, Arizona, United States|Hope Clinical Research, Canoga Park, California, United States|University of California, Los Angeles, Los Angeles, California, United States|San Bernardino Urological Associates Medical Group, San Bernardino, California, United States|Wr-McCr, Llc, San Diego, California, United States|San Diego Clinical Trials, San Diego, California, United States|Sutter Institute for Medical Health, Vacaville, California, United States|Tower Urology, West Los Angeles, California, United States|The Urology Center of Colorado, Denver, Colorado, United States|Urology Associates, P.C, Englewood, Colorado, United States|Adult and Pediatric Urology, Bridgeport, Connecticut, United States|Women's Health Specialty Care, Farmington, Connecticut, United States|CT Clinical Research Center/Urologist Specialist, Middlebury, Connecticut, United States|Innovative Medical Research of South FL, Inc., Aventura, Florida, United States|South Florida Medical Research, Aventura, Florida, United States|Manatee Medical Research Institute, Bradenton, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|Urological Research Network, Miramar, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|Pinellas Urology, Inc., Saint Petersburg, Florida, United States|North Idaho Urology, Coeur d'Alene, Idaho, United States|Idaho Urologic Institute, Meridian, Idaho, United States|Comprehensive Urological Care, Lake Barrington, Illinois, United States|North Shore University Health System, Skokie, Illinois, United States|Urogynecology Associates, PC, Carmel, Indiana, United States|First Urology,PSC, Jeffersonville, Indiana, United States|The Iowa Clinic, West Des Moines, Iowa, United States|DelRicht Research, LLC, New Orleans, Louisiana, United States|Regional Urology, LLC, Shreveport, Louisiana, United States|Chesapeake Urology Associates, Hanover, Maryland, United States|Chesapeake Urology, Owings Mills, Maryland, United States|Bay State Clinical Trials, Inc., Watertown, Massachusetts, United States|Women's Health Care Specialists, Kalamazoo, Michigan, United States|Michigan Institute of Urology, Troy, Michigan, United States|Kansas City Urology Care, Kansas City, Missouri, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Adult Pediatric Urology & Urogynecology, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Premier Urology Group, Edison, New Jersey, United States|Urologic Research and Consulting LLC, Englewood, New Jersey, United States|Delaware Valley Urology, Mount Laurel, New Jersey, United States|Brooklyn Urology Research Group, Brooklyn, New York, United States|Western New York Urology Associates, Cheektowaga, New York, United States|AccuMed Research Associates, Garden City, New York, United States|Urological Surgeons of Long Island, Garden City, New York, United States|Manhattan Medical Research Practice PLLC, New York, New York, United States|Urology Institute of Long Island, Plainview, New York, United States|Associated Medical Professionals- Urology, Syracuse, New York, United States|American Health Research, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|FirstHealth Urogynecology, Hamlet, North Carolina, United States|Associated Urologists of North Carolina, Raleigh, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|The Center for Men's & Women's Urology, Gresham, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Houston Metro Urology, Houston, Texas, United States|Virginia Urology, Richmond, Virginia, United States|Urology of Virginia, Virginia Beach, Virginia, United States|Washington Urology and Urogynecology Associates, Kirkland, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Multicare Allenmore Hospital, Tacoma, Washington, United States|Aurora Research Institute, West Allis, Wisconsin, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03320850"
85,"NCT03316898","A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: AGN-242071|Drug: Placebo|Drug: Donepezil|Drug: Memantine","Change from Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) for Whole Brain, Hippocampal and Dorsolateral Prefrontal Cortices|Percentage of Participants with Treatment-Emergent Adverse Events (TEAE)|Percentage of Participants with Changes from Baseline in Clinically Significant Clinical Laboratory Values|Percentage of Participants with Changes from Baseline in Clinically Significant Vital Signs|Percentage of Participants with Changes from Baseline in Clinically Significant Electrocardiogram (ECG) Findings|Percentage of Participants who have Suicidal Ideation or Behaviours as determined by Columbia-Suicide Severity Rating Scale (C-SSRS)|Clearance of AGN-242071|Volume of Distribution of AGN-242071|Cmax: Maximum Plasma concentration for AGN-242071|AUC: Area Under the Curve for AGN-242071","Allergan","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3142-101-001","September 30, 2018","November 4, 2018","November 4, 2018","October 20, 2017",,"November 2, 2018","ATP Clinical Research, Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Synergy Research Centers, Lemon Grove, California, United States|Collaborative Neuroscience, Long Beach, California, United States|Alliance Research, Long Beach, California, United States|Syrentis Clinical Research, Santa Ana, California, United States",,"https://ClinicalTrials.gov/show/NCT03316898"
86,"NCT03302559","Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage",,"Completed","Has Results","Skin Care","Other: Retinol Complex 0.5|Other: Facial cleanser|Other: Moisturizing lotion|Other: Sunscreen|Device: Skin Imaging","Change From Baseline in Overall Photodamage Score|Change From Baseline in Appearance of Fine Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed)|Change From Baseline in Appearance of Coarse Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed)|Change From Baseline in Tactile Roughness Score|Change From Baseline in Skin Roughness Score Using the Allergan Skin Roughness Visual Scale|Change From Baseline in Appearance of Fine Lines Score Using the Allergan Fine Lines Visual Scale|Investigator's Global Improvement Assessment for Overall Photodamage|Investigator's Global Improvement Assessment for the Appearance of Fine Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed)|Investigator's Global Improvement Assessment for the Appearance of Coarse Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed)|Investigator's Global Improvement Assessment for Tactile Roughness|Change From Baseline in Spectrophotometer L* Value (a Measurement of Skin Brightness)","Allergan","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRIC17-RET05","September 18, 2017","April 30, 2018","April 30, 2018","October 5, 2017","June 4, 2019","June 4, 2019","SkinMedica Clinical Research and Innovation Center, Irvine, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03302559/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03302559"
87,"NCT03285308","A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01",,"Recruiting","No Results Available","Gastroparesis|Diabetes Mellitus","Drug: Relamorelin|Drug: Placebo","Percentage of patients meeting the diabetic gastroparesis symptom responder criterion during the 12 weeks of treatment|Percentage of patients meeting the vomiting symptom responder criterion in each of the last 6 of the 12 weeks of treatment|Percentage of Patients Meeting the Nausea Responder Criterion|Percentage of Patients Meeting the Abdominal Pain Responder Criterion|Percentage of Patients Meeting the Bloating Responder Criterion|Percentage of Patients Meeting the Postprandial Fullness Responder Criterion|Number of Patients who experienced one or more Treatment Emergent Adverse Event (TEAE)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RLM-MD-01|2017-002136-16","September 29, 2017","September 21, 2021","September 21, 2021","September 18, 2017",,"January 3, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|Avant Research Associates, Huntsville, Alabama, United States|Del Sol Research Management, LLC, Chandler, Arizona, United States|Synexus Clinical Research US, Inc., Fountain Hills, Arizona, United States|Central Arizona Medical Associates, Mesa, Arizona, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|CHI St. Vincent's Gastroenterology: John Tyler Baber, MD, Little Rock, Arkansas, United States|Arkansas Gastorenterology, North Little Rock, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|Southern California Research Center, Coronado, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Citrus Valley Gastroenterology Clinic, Covina, California, United States|Valley View Wellness and Medical Center - VVCRD Clinical Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Upland Clinical Research, Upland, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Denver Esophageal and Stomach Center, Englewood, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|TrialSpark, Inc., Washington, District of Columbia, United States|West Central Gastroenterology, Clearwater, Florida, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|American Research Institute, Inc, Cutler Bay, Florida, United States|Top Medical Research, Inc., Cutler Bay, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Cfagi Llc, Maitland, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Gulf Region Clinical Research Institute, Pensacola, Florida, United States|University of South Florida, Tampa, Florida, United States|West Central Gastroenterology, Tampa, Florida, United States|Summit Clinical Research, LLC., Athens, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, LLC, Bastrop, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Boston VA Healthcare System, West Roxbury, Massachusetts, United States|Biocon Clinical Research, LLC006, Caro, Michigan, United States|Vida Clinical Studies, Dearborn, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Troy Gastroenterology, PC dba Center for Digestive Health, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|National Diabetes and Obesity Research Institute - Gen 1 Research, Biloxi, Mississippi, United States|Montana Medical Research, Missoula, Montana, United States|Diabetes and Endocrine Associates, P.C., Omaha, Nebraska, United States|Synexus Clinical Research, Henderson, Nevada, United States|Clinical Research of South Nevada - CROSN, Las Vegas, Nevada, United States|Advanced Biomedical Research of America ABRA, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology, Brick, New Jersey, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|CHEAR Center, LLC, Bronx, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare-Charlotte, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Concord, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Family Practice Center of Wadsworth, Inc., Wadsworth, Ohio, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Carolina Medical Research, Clinton, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Avant Research Associates,LLC, Austin, Texas, United States|DiscoveResearch, Inc, Beaumont, Texas, United States|Synexus Clinical Research US, Inc., Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|SAGACT PLLC., San Antonio Gastroenterology Associates, PA, San Antonio, Texas, United States|Digestive & Liver Disease Center of San Antonio, PLLC, San Antonio, Texas, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Cardinal Internal Medicine, Woodbridge, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Nepean Hospital, Kingswood, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|MHAT Dr. Tota Venkova AD, Gabrovo, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|Acibadem City Clinic Oncology Center, Sofia, Bulgaria|CHU de Bordeaux - Hopital Haut Leveque, Pessac, Gironde, France|Hopital Louis Mourier, Service d'Hepato Gastro-enterologie, Colombes, France|Corbeil Essonnes, Corbeil Essonnes cedex, France|Grenoble, Grenoble, France|Hospice Civils de Lyon - Hôpital Edouard Herriot, Lyon, France|CHU Nantes, Nantes Cedex 1, France|CHU de Poitiers, Poitiers, France|Hopital Charles Nicolle, Rouen Cedex, France|CHRU Nancy, Vandoeuvre-les-Nancy, France|Centre de Recherche Clinique, Venissieux, France|Anu Hospitals, Vijayawada, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology, Ahmedabad, Gujarat, India|Zydus Hospital, Ahmedabad, Gujarat, India|Surat Institute of Digestive Sciences Hospitals, Surat, Gujarat, India|Lifecare Clinic and Research Centre - Internal Med/Diabetology, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Victoria Hospital Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre, Mangalore, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|Chopda Medicare & Research Centre Pvt.Ltd, Magnum Heart Institute, Nashik, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|S.P.Medical College & Group of Hospitals Bikaner, Bikaner, Rajasthan, India|S R Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Diabetic Thyroid and Endocrine Centre, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|M.V. Hospital for Diabetes & Diabetes Research Centre, Chennai, Tamil Nadu, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Telangana, India|M V Hospital & Research Centre, Lucknow, Uttar Pradesh, India|IPGME&R and SSKM Hospital, Kolkata, West Bengal, India|M. S. Ramaiah medical College and Hospitals, Bangalore, India|Arthur Asirvatham Hospital, Madurai, India|Sir Ganga Ram Hospital, New Delhi, India|Soroka University Medical Center, Beer Sheba, Israel|Bnei-Zion M.C., Haifa, Israel|The E. Wolfson Medical Center, Holon, Israel|Digestive Diseases Institute, Jerusalem, Israel|Holy Family Hospital, Nazareth, Israel|Gastroenterology Institute, Petach Tikva, Israel|Endocrinology & Diabetes Center, Safed, Israel|Gastroenterology Institute, Tel Aviv, Israel|Humanitas Research Hospital, Rozzano, Milan, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy|Azienda Ospedaliera Rilievo Nazionale Alta Specialita (ARNAS) Garibaldi, Catania, Sicily, Italy|Ospedale Cardinal Massaia, Asti, Italy|University of Bari, Bari, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|AO Universitaria San Martino - IRCCS, Genova, Italy|Federico II University of Naples, Napoli, Italy|University-Hospital of Padova, Padova, Italy|IRCCS S.Matteo Hospital Foundation, University of Pavia, Pavia, Italy|AOU Pisana Gastroenterologia Universitaria, Pisa, Italy|Policlinico Gemelli, Divisione di Endocrinologia e Malattie del Metabolismo, Rome, Italy|Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Clinical Institute Beato Matteo, Vigevano, Italy|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Manila Doctors Hospital, Ermita, Ermita Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metro Manila 1300, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|West Visayas State University Medical Center, IloIlo City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Synexus Polska Sp.z o.o., Pomorskie, Gdansk, Poland|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Kraków-Podgórze, Poland|Vitamed Galaj i Cichomski sp.j., Bydgoszcz, Kuj-pom, Poland|Szpital Wojewódzki, Zamość, Lubelskie, Poland|CenterMed Krakow Ltd, Krakow, Malopolska, Poland|Centrum Medyczne Pratia S.A. Warsaw, Poland, Warsaw, Mazowian, Poland|Diabetmed-SMO, Bialystok, Podlaski, Poland|Endoskopia Sp. Z O.O., Sopot, Pomorskie, Poland|Synexus Polska Sp. z o.o.Oddzial w Poznaniu, Poznan, Poznañ, Poland|State Hospital, Olsztyn, Warmia-Mazury, Poland|Department of Endocrinology, Diabetology an Internal Medcine Medical Unversity Bialystok, Bialystok, Poland|Powiatowe Centrum Medyczne w Wolowie Sp. z o.o., Brzeg Dolny, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Silmedic Sp z o o, Katowice, Poland|DRS Katowice, Katowice, Poland|Instytut Medycyny Wsi im. Witolda Chodzki w Lublinie, Lublin, Poland|Oddzial Gastroenterologii Mazowieckie Centrum Rehabilitacji Stocer sp. Z o.o., Pruszkow, Poland|Wojskowy Instytut Medyczny, Warszawa 44, Poland|DRS Wroclaw, Wroclaw, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|King Fahad Specialist Hospital - Dammam, Dammam, Ash Sharqiyah, Saudi Arabia|Hayyal Jamia Hospital, Jeddah, Saudi Arabia|National University Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital Universitario la Paz, Madrid, Spain|Hospital Universitario Principe de Asturias, Madrid, Spain|Hospital Universitario De Salamanca, Salamanca, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|City Hospital 3, Kryvyi Rih, Dnipropetrovsk Region, Ukraine|Odesa regional clinical hospital, Odesa, Odesa Region, Ukraine|Municipal Institution Lutsk City Clinical Hospital, Lutsk, Volyns'ka Oblast, Ukraine|Municipal Institution City Hospital No. 7, Zaporizhzhia, Zaporizhzhia Region, Ukraine|Chernihiv City Hospital No 2 of Chernihiv City Council, Chernihiv, Ukraine|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Regional Public Organization ""Chernivtsi Regional Endocrinology Center"", Chernivtsi, Ukraine|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Ukraine|SU"" Clinic of medical academy"" of SI ""Dnepropetrovsk medical cacadamy of MoH of Ukraine"", Dnipro, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Kharkiv City Clinical Hospital 2 named of Prof. O.O. Shalimov, Kharkiv, Ukraine|GI ""L.T. Maloi National institute of therapy NAMS of Ukraine"", Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Kyiv municipal clinical endocrinological center, Kyiv, Ukraine|AS PVNZ, Kyiv, Ukraine|Medical and Diagnostic Center ADONIS, Kyiv, Ukraine|Kyiv Railway hospital on the railway transport #2 of the branch ""health, Kyiv, Ukraine|Medical Center Universal Clinic Oberig, Kyiv, Ukraine|Administration of Medical Service and Rehabilitation of State Joint-Stock Holding Company Artem, Kyiv, Ukraine|Institute of Endocrinology and Metabolism im. V. P. Komisarenka NAMS Ukraine, Kyiv, Ukraine|Mykolayiv City Hospital 1, Mykolaiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Municipal Institution of Sumy Regional Council Sumy Regional Clinical Hospital, Sumy, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Medica Clinical Investigational Center of Medical Center Health Clinic, LLC, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|City Clinical Hospital N 1, Vinnytsia, Ukraine|Scientific and Research Institute of Invalid Rehabilitation of MOH of Ukraine on the base of Pirogov National Medical University, Vinnytsya, Ukraine|Municipal Institution 6th City Clinical Hospital, Dept of Gastroenterology, Zaporizhzhia, Ukraine|Communal Institution Zaporizhzhia, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03285308"
88,"NCT03274999","Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use",,"Terminated","No Results Available","Dry Eye Syndromes","Device: TrueTear™ Application","Change from Baseline (Pre-application) in Tear Meniscus Height (TMH) at Eye Opening and Pre-Blink|Change from Baseline (Pre-application) in Tear Lipid Layer Thickness at Eye Opening and Pre-Blink|Change from Baseline (Pre-application) in Non-Invasive Tear Film Break-Up Time (NIBUT)|Change from Pre-application in Protective Index (PI)|Change from Pre-application in Exposed Area (EA)","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCUN-020","October 18, 2017","November 9, 2017","November 9, 2017","September 7, 2017",,"November 14, 2018","Ocular Technology Group International, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03274999"
89,"NCT03233438","Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",,"Completed","Has Results","Bacterial Infections|Acute Bacterial Skin and Skin Structure Infection","Drug: Dalbavancin|Drug: Usual Care","Number of Infection-related Total Admitted Hospital Days|Number of Total Admitted Hospital Days|Number of Participants With Infection-related Major Surgical Interventions That Required Operating Room Time|Number of Participants With Infection-related Hospitalizations|Number of Participants With Infection-related Hospitalizations That Resulted in Admission to Intensive Care Unit|Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital|Number of Participants With Infection-related Emergency Department (ED) Visits|Number of Participants With Infection-related Outpatient Healthcare Visits|Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy|Number of Participants With Infection-related Healthcare Visits Due to PICC Line or Central Line Used to Administer Antibiotic Therapy|Change From Baseline in Response to Treatment at End of Treatment Visit|Number of Participants With Serious Adverse Events (SAEs)|Patient Satisfaction With Care: Overall Health|Patient Satisfaction With Care: Wait in Emergency Room|Patient Satisfaction With Care: Hospitalization|Patient Satisfaction With Care: Satisfaction With Hospital Stay|Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay|Patient Satisfaction With Care: Received IV Antibiotic Therapy for Skin Infections|Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy|Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV|Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV|Patient Satisfaction With Care: IV Therapy Hindering Normal Activities of Daily Living|Patient Satisfaction With Care: Concerned About Receiving Your IV Therapy|Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day|Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV|Patient Satisfaction With Care: Regimen Preferred if Treated Again for a Similar Skin Infection With IV|Patient Satisfaction With Care: Time Willing to Spend Receiving Each IV|Patient Satisfaction With Care: Find Value in a Physician|Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire|Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire|Healthcare Costs","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","91","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-US-ID-0528","July 24, 2017","October 30, 2018","October 30, 2018","July 28, 2017","January 18, 2020","January 18, 2020","Weill Cornell Medicine, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03233438/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03233438/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03233438"
90,"NCT03226769","Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease",,"Completed","No Results Available","Meibomian Glands|Dry Eye Syndromes","Device: TrueTear|Device: Thermalon Dry Eye Compress","Signs of MGD","Allergan","All","22 Years and older   (Adult, Older Adult)","Not Applicable","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCUN-023","July 26, 2017","October 29, 2017","October 29, 2017","July 24, 2017",,"October 10, 2018","Andover Eye Associates, Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03226769"
91,"NCT03208673","Optive Brand For Day And Night Dry Eye Management",,"Completed","Has Results","Dry Eye","Device: Optive® Fusion + Optive® Gel Drop","Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score|Measured Lissamine Green Bulbar Conjunctival Staining (mm2)|Change From Baseline in Visual Analogue Scale (VAS): Symptomatology Upon Waking","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-EAME-EYE-0485","July 3, 2017","September 6, 2017","September 6, 2017","July 5, 2017","June 20, 2019","June 20, 2019","Ocular Technology Group - international, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03208673/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03208673/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03208673"
92,"NCT03194269","Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent Ears","FOLD","Active, not recruiting","No Results Available","Prominent Ears","Device: EARFOLD®","Change from baseline pre-insertion in EAR-Q Ears Appearance Questionnaire score|Change from baseline pre-insertion in EAR-Q Ears Appearance overall score at 12 months post-implantation|Change from baseline pre-insertion in EAR-Q Ears Appearance overall score at 24 months post-implantation|Percentage of patients that require re-operation at any moment|Percentage of patients with recurrence of ear prominence|Change from baseline of Short Form-12 score at Month 3 for subjects over 18 years|Change from baseline of Short Form-12 score at Month 12 for subjects over 18 years|Change from baseline of Short Form-12 score at Month 24 for subjects over 18 years|Change from baseline of Short Form-10 score at Month 3 for subjects under 18 years old|Change from baseline of Short Form-10 score at Month 12 for subjects under 18 years old|Change from baseline of Short Form-10 score at Month 24 for subjects under 18 years old|Change from baseline in maximum helix to scalp distance from before PREFOLD® insertion at Month 3|Change from baseline in maximum helix to scalp distance from before PREFOLD® insertion at Month 12|Change from baseline in maximum helix to scalp distance from before PREFOLD® insertion at Month 24|Maintenance of maximum helix to scalp distance at 12 months compared to 3 months visit post insertion of EARFOLD|Maintenance of maximum helix to scalp distance at 24 months compared to 3 months visit post insertion of EARFOLD|Change in maximum helix to scalp distance from PREFOLD® insertion to post insertion distances at Month 3|Change in maximum helix to scalp distance from PREFOLD® insertion to post insertion distances at Month 12|Change in maximum helix to scalp distance from PREFOLD® insertion to post insertion distances at Month 24|Duration of EARFOLD® insertion procedure|Change from baseline pre-insertion in EAR-Q Social Function Questionnaire at Month 3|Change from baseline pre-insertion in EAR-Q Social Function Questionnaire at Month 12|Change from baseline pre-insertion in EAR-Q Social Function Questionnaire at Month 24|Change from baseline pre-insertion in EAR-Q School Function Questionnaire at Month 3|Change from baseline pre-insertion in EAR-Q School Function Questionnaire at Month 12|Change from baseline pre-insertion in EAR-Q School Function Questionnaire at Month 24|Change from baseline pre-insertion in EAR-Q Psychological Function Questionnaire at Month 3|Change from baseline pre-insertion in EAR-Q Psychological Function Questionnaire at Month 12|Change from baseline pre-insertion in EAR-Q Psychological Function Questionnaire at Month 24|Return to normal activities questionnaire after EARFOLD® surgery at Month 3","Allergan","All","7 Years and older   (Child, Adult, Older Adult)","Not Applicable","84","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-EAME-FAS-0469","August 17, 2017","October 30, 2021","October 30, 2021","June 21, 2017",,"December 3, 2019","Royal Derby Hospital, Derby, Derbyshire, United Kingdom|La Belle Forme, Glasgow, Scotland, United Kingdom|The Private Health Practice, Salisbury, Wiltshire, United Kingdom|AL Aesthetics, West Midlands, Wolverhampton, United Kingdom|Sthetix, Liverpool, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03194269"
93,"NCT03193359","Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine",,"Withdrawn","No Results Available","Migraine Disorders","Biological: botulinum toxin Type A","Number of Participants with Adverse Events (AEs)|Percentage of Participants with AEs Leading to Discontinuation|Change from Baseline in Vital Signs|Change from Baseline in 12-Lead Electrocardiograms (ECGs) Parameters|Change from Baseline in Clinical Laboratory Parameters|Change from Baseline in the Frequency of Headache Days during 28-Day Period Ending with Weeks 12 and 24|Change from Baseline in Total Cumulative Hours of Headache Days during 28-Day period","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1313-302-008","January 15, 2018","September 9, 2021","September 9, 2021","June 20, 2017",,"July 14, 2017",,,"https://ClinicalTrials.gov/show/NCT03193359"
94,"NCT03193346","BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine",,"Withdrawn","No Results Available","Migraine Disorders","Biological: botulinum toxin Type A|Drug: placebo (sodium chloride 0.9 mg)","Change from Baseline in the Frequency of Headache Days during 28-Day Period Ending with Week 24|Change from Baseline in the Frequency of Headache Days during 28-Day Period|Change from Baseline in the Frequency of Migraine/Probable Migraine Days during 28-Day Period|Change from Baseline in the Number of Moderate/Severe Headache Days during 28-Day Period|Change from Baseline in Total Cumulative Hours of Headache Days during 28-Day Period","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1313-301-008","July 3, 2017","March 25, 2021","March 25, 2021","June 20, 2017",,"July 14, 2017",,,"https://ClinicalTrials.gov/show/NCT03193346"
95,"NCT03166618","Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing",,"Terminated","Has Results","Temple Hollowing","Device: Juvéderm® VOLUMA XC","Percentage of Participants With at Least a 1-Point Improvement (Decrease) in Both Temples as Assessed by the Evaluating Investigator Using the Allergan Temple Hollowing Scale (ATHS)|Percentage of Participants ""Improved"" or ""Much Improved"" as Assessed by the Evaluating Investigator Using the Global Aesthetic Improvement Scale (GAIS)|Percentage of Participants ""Improved"" or ""Much Improved"" as Assessed by the Participant Using the GAIS","Allergan","All","22 Years and older   (Adult, Older Adult)","Not Applicable","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","VOLUMA-007","April 24, 2017","July 21, 2017","July 21, 2017","May 25, 2017","October 18, 2018","October 18, 2018","Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03166618/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03166618"
96,"NCT03148756","Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis",,"Terminated","Has Results","Endocarditis|Bacteremia","Drug: Dalbavancin|Drug: Standard of Care","Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population|Percentage of Participants With Clinical Outcome of Success at Day 42 in the ITT Population|Percentage of Participants With Clinical Outcome of Success at Day 42 in the Clinically Evaluable (CE) Population|Number of Participants With Day 84 Mortality in the Safety Population|Percentage of Participants With Clinical Outcome of Success at Day 84 in the CE Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the ITT Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the ITT Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the CE Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the CE Population|Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the ITT Population|Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the ITT Population|Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the CE Population|Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the CE Population","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DAL-MD-09","May 12, 2017","August 4, 2017","August 4, 2017","May 11, 2017","September 10, 2018","September 10, 2018","Midway Immunology and Research Center, Fort Pierce, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03148756/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03148756"
97,"NCT03091439","Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis",,"Terminated","Has Results","Osteomyelitis","Drug: Dalbavancin|Drug: Standard of Care","Number of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population|Number of Participants With Clinical Improvement at Day 28 in the Modified Intent-to-Treat (mITT) Population|Number of Participants With Clinical Improvement at Day 28 in the CE Population|Number of Participants With Clinical Response at Day 42 in the mITT Population|Number of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population|Number of Participants With Clinical Response at Day 180 in the mITT and CE Populations|Number of Participants With Clinical Response at Day 365 in the mITT and CE Populations|Number of Participants With Clinical Response by Pathogen at Day 42 in the CE Population|Number of Participants With Clinical Response by Pathogen at Day 180 in the CE Population","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3026-201-008","May 15, 2017","August 31, 2017","August 31, 2017","March 27, 2017","September 26, 2018","September 26, 2018","Midway Immunology and Research Center, Fort Pierce, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03091439/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03091439"
98,"NCT03052764","Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence","LO-BOT","Completed","Has Results","Urinary Bladder, Overactive|Urinary Incontinence","Biological: onabotulinumtoxinA|Drug: Placebo (saline)","Change From Baseline in Daily Average Number of Urinary Incontinence Episodes|Percentage of Participants Who Achieved Complete Continence|Change From Baseline in Daily Average Number of Micturition Episodes|Change From Baseline in Daily Average Number of Urgency Episodes|Change From Baseline in Daily Average Number of Nocturia Episodes|Percentage of Participants Who Have a Positive Treatment Response on the Treatment Benefit Scale (TBS)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMO-US-URO-0470","December 12, 2016","December 10, 2018","December 10, 2018","February 14, 2017","December 24, 2019","December 24, 2019","Orange County Urology Associates, Laguna Hills, California, United States|Tower Urology, Los Angeles, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Genitourinary Surgical Consultants, Denver, Colorado, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|PMG Research of Christie Clinic, Champaign, Illinois, United States|Deaconess Clinic, Inc., Evansville, Indiana, United States|Women's Health Advantage, Fort Wayne, Indiana, United States|Urogynecology Associates, Indianapolis, Indiana, United States|Urology of Indiana, Noblesville, Indiana, United States|Iowa Clinic, West Des Moines, Iowa, United States|Regional Urology, Shreveport, Louisiana, United States|Chesapeake Urology, Owings Mills, Maryland, United States|Beyer Research, Kalamazoo, Michigan, United States|Michigan Institute of Urology, P.C., Troy, Michigan, United States|Adult and Pediatric Urology, Omaha, Nebraska, United States|Premier Urology LLC, Edison, New Jersey, United States|Western New York Urology Associates, Cheektowaga, New York, United States|Manhattan Medical Research, New York, New York, United States|Advanced Urology Centers of NY A division of IMP, Plainview, New York, United States|Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, United States|Alliance Urology Specialists, Greensboro, North Carolina, United States|Sandhills Medical Center, Hamlet, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States|Center for Pelvic Health, Franklin, Tennessee, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Virginia Urology, Richmond, Virginia, United States|Virginia Urology Center, Richmond, Virginia, United States|Urology of Virginia, Virginia Beach, Virginia, United States|Integrity Medical Research, LLC, Mountlake Terrace, Washington, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03052764/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03052764/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03052764"
99,"NCT03043287","Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)",,"Active, not recruiting","No Results Available","Urinary Bladder, Overactive","Biological: onabotulinumtoxinA","Pre-BOTOX® Injection VE Cutoff-Ratios that Predict the Risk of CIC following Treatment with 100-200U of BOTOX®|Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX®","Allergan","All","18 Years and older   (Adult, Older Adult)",,"420","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CMO-US-URO-0506","May 12, 2017","September 9, 2019","September 30, 2019","February 6, 2017",,"September 13, 2019","Regional Urology, Shreveport, Louisiana, United States|Chesapeake Urology Associates, LLC, Baltimore, Maryland, United States|Virginia Urology, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03043287"
100,"NCT03003416","Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)","Louvre 3","Completed","No Results Available","Diabetic Macular Edema","Drug: dexamethasone intravitreal implant","Best Gain in Best Corrected Visual Acuity (BCVA) compared to Baseline Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Time to Achieve Maximum Gain in BCVA|Change from Baseline in BCVA|Percentage of Participants with a Gain (Improvement) in BCVA of at Least 10 Letters from Baseline|Percentage of Participants with a Gain (Improvement) in BCVA of at Least 15 Letters from Baseline|Change from Baseline in Retinal Thickness|Percentage of Participants with a 20% Reduction in Retinal Thickness compared to Baseline|Percentage of Participants with Disappearance of DME defined by Disappearance of Cyst or Obtaining a Normal Retinal Thickness|Percentage of Participants Categorized by Demographic Characteristics Treated or Not Treated with Ozurdex®|Percentage of Physicians Categorized by Age, Sex, Type of Practice, Number of Yearly Injections|Percentage of Participants Categorized by Characteristics of Disease (DME or Diabetes)|Percentage of Participants Categorized by Treatment Methods at Inclusion (Therapeutic Decision for inclusion or Reason for Non-Treatment)|Percentage of Participants Categorized by Conditions when Placed on Treatment (Patient Characteristics, Glycosylated Hemoglobin (HbA1c) Level Control, Blood Pressure Control, Prior Treatments, Prior Treatment Failure)|Percentage of Participants Categorized by Conditions when Use of Ozurdex® (Number of Injections, Number of Follow-up Visits, Criteria for Retreatment and Discontinuation of Treatment)|Percentage of Participants with at Least 1 Adverse Event (AE) based on intensity, relationship with the treatment and severity|Percentage of Participants by Intra-ocular Pressure (IOP) Categories (≥25 and ≥35 mmHg)|Number of Participants with Intra-ocular Pressure (IOP) Changes >10 mmHg from Baseline|Percentage of Participants Treated with a Hypotonic Agent, Laser, Filtration Surgery|Number of Participants with Incident Cataracts|Number of Participants with Cataract Surgeries Related to Treatment or Injection|Percentage of Participants with Serious Adverse Events|Percentage of Participants with Death","Allergan","All","18 Years and older   (Adult, Older Adult)",,"115","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GMA-EAME-EYE-0440","October 19, 2017","December 19, 2018","December 19, 2018","December 28, 2016",,"March 14, 2019","Centre MGM, Aix-En-Provence, France|Ballanger, Aulnay-Sous-Bois, France|CH BLOIS, Blois, France|CH Avicennes Bobigny, Bobigny, France|Centre Rétine Gallien à Bordeaux, Bordeaux, France|CHU Bordeaux, Bordeaux, France|CHU Brest, Brest, France|CHI Créteil, Creteil, France|CH SCORFF - Lorient, Lorient, France|Hopital De La Croix Rousse, Lyon, France|Clinique Monticelli, Marseille, France|Hopital de la Timone, Marseille, France|CHR Annecy, Metz-Tessy, France|CHU Pasteur 2, Nice, France|Chno 1520, Paris, France|Hopital Saint Joseph, Paris, France|Fondation Rothschild, Paris, France|Lariboisiere, Paris, France|COCHIN, Paris, France|Hopital Poissy, Poissy, France|Hôpital de La Milétrie Poitiers, Poitiers, France|Hopital Saint Germain en Laye, Saint Germain En Laye, France|Centre OPHTA.Kervision, Saint-Herblain, France|Maison Rouge, Strasbourg, France|Chu Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03003416"
101,"NCT02980783","A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions","BEAM","Completed","Has Results","Cheek Line Depressions","Device: Juvéderm® VOLIFT®™ with Lidocaine","Percentage of Participants by Improvement Rating (Improved and Not Improved) of Their Dynamic Radial Cheek Lines as Assessed by the Participant Using the Global Aesthetic Improvement Scale (GAIS)|Change From Baseline in Mean Roughness (Ra) of the Radial Cheek Lines at Maximum Smile as Assessed by DERMATOP®|Change From Baseline in Mean Texture (Rz) of the Radial Cheek Lines at Maximum Smile as Assessed by DERMATOP®|Change From Baseline in Mean Amplitude (Rt) of the Radial Cheek Lines at Maximum Smile as Assessed by DERMATOP®|Change From Baseline in Wrinkle Volume of Radial Cheek Lines at Maximum Smile|Percentage of Participants by Improvement Rating (Response) of the Participants' Dynamic Radial Cheek Lines as Assessed by the Investigator Using the GAIS|Percentage of Participants by Self-Perceived Age Category as Assessed by the Self-Perception of Age (SPA) Questionnaire|Mean Score for the Level of Naturalness of the Appearance of Participants' Dynamic Radial Cheek Lines as Assessed by a Participant Questionnaire","Allergan","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMA-EAME-FAS-0397","October 13, 2016","December 14, 2016","December 14, 2016","December 2, 2016","February 15, 2019","February 15, 2019","Laboratoire DERMSCAN, Lyon, France",,"https://ClinicalTrials.gov/show/NCT02980783"
102,"NCT02977507","Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma",,"Completed","Has Results","Melasma","Other: Lytera 2.0|Drug: 4% Hydroquinone Topical Cream|Other: SkinMedica Facial Cleanser|Other: SkinMedica Rejuvenative Moisturizer|Other: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen","Change From Baseline in Melasma Severity Rating Scale Score to Week 12|Change From Baseline in Overall Hyperpigmentation Scale Score to Week 12|Change From Baseline in Melasma Area and Severity Index (MASI) Score to Week 12|Number of Participants by Responses for Self-Assessment Questionnaire: Overall Improvement in Skin Condition|Number of Participants by Responses for Self-Assessment Questionnaire: Overall Satisfaction With the Test Product|Number of Participants by Responses for Self-Assessment Questionnaire: Test Product Preference|Change From Baseline in Melasma Quality of Life (MELASQOL) Scale Total Score to Week 12|Investigator's Global Improvement Assessment for Overall Hyperpigmentation Score to Week 12|Change From Baseline in Mexameter Measurement of Target Hyperpigmentation Lesion to Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SKM16-LYT-MEL","December 13, 2016","October 9, 2017","October 9, 2017","November 30, 2016","November 7, 2018","December 19, 2018","Mount Sinai St. Luke's Hospital, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02977507/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02977507"
103,"NCT02965846","Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye",,"Terminated","Has Results","Dry Eye Syndromes","Drug: AGN-195263|Drug: Vehicle","Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe)|Change From Baseline in Tearfilm Break Up Time (TBUT)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","195263-010","December 13, 2016","June 13, 2017","June 13, 2017","November 17, 2016","November 30, 2018","November 30, 2018","Sall Research Medical Center, Artesia, California, United States|Lugene Eye Institute, Glendale, California, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Devers Eye Institute, Portland, Oregon, United States|Scott and Christie Associates, Cranberry Township, Pennsylvania, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Piedmont Eye Center, Lynchburg, Virginia, United States|Fakultni nemocnice Ostrava, Ostrava, Czechia|Ocni klinika OFTEX, Pardubice, Czechia|FN Kralovske Vinohrady, Ocni Klinika, Praha 10, Czechia|Oční ambulance, Velká Bíteš, Czechia|CHU de Bordeaux, Service d'Ophtalmologie, Bordeaux, France|CHU Hopital Morvan (Bat 4) Service Daviel Ophtalmologie, Brest Cedex, France|CHU Limoges - Hôpital Dupuytren, Limoges Cedex, France|Augenklinik Universitatsklinikum, Dusseldorf, Germany|University Eye Hospital, Freiburg, Germany|University Hospital of Cologne, Dept of Ophthalmology, Koln, Germany|Gutenberg University Medical School, Dept of Ophthalmology, Mainz, Germany|Ludwig-Maximilians-University, Dept of Ophthalmology, Munich, Germany|St. Franziskus Hospital Augenabteilung, Munster, Germany|Dept. of Ophthalmology Semmelweis University, Budapest, Hungary|University of Debrecen, Dept of Opthalmology, (DE OEC Szemklinika), Debrecen, Hungary|University of Szeged Szent-Györgyi Albert Clinical Center, Faculty of Medicine, Dept of Ophthalmology, Szeged, Hungary|Rapallo Hospital, Opthalmology Department, Genova, Italy|Istituto di Oftalmologia, Messina, Italy|Ospedale San Giuseppe, Universita di Milano, Milano, Italy|Istituto Di Ricovero E Cura A Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele), Milano, Italy|University of Pisa, Neurosciences - Section of Ophthalmology, Pisa, Italy|Asian Eye Institute, Makati City, Philippines|Peregrine Eye and Laser Institute, Makati City, Philippines|The Medical City, Pasig City, Philippines|Prywatna Klinika Okulistyczna OFTALMIKA, Bydgoszcz, Poland|Szpital Specjalistyczny nr 1 w Bytomiu, Bytom, Poland|Optimum Profesorskie Centrum Okulistyki, Gdansk, Poland|Specjalistyczna Praktyka Lekarska prof. Edward Wylegala, Katowice, Poland|Uniwersyteck Szpital Kliniczny im. Jana Mikulicza-Radeckiego, Wroclaw, Poland|Institto de Microcirugia Ocular C/Josep Maria Llado, Barcelona, Spain|Clinico de Barcelona Casa de la Maternidad, Barcelona, Spain|Clinica Oftalmologica, Huelva, Spain|Instituto Oftalmologico Fernandez-Vega, Oviedo, Principado De Asturias, Spain|Cartuja Vision, Sevilla, Spain|University of Valladolid, Facultad Medicina, Valladolid, Spain|Buddhist Tzu Chi General Hospital, Hualien, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Ege Üniv. Tıp Fakültesi, Izmir, Turkey|Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Turkey|Newcastle University School of Medicine, Dept of Ophthamology, Newcastle-upon-Tyne, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02965846/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02965846"
104,"NCT02961764","Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",,"Completed","No Results Available","Acute Bacterial Skin and Skin Structure Infections","Drug: Usual Care|Drug: Dalbavancin","Number of Total Admitted Hospital Days|Number of Infection-related Total Admitted Hospital Days|Hospital Admission Rate at Initial Episode of Care|Emergency Department (ED) Length of Stay at Initial Episode of Care|Number of Infection-related Major Surgical Interventions that Required Operating Room Time|Number of Infection-related Hospitalizations|Number of Infection-related Hospitalizations during Initial Care and Follow-up that Resulted in Admission to Intensive Care Unit|Number of All Cause Hospitalizations in the 30 Days post Discharge from the Hospital or Release from the ED|Number of Infection-related ED Visits|Number of Infection-related Outpatient Healthcare Visits|Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy|Number of Infection-related Healthcare Visits due to PICC Line or Central Line used to Administer Antibiotic Therapy|Number of Participants with Serious Adverse Events (SAEs)|Patient Satisfaction with Care as Assessed by a 21-Item Questionnaire|Number of Days with Work and Productivity Loss Assessed by the 6-Item Work Productivity and Activity Impairment Specific Health Problem (WPAI:SHP) Questionnaire|Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","322","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-US-ID-0476","November 29, 2016","March 27, 2019","March 27, 2019","November 11, 2016",,"April 9, 2019","Maricopa Medical Center, Phoenix, Arizona, United States|Olive View-UCLA Medical Center, Sylmar, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Tampa General Hospital, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wayne State University, Detroit, Michigan, United States|ProMedica Monroe Regional Hospital, Monroe, Michigan, United States|Truman Medical Centers, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02961764"
105,"NCT02959983","Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use",,"Completed","Has Results","Irritable Bowel Syndrome With Diarrhea","Drug: Eluxadoline|Drug: Placebo","Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores|Percentage of Stool Consistency Responders|Percentage of Pain Responders|Percentage of Monthly Composite Responders","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMO-US-GI-0429","October 25, 2016","January 22, 2018","January 22, 2018","November 9, 2016","February 15, 2019","February 15, 2019","Clinical Research Associates, LLC, Huntsville, Alabama, United States|The Center for Clinical Trials, Saraland, Alabama, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Med Investigations, Carmichael, California, United States|GW Research Inc, Chula Vista, California, United States|Diagnamics Inc, Encinitas, California, United States|Behavioral Research Specialists, LLC, Irvine, California, United States|Providence Clinical Research, North Hollywood, California, United States|Shahram Jacobs MD INC., Sherman Oaks, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Upland Clinical Research, Upland, California, United States|Advanced RX Clinicial Research Group, Inc., Westminster, California, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Digestive Care of N. Broward, Coral Springs, Florida, United States|Homestead Medical Research, Homestead, Florida, United States|Clinical Neuroscience Solutions Inc., Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Precision Clinical Research LLC, Lauderdale Lakes, Florida, United States|Ocean Blue Medical Research Center, Inc, Miami Springs, Florida, United States|Pharmax Research Clinic Inc., Miami, Florida, United States|Well Pharma Medical Research, Corp., Miami, Florida, United States|Bravo Health Care Center, North Bay Village, Florida, United States|Clinical Neuroscience Solutions Inc., Orlando, Florida, United States|Clinical Research of West Florida Inc., Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|RNA America, LLC, Buford, Georgia, United States|Northwestern University Feinbery School of Medicine, Chicago, Illinois, United States|Pharmakon Inc, Evergreen Park, Illinois, United States|Investigators Research, Brownsburg, Indiana, United States|Radiant Research, Inc., Evansville, Indiana, United States|Clinical Research Advantage Inc/Radiant Research Inc., Evansville, Indiana, United States|Gtc Research, Shawnee Mission, Kansas, United States|Investigative Clinical Research, Annapolis, Maryland, United States|MGG Group Co. Inc. Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Clinical Research Insititute of Michigan LLC, Chesterfield, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC, Wyoming, Michigan, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Women's Clinic of Lincoln, P.C., Lincoln, Nebraska, United States|Quality Clinical Research Inc., Omaha, Nebraska, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Advanced Research Institute, Reno, Nevada, United States|Drug Trials Brooklyn, Brooklyn, New York, United States|NY Scientific, Brooklyn, New York, United States|Long Island Gastrointestinal Group LLP, Great Neck, New York, United States|IMA Medical Research, PC, Kew Gardens, New York, United States|Charlotte Gastroenterology & Hepatology, PLLC, Charlotte, North Carolina, United States|Peters Medical Research LLC, High Point, North Carolina, United States|North State Clincial Research PLLC, Lenoir, North Carolina, United States|Wake Research Associates LLC, Raleigh, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|Clinical Inquest Center Ltd, Beavercreek, Ohio, United States|Hometown Urgent Care and Research, Cincinnati, Ohio, United States|Buckeye Health and Research, Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Hometown Urgent Care and Research, Huber Heights, Ohio, United States|Central Sooner Research, Norman, Oklahoma, United States|The Oregon Center for Clinical Investigations, INC., Salem, Oregon, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|CNS Healthcare, Memphis, Tennessee, United States|Premier Family Physicians, Austin, Texas, United States|Family Medicine Associate of Texas, Carrollton, Texas, United States|Multi-Phase Trials LLC, San Antonio, Texas, United States|Health Texas Research Institute, San Antonio, Texas, United States|Discovery Clinical Trials - Stone Oak, San Antonio, Texas, United States|Carl Meisner Medical Clinic, Sugar Land, Texas, United States|Advanced Research Institute - Ogden, Ogden, Utah, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Gastroenterology Associates of Northern Virginia, Fairfax, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Corunna Medical Research Centre, Corunna, Ontario, Canada|Manna Research, Etobicoke, Ontario, Canada|SKDS Research Inc, Newmarket, Ontario, Canada|University of Calgary, Calgary, Canada|Viable Clinical Research Corp., Nova Scotia, Canada|Centre de reserche St Louis, Quebec, Canada|Dynamik Research Inc, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02959983/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02959983/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02959983"
106,"NCT02951975","Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye","Louvre 2","Terminated","No Results Available","Non-infectious Uveitis","Drug: dexamethasone intravitreal implant","Percentage of Participants with Best Corrected Visual Acuity (BCVA) ≥15 Letters|Percentage of Participants with a Gain (Improvement) in BCVA of at Least 15 Letters from Baseline|Change from Baseline in BCVA|Change from Baseline in Vitreous Haze Score Using a 5-Point Scale|Change from Baseline in Macular Thickness|Percentage of Participants Categorized by Comorbidities (Diseases Associated with Inflammation, Other Ophthalmic Diseases, General Comorbidities)|Change from Baseline in the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ25) Score Using a 25 Item Questionnaire|Number of Repeat Treatments with OZURDEX® and Other Drugs|Time Between Repeat Treatments with OZURDEX® and Other Drugs|Percentage of Participants with Adverse Events (AEs)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"246","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GMA-EAME-EYE-0368","January 25, 2017","November 28, 2018","December 19, 2018","November 1, 2016",,"August 2, 2019","CHU Amiens, Amiens, France|IOP Institut Ophtalmologique de Picardie, Amiens, France|Centre Rétine Gallien, Bordeaux, France|Hopital Pellegrin, Bordeaux, France|CHI de Créteil, Creteil, France|CHU Dijon, Dijon, France|Centre Pôle Vision Val d'Ouest, Ecully, France|Hopital Claude Huriez, Lille, France|Hopital De La Croix Rousse, Lyon, France|Clinique Monticelli, Marseille, France|Hopital de la Timone, Marseille, France|Hopital Gui De Chauliac, Montpellier, France|SEL Ophtalliance, Nantes, France|Hopital Hotel Dieu Et Hme, Nantes, France|CHU Pasteur 2, Nice, France|Hôpital Lariboisière (AP-HP), Paris, France|GH Pitie Salpêtrière (AP-HP), Paris, France|GH Cochin St Vincent De Paul (AP-HP), Paris, France|Fondation Rothschild, Paris, France|Hopital La Milétrie, Poitiers, France|Chu Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02951975"
107,"NCT02877069","Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment of Superficial Cutaneous Depressions",,"Completed","No Results Available","Skin Roughness","Device: VYC-12 HA injectable gel","Percentage of Participants with a ≥1 Point Improvement in the 5-Point Allergan Skin Roughness Scale (ASRS) compared to Baseline|Change from Baseline in Instrument Measures of Cheek Skin Smoothness|Change from Baseline in Instrument Measures of Cheek Skin Hydration|Change from Baseline in Instrument Measures of Cheek Skin Elasticity","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","134","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","V12-001","September 2015","January 2016","October 2016","August 24, 2016",,"October 21, 2016","Laboratoire Dermscan-Pharmascan, Lyon, Auvergne-Rhône-Alpes, France",,"https://ClinicalTrials.gov/show/NCT02877069"
108,"NCT02873221","An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine",,"Completed","Has Results","Migraine, With or Without Aura","Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant|Drug: Usual Care","Percentage of Participants With at Least 1 Treatment Emergent Adverse Event|Number of Participants With Clinically Significant Laboratory Values|Number of Participants With Clinically Significant Electrocardiograms (ECGs) Findings|Number of Participants With Clinically Significant Vital Sign Measurements|Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales","Allergan","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 3","1254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UBR-MD-04","September 13, 2016","August 2, 2018","August 2, 2018","August 19, 2016","August 28, 2019","August 28, 2019","Radiant Research, Inc., Birmingham, Alabama, United States|East Family Physicians PC/Radiant Research, Inc., Chandler, Arizona, United States|Desert Clinical Research /Radiant Research, Inc., Mesa, Arizona, United States|Xenoscience, Inc., Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Radiant Research Inc., Tucson, Arizona, United States|Orange Grove Family Practice/Radiant Research, Inc., Tucson, Arizona, United States|Principals Research Group, Inc., Hot Springs, Arkansas, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Axiom Research, Apple Valley, California, United States|Hope Clinical Research, Canoga Park, California, United States|Med Center Medical Clinic Carmichael, Carmichael, California, United States|Axiom Research, LLC, Colton, California, United States|Pharmacology Research Institute, Encino, California, United States|Encino Research Center/T Joseph Raoof MD Inc, Encino, California, United States|Neuro-Pain Medical Center, Inc, Fresno, California, United States|California Headache and Balance Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Grossmont Center For Clinical Research, La Mesa, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|Synergy San Diego, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Desert Valley Research, Rancho Mirage, California, United States|George J Rederich MD, Inc., Redondo Beach, California, United States|Artemis Institute For Clinical Research, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Southern California Research Center, Simi Valley, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Radiant Research, Vista, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Clinicos LLC, Colorado Springs, Colorado, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Delta Waves, Inc, Colorado Springs, Colorado, United States|Denver Neurological Research, Denver, Colorado, United States|Summit Headache and Neurologic Institute, Englewood, Colorado, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, PC, Fairfield, Connecticut, United States|Aventura Neurological Associates, PA, Aventura, Florida, United States|Clinical Research South Florida, Coral Gables, Florida, United States|Avail Clinical Research, DeLand, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Wilks & Safirstein MD PA D/B/A MD Clinical, Hallandale Beach, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Broward Research, Hollywood, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|LCC Medical Research, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Clinical Neuroscience Solutions, Inc - Memphis, TN, Orlando, Florida, United States|Palm Beach Neurological Center / Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Qps Mra, Llc, South Miami, Florida, United States|Meridien Research, Spring Hill, Florida, United States|University of South Florida, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Neurology Research Institute Palm Beach, West Palm Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Midtown Neurology, Atlanta, Georgia, United States|NeuroTrials Research Inc, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Michigan Ave. Internists /Radiant Research, Inc., Chicago, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, LLC, Chicago, Illinois, United States|Robbins Headache Clinic, Riverwoods, Illinois, United States|Deaconess Clinic Inc., Evansville, Indiana, United States|Josephson Wallack Munshower Neurology, P.C., Indianapolis, Indiana, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|College Park Family Care Center Physicians Group- Neurology Research Dept, Overland Park, Kansas, United States|Kansas Institute of Research, Overland Park, Kansas, United States|Kentucky Pediatric Research Inc, Bardstown, Kentucky, United States|Norton Neurology Services, Louisville, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Pharma Site Research, Baltimore, Maryland, United States|Seton Medical Group, Baltimore, Maryland, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Beacon Clinical Research, LLC, Quincy, Massachusetts, United States|Medvadis Research Corporation, Watertown, Massachusetts, United States|New England Regional Headache Center, Worcester, Massachusetts, United States|Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Women's Health Care Specialists, Kalamazoo, Michigan, United States|The Minneapolis Clinic of Neurology, Ltd., Golden Valley, Minnesota, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|The Headache Center, Ridgeland, Mississippi, United States|Clinvest, Springfield, Missouri, United States|Prairie Fields Family Medicine, Fremont, Nebraska, United States|Clinical Research Advantage, Inc/Synexus USA, Omaha, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Diagnostic Center of Medicine - Durango / Radiant Research, Inc., Las Vegas, Nevada, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|DENT Neurosciences Research Center, Amherst, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Central New York Clinical Research, Manlius, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Headache Wellness Center, Greensboro, North Carolina, United States|Neurology Associates, P.A., Hickory, North Carolina, United States|Lake Shore Clinical Research, LLC, Mooresville, North Carolina, United States|Wake Research Associates LLC, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC, Fargo, North Dakota, United States|Radiant Research, Inc., Akron, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Patient Priority Clinical Sites, Cincinnati, Ohio, United States|University of cincinnati, Cincinnati, Ohio, United States|CTI Clinical research Center, Cincinnati, Ohio, United States|Radiant Research, Inc, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Ohio Clinical Research, LLC, Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|NPC Research, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Sooner Clinical Research Inc, Oklahoma City, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Oregon Center For Clinical Investigations Inc, Portland, Oregon, United States|Clinical Research Philadelphia, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Radiant Research, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Vista Clinical Research, Columbia, South Carolina, United States|Hillcrest Clinical Research LLC, Simpsonville, South Carolina, United States|Clinsearch, LLC, Chattanooga, Tennessee, United States|Middle Tennessee Clinical Research, Fayetteville, Tennessee, United States|Holston Medical Group, P.C., Kingsport, Tennessee, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|CNS Healthcare, Memphis, Tennessee, United States|Future Search Trials, Austin, Texas, United States|Tekton Research, Austin, Texas, United States|Texas Neurology, P.A., Dallas, Texas, United States|Futuresearch Trials of Dallas, LP, Dallas, Texas, United States|Radiant Research, Inc., Dallas, Texas, United States|Research Trials Worldwide, LLC, Humble, Texas, United States|Red Star Research, LLC, Lake Jackson, Texas, United States|Clinical Trials Texas, Inc, San Antonio, Texas, United States|Road Runner Research, San Antonio, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic Draper, Draper, Utah, United States|Advanced Research Institute, Ogden, Utah, United States|Granger Medical Clinic - Riverton, Riverton, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Highland Clinical Reserach, Salt Lake City, Utah, United States|Charlottesville Medical Research Center, LLC, Charlottesville, Virginia, United States|Clinical Research Associates Tidewater, Norfolk, Virginia, United States|Blue Ridge Research Center, Roanoke, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|The Polyclinic, Seattle, Washington, United States|South Puget Sound Neurology, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02873221/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02873221/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02873221"
109,"NCT02867709","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","ACHIEVE II","Completed","Has Results","Migraine, With or Without Aura","Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant","Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose|Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose|Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose|Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose|Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose|Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1686","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UBR-MD-02","August 26, 2016","January 25, 2018","February 26, 2018","August 16, 2016","January 29, 2019","March 19, 2019","Clinical Research Advantage, Inc./Simon Williamson Clinic, Birmingham, Alabama, United States|Clinical Research Advantage, Inc./East Valley Family Physicians, PLC, Chandler, Arizona, United States|St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI), Phoenix, Arizona, United States|Clinical Research Advantage, Inc./Central Phoenix Medical Clinic, LLC, Phoenix, Arizona, United States|Mayo Clinic Arizona, May Clinic Scottsdale, Scottsdale, Arizona, United States|Radiant Research Inc., Tucson, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Axiom Research, LLC, Apple Valley, California, United States|Hope Clinical Research, Canoga Park, California, United States|Axiom Research, LLC, Colton, California, United States|Pharmacology Research Institute, Encino, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|California Headache and Balance Center, Fresno, California, United States|Sun Valley Research Center, Imperial, California, United States|Grossmont Center For Clinical Research, La Mesa, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|California Advanced Neurotherapeutic, Inc., Los Angeles, California, United States|Cedars Sinai Pain Center, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Desert Valley Research, Rancho Mirage, California, United States|George J Rederich MD, Inc, Redondo Beach, California, United States|Artemis Institute For Clinical Research, San Diego, California, United States|Clinical Research Advantage, Inc./Cassidy Medical Group-Vista, Vista, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Radiant Clinical Research, Washington, District of Columbia, United States|Aventura Neurological Associates, Aventura, Florida, United States|Clinical Research South Florida, Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Broward Research Group, Hollywood, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Well Pharma Medical Research, Corp., Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|QPS MRA, LLC (Miami Research Associates), South Miami, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|The Kaufmann Clinic, Inc., Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Clinical Research Advantage, Inc./Michigan Avenue Internists, Chicago, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Robbins Headache Clinic, Riverwoods, Illinois, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States|Norton Neurology Services MS Services, Louisville, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Seton Medical Group, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Beacon Clinical Research, LLC, Quincy, Massachusetts, United States|New England Regional Headache Center, Inc., Worcester, Massachusetts, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|The Headache Center, Ridgeland, Mississippi, United States|Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Clinical Research Advantage, Inc, Omaha, Nebraska, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Hope Research Institute, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|DENT Neurosciences Research Center, Amherst, New York, United States|Cushing Neuroscience Institute North Shore-LIJ Medical Group, Great Neck, New York, United States|ProHealth Care Associates, LLP, Plainview, New York, United States|Upstate Clinical Research Associates, LLC, Williamsville, New York, United States|Westchester Neuro. Const, Yonkers, New York, United States|Carolina Headache Institute, Durham, North Carolina, United States|Headache Wellness Center, PC, Greensboro, North Carolina, United States|Lake Shore Clinical Research, LLC, Mooresville, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|Plains Clinical Research Center, LLC, Fargo, North Dakota, United States|Radiant Research, Inc., Akron, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|University of Cincinnati Dept of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Abington Neurological Associates, Ltd., Willow Grove, Pennsylvania, United States|Radiant Research, Inc., Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Vista Clinical Research, Columbia, South Carolina, United States|Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States|Middle Tennessee Clinical Research, Fayetteville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Baptist Memorial Medical Group (Neurology Specialist - Headache Clinic), Memphis, Tennessee, United States|Texas Neurology, P.A., Dallas, Texas, United States|Radiant Research, Inc, Dallas, Texas, United States|Research Trials Worldwide, LLC, Humble, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Charlottesville Medical Research Center, LLC, Charlottesville, Virginia, United States|iNeuro Headache Specialist, McLean, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|Blue Ridge Research Center, LLC, Roanoke, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Summit Research Network Seattle, LLC, Seattle, Washington, United States|South Puget Sound Neurology, Tacoma, Washington, United States|West Virginia University, Department of Neurology, Morgantown, West Virginia, United States|Medical College of Wisconsin, Department of Neurology, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02867709/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02867709/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02867709"
110,"NCT02863705","Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)",,"Completed","No Results Available","Glaucoma, Open-Angle|Normal Tension Glaucoma","Drug: brimonidine tartrate/timolol malate Ophthalmic Solution|Drug: bimatoprost ophthalmic solution 0.01%","Mean IOP change from Baseline (11AM point)|Mean IOP change from Baseline (9AM point)|Mean change in Mean deviation (MD) from Baseline|Mean change in Pattern standard deviation (PSD) from Baseline|Mean change in Visual field index (VFI) from Baseline|Mean change in cup to disc ratio (C/D ratio) from Baseline|Rate of VF progression measured as change in VF index over time|Mean duration of achieving the target IOP with COMBIGAN® alone|The percentage of subjects of achieving the target IOP with COMBIGAN® alone during 12 months|Definition of patient demographics (descriptive analysis of age and gender)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","118","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMO-AP-EYE-0428","July 5, 2016","July 25, 2018","July 25, 2018","August 11, 2016",,"August 31, 2018","Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of|Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea, Republic of|Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of|Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of|Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02863705"
111,"NCT02859766","Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD",,"Completed","No Results Available","Macular Degeneration","Drug: Abicipar pegol","Peak Serum Concentration (CMax) for Free and VEGF-Bound Abicipar|Serum Concentration Immediately before Next Dose (Ctrough) for Free and VEGF-Bound Abicipar|Time to Cmax (Tmax) for Free and VEGF-Bound Abicipar|Terminal Elimination Half-Life (t1/2) for Free and VEGF-Bound Abicipar|Area Under the Serum Concentration-Time Curve from Zero to the End of the Dosing Interval ""tau"" (AUC0-tau) for Free and VEGF-Bound Abicipar|Area Under the Serum Concentration-Time Curve from Zero to Infinity (AUC0-inf) for Free and VEGF-Bound Abicipar|Serum Levels of Anti-abicipar Antibodies|Percentage of Participants with Treatment Emergent Adverse Events|Best Corrected Visual Acuity using an Eye Chart|Percentage of Participants with Change from Baseline in Full Ophthalmic Exam Findings [i.e. Slit Lamp Exam, Intraocular Pressure (IOP) Measurements, Funduscopic Exam]|Changes from Baseline in General Physical Condition as Measured through General Physical Exam|Percentage of Participants with Changes from Baseline in Vital Signs (Blood Pressure, Pulse Rate)|Percentage of Participants with Change from Baseline in Clinically Relevant Laboratory Values (Serum Chemistry, Hematology, Urinalysis)","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150998-012","December 7, 2016","October 20, 2017","October 20, 2017","August 9, 2016",,"February 8, 2018","Retinal Consultants of Arizona, Gilbert, Arizona, United States|Win Retina, Arcadia, California, United States|Retina Vitreous Associates Medical Group, Beverly Hills, California, United States|Atlantis Retina Institute (Atlantis Eyecare), Huntington Beach, California, United States|Jacobs Retina Center, Shiley Eye Institute, UCSD, La Jolla, California, United States|California Eye Specialists Medical Group, Inc-Private Clinic, Pasadena, California, United States|University of Miami, Coral Gables, Florida, United States|The Eye Institute of West Florida, Largo, Florida, United States|Retina Specialty Institute, Pensacola, Florida, United States|East Florida Eye Insititute, Stuart, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Raj K. Maturi, MD, Indianapolis, Indiana, United States|Massachusetts Eye & Ear, Boston, Massachusetts, United States|Eyesight Ophthalmic Services, PA, Portsmouth, New Hampshire, United States|Caroline Eye Associates, Southern Pines, North Carolina, United States|Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States|Rocky Mountain Retina Consultants, Salt Lake City, Utah, United States|Davis Duehr Dean, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02859766"
112,"NCT02848326","Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention",,"Completed","Has Results","Migraine, With or Without Aura","Drug: Atogepant|Drug: Placebo-matching Atogepant","Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period|Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period|Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period|Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","834","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CGP-MD-01","September 6, 2016","April 2, 2018","April 23, 2018","July 28, 2016","December 6, 2018","December 6, 2018","Achieve Clinical Research, Birmingham, Alabama, United States|Radiant Research, Inc., Chandler, Arizona, United States|The Research Center of Southern California, LLC, Carlsbad, California, United States|Neuro-Pain Medical Center, Inc, Fresno, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Downtown LA Research Center, Inc., Los Angeles, California, United States|Excell Research, Oceanside, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Diablo Clinical Research Inc, Walnut Creek, California, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Hartford Headache Center, East Hartford, Connecticut, United States|Associated Neurologists of Southern Connecticut, P. C., Fairfield, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|The George Washington University, Washington, District of Columbia, United States|Clinical Research South Florida, Coral Gables, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|Suncoast Research, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Palm Beach Neurological Center / Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Infinity Clinical Research LLC, Sunrise, Florida, United States|Meridien Research, Tampa, Florida, United States|Neurology Research Institute Palm Beach, West Palm Beach, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Radiant Research, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Sandy Springs, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Northwest Clinical Trials, Inc., Boise, Idaho, United States|Healthcare Research Network II, LLC, Blue Island, Illinois, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Medvadis Research Corporation, Watertown, Massachusetts, United States|New England Regional Headache Center, Worcester, Massachusetts, United States|Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Mercy Research, Springfield, Missouri, United States|Clinvest, Springfield, Missouri, United States|Quality Clinical Research, Inc, Omaha, Nebraska, United States|Altea Research Institute, Las Vegas, Nevada, United States|Renown Institute for Neuroscience, Reno, Nevada, United States|Hassman Research Institute - NJ, Berlin, New Jersey, United States|Amici Clinical Research, Warren, New Jersey, United States|DENT Neurosciences Research Center, Amherst, New York, United States|Radiant Research, Inc., Jamaica, New York, United States|Carolina Headache Institute, Durham, North Carolina, United States|Wake Research Associates LLC, Raleigh, North Carolina, United States|Ohio Clinical Research, LLC, Willoughby Hills, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|Lehigh Center For Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Cns Healthcare, Memphis, Tennessee, United States|Nashville Neuroscience Group, Nashville, Tennessee, United States|Tekton Research, Austin, Texas, United States|DermResearch Inc, Austin, Texas, United States|DiscoveResearch, Inc., Bryan, Texas, United States|Synexus US, L.P. Formally known as Texas Pharmaceutical Research, LP, DBA Research Across America, Dallas, Texas, United States|Central Texas Neurology Consultant, Round Rock, Texas, United States|Radiant Research, San Antonio Center for Clinical Research, San Antonio, Texas, United States|Road Runner Research LTD, San Antonio, Texas, United States|ClinPoint Trials, LLC, Waxahachie, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Women's Clinical Research Center, Seattle, Washington, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02848326/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02848326/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02848326"
113,"NCT02848300","Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia",,"Completed","No Results Available","Androgenetic Alopecia","Drug: Bimatoprost 1% Formulation A|Drug: Bimatoprost 1% Formulation B","Drug Concentration in Skin Biopsy Samples|Percentage of Participants with at Least 1 Treatment Emergent Adverse Event","Allergan","Male","18 Years to 49 Years   (Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1666-101-012","July 2016","October 2016","October 2016","July 28, 2016",,"October 26, 2016","DermResearch, LLC, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02848300"
114,"NCT02833077","A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation",,"Completed","No Results Available","Chin Retrusion","Device: JUVÉDERM VOLUMA® XC","≥ 1-Point Improvement on the 5-Point Allergan Chin Retrusion Scale Score|Change from Baseline on the 100-Point Subject Assessed Chin Satisfaction Module of the FACE-Q Questionnaire|≥ 1-Point Improvement on the 5-Point Global Aesthetic Improvement Scale (GAIS) for the Chin Area by the Evaluating Investigator|≥ 1-Point Improvement on the 5-Point Global Aesthetic Improvement Scale (GAIS) for the Chin Area by the Subject","Allergan","All","22 Years and older   (Adult, Older Adult)","Not Applicable","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Voluma-006","June 28, 2016","February 6, 2018","October 11, 2018","July 14, 2016",,"February 18, 2019","Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc., San Diego, California, United States|Skin Research Institute, Coral Gables, Florida, United States|Baumann Cosmetic and Res. Institute, Miami Beach, Florida, United States|Research Institute of the Southeast, West Palm Beach, Florida, United States|DeNova Research, Chicago, Illinois, United States|Callender Dermatology and Cosmetic Center, Glenn Dale, Maryland, United States|SkinCare Physicians of Chestnut Hill, Chestnut Hill, Massachusetts, United States|St Louis University Medical Center Dept. of Dermatology, Des Peres, Missouri, United States|Image Dermatology, PC, Montclair, New Jersey, United States|Williams Plastic Surgery Specialists, Latham, New York, United States|The Center for Dermatology, Cosmetics, & Laser Surgery, Mount Kisco, New York, United States|Dermatology & Laser Center of Charleston Center for Clinical Research, Charleston, South Carolina, United States|Nashville Centre for Laser and Facial Surgery, Nashville, Tennessee, United States|Premier Clinical Research; Spokane Dermatology Clinic, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02833077"
115,"NCT02828020","Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","ACHIEVE I","Completed","Has Results","Migraine, With or Without Aura","Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant","Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose|Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose|Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose|Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose|Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose|Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1672","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UBR-MD-01","July 22, 2016","December 13, 2017","December 14, 2017","July 11, 2016","January 3, 2019","January 3, 2019","Clinical Research Advantage, Inc./Desert Clinical Research, LLC., Mesa, Arizona, United States|Xenoscience, Inc., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./Orange Grove Family Practice, Tucson, Arizona, United States|Principals Research Group, Inc., Hot Springs, Arkansas, United States|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States|The Research Center of Southern California, LLC, Carlsbad, California, United States|Med Center, Carmichael, California, United States|T. Joseph Raoof MD, Inc./Encino Research Center, Encino, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Collaborative Neuroscience Network, LLC., Long Beach, California, United States|Synergy San Diego, National City, California, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States|North County Clinical Research, Oceanside, California, United States|Medical Center for Clinical Research, San Diego, California, United States|CA Medical Clinic for Headache, Santa Monica, California, United States|Southern California Research LLC, Simi Valley, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Delta Waves, Inc, Colorado Springs, Colorado, United States|Denver Neurological Research, Denver, Colorado, United States|Associated Neurologists, P.C., Danbury, Connecticut, United States|Associated Neurolgists of Southern Connecticut, PC, Fairfield, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|CPI MD Clinical, Hallandale Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Meridien Research, Spring Hill, Florida, United States|University of South Florida, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Neurology Research Institute, West Palm Beach, Florida, United States|Midtown Neurology, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Deaconess Clinic, Medical Office Building 1 Research Institute, Newburgh, Indiana, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Kansas Institute of Research, Overland Park, Kansas, United States|College Park Family Care Center Physicians Group - Neurology Research Department, Overland Park, Kansas, United States|Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Northeast Medical Research Associates, Inc, South Dartmouth, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Michigan Head-Pain & Neurological Institute, Ann Arbor, Michigan, United States|Beyer Research, Kalamazoo, Michigan, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Clinvest Research, LLC, Springfield, Missouri, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Diagnostic Center of Medicine - Durango, Las Vegas, Nevada, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Central New York Clinical Research, Manlius, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Neurology Associates, P.A., Hickory, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC., Winston-Salem, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Aventiv Research, Inc, Columbus, Ohio, United States|Ohio Clinical Research, LLC, Lyndhurst, Ohio, United States|MPH IPS Research Company, Oklahoma City, Oklahoma, United States|NPC Research, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Oregon Center For Clinical Investigations Inc. (OCCI, Inc.), Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|BTC of Lincoln, Lincoln, Rhode Island, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Red Star Research, LLC, Lake Jackson, Texas, United States|Clinical Trials Texas, Inc, San Antonio, Texas, United States|Road Runner Research, Ltd., San Antonio, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic Draper, Draper, Utah, United States|Granger Medical Clinic-Riverton, Riverton, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|The Polyclinic Madison Center, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02828020/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02828020/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02828020"
116,"NCT02815293","Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye",,"Terminated","Has Results","Dry Eye Syndromes","Drug: AGN-195263|Drug: Vehicle","Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe)|Change From Baseline in Tearfilm Break Up Time (TBUT)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","195263-009","September 30, 2016","June 21, 2017","June 21, 2017","June 28, 2016","February 19, 2019","February 19, 2019","Arizona Eye Center, Chandler, Arizona, United States|Clearsight, Fullerton, California, United States|Orange County Ophthalmology Medical Group, Garden Grove, California, United States|Montebello Medical Center, Inc., Montebello, California, United States|Eye Research Foundation, Newport Beach, California, United States|North Bay Eye Associates, Petaluma, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Centennial Eye and Cosmetic Associates, Centennial, Colorado, United States|Specialty Eye Care, Parker, Colorado, United States|Argus Research at Cape Coral Eye Center, Cape Coral, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Eye Care Centers Management, Inc. dba Clayton Eye Center, Morrow, Georgia, United States|Taustine Eye Center, Louisville, Kentucky, United States|Eye Doctors of Washington, Chevy Chase, Maryland, United States|Ophthalmology Consultants, Ltd, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Comprehensive Eye Care, Washington, Missouri, United States|Cornerstone Eye Care, LLC, High Point, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Carolina Macula and Retina, Mount Pleasant, South Carolina, United States|Nashville Vision Associates, LLC, Nashville, Tennessee, United States|Robert Cizik Eye Clinic, Houston, Texas, United States|Houston Eye Associates, Kingwood, Texas, United States|Brazosport Eye Institute, Lake Jackson, Texas, United States|The Eye Clinic of Texas, an affiliate of Houston Eye Associates, League City, Texas, United States|DCT- Shah Research, LLC dba Discovery Clinical Trials, Mission, Texas, United States|R and R Eye Research, LLC, San Antonio, Texas, United States|Stacy R. Smith, M.D., P.C., Salt Lake City, Utah, United States|The Eye Centers of Racine and Kenosha, Racine, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02815293/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02815293"
117,"NCT02814916","Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA",,"Recruiting","No Results Available","Methicillin-Resistant Staphylococcus Aureus|Bacterial Infections|Staphylococcal Skin Infections","Drug: Dalbavancin single dose|Drug: Dalbavancin two dose|Drug: Comparator","Number of patients with abnormal audiologic assessment|Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora|Clinical response|Clinical response evaluated at the end of treatment (EOT) visit: Cure|Clinical response evaluated at the end of treatment (EOT) visit: Improvement|Clinical response evaluated at the end of treatment (EOT) visit: Failure|Clinical response evaluated at the end of treatment (EOT) visit: Unknown|Clinical response evaluated at the test of cure visit: Cure|Clinical response evaluated at the test of cure visit: Failure|Clinical response evaluated at the test of cure visit: Unknown|Clinical response evaluated at follow-up visit: Cure|Clinical response evaluated at follow-up visit: Failure|Clinical response evaluated at follow-up visit: Unknown|Presence of baseline pathogen after treatment|All-cause mortality: For patients age birth to < 3 months, all-cause mortality will be determined at test of cure (TOC) visit|Dalbavancin plasma concentration","Allergan","All","up to 17 Years   (Child)","Phase 3","212","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DUR001-306|2014-005281-30","March 30, 2017","December 31, 2021","December 31, 2021","June 28, 2016",,"January 18, 2020","University of South Alabama, Mobile, Alabama, United States|Maricopa Integrated Health System, Phoenix, Arizona, United States|Southbay Pharma Research, La Palma, California, United States|University of California Los Angeles campus, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Revival Research, Doral, Florida, United States|Global Research Holdings, LLC, Panama City, Florida, United States|Florida Health Sciences Center dba Tampa General Hospital, Tampa, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Children's Mercy Kansas City, Kansas City, Kansas, United States|Our Lady of Lake Regional Medical Center, Baton Rouge, Louisiana, United States|Childen's Hospital of Michigan, Detroit, Michigan, United States|University of Missouri Dermatology and Skin Surgery, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York University School of Medicine, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|Hospital de Ninos Dr. Orlando Alassia, Santa Fe, Argentina|Grodno Regional Infectious Disease Hospital, Grodno, Belarus|Mogilev Regional Children's Hospital, Mogilev, Belarus|Vitebsk Regional Clinical Center for Children, Vitebsk, Belarus|Medical Center - 1 Sevlievo EOOD, Sevlievo, Gabrovo, Bulgaria|University Multiprofile Hospital for Active Treatment - ""Deva Maria"" EOOD Burgas (UMHAT Deva Maria) Surgery Department, Burgas, Bulgaria|MHAT (Multiprofile Hospital for Active Treatment), Kozloduy, Bulgaria|UMHAT (University Multiprofile Hospital for Active Treatment) Dr. Georgi Stranski, EAD Pediatric Clinic, Pleven, Bulgaria|UMHAT (University Multiprofile Hospital for Active Treatment) Dr. Georgi Stranski, EAD Second Surgery Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ( UMHAT) ""Sveti Georgi"" EAD, Plovdiv Department of pediatric surgery - pediatric surgery, Plovdiv, Bulgaria|""UMHAT (University Multiprofile Hospital for Active Treatment) Sveti Georgi EAD, Plovdiv, Bulgaria|UMHAT Kanev AD, Ruse, Bulgaria|MHATEM (University Multiprofile Hospital for Active Treatment and Emergency Medicine) N.I.Pirogov Septic Surgery Clinic, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Pediatric Diseases Prof. Ivan Mitev EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment (UMHAT), Stara Zagora, Bulgaria|Hospital de Ninos Dr. Roberto del Rio, Independencia, RM, Chile|Hospital San Vicente de Paul en Medellin, Medellin, Antioquia, Colombia|Hospital General de Medellin Luz Castro de Gutierrez, Medellin, Antioquia, Colombia|Fundacion Cardio Infantil, Bogota, Colombia|Clinica Universidad de la Sabana, Chia, Colombia|LTD Unimedi Kakheti Batumi Maternal and Child Healthcare Center, Batumi, Georgia|LEPL Tbilisi State Medical University Givi Zhvania Academic Clinic of Pediatry, Tbilisi, Georgia|LTD M. Iashvili Children's Central Hospital, Tbilisi, Georgia|LTD Unimedi Kakheti Children New Hospital, Tbilisi, Georgia|University General Hospital of Athens Attikon 3rd Department of Pediatrics, Athens, Chaidari, Greece|Aghia Sophia Childrens Hospital, Athens, Greece|""General Childrens Hospital of Athens P A Kyriakou, Athens, Greece|General Hospital Paidon Pentelis, Athens, Greece|General Hospital Paidon Pentelis, Athens, Greece|Hippokration General Hospital of Thessaloniki Aristotle University, 3rd Dept, Thessaloniki, Greece|""Papageorgiou General Hospital of Thessaloniki, 4th Department of Pediatrics, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece|Clinica Medica Especializada en Pediatria, Guatemala, Guatemala|Hospital Roosevelt Pediatric Department, 3rd floor, Guatemala, Guatemala|Hospital del Centro Medico Infectology Department, Guatemala, Guatemala|Liepaja Regional Hospital, Liepaja, Kurzeme, Latvia|Daugavpils Regional Hospital, Daugavpils, Latvia|Children's Clinical University Hospital, Riga, Latvia|Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania|Klaipeda Children's Hospital, Klaipeda, Lithuania|Public Institution Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania|Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Hospital General Dr. Agustin O'Horan, Merida, Yucatan, Mexico|Instituto Nacional de Pediatria, Mexico, Mexico|Hospital Infantil de Mexico Federico Gomez, Mexico, Mexico|Hospital Materno Infantil José Domingo de Obaldía, Chiriqui, Panama|Hospital Del Niño Dr. José Renán Esquivel, Panama City, Panama|Wojewódzki Szpital Obserwacyjno-Zakaźny, Bydgoszcz, Kujawsko-Pomorskie, Poland|Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu, Poznań, Województwo Wielkopolskie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Warszawa, Poland|Spitalul Clinic Judetean de Urgenta Craiova, Craiova, Jud. Dolj, Romania|Spitalul Clinic de Urganta pentru Copii ""Sfanta Maria"" Iasi, Iasi, Jud. Iasi, Romania|Spitalul Clinic Judeatean Mures, Targu Mures, Jud. Mures, Romania|Spitalul Clinic de Urgenta pentru Copii ""Louis Turcanu"", Timisoara, Jud. Timis, Romania|Institutul National de Boli Infectioase ""Prof. Dr. Matei Bals"", Bucuresti, Romania|Spitalul Clinic de Boli Infectioase si Tropicale ""Dr. Victor Babes"", Bucuresti, Romania|Vologda Regional Children's Clinical Hospital, Vologda, Vologda Region, Russian Federation|Smolensk State Medical University, Smolensk, Russian Federation|Stavropol State Medical University, Stavropol, Russian Federation|Peermed Clinical Trial Centre, Kempton Park, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain|Hospital Universitario Donostia, Donostia-San Sebastian, Gipuzkoa, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre Edificio Materno Infantil, Servicio de Pediatria, Madrid, Spain|Hospital La Paz, Madrid, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital La Fe, Valencia, Spain|Central City Clinical Hospital, Pediatric Surgery Department, State Institution of higher Education ""Uzhhorod National University"", Faculty of Postgraduate Education and Pre-University Preparation, Chair of Surgical Specialties, Uzhhorod, Zakarpatska Region, Ukraine|Communal Institution ""Dnipropetrovsk Regional Children's Clinical Hospital"""" Dnipropetrovsk Regional Council"""", Surgery department, State Institution """"Dnipropetrovsk Medical Academy of MoH of Ukraine"""", Chair of Pediatric surgery, Dnipro, Ukraine|Surgery Department, Ivano-Frankivsk Regional Pediatric Clinical Hospital,, Ivano-Frankivsk, Ukraine|PE PMC Acinus, Kropyvnytskyi, Ukraine|Lviv National Medical University, Lviv, Ukraine|Higher State Educational Institute of Ukraine ""Ukrainian Medical Stomatological Academy"" based on Children's City Clinical Hospital of Poltava City, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT02814916"
118,"NCT02781311","A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males",,"Completed","Has Results","Alopecia","Drug: Setipiprant|Drug: Placebo|Drug: Finasteride","Change From Baseline in Target Area Hair Count (TAHC) at Week 24|Subject Self-Assessment (SSA) Score in Hair Growth at Week 24","Allergan","Male","18 Years to 49 Years   (Adult)","Phase 2","169","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1922-201-002","July 14, 2016","March 15, 2018","May 22, 2018","May 24, 2016","April 5, 2019","April 5, 2019","Burke Pharmaceutical Research, Hot Springs, Arkansas, United States|Petrus Center for Aesthetic Surgery & Hair Transplantation, Little Rock, Arkansas, United States|Therapeutics Clinical Research, San Diego, California, United States|Radiant Research, Inc., Santa Rosa, California, United States|DeNova Research, Chicago, Illinois, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Michigan Center for Skin Care Research, Clinton Township, Michigan, United States|Minnesota Clinical Study Center, Fridley, Minnesota, United States|University of Minnesota Department of Dermatology Division of Clinical research, Minneapolis, Minnesota, United States|Wake Forest University Health Sciences Department of Dermatology Medical Center Boulevard, Winston-Salem, North Carolina, United States|Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States|NW Dermatology and Research Center, Portland, Oregon, United States|Oregon Medical Research Center, Portland, Oregon, United States|Penn State Hershey Medical Center Dermatology Research Office, Hershey, Pennsylvania, United States|Radiant Research, Inc., Greer, South Carolina, United States|DermResearch, Inc, Austin, Texas, United States|Suzzane Bruce and Associates P.A., The Center for Skin Research, Katy, Texas, United States|The Education & Research Foundation, Inc, Lynchburg, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02781311/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02781311/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02781311"
119,"NCT02780115","A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia",,"Completed","No Results Available","Presbyopia","Drug: AGN-199201 ophthalmic solution|Drug: AGN-190584 ophthalmic solution|Drug: AGN-199201 Vehicle|Drug: AGN-190584 Vehicle","Average Change from Baseline in Uncorrected Near Visual Acuity (UNVA) Letters","Allergan","All","40 Years to 55 Years   (Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","199201-010","May 26, 2016","October 31, 2017","October 31, 2017","May 23, 2016",,"October 18, 2018","Retina Institute of California Medical Group, Arcadia, California, United States|Sall Research Medical Center, Artesia, California, United States|WCCT Global, LLC, Cypress, California, United States|Specialty Eye Care Medical Center, Glendale, California, United States|Lugene Eye Institute, Glendale, California, United States|The Eye Research Foundation, Newport Beach, California, United States|Stanford Eye and Laser Center, Palo Alto, California, United States|Wolstan and Golberg Eye Associates, Torrance, California, United States|MedEye Associates, Miami, Florida, United States|Central Florida Eye Institute, Ocala, Florida, United States|Center for Sight, Sarasota, Florida, United States|Clayton Eye Center, Morrow, Georgia, United States|Silverstein Eye Centers, Louisville, Kentucky, United States|The Eye Care Institute, Louisville, Kentucky, United States|Specialized Eye Care, Baltimore, Maryland, United States|James D. Branch, Winston-Salem, North Carolina, United States|Devers Eye Institute, Portland, Oregon, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Total Eye Care, PA, Memphis, Tennessee, United States|Cataract and Glaucoma Center, El Paso, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|R and R Eye Research, LLC, San Antonio, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Hoopes Durrie Rivera Research, LLC, Draper, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02780115"
120,"NCT02731911","Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study",,"Completed","No Results Available","Diabetic Macular Oedema","Drug: dexamethasone intravitreal implant","Mean change in Best Corrected Visual Acuity (BCVA) from baseline|Mean change in Central Retinal Thickness (CRT) from baseline|Percentage of patients with a BCVA improvement of 15 letters or more|Percentage of patients with a BCVA improvement of 10 letters or more|BCVA average mean from baseline in area under the curve (AUC) analysis|Number of Intraocular Pressure (IOP)-lowering treatments used to control IOP increase|Mean BCVA at each injection number|Mean change from baseline in BCVA at each injection number|Mean change in BCVA across all the study injection numbers|Percentage of patients with BCVA improvement|Percentage of BCVA losers|Percentage of patients improving to 20/40 or better|Mean number of Ozurdex injections|Mean interval between Ozurdex® injections|Change from baseline in central subfield retinal thickness by Optical Coherence Tomography (OCT) before each follow-up injection number","Allergan","All","18 Years and older   (Adult, Older Adult)",,"202","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CMO-AP-EYE-0438","April 29, 2016","October 22, 2018","October 22, 2018","April 8, 2016",,"January 23, 2019","Retina and Macula Specialists,Hurstville, Hurtsville, New South Wales, Australia|Retina Associates, Liverpool, New South Wales, Australia|Retina and Macula Specialists, Miranda, Miranda, New South Wales, Australia|Eye Doctors Mona Vale, Mona Vale, New South Wales, Australia|Marsden Eye Clinic, Parramatta, New South Wales, Australia|Retina & Vitreous Centre Strathfield, Strathfield, New South Wales, Australia|Strathfield Retina, Strathfield, New South Wales, Australia|Retina & Vitreous Centre City, Sydney, New South Wales, Australia|Sydney Eye and Retina Clinic, Sydney, New South Wales, Australia|Sydney Eye Hospital/Macular Diseases Centre, Sydney, New South Wales, Australia|Sydney West Retina, Westmead, New South Wales, Australia|Terrace Eye Centre, Brisbane, Queensland, Australia|Caboolture Eye Surgery, Caboolture, Queensland, Australia|Peninsula Eye Hospital, Redcliffe, Queensland, Australia|The Qld Eye Institute, South Brisbane, Queensland, Australia|Adelaide Eye & Retina Centre, Adelaide, South Australia, Australia|Department of Opthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia|Hobart Eye Surgeons, Hobart, Tasmania, Australia|Tasmanian Eye Institute, Launceston, Tasmania, Australia|Essendon Retina, Essendon, Victoria, Australia|Victoria Parade Eye Consultants, Fitzroy, Victoria, Australia|Vision Eye Institute, Footscry, Victoria, Australia|Lions Eye Institute, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02731911"
121,"NCT02688790","Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection",,"Terminated","No Results Available","Bacterial Infections","Drug: Dalbavancin","Plasma concentration of dalbavancin|Number of patients experiencing a treatment emergent adverse event|Maximum plasma drug concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Apparent total body clearance (CL) of drug from plasma|Apparent volume of distribution volume of distribution (V)|Terminal elimination half-life (T1/2).","Allergan","All","up to 28 Days   (Child)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DAL-PK-02","April 1, 2016","April 3, 2019","April 3, 2019","February 23, 2016",,"November 29, 2019","Mary Birch Hospital for Women and Newborns, San Diego, California, United States|University of California, San Diego, San Diego, California, United States|University of Louisville, Louisville, Kentucky, United States|Children's Mercy Kansas City, Kansas City, Missouri, United States|Duke Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02688790"
122,"NCT02676310","Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)",,"Terminated","No Results Available","Alopecia|Alopecia, Androgenetic|Baldness","Drug: Bimatoprost","Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)|Change from Baseline in Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale|Maximum plasma level (Cmax) of bimatoprost and its acid metabolite","Allergan","Male","18 Years to 49 Years   (Adult)","Phase 1","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","192024-085","March 2016","January 2017","March 2017","February 8, 2016",,"March 17, 2017","DermResearch, LLC, Austin, Texas, United States|J&S Studies Inc., College Station, Texas, United States|E&R Research Foundation, Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02676310"
123,"NCT02673047","Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder","BOREAL","Completed","No Results Available","Urinary Bladder, Overactive|Urinary Bladder, Neurogenic","Biological: botulinum toxin Type A","Target Patients Prescribed Botox® in Clinical Practice|Treatments Previously Prescribed|Number of Sites Injected|Total Dose of Botox® Used|Types of Anaesthesia and Antibiotic Prophylaxis Used|Cytobacteriological Examination of the Urine|Total Number of Botox® Cycles in Non-naive Patients (previously received Botox®)|Length of Botox® Treatment in Non-naive Patients|Time Since Last Botox® Injection in Non-naive Patients|Characteristics of Injector Sites (Locations)|Characteristics of Injector Physicians|Characteristics of Patients|Number of Patients by Pathology History|Number of Patients by Medical and Surgical History|Reduction of Number of Daily Urinary Incontinence Episodes in Non-naive Patients|Percentage of Continent Patients in Non-naive Patients|Number of Adverse Events during the Visit","Allergan","All","18 Years and older   (Adult, Older Adult)",,"474","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/NS/OAB/006","February 2016","August 2016","August 2016","February 3, 2016",,"October 24, 2016","Site D'Aix En Provence, AIX en Provence, France|CL Toulouse Lautrec, Albi, France|CHU Angers, Angers Cedex 01, France|CH Angouleme, Angouleme Cedex 9, France|CH Avranches Granville, Avranches, France|CH Bagnols Sur Ceze, Bagnols-Sur-Ceze, France|CH Belfort, Belfort Cedex, France|CHU Besancon, Besancon Cedex, France|CHU Bordeaux, Bordeaux Cedex, France|CL Saint Augustin, Bordeaux, France|CH de Cahors, Cahors, France|CH Châlons-en-Champagne, Chalons-En-Champagne, France|CHU Clermont Ferrand, Clermont-Ferrand, France|CH Colmar, Colmar Cedex, France|CHU Mondor (APHP), Creteil, France|CH Hopale Ctre Calot/Helio, Cucq, France|CHU Dijon, Dijon Cedex, France|CHI E.Durkheim Plateau de La Justice, Epinal Cedex, France|CH Raymond Poincare (APHP), Garches, France|CH Renee Sabran Hyeres (HCL), Giens-Hyeres, France|GH de la Rochelle Ré-Aunis, La Rochelle, France|CH Bicêtre (APHP), Le Kremlin-Bicetre, France|CH Le Mans, Le Mans Cedex 9, France|CHU Limoges, Limoges Cedex, France|CL Mutualiste Porte de L'Orient, Lorient, France|CH de la Conception (APHM), Marseille, France|CH Mont de Marsan, Mont de Marsan, France|CL Beau Soleil, Montpellier, France|CHU Montpellier, Montpellier, France|CH Mulhouse, Mulhouse, France|CHU Nimes, Nimes, France|GH Saint Joseph, Paris, France|CH Tenon (APHP), Paris, France|CH Lyon Sud (HCL), Pierre-Benite Cedex, France|CH de Pontoise, Pointoise Cedex, France|USLD de Lusignan, Poitiers Cedex, France|CH Annecy, Pringy Cedex, France|SIH Privas La Voulte, Privas, France|Polyclinique Les Bleuets, Reims, France|CHU de Rennes, Rennes Cedex, France|CHU de Rouen, Rouen Cedex, France|CL de L'Alliance Saint Cyr/Loire, Saint Cyr/Loire, France|CH Saint-Avold, Saint-Avold, France|CL Mutualiste Chirurgicale, Saint-Etienne, France|CH de Saintonge (Saintes), Saintes Cedex, France|Hôpital Civil / Nouvel Hôpital Civil, Strasbourg, France|CH Foch, Suresnes, France|Clinique de l'Ormeau Pyrénées, Tarbes, France|CHU Toulouse, Toulouse Cedex 9, France|CHU Tours, Tours Cedex 09, France",,"https://ClinicalTrials.gov/show/NCT02673047"
124,"NCT02636946","A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Recruiting","No Results Available","Glaucoma|Open-Angle Ocular Hypertension","Drug: Bimatoprost SR|Drug: Sham Bimatoprost SR|Procedure: Selective Laser Trabeculoplasty|Procedure: Sham Selective Laser Trabeculoplasty","Change from Baseline in Intraocular Pressure (IOP) at Week 24|Change from Baseline in IOP at Week 4|Change from Baseline in IOP at Week 12|IOP change from baseline time-weighted average through Week 24|IOP change from baseline at Week 8|IOP change from baseline at Week 15|IOP change from baseline at Week 20|IOP at each visit|Time to onset of effect (time to first achieving ≥ 20% IOP reduction)|Time to initial use of nonstudy IOP-lowering treatment as determined by the investigator|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 4|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 12|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 24|Percentage of SLT eyes achieving ≥ 20% reduction at Week 4|Percentage of SLT eyes achieving ≥ 20% reduction at Week 12|Percentage of SLT eyes achieving ≥ 20% reduction at Week 24","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-095|2015‐003631‐34","February 24, 2016","February 28, 2021","February 28, 2021","December 22, 2015",,"January 7, 2020","Eye Center South, Dothan, Alabama, United States|Arizona Eye Center Phoenix, Chandler, Arizona, United States|Walman Eye Center, Sun City, Arizona, United States|Montebello Medical Center, Inc., Montebello, California, United States|Shasta Eye Medical Group, Inc, Redding, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Eye Associates of Colorado Springs, Colorado Springs, Colorado, United States|Nature Coast Clinical Research, Crystal River, Florida, United States|The Eye Institute for Medicine and Surgery, Melbourne, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Emory University Eye Center, Atlanta, Georgia, United States|Gainesvillle Eye Associates/Accusite Surgical, Gainesville, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|North Shore Glaucoma & North Shore Eye Physicians, Libertyville, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|The Eye Care Institute, Louisville, Kentucky, United States|The Ophthalmology Group, LLC, Paducah, Kentucky, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Galanis Cataract and Laser Eye Center, Saint Louis, Missouri, United States|Surgicenter of Vineland/Eye Associates, Vineland, New Jersey, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Glaucoma Consultants of Capital Region, Slingerlands, New York, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Charlotte Eye Ear Nose and Throat Associates PA, Charlotte, North Carolina, United States|James D. Branch MD, Winston-Salem, North Carolina, United States|Bergstrom Eye Research, LLC, Fargo, North Dakota, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|The Cataract & Glaucoma Center, El Paso, Texas, United States|Houston Eye Associates, Houston, Texas, United States|DCT- Shah Research, LLC dba Discovery Clinical Trials, Mission, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|Vistar Eye Center, Roanoke, Virginia, United States|University of Washington Eye Institute, Seattle, Washington, United States|Centre D'ophtalmologie a Mons, Mons, Hainaut, Belgium|Adjunct Clinic Head University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium|CHU Sart-tilman, Liege, Belgium|Fakultni Nemocnice Ostrava, Ostrava, Poruba, Czechia|Glostrup Hospital, Glostrup, Denmark|CHU de Bordeaux Hopital Pellegrin Service Ophtalmologie, Bordeaux, France|Centre ophtalmologie Pole vision, Ecully, France|CHU Dupuytren - Service d'ophtalmologie, Limoges, France|Clinique Sourdille, Nantes, France|CHU de Nice - Hopital Pasteur 2 - Service Ophtalmologie, Nice, France|Centre Hospitalier National d Ophtalmologie (CHNO) des Quinze-Vingts, Paris, France|Hopital Necker - Service dΓÇÖOphtalmologie, Paris, France|Hôpital Pierre-Paul Riquet, Toulouse, France|Universit degli Studi di Chieti-Pescara, Chieti, Italy|Clinica Oculistica Di.N.O.G.M.I., Genova, Italy|Università degli Studi di Parma, Parma, Italy|University of Pisa (Azienda Ospedaliero-Universitaria Pisana Cisanello Hospital), Pisa, Italy|Azienda Ospedaliera Perugia, San Sisto, Italy|Nuovo Ospedale di Sassuolo, Sassuolo, Italy|University of Udine, Udine, Italy|OFTALMIKA Sp. z o.o., ul., Bydgoszcz, Poland|Klinika Diagnostyki i Mikrochirurgii Jaskry, Lublin, Poland|Centrum Diagnostykii Mikrochirurgii Oka LENS ul., Olsztyn, Poland|SPEKTRUM O┼¢rodek Okulistyki Klinicznej, Wroclaw, Poland|Research Institute of Ocular Diseases, Moscow, Russian Federation|S.Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation|S. Fyodorov Eye Microsurgery Federal State Institution, Novosibirsk, Russian Federation|GBOU VPO ""Omsk state medical University"" of Ministry of Health of Russia, Omsk, Russian Federation|Academician I.P. Pavlov First St. Petersburg state medical university, Saint Petersburg, Russian Federation|Samara State Medical University, Samara, Russian Federation|Singapore National Eye Centre - Singapore Eye Research Institute, Singapore, Singapore|Institut Catala de la Retina, Barcelona, Spain|Centro de Oftalmologia Barraquer, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|CHU de Nantes, Nantes, Spain|Hospital Universitario, Sevilla, Spain|Pio del Rio Hortega University Hospital, Valladolid, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Chiang Mai University CMU - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Thammasat University Hospital, Pathumthani, Thailand",,"https://ClinicalTrials.gov/show/NCT02636946"
125,"NCT02634437","Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects",,"Completed","No Results Available","Renal Function","Drug: Ulipristal acetate","Area under the plasma concentration versus time curve of ulipristal acetate from time 0 to time t (AUC 0-t)|Maximum plasma drug concentration (Cmax) of ulipristal acetate|Time of maximum plasma drug concentration (Tmax) of ulipristal acetate|Terminal elimination half-life (T½) of ulipristal acetate|Apparent total body clearance of ulipristal acetate from plasma after extravascular administration (CL/F) of ulipristal acetate|Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of ulipristal acetate|Area under the plasma concentration versus time curve of ulipristal acetate from time 0 to infinity (AUC 0-∞)|Area under the plasma concentration versus time curve of PGL4002 (ulipristal acetate active metabolite) from time 0 to time t (AUC 0-t)|Time of maximum plasma drug concentration (Tmax) of PGL4002 (ulipristal acetate active metabolite)|Terminal elimination half-life (T½) of PGL4002 (ulipristal acetate active metabolite)|Maximum plasma drug concentration (Cmax) of PGL4002 (ulipristal acetate active metabolite)|Cumulative amount of ulipristal acetate excreted into urine from time zero to time t (Ae0-t)|Renal clearance of ulipristal acetate from plasma (CLR)|Percent of dose excreted as unchanged ulipristal acetate in urine (%Dose)|Cumulative amount of PGL4002 excreted into urine from time zero to time t (Ae0-t)|Renal clearance of PGL4002 from plasma (CLR)|Area under the plasma concentration versus time curve of PGL4002 (ulipristal acetate active metabolite) from time 0 to infinity (AUC 0-∞)","Allergan","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UPA-PK-02","December 1, 2015","December 9, 2016","December 9, 2016","December 18, 2015",,"February 8, 2018","Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States|Clinical Pharmacology of Miami, Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Prism Clinical Research, Saint Paul, Minnesota, United States|QPS Bio-Kinetic, Springfield, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02634437"
126,"NCT02601287","A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients",,"Completed","No Results Available","Urinary Incontinence|Overactive Bladder","Biological: Botulinum Toxin Type A","Change from the baseline in the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) total score","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","168","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-151","November 2015","July 2016","July 2016","November 10, 2015",,"July 21, 2016","Pusan National University Hospital, Busan, Korea, Korea, Republic of|The Catholic University of Korea Bucheion St. Mary Hospital, Gyeonggi-do, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02601287"
127,"NCT02595528","A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia",,"Completed","No Results Available","Presbyopia","Drug: AGN-199201 ophthalmic solution|Drug: AGN-190584 ophthalmic solution|Drug: AGN-190584 vehicle|Drug: AGN-199201 + AGN-190584 Combination|Drug: AGN-199201 vehicle","Weighted Average Change from Baseline in Uncorrected Near Visual Acuity (UNVA) Letters","Allergan","All","40 Years to 50 Years   (Adult)","Phase 2","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","199201-009","April 29, 2016","October 18, 2017","October 18, 2017","November 3, 2015",,"October 18, 2018","Sall Research Medical Center, Artesia, California, United States|Milton M. Hom, OD, FAAO, Azusa, California, United States|WCCT Global, LLC, Costa Mesa, California, United States|The Eye Research Foundation, Newport Beach, California, United States|North Bay Eye Associates, Inc., Petaluma, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|West Coast Eye Care, San Diego, California, United States|Corneal Consultants of Colorado, P.C., Littleton, Colorado, United States|Mid Florida Eye Center, Mount Dora, Florida, United States|Clayton Eye Center, Morrow, Georgia, United States|Price Vision Group, Indianapolis, Indiana, United States|Specialized Eye Care, Baltimore, Maryland, United States|Comprehensive Eye Care, Ltd, Washington, Missouri, United States|Cleveland Eye Clinic, Brecksville, Ohio, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Total Eye Care, PA, Memphis, Tennessee, United States|Cataract and Glaucoma Center, El Paso, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Hoopes Durrie Rivera Research, LLC, Draper, Utah, United States|The Eye Centers of Racine & Kenosha, Kenosha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02595528"
128,"NCT02590250","A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India",,"Completed","No Results Available","Urinary Incontinence|Overactive Bladder","Biological: botulinum toxin Type A","Change from the baseline value of the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"250","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","191622-140","December 16, 2015","August 7, 2017","August 7, 2017","October 29, 2015",,"March 26, 2018","NU Hospitals, Padmanabha Nagar, Banglore, India|Dr. Ram Manohar Lohia Hospital, New Delhi, Delhi, India|Indian Spinal Injuries Centre, New Delhi, Delhi, India|Bodyline Hospitals, Ahmedabad, Gujarat, India|Fortis Hospitals, Bengaluru, Karnataka, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, Maharashtra, India|AMAI Charitable Trust's ACE Hospital and Research Centre, Pune, Maharashtra, India|Inamdar Multispeciality Hospital, Pune, Maharashtra, India|Fortis Escorts Heart Institute, Okhla Road, New Delhi, India|Christian Medical College & Hospital, Ludhiana, Punjab, India|Christian Medical College and Hospital, Vellore, Tamil Nadu, India|Global Hospital, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT02590250"
129,"NCT02580578","A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids",,"Active, not recruiting","No Results Available","Leiomyoma","Other: No Intervention","Uterine Fibroid Symptom Quality of Life 37-Item Questionnaire (UFS QoL)|Ruta Menorrhagia (Bleeding) 15-Item Questionnaire|Number of Participants with Adverse Drug Reactions","Allergan","Female","18 Years and older   (Adult, Older Adult)",,"1500","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CMO-CAN-WH-0412","July 31, 2015","February 13, 2020","February 13, 2020","October 20, 2015",,"August 16, 2019","Peter Lougheed Centre/University of Calgary, Calgary, Alberta, Canada|Urestky Edmonton Clinic, Edmonton, Alberta, Canada|Sanders Vancouver Clinic, Vancouver, British Columbia, Canada|Children's and Women's Health Centre of British Columbia - The University of British Columbia, Vancouver, British Columbia, Canada|Southern Health Centre, White Rock, British Columbia, Canada|Landau Fredericton Clinic, Fredericton, New Brunswick, Canada|Strand Clinic, St. John, Newfoundland and Labrador, Canada|IWK Healtch Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|Minimally Invasive Gynecology Clinic, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|St. Micheals Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|South Windsor Women's Health, Windsor, Ontario, Canada|Centre Gynécologie et Maternité, Lasalle, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Clinique de Gynécologie & Obstétrique Pierre Boucher, Montreal, Quebec, Canada|Complexe Medical Saint-Laurent, Saint-Laurent, Quebec, Canada|University of Saskatchewan, Regina, Saskatchewan, Canada|CHU de Québec-Universite Laval, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT02580578"
130,"NCT02574637","Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease",,"Terminated","No Results Available","Crohn's Disease","Drug: MEDI2070 High dose|Drug: MEDI2070 High-Med dose|Drug: MEDI2070 Low-Med dose|Drug: MEDI2070 Low dose|Drug: Placebo","The primary endpoint of the study is Crohn's Disease Activity Index (CDAI) clinical remission at Week 8, defined by a CDAI score of < 150|A decrease in stool frequency from baseline at Week 8, Week 16 and Week 28|A reduction of at least 100 points from baseline in Crohn's Disease Activity Index (CDAI) at Week 8, Week 16 and Week 28|Crohn's Disease Activity Index (CDAI) clinical remission at Week 16 and Week 28|Simple Endoscopic Score for Crohn's Disease (SES-CD) improvement in gut mucosa at Week 16 and Week 28|Sustained decrease in stool frequency from baseline at Week 8 and Week 28|Crohn's Disease Activity Index (CDAI) Modified sustained clinical remission at Week 8 and Week 28|Simple Endoscopic Score for Crohn's Disease (SES-CD) sustained improvement in gut mucosa at Week 16 and Week 28|Correlate biomarkers with clinical outcomes at Week 8|Serum concentration evaluation of MEDI2070 levels|Number of incidences of Anti-drug antibodies (ADA) against MEDI2070|Number of incidences of treatment-emergent adverse events|Number of incidences of treatment-emergent serious adverse events|Number of incidences of treatment-emergent adverse events of special interest|Number of incidences of adverse events leading to investigational product discontinuation|Number of incidences of specific laboratory abnormalities|A decrease in abdominal pain from baseline at Week 8, Week 16 and Week 28|Sustained decrease abdominal pain from baseline at Week 8 and Week 28","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5170C00002|2015-000609-38","January 5, 2016","July 28, 2017","January 29, 2018","October 14, 2015",,"July 26, 2018","Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States|South Denver Gastroenterology, PC, Lone Tree, Colorado, United States|Clinical Research of West Florida - Corporate, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Digestive Health, Topeka, Kansas, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Clinical Trials of SW Louisiana, LLC, Lake Charles, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Revive Research Institute, Southfield, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|New York University Medical Center, Great Neck, New York, United States|Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States|Clinical Inquest Center Ltd, Dayton, Ohio, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Erlanger Health System, Chattanooga, Tennessee, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Gastroenterology Research of America, Houston, Texas, United States|Baylor Research Institute, Temple, Texas, United States|Allegiance Research Specialists, LLC, Milwaukee, Wisconsin, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Imeldaziekenhuis, Bonheiden, Belgium|UZ Leuven, Leuven, Belgium|London Health Science Centre, London, Ontario, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|CHU de Toulouse - Hôpital Rangueil, Toulouse Cedex 9, Haute Garonne, France|CHU Rennes - Hôpital Pontchaillou, Rennes, Ille Et Vilaine, France|CHU Saint Etienne - Hôpital Nord, Saint Etienne, Loire, France|Hôpital de Brabois Adultes, Vandoeuvre-Les-Nancy, Meurthe Et Moselle, France|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|St. Johannes Hospital, Dortmund, Nordrhein Westfalen, Germany|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Kaplan Medical Center, Rechovot, Israel|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Maastricht University Medical Center, Maastricht, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|TSBIH ""Territorial Clinical Hospital"", Krasnoyarsk, Russian Federation|Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02574637"
131,"NCT02571712","Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost 0.03% plus timolol 0.5%","Incidence of Adverse Events","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","750","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","192024-094","November 10, 2015","June 21, 2018","June 21, 2018","October 8, 2015",,"July 5, 2018","Beijing Hospital, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Beijing Tongren hospital Capital Medical University, Beijing, Beijing, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China|Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Tianjin Eye Hospital, Tianjin, Tianjin, China|Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China|Henan Provincial Eye Hospital, Henan, Zhengzhou, China",,"https://ClinicalTrials.gov/show/NCT02571712"
132,"NCT02559908","A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creation of Facial Volume in the Chin and Jaw",,"Completed","No Results Available","Chin Retrusion","Device: Hyaluronic Acid Injectable Gel","Change from Baseline in the Glabella-Subnasale-Pogonion (G-Sn-Pog) Angle|Percentage of Responders based on the Investigator's Assessment of Improvement in the Chin and Jaw Area using the 5-point Global Aesthetic Improvement Scale (GAIS)|Percentage of Responders based on the Participant's Assessment of Improvement in the Chin and Jaw Area using the 5-point GAIS","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","V25L-001","February 26, 2015","February 12, 2016","December 1, 2017","September 25, 2015",,"December 13, 2017","Cabinet medical Solferino, Paris, France|Centre de Chirurgie Esthetique, Toulouse, France|Hautzentrum Altenbochum - RuhrDERM Gemeinschaftspraxis Dr. med. Ardabili - Dr. med. Niesmann, Bochum, Germany|Dermatolgie Köln am Rhein, Cologne, Germany|Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH, Darmstadt, Germany|Rotes Kreuz Krankenhaus Kassel Gemeinnützige GmbH Klinik für Plastische, Rekonstruktive und Ästhetische Chirurgie, Kassel, Germany|Praxisgemeinschaft Theatiner46 Dres. Ogilvie und Dr. Bernd Schuster, Munich, Germany|Dermatogische Privatpraxis CentroDerm GmbH, Wuppertal, Germany|Kliniek Dokter Frodo Gaymans, Amsterdam, Netherlands|Joost Kroon Cosmetische Kliniek, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02559908"
133,"NCT02558283","A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults",,"Completed","No Results Available","Nasolabial Fold","Device: JUVÉDERM® VOLIFT® with Lidocaine|Device: Restylane®","Investigator's Assessment of Severity of Each Nasolabial Fold (NLF) on the 5-Point NLF Severity Scale (NLFSS)|Subject's Assessment of Procedural Pain on an 11-Point Scale|Investigator's Assessment of Each NLF on the 5-Point Global Aesthetic Improvement Scale (GAIS)|Subject's Assessment of Each NLF on the 5-Point GAIS","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","VOLIFT-002","January 25, 2016","June 19, 2017","June 19, 2017","September 23, 2015",,"August 30, 2017","China Japan Friendship Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|General Hospital of Guangzhou Military Command of PLA, Guangzhou, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Guangzhou, China|Shanghai 9th Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02558283"
134,"NCT02557971","Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder",,"Completed","No Results Available","Urinary Bladder, Overactive","Drug: onabotulinumtoxinA","Percentage of Participants with Post-Procedure Urinary Retention requiring Catheterization|Length of Time of Clean Intermittent Catheterization (CIC) Use|Percentage of Participants with Urinary Tract Infection (UTI)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"315","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-US-OAB-0403","August 2015","July 2016","July 2016","September 23, 2015",,"September 2, 2016","University of California, Davis, Davis, California, United States|Capital Region Urology, Irvine, California, United States|The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System, Charlotte, North Carolina, United States|Alliance Urology Specialists, PA, Greensboro, North Carolina, United States|Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners, Winston-Salem, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Virginia Women's Center Inc., Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02557971"
135,"NCT02556736","RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa",,"Recruiting","No Results Available","Advanced Retinitis Pigmentosa","Drug: RST-001","Safety|To establish the maximum tolerated dose of RST-001|To evaluate the preliminary efficacy of RST-001 in patients with advanced RP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RST-001-CP-0001","December 14, 2015","December 3, 2020","April 24, 2035","September 22, 2015",,"December 4, 2019","University of California, San Francisco- Dept. of Ophthalmology, San Francisco, California, United States|Duke Eye Center, Durham, North Carolina, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Retina Foundation of the Southwest, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02556736"
136,"NCT02555761","Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea",,"Completed","No Results Available","Conjunctivitis, Allergic","Drug: Alcaftadine Ophthalmic Solution 0.25%","Number of Participants with Adverse Events","Allergan","All","2 Years and older   (Child, Adult, Older Adult)",,"3423","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","229666-007","October 19, 2015","March 19, 2018","March 19, 2018","September 22, 2015",,"July 5, 2019","Seo-myeon St.Mary's Hospital, Busan, Korea, Republic of|SeoMyeon St. Eye Clinic, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Soojung Eye Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Saint Mary Bright Eye Clinic, Busan, Korea, Republic of|Daeyeon St.mary's Eye Center, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Pusan National University Yangsan Hospital, Busan, Korea, Republic of|Barun Sungmo Eye Clinic, Busan, Korea, Republic of|chamjoeun Ophthalmic Clinic, Busan, Korea, Republic of|Soonchunhyang University Cheonan Hospital, Chungcheongnam-do, Korea, Republic of|Cheil eye hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyoungpook national university hospital, Daegu, Korea, Republic of|Daegu Nune Eye Hospital, Daegu, Korea, Republic of|Saebom Eye Clinic, Daejeon, Korea, Republic of|Jungbuwoorieye Clinic, Daejeon, Korea, Republic of|Chonnam National University Hospital, Daejeon, Korea, Republic of|Clean Eye clinic, Daejeon, Korea, Republic of|Eye Love Eye Center, Daejeon, Korea, Republic of|Chonnam National University Hospital, Daejoen, Korea, Republic of|Konyang University Hospital, Daejoen, Korea, Republic of|Konyang University Hospital, Daejon, Korea, Republic of|St. Mary's Eye center, Geyonggi-do, Korea, Republic of|Eins Eye Clinic, Geyonsangnam-do, Korea, Republic of|Happ Eye 21, Gwangju, Korea, Republic of|Gwang Ju Eye Clinic, Gwangju, Korea, Republic of|Bora Eye Clinic, Gwangju, Korea, Republic of|Bora Eye Clinic, Gwangju, Korea, Republic of|Myongji Hospital, Gyeonggi-do, Korea, Republic of|Munsan Jeil Eye Clinic, Gyeonggi-do, Korea, Republic of|Seoul Shinsegae Eye Center, Gyeonggi-do, Korea, Republic of|Eagle Eye Center, Gyeonggi-do, Korea, Republic of|Anyang Seoul Eye Clinic, Gyeonggi-do, Korea, Republic of|Noon-Sarang Eye Hospital, Gyeonggi-do, Korea, Republic of|Bright eye, Gyeonggi-do, Korea, Republic of|Ansan Yonsei Eye Center, Gyeonggi-do, Korea, Republic of|Yonsei Dream Eye Clinic, Gyeonggi-do, Korea, Republic of|Bright Kim's Eye Clinic, Gyeongsangnam-do, Korea, Republic of|Fatima ophthalmology, Gyeongsangnam-do, Korea, Republic of|Gowoon eye clinic, Gyeongsangnam-do, Korea, Republic of|Sungmo Eye Hospital, Haeundae-gu, Korea, Republic of|Hangil Eye Hospital, Incheon, Korea, Republic of|Hangil Eye Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Renessance eye center, Incheon, Korea, Republic of|Bupyung ST.Mary's eye clinic, Incheon, Korea, Republic of|Pureun Eye Center, Jeollabuk-do, Korea, Republic of|Pureun Eye Center, Jeollabuk-do, Korea, Republic of|Onuri Eye Hospital, Jeollabuk-do, Korea, Republic of|Seoul Eye Clinic, Jeollanam-do, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Kyounggi-do, Korea, Republic of|Yonsei Woori Eye Clinic, Seoul, Korea, Republic of|Gangnam ST. Mary's Eye Center, Seoul, Korea, Republic of|Hplus Eye Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Saevit Eye Center, Seoul, Korea, Republic of|Sinchon Yeonsei Eye Hospital, Seoul, Korea, Republic of|Central seoul eye center, Seoul, Korea, Republic of|Ian Eye Center, Seoul, Korea, Republic of|Lee, Im-sun Eye Clinic, Seoul, Korea, Republic of|Yonsei Eye Clinic, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|See Samsung Eye Center, Seoul, Korea, Republic of|Yoon Ho Eye Hospital, Seoul, Korea, Republic of|Apgujeong Eye Center, Seoul, Korea, Republic of|Joeunnun Vision Clinic, Seoul, Korea, Republic of|Nune Eye Hospital, Seoul, Korea, Republic of|GS eye clinic, Seoul, Korea, Republic of|Lee Eye Institute, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|The catholic university of korea Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|Su Yonsei Eye Clinic, Seoul, Korea, Republic of|Kim's Eye Hospital, Seoul, Korea, Republic of|Bright Seoul Ophthalmology, Seoul, Korea, Republic of|The Catholic Unoveristy of Korea, Seoul St Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Park Chang Soo Eye Clinic, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02555761"
137,"NCT02554981","Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®","EMPOWER","Completed","Has Results","Dry Eye Syndromes","Drug: Cyclosporine 0.05% Ophthalmic Emulsion","Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye|Change From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye|Change From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye|Change From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in Font Size|Change From Baseline in Words Read Incorrectly|Change From Baseline in Time to Read Passage|Change From Baseline in Reading Rate|Change From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye|Change From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye|Change From Baseline in Interblink Interval (IBI) in the Worst Eye|Change From Baseline in OSDI© Total Score|Change From Baseline in Driving at Night on the OSDI©|Change From Baseline in Working With a Computer or Bank Machine on the OSDI©|Change From Baseline in Watching Television (TV) on the OSDI©|Change From Baseline in Blurred Vision on the OSDI©|Change From Baseline in Poor Vision on the OSDI©|Change From Baseline in Reading on the OSDI©|Change From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye","Allergan","All","18 Years to 55 Years   (Adult)","Phase 4","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-RES-015-001","July 21, 2015","March 24, 2016","March 24, 2016","September 21, 2015","June 1, 2017","June 1, 2017","Andover Eye Associates, Inc, Andover, Massachusetts, United States|Total Eye Care, PA, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02554981"
138,"NCT02553772","A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.",,"Completed","Has Results","Dry Eye Syndromes","Drug: Carboxymethylcellulose Based Eye Drop|Drug: Carboxymethylcellulose Sodium 0.5%","Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score|Change From Baseline in Tear Break-up Time (TBUT)|Change From Baseline in Corneal Staining Score|Change From Baseline in Conjunctival Staining Score|Change From Baseline in the Schirmer Test","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11182X-001","January 6, 2016","September 9, 2016","September 9, 2016","September 18, 2015","November 17, 2017","November 17, 2017","The Private Practice of Milton Hom, OD, Azusa, California, United States|Havana Research Institute LLC, Burbank, California, United States|Lugene Eye Institute, Glendale, California, United States|Eric M. White, OD, INC, San Diego, California, United States|Moyes Eye Center, PC, Kansas City, Missouri, United States|Ophthalmology Associates, Saint Louis, Missouri, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|Charlotte Eye Ear Nose, Charlotte, North Carolina, United States|Scott and Christie and Associate, Cranberry Township, Pennsylvania, United States|Texan Eye, Austin, Texas, United States|Department of Optometry & Vision Sciences, The University of Melbourne, Parkville, Australia|Prof. M.T. Coroneo Pty. Ltd., Randwick, Australia|The University of New South Wales School of Optometry and Vision Science, Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT02553772"
139,"NCT02507687","Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost SR|Drug: Sham Bimatoprost SR|Procedure: Selective Laser Trabeculoplasty|Procedure: Sham Selective Laser Trabeculoplasty","Change from Baseline in Intraocular Pressure (IOP) at Week 24|Change from Baseline in IOP at Week 4|Change from Baseline in IOP at Week 12|IOP change from baseline time-weighted average through Week 24|IOP change from baseline at Week 8|IOP change from baseline at Week 15|IOP change from baseline at Week 20|IOP at each visit|Time to onset of effect (time to first achieving|Time to initial use of nonstudy IOP-lowering treatment as determined by the investigator|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 4|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 12|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 24|Percentage of SLT eyes achieving ≥ 20% reduction at Week 4|Percentage of SLT eyes achieving ≥ 20% reduction at Week 12|Percentage of SLT eyes achieving ≥ 20% reduction at Week 24","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-093|2015-002131-18","August 27, 2015","October 31, 2020","October 31, 2020","July 24, 2015",,"January 21, 2020","Arizona Glaucoma Specialists, Phoenix, Arizona, United States|M&M Eye Institute, Prescott, Arizona, United States|Acuity Eye Group, Arcadia, California, United States|Orange County Ophthalmology, Garden Grove, California, United States|Specialty Eye Care, Glendale, California, United States|Lugene Eye Institute, Glendale, California, United States|California Eye Specialists Medical Group, Inc., Pasadena, California, United States|North Bay Eye Associates Inc., Petaluma, California, United States|Pacific Eye Associates, San Francisco, California, United States|WCCT Global, Tustin, California, United States|Eye Associates of South West Florida, Fort Myers, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|Ocala Eye, P.A., Ocala, Florida, United States|Logan Ophthalmic Research, LLC, Tamarac, Florida, United States|Accusite Surgical Services, Duluth, Georgia, United States|Intermountain Eye Centers, Boise, Idaho, United States|Sabates Eye Centers, Leawood, Kansas, United States|Stiles Eyecare and Glaucoma Institute, Overland Park, Kansas, United States|UK HealthCare Kentucky, Lexington, Kentucky, United States|Advanced Glaucoma Specialists, Reading, Massachusetts, United States|Kresge Eye Institute, Detroit, Michigan, United States|Huron Ophthalmology P.C., Ypsilanti, Michigan, United States|Midwest Vision Research Foundation/ Pepose Vision Institute, Chesterfield, Missouri, United States|Northern New Jersey Eye Institute, PA, South Orange, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Albemarle Clinical Trials, LLC, Elizabeth City, North Carolina, United States|Cornerstone Eye Care, High Point, North Carolina, United States|BaganStrinden Vision, Fargo, North Dakota, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Family Eye Group, Lancaster, Pennsylvania, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Carolinas Centers for Sight, PC, Florence, South Carolina, United States|Chattanooga Eye Institute, Chattanooga, Tennessee, United States|Keystone Research Ltd., Austin, Texas, United States|Houston Eye Associates, Houston, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|R and R Eye Research LLC, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Emerson Clinical Research Institute, Falls Church, Virginia, United States|Piedmont Eye Center, Inc., Lynchburg, Virginia, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|Bendigo Eye Clinic, Bendigo, Victoria, Australia|Eye Surgery Associates East Melbourne, East Melbourne, Victoria, Australia|Essendon Eye Clinic, Essendon, Victoria, Australia|Melbourne Eye Specialists, Fitzroy, Victoria, Australia|Geelong Eye Clinic, Geelong, Victoria, Australia|Waverley Eye Clinic, Glen Waverley, Victoria, Australia|Vision Eye Institute, Melbourne, Victoria, Australia|The University of Western Australia - Lions Eye Institute, Crawley, Western Australia, Australia|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|St. Joseph's Hamilton Healthcare Hospital, Hamilton, Ontario, Canada|Institut de loeil des Laurentides, Boisbriand, Quebec, Canada|Clinique d'ophthalmologie Bellvue Montreal, Montreal, Quebec, Canada|Ophthalmic Consultant Centres, Mississauga, Canada|Glostrup Hospital, Glostrup, Denmark|SA IVKH, Kohtla-Jarve, Estonia|East-Tallinn Central Hospital, Tallinn, Estonia|O Dr Kai Noor Silmakabinet, Tallinn, Estonia|Eye Clinic dr. Krista Turman, Tallinn, Estonia|Eye Clinic of Tartu University Hospital, Tartu, Estonia|Charité Universitätsmedizin Berlin, Berlin, Germany|Internationale Innovative Ophthalmochirurgie, Dusseldorf, Germany|Klinik und Poliklinik fuer Augenheilkunde, Greifswald, Germany|Universitaetsaugenklinik, Magdeburg, Germany|Universitaetsaugenklinik LMU, Munchen, Germany|Universitaets-Augenklinik, Munster, Germany|Universitat Augenklinik, Ulm, Germany|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|The Rabin Medical Center, Petach Tiqva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Medical Centre, Tel Aviv, Israel|Auckland Eye Limited, Remuera, New Zealand|Capital Eye Specialist - Wellington, Wellington, New Zealand|Asian Eye Institute, Makati City, Metro Manila, Philippines|Peregrine Eye and Laser Institute, Makati City, Metro Manila, Philippines|Asian Eye Center, Makati City, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines|Centrum Diagnostykii Mikrochirurgii Oka LENS ul., Olsztyn, Poland|Queen Elisabeth Hospital Birmingham, Birmingham, United Kingdom|Bristol Eye Hospital, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom|Moorfields Eye hospital, London, United Kingdom|Western Eye Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom|Queen Mary's Hospital Sidcup, Sidcup, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02507687"
140,"NCT02505776","Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan",,"Completed","No Results Available","Eyelash Hypotrichosis","Drug: Bimatoprost cutaneous solution 0.03%","Number of Participants With Adverse Events|Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey","Allergan","All","18 Years and older   (Adult, Older Adult)",,"1699","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","192024-089","December 8, 2014","May 21, 2018","May 21, 2018","July 22, 2015",,"August 14, 2018","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02505776"
141,"NCT02502123","Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®","PREDICT","Completed","No Results Available","Migraine Disorders","Other: No Intervention","Change from Baseline in Migraine-Specific Quality of Life (MSQ) at Treatment 4 Using a 6-Item Questionnaire|Change from Baseline in MSQ at Final Visit Using a 6-Item Questionnaire|Clinician's Global Impression of Change Using a 7-Point Scale|Healthcare Resource Utilization Before and After BOTOX® using a 9-Item Questionnaire|BOTOX® Treatment Regimen for Chronic Migraine|Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Before and After BOTOX® Consisting of 6-Items|Patient Global Assessment of Treatment Satisfaction with BOTOX® using a 3-Item Questionnaire|Change from Baseline in Beck Depression Inventory Scale at Final Visit Using a 21-Item Questionnaire|Reasons Why Treatment with BOTOX® Stopped|Headache Assessment from Patient Diary","Allergan","All","18 Years and older   (Adult, Older Adult)",,"215","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GMA-CAN-NEU-0336","July 2, 2015","January 29, 2019","January 29, 2019","July 20, 2015",,"April 5, 2019","Foothills Medical Centre, Calgary, Alberta, Canada|Hys Medical Centre, Edmonton, Alberta, Canada|Bayside Medical Centre, Brentwood Bay, British Columbia, Canada|Jeff Oyler, Kamloops, British Columbia, Canada|Dhawan Medical Corporation Medical Clinic, Vancouver, British Columbia, Canada|May Ong-Lam, Vancouver, British Columbia, Canada|Island Neurology, Victoria, British Columbia, Canada|Hamilton Headache Clinic, Hamilton, Ontario, Canada|The Shapero Markham Headache and Pain Treatment Centre, Markham, Ontario, Canada|Pain Care Clinics, Mississauga, Ontario, Canada|Toronto Headache & Pain Centre, North York, Ontario, Canada|Hany Demian, Oakville, Ontario, Canada|Nepean Medical Centre, Ottawa, Ontario, Canada|Centre de traitement neurologique, Monthreal, Quebec, Canada|Clinic Greene Avenue, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02502123"
142,"NCT02479139","Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis",,"Completed","Has Results","Hyperhidrosis","Biological: Vehicle|Biological: ANT-1207","Percentage of Participants With Both a Change From Baseline in Hyperhidrosis Disease Severity Scale (HDSS) Score by ≥ 2 Points and a Change From Baseline in Gravimetric Sweat Production (GSP) by ≥ 50%|Percentage of Participants With Hyperhidrosis Disease Severity Scale (HDSS) Score Change From Baseline ≥ 2 Points|Percentage of Participants With Gravimetric Sweat Production (GSP) Change From Baseline ≥ 50%","Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANT-1207-HHID-205","June 3, 2015","February 29, 2016","February 29, 2016","June 24, 2015","September 20, 2017","September 20, 2017","San Marcus Research Clinic, Inc., Hialeah, Florida, United States|Baumann Cosmetic & Research Institute, Miami, Florida, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Research Institute of the Southeast, LLC, West Palm Beach, Florida, United States|Shideler Clinical Research Center, Carmel, Indiana, United States|William Coleman III, MD, APMC, Metairie, Louisiana, United States|Lupo Center for Aesthetic & General Dermatology, New Orleans, Louisiana, United States|Skin Specialists, PC, Omaha, Nebraska, United States|JUVA Skin and Laser Center, New York, New York, United States|Skin Search of Rochester, Inc., Rochester, New York, United States|PMG Research of Cary, Cary, North Carolina, United States|Allus Clinical Research, Jenkintown, Pennsylvania, United States|Dermatology and Laser Center of Charleston, PA, Charleston, South Carolina, United States|The Skin Wellness Center, Knoxville, Tennessee, United States|Tennessee Clinical Research Center, Nashville, Tennessee, United States|Westlake Dermatology Clinical Research Center, Austin, Texas, United States|J&S Studies, Inc., College Station, Texas, United States|Texas Dermatology and Laser Specialists, San Antonio, Texas, United States|Virginia Clinical Research Inc., Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02479139"
143,"NCT02462928","A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration","CDER","Completed","No Results Available","Macular Degeneration","Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure","Percentage of Patients with Best Corrected Visual Acuity (BCVA) Change from Baseline ≤15 Letters in the Study Eye|Change from Baseline in BCVA in the Study Eye|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 3","939","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","150998-005|2014-004579-22|CEDAR","June 25, 2015","April 18, 2018","June 19, 2019","June 4, 2015",,"July 24, 2019","Retinal Research Institute, LLC, Phoenix, Arizona, United States|Associated Retina Consultants, Ltd., Phoenix, Arizona, United States|Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|Retina Associates Southwest, OC, Tucson, Arizona, United States|The Retina Partners, Encino, California, United States|Retina Consultants of Orange County, Fullerton, California, United States|Mark B. Kislinger, MD, PhD, Inc., Glendora, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University, Loma Linda, California, United States|Northern California Retina Vitreous Associates, Mountain View, California, United States|Retina Institute of California, Palm Desert, California, United States|Retina Eye Specialists, Pasadena, California, United States|Doheny Vision Research, Pasadena, California, United States|Orange County Retina Medical Group, Santa Ana, California, United States|California Retina Consultants, Santa Barbara, California, United States|Colorado Retina Associates, PC, Golden, Colorado, United States|Retina Health Center, Fort Myers, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Ocala Eye PA, Ocala, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|Retina Care Specialists, Palm Beach Gardens, Florida, United States|Retina Specialty Institute, Pensacola, Florida, United States|Retina Vitreous Associates of Florida - Saint Petersburg, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Georgia Retina, P.C., Marietta, Georgia, United States|Thomas Eye Group, PC, Sandy Springs, Georgia, United States|Retina Consultants of Hawaii, Inc., 'Aiea, Hawaii, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|University Retina and Macula Associates, Oak Forest, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Raj K. Maturi, M.D., P.C, Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Ochsner Health Center, New Orleans, Louisiana, United States|National Retina Institute, Towson, Maryland, United States|Retina Specialists, Towson, Maryland, United States|Lahey Clinic Medical Center, Peabody, Massachusetts, United States|Kellogg Eye Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Sierra Eye Associates, Reno, Nevada, United States|Retina Associates of New Jersey, Teaneck, New Jersey, United States|Capital Region Retina, PLLC, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Long Island Vitreoretinal Consultants, Great Neck, New York, United States|Ophthalmic Consultants Long Island, Lynbrook, New York, United States|Retina Associates of Western NY, Rochester, New York, United States|Island Retina, Shirley, New York, United States|Carolina Eye Associates, Southern Pines, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Apex Eye Clinical Research, Fairfield, Ohio, United States|Lancaster Retina Specialists, Lancaster, Pennsylvania, United States|Mid Atlantic Retina, Philadelphia, Pennsylvania, United States|Associates in Ophthalmalogy, West Mifflin, Pennsylvania, United States|Retina Consultants of Carolina, Greenville, South Carolina, United States|Charleston Neuroscience Institute, Ladson, South Carolina, United States|Retina Research Institute of Texas, Abilene, Texas, United States|Texas Retina Associates, Arlington, Texas, United States|Texan Eye Care, Austin, Texas, United States|Texas Retina Associates, Dallas, Texas, United States|Houston Eye Associates, Houston, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Retinal Consultants of Houston, Houston, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States|Retina Associates of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Piedmont Eye Center, Inc., Lynchburg, Virginia, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Hospital Universitario Austral, Buenos Aires, Argentina|Kaufer Eye Clinic, Buenos Aires, Argentina|Organizacion Medica de Investigacion, Buenos Aires, Argentina|Oftalmos, Buenos Aires, Argentina|Centro Privado de Ojos Romagosa, Cordoba, Argentina|Instituto Oftalmologico de Cordoba, Cordoba, Argentina|Oftar Centro Privado de Oftalmologia, Mendoza, Argentina|Oftalmologos Especialistas, Santa Fe, Argentina|Grupo Laser Vision, Santa Fe, Argentina|University of Graz, Graz, Austria|Universitatsklinikum Innsbruck, Innsbruck, Austria|AKH Linz Augenheilkunde, Linz, Austria|Konventhospital der Barmherzigen Brüder, Linz, Austria|Instituto Oftalmologica Profesor Arentsen, Santiago, Región Metropolitana, Chile|KYDOFT - Hospital, Santiago, Región Metropolitana, Chile|Fundacion Oftalmologica Nacional, Bogotá, Cundinamarca, Colombia|Centro Medico Imbanaco, Cali, Valle Del Cauca, Colombia|University Hospital Brno, Brno, Czechia|I.P. Pavlova 6, Olomouc, Olomouc, Czechia|The Eye Department Oční klinika, Prague 10, Czechia|General University Hospital - Clinic of Ophthalmology, Prague 2, Czechia|Hopital Pellegrin, Bordeaux, France|Centre Hospitalier Intercommunal de Creteil, Creteil, France|Hopital de la Croix-Rousse, Lyon cedex 04, France|Centre Hospitailier Universitaire de Nantes, Nantes Cedex 1, France|Centre Ophtalmo Imagerie (C.I.L), Paris, France|Centre Ophtalmologique Transparence, Tours, France|Augenklinik Dardenne SE, Bonn, Germany|Klinikum Dresden Friedrichstadt, Dresden, Germany|Augenchirurgie fur den Bereich Makula, Dusseldorf, Germany|Universitat Augenklinik, Freiburg, Germany|Universitatsaugenklinik Gottingen, Goettingen, Germany|Staedtisches Klinikum, Karlsruhe, Germany|Augenklinik der Universität Leipzig, Leipzig, Germany|Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany|Dietrich-Bonhoeffer-Klinikum, Neubrandenburg, Germany|Klinikum d. Universitat Regensburg, Regensburg, Germany|Hong Kong Eye Hospital, Kowloon, Hong Kong|The University of Hong Kong, Pok Fu Lam, Hong Kong|Assaf Harofeh Medical Center, Beer-Yaakov, Israel|Bnai Zion M.C., Haifa, Israel|Rambam Medical Center, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Wolfson Hospital, Holon, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center Beilinson Hospital, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Goldschleger Eye Institute, Tel Hashomer, Israel|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Jongno-gu, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seodaemun-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|Paula Stradina Kliniiskas Universitates Slimnica, Riga, Latvia|Auckland Eye Hospital, Remuera, Auckland N, New Zealand|The University of Auckland, Auckland, New Zealand|Cebu Doctors' University Hospital, Cebu City, Metro Manila, Philippines|Asian Eye Institute, Makati City, Metro Manila, Philippines|Pacific Eyecare & Laser Institute, Makati City, Metro Manila, Philippines|The Medical City, Pasig City, Metro Manila, Philippines|St. Luke's Medical Center, Quezon City, Metro Manila, Philippines|National University Hospital, Singapore, Singapore|Singapore National Eye Centre, Singapore, Singapore|Bellvitge University Hopsital, L'hospitalet de Llobregat, Barcelona, Spain|ICQO, Bilbao, Bizkaia, Spain|Universidad de Navarra, Pamplona, Navarra, Spain|Centro de Oftalmologia Barraquer, Barcelona, Spain|ICOF Hospital Clinic De Barcelona, Barcelona, Spain|Valles Oftalmologia Recerca, Barcelona, Spain|Instituto de Microcirugía Ocular, Barcelona, Spain|Hospital Clinico San Carl, Madrid, Spain|Hospital de la Fe, Valencia, Spain|Hospital General, Valencia, Spain|Instituti U. de Oftalmologia Aplicade-Facultad de Med., Valladolid, Spain|Hospital Clinico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|University Eye Hospital Bern, Bern, Switzerland|Vista Klinik AG, Binningen, Switzerland|Stadtspital Triemli Ophthalmology, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02462928"
144,"NCT02462486","Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration",,"Completed","No Results Available","Macular Degeneration","Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure","Percentage of Patients with Best Corrected Visual Acuity (BCVA) Change from Baseline ≤15 Letters in the Study Eye|Change from Baseline in BCVA in the Study Eye|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 3","946","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","150998-006|2014-004580-20|SEQUOIA","June 25, 2015","April 12, 2018","June 6, 2019","June 4, 2015",,"July 24, 2019","Eye Foundation Hospital, Birmingham, Alabama, United States|Retinal Research Institute, LLC, Gilbert, Arizona, United States|Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States|Northwest Arkansas Retina Associates, P.A., Springdale, Arizona, United States|Retina Centers, PC, Tucson, Arizona, United States|Win Retina, Arcadia, California, United States|Retina Institute of California, Arcadia, California, United States|Retinal Diagnostic Center, Campbell, California, United States|Specialty Eye Care Medical Center, Inc., Glendale, California, United States|University of California at Irvine Gavin Herbert Eye Institute, Irvine, California, United States|Retina Associates of Orange County, Laguna Hills, California, United States|South Coast Retina Center, Long Beach, California, United States|DuPage Medical Group, Ltd., Los Angeles, California, United States|East Bay Retina Consultants, Inc., Oakland, California, United States|San Diego Retina Associates, Oceanside, California, United States|Southern California Desert Retina Consultants, MC, Palm Desert, California, United States|California Eye Specialist Medical Group, Pasadena, California, United States|Retina Consultants, San Diego, Poway, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Kaiser Permanente Riverside Medical Center, Riverside, California, United States|UC Davis Medical Center, Department of Ophthalmology, Sacramento, California, United States|Retinal Consultants Medical Group, Sacramento, California, United States|West Coast Retina Medical Group, Inc., San Francisco, California, United States|Pacific Eye Associates, San Francisco, California, United States|The Eye Associates, Bradenton, Florida, United States|Argus Research at Cape Coral Eye Center, Cape Coral, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|MedEye Associates, Miami, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Sarasota Retina Institute Research Foundation, Sarasota, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Retina Associate of Florida, P.A., Tampa, Florida, United States|Retina Vitreous Associates of Florida - Saint Petersburg, Tampa, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Southeast Retina Center, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Kovach Eye Institute, Elmhurst, Illinois, United States|University Retina and Macula Associates, Oak Forest, Illinois, United States|Wheaton Eye Clinic, Clinical Research Center, LLC, Wheaton, Illinois, United States|Sabates Eye Centers, Leawood, Kansas, United States|Paducah Retinal Center, Paducah, Kentucky, United States|The Retina Care Center, Baltimore, Maryland, United States|Cumberland Valley Retina Consultants, P.C., Hagerstown, Maryland, United States|Vitreo-Retinal Associates, PC, Worcester, Massachusetts, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Retina Center of New Jersey, Bloomfield, New Jersey, United States|Delaware Valley Retina Associates, Lawrenceville, New Jersey, United States|Long Island Vitreoretinal Consultants, Hauppauge, New York, United States|Maculacare - New York, New York, New York, United States|Retina Vitreous Surgeons, Syracuse, New York, United States|Western Carolina Retinal Associates, PA, Asheville, North Carolina, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc, Beachwood, Ohio, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Midwest Retina, Dublin, Ohio, United States|Retina and Vitreous Center of Southern Oregon, PC, Ashland, Oregon, United States|Oregon Health Sciences University, Portland, Oregon, United States|Pennsylvania Retina Specialists, P.C., Camp Hill, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Austin Retina Associates, Austin, Texas, United States|Retina and Vitreous of Texas, Beaumont, Texas, United States|The University of Texas Medical Branch, Galveston, Texas, United States|Premiere Retina Specialists, Midland, Texas, United States|Retina Associates of South Texas, PA, San Antonio, Texas, United States|Strategic Clinical Research Group, LLC, Willow Park, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Eye Consultants, Norfolk, Virginia, United States|Wagner Macula and Retina Center, Virginia Beach, Virginia, United States|Vitreoretinal Associates of Washington, Bellevue, Washington, United States|Spokane Eye Clinical Research, Spokane, Washington, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|Sydney Retina Clinic and Day Surgery, Sydney, New South Wales, Australia|Save Sight Institute, University of Sydney Eye Hospital, Sydney, New South Wales, Australia|Sydney West Retina Pty Ltd, Westmead, New South Wales, Australia|The Royal Victorian Eye & Ear Hospital, Center for Eye Research, East Melbourne, Victoria, Australia|Specialist Eye Group, Glen Waverley, Victoria, Australia|Lions Eye Institute, Nedlands, Western Australia, Australia|Centro Brasileiro de Cirurgia de Olhos - CBCO, Goiânia, Goiás, Brazil|Instistuto da Visao - Hospital de Olhos Ltda, Belo Horizonte, Minas Gerais, Brazil|Hospital Oftalmologico de Sorocaba, Sorocaba, São Paulo, Brazil|Clinica de Olhos Dr. Suel Abujamra, São Paulo, Brazil|Instituto Da Visão UNIFESP EPM (Universidade Federal de São Paulo - Escola Paulista de Medicina), São Paulo, Brazil|Calgary Retina Consultants, Calgary, Alberta, Canada|St Joseph's Health Care London - Ivey Eye Institute, London, Ontario, Canada|Canadian Centre for Advanced Eye Therapeutics Inc, Mississauga, Ontario, Canada|University of Ottawa Eye Institute, Ottawa, Ontario, Canada|Toronto Retina Institute, Toronto, Ontario, Canada|Glostrup Hospital, Glostrup, Denmark|Odense Universitets Hospital, Odense, Denmark|Magyar Honvédség Egészségügyi Központ, Szemészeti Osztály, Budapest, Hungary|Dept. of Ophthalmology Semmelweis University, Budapest, Hungary|Bajcsy-Zsilinszky Hospital, Budapest, Hungary|Szent Imre Teaching Hospital, Budapest, Hungary|Budapest Retina Associates Kft., Budapest, Hungary|University of Debrecen, Department of Ophthalmology, Debrecen, Hungary|Ganglion Medical Centre, Pécs, Hungary|University of Szeged, Dept of Ophthalmology, Szeged, Hungary|Markusovszky Teaching Hospital, Department of Ophthalmology, Szombathely, Hungary|A.O.U Policlinico San Orsola-Malpighi, U.O. Oftalmologia Ciardella (oppure Nuova Area Oftalmologia) Padiglione 1 Palagi, Bologna, Italy|Clinica Oftalmologica Centro regionale di Eccelenza Università degli Studi di Chieti-Pescara ""Gabriele D'Annunzio, Chieti, Italy|Azienda Ospedaliero-Universitaria Careggi - SOD Oculistica, Dipartimento di Chirurgia e Medicina Traslazionale, Firenze, Italy|Clinica Oculistica DINOGMI Università' di Genova, Genova, Italy|Ospedale San Raffaele IRCCS, Department of Ophthalmology, Milano, Italy|Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano, Milan, Italy|Opsedale Luigi Sacco Universita di Milano Dipartimento di Scienze, Milan, Italy|Ospedale Classificato Equiparato Sacro Cuore - Don Calabria, Negrar (Verona), Italy|Azienda Universitaria Ospedaliera Pisana, Ospedale ""Nuovo S.Chiara"" Cisanello, Pisa, Italy|Fondazione G.B. Bietti-IRCCS, Roma, Italy|Ospedale Policlinico Universitario Agostino Gemelli di Roma, Rome, Italy|Clinica Oculistica Ospedale Oftalmico, Torino, Italy|Clinica Oculistica Universitaria, Ospedale Santa Maria della, Udine, Italy|Aichi Medical University Hospital, Nagakute, Aichi, Japan|Japan Community Health Care Organization Chukyo Hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|Kameda Clinic, Kamogawa, Chiba, Japan|Toho University Sakura Medical Center, Sakura, Chiba, Japan|Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan|Kokura Kinen Hospital, Kitakyusyu, Fukuoka, Japan|Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan|Kimura Eye And Internal Medicine Hospital, Kure, Hiroshima, Japan|Sapporo City General Hospital, Sapporo, Hokkaido, Japan|Hyogo Prefectural Amagasaki Hospital General Medical Center, Amagasaki, Hyogo, Japan|Tokyo Medical University Ibaraki Medical Center, Inashiki, Ibaraki, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|Otakeganka Tsukimino Clinic, Yamato, Kanagawa, Japan|Kikuna Yuda Eye Clinic, Yoskohama, Kanagawa, Japan|Mie University Hospital, Tsu, Mie, Japan|Iida Municipal Hospital, Iida, Nagano, Japan|Shiga University of Medical Science Hospital, Otsu, Shiga, Japan|Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan|Nihon University Hospital, Chiyoda, Tokyo, Japan|Chofu Eye Clinic, Chofu, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Takeuchi Eye Clinic, Taito, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Ideta Eye Hospital, Kumamoto, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Nara Medical University Hospital, Nara, Japan|Medical Corporation Jinshikai Nishi Eye Hospital, Osaka, Japan|Musashi Dream Clinic, Osaka, Japan|Tane Memorial Eye Hospital, Osaka, Japan|Tokyo Women's Medical University Hospital, Tokyo, Japan|Academic Medical Center, Amsterdam, Netherlands|Leiden University Medical Center Department of Ophthalmology, Leiden, Netherlands|Rotterdam Eye Hospital, Rotterdam, Netherlands|St. Elisabeth Hospital, Tilburg, Netherlands|Centro Oftalmológico Mácula Diagnóstico y Tratamiento - Macula D&T Eye Center, San Isidro, Lima, Peru|Optimum Profesorskie Centrum Okulistyki, Gdansk, Poland|Klinika Okulistyczna Jasne Blonia, Lodz, Poland|Diagnostic and Microsurgery Center of the Eye LENS, Olsztyn, Poland|Retina Eye Hospital, Warsaw, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego, Klinika Okulistyki, Wrocław, Poland|Scientific Research Institute of Eye Diseases of Russian Academy of Medical Sciences, Moscow, Russian Federation|S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation|Pasteur Medical Centre, Bloemfontein, South Africa|Cape Eye Hospital, Private Practice, Cape Town, South Africa|Pretoria Eye Institute, Private Practice, Pretoria, South Africa|Department of Ophthalmology Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Department of Ophthalmology National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Chang Gung Medical Foundation, Linkou Branch, Taoyuan, Taiwan|Ankara University School of Medicine, Ankara, Turkey|Dokuz Eylul Medical Faculty, Balcova, Izmir, Turkey|Bristol Eye Hospital, Bristol, Avon, United Kingdom|Royal Derby Hospital, Derby, Derbyshire, United Kingdom|Essex County Hospital, Colchester, Essex, United Kingdom|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Aintree University Hospital, Liverpool, Merseyside, United Kingdom|Oxford Eye Hospital, Oxford, Oxfordshire, United Kingdom|Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom|Heart of England NHS Foundation Trust, Good Hope Hospital, Sutton Coldfield, Staffordshire, United Kingdom|Frimley Park Hospital, Camberley, Surrey, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|City Hospital Sunderland, Sunderland, Tyne And Wear, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Hospital of St. Cross, Rugby, Warwickshire, United Kingdom|Bradford Royal Infirmary, Bradford, West Yorkshire, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Barnet Royal Free Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02462486"
145,"NCT02455050","A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief",,"Completed","Has Results","Dry Eye Syndromes","Drug: Carboxymethylcellulose Sodium Based Eye Drops|Drug: Systane® Gel Drops|Drug: Genteal® Lubricant Gel Drops","Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 1|Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 2|Ocular Surface Disease Index© (OSDI©) Score Using a 5-Point Scale in Period 1|Ocular Surface Disease Index© (OSDI©) Score Using a 5-Point Scale in Period 2|Percentage of Participants Selecting Strongly Agree or Agree in the Acceptability Survey Score Using a 5-Point Scale in Period 1|Percentage of Participants Selecting Strongly Agree or Agree in the Acceptability Survey Score Using a 5-Point Scale in Period 2|Subjective Evaluation of Symptoms of Dryness (SESoD) Score Using a 5-Point Scale in Period 1|Subjective Evaluation of Symptoms of Dryness (SESoD) Score Using a 5-Point Scale in Period 2|Percentage of Participants by Response in End of Study Survey: Assessing Comfort, Blur, and Relief of Symptoms (New Eye Drop Formulation Versus Systane®)|Percentage of Participants by Response in End of Study Survey: Assessing Comfort, Blur, and Relief of Symptoms (New Eye Drop Formulation Versus Genteal®)|Distance Visual Acuity in Period 1|Distance Visual Acuity in Period 2|Tear Break-Up Time With Fluorescein in Period 1|Tear Break-Up Time With Fluorescein in Period 2|Eye Drop Experience Survey Score: Assessing Vision, Comfort, and Relief of Symptoms in Period 1|Eye Drop Experience Survey Score: Assessing Vision, Comfort, and Relief of Symptoms in Period 2","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","11193X-002","December 2014","August 2015","August 2015","May 27, 2015","January 4, 2017","January 4, 2017","Azusa, California, United States",,"https://ClinicalTrials.gov/show/NCT02455050"
146,"NCT02438332","Retrospective Study of Reoperation After Primary Augmentation With NATRELLE® INSPIRA® Breast Implants","RANBI-I","Completed","No Results Available","Breast Implantation","Device: Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Device: Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|Device: Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants","Incidence of Reoperations of All Cause Following the Use of Smooth or Textured NATRELLE® INSPIRA® TruForm® 1 or TruForm® 2 Breast Implants|Incidence (by Product Type) of First Reoperation Following the Use of Smooth or Textured NATRELLE® INSPIRA® TruForm®1 or TruForm® 2 Breast Implants|Reasons For Primary Augmentation|Time From the Date of Implant Until First Reoperation|Reasons For Reoperation Incidence|Incidences of Implant Removal With Replacement|Incidences of Implant Removal Without Replacement","Allergan","Female","22 Years and older   (Adult, Older Adult)",,"330","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-CAN-PLS-0337","December 2014","June 2016","June 2016","May 8, 2015",,"July 25, 2016","Banff Plastic Surgery, Banff, Alberta, Canada|Macleod Trail Plastic Surgery, Calgary, Alberta, Canada|Jonathan Toy, Edmonton, Alberta, Canada|Y.E.S MedSpa & Cosmetic Surgery Centre, Langley, British Columbia, Canada|Institute of Cosmetic and Laser Surgery, Oakville, Ontario, Canada|Ottawa Plastic Surgery: Dr. Howard Silverman, Ottawa, Ontario, Canada|Rice Cosmetic Surgery, Toronto, Ontario, Canada|Cosmedical Rejuvenation Clinic, Toronto, Ontario, Canada|Yorkville Institute of Plastic Surgery, Toronto, Ontario, Canada|SpaSurgica, Waterloo, Ontario, Canada|Centre de Medecine et de Chirurgie Ambulatoires Isomed, Boucherville, Quebec, Canada|CCPEM, Montreal, Quebec, Canada|Cosmedica, Pointe-Claire, Quebec, Canada|Cosmetic Surgery Clinic, Waterloo, Quebec, Canada|Sandra McGill MD Inc., Westmount, Quebec, Canada|Clinique de Chirurgie Plastique et Esthétique de la Haute-Ville, Quebec, Canada|Sebastien Nguyen MD Inc., Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02438332"
147,"NCT02435914","Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease",,"Completed","Has Results","Dry Eye Syndromes","Drug: AGN-223575 ophthalmic solution|Drug: AGN-223575 vehicle ophthalmic solution","Change From Baseline in Conjunctival Redness Score in the Study Eye Using a 5-Point Scale|Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score Using a 5-Point Scale|Change From Baseline in Corneal Staining Score of the Study Eye Using a 6-Point Scale|Percentage of Participants With Complete Redness Response (Yes/No) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","223575-002","June 2015","January 2016","January 2016","May 6, 2015","April 5, 2019","April 5, 2019","Arizona Center for Clinical Trials, Phoenix, Arizona, United States|Specialty Eye Ctr. Med. Group, Glendale, California, United States|The Eye Research Foundation, Newport Beach, California, United States|WCCT Global, Santa Ana, California, United States|Eye Associates of Colorado Springs, Colorado Springs, Colorado, United States|West Coast Eye Institute, Lecanto, Florida, United States|Eye Care Centers Management, Inc., Morrow, Georgia, United States|Coastal Research Assoc. LLC, Roswell, Georgia, United States|Chicago Cornea Consultants, Hoffman Estates, Illinois, United States|Durrie Vision, Overland Park, Kansas, United States|Kentucky Center for Vision, Lexington, Kentucky, United States|Tufts Medical Center/ Tufts University School of Medicine, Boston, Massachusetts, United States|Moyes Eye Center, Kansas City, Missouri, United States|Ophthalmology Associates, Saint Louis, Missouri, United States|Comprehensive Eye Care Ltd., Washington, Missouri, United States|Raymond Fong MD, PC, New York, New York, United States|South Shore Eye Care LLP, Wantagh, New York, United States|SE Clinical Research Associates, LLC/ Charolette Eye Ear Nose, Charlotte, North Carolina, United States|Cornerstone Eye Care, High Point, North Carolina, United States|Eye Care Associates of Greater Cincinnati, Cincinnati, Ohio, United States|Mark A. Terry, MD PC/ Devers Eye Institute, Portland, Oregon, United States|Bluestein Custom Vision, Charleston, South Carolina, United States|Carolinas Centers for Sight, PC, Florence, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Keystone Clinical Research, Austin, Texas, United States|Houston Eye Associates, Houston, Texas, United States|Whitsett Vision Group, Houston, Texas, United States|Medical Center Opth. Assoc., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02435914"
148,"NCT02420730","Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye",,"Completed","No Results Available","Healthy Volunteers|Dry Eye Syndromes","Drug: AGN-232411|Drug: AGN-232411 Vehicle","Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","232411-001","June 2015","March 2016","March 2016","April 20, 2015",,"July 14, 2016","Sall Research Center, Artesia, California, United States|Lugene Eye Institute, Glendale, California, United States|Montebello Medical Center, Inc., Montebello, California, United States",,"https://ClinicalTrials.gov/show/NCT02420730"
149,"NCT02417077","Perception of Facial Expression in Subjects With and Without Crow's Feet Lines",,"Completed","No Results Available","Healthy Volunteers","Other: Photographic Review","Independant Observers' Perception of Expressed Emotions on a 7-Point Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"393","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-BTXC-14-001","December 2015","December 2015","December 2015","April 15, 2015",,"March 11, 2016","Saratoga Springs, New York, United States",,"https://ClinicalTrials.gov/show/NCT02417077"
150,"NCT02411110","A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome",,"Completed","Has Results","Cystitis, Interstitial|Painful Bladder Syndrome","Combination Product: LiRIS®|Combination Product: LiRIS Placebo","Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 2","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201025-002","May 21, 2015","October 12, 2016","January 9, 2017","April 8, 2015","January 4, 2018","January 4, 2018","Coastal Clinical Research, Inc., Mobile, Alabama, United States|IC Study LLC, Escondido, California, United States|Tower Urology, Los Angeles, California, United States|Tri Valley Urology Medical Group, Murrieta, California, United States|Genesis Research LLC, San Diego, California, United States|Sutter Health, Vacaville, California, United States|Women's Health Specialty Care, Farmington, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Manatee Medical Research Institute, Bradenton, Florida, United States|Atlanta Medical Research Instititute, Alpharetta, Georgia, United States|Idaho Urologic Institute, Meridian, Idaho, United States|Associated Surgeons and Physicians LLC DBA Women's Health Advantage, Fort Wayne, Indiana, United States|Regional Urology, LLC, Shreveport, Louisiana, United States|Anne Arundel Urology, P.A., Annapolis, Maryland, United States|Chesapeake Urology Research Associates, Baltimore, Maryland, United States|Beyer Research, Kalamazoo, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Saint Louis University School of Medicine Department of Obstetrics, Gynecology, and Women's Health Division of Research, Saint Louis, Missouri, United States|Cooper University Hospita/ Univeristy Urogynecology Associates, Voorhees, New Jersey, United States|Western New York Urology Associates, Cheektowaga, New York, United States|BRANY, as agent The Arthur Smith Institute for North Shore Long Island Jewish Health System, Lake Success, New York, United States|Urology Institute of Long Island, Plainview, New York, United States|McKay Urology, Charlotte, North Carolina, United States|Alliance Urology Specialist, P.A., Greensboro, North Carolina, United States|Eastern Urological Associates, PA, Greenville, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|MetroHealth System, Cleveland, Ohio, United States|Female Sexual and Pelvic Health Institute, Philadelphia, Pennsylvania, United States|Integrity Medical Research (Urology Northwest), Mountlake Terrace, Washington, United States|University of Washington, Seattle, Washington, United States|Silverado Research Inc, Victoria, British Columbia, Canada|Urology Associates/Urologic Medical Research, Kitchener, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02411110"
151,"NCT02395042","A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions",,"Completed","Has Results","Cystitis, Interstitial|Ulcer","Drug: LiRIS®|Drug: LiRIS Placebo","Change From Baseline in the Daily Average Bladder Pain Numeric Rating Scale (NRS)|Change From Baseline in the Number of Hunner's Lesions|Change From Baseline in Composite Score of Hunner's Lesions Calculated Based on Number, Size, and Severity of Lesions","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201025-001","April 15, 2015","June 29, 2017","November 20, 2017","March 20, 2015","October 5, 2018","October 5, 2018","Tri Valley Urology Medical Group, Murrieta, California, United States|Sutter Institute for Medical Research, Vacaville, California, United States|Women's Health Specialty Care, Farmington, Connecticut, United States|Atlanta Medical Research Institute, Alpharetta, Georgia, United States|Anne Arundel Urology, P.A., Annapolis, Maryland, United States|Chesapeake Urology Research Associates, Baltimore, Maryland, United States|Beyer Research, Kalamazoo, Michigan, United States|Beaumont Health System, Royal Oak, Michigan, United States|Washington University School of Medicine Department of Surgery, Saint Louis, Missouri, United States|Western New York Urology Associates, LLC, Cheektowaga, New York, United States|McKay Urology, Charlotte, North Carolina, United States|Eastern Urological Associates, PA, Greenville, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|MetroHealth System/Center for Advanced Gynecology, Cleveland, Ohio, United States|Philadelphia Urosurgical Associates, Philadelphia, Pennsylvania, United States|University of Washington, Seattle, Washington, United States|Aurora Health Care, West Allis, Wisconsin, United States|Silverado Research Inc, Victoria, British Columbia, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02395042/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02395042/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02395042"
152,"NCT02357420","Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis",,"Completed","Has Results","Diabetes Mellitus|Diabetes Mellitus Complications|Gastroparesis","Drug: Relamorelin|Drug: Placebo","Change From Baseline to Week 12 in Weekly Vomiting Episodes|Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain)|Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","393","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RM-131-009|2014-005623-27","January 29, 2015","June 9, 2016","June 9, 2016","February 6, 2015","July 24, 2019","July 24, 2019","Digestive Health Specialist of the Southeast, Dothan, Alabama, United States|Huntsville, Alabama, United States|Desert Sun Clinical Research, Tucson, Arizona, United States|Adobe Clinical Research, Tucson, Arizona, United States|Harrisburg Family Medical Center, Harrisburg, Arkansas, United States|Arkansas Primary Care Clinic, Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|TriWest Research Associates, El Cajon, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Axis Clinical Trials, Los Angeles, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Ventura Clinical Trials, Ventura, California, United States|Danbury Hospital‐ Office of Clinical trials, Danbury, Connecticut, United States|Avail Clinical Research, DeLand, Florida, United States|International Research Associates LLC, Hialeah, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|APF Research, LLC, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Baptist Diabetes Associates, P.A., Miami, Florida, United States|Miami, Florida, United States|International Research Associates LLC, Miami, Florida, United States|Advanced Research Institute Inc, New Port Richey, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|River Birch Research Alliance LLC, Blue Ridge, Georgia, United States|Rockford Gastroenterology Associates, Ltd., Rockford, Illinois, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, Monroe, Louisiana, United States|Clinical Trials of America LA, LLC, West Monroe, Louisiana, United States|Metropolitan Gastroenterology Group, P.C. (Chevy Chase Clinical Research) Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Detroit Clinical Research Center, PC‐Farmington Hills, Farmington Hills, Michigan, United States|Center For Digestive Health, Troy, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Planters Clinic, Port Gibson, Mississippi, United States|Impact Clinical Trials, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Great Neck, New York, United States|New York Clinical Trials, Inc, New York, New York, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|OnSite Clinical Solutions‐ Lexington OnSite Clinical Solutions, LLC, Lexington, North Carolina, United States|Diabetes and Endocrinology Consultants, P.C., Morehead City, North Carolina, United States|OnSite Clinical Solutions, LLC, Statesville, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|Wake Forest University Baptist Health ‐ Dept of Gastroenterology Medical Center Blvd, Winston-Salem, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|MetroHealth Medical Center, Leveland, Ohio, United States|Great Lakes Gastroenterology Research, Mentor, Ohio, United States|Northwest Gastroenterology Clinic, Portland, Oregon, United States|Family Medicine of SayeBrook, Myrtle Beach, South Carolina, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|El Paso, Texas, United States|GI Specialists of Houston, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|The University of Texas Health Science Center & Medical School at Houston, Houston, Texas, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, United States|Gulf Coast Medical Research, LLC, Sugar Land, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States|Khan and Abbasi Research, Chester, Virginia, United States|Healing Hands of Virginia LLC, Richmond, Virginia, United States|Gastroenterology Consultants, Virginia Beach, Virginia, United States|ZainResearch, LLC, Richland, Washington, United States|Hopital Erasme ‐ Universite Libre de Bruxelles, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Herz und Diabeteszentrum Nordrhein Westfalen, Universitätsklinikum der Ruhr‐Universiät Bochum, Bad Oeynhausen, Germany|Praxis Dr. Ott Rabenauer Str., Dippoldiswalde, Germany|GWT‐TUD GmbH, Dresden, Germany|Israelitisches Krankenhaus Orchideenstig, Hamburg, Germany|Diabetes Zentrum und Praxis Prof. Pfützner Parcusstr., Mainz, Germany|Rambam Health Care Campus ‐ Inst. of Endocrinology, Diabetes, and Metabolism, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Rabin Medical Center, Beilinson Hospital Gastroenterology Dept, Petach Tikva, Israel|ZIV Medical Center, Safed, Israel|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorób Kostno‐Stawowych J. Badurski S.J. ul., Bialystok, Poland|NZOZ Witamed al., Kielce, Poland|CenterMed Krakow, Krakow, Poland|Gabinet Lekarski dr n.med. Malgorzata Saryusz‐Wolska ul., Lodz, Poland|NZOZ Pulsmedica ul., Lodz, Poland|KO‐MED Centra Kliniczne, Staszów, Poland|Centrum Badawcze Wspólczesnej Terapii ul., Warszawa, Poland|Warszawa, Poland|Gastroenterology Karolinska University Hospital Karolinska Universitetssjukhuset Gastro Centrum Medicine, Stockholm, Sweden|Uppsala University Hospital Gastroenterology / Mag‐Tarmmottagningen ingang, Uppsala, Sweden|NHS Tayside, Dundee, Scotland, United Kingdom|Wansbeck General Hospital (Northumbria NHS Trust), Ashington, United Kingdom|University Hospital of North Durham University Hospital of North Durham Research and Development Directorate, Durham, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02357420"
153,"NCT02348476","A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Other: No Intervention","The time to first glaucoma therapy escalation occurrence or discontinuation of Simbrinza®|The time to first glaucoma therapy escalation occurrence|The time(s) to additional glaucoma therapy escalation occurrence(s)|Specific AEs and SAEs occurring with a frequency of ≥5%","Allergan","All","18 Years and older   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-SIM-14-024","November 2014","April 2015","April 2015","January 28, 2015",,"September 21, 2015","Wheaton, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02348476"
154,"NCT02280473","A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease",,"Completed","Has Results","Dry Eye Syndromes","Drug: Refresh Optive® Gel Drops|Drug: REFRESH LIQUIGEL®","Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score|Change From Baseline in the OSDI© Score|Change From Baseline in Tear Break-up Time (TBUT)|Change From Baseline in the Combined Corneal and Conjunctival Staining Scores|Change From Baseline in the Schirmer Test","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11193X-001","November 13, 2014","March 16, 2015","March 16, 2015","October 31, 2014","June 7, 2017","April 16, 2019","North Bay Eye Associates, Petaluma, California, United States|Eric M. White, OD, Inc., San Diego, California, United States|Eye Center Northeast, Bangor, Maine, United States|Moyes Eye Center, PC, Kansas City, Missouri, United States|Ophthalmology Associates, Saint Louis, Missouri, United States|Comprehensive Eye Care, Ltd., Washington, Missouri, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|David W. Ferris & Associates, Inc., Warwick, Rhode Island, United States|Primary Eyecare Group, PC, Brentwood, Tennessee, United States|The Eye Center at Southern College of Optometry, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02280473"
155,"NCT02261493","A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides",,"Completed","Has Results","Facial Rhytides|Glabellar Rhytides","Biological: OnabotulinumtoxinA|Drug: Normal Saline","Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at Maximum Eyebrow Elevation|Percentage of Subjects With an Investigator Rating of None or Mild on the 4-Grade FWS for Forehead Line Severity at Maximum Eyebrow Elevation|Percentage of Subjects With ≥1-Grade Improvement From Baseline on the Investigator's FWS Rating of Forehead Line Severity at Rest|Percentage of Subjects Reporting Mostly Satisfied or Very Satisfied on the 5-Point Facial Line Satisfaction Questionnaire (FLSQ) Item 5|Percentage of Subjects With ≥20-Point Improvement From Baseline on the Impact Domain of the FLSQ Among Subjects With Baseline Score ≥ 20 Points|Percentage of Subjects With a ≥3-Point Improvement From Baseline on Item 4 of the 11-Point Facial Line Outcomes (FLO-11) Questionnaire©|Time to Retreatment Eligibility","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","787","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-143|2014-001815-38","October 27, 2014","June 3, 2015","April 20, 2016","October 10, 2014","July 25, 2017","July 25, 2017","The Petrus Center for Aesthetic, Little Rock, Arkansas, United States|Westside Aesthetics, Los Angeles, California, United States|Eye Research Foundation, Newport Beach, California, United States|Steve Yoelin, MD Medical Associates, Inc., Newport Beach, California, United States|Baumann Cosmetic & Research Institute, Miami, Florida, United States|Saint Louis University, Saint Louis, Missouri, United States|The Center For Dermatology Cosmetic and Laser Surgery, Mount Kisco, New York, United States|Tennessee Clinical Research Center, Nashville, Tennessee, United States|The Center for Skin Research, Houston, Texas, United States|Premier Clinical Research, Spokane, Washington, United States|Aalst Dermatology Clinic, Aalst, Belgium|UZ Brussel, Jette, Belgium|Medical Skin Care - Sint-Truiden, Limburg, Belgium|Rosenpark Research, Darmstadt, Germany|Hautzentrum Koeln (Cologne Dermatology), Köln Nordrhein-Westfalen, Germany|Hautok und hautok-cosmetics, München, Germany|Praxisgemeinschaft Theatiner46, München, Germany|Hautzentrum am Starnberger See GmbH, Starnberg, Germany|CentroDerm Study Center, Wuppertal, Germany|Shakespeare House Health Centre, General Practice, Basingstoke, United Kingdom|Medizen Clinic, Birmingham, United Kingdom|The Bosham Clinic, Chichester, United Kingdom|Waverlery Medical Practice, Coatbridge, United Kingdom|The Gatehouse, Whitegate, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02261493"
156,"NCT02261467","A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides",,"Completed","Has Results","Forehead Rhytides|Glabellar Rhytides","Biological: OnabotulinumtoxinA|Drug: Normal Saline","Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at Maximum Eyebrow Elevation|Percentage of Subjects With an Investigator Rating of None or Mild on the 4-Grade FWS for Forehead Line Severity at Maximum Eyebrow Elevation|Percentage of Subjects With ≥1-Grade Improvement From Baseline on the Investigator's FWS Rating of Forehead Line Severity at Rest|Percentage of Subjects Reporting Mostly Satisfied or Very Satisfied on the 5-Point Facial Line Satisfaction Questionnaire (FLSQ) Item 5|Percentage of Subjects With ≥20-Point Improvement From Baseline on the Impact Domain of the FLSQ Among Subjects With Baseline Score ≥ 20 Points|Percentage of Subjects With a ≥3-Point Improvement From Baseline on Item 4 of the 11-Point Facial Line Outcomes (FLO-11) Questionnaire©|Time to Retreatment Eligibility","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","421","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-142|2014-001860-36","October 21, 2014","June 4, 2015","April 26, 2016","October 10, 2014","June 23, 2017","January 8, 2019","Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States|Advanced Research Associates, Glendale, Arizona, United States|Clinical Science Institute, Santa Monica, California, United States|About Skin Dermatology and DermSurgery, PC, Greenwood Village, Colorado, United States|Steven Fagien, MD, PA, Boca Raton, Florida, United States|Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States|Coleman Center For Cosmetic Dermatologic Surgery, Metairie, Louisiana, United States|Henry Ford Medical Center, West Bloomfield, Michigan, United States|NW Dermatology and Research Center, Portland, Oregon, United States|Carruthers Dermatology Centre, Vancouver, British Columbia, Canada|Dr. Shannon Humphrey, Inc., Vancouver, British Columbia, Canada|Jean Carruthers Cosmetic Dermatology, Vancouver, British Columbia, Canada|Sweat Clinics of Canada, Toronto, Ontario, Canada|Arthur Swift Research, Inc., Westmount, Quebec, Canada|Aesthetic Surgery Ireland, Dublin, Ireland|Beacon Face and Dermatology Clinic, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT02261467"
157,"NCT02250651","Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Active, not recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost sustained-release|Other: Sham|Drug: Timolol|Drug: Timolol Vehicle (placebo)","Change from Baseline in Intraocular Pressure (IOP) in the Study Eye|IOP in the Study Eye|Change from Baseline in IOP in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","527","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-092|2014-003186-24","December 16, 2014","October 25, 2018","March 31, 2020","September 26, 2014",,"August 28, 2019","Eye Center South, Dothan, Alabama, United States|Arizona Eye Center, Chandler, Arizona, United States|Vold Vision, Fayetteville, Arkansas, United States|Inland Eye Specialists, Hemet, California, United States|Southern California Eye Physicians and Surgeons, Long Beach, California, United States|Eye Research Foundation, Newport Beach, California, United States|Mark B. Kislinger, MD, Inc., Pasadena, California, United States|North Bay Eye Associates, Inc.,, Petaluma, California, United States|Shasta Eye Medical Group, Redding, California, United States|University of California San Francisco, San Francisco, California, United States|Pacific Eye Surgeons, San Luis Obispo, California, United States|Shepard Eye Center, Santa Maria, California, United States|East West Eye Institute, Torrance, California, United States|Wolstan & Goldberg Eye Assoc, Torrance, California, United States|University of Colorado, Aurora, Colorado, United States|Specialty Eye Care, Parker, Colorado, United States|Danbury Eye Physicians and Surgeons PC, Danbury, Connecticut, United States|Argus Research, Cape Coral, Florida, United States|Bruce A. Segal, MD, Delray Beach, Florida, United States|Eye Associates of Fort Myers, Fort Myers, Florida, United States|Eye Clinic at Shands Medical Plaza, Gainesville, Florida, United States|Bascom Palmer Eye Institute, University of Miami, Palm Beach Gardens, Florida, United States|Center for Sight, Sarasota, Florida, United States|Med Eye Associates, South Miami, Florida, United States|Specialty Retinal Center, Weston, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Virdi Eye Clinic, Rock Island, Illinois, United States|Kentuckiana Inst. Eye Research, Louisville, Kentucky, United States|Wilmar Eye Institute at John Hopkins, Baltimore, Maryland, United States|Clinical Eye Research of Boston, Co., Winchester, Massachusetts, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|New Jersey Medical School, Newark, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Alterman, Modi & Wolter, Poughkeepsie, New York, United States|South Shore Eye Care, Wantagh, New York, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|James D. Branch, MD, Winston-Salem, North Carolina, United States|Bergstrom Eye and Laser Clinic, Fargo, North Dakota, United States|Devers Eye Institute, Portland, Oregon, United States|LeHigh Valley Eye Center, P.C., Allentown, Pennsylvania, United States|Scott & Christie and Associates, PC, Cranberry, Pennsylvania, United States|Scheie Eye Institute, Philadelphia, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|Alkek Eye Center, Houston, Texas, United States|DCT-Shah Research, LLC dba Discovery ClinicalTrials, Mission, Texas, United States|Key Whitman Eye Center, Plano, Texas, United States|Vistar Eye Center, Roanoke, Virginia, United States|Specialty Eyecare Centre, Bellevue, Washington, United States|Wenatchee Valley Hospital, Wenatchee, Washington, United States|The Eye Centers of Racine and Kenosha, Racine, Wisconsin, United States|Hospital Italiano de Buenos Aires - Hospital, Buenos Aires, Argentina|Organización Médica de Investigación, Ciudad Autónoma de BuenosAires, Argentina|Instituto Oftalmologico de Buenos Aires Oftalmos, Ciudad Autónoma de BuenosAires, Argentina|Clinica Privada de Ojos, Mar del Plata, Argentina|OFTAR Centro Privado de Oftalmologia, Mendoza, Argentina|Hospital Universitario Austral, Pilar, Argentina|Centro Médico Grupo Laser Visión, Rosario, Argentina|Centro Medico Oftalmologia Global, Rosario, Argentina|A.C. S. Crichton Prof. Corp, Calgary, Alberta, Canada|Nova Scotia Health Authority,, Halifax, Nova Scotia, Canada|Trimed Eye Center, Barrie, Ontario, Canada|Uptown Eye Specialists, Concord, Ontario, Canada|Galen Eye Centre, Kingston, Ontario, Canada|Ophthalmic Consultant Centres Inc., Mississauga, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Institut de l' Oeil, Boisbriand, Quebec, Canada|Clinique d' ophtalmologie Dr Saurel, Drummondville, Quebec, Canada|""Bellevue Clinic, Montreal, Quebec, Canada|GoGiunta Ophtalmologie, Sherbrooke, Quebec, Canada|Clinica de Oftalmologia Sandiego S.A., Medellin, Antioquia, Colombia|Fundación Oftalmologica Nacional Fundonal, Bogota, Distrito Capital De Bogota, Colombia|Fundacion Oftalmologica de Santander Foscal, Floridablanca, Santander, Colombia|Instituto de Investigaciones, Centro Médico Imbanaco de Cali S.A., Cali, Colombia|Nemocnicni Lekarna, Hradec Kralove, Královéhradecký Kraj, Czechia|Ocni klinika, Brno, Czechia|Ocni klinika Pardubice, Pardubice, Czechia|Al Kasr Al Ainy Cairo University Hospital, Cairo, Giza, Egypt|Menoufia University Hospital, Shebin El Koum Street, Menoufia, Egypt|Ain Shams University Hospitals, Cairo, Egypt|Klinikum der Universität Regensburg, Regensburg, Bayern, Germany|Augen Zentrum Nordwest, Ahaus, Nordrhein-Westfalen, Germany|Augenärzte am St. Franziskus-Hospital, Munster, Nordrhein-Westfalen, Germany|Universitätsklinik Magdeburg, Magdeburg, Sachsen-Anhalt, Germany|Klinisches Studienzentrum, Mainz, Germany|Università degli Studi G. D'Annunzio Chieti-Pescara, Chieti, Abruzzo, Italy|ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Sicilia, Italy|Università Degli Studi di Pisa - Ospedale di Cisanello Pisa, pISA, Toscana, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Ospedale Santa Maria Della Misericordia Di Perugia, Perugia, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Hospital Kuala Lumpur, Cheras, Kuala Lumpur, Malaysia|Capital Eye Specialists, Wellington, New Zealand|National University Hospital, Singapore, Singapore|SingaporeEyeResearch Institute, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Horizon Eye Care Centre, Bloemfontein, Free State, South Africa|Pretoria Eye Institute, Pretoria, Gauteng, South Africa|Eskisehir Osmangazi University Medical Faculty, Meselik, Eskisehir, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi, Pendik, Istanbul, Turkey|Celal Bayar University Medical Faculty, Manisa, Turkey|Addenbrookes Hospital, Cambridge, United Kingdom|Princess Alexandra Eye Pavilion - PPDS, Edinburgh, United Kingdom|James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, United Kingdom|Hinchingbrooke Hospital, Huntingdon, United Kingdom|Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom|Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom|Western Eye Hospital, London, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02250651"
158,"NCT02248844","Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea",,"Completed","No Results Available","Lateral Canthal Lines|Crow's Feet Lines","Biological: Botulinum Toxin Type A","Number of Participants with Adverse Events|Investigator's Assessment of Change in Appearance of Crow's Feet Lines on a 3-Point Scale|Subject's Assessment of Change in Appearance of Crow's Feet Lines on a 7-Point Scale","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)",,"667","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","191622-147","September 26, 2014","August 14, 2017","August 14, 2017","September 25, 2014",,"July 5, 2019","Dr. Robbin Clinic, Gangnam-gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02248844"
159,"NCT02247804","Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost sustained-release|Other: Sham|Drug: Timolol|Drug: Timolol Vehicle (placebo)","Change from Baseline in Intraocular Pressure (IOP) in the Study Eye|IOP in the Study Eye|Change from Baseline in IOP in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","594","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-091|2014-003037-26","October 23, 2014","February 19, 2018","July 19, 2019","September 25, 2014",,"September 19, 2019","Arizona Glaucoma Specialists, Phoenix, Arizona, United States|Lugene Eye Institute, Glendale, California, United States|Lakeside Vision Center, Irvine, California, United States|Hamilton Glaucoma Center, Shiley Eye Center UCSD, La Jolla, California, United States|Atlantis Eye Care, Long Beach, California, United States|Glaucoma Institute of Beverly Hills, Los Angeles, California, United States|Montebello Medical Eye Center Inc., Montebello, California, United States|Stanford University, Palo Alto, California, United States|Foothill Eye Institute, Pasadena, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Grutzmacher, Lewis and Sierra, Inc., Sacramento, California, United States|Pacific Eye Associates, San Francisco, California, United States|Eye Associates of Colorado Springs, Colorado Springs, Colorado, United States|Palm Beach Eye Center, INC, Atlantis, Florida, United States|Nature Coast Clinical Research, Crystal River, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|International Research Center, Tampa, Florida, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Chicago Eye Specialists, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Heart of America Eye Care PA, Shawnee Mission, Kansas, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Eye Doctors of Washington, Chevy Chase, Maryland, United States|MedRACS, LLC, Quincy, Massachusetts, United States|Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Minnesota Eye Constultants, P.A., Bloomington, Minnesota, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Moyes Eye Center, PC, Kansas City, Missouri, United States|Northern New Jersey Eye Institute P.A., South Orange, New Jersey, United States|Eyecare Ophthalmology Associates, PC, Bethpage, New York, United States|Montefiore Medical Center, Bronx, New York, United States|New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States|Rochester Ophthalmological Group PC, Rochester, New York, United States|2000 North Village Avenue, Rockville Centre, New York, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States|8 Medical Park Drive, Asheville, North Carolina, United States|Albemarle Clinical Trials, LLC, Elizabeth City, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Havener Eye Institute, Columbus, Ohio, United States|Drs Fine Hoffman & Sims, LLC, Eugene, Oregon, United States|Wills Eye Institute - Glaucoma Research Center, Philadelphia, Pennsylvania, United States|Associates in Ophthalmology, Pittsburgh, Pennsylvania, United States|Carolinas Centers for Sight PC, Florence, South Carolina, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Nashville Vision Associates, Nashville, Tennessee, United States|Keystone Research, LTD, Austin, Texas, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|The Cataract, Glaucoma & Refractive Surgery Center, El Paso, Texas, United States|Houston Eye Associates, Houston, Texas, United States|Focal Point Vision, San Antonio, Texas, United States|R and R Eye Research, LLC, San Antonio, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Piedmont Eye Center, Lynchburg, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Vision Eye Institute Chatswood, Chatsworth, Australia|Melbourne Eye Specialists, Fitzroy, Australia|Waverley Eye Clinic, Glen Waverley, Australia|Marsden Eye Specialists, Parramatta, Paramatta, Australia|Preston Eye Clinic, Preston, Australia|University of Graz, Graz, Austria|University of Vienna, Vienna, Austria|University Hospitals Leuven, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|Universidade Federal de Goias, Goiania, Goias, Brazil|Elo Oftalmologistas Associados, Belo Horizonte, Minas Gerais, Brazil|Nova Campinas Oftalmologia, Campinas, Sao Paulo, Brazil|Hospital Medicina dos Olhos, Osasco, Sao Paulo, Brazil|Hospital de Olhos MS, Rio Verde, Brazil|Escola Paulista de Medicina, Sao Paulo, Brazil|Hospital das Clínicas - Faculdade de Medicina, Sao Paulo, Brazil|Glostrup Hospital, Glostrup, Denmark|Hong Kong Eye Hospital, Hong Kong, Hong Kong|The University of Hong Kong, Hong Kong, Hong Kong|Ganglion Medical Center, Pecs, Hungary|Markusovszky Korhaz, Szombathely, Hungary|Zala Megyei Kórház, Zalaegerszeg, Hungary|Barzilai Medical Center, Ashkelon, Israel|Bnai Zion M.C., Haifa, Israel|Rambam Medical Center, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Centro Oftalmológico Mácula Diagnóstico y Tratamiento, Lima, Peru|Asian Eye Institute, Makati, Philippines|Pacific Eyecare & Laser Institute, Makati, Philippines|Makati Medical Center, Makati, Philippines|Prywatna Klinika Okulistyczna OFTALMIKA, Bydgoszcz, Poland|Optimum Profesorskie Centrum Okulistyki, Gdansk, Poland|Public Clinical Hospital No. 1, Lublin, Poland|ZOZ OKO- TEST Poradnia Okulistyczna, Nowy Targ, Poland|Diagnostic and Microsurgery Center of the Eye LENS, Olsztyn, Poland|Retina Sp. z o.o, Warsaw, Poland|Klinika Okulistyki WIML, Warsaw, Poland|Uniwersytecki Szpital Kliniczny, Warszawa, Poland|Uniwersyteck Szpital Kliniczny, Wroclaw, Poland|Institut Clinic d'Oftalmologia, Barcelona, Spain|Institut Catala de la Retina, Barcelona, Spain|Hospital General de Catalunya, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital General, Valencia, Spain|Hospital Universitario Rio Hortega, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Buddhist Tzu Chi General Hospital (BTCGH), Hualien, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02247804"
160,"NCT02245958","A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm",,"Completed","No Results Available","Cervical Dystonia|Blepharospasm","Other: No Intervention","Dose of Botulinum Toxin Used to Treat Cervical Dystonia|Dose of Botulinum Toxin Used to Treat Blepharospasm|Botulinum Toxin Inter-injection Intervals|Number of Participants with Adverse Events|Annual Botulinum Toxin Dose per Patient","Allergan","All","18 Years and older   (Adult, Older Adult)",,"44","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-US-NEU-0271","August 2015","December 2015","December 2015","September 22, 2014",,"January 8, 2016","Colonia Roma Z.P., Mexico|Wakefield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02245958"
161,"NCT02230956","BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis",,"Completed","Has Results","Osteoarthritis","Biological: onabotulinumtoxinA|Drug: Normal Saline","Change From Baseline in the 7-Day Average Daily Pain Score Using an 11-Point Scale|Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC™) Pain Score Using an 11-Point Scale|Change From Baseline in the WOMAC™ Physical Function Score Using an 11-Point Scale|Patient Global Impression of Change (GIC) Using a 7-Point Scale|Change From Baseline in the 7-Day Average Daily Worst Pain Score Using an 11-Point Scale","Allergan","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-145|2014-001076-58","October 2014","March 2016","March 2016","September 3, 2014","April 20, 2017","May 31, 2017","Artesia, California, United States|Pardubice, Czechia|Vejle, Denmark",,"https://ClinicalTrials.gov/show/NCT02230956"
162,"NCT02218034","Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris",,"Completed","No Results Available","Acne Vulgaris","Drug: AGN-190168 Formulation 1|Drug: AGN-190168 Formulation 2|Drug: tazarotene gel 0.1%|Drug: tazarotene cream 0.1%","Maximum Plasma Level (Cmax) of AGN-190168|Maximum Plasma Level (Cmax) of AGN-190168 Metabolite|Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale|Local Dermal Tolerability as Assessed by the Investigator Using a 4-Point Scale","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","190168-069","August 2014","March 2015","March 2015","August 15, 2014",,"April 30, 2015","College Station, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02218034"
163,"NCT02197806","Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia",,"Completed","Has Results","Presbyopia","Drug: AGN-199201|Drug: AGN-190584|Drug: AGN-199201 Vehicle","Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye","Allergan","All","40 Years to 55 Years   (Adult)","Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","199201-007","July 2014","October 2014","November 2014","July 23, 2014","December 3, 2015","December 3, 2015","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT02197806"
164,"NCT02195687","BOTOX® in the Treatment of Crow's Feet Lines in China",,"Completed","Has Results","Lateral Canthal Lines|Crow's Feet Lines","Biological: botulinum toxin Type A|Drug: Normal Saline","Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)|Percentage of Subjects With a ≥ 1-grade Improvement on the Investigator's Assessment of CFL Severity at Rest Using the 4-point FWS-A|Percentage of Subjects With a ≥ 1-grade Improvement on the Investigator's Assessment of CFL Severity at Maximum Smile on the 4-point FWS-A|Percentage of Subjects Reporting Their Global Change in Appearance as Very Much Improved or Much Improved Using the 7-point Subject's Global Assessment of Change in CFL (SGA-CFL)|Percentage of Subjects Assessing Their Age-related Facial Appearance as Looking Younger on the Self-Perception of Age (SPA) Questionnaire|Percentage of Subjects Achieving None or Mild on the Subject's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","417","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-113","September 2014","February 2015","June 2015","July 21, 2014","March 14, 2016","March 14, 2016","Beijing, China",,"https://ClinicalTrials.gov/show/NCT02195687"
165,"NCT02191579","Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults",,"Completed","Has Results","Migraine Disorders","Biological: onabotulinumtoxinA|Drug: Topiramate","Percentage of Participants With a ≥ 50% Decrease From Baseline in the Frequency of Headache Days|Change From Baseline in the Frequency of Headache Days Per 28-day Period|Change From Baseline in Headache Impact Test (HIT-6) Total Score|Percentage of Participants With a ≥ 70% Decrease From Baseline in the Frequency of Headache Days","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GMA-US-NEU-0206|FORWARD","August 5, 2014","May 9, 2017","September 1, 2017","July 16, 2014","June 7, 2018","June 7, 2018","St Joseph's Hospital Barrow Neurology Clinics, Phoenix, Arizona, United States|North County Neurology Associates, Encinitas, California, United States|California Headache and Balance Center, Fresno, California, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States|Denver Neurological Clinic, Denver, Colorado, United States|Ki Health Partners LLC DBA New England Institute for Neurology and Headache, Stamford, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton Inc, Boca Raton, Florida, United States|Design Neuroscience Center, Doral, Florida, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Negroski, Sutherland & Hanes Neurology, Sarasota, Florida, United States|Neurology Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Robbins Headache Clinic, Riverwoods, Illinois, United States|International Clinical Research Institute Inc, Overland Park, Kansas, United States|Kansas City Bone and Joint Clinic, Overland Park, Kansas, United States|The NeuroMedical Center, Baton Rouge, Louisiana, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|New England Regional Headache Center Inc, Worcester, Massachusetts, United States|Allegiance Health, Jackson, Michigan, United States|Mercy Health Research, Saint Louis, Missouri, United States|Clinvest, Springfield, Missouri, United States|Renown Institute for Neurosciences, Reno, Nevada, United States|Dent Neurosciences Research Center Incorporated, Amherst, New York, United States|Montefiore Headache Center, Bronx, New York, United States|Island Neurological Associates PC, Plainview, New York, United States|Asheville Neurology Specialists PA, Asheville, North Carolina, United States|Headache Wellness Center, Greensboro, North Carolina, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Main Line Health Lankenau Hospital, Wynnewood, Pennsylvania, United States|Texas Neurology, Dallas, Texas, United States|Puget Sound Neurology, Tacoma, Washington, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02191579/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02191579/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02191579"
166,"NCT02188173","An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)",,"Completed","No Results Available","Macular Edema","Drug: dexamethasone 700 ㎍ intravitreal implant","Maximum Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients with a BCVA Improvement of ≥15 Letters in the Study Eye|Average Change from Baseline in BCVA in the Study Eye|Percentage of Patients with an Increase from Baseline of ≥2 Lines in BCVA in the Study Eye|Percentage of Patients with an Increase from Baseline of ≥3 Lines in BCVA in the Study Eye|Percentage of Patients with BCVA of 20/40 or Better in the Study Eye|Mean Number of Ozurdex Injections in the Study Eye|Mean Time Between Ozurdex Injections in the Study Eye|Change from Baseline in Central Retinal Subfield Thickness (CRT) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GMA-US-EYE-0272|REINFORCE","July 2014","May 2016","May 2016","July 11, 2014",,"June 1, 2016","Retinal Consultants of Phoenix, Phoenix, Arizona, United States|West Coast Retina, San Francisco, California, United States|Orange Co Retina Medical Group, Santa Ana, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Colorado Retina Associates, Denver, Colorado, United States|Illinois Retina Associates, Harvey, Illinois, United States|Raj Maturi, MD PC, Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Associated Retina Consultants, Royal Oak, Michigan, United States|Associated Retinal Consultants, PC, Traverse City, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Eyesight Ophthalmic Services, Portsmouth, New Hampshire, United States|New Jersey Retina, New Brunswick, New Jersey, United States|Long Island Vitreoretinal Consultants - Long Island Retina - Hauppauge, Great Neck, New York, United States|Mid Atlantic Retina, Philadelphia, Pennsylvania, United States|Texas Retina Associates, Arlington, Arlington, Texas, United States|Valley Retina Institute, P.A., McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02188173"
167,"NCT02186119","A Study of Abicipar Pegol in Patients With Diabetic Macular Edema",,"Completed","No Results Available","Macular Edema","Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure","Change from Baseline in Best Corrected Visual Acuity (BCVA)|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Percentage of Patients with a BCVA of ≥70 Letters|Percentage of Patients with Resolution of Macular Edema","Allergan","All","19 Years and older   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","150998-004|PALM","July 2014","June 2015","June 2015","July 10, 2014",,"July 14, 2015","Gilbert, Arizona, United States|Abilene, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02186119"
168,"NCT02181530","Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®",,"Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Other: No Intervention","Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients With an Increase of 2 Lines or More in BCVA in the Study Eye|Percentage of Patients With an Increase of 3 Lines or More in BCVA in the Study Eye|Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)|Time to Improvement of 2 Lines or More in BCVA in the Study Eye|Time to Improvement of 3 Lines or More in BCVA in the Study Eye|Time to OZURDEX® Re-Injection in the Study Eye","Allergan","All","Child, Adult, Older Adult",,"43","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MAF/AGN/OPH/RET/016","July 2014","October 2014","October 2014","July 4, 2014","May 25, 2015","May 25, 2015","Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT02181530"
169,"NCT02181517","A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration",,"Completed","Has Results","Macular Degeneration","Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure","Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 16 Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change From Baseline in BCVA in the Study Eye at Week 20 Using the ETDRS Scale|Percentage of Patients With a BCVA Gain of 15 or More Letters in the Study Eye Using the ETDRS Scale|Percentage of Patients With a BCVA Gain of 10 or More Letters in the Study Eye Using the ETDRS Scale|Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","150998-003|CYPRESS","July 2014","March 2015","March 2015","July 4, 2014","April 5, 2016","May 17, 2016","Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02181517"
170,"NCT02181504","A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration",,"Completed","Has Results","Macular Degeneration","Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure","Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in BCVA in the Study Eye|Percentage of Patients With a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Percentage of Patients With a BCVA Gain of ≥10 Letters in the Study Eye on the ETDRS Scale|Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","150998-002|BAMBOO","September 2014","December 2015","December 2015","July 4, 2014","April 25, 2017","April 25, 2017","Nihon University Hospital, Chiyoda-ku,Tokyo, Japan|1 Fukushima Medical University, Fukushima-shi, Japan|Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan|Okayama University Hospital, Kita-ku, Okayama-shi Okayama, Japan|Shiga University, Otsu-shi, Japan|Tokyo Women's Medical University, Shinjuku-ku, Japan|Nagoya University Hospital, Showa-ku, Nagoya-shi Aichi, Japan|Takeuchi Eye Clinic, Taito Ku Tokyo, Japan|Musashi Dream Clinic, Tennoji-ku Osaka, Japan|Juntendo University Urayas, Urayasu-shi, Japan|Otakeganka Tsukimino Clinic, Yamato Kanagawa, Japan",,"https://ClinicalTrials.gov/show/NCT02181504"
171,"NCT02176421","A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area",,"Completed","Has Results","Infra-orbital Skin Depressions","Device: VOLBELLA® with lidocaine","Percentage of Subjects With a ≥1 Grade Improvement From Baseline in Infra-Orbital Area on the Allergan Infra-Orbital Rating Scale (AIRS) on the Right and Left Side|Percentage of Subjects With a ≥1 Grade Improvement From Baseline in Infra-Orbital Area on the AIRS on the Right and Left Side|Injector Ease of Use on an 11-Point Scale|Percentage of Subjects Assessed by the Investigator as Very Well Improved or Well Improved on the 5-Point Global Aesthetic Improvement Scale (GAIS)|Percentage of Subjects Assessed by the Subjects as Very Well Improved or Well Improved on the 5-Point Global Aesthetic Improvement Scale (GAIS)|Subject Overall Eye Appearance Total Score on the 5-Point Periorbital Aesthetic Appearance Questionnaire (PAAQ)","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAF-AGN-MED-FIL-020","May 15, 2014","August 18, 2014","July 3, 2015","June 27, 2014","July 16, 2015","April 16, 2019","Lyon, Rhône-Alpes, France",,"https://ClinicalTrials.gov/show/NCT02176421"
172,"NCT02176356","Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)",,"Completed","Has Results","Facial Rhytides|Crow's Feet Lines|Glabellar Lines|Nasolabial Fold","Biological: onabotulinumtoxinA|Drug: bimatoprost ophthalmic solution 0.03%|Device: JUVÉDERM® ULTRA XC|Device: JUVÉDERM® ULTRA PLUS XC|Device: JUVÉDERM® VOLUMA® XC","Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire|Change From Baseline in Aging Appearance Using a 7-item Questionnaire|Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)|Change From Baseline in Social Confidence Using an 8-item Questionnaire|Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire|Participant's Self- Perception of Age (SPA)|Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)|Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS|Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)|Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS|Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity|Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity|Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity|Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area","Allergan","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 4","116","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GMA-CMB-14-001","June 30, 2014","May 3, 2015","May 3, 2015","June 27, 2014","June 16, 2016","January 9, 2019","Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02176356"
173,"NCT02161159","An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder","GRACE","Completed","No Results Available","Urinary Incontinence|Urinary Bladder, Overactive","Biological: botulinum toxin Type A","Percentage of Patients Who have Greatly Improved or Improved on the 4-Point Treatment Benefit Scale (TBS)|Change From Baseline in Number of Urinary Incontinence Episodes|Time to Re-Injection of BOTOX®|Number of Nocturia Episodes|Usage of Incontinence Support Products|Percentage of Patients Who Have at Least a 50% Reduction in Urinary Incontinence and Urinary Urgency Incontinence","Allergan","All","18 Years and older   (Adult, Older Adult)",,"515","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/NS/OAB/002","June 2014","January 2016","January 2016","June 11, 2014",,"April 18, 2016","David Brix, Bad Mergentheim, Germany|Urologie Turmschtraße, Berlin, Germany|Uwe-Carsten, Berlin, Germany|Albrecht Kastein, Berlin, Germany|ATURO, Berlin, Germany|MVZ Burgdorf, Burgdorf, Germany|Ev.-Luth. Diakonissenanstalt Dresden, Dresden, Germany|Stefan Carl, Emmendingen, Germany|Zentrum für Urologie FFM, Frankfurt, Germany|Georg-August-Universität Göttingen, Göttingen, Germany|Universitätsklinikum Halle (Saale), Halle (Saale), Germany|Urologikum Hamburg, Hamburg, Germany|Urologische Praxis Volksdorf, Hamburg, Germany|Claudia Olszak-Warnat, Herne, Germany|Westpfalz-Klinikum Kaiserslautern, Kaiserslautern, Germany|Urologie Zentrum Kiel, Kiel, Germany|Joachim Weiß, Lampertheim, Germany|Uro- Vital-Zentrum, GP Hellmeier, Krause et al, Landshut, Germany|Tom Kempe, Leipzig, Germany|Institut Dr. Schulze, Markkleeberg, Germany|Elke Stagge, Mülheim, Germany|Universitätsklinikum Münster, Münster, Germany|Urologen am Stadtpark, Nürnberg, Germany|Urologicum Osnabrück, Osnabrück, Germany|Simone Maier, Reutlingen, Germany|Andres Melchior, Salzatal OT Schiepzig, Germany|Andreas Reinhard Wicht, Sangerhausen, Germany|Franz Hirschle, Singen, Germany|Wolfgang Theurer, Stuttgart, Germany|Benjamin Fischer, Tuttlingen, Germany|Dietmar Jung, Tuttlingen, Germany|Kontinenzzentrum Südwest, Villingen-Schwenningen, Germany|Hospital Universitario Burgos, Burgos, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital de Valme, Sevilla, Spain|Urologimottagningen, Hallands Sjukhus Halmstad, Halmstad, Sweden|Urologiska kliniken, Södersjukhuset AB, Stockholm, Sweden|Karolinska Hospital, Stockholm, Sweden|Karolinska Hospital, Stockholm, Sweden|Kvinnokliniken, Danderyds Sjukhus AB, Stockholm, Sweden|Kirurgkliniken, Västervik Sjukhus, Västervik/Kalmar, Sweden|Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, United Kingdom|Southern General Hospital, Glasgow, Lanarkshire, United Kingdom|Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, West Yorkshire, United Kingdom|University College London Hospitals NHS foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, The Bays, St Mary's Hospital, London, United Kingdom|St Helens & Knowsley Teaching Hospitals NHS Trust, Whiston Hospital, Prescot, Merseyside, United Kingdom|Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02161159"
174,"NCT02161146","AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis",,"Completed","Has Results","Conjunctivitis, Allergic","Drug: AGN-229666|Drug: Vehicle to AGN-229666|Drug: Olopatadine","Ocular Itching Score|Conjunctival Hyperemia Score","Allergan","All","20 Years and older   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","229666-006","June 4, 2014","December 20, 2014","December 20, 2014","June 11, 2014","March 7, 2016","April 17, 2019","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02161146"
175,"NCT02155543","A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects",,"Completed","Has Results","Healthy Volunteers","Drug: AGN-223575 Formulation A|Drug: AGN-223575 Formulation B|Drug: AGN-223575 Formulation C|Drug: AGN-223575 Vehicle","Maximal Plasma Concentration (Cmax) of AGN-223575","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","223575-001","May 2014","December 2014","January 2015","June 4, 2014","April 12, 2016","April 12, 2016","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT02155543"
176,"NCT02147561","A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine",,"Completed","Has Results","Migraine Disorders","Biological: botulinum toxin Type A","Percentage of Patients With Adverse Events|Change From Baseline in Headache Impact Test-6 (HIT-6) Total Score|Physician Global Assessment of Outcome on a 3-Point Scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","280","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-148","July 2014","February 2015","February 2015","May 26, 2014","May 27, 2016","May 27, 2016","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02147561"
177,"NCT02147197","A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas",,"Completed","Has Results","Leiomyoma|Uterine Hemorrhage","Drug: Ulipristal acetate (UPA)|Drug: Placebo","Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment|Time to Absence of Bleeding on Treatment|Percentage of Participants With Absence of Bleeding From Day 11 Through the End of Treatment|Change From Baseline in Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) Revised Activities Subscale Score at the End of Treatment Period","Allergan","Female","18 Years to 50 Years   (Adult)","Phase 3","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UL1309","March 31, 2014","March 29, 2016","March 29, 2016","May 26, 2014","April 5, 2019","April 30, 2019","Watson Investigational Site 125, Tucson, Arizona, United States|Watson Investigational Site 102, San Diego, California, United States|Watson Investigational Site 112, Denver, Colorado, United States|Watson Investigational Site 115, Lakewood, Colorado, United States|Watson Investigational Site 116, Milford, Connecticut, United States|Watson Investigational Site 114, Washington, District of Columbia, United States|Watson Investigational Site 106, Clearwater, Florida, United States|Watson Investigational Site 122, Lake Worth, Florida, United States|Watson Investigational Site 130, Miami, Florida, United States|Watson Investigational Site 105, New Port Richey, Florida, United States|Watson Investigational Site 104, Orlando, Florida, United States|Watson Investigational Site 120, Orlando, Florida, United States|Watson Investigational Site 103, Atlanta, Georgia, United States|Watson Investigational Site 123, Atlanta, Georgia, United States|Watson Investigational Site 111, Augusta, Georgia, United States|Watson Investigational Site 124, Idaho Falls, Idaho, United States|Watson Investigational Site 131, Brownsburg, Indiana, United States|Watson Investigational Site 129, Shawnee Mission, Kansas, United States|Watson Investigational Site 132, Metairie, Louisiana, United States|Watson Investigational Site 110, Norfolk, Nebraska, United States|Watson Investigational Site 113, Albuquerque, New Mexico, United States|Watson Investigational Site 121, Raleigh, North Carolina, United States|Watson Investigational Site 109, Winston-Salem, North Carolina, United States|Watson Investigational Site 107, Columbus, Ohio, United States|Watson Investigational Site 119, Jenkintown, Pennsylvania, United States|Watson Investigational Site 108, Myrtle Beach, South Carolina, United States|Watson Investigational Site 101, Chattanooga, Tennessee, United States|Watson Investigational Site 126, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02147197"
178,"NCT02147158","A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas",,"Completed","Has Results","Leiomyoma|Uterine Hemorrhage","Drug: Ulipristal acetate (UPA)|Drug: Placebo","Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1|Time to Absence of Bleeding on Treatment During Treatment Course 1|Percentage of Participants With Absence of Bleeding From Day 11 Through the End of Treatment Course 1|Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 2|Time to Absence of Bleeding on Treatment During Treatment Course 2|Change From Baseline in Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) Revised Activities Subscale Score at the End of Treatment Course 1","Allergan","Female","18 Years to 50 Years   (Adult)","Phase 3","432","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UL1208","January 29, 2014","November 24, 2016","November 24, 2016","May 26, 2014","June 4, 2019","June 4, 2019","Watson Investigational Site 138, Mesa, Arizona, United States|Watson Investigational Site 147, Phoenix, Arizona, United States|Watson Investigational Site 106, Scottsdale, Arizona, United States|Watson Investigational Site 124, Tucson, Arizona, United States|Watson Investigational Site 155, Little Rock, Arkansas, United States|Watson Investigational Site 155, Encino, California, United States|Watson Investigational Site 157, Hawaiian Gardens, California, United States|Watson Investigational Site 134, La Mesa, California, United States|Watson Investigational Site 127, San Diego, California, United States|Watson Investigational Site 151, San Diego, California, United States|Watson Investigational Site 159, Denver, Colorado, United States|Watson Investigational Site 131, Clearwater, Florida, United States|Watson Investigational Site 135, Miramar, Florida, United States|Watson Investigational Site 132, North Miami, Florida, United States|Watson Investigational Site 161, Orlando, Florida, United States|Watson Investigational Site 123, Plantation, Florida, United States|Watson Investigational Site 112, Sarasota, Florida, United States|Watson Investigational Site 102, Wellington, Florida, United States|Watson Investigational Site 101, West Palm Beach, Florida, United States|Watson Investigational Site 160, Atlanta, Georgia, United States|Watson Investigational Site 103, Sandy Springs, Georgia, United States|Watson Investigational Site 117, Savannah, Georgia, United States|Watson Investigational Site 113, Champaign, Illinois, United States|Watson Investigational Site 119, Schaumburg, Illinois, United States|Watson Investigational Site 162, Brownsburg, Indiana, United States|Watson Investigational Site 104, Granger, Indiana, United States|Watson Investigational Site 150, Covington, Louisiana, United States|Watson Investigational Site 130, Metairie, Louisiana, United States|Watson Investigational Site 116, New Orleans, Louisiana, United States|Watson Investigational Site 108, Las Vegas, Nevada, United States|Watson Investigational Site 107, Las Vegas, Nevada, United States|Watson Investigational Site 111, Lawrenceville, New Jersey, United States|Watson Investigational Site 158, Moorestown, New Jersey, United States|Watson Investigational Site 115, Albuquerque, New Mexico, United States|Watson Investigational Site 155, Bronx, New York, United States|Watson Investigational Site 126, Durham, North Carolina, United States|Watson Investigational Site 128, Greensboro, North Carolina, United States|Watson Investigational Site 145, New Bern, North Carolina, United States|Watson Investigational Site 146, Raleigh, North Carolina, United States|Watson Investigational Site 118, Winston-Salem, North Carolina, United States|Watson Investigational Site 155, Cincinnati, Ohio, United States|Watson Investigational Site 155, Cleveland, Ohio, United States|Watson Investigational Site 148, Cleveland, Ohio, United States|Watson Investigational Site 139, Englewood, Ohio, United States|Watson Investigational Site 133, Philadelphia, Pennsylvania, United States|Watson investigational site 142, Pittsburgh, Pennsylvania, United States|Watson Investigational Site 105, West Reading, Pennsylvania, United States|Watson Investigational Site 136, Bluffton, South Carolina, United States|Watson Investigational Site 110, Charleston, South Carolina, United States|Watson Investigational Site 153, Columbia, South Carolina, United States|Watson Investigational Site 154, Greenville, South Carolina, United States|Watson Investigational Site 155, Knoxville, Tennessee, United States|Watson Investigational Site 122, Dallas, Texas, United States|Watson Investigational Site 114, Frisco, Texas, United States|Watson Investigational Site 109, Houston, Texas, United States|Watson Investigational Site 155, Houston, Texas, United States|Watson Investigational Site 120, San Antonio, Texas, United States|Watson Investigational Site 129, Webster, Texas, United States|Watson Investigational Site 152, Norfolk, Virginia, United States|Watson Investigational Site 137, Virginia Beach, Virginia, United States|Watson Investigational Site 121, Seattle, Washington, United States|Watson Investigational Site 140, Hamilton, Ontario, Canada|Watson Investigational Site 144, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02147158"
179,"NCT02145689","Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity",,"Withdrawn","No Results Available","Muscle Spasticity|Stroke","Biological: onabotulinumtoxinA","Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Treated Muscle Groups Using a 6-Point Scale|Clinical Global Impression (CGI) of Overall Change by Physician Compared to Baseline Using a 9-Point Scale|Change from Baseline in Pain on an 11-Point Scale|Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","191622-129|2013-002327-42","August 2014","May 2017","May 2017","May 23, 2014",,"August 13, 2014",,,"https://ClinicalTrials.gov/show/NCT02145689"
180,"NCT02145676","OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity",,"Terminated","Has Results","Muscle Spasticity|Stroke","Biological: onabotulinumtoxinA|Drug: placebo (normal saline)","Change From Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale|Change From Baseline in the MAS-B Score of Shoulder Adductors Using a 6-Point Scale|Change From Baseline in Pain on an 11-Point Scale|Change From Baseline in the Dressing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)|Change From Baseline in the Showering/Bathing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)|Change From Baseline in the Self-Care Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","191622-127|2013-002346-37","May 2014","December 2015","December 2015","May 23, 2014","February 14, 2017","April 12, 2017","Overland Park, Kansas, United States|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02145676"
181,"NCT02145650","Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs","STRETCh","Withdrawn","No Results Available","Muscle Spasticity","Other: No Intervention","Investigator Assessment of Spasticity Severity using a 5-Point Scale|Percentage of Participants with Spasticity not Receiving Treatment|Spasticity Symptom Assessment Score using a 21-item Questionnaire|Spasticity Impact Assessment Score using a 32-item Questionnaire|Percentage of Participants with Spasticity Receiving Treatment|Referral Patterns for Spasticity Management|Spasticity Screening Tool Score using a 13-item Questionnaire","Allergan","All","2 Years and older   (Child, Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EPI-SPAS-001","May 2014","August 2015","August 2015","May 23, 2014",,"November 3, 2015","Toms River, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02145650"
182,"NCT02132572","Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants","RANBI","Completed","Has Results","Breast Implantation","Device: BIOCELL™ Textured 410 Implant","Percentage of Subjects With First Reoperation Following Use of a BIOCELL™ Textured 410 Implant","Allergan","Female","18 Years and older   (Adult, Older Adult)",,"201","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MAF-AGN-MED-BRE-003","May 2014","October 2014","October 2014","May 7, 2014","September 13, 2016","September 13, 2016","Bordeaux, France|Düsseldorf, Germany|Tel Aviv, Israel|Madrid, Spain|East Grinstead, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02132572"
183,"NCT02132117","Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea",,"Completed","Has Results","Erythema|Rosacea","Drug: Oxymetazoline HCL Cream 1.0%|Drug: Vehicle to Oxymetazoline HCL Cream","Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales|Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29|Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29|Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29|Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29|Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","445","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","199201-005","June 2014","April 2015","May 2015","May 7, 2014","August 2, 2016","November 18, 2019","College Station, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02132117"
184,"NCT02131636","Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea",,"Completed","Has Results","Erythema|Rosacea","Drug: AGN-199201|Drug: Vehicle to AGN-199201","Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales|Percentage of Patients With at Least a 2-Grade Decrease From Baseline on the SSA 5-point Scale|Percent Change From Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)|Percentage of Patients Reporting Treatment Satisfaction on the Satisfaction Assessment for Rosacea Facial Redness (SA-RFR) Questionnaire Item 9|Change From Baseline on the SA-RFR Questionnaire Item #4|Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","199201-004","May 2014","November 2014","December 2014","May 6, 2014","March 10, 2016","November 18, 2019","Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02131636"
185,"NCT02121847","Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","IMPACT","Completed","Has Results","Dry Eye Syndromes","Drug: cyclosporine 0.05% ophthalmic emulsion|Drug: carboxymethylcellulose-based lubricant eye drops","Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye|Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye|Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)|Change From Baseline in Driving at Night on the OSDI|Change From Baseline in Working With a Computer or Bank Machine on the OSDI|Change From Baseline in Watching TV on the OSDI|Change From Baseline in Reading Rate|Change From Baseline in Words Read Incorrectly|Change From Baseline in Font Size|Change From Baseline in OSDI|Change From Baseline in Ocular Discomfort on a 4-point Scale|Change From Baseline in Tear Film Break-up Time in the Worse Eye|Change From Baseline in the Interblink Interval in the Worse Eye|Change From Baseline in Conjunctival Redness in the Worse Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMA-RES-014-001","April 3, 2014","September 23, 2014","September 23, 2014","April 24, 2014","April 25, 2016","April 18, 2019","Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02121847"
186,"NCT02121262","A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema",,"Active, not recruiting","No Results Available","Macular Edema","Drug: 700 μg dexamethasone|Procedure: Laser Photocoagulation","Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients with BCVA Improvement ≥15 Letters from Baseline in the Study Eye|Change from Baseline in Central Retinal Thickness by Optical Coherence Tomography (OCT) in the Study Eye|Change from Baseline in Total Macular Leakage Area by Fluorescein Angiography (FA) in the Study Eye","Allergan|Tigermed Consulting Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","284","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","206207-026","December 31, 2016","October 11, 2019","October 11, 2019","April 23, 2014",,"April 16, 2019","Peking University First Hospital, Beijing, Beijing, China|People's Hospital of Peking University, Beijing, Beijing, China|Beijing Friendship Hospital of Capital Medical University, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Beijing TongRen Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Zhongshan Ophthalmic Center, Sun Yet-Sen University, Guangzhou, Guangdong, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|The First Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|The 2nd hospital of JiLin University, Changchun, Jilin, China|The Eye and ENT Hospital, Affiliated of Fudan University, Shanghai, Shanghai, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Tianjin Eye Hospital, Tianjin, Tianjin, China|TianJin Medical University Eye Hospital, Tianjin, Tianjin, China|Wenzhou Ophthalmic Centre, Wenzhou, Zhejiang, China|Asian Eye Institute, Makati City, Metro Manila, Philippines|Peregrine Eye and Laser Institute, Makati City, Metro Manila, Philippines",,"https://ClinicalTrials.gov/show/NCT02121262"
187,"NCT02117687","A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye",,"Completed","Has Results","Dry Eye Syndromes|Keratoconjunctivitis Sicca","Drug: carboxymethylcellulose 0.5%/glycerin 0.9%|Drug: sodium hyaluronate 0.18%","Change From Baseline in Global Ocular Staining Score in the Study Eye|Change From Baseline in Ocular Surface Disease Index© (OSDI) Score|Change From Baseline in the Schirmer Test in the Study Eye|Subject Assessment of Dry Eye Symptoms on a 5-Point Scale|Subject Global Assessment of Treatment Efficacy on a 5-Point Scale|Subject Assessment of Treatment Acceptability on a 5-Point Scale|Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale|Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye|Work Productivity and Activity Impairment Questionnaire Score|Change From Baseline in Corneal Staining in the Study Eye|Change From Baseline in Conjunctival Staining in the Study Eye|Conjunctival Hyperaemia in the Study Eye|Study Product Use","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MAF-AGN-OPH-DE-016","May 14, 2014","January 27, 2015","March 17, 2015","April 21, 2014","February 19, 2016","April 18, 2019","Paris, France|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02117687"
188,"NCT02116361","OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females",,"Completed","Has Results","Depressive Disorder, Major","Biological: onabotulinumtoxinA|Drug: Normal Saline","Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline Values in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Baseline Values for the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score|Change From Baseline Values in the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score|Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)|Change From Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)","Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-135","April 22, 2014","August 25, 2016","December 22, 2016","April 16, 2014","December 19, 2017","December 19, 2017","Woodland International Research Group, Little Rock, Alaska, United States|CITrials, Bellflower, California, United States|Radiant Research/Comprehensive Clinical Development, Inc., Cerritos, California, United States|Collaborative Neuroscience Network Inc., Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Excell Research, Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Compass Research LLC-North Clinic, Leesburg, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Uptown Research Institute, LLC, Chicago, Illinois, United States|Psychiatric Medicine Associates, LLC, Skokie, Illinois, United States|St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States|Integrative Clinical Trials, Brooklyn, New York, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Clinical Neuroscience Solutions, INC, Memphis, Tennessee, United States|KRK Medical Research, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Virginia Commonwealth University Clinical Research Services Unit, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Zain Research LLC, Richland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02116361"
189,"NCT02097719","Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost 0.01%|Drug: travoprost 0.004%|Drug: timolol 0.5%|Drug: hypromellose 0.3%","Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-LUM-12-022","May 2014","December 2014","December 2014","March 27, 2014","January 14, 2016","January 14, 2016","Racine, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02097719"
190,"NCT02097121","OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)",,"Recruiting","No Results Available","Urinary Incontinence|Urinary Bladder, Overactive","Biological: OnabotulinumtoxinA","Change from Baseline in Number of Daytime Urinary Incontinence Episodes|Change from Baseline in Number of Daytime Micturition Episodes|Volume Voided Per Micturition|Change from Baseline in Number of Daytime Urgency Episodes|Percentage of Patients with Night Time Urinary Incontinence|Percentage of Patients with Absence of Night Time Urinary Incontinence|Change from Baseline in the 20-Item Pediatric Incontinence Questionnaire (PinQ) Score|Percentage of Patients With a Positive Treatment Response on the Modified Treatment Benefit Scale (TBS)|Time to Patient Request for Retreatment|Time to Patient Qualification for Retreatment","Allergan","All","12 Years to 17 Years   (Child)","Phase 3","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","191622-137|2014-000464-17","May 23, 2014","January 15, 2021","January 29, 2023","March 26, 2014",,"December 24, 2019","Children's of Alabama, Birmingham, Alabama, United States|Alaska Urological Institute DBA Alaska Clinical Research Center, Anchorage, Alaska, United States|CHOC Children's Urology Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Orlando Health- Arnold Palmer Hospital for Children Pediatric Urology, Orlando, Florida, United States|William Beaumont Hospital Research Institute, Royal Oak, Michigan, United States|Urologic Consultants, PC, Wyoming, Michigan, United States|Washington University School of Medicine Pediatric Urology, St. Louis Children's Hospital, Saint Louis, Missouri, United States|Pediatric Urology Associates, PC, Tarrytown, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Associated Urologists of North Carolina, PA, Raleigh, North Carolina, United States|University Hospitals Case Medical Center (UHCMC), Cleveland, Ohio, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Monash Children's Hospital, Clayton, Victoria, Australia|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Campus Gasthuisberg, Leuven, Belgium|Alberta Children's Hospital, Calgary, Alberta, Canada|The Hospital for Sick Children Division of Urology, Toronto, Ontario, Canada|Fakultni nemocnice Olomouc, Olomouc, Czechia|Hopital Pellegrin, Bordeaux, France|Hôpital Mère et l'Enfant, Limoges, France|Hopitaux Pediatriques de Nice, Nice, France|Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany|Urologische Gemeinschaftspraxi, Emmendingen, Germany|Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Dep. of Urology, Lübeck, Germany|Azienda Ospedaliero Universitaria Seconda Università degli Sudi di Napoli U.O. Chirurgia Pediatrica, Napoli, Italy|Dipartimento di nefrologia, Rome, Italy|Maastricht University Medical Centre (MUMC), Maastricht, Netherlands|Pediatric Urology Center Nijmegen, Geert Grooteplein 10 (route 609), Nijmegen, Nijmegen, Netherlands|Universitair Medisch centrum Rotterdam, Rotterdam, Netherlands|Barnemedisinsk avdeling Oslo Un+Z15iversity Hospital, Oslo, Norway|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Specjalistyczny Gabinet Lekarski, Poznan, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, Warsaw, Poland|St Georges Hospital, Port Elizabeth, South Africa|Royal Aberdeen Children's Hospital, Aberdeen, United Kingdom|Department of Paediatric Urology Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom|University College London Hospital, London, United Kingdom|Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, United Kingdom|Royal Berkshire NHS Foundation trust, Reading, United Kingdom|Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02097121"
191,"NCT02095158","A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea",,"Completed","Has Results","Erythema|Rosacea","Drug: Oxymetazoline HCL Cream 1.0%","Percentage of Participants With Treatment-Related Adverse Events|Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","199201-006","April 2014","August 2015","September 2015","March 24, 2014","September 21, 2016","November 18, 2019","Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02095158"
192,"NCT02087085","A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration","BEACON","Terminated","Has Results","Geographic Atrophy|Macular Degeneration","Drug: 400 µg Brimonidine Implant|Other: Sham","Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24|Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24|Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24","Allergan","All","55 Years and older   (Adult, Older Adult)","Phase 2","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","190342-038|2013-003320-36","May 9, 2014","March 30, 2018","March 30, 2018","March 14, 2014","April 23, 2019","April 23, 2019","Retinal Consultants of Arizona, Ltd., Retinal Research Institute, Phoenix, Arizona, United States|Associated Retina Consultants, Phoenix, Arizona, United States|University of California, San Diego, Jacobs Retina Center, Shiley Eye Center, La Jolla, California, United States|Northern California Retina Vitreous Associates, Mountain View, California, United States|Retina Consultants of Southern Colorado, PC, Colorado Springs, Colorado, United States|""National Ophthalmic Research Institute Retina Consultants of Southwest Florida"", Fort Myers, Florida, United States|Retina Specialty Institute, Pensacola, Florida, United States|Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States|Southern Vitreoretinal Associates, PL, Tallahassee, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Georgia Retina, Decatur, Georgia, United States|Raj K. Maturi, MD, Indianapolis, Indiana, United States|Retina Associates of Western New York, Rochester, New York, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|Oregon Retina, LLP, Eugene, Oregon, United States|Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States|Mid Atlantic Retina, Wills Eye Retina Surgeons, Philadelphia, Pennsylvania, United States|Retina Research Institute of Texas, Abilene, Texas, United States|Texas Retina Associates, Arlington, Texas, United States|""Austin Retina Associates "", Austin, Texas, United States|Retina Foundation of the Southwest, Dallas, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Strategic Clinical Research Group, LLC, Willow Park, Texas, United States|Center for Eye Research Australia, Melbourne, Victoria, Australia|Lions Eye Institute, University of Western Australia, Nedlands, Australia|Service d'Ophtalmologie, Bordeaux, France|""Centre Hospitalier Intercommunal de Creteil "", Creteil, France|""Universitat Bonn, Abteilung fur Augenheilkunde "", Bonn, Germany|STZ Eyetrial, Tübingen, Germany|Università di Cagliari (presidio San Giovanni di Dio), Bologna, Italy|Università di Cagliari (presidio San Giovanni di Dio), Cagliari, Italy|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|""Dir IV Clinica Oculistica di Milano, Ospedale Generale """"Luigi Sacco"""" "", Milano, Italy|Universita degli Studi di Padova, Dipartimento di Neuroscienze, Padova, Italy|Universita degli Studi di Torino, Torino, Italy|Clinical Research Unit, Level2, Bristol Eye Hospital, Lower Maudlin Street, Bristol, United Kingdom|Frimley Park Hospital, Eye clinical trials Unit, Department of Opthalmology, Camberley, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Macular Unit, Hospital of St Cross, Rugby, United Kingdom|Royal Hallamshire Hospital, Eye Department, Sheffield, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02087085/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02087085/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02087085"
193,"NCT02082262","AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis",,"Completed","Has Results","Conjunctivitis, Allergic","Drug: AGN-229666","Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale","Allergan","All","10 Years and older   (Child, Adult, Older Adult)","Phase 3","140","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","229666-005","March 2014","July 2014","July 2014","March 10, 2014","October 8, 2015","March 14, 2016","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02082262"
194,"NCT02072928","Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium",,"Completed","Has Results","Urinary Incontinence","Biological: botulinum toxin Type A","Change From Baseline in Anticholinergic Drug Use","Allergan","All","18 Years and older   (Adult, Older Adult)",,"55","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","MAF/AGN/NS/OAB/005","January 28, 2014","September 30, 2015","September 30, 2015","February 27, 2014","December 15, 2017","December 15, 2017","UZA, Edegem, Belgium|CHU de Liège, Esneux, Belgium|UZ Gent, Ghent, Belgium|Centre Hospitalier Regional de Huy, HUY, Belgium|UZ Leuven, Leuven, Belgium|Maria Ziekenhuis Noord-Limburg, Overpelt, Belgium",,"https://ClinicalTrials.gov/show/NCT02072928"
195,"NCT02061683","A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension","LOTUS","Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost 0.03%","Intraocular Pressure (IOP) in the Study Eye|Percentage of Patients With an Adverse Event of Conjunctival Hyperemia","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","263","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN-BIM-0901","April 19, 2010","June 24, 2011","June 24, 2011","February 13, 2014","June 18, 2014","April 18, 2019","Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02061683"
196,"NCT02043145","Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea",,"Completed","Has Results","Hyperhidrosis|Muscle Spasticity|Glabellar Lines","Biological: botulinum toxin Type A","Number of Patients With Adverse Events (AEs) and Serious Adverse Drug Reactions (SADRs)|Change From Baseline in the Hyperhidrosis Disease Severity Scale (HDSS) Using a 4-Point Scale|Change From Baseline in the Modified Ashworth Scale (MAS) Using a 6-Point Scale|Change From Baseline in the Investigator Assessment of Glabellar Line Severity Using a 4-point Scale","Allergan",,"18 Years to 65 Years   (Adult, Older Adult)",,"727","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPI-MULT-100","July 2008","April 2012","April 2012","January 23, 2014","June 13, 2014","June 13, 2014","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02043145"
197,"NCT02032407","A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone Gel","Change From Baseline in the Global Assessment of Acne Severity (GAAS) Score by Physician|Change From Baseline in the GAAS|Percent Change From Baseline in Total Lesion Counts|Percent Change From Baseline in Inflammatory Lesion Counts|Percent Change From Baseline in Non-Inflammatory Lesion Counts|Percentage of Participants With 0 (None) or 1 (Minimal) on the GAAS|Acne Symptom and Impact Scale (ASIS) Sign Domain Score|ASIS Impact Domain Score","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 4","68","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMA-ACZ-13-001","December 2013","June 2014","September 2014","January 10, 2014","August 19, 2015","August 19, 2015","Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02032407"
198,"NCT02028754","A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms","RLOTUS","Completed","Has Results","Dry Eye Syndromes|Cataract","Drug: Sodium Carboxymethylcellulose|Drug: Levofloxacin|Drug: Prednisolone","Tear Break-Up Time (TBUT) in the Study Eye|Fluorescein Staining Score in the Study Eye|Lissamine Green Staining Score in the Study Eye|Results of Schirmer I Test With Anesthetics in the Study Eye|Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye|Subjective Symptom Total Score in the Study Eye","Allergan","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 4","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN-CMC-1101","July 2011","May 2013","May 2013","January 7, 2014","April 23, 2014","April 23, 2014","Hangzhou, China",,"https://ClinicalTrials.gov/show/NCT02028754"
199,"NCT02020512","A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension","LOTUSDI","Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: 0.03% Bimatoprost","Change From Baseline in Intraocular Pressure (IOP) in the Study Eye","Allergan","All","Child, Adult, Older Adult","Phase 4","87","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN-BIM-1102","July 2011","December 2012","December 2012","December 25, 2013","July 21, 2014","July 21, 2014","Guangzhou, China",,"https://ClinicalTrials.gov/show/NCT02020512"
200,"NCT02013791","Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease",,"Terminated","Has Results","Dry Eye Syndromes","Drug: Vehicle|Other: Sham|Drug: Cyclosporine New Ophthalmic Formulation","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192371-024","April 29, 2014","April 12, 2017","April 12, 2017","December 17, 2013","May 15, 2018","May 15, 2018","Sall Research Medical Center, Artesia, California, United States|Lugene Eye Institute, Glendale, California, United States|Lakeside Vision Center, Irvine, California, United States|Steve Yoelin MD Medical Asscociates, Newport Beach, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Vision Institute, Colorado Springs, Colorado, United States|Johns Hopkins University - Wilmer Eye Institute, Baltimore, Maryland, United States|Eye Centers of Racine and Kenosha, Kenosha, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02013791/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02013791/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02013791"
201,"NCT02010788","Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea",,"Completed","No Results Available","Urinary Incontinence|Urinary Bladder, Overactive","Biological: botulinum toxin Type A","Number of Participants with Adverse Events and Adverse Drug Reactions|International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) Total Score","Allergan","All","18 Years and older   (Adult, Older Adult)",,"523","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","191622-134","February 2014","July 2016","July 2016","December 13, 2013",,"September 22, 2016","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02010788"
202,"NCT02010775","Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy",,"Completed","Has Results","Masseter Muscle Hypertrophy","Biological: botulinum toxin Type A|Drug: Normal saline","Change From Baseline in Lower Facial Volume Using VECTRA 3D Images|Percentage of Participants Who Achieved a Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 as Assessed by the Investigator","Allergan","All","18 Years to 50 Years   (Adult)","Phase 2","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-130","January 20, 2014","March 7, 2017","November 29, 2017","December 13, 2013","May 28, 2019","May 28, 2019","Shape Clinic, Darlinghurst, New South Wales, Australia|Central Sydney Dermatology, Sydney, New South Wales, Australia|Esteem Beauty & Day Spa, Main Beach, Queensland, Australia|The Rose Medical & Aesthetic Centre, North Fremantle, Western Australia, Australia|Dr. Jean Carruthers Cosmetic Surgery, Inc., Vancouver, British Columbia, Canada|Dr. Shannon Humphrey Inc., Vancouver, British Columbia, Canada|Project Skin MD, Vancouver, British Columbia, Canada|Pacific Dermaesthetics, Vancouver, British Columbia, Canada|Bertucci MedSpa, Woodbridge, Ontario, Canada|Arthur Swift Research Inc., Montreal, Quebec, Canada|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Chang Gung Memorial Hospital of CGMF, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02010775/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02010775/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02010775"
203,"NCT02003534","A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension","APOTUS","Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: 0.15% Brimonidine Tartrate","Change From Baseline in Intraocular Pressure (IOP) in the Study Eye","Allergan","All","Child, Adult, Older Adult","Phase 4","376","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN-BRI-1002","July 2010","February 2013","February 2013","December 6, 2013","July 22, 2014","July 22, 2014","Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02003534"
204,"NCT01999348","A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting",,"Completed","Has Results","Glaucoma, Primary Open Angle|Ocular Hypertension","Drug: Fixed Combination Bimatoprost and Timolol","Change From Baseline in Intraocular Pressure (IOP) in the Study Eye|Physician Assessment of IOP-Lowering Effect in the Study Eye Using a 3-Point Scale|Patient Assessment of Tolerability on a 4-Point Scale|Physician Assessment of Tolerability on a 4-Point Scale|Percentage of Patients Who Discontinued Treatment|Percentage of Patients Prescribed by the Physician to Continue Treatment|Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale","Allergan","All","Child, Adult, Older Adult",,"1553","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/OPH/GLA/039","November 25, 2013","December 19, 2014","December 19, 2014","December 3, 2013","December 9, 2015","April 19, 2019","Wiesloch, Germany",,"https://ClinicalTrials.gov/show/NCT01999348"
205,"NCT01998581","A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement",,"Completed","Has Results","Subjects Desiring Lip Augmentation","Device: JUVEDERM VOLBELLA® XC|Device: Restylane-L®","Change From Baseline in Evaluating Investigator's Assessment of Lip Fullness on a 5-Point Scale|Percentage of Subjects in the JUVEDERM VOLBELLA® XC Treatment Arm With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS)|Change From Baseline in Subject Satisfaction With Lips on the Lip Module of the FACE-Q Questionnaire","Allergan","All","22 Years and older   (Adult, Older Adult)","Not Applicable","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","VOLBELLA-004","November 1, 2013","August 4, 2014","May 29, 2015","December 2, 2013","December 5, 2016","April 26, 2019","New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01998581"
206,"NCT01987765","Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea",,"Completed","Has Results","Conjunctivitis, Allergic","Drug: Relestat Ophthalmic Solution 0.05%","Percentage of Patients Reporting Adverse Events|Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale","Allergan","All","Child, Adult, Older Adult",,"847","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","198027-A","January 2009","September 2012","September 2012","November 19, 2013","April 29, 2014","April 29, 2014","Gangwon-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01987765"
207,"NCT01987752","Safety and Efficacy of Combigan® Ophthalmic Solution in Korea",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: brimonidine tartrate/timolol maleate Ophthalmic Solution","Percentage of Participants Reporting Adverse Events|Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)","Allergan","All","Child, Adult, Older Adult",,"732","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","190342-040","January 2009","November 2011","November 2011","November 19, 2013","April 4, 2014","April 4, 2014","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01987752"
208,"NCT01979887","Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction",,"Completed","No Results Available","Meibomian Glands","Procedure: Meibum Expression","Meibum Quality Score in the Study Eye as Assessed by the Investigator Using a 4-Point Scale","Allergan","All","40 Years and older   (Adult, Older Adult)",,"75","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","195263-007","November 2013","July 2014","July 2014","November 8, 2013",,"August 15, 2014","Houston, Texas, United States|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01979887"
209,"NCT01976663","A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds",,"Completed","Has Results","Moderate to Severe Nasolabial Folds","Device: JUVEDERM VOLIFT® XC|Device: Control","Mean Change From Baseline in Nasolabial Fold Severity Using the 5-Point Nasolabial Fold Severity Scale (NLFSS)|Percentage of Nasolabial Folds With ≥1-Point Improvement|Mean Change From Baseline in Overall Nasolabial Folds FACE-Q Score","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","S17L-001","October 29, 2013","March 17, 2015","October 26, 2015","November 6, 2013","May 22, 2017","May 10, 2019","Total Skin and Beauty Dermatology Center P.C., Birmingham, Alabama, United States|Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California, United States|San Francisco, California, United States|Dermatology Research Institute, LLC, Coral Gables, Florida, United States|Skin Research Institute, Coral Gables, Florida, United States|West Palm Beach, Florida, United States|Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01976663"
210,"NCT01976650","Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea",,"Completed","Has Results","Retinal Vein Occlusion","Drug: dexamethasone 700 ㎍ intravitreal implant","Number of Patients With Adverse Events or Adverse Drug Reactions|Percentage of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)",,"724","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","206207-029","March 2011","March 2015","March 2015","November 6, 2013","January 13, 2016","January 13, 2016","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01976650"
211,"NCT01976624","Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost/timolol","Number of Participants With Adverse Events and Adverse Drug Reactions|Change From Baseline in Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"756","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","192024-087","August 2009","January 2014","January 2014","November 6, 2013","July 21, 2015","September 28, 2015","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01976624"
212,"NCT01976611","Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea",,"Completed","No Results Available","Migraine Disorders|Headache","Biological: botulinum toxin Type A","Number of Participants with Adverse Events and Adverse Drug Reactions|Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"402","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","191622-139","June 2012","February 2015","February 2015","November 6, 2013",,"April 8, 2015","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01976611"
213,"NCT01970397","JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines",,"Completed","Has Results","Patients With Moderate to Severe Perioral Lines","Device: JUVEDERM® Ultra XC|Device: Belotero Balance®","Percentage of Participants With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS)|Participant Assessed Procedural and Post-Procedural Pain Levels|Subject's Global Assessment of Change in Appearance of Perioral Lines","Allergan","All","35 Years and older   (Adult, Older Adult)","Not Applicable","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GMA-JUV13001","October 21, 2013","August 4, 2014","August 4, 2014","October 28, 2013","September 2, 2015","April 16, 2019","Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01970397"
214,"NCT01969162","Tear Collection in Adult Volunteers",,"Completed","Has Results","Healthy Volunteers","Procedure: Tear Sample Collection","Tear Lipid Composition Profile","Allergan","All","18 Years to 40 Years   (Adult)",,"35","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","195263-008","September 2013","November 2013","November 2013","October 25, 2013","November 21, 2014","November 21, 2014","Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01969162"
215,"NCT01946126","A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache",,"Completed","Has Results","Migraine Disorders|Headache","Other: No Intervention","Presence or Absence of Prophylactic Medication for Headache/Migraine|Number of Unique Prophylactic Medications for Headache/Migraine Reported|Number of Days With a Headache Recorded at the Visit With the Highest Number of Headaches|Highest Number of Headache Days Per Month at a Qualifying Visit|Number of Visits for Headache Diagnosis","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)",,"459","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-BTX-CM-13-592","March 2014","April 2014","April 2014","September 19, 2013","March 15, 2016","March 15, 2016","Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01946126"
216,"NCT01945489","OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder","COMFORT","Completed","Has Results","Overactive Bladder","Biological: onabotulinumtoxinA|Drug: Normal saline","Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes|Change From Baseline in the Daily Average Number of Episodes of Urinary Incontinence|Change From Baseline in King's Health Questionnaire (KHQ) Domain Scores|Change From Baseline in the Daily Average Number of Micturition Episodes|Change From Baseline in the Daily Average Number of Urgency Episodes|Change From Baseline in the Daily Average Number of Nocturia Episodes","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-OAB-113","October 28, 2013","May 24, 2016","January 5, 2017","September 18, 2013","November 6, 2017","November 6, 2017","Urologic Clinics of North Alabama, Huntsville, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|South Orange County Medical Research Center, Laguna Hills, California, United States|University of Southern California, Los Angeles, California, United States|Genesis Research LLC, San Diego, California, United States|U. Colorado, School of Med., Aurora, Colorado, United States|Genitourinary Surgical Consultants, Denver, Colorado, United States|Urology Associates of Norwalk, Norwalk, Connecticut, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|Bladder and Prostate Health Investigations, LLC, Miramar, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Urology Health Team, PLLC, Ocala, Florida, United States|Southeastern Research Group, Inc., Tallahassee, Florida, United States|Atlanta Medical Research Institute, Alpharetta, Georgia, United States|Northeast Indiana, Fort Wayne, Indiana, United States|Urogynecology Associates, Indianapolis, Indiana, United States|Deaconess Clinic, Inc., Newburgh, Indiana, United States|Urology of Indiana, LLC, Noblesville, Indiana, United States|Regional Urology, LLC, Shreveport, Louisiana, United States|Chesapeake Urology Research Associates, Owings Mills, Maryland, United States|Brooklyn Urology Research Group, Brooklyn, New York, United States|Accumed Research, Garden City, New York, United States|Manhattan Medical Research, New York, New York, United States|Premier Medical Group of the Hudson Valley, Newburgh, New York, United States|Advanced Urology Centers of NY A division of IMP, Plainview, New York, United States|Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, United States|Associated Medical Professionals of New York, PLLC, Syracuse, New York, United States|Carolina Urology Partners, PLLC, Gastonia, North Carolina, United States|Associated Urologists of North Carolina, Raleigh, North Carolina, United States|TriState Urologic Services PSC Inc., dba The Urology Group, Cincinnati, Ohio, United States|University Hospital Case Medical Center, Cleveland, Ohio, United States|Institute of Pelvic Medicine and Reconstructive Surgery, Allentown, Pennsylvania, United States|Urologic Consultants of Southern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States|Mount Nittany Medical Center Health Services, Inc. dba Mount Nittany Physician Group, State College, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Virginia Women's Center, Richmond, Virginia, United States|Virginia Urology, Richmond, Virginia, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, United States|Integrity Medical Research, LLC, Mountlake Terrace, Washington, United States|The Polyclinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01945489"
217,"NCT01930799","Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns",,"Completed","Has Results","Multiple Sclerosis|Urinary Bladder Diseases","Behavioral: Systematic Screening and Education Regimen","Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores|Percentage of Patients Who Agree/Completely Agree With Each Question on the Patient Post-Video Questionnaire","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GMA-NDO-112","August 2013","March 2015","March 2015","August 29, 2013","May 27, 2016","May 27, 2016","Fresno, California, United States",,"https://ClinicalTrials.gov/show/NCT01930799"
218,"NCT01930786","An Adult Spasticity Registry of OnabotulinumtoxinA Treatment","ASPIRE","Completed","No Results Available","Muscle Spasticity","Drug: onabotulinumtoxinA","Percentage of Patients Reporting Satisfaction with Treatment|Percentage of Health Care Providers Reporting Satisfaction with Treatment|Physical Functioning on a 5-Point Scale|Severity of Pain on an 11-Point Scale|Disability Assessment on a 4-Point Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"744","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GMA-BTX-SP-12-001","October 16, 2013","October 9, 2017","October 9, 2017","August 29, 2013",,"February 11, 2019","Loma Linda University School Of Medicine, Loma Linda, California, United States|MS Center of California, Newport Beach, California, United States|Sutter Health General Hospital, Sacramento, California, United States|Design Neuroscience Center, Doral, Florida, United States|Brooks Rehabilitation Hospital, Jacksonville, Florida, United States|Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States|Gil, Ramon A., Port Charlotte, Florida, United States|Kernan Hospital, Baltimore, Maryland, United States|MedTechnical, PLLC, Silver Spring, Maryland, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States|The Curators of the University of Missouri on behalf of University of Missouri Health Care, Columbia, Missouri, United States|Seacoast Physiatry, Exeter, New Hampshire, United States|CentraState Medical Center, Freehold, New Jersey, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Dayton Center for Neurological Disorders, Dayton, Ohio, United States|Albert Einstein Healthcare Network, Moss Rehabilitation Hospital, Elkins Park, Pennsylvania, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Penn Medicine Rittenhouse, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Metrolina Neurological Assoc., PA, Rock Hill, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Memorial Hermann Hospital, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Center for Neurological Disorders, S.C., Milwaukee, Wisconsin, United States|Hôpital Morvan, Brest cedex 2, Finistere, France|Pôle Saint Helier, Rennes cedex, Ille Et Vilaine, France|CHU de Grenoble - Hôpital Sud, Echirolles cedex, Isere, France|Hopital Saint Philibert - GHICL Lille, Lomme Cedex, Nord, France|Centre Hospitalier de Pau, Pau cedex, Pyrenees Atlantiques, France|Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitaetsklinikum Muenster, Muenster, Nordrhein Westfalen, Germany|Universitaetsklinikum Leipzig AoeR, Leipzig, Sachsen, Germany|Universitaetsklinikum Jena, Jena, Thueringen, Germany|Parkinson Klinik Wolfach GmbH & Co KG, Baden Wuerttemberg, Germany|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero - Universitaria Maggiore delle Carità, Novara, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hospital Universitario Mutua de Terrassa, Terrasa, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital de Conxo (Santiago de Compostela) GALICIA, Santiago De Compestela, Pontevedra, Spain|Hospital del Mar, Barcelona, Spain|Vall d'Hebron Institut de Recerca-VHIR, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Taipei Medical University Hospital, Taipei City, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|The National Hospital for Neurology & Neurosurgery, London, Greater London, United Kingdom|Birch Hill Hospital, Rochdale, Greater Manchester, United Kingdom|The Walton Centre, Liverpool, Merseyside, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, United Kingdom|Kent and Canterbury Hospital, Kent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01930786"
219,"NCT01918371","A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema",,"Completed","Has Results","Retinal Vein Occlusion|Macular Edema","Drug: Anti-VEGF","Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 2|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 3|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 4|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 5|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 6|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 7|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 8|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 9|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 10|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 11|Percentage of Participants With BCVA of 20/40 or Better in the Study Eye|Percentage of Participants With CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Percentage of Participants With Both BCVA 20/40 or Better or CRT ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Mean BCVA in the Study Eye|Change From Baseline in BCVA in the Study Eye|Percentage of Participants With an Increase From Baseline of ≥2 Lines in BCVA in the Study Eye|Percentage of Participants With an Increase From Baseline of ≥3 Lines in BCVA in the Study Eye|Change From Baseline in CRT by OCT in the Study Eye|Time to Improvement of ≥2 Lines in BCVA in the Study Eye|Time to Improvement of ≥3 Lines in BCVA in the Study Eye|Time to Improvement in BCVA to 20/40 or Better in the Study Eye|Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Time Between Anti-VEGF Injections in the Study Eye|Number of Intravitreal Anti-VEGF Injections in the Study Eye|Percentage of Participants Switching to a Second or Third Anti-VEGF Agent After First Injection in the Study Eye|Percentage of Participants Switching Among Different Anti-VEGF Agents in the Study Eye|Percentage of Participants Undergoing Focal Laser Surgery in the Study Eye|Percentage of Participants Undergoing Panretinal Photocoagulation (PRP) Surgery in the Study Eye|Percentage of Participants With a Loss (Decrease) in BCVA of ≥1 Line From Baseline in the Study Eye|Percentage of Participants With a Gain (Increase) in BCVA of ≥1 Line From Baseline in the Study Eye|Percentage of Participants With No Change in BCVA From Baseline in the Study Eye|Percentage of Participants Undergoing Glaucoma Laser Surgery in the Study Eye|Percentage of Participants Undergoing Incisional Glaucoma Surgery in the Study Eye|Percentage of Phakic Patients With Cataract Surgery in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)",,"323","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","GMA-OZU-13-598","August 2, 2013","September 4, 2014","September 4, 2014","August 7, 2013","May 26, 2016","April 18, 2019","San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01918371"
220,"NCT01917006","A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation",,"Terminated","Has Results","Premature Ejaculation","Drug: OnabotulinumtoxinA|Drug: Normal Saline","Change From Baseline in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT)|Change From Baseline in Average IELT|Change From Baseline in Geometric Mean IELT","Allergan","Male","18 Years to 50 Years   (Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-133|2013-001650-94","August 7, 2013","August 15, 2017","August 15, 2017","August 6, 2013","October 18, 2018","October 18, 2018","San Diego Sexual Medicine, San Diego, California, United States|LA Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Connecticut Clinical Research Center, Middlebury, Connecticut, United States|Center for Marital and Sexual Health of South Florida, West Palm Beach, Florida, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Manhattan Medical Research, New York, New York, United States|Celerion, Belfast, United Kingdom|King's College Hospital, London, United Kingdom|Queen Anne Street Medical Center, London, United Kingdom|St Mary's Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT01917006/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT01917006/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01917006"
221,"NCT01904721","A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)",,"Completed","Has Results","Alopecia|Alopecia, Androgenetic|Baldness","Drug: Bimatoprost Solution 1|Drug: Bimatoprost Solution 2|Drug: Bimatoprost Vehicle","Change From Baseline in Target Area Hair Count (TAHC)|Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score|Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score|Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score|Change From Baseline in Target Area Hair Width (TAHW)|Change From Baseline in Target Area Hair Darkness (TAHD)","Allergan","Male","18 Years to 49 Years   (Adult)","Phase 2","244","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","192024-084","August 2013","September 2014","January 2015","July 22, 2013","December 9, 2015","March 22, 2016","Fridley, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01904721"
222,"NCT01903720","A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion","COBALT","Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Drug: dexamethasone implant","Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 6|Change From Baseline in Central Retinal Thickness (CRT) at Month 6|Change From Baseline in BCVA at Month 12|Change From Baseline in CRT at Month 12|Change From Baseline in BCVA at Each Visit|Change From Baseline in CRT at Each Visit|Percentage of Participants With a Change From Baseline of 15 or More Letters in BCVA|Percentage of Participants Receiving a Second Injection|Percentage of Participants Receiving a Third Injection|Time to Second Injection|Time to Third Injection|Percentage of Participants Who Received Laser Treatments","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","71","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APMA-OZU-01-01","July 16, 2013","September 24, 2014","March 30, 2015","July 19, 2013","July 21, 2016","April 17, 2019","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01903720"
223,"NCT01886690","A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery",,"Completed","Has Results","Bilateral LASIK Surgery","Drug: carboxymethylcellulose sodium based new eye drop formulation|Drug: carboxymethylcellulose sodium based eye drops","Ocular Surface Disease Index© (OSDI) Score Using a 5-Point Scale|Change From Baseline in Corneal Staining in the Worse Eye|Change From Baseline in Tear Break-up Time (TBUT) in the Worse Eye|Change From Baseline in the Schirmer Test in the Worse Eye|Change From Baseline in Uncorrected Visual Acuity in the Worse Eye","Allergan","All","18 Years to 60 Years   (Adult)","Phase 3","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11002X-002","August 20, 2013","August 18, 2014","August 18, 2014","June 26, 2013","October 5, 2015","April 16, 2019","New South Wales, Australia|Kelowna, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01886690"
224,"NCT01882413","A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal","REVEAL","Completed","Has Results","Dry Eye Syndromes","Other: No intervention","Percentage of Patients With a Presence of Matrix Metalloproteinase-9 (MMP-9) in the Study Eye|Percentage of Participants Suspected of Having Dry Eye With Elevated MMP-9|Percentage of Participants With Elevated MMP-9 Without Prior Diagnosis or Physician Recommended Intervention|Percentage of Participants With Elevated MMP-9 With Dry Eye Symptoms Without Conjunctival or Corneal Staining|Percentage of Participants With Elevated MMP-9 With Dry Eye Symptoms Without Any Signs|Percentage of Participants With Elevated MMP-9 With at Least One Dry Eye Sign Without Dry Eye Symptoms|Percentage of Participants With Elevated MMP-9 With at Least One Dry Eye Sign and Dry Eye Symptoms|Percentage of Participants With Elevated MMP-9 Who Routinely Use Artificial Tears|Percentage of Participants With Elevated MMP-9 With Punctal Plugs|Percentage of Participants With Elevated MMP-9 With Corneal Staining Grade ≥ 1 and ≥ 2|Percentage of Participants With Elevated MMP-9 and an Ocular Surface Disease Index® (OSDI®) > 12, > 22 and ≥ 32","Allergan","All","50 Years and older   (Adult, Older Adult)",,"204","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GMA-RES-012-001","June 2013","March 2014","March 2014","June 20, 2013","December 3, 2015","December 3, 2015","Brandon, Manitoba, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Boisbriand, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01882413"
225,"NCT01881126","An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost 0.01%|Drug: travatan 0.004%|Drug: timolol 0.5%|Drug: hypromellose 0.3%","Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-LUM-12-021","June 2013","October 2014","October 2014","June 19, 2013","November 30, 2015","November 30, 2015","Barrie, Ontario, Canada|Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01881126"
226,"NCT01879683","A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions",,"Completed","Has Results","Chronic Interstitial Cystitis","Drug: LiRIS® 400 mg","Percentage of Participants by Change From Baseline in Appearance of Hunner's Lesions at Day 14|Percentage of Participants by Change From Baseline in Appearance of Hunner's Lesions at Day 28|Change From Baseline in Patient Reported Interstitial Cystitis (IC) Symptom: Average Bladder Pain|Change From Baseline in Patient Reported IC Symptom: Daily Total Voids","Allergan|TARIS Biomedical, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAR-100-105","July 2013","May 2014","June 2014","June 18, 2013","December 18, 2015","December 18, 2015","Advance Urology Institute, Daytona Beach, Florida, United States|William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01879683"
227,"NCT01863953","A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Fixed-Combination Bimatoprost/Brimonidine|Drug: Bimatoprost Ophthalmic Solution 0.01%|Drug: Vehicle Ophthalmic Solution|Drug: Brimonidine Tartrate Ophthalmic Solution 0.2%","Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)|Change From Baseline in Average Eye Mean Diurnal IOP|Average Eye Mean Diurnal IOP","Allergan","All","40 Years and older   (Adult, Older Adult)","Phase 2","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-082","June 2013","December 2013","December 2013","May 29, 2013","January 26, 2015","January 26, 2015","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01863953"
228,"NCT01854905","An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy",,"Completed","Has Results","Dry Eye Syndromes","Other: No Treatment","Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF-AGN-OPH-DE-015","May 2013","September 2013","September 2013","May 16, 2013","March 14, 2014","March 14, 2014","Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01854905"
229,"NCT01853605","NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study",,"Terminated","Has Results","Breast Augmentation|Breast Reconstruction|Breast Implant Revision","Device: Anatomically shaped silicone gel-filled breast implants","Subject Satisfaction With Breast Implants on a 5-Point Scale|Investigator Satisfaction With Breast Implants on a 5-Point Scale|Local Complications","Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","3811","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","410CA-002","April 2003","August 2014","August 2014","May 15, 2013","August 11, 2015","August 11, 2015","Eugene, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01853605"
230,"NCT01853085","A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons",,"Completed","Has Results","Glaucoma, Primary Open Angle|Ocular Hypertension","Drug: Bimatoprost Ophthalmic Solution","Intraocular Pressure (IOP) in the Study Eye at Baseline|IOP in the Study Eye at Week 12|Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale|Patient Assessment of Tolerability on a 4-Point Scale|Physician Assessment of Tolerability on a 4-Point Scale|Number of Patients Who Discontinue Treatment With Lumigan® UD Prior to 12 Weeks of Treatment|Number of Patients Who Continue Treatment|Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale","Allergan","All","Child, Adult, Older Adult",,"1830","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/OPH/GLA/038","April 1, 2013","March 1, 2014","March 1, 2014","May 14, 2013","May 28, 2015","April 19, 2019","Wiesloch, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT01853085"
231,"NCT01852058","A Long-Term Extension Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity",,"Completed","No Results Available","Urinary Incontinence","Biological: OnabotulinumtoxinA","Change from Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes|Change from Baseline in Average Urine Volume at First Morning Catheterization|Percentage of Patients With Night Time Urinary Incontinence|Time to Patient Request for Retreatment|Time to Patient Qualification for Retreatment","Allergan","All","5 Years to 17 Years   (Child)","Phase 3","95","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-121|2012-004898-30","January 6, 2014","November 22, 2018","October 3, 2019","May 13, 2013",,"December 24, 2019","University of Alabama at Birmingham Division of Urology Research Office, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|William Beaumont Hospital Research Institute, Royal Oak, Michigan, United States|St. Louis Children's Hospital Division of Urology, Saint Louis, Missouri, United States|Pediatric Urology Associates, PC, Tarrytown, New York, United States|McKay Urology Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center Cincinnati Center for Clinical Research and Outpatient Clinic, Cincinnati, Ohio, United States|Oklahoma Children's Hospital, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Children's Hospital of Wisconsin Department of Pediatric Urology, Milwaukee, Wisconsin, United States|UZ Antwerpen, Antwerpen, Belgium|Ghent University Hospital, Gent, Belgium|UZ Leuven, Leuven, Belgium|McMaster University Medical Centre, Hamilton, Ontario, Canada|CHU Sainte Justine, Montreal, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Hopital Pellegrin - Enfants, Bordeaux, France|CHU de Limoges - HÃ´pital MÃ¨re et l'Enfant, Limoges, France|Hôpital Necker Enfants-Malades, Paris, France|Seconda Università di Napoli, Naples, Italy|Bambin Gesù- Ospedale Pediatrico, Rome, Italy|Copernicus Podmiot Leczniczy Sp. z o. o. Kliniczny Oddział Chirurgii i Urologii Dzieci i Młodzieży GUMed, Gdansk, Poland|Specjalistyczny Gabinet Lekarski, Poznań, Poland|Medical University of Wroclaw, Wroclaw, Poland|University of Ankara, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01852058"
232,"NCT01852045","Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients",,"Completed","Has Results","Urinary Incontinence","Biological: OnabotulinumtoxinA","Change From Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes|Number of Participants With Treatment Emergent Adverse Events (TEAE)|Change From Baseline in Average Urine Volume at First Morning Catheterization|Percentage of Participants With Night Time Urinary Incontinence|Change From Baseline in Maximum Cystometric Capacity (MCC)|Percentage of Participants With Involuntary Detrusor Contractions (IDC)|Change From Baseline in Maximum Detrusor Pressure During the First IDC (PdetMax1stIDC) in Participants With IDC|Change From Baseline in Maximum Detrusor Pressure (PdetMax) During the Storage Phase|Change From Baseline in Detrusor Leak Point Pressure (DLPP) During the Storage Phase|Time to Participant Request for Retreatment|Time to Participant Qualification for Retreatment","Allergan","All","5 Years to 17 Years   (Child)","Phase 3","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-120|2012-004877-26","July 2, 2013","October 11, 2018","October 11, 2018","May 13, 2013","October 30, 2019","November 21, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|William Beaumont Hospital Research Institute, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Pediatric Urology Associates, PC, Tarrytown, New York, United States|McKay Urology Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oklahoma Childrens Hospital, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|UZ Antwerpen, Antwerpen, Belgium|UZ Gent , Urology, Gent, Belgium|UZ Leuven, Leuven, Belgium|McMaster University Medical Centre, Hamilton, Ontario, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Hopital Pellegrin - Enfants, Bordeaux, France|CHU de Limoges - Hopital Mere et l'Enfant, Limoges, France|Hopital Trousseau, Paris, France|Necker Enfants Malades Hospital, Paris, France|Seconda Università di Napoli, Caserta, Italy|IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy|Copernicus Podmiot Leczniczy Sp. z o. o., Kliniczny Oddzial Chirurgii i Urologii Dzieci i Mlodziezy GUMed, Gdansk, Poland|Specjalistyczny Gabinet Lekarski, Poznan, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01852045/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01852045/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01852045"
233,"NCT01846039","JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose",,"Completed","Has Results","Asian Nose Enhancement","Device: Crosslinked hyaluronic acid gel","Percentage of Participants With a ≥ 1 Grade Improvement on the Assessment of Aesthetic Improvement Scale (AAIS) as Assessed by the Central Evaluating Physician at Day 113|Percentage of Participants With a ≥ 1 Grade Improvement on the AAIS as Assessed by the Patient at Day 113|Percentage of Participants With a ≥ 1 Grade Improvement on the AAIS as Assessed by the Central Evaluating Physician|Percentage of Participants With a ≥ 1 Grade Improvement on the AAIS as Assessed by the Patient|Percentage of Participants Satisfied or Very Satisfied Based on the Nose Satisfaction Scale (NSS)|Percentage of Participants Satisfied or Very Satisfied Based on the Treatment Satisfaction Scale (TSS)|Percentage of Participants Who Would Recommend VOLUMA Treatment of the Nose to Others","Allergan","All","20 Years and older   (Adult, Older Adult)","Not Applicable","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VOLXC-AP-ND-001","April 1, 2013","September 1, 2013","August 5, 2014","May 3, 2013","October 9, 2015","April 16, 2019","Sydney, New South Wales, Australia|Gold Coast, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT01846039"
234,"NCT01844388","A Study to Compare a New Eye Drop Formulation With Refresh Contacts®",,"Completed","Has Results","Contact Lens Lubrication","Drug: carboxymethylcellulose based eye drop formula|Drug: carboxymethylcellulose sodium based eye drop solution","Percentage of Participants With Contact Lens Distance Visual Acuity Change From Baseline","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10077X-001","May 29, 2013","December 2, 2013","December 2, 2013","May 1, 2013","September 29, 2014","April 16, 2019","Bloomington, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01844388"
235,"NCT01833741","A Study of LUMIGAN® RC in the Clinical Setting",,"Completed","Has Results","Glaucoma, Primary Open Angle|Ocular Hypertension","Drug: Bimatoprost 0.01%","Percentage of Treatment-Naive Patients With Ocular Hyperemia|Percentage of Previously Treated (Switched) Patients With Ocular Hyperemia|Percentage of Patients Treated With Adjunctive Therapy With Ocular Hyperemia|Percent Change From Baseline in Intraocular Pressure (IOP) in the Study Eye of Treatment-Naive Patients|Percent Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients|Percent Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy|Change From Baseline in IOP in the Study Eye of Treatment-Naive Patients|Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients|Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy|Percentage of Patients Discontinuing Due to Ocular Adverse Events","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","1137","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEAR","December 2009","March 2011","March 2011","April 17, 2013","September 26, 2013","September 26, 2013","Barrie, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01833741"
236,"NCT01833130","Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)",,"Completed","Has Results","Chronic Migraine","Biological: OnabotulinumtoxinA|Drug: Normal saline (placebo)","Change From Baseline in the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire Total Score|Change From Baseline in the Symptom Severity Score (SSS) Subdomain of the Assessment of Chronic Migraine Symptoms (ACM-S) Questionnaire|Change From Baseline in the Symptom Experience Score (SES) Subdomain of the ACM-S Questionnaire|Change From Baseline in the Activities of Daily Living Impact (ADL-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Emotions Impact (EMO-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Work/School Impact (WS-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Social Impact (SOC-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Leisure Activities Impact (LEA-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Household Activities Impact (HOS-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Energy Impact (ENE-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Cognitive Impact (COG-I) Domain of the ACM-I Questionnaire|Change From Baseline in the General Impact (GEN-I) Domain of the ACM-I Questionnaire|Change From Baseline in the Headache Impact Test-6 (HIT-6) Questionnaire Total Score|Change From Baseline in the Role Function-Restrictive (RR) Domain of the Migraine Specific Questionnaire (MSQ)|Change From Baseline in the Role Function-Preventive (RP) Domain of the MSQ|Change From Baseline in the Emotional Function (EF) Domain of the MSQ","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GMA-BTX-CM-12-545","April 2013","September 2014","September 2014","April 16, 2013","October 21, 2015","October 21, 2015","San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01833130"
237,"NCT01830140","A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.01%|Drug: Bimatoprost 0.03%","Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-081","July 2013","May 2014","May 2014","April 12, 2013","May 6, 2015","May 6, 2015","Artesia, California, United States|El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01830140"
238,"NCT01824303","Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis",,"Terminated","Has Results","Interstitial Cystitis","Drug: LiRIS 400 mg|Other: LiRIS Placebo","Change From Baseline in Participant Reported Average Bladder Pain on a Numerical Rating Scale (NRS)|Change From Baseline in Total Daily Voids|Change From Baseline in Night-Time Daily Voids|Change From Baseline in Average Void Volume Per Micturition|Change From Baseline in Post-Void Bladder Pain|Change From Baseline in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) Score|Change From Baseline in O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) Score|Change From Baseline in Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS)|Change From Baseline in Brief Pain Inventory (BPI)","Allergan|TARIS Biomedical, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAR-100-202","March 2013","November 2014","December 2014","April 4, 2013","November 26, 2015","January 26, 2016","Citrus Valley Medical Research , Inc., Glendora, California, United States|Atlantic Urological Associates, Daytona Beach, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|The UrogynecologyCenter, LLC, Overland Park, Kansas, United States|Female Pelvic Medicine & Urogynecology Institute of MI, Grand Rapids, Michigan, United States|William Beaumont Hospitals, Royal Oak, Michigan, United States|North Shore - Long Island Jewish Heath System - Monter Cancer Center, New Hyde Park, New York, United States|Premier Medical Group of the Hudson Valley PC, Newburgh, New York, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States|Alliance Urology Specialists, PA, Greensboro, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Volunteer Research Group, University of Tennessee Medical Center, Knoxville, Tennessee, United States|Exdeo Clinical Research Inc., Abbotsford, British Columbia, Canada|Centre for Applied Urological Research, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01824303"
239,"NCT01821534","Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification",,"Completed","Has Results","Healthy Volunteers","Other: No Intervention","Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS)|Intra-rater Reliability Using a MMPS|Inter-rater Reliability Using a Lower Facial Shape Classification (LFSC)|Intra-rater Reliability Using a LFSC","Allergan","All","18 Years and older   (Adult, Older Adult)",,"201","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","191622-128","March 2013","May 2013","May 2013","April 1, 2013","April 30, 2014","April 30, 2014","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01821534"
240,"NCT01814774","A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm",,"Completed","Has Results","Cervical Dystonia|Blepharospasm","Other: No Intervention","Dose of Botulinum Toxin Used to Treat Cervical Dystonia|Dose of Botulinum Toxin Used to Treat Blepharospasm|Number of Participants With Adverse Events|Botulinum Toxin Inter-injection Interval","Allergan","All","18 Years and older   (Adult, Older Adult)",,"48","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TRU2011","January 2013","July 2013","July 2013","March 20, 2013","July 3, 2014","July 3, 2014","Bergen, Norway|Wakefield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01814774"
241,"NCT01814761","A Study of Bimatoprost 0.01% in the Clinical Setting","APPEAL-Taiwan","Completed","Has Results","Glaucoma, Primary Open Angle|Ocular Hypertension","Drug: Bimatoprost 0.01%","Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale|Change From Baseline in Intraocular Pressure (IOP) in the Study Eye|Percentage of Patients Who Discontinue Due to an Adverse Event|Overall Percent Change From Baseline in IOP","Allergan","All","20 Years and older   (Adult, Older Adult)",,"312","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GMA-AP-EYE-AGN-001","May 2013","August 2014","August 2014","March 20, 2013","October 26, 2015","October 26, 2015","Taichung City, Taiwan",,"https://ClinicalTrials.gov/show/NCT01814761"
242,"NCT01814670","Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines",,"Completed","Has Results","Glabellar Rhytides","Biological: botulinum toxin Type A","Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Investigator Assessed Facial Wrinkle Scale of Glabellar Rhytides at Maximum Contraction|Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Subject Assessed Facial Wrinkle Scale of Glabellar Rhytides at Maximum Contraction|Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Investigator Assessed Facial Wrinkle Scale of Glabellar Rhytides at Rest|Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Subject Assessed Facial Wrinkle Scale of Glabellar Rhytides at Rest","Allergan","All","18 Years to 60 Years   (Adult)","Phase 4","185","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP-BTXC-12-001","March 6, 2013","July 31, 2014","October 29, 2014","March 20, 2013","September 1, 2015","April 17, 2019","Beijing, China",,"https://ClinicalTrials.gov/show/NCT01814670"
243,"NCT01805323","A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema",,"Completed","Has Results","Macular Edema","Drug: Dexamethasone Intravitreal Implant","Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)|Peak Mean Change From Baseline in Central Retinal Thickness (CRT)","Allergan","All","Child, Adult, Older Adult",,"101","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CMA-OZU-12-001","September 1, 2012","April 15, 2013","April 15, 2013","March 6, 2013","May 30, 2014","April 17, 2019","Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01805323"
244,"NCT01797094","BOTOX® in the Treatment of Upper Facial Lines in Japan",,"Completed","Has Results","Upper Facial Rhytides|Crow's Feet Lines|Glabellar Lines|Frown Lines","Biological: botulinum toxin Type A (44U)|Biological: botulinum toxin Type A (32U)","Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)|Percentage of Participants Much Improved or Very Much Improved in the Subject's Assessment of Appearance of CFL as Measured by the Global Assessment of Change in Crow's Feet Lines (SGA-CFL)|Percentage of Participants With a ≥2-Point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 2 at Day 30|Percentage of Participants With a ≥2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 5 at Day 30|Percentage of Participants With a ≥3-Point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 8 at Day 30|Percentage of Participants Who Rate Themselves in a Younger Self-Perception of Age Category Than at Baseline|Percentage of Participants Mostly or Very Satisfied With Their Crow's Feet Lines on the Facial Line Satisfaction Questionnaire","Allergan","All","20 Years to 64 Years   (Adult)","Phase 3","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-122","February 2013","July 2013","July 2014","February 22, 2013","February 10, 2015","February 10, 2015","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01797094"
245,"NCT01797081","BOTOX® in the Treatment of Crow's Feet Lines in Japan",,"Completed","Has Results","Lateral Canthus Rhytides|Crow's Feet Lines","Biological: botulinum toxin Type A (24 U)|Biological: botulinum toxin Type A (12 U)|Other: Normal Saline","Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)|Percentage of Participants Achieving a ≥1-Grade Improvement From Baseline on the Investigator's Assessment of the Severity of CFL at Rest Using the FWS-A|Percentage of Participants Much Improved or Very Much Improved in the Subject's Assessment of Appearance of CFL as Measured by the Global Assessment of Change in Crow's Feet Lines|Percentage of Participants Who Rate Themselves in a Younger Self-Perception of Age Category Than at Baseline","Allergan","All","20 Years to 64 Years   (Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-114","January 31, 2013","July 18, 2013","July 7, 2014","February 22, 2013","February 10, 2015","April 16, 2019","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01797081"
246,"NCT01785836","An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris",,"Withdrawn","No Results Available","Acne Vulgaris","Drug: Dapsone Formulation A|Drug: Dapsone Formulation B|Drug: Dapsone Formulation C|Drug: Dapsone 5% Gel","Change from Baseline in Inflammatory Lesion Count|Change from Baseline in Non-Inflammatory Lesion Count|Change from Baseline in Total Lesion Count|Percentage of Subjects With a Global Acne Assessment Score (GAAS) of 0 or 1","Allergan","All","12 Years to 35 Years   (Child, Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","225678-005","March 2013","October 2013","October 2013","February 7, 2013",,"February 25, 2013",,,"https://ClinicalTrials.gov/show/NCT01785836"
247,"NCT01781962","A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension",,"Terminated","Has Results","Open-angle Glaucoma|Ocular Hypertension","Other: No Treatment","Anterior Angle Width Using Anterior Segment Optical Coherence Tomography (AS OCT)|Number of Study Eyes in Each Shaffer Grade Using Gonioscopic Lens|Number of Study Eyes in Each Step Grade Using Gonioscopic Lens","Allergan","All","18 Years and older   (Adult, Older Adult)",,"206","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","192024-077","January 2013","June 2013","June 2013","February 1, 2013","July 31, 2014","July 31, 2014","Beijing, China",,"https://ClinicalTrials.gov/show/NCT01781962"
248,"NCT01777620","A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides",,"Completed","Has Results","Facial Rhytides","Biological: onabotulinumtoxinA|Drug: Normal Saline","Percentage of Participants Satisfied With Treatment of Glabellar Lines Assessed Using the Facial Line Satisfaction Questionnaire (FLSQ)|Percentage of Participants Satisfied With Treatment of Crow's Feet Lines (CFL) and Glabellar Lines Assessed Using the FLSQ|Percentage of Participants Satisfied With Duration of Treatment of Glabellar Lines Assessed Using the FLSQ|Percentage of Participants Where Treatment of Glabellar Lines Met Expectation Assessed Using the FLSQ|Percentage of Participants Satisfied With Duration of Treatment of CFL and Glabellar Lines Assessed Using the FLSQ|Percentage of Participants Where Treatment of CFL and Glabellar Lines Met Expectation Assessed Using the FLSQ|Percentage of Participants Who Were Likely to Continue Treatment of Glabellar Lines Assessed Using the FLSQ|Percentage of Participants Who Were Likely to Continue Treatment of CFL and Glabellar Lines Assessed Using the FLSQ|Percentage of Participants With a Score of None or Mild in the Investigator's Assessment of the Severity of Glabellar Lines at Maximum Frown Assessed Using the FWS|Percentage of Participants With at Least a 1-Grade Improvement in the Investigator's Assessment of the Severity of CFL at Maximum Smile Assessed Using the FWS","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-BTXC-12-001","January 31, 2013","May 29, 2013","July 31, 2013","January 29, 2013","May 30, 2014","April 17, 2019","Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01777620"
249,"NCT01773122","Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone Formulation A|Drug: Dapsone Formulation B|Drug: Dapsone Formulation C|Drug: Dapsone 5% Gel","Maximum Plasma Level (Cmax) of Dapsone|Maximum Plasma Level (Cmax) of Dapsone Metabolites","Allergan","All","16 Years to 35 Years   (Child, Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","225678-004","January 21, 2013","May 5, 2013","May 5, 2013","January 23, 2013","March 26, 2014","April 24, 2019","College Station, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01773122"
250,"NCT01767519","A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence",,"Completed","Has Results","Overactive Bladder|Urinary Incontinence","Biological: BOTOX®|Drug: solifenacin|Drug: Botox placebo (normal saline)|Drug: solifenacin placebo","Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1|Percentage of Patients With 100% Reduction in Incontinence Episodes in Treatment Cycle 1|Percentage of Patients With a Positive Response on the Single-Item Treatment Benefit Scale During Treatment Cycle 1|Change From Study Baseline in the Number of Micturition Episodes in Treatment Cycle 1|Change From Study Baseline in the Number of Nocturia Episodes in Treatment Cycle 1|Change From Study Baseline in the Role Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1|Change From Study Baseline in the Social Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","356","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-125","March 1, 2013","September 30, 2014","March 18, 2015","January 14, 2013","January 12, 2016","April 23, 2019","Newport Beach, California, United States|Leuven, Belgium|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Prague 6, Czechia|Berlin, Germany|Warsaw, Poland|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01767519"
251,"NCT01765764","Bimatoprost for the Treatment of Eyebrow Hypotrichosis",,"Completed","Has Results","Eyebrow Hypotrichosis","Drug: bimatoprost solution|Drug: Vehicle to bimatoprost solution","Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale|Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA)|Change From Baseline in Eyebrow Darkness as Measured Using DMSIA|Percentage of Participants With 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","357","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-043","March 13, 2013","January 31, 2014","February 11, 2014","January 10, 2013","January 26, 2015","April 23, 2019","Houston, Texas, United States|Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01765764"
252,"NCT01754766","AGN-229666 for the Treatment of Allergic Conjunctivitis",,"Completed","Has Results","Allergic Conjunctivitis","Drug: AGN-229666|Other: vehicle of AGN-229666","Ocular Itching Score at Day 1|Ocular Itching Score at Day 15|Conjunctival Hyperemia Score","Allergan","All","20 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","229666-002","October 2012","January 2013","February 2013","December 21, 2012","February 4, 2014","February 4, 2014","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01754766"
253,"NCT01749423","A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines",,"Withdrawn","No Results Available","Chronic Migraine, Headache","Biological: OnabotulinumtoxinA","Number of Headache Days","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","GMA-BTX-CM-12-518","November 2012","December 2013","December 2013","December 13, 2012",,"February 3, 2014",,,"https://ClinicalTrials.gov/show/NCT01749423"
254,"NCT01749410","A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines",,"Completed","Has Results","Chronic Migraine, Headaches","Biological: onabotulinumtoxinA","Change From Baseline in the Number of Headache Days","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)",,"33","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","GMA-BTX-CM-12-491","May 2013","May 2014","May 2014","December 13, 2012","September 10, 2015","September 10, 2015","Encinitas, California, United States",,"https://ClinicalTrials.gov/show/NCT01749410"
255,"NCT01735214","An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy","Change From Baseline in Intraocular Pressure (IOP) in the Right Eye|Change From Baseline in Intraocular Pressure (IOP) in the Left Eye|Patient Assessment of Overall Tolerability With New Treatment Using a 4-Point Scale|Physician Assessment of Tolerability With New Treatment Using a 4-Point Scale|Percentage of Participants Who Discontinue the Use of New Treatment Prior to 12 Weeks|Percentage of Participants Who Continue the New Treatment After 12 Weeks|Physician Assessment of Adherence to New Treatment Using a 4-Point Scale|Physician Assessment of Efficacy Using a 5-Point Scale|Percentage of Participants Reaching Individual IOP Target After 12 Weeks","Allergan","All","18 Years and older   (Adult, Older Adult)",,"358","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/OPH/GLA/037","March 7, 2013","April 10, 2014","April 10, 2014","November 28, 2012","April 27, 2015","April 18, 2019","Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01735214"
256,"NCT01735201","AGN-199201 for the Treatment of Erythema With Rosacea",,"Completed","Has Results","Rosacea|Erythema","Drug: AGN-199201 Dose A|Drug: AGN-199201 Dose B|Drug: AGN-199201 Dose C|Drug: AGN-199201 Vehicle","Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA)|Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 0.5 Hour Post-Dose on Day 28|Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 1 Hour Post-Dose on Day 28","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","357","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","199201-002","December 2012","May 2013","June 2013","November 28, 2012","May 30, 2014","November 18, 2019","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01735201"
257,"NCT01732757","A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis",,"Completed","Has Results","Conjunctivitis, Allergic","Drug: Alcaftadine 0.25%|Drug: Olopatadine 0.2%|Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%","Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0|Ocular Itching Evaluated by the Subject at 5 and 7 Minutes Post Challenge on Day 0|Percentage of Subjects With Minimal Itching Score at 3, 5, and 7 Minutes Post Challenge on Day 0|Percentage of Subjects With a Zero Itch Score at 3, 5, and 7 Minutes Post Challenge on Day 0|Percentage of Subject Eyes in Each Category of the Itching Score Distribution Post Challenge on Day 0|Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0|Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0|Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0|Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0|Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 0|Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 0","Allergan","All","10 Years and older   (Child, Adult, Older Adult)","Phase 4","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GMA-LAS-12-023","November 2012","December 2012","December 2012","November 26, 2012","January 14, 2014","January 14, 2014","Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01732757"
258,"NCT01714726","Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.",,"Completed","Has Results","Crohn's Disease","Drug: MEDI2070|Drug: placebo","Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8|Percentage of Participants With CDAI Remission at Week 8|Percentage of Participants With CDAI-100 Point Improvement at Week 8|Percentage of Participants With CDAI-70 Point Improvement at Week 8|Percentage of Participants With CDAI Response at Week 12|Change From Baseline in CDAI Total Score at Week 8|Number of Participants With Treatment Emergent Adverse Events (TEAEs) Double-blind Period|Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) in Double-blind Period|Number of Participants With TEAEs in Open-label Period|Number of Participants With TESAEs in Open-label Period|Number of Participants With Clinical Laboratory Abnormalities as TEAEs in Double-blind Period|Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Open-label Period|Number of Participants With Vital Signs Abnormalities Reported as TEAEs in Double-blind Period|Number of Participants With Vital Signs Abnormalities Reported as TEAEs in Open-label Period|Maximum Mean Serum Concentration of MEDI2070 in Doubleblind Period|Maximum Mean Serum Concentration of MEDI2070 in Open-label Period|Number of Participants With Positive Anti-drug Antibody (ADA) to MEDI2070 in Double-blind Period|Number of Participants With ADA Positive to MEDI2070 in Open-label Period","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5170C00001|2012-004098-26","February 1, 2013","May 20, 2014","December 14, 2016","October 26, 2012","March 6, 2019","March 6, 2019","Precision Research Institute, LLC, Chula Vista, California, United States|Rocky Mountain Clinical Research, Lakewood, Colorado, United States|Borland Groover Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Gastroenterology Associates of Central Georgia, Macon, Georgia, United States|University Chicago Medical Center, Chicago, Illinois, United States|Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States|University of Michigan Health Care System, Ann Arbor, Michigan, United States|Troy Internal Medicine PC, Troy, Michigan, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|Weill Medical College, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Charlotte Gastroenterology & Hepatology, Charlotte, North Carolina, United States|Consultants for Clinical Research Inc., Cincinnati, Ohio, United States|Zeidler Ledcor Centre, Edmonton, Alberta, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Vaughan, Ontario, Canada|Hepato-Gastroenterologie HK, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava -, Ostrava-Poruba, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|CHU Amiens Picardie Service Hépato-gastroentérologie, Amiens Cedex 1, France|Hôpital Beaujon Service de Gastroentérologie et Assistance Nutritive, Clichy, France|Hôpital Charles Nicolle Service d'Hepato-Gastroentérologie1, Rue De Germont Pavillon Derocque, Rouen, France|Hôpital de Rangueil1 avenue du Professeur Jean Poulhès Service de Gastroentérologie et de Nutrition, Toulouse Cedex 9, France|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Praxis Dr. med. Constanze & Dr. med. Wolfgang Brandt Facharzt für Innere MedizinRudolf-Breitscheid-Str., Potsdam, Germany|Peterfy S. utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, Hungary|Szent János Kórház és Észak-budai Egyesített Kórházak, Budapest, Hungary|Vas Megyei Markusovszky Kórház Nonprofit Zrt., Budapest, Hungary|Azienda Ospedaliera Policlinico S. Orsola - Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ii Università Degli Studi Di Napoli, Napoli, Italy|A.O. Policlinico Universitario ""Tor Vergata"", Roma, Italy|Università Cattolica del Sacro Cuore-Policlinico A. Gemelli Complesso Integrato Columbus, Roma, Italy|Istituto Clinico ""Humanitas"", Rozzano, Italy|Szpital Uniwersytecki nr 2 im. Jana Biziela w Bydgoszczy Centrum Endoskopii Zabiegowej, Bydgoszcz, Poland|Endoskopia Sp. z o. o. ul., Sopot, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|CEIC Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|CEIC Hospital Universitàrio de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Saint Pau Avda. Sant Antoni Mª Claret, Barcelona, Spain|Sabadell, H. Parc Taulí,Ap.Digestivo Aparatro DigestivoParc Taulí, Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01714726"
259,"NCT01711424","An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease",,"Completed","Has Results","Dry Eye Syndromes","Drug: OPTIVE PLUS®","Number of Participants Very Satisfied or Satisfied With OPTIVE PLUS®|Number of Participants Where Physician Was Very Satisfied or Satisfied With OPTIVE PLUS®|Tear Break Up Time (TBUT)|Schirmer Score","Allergan","All","18 Years and older   (Adult, Older Adult)",,"1209","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/DE/012","September 2012","March 2013","March 2013","October 22, 2012","March 17, 2014","March 17, 2014","Stuttgart, Baden-Wuerttemberg, Germany",,"https://ClinicalTrials.gov/show/NCT01711424"
260,"NCT01698554","Bimatoprost in the Treatment of Eyelash Hypotrichosis",,"Completed","Has Results","Idiopathic Eyelash Hypotrichosis","Drug: bimatoprost formulation A solution|Drug: bimatoprost solution 0.03 %|Drug: vehicle of bimatoprost formulation A solution|Drug: vehicle of bimatoprost solution 0.03 %","Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA)|Change From Baseline in Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)|Change From Baseline in Upper Eyelash Thickness/Fullness as Measured Using DIA|Change From Baseline in Upper Eyelash Intensity (Darkness) as Measured Using DIA|Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","464","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-046|2012-003007-35","November 2012","February 2014","March 2014","October 3, 2012","February 10, 2015","February 10, 2015","Newport Beach, California, United States|St. Petersburg, Russian Federation|Stockholm, Sweden|Norfolk, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01698554"
261,"NCT01686581","An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine",,"Completed","Has Results","Migraine Disorders","Drug: botulinum toxin Type A","Percentage of Participants Admitted to the Hospital for Headache|Mean Number of Days of Headache-related Hospital Admissions|Percentage of Participants Who Visited Any Healthcare Professional (HCP)|Change From Baseline in Migraine-Specific Quality of Life Questionnaire (MSQ) Score|Change From Baseline in the EQ-5D Questionnaire Total Score|Change From Baseline in the Health State Score of the EQ-5D Questionnaire|Change From Baseline in the Number of Headache Days|Percentage of Participants With Good or Very Good Responses on the 4-Point Treatment Satisfaction Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"641","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/NS/CM/002","July 23, 2012","October 12, 2016","October 12, 2016","September 18, 2012","November 9, 2018","November 9, 2018","Nicole Strickling, Aachen, Germany|Manfred Oberling, Bad Camberg, Germany|Kathrin Krome, Bamberg, Germany|Heike Förster, Baunatal, Germany|MVZ Schmerzzentrum Berlin, Berlin, Germany|Christoph Engelmann, Berlin, Germany|Andreas Kupsch, Berlin, Germany|Hans-Dieter Zug, Böblingen, Germany|Andreas Schwittay, Böhlen, Germany|Bezirksklinikum Mainkofen, Deggendorf, Germany|Ulrike Kirchhöfer, Erfurt, Germany|Michael Kiszka, Erfurt, Germany|Astrid Gendolla, Essen, Germany|Jürgen Hamacher, Essen, Germany|Schmerzzentrum Rhein Main in Frankfurt, Frankfurt, Germany|Bernhard Hellwig, Freiburg, Germany|Peter Asmus, Geldern, Germany|G. Müller-Schwefe, Göppingen, Germany|Borries Kukowski, Göttingen, Germany|Veit Becker, Hamburg, Germany|Hanno Jaeger, Hamburg, Germany|Klaus Gerlach, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Ulrike Köhler, Heidelberg, Germany|Frank Halbgewachs, Heidenheim, Germany|Dirk Buschmann, Herford, Germany|Rotes Kreuz Krankenhaus Kassel, Kassel, Germany|Schmerzklinik Kiel, Kiel, Germany|Migräne-Klinik Königstein, Königstein, Germany|Neuroscience Center Leipzig, Leipzig, Germany|Dietmar Walter Noack, Limburgerhof, Germany|Lothar Klimpel, Limburgerhof, Germany|St.-Marien-Hospital GmbH, Lünen, Germany|Olaf Günther, Magdeburg, Germany|Institut für Forschung und Prävention, Mainz, Germany|Stephan Nautscher-Timmermann, Mühlhausen, Germany|Praxis für Neurologie und SchmerzMedizin, München, Germany|Matthias Haslbeck, München, Germany|Klinikum der Universität München - Großhadern, Neurologische Klinik, München, Germany|Neurologie und Kopfschmerzzentrum Münchner Freiheit, München, Germany|Schmerztherapiezentrum Münster, Münster, Germany|Dr. Becker Rhein-Sieg-Klinik, Nümbrecht, Germany|Roland Leger, Nürnberg, Germany|Matthias Röder, Oberhausen, Germany|mediPlan Klinik GmbH, Ostfildern, Germany|Frank Freitag, Potsdam, Germany|Universität Rostock, Klinik für Neurologie, Rostock, Germany|Ingo Palutke, Stadtroda, Germany|Heinz Peter Herbst, Stuttgart, Germany|Anselm Kornhuber, Ulm, Germany|Universitätsklinikum Ulm, Klinik für Neurologie, Ulm, Germany|Volker Heinicke, Weimar, Germany|Parkinson-Klinik Wolfach, Wolfach, Germany|Michaela Krause, Wolfratshausen, Germany|Jochen Ulzheimer, Würzburg, Germany|Dorothea Händel, Zwickau, Germany|Ospedale Careggi, Firenze, Italy|Istituto Neurologico Carlo Besta di Milano, Milano, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Italy|Hodeverket Headache Clinic, Sandnes, Norway|LLC Neyroklinika, Khabarovsk, Russian Federation|LLC Center for Interdisciplinary Dentistry and Neurology, Moscow, Russian Federation|LLC Clinic Sesil +, Moscow, Russian Federation|LLC University Headache Clinic, Moscow, Russian Federation|LLC Sibneuromed, Novosibirsk, Russian Federation|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Santiago de Compostela, Santiago de Compostela, Spain|Hospital Galdácano, Usansolo, Spain|Löfvingkliniken, Göteborg, Sweden|Centralsjukhuset i Karlstad, Karlstad, Sweden|Läkarhuset Utsikten, Stockholm, Sweden|Spire Hull and East Riding Hospital, Anlaby, United Kingdom|University Hospital of North Staffordshire, Neurology Research Unit, Stoke on Trent, United Kingdom|Mid Yorkshire NHS Trust, Wakefield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01686581"
262,"NCT01684436","Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye",,"Completed","Has Results","Dry Eye","Device: Punctal Plug","Concentration of Tear Cytokine Levels Before Punctal Plug Insertion in the Study Eye|Concentration of Tear Cytokine Levels Following Punctal Plug Insertion in the Study Eye|Corneal Fluorescein Staining Score in the Study Eye|Tear Film Break-up Time (TBUT)|Schirmer's Test Score|Dry Eye Questionnaire Irritation Score","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APMA-DE-0812","October 1, 2012","July 31, 2013","July 31, 2013","September 13, 2012","August 15, 2014","April 17, 2019","Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01684436"
263,"NCT01680497","Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds",,"Completed","Has Results","Moderate to Severe Nasolabial Folds","Device: Crosslinked hyaluronic acid dermal filler","Investigator Assessment of Nasolabial Fold Severity Using the 5-point Nasolabial Fold Severity Scale (NLFSS)|Investigator Assessment of Nasolabial Fold Severity Using the 5-point NLFSS|Investigator Satisfaction With Aesthetic Outcome on an 11-Point Scale|Investigator Assessment of Ease of Injection Use on a 10-Point Scale|Subject Assessment of Nasolabial Fold Severity Using the 5-point NLFSS|Subject Satisfaction With Aesthetic Outcome on an 11-Point Scale|Subject Assessments of Pain, Swelling, and Bruising Intensity on an 11-Point Scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAF/AGN/MED/FIL/018","June 1, 2012","March 6, 2014","March 6, 2014","September 7, 2012","June 23, 2015","April 16, 2019","Darmstadt, Germany|Koln, Germany|Naarden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01680497"
264,"NCT01678924","A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia",,"Terminated","Has Results","Neuralgia, Postherpetic","Drug: AGN-214868|Drug: AGN-214868 Placebo (Vehicle)","Change From Baseline in Average Pain Intensity Score - Cohort 1|Change From Baseline in Average Pain Intensity Score - Cohort 2|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 1|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 2|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 3|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 4|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 5|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 6|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 7|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 8|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 9|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 10|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 11|Percentage of Average Pain Intensity Score Responders - Cohort 1 - Week 12|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 1|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 2|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 3|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 4|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 5|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 6|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 7|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 8|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 9|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 10|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 11|Percentage of Average Pain Intensity Score Responders - Cohort 2 - Week 12|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 1 - Week 2|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 1 - Week 4|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 1 - Week 8|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 1 - Week 12|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 2 - Week 2|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 2 - Week 4|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 2 - Week 8|Change From Baseline in Maximal Area of Spontaneous Pain - Cohort 2 - Week 12|Change From Baseline in Area of Allodynia - Cohort 1 - Week 2|Change From Baseline in Area of Allodynia - Cohort 1 - Week 4|Change From Baseline in Area of Allodynia - Cohort 1 - Week 8|Change From Baseline in Area of Allodynia - Cohort 1 - Week 12|Change From Baseline in Area of Allodynia - Cohort 2 - Week 2|Change From Baseline in Area of Allodynia - Cohort 2 - Week 4|Change From Baseline in Area of Allodynia - Cohort 2 - Week 8|Change From Baseline in Area of Allodynia - Cohort 2 - Week 12|Change From Baseline in Evoked Pain Score in the Area of Allodynia Cohort 1 - Week 2|Change From Baseline in Evoked Pain Score in the Area of Allodynia Cohort 1 - Week 4|Change From Baseline in Evoked Pain Score in the Area of Allodynia Cohort 1 - Week 8|Change From Baseline in Evoked Pain Score in the Area of Allodynia Cohort 1 - Week 12|Change From Baseline in Evoked Pain Score in the Area of Allodynia - Cohort 2 - Week 2|Change From Baseline in Evoked Pain Score in the Area of Allodynia - Cohort 2 - Week 4|Change From Baseline in Evoked Pain Score in the Area of Allodynia - Cohort 2 - Week 8|Change From Baseline in Evoked Pain Score in the Area of Allodynia - Cohort 2 - Week 12","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","214868-007|2012-002240-24","January 2013","May 2015","September 2015","September 5, 2012","January 7, 2020","January 7, 2020","Agave Clinical Research, LLC, Mesa, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Neuro-Pain Medical Center, Fresno, California, United States|University of California, Irvine, Irvine, California, United States|Loma Linda University, Loma Linda, California, United States|Northern California Research Corp, Sacramento, California, United States|Neurological Research Institute, Santa Monica, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Riverside Clinical Research, Edgewater, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Drug Studies America, Marietta, Georgia, United States|Injury Care Research, LLC, Boise, Idaho, United States|Millennium Pain Center, Bloomington, Illinois, United States|Beacon Clinical Research, Brockton, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|Michigan Head Pain and Neurology Institute, Ann Arbor, Michigan, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|Clinvest Headache Care Center, Springfield, Missouri, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|The Medical Research Network, LLC, New York, New York, United States|Island Neurological Associates, P.C., Plainview, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Plains Medical Clinic, Fargo, North Dakota, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Allegheny Pain Management, Altoona, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Clinical Trials of South Carolina, LLC, Charleston, South Carolina, United States|PharmaCorp Clinical Trials, Inc, Charleston, South Carolina, United States|Clinical Research of Charleston, Mount Pleasant, South Carolina, United States|Center for Clinical Studies, Webster, Texas, United States|MultiCare Neuroscience Center of Washington, Tacoma, Washington, United States|SMZ-Ost Donauspital, Vienna, Austria|AKH Wien, Wien, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|Pro scientia med im MARE Klinikum, Kiel, Schleswig-Holstein, Germany|Berlin Research Centre, Berlin, Germany|Regionales Schmerzzentrum DGS, Bielefeld, Germany|Bochum Research Centre, Bochum, Germany|Das Schmerzzentrum Celle, Celle, Germany|Ambulant study centre, Cologne, Germany|Leiter des Universitats Schmerz Centrums (USC), Dresden, Germany|Neuro-Consil GmbH, Düsseldorf, Germany|Frankfurt Research Centre, Frankfurt, Germany|Schmerz und Palliativzentrum Fulda, Fulda, Germany|Schmerz und Palliativ- Zentrum Goeppingen, Goeppingen, Germany|Klinikum Hanau GmbH, Hanau, Germany|Neurologische Praxis Heidenheim, Heidenheim, Germany|Facharzt fur Neurologie, Hoppegarten, Germany|Schmerzklinik Kiel, Kiel, Germany|Medamed GmbH, Leipzig, Germany|Leipzig Research Centre, Leipzig, Germany|Magdeburg Research Centre, Magdeburg, Germany|Regionales Schmerz- und Palliativ Zentrum DGS Mainz, Mainz, Germany|Universitätsklinik Ulm, Ulm, Germany|Schmerztherapiezentrum Villingen-Schwenningen, Villingen-Schwenningen, Germany|Poznański Ośrodek Medyczny NOVAMED, Poznan, Poznañ, Poland|Medica Pro Familia Sp. Z.o.o SKA, Gdynia, Poland|Medica Pro Familia Sp. Z.o.o SKA, Katowice, Poland|Malopolskie Centrum Medyczne S.C., Krakow, Poland|Specjalistyczny Gabinet Neurologiczny, Krakow, Poland|Nzoz Neuromed, Lublin, Poland|NZOZ Neuro-Kard, Poznan, Poland|Niepubliczny Zaklad Opieki Zdrowotnej, Swidnik, Poland|Osrodek Badan Klinicznych Euromedis Sp. z o.o., Szczecin, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|Medica Pro Familia Warszawa, Warszawa, Poland|Synexus SCM sp. z o.o., Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT01678924"
265,"NCT01664949","A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease",,"Completed","Has Results","Dry Eye Disease","Drug: Carboxymethylcellulose Based Eye Drop Formulation A|Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops","Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Day 90|Change From Baseline in Tear Break-up Time (TBUT)|Change From Baseline in Corneal Staining|Change From Baseline in Conjunctival Staining|Change From Baseline in the Schirmer Test","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11002X-001|2012-002238-35","January 2013","May 2014","May 2014","August 14, 2012","June 8, 2015","September 21, 2015","Randwick, New South Wales, Australia|Leuven, Belgium|Marseille, France|Tours Cedex, France|Freiburg, Germany|Padova, Italy|Parma, Italy|Moscow, Russian Federation|Huelva, Spain|Valencia, Spain|Southampton, Hampshire, United Kingdom|Great Yarmouth, Norfolk, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01664949"
266,"NCT01662492","A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine",,"Completed","Has Results","Migraine Disorders","Biological: Botulinum toxin type A Dose 1|Biological: Botulinum toxin type A Dose 2|Drug: Placebo (Normal Saline)","Change From Baseline in the Frequency of Headache Days|Change From Baseline in the Frequency of Severe Headache Days|Change From Baseline in the Total Cumulative Hours of Headache on Headache Days|Percentage of Patients With ≥ 50% Decrease From Baseline in the Frequency of Headache Days|Percentage of Patients Who Are Prescribed Oral Rescue Migraine Prophylactic Treatment","Allergan","All","12 Years to 17 Years   (Child)","Phase 3","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","191622-103","October 2012","August 2016","August 2016","August 10, 2012","September 5, 2017","September 5, 2017","Phoenix Children's Hospital, Phoenix, Arizona, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|The Research Center of Southern California, Oceanside, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Pediatric Neurology, PA, Orlando, Florida, United States|The Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Advanced Clinical Research, Meridian, Idaho, United States|Josephson Wallack Munshower Neurology, P.C., Indianapolis, Indiana, United States|CPFCC Neurology Research Department, Overland Park, Kansas, United States|Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan, United States|CORE (Center for Outpatient Research), Springfield, Missouri, United States|Renown Institution for Neurosciences, Reno, Nevada, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Jill Waldo, CCRC, Pittsburgh, Pennsylvania, United States|Nashville Neuroscience Group, Nashville, Tennessee, United States|Texas Association of Pediatric Neurology/Road Runner Research, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01662492"
267,"NCT01660802","Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)",,"Completed","Has Results","Macular Edema","Drug: 700 μg Dexamethasone|Other: Sham","Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye|Average Change From Baseline in BCVA in the Study Eye|Change From Baseline in BCVA in the Study Eye|Percentage of Patients With BCVA Improvement of ≥15 Letters From Baseline in the Study Eye","Allergan","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206207-020","September 4, 2012","March 31, 2014","May 20, 2014","August 9, 2012","June 8, 2015","April 17, 2019","Beijing, China",,"https://ClinicalTrials.gov/show/NCT01660802"
268,"NCT01657370","A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)",,"Completed","Has Results","Migraine","Drug: MK-1602|Drug: Placebo|Drug: Rescue medication","Dry Blood Spot (DBS) MK-1602 Concentration at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants With Pain Relief (PR) at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants Reporting Absence of Photophobia at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants With Sustained Pain Freedom (SPF) From 2-24 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants With Sustained Pain Relief (SPR) From 2-24 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose on Migraine Treatment Day|Percentage of Participants With TMF From 2-24 Hours Post-Dose on Migraine Treatment Day","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1602-007","August 2012","November 2012","December 2012","August 6, 2012","December 9, 2016","December 9, 2016",,,"https://ClinicalTrials.gov/show/NCT01657370"
269,"NCT01655862","A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie) Treated With OnabotulinumtoxinA",,"Completed","No Results Available","Torticollis","Biological: OnabotulinumtoxinA","Change from Baseline in Cervical Dystonia Impact Profile Questionnaire (CDIP-58) Score|Patient's Global Impression of Change (PGIC) Using a 7-Point Scale|Work Productivity Assessment Using a 10-Item Questionnaire|Change from Baseline in Hospital Anxiety and Depression Scale (HAD) Score|Reasons for Withdrawal of Treatment","Allergan","All","16 Years and older   (Child, Adult, Older Adult)",,"62","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CMA-BTX-12-001","July 2012","February 2017","February 2017","August 2, 2012",,"March 30, 2017","Clinique Neuro-Rive Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Chum-Notre-Dame, Montreal, Quebec, Canada|Queen Elizabeth Health Centre: Medical Specialist Clinic, Montreal, Quebec, Canada|CHU - Sherbrooke, Sherbrooke, Quebec, Canada|Polyclinique Medicale des Ponts, St-Romuald, Quebec, Canada|CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec, Canada|Centre Medical Le Mesnil, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01655862"
270,"NCT01648530","Chronic Migraine Epidemiology and Outcomes Study",,"Completed","Has Results","Migraine Disorders","Other: No Treatment","Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM)|Migraine Disability Assessment (MIDAS)","Allergan","All","Child, Adult, Older Adult",,"16789","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GMA-BTX-12-470","July 2012","November 2013","November 2013","July 24, 2012","January 29, 2015","January 29, 2015",,,"https://ClinicalTrials.gov/show/NCT01648530"
271,"NCT01646151","A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost","Intraocular Pressure (IOP) at Baseline|IOP at Week 12|Physician Evaluation of IOP Lowering in the Study Eye(s)|Patient Assessment of Tolerability on a 4-Point Scale|Physician Assessment of Tolerability on a 4-Point Scale|Physician Assessment of Patient Compliance Compared to Previous Therapy|Percentage of Patients Who Discontinue Treatment With Bimatoprost-Containing Eye Drops Prior to 12 Weeks of Treatment|Percentage of Patients Who Continue Treatment With Bimatoprost-Containing Eye Drops","Allergan","All","Child, Adult, Older Adult",,"2580","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/GLA/033","May 2012","April 2013","April 2013","July 20, 2012","June 13, 2014","June 13, 2014","Dresden, Germany|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01646151"
272,"NCT01639755","European New Texture Implant Clinical Experience With Shaped Breast Implants",,"Completed","Has Results","Breast Augmentation","Device: new texture shaped breast implants","Investigator Overall Satisfaction With the Device Using a 5-Point Scale|Subject Satisfaction With Breasts Using the BREAST-Q Questionnaire|Investigator Evaluation of Whether the Implant is Palpably Distinguishable From the Tissue|Percentage of Participants With Capsular Contracture Evaluated by Four-Grade Baker Scale|Percentage of Participants With Local Complications","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 4","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ENTICE-002","June 18, 2012","January 30, 2013","October 16, 2017","July 13, 2012","July 29, 2015","November 30, 2017","Klinik 34, Göteburg, Sweden|Akademikliniken 10, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01639755"
273,"NCT01639742","European New Texture Implant Clinical Experience With Round Breast Implants",,"Completed","Has Results","Breast Augmentation","Device: New texture round breast implants","Investigator Overall Satisfaction With the Device Using a 5-Point Scale|Subject Satisfaction With Breasts Using the BREAST-Q Questionnaire|Investigator Evaluation of Whether the Implant is Palpably Distinguishable From the Tissue|Percentage of Participants With Capsular Contracture Evaluated by Four-Grade Baker Scale|Percentage of Participants With Local Complications","Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ENTICE-001","June 18, 2012","January 30, 2013","October 12, 2017","July 13, 2012","July 29, 2015","November 30, 2017","Praxisklinik Siepe Friedrichstraße 57, Bonn, Germany|Malteser Krankenhaus, Bonn, Germany|Akademikliniken 10, Stockholm, Sweden|Dolan Park Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01639742"
274,"NCT01637246","A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Any Fixed Combination Therapy","Change From Baseline in Intraocular Pressure (IOP)|Patient Assessment of Tolerability Using a 4-Point Scale|Physician Assessment of Tolerability Using a 4-Point Scale|Percentage of Patients Who Maintained Better Compliance With Treatment|Percentage of Patients Continuing on Therapy After 12 Weeks","Allergan","All","Child, Adult, Older Adult",,"4385","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MAF/AGN/OPH/GLA/017|AGN-EPI-2009-02","April 2009","November 2011","November 2011","July 11, 2012","September 21, 2012","September 21, 2012","Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01637246"
275,"NCT01636765","Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale",,"Completed","Has Results","Erythema|Rosacea","Drug: No Intervention","Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale|Intra-rater Reliability of the CEA Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"104","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","199201-003","May 2012","July 2012","July 2012","July 10, 2012","November 15, 2013","November 18, 2019","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01636765"
276,"NCT01633788","A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction",,"Completed","Has Results","Meibomian Gland Dysfunction","Drug: AGN-195263 0.1%|Drug: AGN-195263 0.03%|Drug: AGN-195263 0.01%|Drug: AGN-195263 Vehicle","Percentage of Meibum Quality Responders in the Study Eye|Percentage of Maximum Meibum Quality Score (MMQS) Responders in the Study Eye|Percentage of Complete Overall Ocular Discomfort Responders","Allergan","All","40 Years and older   (Adult, Older Adult)","Phase 2","232","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","195263-006","August 22, 2012","February 5, 2015","February 5, 2015","July 4, 2012","September 8, 2017","September 8, 2017","Cornea Consultants of Arizona, Phoenix, Arizona, United States|University of Arkansas for Medical, Little Rock, Arkansas, United States|Sall Research Medical Center, Artesia, California, United States|Orange County Ophthalmology Medical Group, Inc., Garden Grove, California, United States|Lugene Eye Institute, Glendale, California, United States|Lakeside Vision Center, Irvine, California, United States|Scripps Clinic, La Jolla, California, United States|North Valley Eye Medical Group, Inc., Mission Hills, California, United States|Eye Research Foundation, Newport Beach, California, United States|North Bay Eye Associates, Inc., Petaluma, California, United States|Centennial Eye Associates, Centennial, Colorado, United States|Colorado Eye Associates, PC, Colorado Springs, Colorado, United States|Danbury Eye Physicians & Surgeons, PC, Danbury, Connecticut, United States|The Eye Associates of Manatee, LLP, Bradenton, Florida, United States|Wohl Eye Center, Bloomingdale, Illinois, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Durrie Vision, Overland Park, Kansas, United States|Taustine Eye Center, Louisville, Kentucky, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|Ophthalmology Associates, Saint Louis, Missouri, United States|Comprehensive Eye Care, Ltd., Washington, Missouri, United States|Northern New Jersey Eye Institute, PA, South Orange, New Jersey, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|Ophthalmic Consultants Long Island, Rockville Centre, New York, United States|South Shore Eye Care, LLP, Wantagh, New York, United States|Cornerstone Eye Care, High Point, North Carolina, United States|Drs. Fine, Hoffman, and Packer, LLC, Eugene, Oregon, United States|Vision Center of Texas, PA, Cedar Park, Texas, United States|University of Houston, College of Optometry, Houston, Texas, United States|Focus Clinical Research, Salt Lake City, Utah, United States|Stacy Smith, MD, PC, Salt Lake City, Utah, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01633788"
277,"NCT01632423","A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost 0.01%","Change From Baseline in Intraocular Pressure (IOP)|Patient Assessment of Tolerability Using a 4-Point Scale|Physician Assessment of Tolerability Using a 4-Point Scale|Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks|Patients Who Will Continue Use of Lumigan® After 14 Weeks","Allergan","All","Child, Adult, Older Adult",,"10337","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/OPH/GLA/025","February 2010","November 2010","November 2010","July 3, 2012","September 21, 2012","September 21, 2012","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01632423"
278,"NCT01629407","A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years",,"Completed","No Results Available","Glaucoma, Open-Angle","Other: Standard of Care","Change from Baseline in Visual Field|Change from Baseline in Intraocular Pressure (IOP)","Allergan","All","Child, Adult, Older Adult",,"315","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/GLA/015","June 2009","May 2013","May 2013","June 27, 2012",,"June 20, 2013","Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01629407"
279,"NCT01628614","A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Other: Standard of Care","Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline|Percentage of Patients With an IOP Reduction ≥10% From Baseline|Percentage of Patients With an IOP Reduction ≥20% From Baseline","Allergan","All","Child, Adult, Older Adult",,"4812","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/OPH/GLA/028|AGN-EPI-2010-01","November 2010","July 2011","July 2011","June 27, 2012","September 5, 2012","September 5, 2012","Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01628614"
280,"NCT01628601","GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Fixed combination 0.3 mg bimatoprost and 5 mg timolol","Change From Baseline in Intraocular Pressure (IOP)|Physician Assessment of Tolerability Using a 4-Point Scale|Patient Assessment of Tolerability Using a 4-Point Scale|Physician Assessment of Adherence to GANfort®|Patients Continuing With GANfort® After 18 Weeks","Allergan","All","Child, Adult, Older Adult",,"392","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/GLA/027","May 2010","June 2011","June 2011","June 27, 2012","September 24, 2012","September 24, 2012","Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01628601"
281,"NCT01628588","Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost 0.01%","Change From Baseline in Intraocular Pressure (IOP)|Patient Assessment of Tolerability Using a 4-Point Scale|Physician Assessment of Tolerability Using a 4-Point Scale|Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks|Patients Who Will Continue Use of Lumigan® After 14 Weeks","Allergan","All","Child, Adult, Older Adult",,"854","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAF/AGN/OPH/GLA/026","March 2010","December 2010","December 2010","June 27, 2012","September 24, 2012","September 24, 2012","Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01628588"
282,"NCT01623479","An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes",,"Completed","Has Results","Eyelash Hypotrichosis","Drug: bimatoprost 0.03%","Percentage of Subjects Satisfied With Latisse®|Number of Applications of Latisse® Per Week|Percentage of Subjects Satisfied Wtih Their Eyelashes","Allergan","All","18 Years and older   (Adult, Older Adult)",,"585","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","GMA-LTS-10-001|CED2009","November 19, 2010","September 1, 2011","September 1, 2011","June 20, 2012","September 19, 2012","April 16, 2019","Santa Ana, California, United States",,"https://ClinicalTrials.gov/show/NCT01623479"
283,"NCT01618266","Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion",,"Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Drug: dexamethasone intravitreal implant","Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in BCVA in the Study Eye Diagnosed With Branch Retinal Vein Occlusion (BRVO)|Change From Baseline in BCVA in the Study Eye Diagnosed With Central Retinal Vein Occlusion (CRVO)|Change From Baseline in BCVA in the Study Eye in Previously Treatment Naïve Patients|Change From Baseline in BCVA in the Study Eye in Patients Previously Treated With Ozurdex®|Change From Baseline in BCVA in the Study Eye in Patients Previously Naïve to Ozurdex® Treatment|Change From Baseline in BCVA in the Study Eye Based on Macular Edema Onset <3 Months|Change From Baseline in BCVA in the Study Eye Based on Macular Edema Onset ≥3 Months|Change From Baseline in BCVA in the Study Eye in Patients Only Treated With Ozurdex®|Change From Baseline in BCVA in the Study Eye in Patients Receiving Ozurdex® and Then Other RVO Treatments|Percentage of Patients With BCVA Improvement of ≥15 Letters From Baseline in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)",,"375","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/RET/009","November 2011","April 2013","October 2014","June 13, 2012","February 11, 2016","March 14, 2016","Paris, France",,"https://ClinicalTrials.gov/show/NCT01618266"
284,"NCT01613248","A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)",,"Completed","Has Results","Migraine","Drug: MK-1602|Drug: Placebo-matching MK-1602|Drug: Rescue medication","Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose|Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose|Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose|Number of Participants With One or More Adverse Events Within 14 Days Post-Dose|Number of Participants Who Discontinued From Study Due to Adverse Events|Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose|Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose|Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose|Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose|Percentage of Participants Reporting SPF 2-48 Hours Post-Dose|Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose|Percentage of Participants Reporting SPR 2-48 Hours Post-Dose|Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose|Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose|Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","834","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1602-006","July 1, 2012","December 1, 2012","December 1, 2012","June 7, 2012","September 30, 2016","January 8, 2019",,,"https://ClinicalTrials.gov/show/NCT01613248"
285,"NCT01608672","Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®",,"Completed","Has Results","Glabellar Lines","Biological: botulinum toxin Type A","Percentage of Participants Mostly or Very Satisfied With Their Glabellar Lines on the Facial Line Satisfaction Questionnaire (FLSQ)|Percentage of Participants Mostly or Very Satisfied With Effectiveness of ≥ 5 Years BOTOX® Treatments Using the Patient Questionnaire|Percentage of Participants Where Physician Was Mostly or Very Satisfied With Effectiveness of ≥ 5 Years BOTOX® Treatments Using the Physician Questionnaire","Allergan","All","18 Years and older   (Adult, Older Adult)",,"207","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","GMA-BTXC-11-004","April 1, 2012","December 31, 2012","December 31, 2012","May 31, 2012","December 23, 2013","April 16, 2019","Coral Gables, Florida, United States|South Yarra, Australia|Sao Paolo, Brazil|Niagara Falls, Ontario, Canada|Cannes, France",,"https://ClinicalTrials.gov/show/NCT01608672"
286,"NCT01608659","An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A",,"Completed","Has Results","Facial Rhytides","Drug: botulinum toxin Type A","Average Total Dose Per Treatment Period|Inter-Injection Interval Duration of Each Treatment Period|Percent of Subjects Reporting Satisfaction With Treatment Effects","Allergan","Female","18 Years and older   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","GMA-BTXC-10-001","April 1, 2011","June 17, 2011","June 17, 2011","May 31, 2012","August 1, 2012","April 17, 2019","Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT01608659"
287,"NCT01605942","A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery",,"Terminated","Has Results","Cataract","Drug: Dexamethasone Drug Delivery System|Drug: Placebo Drug Delivery System","Number of Patients With Clearance of Anterior Chamber Inflammation|Plasma Levels of Dexamethasone","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","206207-027","June 2012","September 2012","September 2012","May 25, 2012","July 1, 2015","July 1, 2015","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01605942"
288,"NCT01603641","BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity",,"Completed","Has Results","Pediatrics|Muscle Spasticity|Cerebral Palsy","Biological: Botulinum Toxin Type A","Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)","Allergan","All","2 Years to 17 Years   (Child)","Phase 3","370","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-112|2012-000084-24","November 5, 2012","August 25, 2018","August 25, 2018","May 22, 2012","August 21, 2019","August 21, 2019","ABS Health, LLC, Pasadena, California, United States|Harrison Clinical Management, Pomona, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Pediatric Neurology, P.A., Orlando, Florida, United States|Children's Healthcare of Atlanta Children's Rehabilitation Associates, Atlanta, Georgia, United States|Shirley Ryan Ability Lab, Chicago, Illinois, United States|Beaumont Children's Hospital Pediatric Research, Royal Oak, Michigan, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Clinical Research Center of New Jersey, Voorhees, New Jersey, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Columbia University Dept. of Rehab. & Regenerative Medicine, New York, New York, United States|OnSite Clinical Solutions, LLC, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine Texas Children's Hospital, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Semmelweis Egyetem- Ortopédiai Klinika Karolina út 27, Budapest, Hungary|Debrecen University Clinical Center, Orthopedic Clinic, Debrecen, Hungary|Istituto IRCCS G. Salini, Genoa, Italy|Daegu Fatima Hospital, Daegu, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Philippine Orthopedic Center, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Philippine Children's Medical Center, Quezon City, Philippines|Uniwersytecki Dzieciecy Szpita, Białystok, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Centrum Rehabilitacji Krok po Kroku, Gdansk, Poland|Specjalistyczny Gabinet Neurologiczny, Krakow, Poland|Centrum Medyczne ""POMOC"", Lodz, Poland|INTERMED, Lublin, Lublin, Poland|CRH ŻAGIEL MED, Lublin, Lublin, Poland|Szpital Wojewodzki Nr 2, Rzeszow, Poland|Poradnia Rehab - Neurologiczneij dla Dzieci I Mlodziezy Aga, Warsaw, Poland|NZOZ Mazowieckie Centrum, Warsaw, Poland|Childrens Republic Hospital, Kazan, Russian Federation|Smolensk Regional Hospital- Regional Budget State Healthcare institution, Smolensk, Russian Federation|Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region, Tyumen, Russian Federation|Maharaj Nakorn ChiangMai Hospital, ChiangMai, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Ankara Diskapi Yildrim Beyazit, Ankara, Turkey|Kocaeli Üniversitesi, Kocaeli, Turkey|Selçuk Üniversitesi, Konya, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01603641/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01603641/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01603641"
289,"NCT01603628","BOTOX® Treatment in Pediatric Lower Limb Spasticity",,"Completed","Has Results","Pediatrics|Muscle Spasticity|Cerebral Palsy","Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo)","Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6|Average Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 6|Goal Attainment Score (GAS) as Assessed by Physician Using a 6-Point Scale|Change From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)","Allergan","All","2 Years to 16 Years   (Child)","Phase 3","384","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-111|2012-000042-35","September 11, 2012","June 28, 2017","June 28, 2017","May 22, 2012","August 14, 2018","August 14, 2018","AMS Neurology, Pasadena, California, United States|Harrison Clinical Management, Pomona, California, United States|Children's Hospital Colorado Dept. of PM&R, Aurora, Colorado, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|New England Center for Clinical Research, Stamford, Connecticut, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Pediatric Neurology, PA, Orlando, Florida, United States|Children's Healthcare of Atlanta Children's Rehabilitation Associates, Atlanta, Georgia, United States|Rehab Institute of Chicago, Chicago, Illinois, United States|The Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Clinical Research Center of New Jersey, Voorhees, New Jersey, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Columbia University Medical Center Dept. of Rehab. & Regenerative Medicine, New York, New York, United States|OnSite Clinical Solutions, LLC, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine Texas Children's Hospital, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Semmelweis Egyetem- Ortopédiai Klinika, Budapest, Hungary|Debrecen University Clinical Center, Orthopedic Clinic, Debrecen, Hungary|Istituto IRCCS G. Gaslini, Genoa, Italy|Daegu Fatima Hospital, Daegu, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Philippine Orthopedic Center, Quezon City, Philippines|St. Luke's Medical Center-Quezon City, Quezon City, Philippines|Philippine Children's Medical Center, Quezon City, Philippines|Uniwersytecki Dzieciecy Szpita, Białystok, Poland|Uni Centrum Kliniczne, Gdansk, Poland|Centrum Rehabilitacji Krok po Kroku, Gdansk, Poland|Specjal. Gabinet Neurologiczny, Krakow, Poland|INTERMED, Lublin, Lublin, Poland|CRH ŻAGIEL MED, Lublin, Lublin, Poland|Szpital Wojewódzki Nr 2, Rzeszów, Poland|Neuro - Dzieci I Mlodziezy Aga, Warsaw, Poland|NZOZ Mazowieckie Centrum, Warsaw, Poland|Childrens Republic Hospital, Kazan, Russian Federation|Smolensk Regional Hospital- Regional Budget State Healthcare institution, Smolensk, Russian Federation|Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region, Tyumen, Russian Federation|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Ankara Diskapi Yildrim Beyazit, Ankara, Turkey|Kocaeli Üniversitesi, Kocaeli, Turkey|Selçuk Üniversitesi, Konya, Turkey","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT01603628/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT01603628/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01603628"
290,"NCT01603615","BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity",,"Completed","Has Results","Pediatrics|Muscle Spasticity|Cerebral Palsy|Stroke","Biological: Botulinum Toxin Type A","Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE)","Allergan","All","2 Years to 17 Years   (Child)","Phase 3","220","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-105|2012-000043-27","October 30, 2012","September 3, 2018","September 3, 2018","May 22, 2012","August 21, 2019","August 21, 2019","ABS Health, LLC, Pasadena, California, United States|Harrison Clinical Management, Pomona, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Children's Hospital Colorado Dept. of PM&R, Aurora, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|New England Center for Clinical Research, Stamford, Connecticut, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Pediatric Neurology, PA, Orlando, Florida, United States|Children's Healthcare of Atlanta Children's Rehabilitation Associates, Atlanta, Georgia, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|The Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Clinical Research Center of New Jersey, Voorhees, New Jersey, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Columbia University Pediatric Physical Medicine & Rehabilitation, Dept. of Rehabilitation & Regenerative Medicine Harkness, New York, New York, United States|OnSite Clinical Solutions, LLC, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine Texas Children's Hospital, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Holland Bloorview Kids Rehab, Toronto, Ontario, Canada|Debrecen University Clinical Center, Orthopedic Clinic, Debrecen, Hungary|Daegu Fatima Hospital, Daegu, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|De La Salle Health Sciences Institute, Cavite, Philippines|Philippine Children's Medical Center, Quezon City, Philippines|Uni Centrum Kliniczne, Gdansk, Poland|Specjal. Gabinet Neurologiczny, Krakow, Poland|Centrum Medyczne ""POMOC"", Lodz, Poland|INTERMED, Lublin, Lublin, Poland|CRH ŻAGIEL MED, Lublin, Lublin, Poland|Centrum Profilatyki I Terapii, Warsaw, Poland|NZOZ Mazowieckie Centrum, Warsaw, Poland|Childrens Republic Hospital, Kazan, Russian Federation|Smolensk Regional Hospital- Regional Budget State Healthcare institution, Smolensk, Russian Federation|Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region, Tyumen, Russian Federation|Siriraj Hospital Dept of Rehabilitation Medicine, Faculty of Medicine, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Kocaeli Üniversitesi, Kocaeli, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01603615/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01603615/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01603615"
291,"NCT01603602","BOTOX® Treatment in Pediatric Upper Limb Spasticity",,"Completed","Has Results","Pediatrics|Muscle Spasticity|Cerebral Palsy|Stroke","Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo)","Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of the Principal Muscle Group at Weeks 4 and 6|Average Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 6|Average Change From Baseline in MAS-B Score of the Finger Flexor Muscle Group at Weeks 4 and 6|Goal Attainment Score (GAS) as Assessed by Physician Using a 6-Point Scale|Change From Baseline in Severity of Spasticity of the Principal Muscle Group (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)","Allergan","All","2 Years to 16 Years   (Child)","Phase 3","235","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-101|2012-000062-38","July 12, 2012","June 29, 2017","July 6, 2017","May 22, 2012","August 14, 2018","August 14, 2018","AMS Neurology, Pasadena, California, United States|Harrison Clinical Management, Pomona, California, United States|Children's Hospital Colorado Dept. of PM&R, Aurora, Colorado, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Pediatric Neurology, PA, Orlando, Florida, United States|Children's Healthcare of Atlanta Children's Rehabilitation Associates, Atlanta, Georgia, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Clinical Research Center of New Jersey, Voorhees, New Jersey, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Columbia University Medical Center Dept. of Rehab. & Regenerative Medicine, New York, New York, United States|OnSite Clinical Solutions, LLC, Charlotte, North Carolina, United States|PMG Research if Charlotte, LLC, Charlotte, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine Texas Children's Hospital, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Holland Bloorview Kids Rehab, Toronto, Ontario, Canada|Debrecen University Clinical Center, Orthopedic Clinic, Debrecen, Hungary|Daegu Fatima Hospital, Daegu, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|De La Salle University Medical Center, Dasmarinas, Cavite, Philippines|Philippine Children's Medical Center, Bagong Pag-asa, Quezon City, Philippines|Uni Centrum Kliniczne, Gdansk, Poland|Specjal. Gabinet Neurologiczny, Krakow, Poland|Centrum Medyczne ""POMOC"", Lodz, Poland|INTERMED, Lublin, Lublin, Poland|CRH ŻAGIEL MED, Lublin, Lublin, Poland|Neuro - Dzieci I Mlodziezy Aga, Warsaw, Poland|NZOZ Mazowieckie Centrum, Warsaw, Poland|Childrens Republic Hospital, Kazan, Russian Federation|Smolensk Regional Hospital- Regional Budget State Healthcare institution, Smolensk, Russian Federation|Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region, Tyumen, Russian Federation|Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Ankara Diskapi Yildrim Beyazit, Ankara, Turkey|Kocaeli Üniversitesi, Kocaeli, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01603602/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01603602/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01603602"
292,"NCT01600729","Reliability of the Facial Wrinkle Scale in Japanese Subjects",,"Completed","Has Results","Facial Rhytides","Drug: No Intervention","Inter-rater Reliability of Assessment of Facial Lines Using the 4-Point Facial Wrinkle Scale (FWS-A)|Intra-rater Reliability of Assessment of Facial Lines Using the 4-Point Facial Wrinkle Scale (FWS-A)","Allergan","All","20 Years to 64 Years   (Adult)",,"66","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","191622-119","June 2012","July 2012","July 2012","May 17, 2012","September 17, 2013","September 30, 2013","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01600729"
293,"NCT01600716","Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)",,"Completed","Has Results","Urinary Incontinence|Multiple Sclerosis|Neurogenic Bladder","Biological: OnabotulinumtoxinA|Drug: Placebo (Normal Saline)","Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes|Change From Baseline in Maximum Cystometric Capacity (MCC)|Change From Baseline in Maximum Detrusor Pressure During the First Involuntary Detrusor Contraction (IDC)|Change From Baseline in Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-117","June 13, 2012","April 4, 2014","March 27, 2015","May 17, 2012","March 22, 2016","April 30, 2019","Mountlake Terrace, Washington, United States|Liege, Belgium|Victoria, British Columbia, Canada|Kitchener, Ontario, Canada|Olomouc, Czechia|Garches, France|Marseille, France|Warsaw, Poland|Porto, Portugal|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01600716"
294,"NCT01594970","A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost 0.01%","Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale|Change From Baseline in Intraocular Pressure (IOP)|Overall Percent Change From Baseline in IOP","Allergan","All","20 Years and older   (Adult, Older Adult)","Phase 4","800","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","APMA-001211","March 2012","January 2013","January 2013","May 9, 2012","January 28, 2014","January 28, 2014","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01594970"
295,"NCT01589510","A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost 0.01% ophthalmic solution","Intraocular Pressure (IOP) at Baseline|IOP at Week 14|Physician Evaluation of IOP Lowering in the Study Eye(s)|Patient Assessment of Tolerability on a 4-Point Scale|Physician Assessment of Tolerability on a 4-Point Scale|Percentage of Patients Who Discontinue Lumigan® 0.01% Prior to 14 Weeks of Treatment|Percentage of Patients Who Continue Lumigan® 0.01% Treatment|Physician Assessment of Patient Compliance Compared to Previous Therapy","Allergan","All","16 Years and older   (Child, Adult, Older Adult)",,"419","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/GLA/034","April 2012","February 2013","February 2013","May 2, 2012","June 13, 2014","June 13, 2014","Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01589510"
296,"NCT01579084","Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea",,"Completed","Has Results","Rosacea|Erythema","Drug: AGN-199201 Formulation A|Drug: AGN-199201 Formulation B|Drug: AGN-199201 Formulation C|Drug: AGN-199201 Vehicle","Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1|Percentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 5|Percentage of Responders With at Least a 2-Grade Decrease From Baseline on CEA|Percentage of Responders With at Least a 2-Grade Decrease From Baseline on SSA","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","199201-001","April 2012","June 2012","June 2012","April 17, 2012","November 15, 2013","November 18, 2019","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01579084"
297,"NCT01575054","BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity",,"Completed","Has Results","Muscle Spasticity","Biological: botulinum toxin Type A|Drug: Normal Saline","Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale|Clinical Global Impression (CGI) of Overall Change by Physician Using a 9-Point Scale|Goal Attainment Scores on the 6-Point Physician-Assessed Goal Attainment Scale (GAS)|Change From Baseline in Average Pain Score While Walking on the 11-Point Pain Scale|Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Optional Muscles Using a 6-Point Scale","Allergan","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","468","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-116|2011-004980-63","May 2012","September 2014","July 2015","April 11, 2012","February 1, 2016","September 28, 2016","Downey, California, United States|Daytona Beach, Florida, United States|Montreal, Quebec, Canada|Prague, Czech Republic|Wiesbaden, Germany|Würzburg, Germany|Budapest, Hungary|Gyeonggi-Do, Korea, Republic of|Krakow, Poland|Krasnoyarsk, Russian Federation|Stoke-on-Trent, England, United Kingdom|Fazakerley, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01575054"
298,"NCT01571557","A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)",,"Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Drug: dexamethasone 700 ug intravitreal implant","Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients With an Increase of ≥2 Lines From Baseline BCVA in the Study Eye|Percentage of Patients With an Increase of ≥3 Lines From Baseline BCVA in the Study Eye|Mean Change From Baseline in Central Retinal Thickness","Allergan","All","18 Years and older   (Adult, Older Adult)",,"573","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/RET/011","April 30, 2012","March 31, 2014","June 30, 2014","April 5, 2012","July 20, 2015","April 19, 2019","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01571557"
299,"NCT01568021","Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)",,"Completed","Has Results","Retinal Vein Occlusion|Macular Edema","Other: No Intervention","Time to First Re-treatment|Change From Baseline in Best Corrected Visual Acuity (BCVA) Score|Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT)","Allergan","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/RET/007","October 2011","November 2013","November 2013","April 2, 2012","February 10, 2015","February 10, 2015","Glostrup, Denmark|Oslo, Norway|Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01568021"
300,"NCT01568008","Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",,"Completed","Has Results","Open-Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.01% ophthalmic solution","Intraocular Pressure (IOP) at Baseline|Intraocular Pressure (IOP) at Week 12|Patient Assessment of Treatment Tolerability Using a 4-Point Scale|Physician Assessment of Treatment Tolerability Using a 4-Point Scale|Physician Reported Reasons for Treatment Discontinuation|Number of Patients Continuing Treatment After 12 Weeks","Allergan","All","18 Years and older   (Adult, Older Adult)",,"933","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/GLA/031","October 2011","September 2012","September 2012","April 2, 2012","September 20, 2013","September 20, 2013","Gent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT01568008"
301,"NCT01566526","Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion",,"Completed","Has Results","Retinal Vein Occlusion|Macular Oedema","Drug: dexamethasone intravitreal implant 0.7 mg","Time to OZURDEX® Re-Injection in the Study Eye|Change From Baseline in Best Corrected Visual Acuity (BCVA) 7 to 12 Weeks Following Last Injection in the Study Eye|Percentage of Patients With an Increase of 2 Lines or More in BCVA From Baseline in the Study Eye|Percentage of Patients With an Increase of 3 Lines or More in BCVA From Baseline in the Study Eye|Change From Baseline in Central Retinal Thickness in the Study Eye by Optical Coherence Tomography (OCT) 7 to 12 Weeks Following Last Injection|Time to Improvement of 2 Lines or More in Best Corrected Visual Acuity (BCVA) in the Study Eye|Time to Improvement of 3 Lines or More in Best Corrected Visual Acuity (BCVA) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)",,"26","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MAF/AGN/OPH/RET/012","March 2012","June 2012","June 2012","March 29, 2012","May 27, 2013","May 27, 2013","Antwerpen, Belgium",,"https://ClinicalTrials.gov/show/NCT01566526"
302,"NCT01547598","Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: travoprost ophthalmic solution 0.004%|Drug: travoprost 0.004% / timolol 0.5% combination ophthalmic solution|Drug: Bimatoprost ophthalmic solution 0.01%","Mean Diurnal Intraocular Pressure (IOP)|Change From Baseline in Mean IOP at Week 12|Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline|Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg|Change From Baseline in Mean IOP at Week 6","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","135","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-LUM-11-020","December 2011","July 2013","July 2013","March 8, 2012","August 15, 2014","August 15, 2014","Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01547598"
303,"NCT01540370","Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Other: No Treatment","Intra- Examiner Agreement in Angle Width by Goniometric Lens|Inter- Examiner Agreement in Angle Width by Goniometric Lens","Allergan","All","18 Years and older   (Adult, Older Adult)",,"102","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","192024-076","February 2012","July 2012","July 2012","February 28, 2012","September 19, 2013","September 19, 2013","Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01540370"
304,"NCT01539577","A Long-Term Safety Study of OZURDEX® in Clinical Practice",,"Completed","No Results Available","Retinal Vein Occlusion|Macular Edema|Uveitis, Posterior","Drug: dexamethasone 700 μg intravitreal implant","Incidence of Patients Reporting Serious Adverse Events|Incidence of Patients Reporting Ophthalmic Adverse Events of Special Interest","Allergan","All","18 Years and older   (Adult, Older Adult)",,"875","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","206207-025","March 2012","March 2016","March 2016","February 27, 2012",,"April 20, 2016","Paris, France|Ulm, Germany|Barcelona, Spain|Bradford, West Yorks, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01539577"
305,"NCT01525173","A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: 0.1% brimonidine tartrate ophthalmic solution|Drug: 0.01% bimatoprost ophthalmic solution|Drug: 0.2% hypromellose lubricant eye drops|Drug: latanoprost 0.005% ophthalmic solution","Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-LUM-11-019","January 2012","October 2012","October 2012","February 2, 2012","December 4, 2013","December 4, 2013","Deerfield Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01525173"
306,"NCT01518270","Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women",,"Completed","Has Results","Health","Other: No treatment","Eyelash Length as Measured by Digital Image Analysis (DIA)|Eyelash Thickness as Measured by Digital Image Analysis (DIA)|Eyelash Darkness as Measured by Digital Image Analysis (DIA)","Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)",,"179","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","GMA-LTS-11-003","December 1, 2011","December 16, 2011","December 16, 2011","January 25, 2012","December 5, 2012","May 1, 2019","Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT01518270"
307,"NCT01518257","Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain",,"Completed","Has Results","Osteoarthritis","Biological: botulinum toxin Type A|Drug: Normal Saline","Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 4|Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 8|Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 12|Change From Baseline in Western Ontario and McMaster Universities Arthritis (WOMAC™) Total Index Score|Change From Baseline in WOMAC Pain Score|Change From Baseline in WOMAC Physical Function Score|Patient Global Impression of Change Score","Allergan","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-102","January 2012","January 2013","January 2013","January 25, 2012","August 7, 2014","August 7, 2014","Aalborg, Denmark",,"https://ClinicalTrials.gov/show/NCT01518257"
308,"NCT01516892","A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine",,"Completed","Has Results","Migraine Disorders","Biological: onabotulinumtoxinA","Change From Baseline in the Frequency of Headache Days|Change From Baseline in Headache Impact Test Questionnaire (HIT-6) Total Score","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","716","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMA-BTX-CM-10-001|The COMPEL Study","December 2011","November 2015","November 2015","January 25, 2012","January 6, 2017","January 6, 2017","Arizona Neurological Institute, Scottsdale, Arizona, United States|The Research Center of Southern California, LLC, Encinitas, California, United States|USC Neurology, Los Angeles, California, United States|UCSF Headache Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Tampa General Hospital, Tampa, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Robbins Headache Clinic, Northbrook, Illinois, United States|Mid-Atlantic Headache Institute, Baltimore, Maryland, United States|Kaiser Permanente Research Office/Neurology Department, Largo, Maryland, United States|Clinvest Research, Springfield, Missouri, United States|Mercy Health Research, St. Louis, Missouri, United States|Renown Institute for Neurosciences, Reno, Nevada, United States|Dent Neurologic Institute, Amherst, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Headache Wellness Center, Greensboro, North Carolina, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Wesley Headache Clinic, Cordova, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Dr. Joseph Frasca, Adelaide, Australia|Dr. Con Yiannikas, Burwood, Australia|Associate Professor Richard Stark, Melbourne, Australia|Richmmond Neurology, Richmond, Australia|Associate Professor John O'Sullivan, Spring Hill, Australia|Hallym University Sacred Heart Hospital, Dongan-gu, Anyang, Anyang Gyeonggi-do, Korea, Republic of|Uijeongbu St. Mary's Hospital, Uijeongbu Si, Gyeonggi-Do, Korea, Republic of|Kangbuk Samsung Hospital, Jongno-Gu, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Jongno-Gu, Seoul, Korea, Republic of|Seoul Eulji Hospital, Nowon-Gu, Seoul, Korea, Republic of|Yonsei University Dental Hospital, Seodaemum-Gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01516892"
309,"NCT01492400","Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema",,"Completed","Has Results","Macular Edema","Drug: dexamethasone Intravitreal Implant|Drug: ranibizumab","Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye|Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","206207-024","March 9, 2012","February 13, 2014","February 13, 2014","December 15, 2011","January 29, 2015","April 17, 2019","Arlington, Texas, United States|Brussels, Belgium|Copenhagen, Denmark|Glostrup, Denmark|Paris, France|Ahaus, Germany|Tel Aviv, Israel|Udine, Italy|Nijmegen, Netherlands|Coimbra, Portugal|Pretoria, South Africa|Barcelona, Spain|London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01492400"
310,"NCT01489670","Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost 0.01% ophthalmic solution","Intraocular Pressure (IOP) at Baseline|Intraocular Pressure (IOP) at Week 12|Physician Evaluation of Efficacy Using a 5-Point Scale|Patient Evaluation of Tolerability of Treatment Using a 4-Point Scale|Physician Evaluation of Tolerability of Treatment|Physician Reported Reasons for Early Discontinuation of Treatment|Number of Patients Continuing Treatment After 12 Weeks","Allergan","All","18 Years and older   (Adult, Older Adult)",,"387","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/OPH/GLA/032","September 2011","March 2013","March 2013","December 12, 2011","March 28, 2014","March 28, 2014","Bülach, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01489670"
311,"NCT01475253","Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis",,"Terminated","Has Results","Interstitial Cystitis","Drug: Lidocaine Releasing Intravesical System - LiRIS®|Other: LiRIS Placebo|Procedure: Sham Cystoscopy Procedure","Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale (VAS) at Day 7|Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale (VAS) at Day 14|Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale (VAS) ay Day 28|Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale (VAS) at Day 42|Percentage of Responders Using the Global Response Assessment (GRA)|Change From Baseline in Urinary Urgency as Assessed by VAS|Change From Baseline in Voiding Frequency|Change Form Baseline in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) Score|Change From Baseline in Interstitial Cystitis Problem Index (ICPI) Score|Percentage of Participants With Change From Baseline in Cystoscopic Examination Findings","Allergan|TARIS Biomedical, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAR-100-201","November 2011","December 2012","December 2012","November 21, 2011","September 21, 2015","September 21, 2015","Clinical Trials of Arizona, Glendale, Arizona, United States|Citrus Valley Medical Research, Inc, Glendora, California, United States|Stanford University Department of Urology, Stanford, California, United States|Genitourinary Surgical Consultants, Denver, Colorado, United States|Women's Health Specialty Care, Farmington, Connecticut, United States|Grove Hill Clinical Research, New Britain, Connecticut, United States|Manatee Medical Research Institute, LLC, Bradenton, Florida, United States|North Idaho Urology, Coeur D'Alene, Idaho, United States|Idaho Urologic Center, Meridian, Idaho, United States|First Urology, Jeffersonville, Indiana, United States|Regional Urology LLC, Shreveport, Louisiana, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Bay State Clinical Trials, Inc, Watertown, Massachusetts, United States|Female Pelvic Medicine & Urogynecology, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|CRC of Jackson and Southeast Urogynecology, Jackson, Mississippi, United States|Sheldon Freedman, MD Ltd, Las Vegas, Nevada, United States|Arthur Smith Institute for Urology, New Hyde Park, New York, United States|University of Rochester, Department of Urology, Rochester, New York, United States|Alliance Urology Specialists, Greensboro, North Carolina, United States|Wake Forest University Health Sciences Medical Center, Winston-Salem, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Penn. Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Urology Ambulatory Care, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Integrity Medical Research, Mountlake Terrace, Washington, United States|Pacific Urological Research, Victoria, British Columbia, Canada|Centre for Applied Urologic Research/Kingston General Hospital, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01475253"
312,"NCT01470118","A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis",,"Completed","Has Results","Conjunctivitis, Allergic","Drug: alcaftadine 0.25% ophthalmic solution|Drug: olopatadine 0.2% ophthalmic solution|Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%","Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16|Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24|Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24|Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24|Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24|Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24|Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24|Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24","Allergan","All","10 Years and older   (Child, Adult, Older Adult)","Phase 4","127","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GMA-LAS-011-001","October 2011","December 2011","December 2011","November 11, 2011","February 21, 2013","February 21, 2013","Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01470118"
313,"NCT01459588","Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",,"Completed","Has Results","Dry Eye Syndromes","Drug: Carboxymethylcellulose Based Eye Drop Formulation A|Drug: Carboxymethylcellulose Based Eye Drop Formulation B|Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Drug: Carboxymethylcellulose Based Lubricant Eye Drops","Change From Baseline in Ocular Surface Disease Index© Questionnaire Score|Change From Baseline in Tear Break-up Time|Change From Baseline in Corneal Staining|Change From Baseline in Conjunctival Staining|Change From Baseline in Schirmer Test Results","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10146X-001","October 1, 2011","February 15, 2012","February 15, 2012","October 25, 2011","March 14, 2013","April 16, 2019","Petaluma, California, United States",,"https://ClinicalTrials.gov/show/NCT01459588"
314,"NCT01448525","Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence",,"Completed","Has Results","Hypotrichosis","Drug: bimatoprost ophthalmic solution 0.03%|Drug: bimatoprost vehicle solution","Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall|Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score","Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-LTS-11-002","October 2011","April 2012","April 2012","October 7, 2011","May 22, 2013","May 22, 2013","Coral Gables, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01448525"
315,"NCT01445626","A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)",,"Completed","Has Results","Macular Edema","Drug: dexamethasone intravitreal implant 0.7 mg","Time to OZURDEX® Re-injection|Change From Baseline in Best Corrected Visual Acuity (BCVA) 7 to 12 Weeks Following the Last Injection|Percentage of Patients With an Increase of 2 Lines or More in BCVA|Percentage of Patients With an Increase of 3 Lines or More in BCVA|Change From Baseline in Central Retinal Thickness by Optical Coherence Tomography (OCT) 7 to 12 Weeks Following the Last Injection|Time to Improvement of 2 Lines or More in BCVA|Time to Improvement of 3 Lines or More in BCVA","Allergan","All","18 Years and older   (Adult, Older Adult)",,"87","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MAF/AGN/OPH/RET/010","October 2011","January 2012","January 2012","October 4, 2011","February 18, 2013","February 18, 2013","Muenster, Germany",,"https://ClinicalTrials.gov/show/NCT01445626"
316,"NCT01432379","BOTOX® Prophylaxis in Patients With Chronic Migraine",,"Completed","Has Results","Migraine Disorders","Biological: botulinum toxin Type A","Incidence Rate of Dysphagia|Incidence Rate of Intractable Migraine","Allergan","All","18 Years and older   (Adult, Older Adult)",,"1168","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","191622-110","September 9, 2011","May 12, 2015","May 12, 2015","September 13, 2011","December 12, 2016","January 8, 2019","Munich, Germany|Oviedo, Spain|Stockholm, Sweden|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01432379"
317,"NCT01427751","Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion",,"Completed","Has Results","Retinal Vein Occlusion|Macular Edema","Drug: dexamethasone intravitreal implant|Biological: ranibizumab","Change From Baseline in Best Corrected Visual Acuity (BCVA)|Change From Baseline in Central Retinal Subfield Thickness Using Optical Coherence Tomography (OCT)|Percentage of Patients With 15-or-More Letter Improvement in BCVA|Percentage of Patients With a 15-or-More Letter Decrease in BCVA|Time to BCVA Improvement of 15-or-More Letters|Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)|Percentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MAF-AGN-OPH-RET-004|2010-023900-29","October 11, 2011","November 4, 2014","November 4, 2014","September 2, 2011","February 15, 2016","April 18, 2019","Paris, France|Munich, Germany|Tel Aviv, Israel|Milan, Italy|Madrid, Spain|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01427751"
318,"NCT01426113","A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma",,"Terminated","Has Results","Glaucoma","Drug: bimatoprost ophthalmic solution formulation A|Drug: timolol ophthalmic solution|Drug: bimatoprost vehicle","Change From Baseline in Intraocular Pressure (IOP) in the Study Eye","Allergan","All","2 Months to 17 Years   (Child)","Phase 3","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","192024-056","September 2011","October 2014","October 2014","August 31, 2011","October 2, 2015","October 2, 2015","Louisville, Kentucky, United States|Amiens, France|Milan, Italy|Parma, Italy|Seoul, Korea, Republic of|Makati, Philippines|Taguig, Philippines|Taipei, Taiwan|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01426113"
319,"NCT01425320","Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne",,"Withdrawn","No Results Available","Acne Vulgaris","Drug: Fixed Combination dapsone/adapalene Formulation A Gel|Drug: Fixed Combination dapsone/adapalene Formulation B Gel|Drug: dapsone 5% gel|Drug: adapalene 0.3% gel","Plasma Levels of Dapsone|Plasma Levels of Adapalene|Local Dermal Tolerability Rating Using a 4-Point Scale","Allergan","All","18 Years to 64 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","225678-003","January 2013","June 2013","June 2013","August 30, 2011",,"November 19, 2012",,,"https://ClinicalTrials.gov/show/NCT01425320"
320,"NCT01412086","Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale",,"Completed","Has Results","Healthy Volunteers","Drug: No Intervention","Inter-rater Reliability of Physician Raters Using the Global Eyebrow Assessment (GEBA) Scale|Intra-rater Reliability of Physician Raters Using the Global Eyebrow Assessment (GEBA) Scale","Allergan","All","18 Years and older   (Adult, Older Adult)",,"112","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","192024-068","August 2011","September 2011","September 2011","August 9, 2011","October 29, 2012","October 29, 2012","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01412086"
321,"NCT01411696","Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)",,"Completed","Has Results","Retinal Vein Occlusion|Macular Edema","Drug: dexamethasone intravitreal implant 0.7 mg","Change From Baseline in Best Corrected Visual Acuity (BCVA) 4 to 20 Weeks Following the Last OZURDEX® (Dexamethasone Intravitreal Implant) Injection|Percentage of Participants With an Increase of 2 Lines or More in BCVA|Percentage of Participants With an Increase of 3 Lines or More in BCVA|Change From Baseline in Central Retinal Thickness by Optical Coherence Tomography (OCT) 4 to 20 Weeks After Each Injection","Allergan","All","18 Years and older   (Adult, Older Adult)",,"289","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GMA-OZU-09-011|GMA-320","July 2011","March 2012","March 2012","August 8, 2011","April 16, 2013","April 16, 2013","San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01411696"
322,"NCT01397409","Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)",,"Completed","Has Results","Age-related Macular Degeneration","Drug: AGN-150998|Drug: ranibizumab|Other: Sham Injection","Highest Tolerated Dose (HTD) of AGN-150998|Stage 1: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye|Stage 2: Time Between Baseline Treatment and Recurrence of Active Disease|Stage 3: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Stage 2: Time Between Second Treatment and Recurrence of Active Disease|Stage 2: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye|Stage 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Stage 3: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye|Stage 3: Change From Baseline in BCVA in the Study Eye","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","150998-001|2011-002526-43|REACH Study","September 1, 2011","March 31, 2014","April 30, 2014","July 19, 2011","June 18, 2015","April 16, 2019","Phoenix, Arizona, United States|Sydney, New South Wales, Australia|Vienna, Austria|Créteil, France|Bonn, Germany|Tel Aviv, Israel|Firenze, Italy|Binningen, Switzerland",,"https://ClinicalTrials.gov/show/NCT01397409"
323,"NCT01391312","Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines",,"Completed","Has Results","Glabellar Frown Lines","Biological: botulinum toxin Type A|Drug: normal saline (placebo)","Percentage of Participants With Improvement in Subject Global Assessment of Change at Day 30|Percentage of Facial Wrinkle Scale Responders at Maximum Attempted Muscle Contraction at Day 30|Percentage of Facial Wrinkle Scale Responders at Maximum Attempted Muscle Contraction at Day 60","Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-BTXC-11-001","June 2011","October 2011","October 2011","July 12, 2011","September 25, 2012","September 25, 2012","East Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01391312"
324,"NCT01391299","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines",,"Completed","Has Results","Facial Rhytides|Glabellar Frown Lines","Biological: botulinum toxin Type A|Drug: Normal Saline","Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum Eyebrow Elevation|Percentage of Participants Achieving a Score of None or Mild by Subject-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum Eyebrow Elevation|Percentage of Participants Achieving Satisfied or Very Satisfied by Subject Assessment of Satisfaction of Appearance of Forehead Lines|Percentage of Participants With a ≥1 Grade Improvement From Baseline by Investigator-Assessed FWS in Forehead Lines at Rest|Percentage of Participants With a ≥1 Grade Improvement From Baseline by Subject-Assessed FWS in Forehead Lines at Rest","Allergan","All","19 Years and older   (Adult, Older Adult)","Not Applicable","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-BTXC-10-002","June 1, 2011","October 18, 2011","February 28, 2012","July 12, 2011","November 26, 2012","April 17, 2019","Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01391299"
325,"NCT01391286","Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis",,"Completed","Has Results","Eyelash Hypotrichosis","Drug: bimatoprost solution 0.03%|Drug: bimatoprost vehicle solution","Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)|Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)|Change From Baseline in Eyelash Thickness as Measured by DIA|Change From Baseline in Eyelash Darkness as Measured by DIA","Allergan","All","20 Years and older   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-067","July 1, 2011","May 25, 2012","May 25, 2012","July 12, 2011","July 9, 2013","July 8, 2019","Chiba, Japan",,"https://ClinicalTrials.gov/show/NCT01391286"
326,"NCT01391273","Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis",,"Completed","Has Results","Eyelash Hypotrichosis","Drug: bimatoprost solution 0.03%|Drug: bimatoprost vehicle solution","Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)|Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)|Change From Baseline in Eyelash Thickness as Measured by DIA|Change From Baseline in Eyelash Darkness as Measured by DIA","Allergan","All","20 Years and older   (Adult, Older Adult)","Phase 3","173","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-059","July 1, 2011","May 19, 2012","May 19, 2012","July 12, 2011","July 9, 2013","July 8, 2019","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01391273"
327,"NCT01389232","The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery in Europe",,"Completed","No Results Available","Soft Tissue Support and Repair","Device: SeriScaffold® Surgical Scaffold","Investigator satisfaction following use of SeriScaffold® surgical scaffold evaluated using an 11-point scale questionnaire","Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SURE-002","June 2011","August 2013","February 2015","July 8, 2011",,"May 12, 2015","Dusseldorf, Germany|Milan, Italy|Barcelona, Spain|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01389232"
328,"NCT01387074","Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity",,"Completed","Has Results","Muscle Spasticity","Biological: botulinum toxin Type A","Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Elbow at Baseline|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Elbow at Week 24|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Wrist at Baseline|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Wrist at Week 24|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Fingers at Baseline|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Fingers at Week 24|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Thumb at Baseline|Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Thumb at Week 24","Allergan","All","18 Years and older   (Adult, Older Adult)",,"108","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/NS/SPA/018","June 2011","January 2013","January 2013","July 4, 2011","February 3, 2014","February 3, 2014","Itzehoe, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT01387074"
329,"NCT01384214","Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia",,"Completed","No Results Available","Torticollis","Biological: botulinum toxin Type A","Change from Baseline in Oropharyngeal Swallow Efficiency (OPSE)|Toronto Western Spasmodic Torticollis Scale (TWSTRS) Total Score|Physician Assessment of Cervical Dystonia Severity|Global Assessment of Benefit by Physician|Global Assessment of Benefit by Patient|Patient Visual Analog Assessment of Pain","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedAff-BTX-0716","October 2008","June 2009","June 2009","June 29, 2011",,"June 29, 2011","Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT01384214"
330,"NCT01383681","Retrospective Study of Patients With Spasticity in the Spanish Population",,"Completed","Has Results","Muscle Spasticity","Other: No treatment","Physician Assessment of Spasticity","Allergan","All","18 Years and older   (Adult, Older Adult)",,"235","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","MAF/AGN/NS/SPA/019","February 2011","October 2012","October 2012","June 28, 2011","November 14, 2013","November 14, 2013","Mataro, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01383681"
331,"NCT01325350","Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss",,"Completed","Has Results","Alopecia|Baldness","Drug: bimatoprost Formulation A|Drug: bimatoprost Formulation B|Drug: bimatoprost Formulation C|Drug: bimatoprost vehicle solution|Drug: minoxidil 2% solution","Change From Baseline in Target Area Hair Count (TAHC)|Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score|Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score|Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score|Change From Baseline in Target Area Hair Width (TAHW)|Change From Baseline in Target Area Hair Darkness (TAHD)","Allergan","Female","18 Years to 59 Years   (Adult)","Phase 2","306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-058|2011-000380-27","June 2011","July 2012","September 2012","March 29, 2011","April 9, 2014","April 9, 2014","Portland, Oregon, United States|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01325350"
332,"NCT01325337","Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia",,"Completed","Has Results","Alopecia|Alopecia, Androgenetic|Baldness","Drug: bimatoprost Formulation A|Drug: bimatoprost Formulation B|Drug: bimatoprost Formulation C|Drug: bimatoprost vehicle solution|Drug: minoxidil 5% solution","Change From Baseline in Target Area Hair Count (TAHC)|Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score|Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score|Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score|Change From Baseline in Target Area Hair Width (TAHW)|Change From Baseline in Target Area Hair Darkness (TAHD)","Allergan","Male","18 Years to 49 Years   (Adult)","Phase 2","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-057|2011-000379-15","June 2011","August 2012","September 2012","March 29, 2011","April 10, 2014","April 10, 2014","Portland, Oregon, United States|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01325337"
333,"NCT01319773","Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye",,"Completed","Has Results","Dry Eye Syndromes","Drug: cyclosporine ophthalmic emulsion Formulation A|Drug: cyclosporine ophthalmic emulsion Formulation B|Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|Drug: cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B","Concentration of Cyclosporine Measured in Blood at Day 1 in the Parallel-Group Phase (PGP)|Number of Subjects Who Reported Ocular Symptoms During the Parallel-Group Phase (PGP)|Number of Eyes With Ocular Symptoms Post-Dose During the Paired-Eye Phase (PEP) at Day 1","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","192371-021","November 2010","January 2011","January 2011","March 22, 2011","March 2, 2012","September 7, 2015","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01319773"
334,"NCT01319318","Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy",,"Completed","Has Results","Vitrectomy","Procedure: Pars Plana Vitrectomy","Percentage of Participants With Vitreous Cell Count of 0","Allergan","All","18 Years and older   (Adult, Older Adult)",,"25","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GMA-OZU-10-017","March 2011","June 2012","June 2012","March 21, 2011","July 2, 2013","July 2, 2013","San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01319318"
335,"NCT01298700","Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost 0.01% ophthalmic solution|Drug: bimatoprost 0.03% ophthalmic solution","Percentage of Participants Reporting One or More Treatment-Related Ocular Surface Adverse Events|Percentage of Participants Reporting One or More Treatment-Related Ocular Surface Adverse Events Excluding ""Conjunctival Hyperemia""","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","806","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-054|2010-023917-68","May 31, 2011","December 6, 2016","December 6, 2016","February 18, 2011","September 17, 2018","September 17, 2018","UZ Leuven, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|University Hospital Brno, Brno, Czechia|Eye Clinic, Frydstejn, Czechia|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|Clinique Montcelli, Marseille, France|Universitat Augenklinik, Freiburg, Germany|Univ. des Saarlandes, Homburg Saar, Germany|Johannes Gutenberg Univ Mainz, Mainz, Germany|Thelen Private Practice, Műnster, Germany|Augenzentrum Siegburg, Siegburg, Germany|Department of Ophthalmology, University of Tuebingen, Tubingen, Germany|Budapest Retina Associates Kft., Budapest, Hungary|University Med. School of Debrecen, Debrecen, Hungary|Josa Andras Oktatokorhaz, Nyíregyháza, Hungary|University of Szeged Szent-Gyorgyi Albert Clinical Center, Szeged, Hungary|Carmel Medical Center, Haifa, Israel|Glaucoma Service The Rabin Medical Center, Petach Tiqva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel-Hashomer, Israel|Azienda Ospedaliera Universitaria, Catania, Italy|Azlenda Ospedaliero Universitaria Careggi Viale, Firenze, Italy|Istituto Scientifico San Raffaele, Milano, Italy|Dipartimento di Scienze Otorino-Odonto-Oftalmologiche e Cerv, Parma, Italy|Fondazione G.B. Bietti per l'Oftalmologia I.R.C.C.S., Rome, Italy|EuroMedic Kliniki Specjalistyczne, Katowice, Poland|ZOZ OKO- TEST Poradnia Okulistyczna, Nowy Targ, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu, Poznan, Poland|Samodzielny Publiczny Szpital, Szczecin, Poland|Osrodek Badan Klinicznych Euromedis Sp. z o.o., Szczecin, Poland|Samodzielny Szpital Kliniczny, Warszawa, Poland|Akad. Med. w Warszawie - Ketedra I Klin. Okulistki Wyzialu L, Warszawa, Poland|Centro de Ojos de La Coruña, A Coruña, Spain|Hospital de Torrevieja, Alicante, Spain|Instituro Condal de Oftalmologia, Barcelona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|Valles Oftalmologia Recerca, Barcelona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Instituto oftalmologico Fernandez Vega, Oviedo, Spain|Fundacion Oftalmologica Del Mediterraneo, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Birmingham & Midland Eye Center, Birmingham, United Kingdom|Huntingdon Glaucoma Diagnostic & Research Centre, Huntingdon, United Kingdom|Western Eye Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Norfolk and Norwich Hospital, Norwich, United Kingdom|University Hospital Nottingham, Nottingham, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01298700"
336,"NCT01294384","Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease",,"Completed","Has Results","Dry Eye Syndromes","Drug: carboxymethylcellulose sodium based New Eye Drop Formulation 1|Drug: carboxymethylcellulose sodium based New Eye Drop Formulation 2|Drug: carboxymethylcellulose sodium based Eye Drops","Change From Baseline in Ocular Surface Disease Index© (OSDI) Score|Change From Baseline in Visual Analog (VAS) Symptom Scale: Dryness|Percentage of Participants Much Better or Better in Near Visual Acuity (Low Contrast)|Percentage of Participants Much Better or Better in Near Visual Acuity (High Contrast)|Change From Baseline in Tear Break-Up Time (TBUT)|Change From Baseline in Corneal Staining|Change From Baseline in Conjunctival Staining|Change From Baseline in Schirmer Test","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10078X-001","May 1, 2011","September 25, 2012","September 25, 2012","February 11, 2011","November 25, 2013","April 16, 2019","Randwick, New South Wales, Australia|St. John's, Newfoundland and Labrador, Canada",,"https://ClinicalTrials.gov/show/NCT01294384"
337,"NCT01291108","Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: AGN-210669|Drug: bimatoprost|Drug: bimatoprost vehicle","Change From Baseline in Average Eye IOP|Change From Baseline in Worse Eye IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","210669-013","April 2011","October 2011","October 2011","February 8, 2011","November 6, 2013","November 6, 2013","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01291108"
338,"NCT01284166","Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Withdrawn","No Results Available","Glaucoma|Ocular Hypertension","Drug: dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution","Change from Baseline in Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Dorzo-Brimo-Timo/2010","July 2013","May 2014","May 2014","January 26, 2011",,"July 18, 2013",,,"https://ClinicalTrials.gov/show/NCT01284166"
339,"NCT01271452","Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines",,"Completed","Has Results","Glabellar Lines","Biological: botulinum toxin type A","Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial Wrinkle Scale (FWS)|Number of Subjects With a Treatment Response at Day 84 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS|Number of Subjects With a Treatment Response at Day 98 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS|Number of Subjects With a Treatment Response at Day 112 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS|Number of Subjects With a Treatment Response at Day 28 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS|Number of Subjects With a Treatment Response at Day 84 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS|Number of Subjects With a Treatment Response at Day 98 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS|Number of Subjects With a Treatment Response at Day 112 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","224","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAF/AGN/Facial/011|2010-021401-20","September 2010","January 2011","April 2011","January 6, 2011","January 16, 2012","January 29, 2019","Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT01271452"
340,"NCT01258309","Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Conjunctivitis, Allergic","Drug: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|Drug: olopatadine hydrochloride 0.1% ophthalmic solution","Ocular Itching|Hyperemia|Chemosis|Ocular mucous discharge","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Olo-keto/2009","December 2010","January 2011","January 2011","December 10, 2010",,"January 25, 2012","Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT01258309"
341,"NCT01258205","Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects",,"Completed","No Results Available","Crohn's Disease","Drug: AMG 139","Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139|Characterization of the pharmacokinetic (PK) parameters (AUCtau, Cmax, tmax) for AMG 139 after multiple IV and SC dose administrations in healthy subjects and subjects with mild to severe CD","Allergan","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20090519","February 28, 2011","February 18, 2015","February 18, 2015","December 10, 2010",,"May 19, 2017","Comprehensive Clinical Research, Berlin, New Jersey, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States|Virginia Commonwealth University, Richmond, Virginia, United States|QPharm Pty Limited, Herston, Queensland, Australia|Clinical Medical and Analytical eXellence CMAX, Adelaide, South Australia, Australia|Centre for Clinical Studies (Alfred), Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01258205"
342,"NCT01253902","Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost ophthalmic solution 0.01%|Drug: travoprost ophthalmic solution 0.004%|Drug: latanoprost ophthalmic solution 0.005%","Mean Conjunctival Hyperemia at Week 12|Mean Corneal Staining With Fluorescein at Week 12|Mean Tear Break Up Time (TBUT) at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-LUM-09-014","December 2010","October 2011","October 2011","December 6, 2010","November 7, 2012","November 7, 2012","Rogers, Arkansas, United States|Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01253902"
343,"NCT01252147","Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment Scale for Assessment of Overall Eyelash Prominence",,"Completed","Has Results","Healthy Volunteers","Other: No treatment","Overall Inter-Rater Reliability of Assessing Overall Eyelash Prominence Using the Japanese Global Eyelash Assessment Scale (GEA-J) at Day 1|Overall Intra-Rater Reliability of Assessing Overall Eyelash Prominence Using the Japanese Global Eyelash Assessment Scale (GEA-J) at Day 1","Allergan","All","20 Years and older   (Adult, Older Adult)",,"68","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","192024-066","December 2010","December 2010","December 2010","December 2, 2010","September 28, 2012","September 28, 2012","Ueno, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01252147"
344,"NCT01243567","Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated",,"Completed","Has Results","Glaucoma, Open-Angle","Drug: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Drug: latanoprost 0.005% ophthalmic solution","Change From Baseline in Average Intraocular Pressure (IOP)|Change From Baseline IOP|Percentage of Patients Reaching a Predefined Target Pressure Threshold|Absolute Difference Between Patient's Highest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading|Absolute Difference Between Patient's Lowest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading","Allergan","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MAF-AGN-OPH-GLA-010|2009-012799-28","June 1, 2010","February 14, 2012","February 14, 2012","November 18, 2010","February 26, 2013","April 18, 2019","Coimbra, Portugal|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01243567"
345,"NCT01241240","Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution","Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12|Change From Baseline in Mean Worse Eye IOP|Mean Worse Eye IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-063","March 2011","September 2013","September 2013","November 16, 2010","September 10, 2014","September 10, 2014","Bogotá, Colombia|Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT01241240"
346,"NCT01231334","A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone plus Adapalene|Drug: Clindamycin/benzoyl peroxide plus Adapalene","Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12|Change From Baseline in Global Acne Assessment Score (GAAS) at Week 12|Percentage of Participants at Week 12 Having at Least a One Point Decrease in Overall Disease Severity|Percent Change From Baseline in Inflammatory Lesion Counts at Week 12|Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12|Percent Change From Baseline in Total Lesion Count at Week 12|Percentage of Participants Demonstrating a ≥ 1 Category Increase in Tolerability From Baseline at Week 12","Allergan","Female","18 Years to 40 Years   (Adult)","Phase 4","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-ACZ1001","August 2010","June 2011","June 2011","November 1, 2010","July 27, 2012","July 27, 2012","Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01231334"
347,"NCT01229462","Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution|Drug: brimonidine tartrate ophthalmic solution|Drug: timolol ophthalmic solution|Other: fixed combination vehicle","Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","190342-035","October 2010","September 2011","September 2011","October 27, 2010","September 14, 2012","September 14, 2012","Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01229462"
348,"NCT01229423","Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects",,"Completed","Has Results","Eyelash Hypotrichosis","Drug: bimatoprost 0.03%","Change From Baseline in Eyelash Length at Week 20|Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20|Change From Baseline in Eyelash Thickness at Week 20|Change From Baseline in Eyelash Intensity (Darkness) at Week 20|Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20|Percentage of Subjects Satisfied With Treatment at Week 20","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 4","62","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAT-KOR-01","November 2009","June 2010","October 2010","October 27, 2010","January 23, 2012","January 29, 2019","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01229423"
349,"NCT01229410","Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy",,"Completed","Has Results","Vitrectomy","Drug: 400 µg Brimonidine Tartrate Implant|Drug: 200 µg Brimonidine Tartrate Implant","Highest Vitreous Humor Level of Brimonidine in the Study Eye|Highest Aqueous Humor Level of Brimonidine in the Study Eye|Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","190342-036","December 2010","May 2011","October 2011","October 27, 2010","August 5, 2013","August 5, 2013","Salt Lake City, Utah, United States|Prague, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01229410"
350,"NCT01224015","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines",,"Completed","Has Results","Facial Rhytides|Crow's Feet Lines|Glabellar Lines","Drug: normal saline|Biological: onabotulinumtoxinA 44 U|Biological: onabotulinumtoxinA 24 U","Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","684","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-104|2010-021271-83","May 2011","October 2011","February 2012","October 19, 2010","February 25, 2014","February 25, 2014","Newport Beach, California, United States|Vancouver, British Columbia, Canada|Antibes, France|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01224015"
351,"NCT01217606","Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution","Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test|Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure|Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","185","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-062","January 2011","September 2014","June 2015","October 8, 2010","November 9, 2015","December 20, 2016","São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01217606"
352,"NCT01216943","Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution","Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","126","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","192024-049","November 2010","August 2012","August 2012","October 7, 2010","September 19, 2013","September 19, 2013","Coimbatore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT01216943"
353,"NCT01215786","Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|Drug: timolol ophthalmic solution 0.5%|Drug: AGN-207281 vehicle ophthalmic solution (Placebo)","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14|Mean Concentration of AGN-207281 in Plasma at Day 7|Mean Concentration of AGN-207281 in Plasma at Day 14","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","207281-004","October 2010","December 2010","December 2010","October 7, 2010","January 16, 2012","August 17, 2015","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01215786"
354,"NCT01197495","Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation",,"Completed","Has Results","Lip Augmentation","Device: hyaluronic acid gel","Percentage of Subjects With ≥1-Point Improvement on the Investigator Assessed 5-point Lip Fullness Scale 2 (LFS2)|Percentage of Subjects With ≥1-Point Improvement on the Perioral Line (POL) Severity Scale|Percentage of Oral Commissures With ≥1-Point Improvement on the Oral Commissures Severity (OCS) Scale|Percentage of Subjects Achieving Their Personal Treatment Goal of Overall Lip Fullness|Duration Effect of Treatment on Lip Fullness","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","JULIDO-002","August 1, 2010","June 19, 2014","June 15, 2015","September 9, 2010","June 7, 2016","April 16, 2019","Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01197495"
355,"NCT01192568","Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder",,"Recruiting","No Results Available","Overactive Detrusor|Neurogenic Bladder","Drug: Oxybutynin","Percentage of catheterizations without a leaking accident.|Average volume of urine collected per catheterization (for Pre-Amendment 3 population only)|Average volume of urine collected at first (morning awakening) catheterization|Average number of catheterizations per day|Average volume of urine collected per catheterization","Allergan","All","3 Years to 16 Years   (Child)","Phase 4","58","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OG09002","May 2, 2011","June 18, 2020","June 18, 2020","September 1, 2010",,"May 14, 2019","Loma Linda University Health, Loma Linda, California, United States|Atlantic Urology Medical Group, Long Beach, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Urology Associates, Englewood, Colorado, United States|Augusta University, Augusta, Georgia, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Albany Medical College, Albany, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Associated Urologists of North Carolina, Raleigh, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Texas Children's Hospital - BCM, Houston, Texas, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Centro de Investigaciones Clinicas, San Jorge Children's Hospital, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01192568"
356,"NCT01189760","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines",,"Completed","Has Results","Facial Rhytides|Crow's Feet Lines|Glabellar Lines","Biological: onabotulinumtoxinA 24 U|Biological: onabotulinumtoxinA 44 U|Drug: normal saline","Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile|Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines|Percentage of Participants With a ≥ 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Maximum Smile|Percentage of Participants With a ≥ 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Rest|Subject Global Assessment of Change in Crow's Feet Lines (SGA-CFL) Score|Percentage of Participants Who Judged Themselves in a Younger Self-Perception of Age Category Than at Baseline|Percentage of Participants With a ≥ 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 2 at Day 30|Percentage of Participants With a ≥ 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 5 at Day 30|Percentage of Participants With a ≥ 3-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 8 at Day 30","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","917","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-099","September 1, 2010","March 1, 2011","September 1, 2011","August 27, 2010","December 3, 2013","April 16, 2019","Newport Beach, California, United States|Vancouver, British Columbia, Canada|Antibes, France|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01189760"
357,"NCT01189747","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines",,"Completed","Has Results","Lateral Canthus Rhytides|Crow's Feet Lines","Biological: onabotulinumtoxinA|Drug: normal saline","Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile|Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator's Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines|Percentage of Participants With a ≥ 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Maximum Smile|Percentage of Participants With a ≥ 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Rest|Subject Global Assessment of Change in Crow's Feet Lines (SGA-CFL) Score|Percentage of Participants Who Judged Themselves in a Younger Self-Perception of Age Category Than at Baseline|Percentage of Participants With a ≥ 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 2 at Day 30|Percentage of Participants With a ≥ 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 5 at Day 30|Percentage of Participants With a ≥ 3-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 8 at Day 30","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","446","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-098","October 1, 2010","April 1, 2011","July 1, 2011","August 27, 2010","December 3, 2013","May 7, 2019","Newport Beach, California, United States|Aalst, Belgium|Vancouver, British Columbia, Canada|Sutton Coldfield, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01189747"
358,"NCT01189279","Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia",,"Completed","Has Results","Alopecia|Alopecia, Androgenetic|Baldness","Drug: bimatoprost Formulation A|Drug: bimatoprost Formulation B|Drug: bimatoprost Formulation C","Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost|Maximum Plasma Level (Cmax) Following Multiple Doses of Bimatoprost|Percentage of Patients With Clinically Significant Electrocardiogram (ECG) Findings|Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Patient Assessment|Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Dermatologist Assessment","Allergan","All","18 Years to 64 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-053","October 2010","January 2011","February 2011","August 26, 2010","August 30, 2013","August 30, 2013","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01189279"
359,"NCT01178827","Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial",,"Completed","Has Results","Overactive Bladder","Drug: trospium chloride|Drug: oxybutynin IR|Drug: oxybutynin IR placebo","Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose|Cerebral Spinal Fluid Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose|Plasma Levels of Sanctura XR® at Day 10 Post-dose|Plasma Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose|Change From Baseline in Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) up to Day 10|Change From Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10|Change From Baseline in Total Recall Score as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) up to Day 10|Change From Baseline in Delayed Recall Score as Measured by the BVMT-R up to Day 10","Allergan","All","60 Years and older   (Adult, Older Adult)","Phase 4","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MA-SXR-09-005","August 2010","March 2011","March 2011","August 10, 2010","August 16, 2012","February 26, 2016","Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01178827"
360,"NCT01177098","Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution|Drug: bimatoprost/timolol fixed combination ophthalmic solution","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12|Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2|Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6|Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12|Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12|Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-050|2010-021507-24","October 2010","February 2012","February 2012","August 6, 2010","March 12, 2013","March 29, 2013","Artesia, California, United States|Sydney, New South Wales, Australia|Brno, Czech Republic|Leipzig, Germany|Budapest, Hungary|Tel Aviv, Israel|Saint-Petersburg, Russian Federation|Valencia, Spain|London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01177098"
361,"NCT01170884","Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|Drug: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops","Mean Diurnal Intraocular Pressure (IOP) at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-COM-09-013","December 2009","September 2010","September 2010","July 27, 2010","January 12, 2012","April 24, 2019","Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01170884"
362,"NCT01161771","Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye",,"Completed","Has Results","Dry Eye","Procedure: Cataract Surgery and Limbal relaxing incision","The Percentage of Subjects at Month 3 With Corneal Sensitivity < 50 Millimeters (mm) at Any of the Locations Measured|Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score at Month 3|Change From Baseline in Corneal Staining at Month 3|Change From Baseline in Conjunctival Staining at Month 3|Change From Baseline in Tear Break-Up Time at Month 3|Change From Baseline in Schirmer's Test at Month 3","Allergan","All","50 Years and older   (Adult, Older Adult)",,"32","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MA-RES-09-004","May 2010","December 2010","December 2010","July 14, 2010","July 26, 2012","July 26, 2012","Long Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT01161771"
363,"NCT01157377","Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence",,"Completed","Has Results","Urinary Bladder, Overactive","Drug: AGN-214868|Drug: AGN-214868 placebo","Change From Baseline in the Daily Average Number of Micturition (Urination) Episodes","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","214868-004","October 2010","February 2013","May 2013","July 7, 2010","March 19, 2014","March 19, 2014","Richmond, Virginia, United States|Lyon, France|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01157377"
364,"NCT01157364","Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: bimatoprost 20 µg generation 2|Drug: bimatoprost 15 µg generation 2|Drug: bimatoprost 10 µg generation 2|Drug: bimatoprost 6 µg generation 2|Drug: bimatoprost 15 µg generation 1|Drug: bimatoprost 10 µg generation 1|Drug: bimatoprost 0.03%","Change from Baseline in Cycle 1 Time-Matched Intraocular Pressure (IOP) in the Study Eye for Generation 2 Groups|Change from Baseline in Cycle 1 Mean Diurnal IOP in the Study Eye for Generation 2 Groups|Time to Escape Treatment|Time to Second Injection","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-041D|2011-005091-42","September 23, 2010","July 27, 2016","August 4, 2017","July 7, 2010",,"January 16, 2018","Sall Research Medical Center, Artesia, California, United States|Shiley Eye Center, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, California, United States|Doheny Eye Institute, Los Angeles, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Shasta Eye Medical Group, Inc., Redding, California, United States|Grutzmacher and Lewis, Inc., Sacramento, California, United States|Pacific Eye Surgeons, San Luis Obispo, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Specialty Eye Care, Parker, Colorado, United States|The Eye Associates of Manatee, Bradenton, Florida, United States|Emory University, The Emory Eye Center, Atlanta, Georgia, United States|Coastal Research Associates, Roswell, Georgia, United States|Springfield Clinic, Springfield, Illinois, United States|Glaucoma Consultants, Baltimore, Maryland, United States|Tufts Medical Center/New England Eye Center, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Clinical Eye Research of Boston/ Charles River Eye Associates, Winchester, Massachusetts, United States|Moyes Eye Center, Kansas City, Missouri, United States|Northern New Jersey Eye Institute PA, South Orange, New Jersey, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Glaucoma Associates of NY, New York, New York, United States|Rochester Ophthalmological Group PC, Rochester, New York, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|Cornerstone Eye Care, High Point, North Carolina, United States|James D. Branch, MD, Winston-Salem, North Carolina, United States|Legacy Good Samaritan - Devers Eye Institute, Portland, Oregon, United States|Scott & Christie and Associates, Cranberry Township, Pennsylvania, United States|Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States|Keystone Research LTD, Austin, Texas, United States|Glaucoma Associates of TX, Dallas, Texas, United States|R and R Eye Research, San Antonio, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Focus Clinical Research, Salt Lake City, Utah, United States|Spokane Eye Clinical Research, Spokane, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Melbourne Eye Specialists, Fitzroy, Australia|Eye Associates, Sydney New South Wales, Australia|UZ Leuven, Campus St. Rafael, Dienst Oogheelkunde, Belgium|Universidade Federal de São Paulo/Escola Paulista de Medicina/Hospital São Paulo Departamento de Oftalmologia, Sao Paulo, Brazil|A.C. S. Crichton Prof. Corp, Calgary, Alberta, Canada|Eye Care Center, Halifax, Nova Scotia, Canada|Anjema Eye Institute, Chatham, Ontario, Canada|Galen Eye Centre, Kingston, Ontario, Canada|Ivey Eye Institute, London, Ontario, Canada|Institut de l'œil des Laurentides, Boisbriand, Quebec, Canada|Clarity Eye Institute, Vaughan, Canada|Staedtisches Klinikum Department of Opthalmology, Karlsruhe, Germany|Kaplan Medical Center, Rohovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Sam Rothberg Glaucoma Center,, Tel-Hashomer, Israel|Asian Eye Institute, Makati City, Philippines|Pacific Eye and Laser Institute (PELI), Makati City, Philippines|St. Lukes Medical Center-Quezon City, Metro Manila, Philippines|Singapore National Eye Center, Singapore, Singapore|Valles Oftalmologia Recerca, Hospital General de Catalunya,, Sant Cugat, Spain|Fundacion Oftalmologica Del Mediterraneo, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01157364"
365,"NCT01151904","Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients",,"Terminated","Has Results","Glaucoma, Angle-Closure","Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|Drug: latanoprost","Change From Baseline in Intraocular Pressure (IOP)|Change From Baseline in IOP|Percentage of Responders With an IOP Reduction ≥20% From Baseline","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","17","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-COM004","November 2009","February 2012","February 2012","June 29, 2010","February 6, 2013","February 6, 2013","Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01151904"
366,"NCT01150565","Safety Study of LiRIS in Interstitial Cystitis (IC) Patients",,"Completed","No Results Available","Interstitial Cystitis","Drug: LiRIS low dose and LiRIS high dose","Cystoscopic examination|Bladder pain","Allergan|TARIS Biomedical, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","TAR-100-103","July 2010","September 2011","September 2011","June 25, 2010",,"November 25, 2014","Dr. Steinhoff Clinical Research, Victoria, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax Infirmary, Halifax, Nova Scotia, Canada|Centre for Applied Urological Research, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01150565"
367,"NCT01129531","A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia",,"Completed","Has Results","Neuralgia, Postherpetic","Drug: AGN-214868|Drug: Placebo to AGN-214868","Change From Baseline in the Average Pain Intensity Score at Week 12|Change From Baseline in Area of Spontaneous Pain|Change From Baseline in Area of Allodynia|Change From Baseline in Evoked Pain Score in the Area of Allodynia","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","214868-002","June 2010","October 2011","January 2012","May 24, 2010","November 15, 2013","November 15, 2013","Orlando, Florida, United States|Brno, Czech Republic|Kiel, Germany|Katowice, Poland",,"https://ClinicalTrials.gov/show/NCT01129531"
368,"NCT01122511","Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration",,"Terminated","Has Results","Subfoveal Choroidal Neovascularization|Age-Related Maculopathy","Drug: 700 ug dexamethasone|Biological: ranibizumab|Other: sham","Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12|The Percentage of Patients Having 15 or More Letter Improvement From Baseline in Best Corrected Visual Acuity at Month 12|Change From Baseline in Central Retinal Thickness at Month 12 as Measured by Optical Coherence Tomography|Change From Baseline in Area Leakage of Choroidal Neovascularization at Month 12 as Measured by Fluorescein Angiography","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","206207-021","August 2010","May 2011","May 2011","May 13, 2010","September 5, 2012","September 5, 2012","Fort Myers, Florida, United States|Abilene, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01122511"
369,"NCT01110499","Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Ocular Hypertension|Primary Open-Angle Glaucoma","Drug: AGN-210961 Formulation 1|Drug: AGN-210961 Formulation 2|Drug: AGN-210961 Formulation 3|Drug: AGN-210961 Formulation 4|Drug: AGN-210961 Formulation 5|Drug: AGN-210961 Formulation 6|Drug: AGN-210961 Formulation 7|Drug: bimatoprost ophthalmic solution 0.03%","Part 1: Change From Baseline in Intraocular Pressure (IOP)|Part 2: Change From Baseline in Average Eye Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","210961-002","June 2010","May 2011","June 2011","April 26, 2010","August 5, 2014","August 5, 2014","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01110499"
370,"NCT01109056","Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium",,"Completed","Has Results","Pterygium","Drug: cyclosporine ophthalmic emulsion 0.05%|Drug: Vehicle","Number of Pterygium Hyperemia Responders at Week 16|Change From Baseline in Severity Grade of Pterygium Hyperemia at Week 16|Change From Baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire Score at Week 16","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192371-019","June 2010","May 2011","June 2011","April 22, 2010","June 25, 2012","June 25, 2012","Glendale, California, United States|Randwick, New South Wales, Australia|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01109056"
371,"NCT01107392","Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia",,"Completed","Has Results","Benign Prostatic Hyperplasia","Drug: botulinum toxin Type A|Drug: Normal saline","Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12|Change From Baseline in the Total International Prostate Symptom Score (IPSS)|Change From Baseline in Peak Urine Flow Rate|Duration of Effect","Allergan","Male","45 Years and older   (Adult, Older Adult)","Phase 2","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-100","August 1, 2010","March 16, 2012","June 8, 2012","April 21, 2010","April 4, 2014","May 3, 2019","Newport Beach, California, United States|Surrey, British Columbia, Canada|Praha, Czechia|Paris, France|Munich, Germany|Seoul, Korea, Republic of|Manila, Philippines|Poznan, Poland",,"https://ClinicalTrials.gov/show/NCT01107392"
372,"NCT01099774","Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution|Drug: Bimatoprost 0.03% Ophthalmic Solution","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12|Average Eye IOP at Week 12|Average Eye IOP at Week 6|Average Eye IOP at Week 2","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","597","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-048","May 1, 2010","April 29, 2011","April 29, 2011","April 8, 2010","April 27, 2012","April 17, 2019","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01099774"
373,"NCT01094093","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: AMG 139","Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139|Characterization of the pharmacokinetics (PK) of AMG 139|Psoriasis Activity and Severity Index (PASI) scores (Part B only)","Allergan","All","18 Years to 55 Years   (Adult)","Phase 1","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20080767","April 11, 2010","July 26, 2011","July 26, 2011","March 26, 2010",,"May 19, 2017","Nucleus Network Limited, Melbourne, Victoria, Australia|Clinical Medical and Analytical eXcellence (CMAX), Adelaide, Australia|QPharm Pty Limited, Herston, Australia|Auckland Clinical Studies Ltd, Grafton, New Zealand",,"https://ClinicalTrials.gov/show/NCT01094093"
374,"NCT01089751","Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily",,"Completed","Has Results","Overactive Bladder","Drug: trospium chloride|Drug: placebo","Percentage of Patients Continent (PPC)|Change From Baseline in Continent Days Per Week (CDW)|Change From Baseline in Nocturic Toilet Voids|Change From Baseline in Urgency-Related Toilet Voids|Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)|Change From Baseline in Voided Volume|Change From Baseline in Urgency Severity|Change From Baseline in Urgency Urinary Incontinence (UUI)","Allergan","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","322","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-SXR-09-004","March 2010","June 2012","June 2012","March 19, 2010","September 26, 2013","September 26, 2013","La Mesa, California, United States",,"https://ClinicalTrials.gov/show/NCT01089751"
375,"NCT01086761","Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration",,"Terminated","Has Results","Wet Age-Related Macular Degeneration","Biological: MP0112","Maximal Tolerated Dose (MTD) Following a Single Injection|Percentage of Participants With Stable or Improved Best Corrected Visual Acuity (BCVA)|Change From Baseline in Central Area Retinal Thickness|Area of Leakage as Measured by Fluorescein Angiography|Area of Lesion as Measured by Fluorescein Angiography|Maximum Serum Concentration (Cmax) of MP0112 at Day 3|Number of Participants With Positive Binding Anti-MP0112 Antibodies","Allergan|Molecular Partners AG","All","50 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP0112-CP01","March 2010","November 2010","November 2010","March 15, 2010","May 12, 2014","May 12, 2014","Fakultni Nemocnice Brno, Brno, Czech, Czech Republic|Fakultni Nemocnice Olomouc, Olomouc, Czech, Czech Republic|Ustrendi Vojenska Nemocnice, Praha, Czech, Czech Republic|Hopital Intercommunual de Creteil, Creteil, France|Centre Rabelais, Lyon, France|Centre Paradis-Monticelli, Marseille, France|Hopitaux Universitaires, Strasbourg, France|Inselspital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT01086761"
376,"NCT01080209","Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System",,"Completed","Has Results","Patients Who Participated in an Intravitreal Brimo PS DDS® Study","Drug: Brimo PS DDS®|Other: Sham","Number of Patients With No Visible Implants in the Study Eye|Number of Patients With Vision Loss in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","215","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)","190342-033D","February 2010","February 2014","February 2014","March 4, 2010","February 20, 2015","February 20, 2015","Artesia, California, United States|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|Brno, Czech Republic|Paris, France|Karlsruhe, Germany|New Delhi, India|Tel Aviv, Israel|Udine, Italy|Seoul, Korea, Republic of|Makati, Philippines|Coimbra, Portugal|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01080209"
377,"NCT01068964","Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Open-angle Glaucoma|Ocular Hypertension","Drug: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|Drug: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution","The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4","Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","235","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-052","February 1, 2010","September 1, 2010","September 1, 2010","February 17, 2010","January 20, 2012","April 17, 2019","Beijing, China",,"https://ClinicalTrials.gov/show/NCT01068964"
378,"NCT01064882","Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence",,"Completed","Has Results","Eyelash Hypotrichosis","Drug: bimatoprost ophthalmic solution 0.005%|Drug: bimatoprost ophthalmic solution 0.015%|Drug: bimatoprost ophthalmic solution 0.03%","Change From Baseline in Eyelash Length at Month 3|Change From Baseline in Upper Eyelash Thickness at Month 3|Change From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3|Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3|Change From Baseline in Overall Eyelash Satisfaction at Month 3|Change From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3|Treatment Satisfaction Questionnaire Score at Month 3","Allergan","Female","30 Years to 55 Years   (Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-051","March 2010","July 2010","July 2010","February 9, 2010","December 9, 2011","December 9, 2011","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01064882"
379,"NCT01042678","Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema",,"Terminated","Has Results","Diabetic Macular Edema","Biological: MP0112","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Best-Corrected Visual Acuity (BCVA)|Change From Baseline in Foveal Thickness as Measured by Optical Coherence Tomography (OCT)|Serum Levels of MP0112|Aqueous Humor Levels of MP0112|Number of Participants With Positive Binding Anti-MP0112 Antibodies","Allergan|Molecular Partners AG","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP0112-CP02","February 2010","December 2010","December 2010","January 5, 2010","May 13, 2014","May 13, 2014","Wilmer Eye Institute, Baltimore, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Retina Research Center, Austin, Texas, United States|Retina Consultants of Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01042678"
380,"NCT01029535","Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency",,"Completed","Has Results","Mid-face Volume Deficiency","Device: Cross-linked hyaluronic acid gel","Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 4|Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 8|Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Physician's Global Aesthetic Improvement Scale (GAIS) at Week 4|Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Physician's Global Aesthetic Improvement Scale (GAIS) at Week 8|Percentage of Participants a ≥1 Point Improvement From Baseline in the Physician's Mid-face Volume Deficit Scale (MFVDS) at Week 4|Percentage of Participants a ≥ 1 Point Improvement From Baseline in the Physician's Mid-face Volume Deficit Scale (MFVDS) at Week 8|Percentage of Participants Who Maintained Their Week 8 MFVDS Scores at Week 52|Percentage of Participants Who Maintained Their Week 8 MFVDS Scores at Week 78|Percentage of Participants Who Maintained Their Week 8 MFVDS Scores at Week 104|Percentage of Participants Who Maintained Their Week 8 Subject's GAIS Scores at Week 52|Percentage of Participants Who Maintained Their Week 8 Subject's GAIS Scores at Week 78|Percentage of Participants Who Maintained Their Week 8 Subject's GAIS Scores at Week 104|Percentage of Participants Who Maintained Their Week 8 Physician's GAIS Scores at Week 52|Percentage of Participants Who Maintained Their Week 8 Physician's GAIS Scores at Week 78|Percentage of Participants Who Maintained Their Week 8 Physician's GAIS Scores at Week 104|Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Investigator's Wrinkle Assessment Scale (WAS)|Change From Baseline in the MFVDS Score|Physician Assessment of Global Aesthetic Improvement Score (GAIS)|Subject's Assessment of Global Aesthetic Improvement Score (GAIS)|Change From Baseline in the Subject's Self-Perception of Age (SPA)|Percentage of Participants Satisfied or Very Satisfied With the Treatment","Allergan","All","30 Years to 60 Years   (Adult)","Not Applicable","103","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VOL-AP01","January 2009","April 2011","October 2011","December 10, 2009","February 20, 2013","March 9, 2016","Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT01029535"
381,"NCT01027650","Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)",,"Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Drug: AGN208397 intravitreal injection|Drug: dexamethasone intravitreal implant","Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 1|Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 2|Change From Baseline at Month 1 in Best Corrected Visual Acuity (BCVA) in the Study Eye During Stage 1|Change From Baseline at Month 1 in BCVA in the Study Eye During Stage 2|Change From Baseline at Month 12 in Retinal Thickness in the Study Eye During Stage 1|Change From Baseline at Month 12 in Retinal Thickness in the Study Eye During Stage 2|Change From Baseline at Month 12 in BCVA in the Study Eye During Stage 1|Change From Baseline at Month 12 in BCVA in the Study Eye During Stage 2","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","208397-001","March 2010","April 2012","February 2013","December 8, 2009","April 29, 2014","April 29, 2014","Phoenix, Arizona, United States|East Melbourne, Victoria, Australia|London, Ontario, Canada|Tel Aviv, Israel|Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01027650"
382,"NCT01023841","Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children",,"Completed","Has Results","Eyelash Hypotrichosis|Alopecia Areata","Drug: bimatoprost ophthalmic solution 0.03%|Drug: Vehicle Sterile Solution","Percentage of Participants With Adverse Events|Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score|Change From Baseline Upper Eyelash Length as Measured by Digital Image Analysis (DIA)|Change From Baseline in Upper Eyelash Thickness as Measured by DIA|Change From Baseline in Upper Eyelash Darkness as Measured by DIA","Allergan","All","5 Years to 17 Years   (Child)","Phase 4","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-040","June 1, 2010","November 2, 2012","November 30, 2012","December 2, 2009","September 13, 2013","April 17, 2019","Newport Beach, California, United States|São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01023841"
383,"NCT01010282","Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects",,"Completed","Has Results","Dry Eye Syndrome","Drug: Glycerin and Polysorbate 80 based artificial tear|Drug: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|Drug: Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear","Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90|Change From Baseline in the Ocular Surface Disease Index (OSDI) Total Score at Day 90|Change From Baseline in Tear Break-up Time (TBUT) at Day 90|Change From Baseline in Corneal Staining at Day 90|Change From Baseline in Conjunctival Staining Severity Score at Day 90","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","AG9965-002","November 2009","April 2010","April 2010","November 10, 2009","December 13, 2011","August 17, 2015","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01010282"
384,"NCT01001195","Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: AGN-210669 ophthalmic solution, 0.1%|Drug: AGN-210669 ophthalmic solution, 0.075%|Drug: AGN-210669 ophthalmic solution, 0.05%|Drug: bimatoprost ophthalmic solution 0.03%","Change From Baseline in Average Eye Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","210669-010","November 2009","April 2010","April 2010","October 26, 2009","October 18, 2013","October 18, 2013","Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01001195"
385,"NCT00991458","Study of Cyclosporine in Post-LASIK Patients",,"Completed","Has Results","Laser In Situ Keratomileusis","Drug: Cyclosporine 0.010% eye drops|Drug: Cyclosporine 0.005% eye drops|Drug: Placebo (Vehicle for Cyclosporine)","Time to Cure|Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment|Percentage of Patients With Cumulative Poor Vision|Worst Outcome Post-LASIK Surgery in Reading Speed Assessment","Allergan","All","21 Years to 50 Years   (Adult)","Phase 2","621","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192371-018","October 2009","April 2011","April 2011","October 8, 2009","July 11, 2013","July 11, 2013","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00991458"
386,"NCT00987727","Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye",,"Completed","Has Results","Dry Eye Syndromes|Keratoconjunctivitis Sicca","Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|Drug: sodium hyaluronate 0.18% (VISMED® Multi)","Change From Baseline in Global Ocular Staining Score at Day 35|Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MAF-AGN-OPH-DE-011","November 2009","July 2010","September 2010","October 1, 2009","September 21, 2011","September 21, 2011","Paris, France",,"https://ClinicalTrials.gov/show/NCT00987727"
387,"NCT00986401","Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects",,"Completed","Has Results","Healthy","Drug: Trospium Chloride (Sanctura XR®)|Drug: Metformin hydrochloride (Glucophage®)","Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®|Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®","Allergan","All","18 Years to 45 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","MA-SXR-09-002","October 2009","November 2009","November 2009","September 30, 2009","December 19, 2011","December 19, 2011","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00986401"
388,"NCT00978042","Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation",,"Completed","Has Results","Mid-facial Volume Deficit Related to Aging","Device: Juvéderm® VOLUMA XC","Responder Rate Based on Improvement in Score on Validated 6-point Mid-Face Volume Deficit Scale (MFVDS)|Duration of Treatment Effect|Responder Rate Based on Improvement in Score on Global Aesthetic Improvement Scale (GAIS)|Responder Rate Based on Improvement in Score on MFVDS by Facial Region","Allergan","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","345","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","VOLUMA-002","August 2009","November 2012","April 2014","September 16, 2009","February 13, 2014","November 3, 2015","Los Angeles, California, United States|Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00978042"
389,"NCT00972374","Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function",,"Completed","Has Results","Rhegmatogenous Macula-off Retinal Detachment","Drug: 400 ug Brimonidine Implant|Drug: 200 ug Brimonidine Implant|Other: Sham (no implant)","Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","190342-031D","November 2009","October 2010","July 2011","September 4, 2009","April 24, 2013","April 24, 2013","Abilene, Texas, United States|New Delhi, India|Tel Aviv, Israel|Seoul, Korea, Republic of|Makati, Philippines|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00972374"
390,"NCT00958035","Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis",,"Completed","Has Results","Hypotrichosis","Drug: bimatoprost ophthalmic 0.03% solution|Drug: vehicle sterile solution (placebo)","Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-039","November 2009","July 2010","August 2010","August 13, 2009","January 5, 2012","January 5, 2012","Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00958035"
391,"NCT00938704","Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms",,"Completed","Has Results","Dry Eye Syndromes","Drug: carboxymethylcellulose 0.5% +glycerin 0.9%|Drug: sodium hyaluronate 0.18%","Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2|Change From Baseline in Tear Breakup Time (TBUT) at Week 2|Change From Baseline in Corneal Staining at Week 2|Change From Baseline in Conjunctival Staining (Temporal) at Week 2|Change From Baseline in Conjunctival Staining (Nasal) at Week 2","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MA-OPT-09-002","June 2009","June 2009","June 2009","July 14, 2009","October 31, 2011","October 31, 2011","Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00938704"
392,"NCT00932477","Safety and Tolerability of Artificial Tears in Dry Eye Subjects",,"Completed","Has Results","Dry Eye Syndrome","Drug: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|Drug: Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|Drug: Glycerin and Polysorbate 80 based artificial tear","Tolerability Questionnaire Mean Scores at 1 Week|Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week|Best-Corrected Visual Acuity (BCVA) Status at 1 Week|The Number of Ophthalmic Adverse Events at 1 Week","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","AG9965-001","August 2009","September 2009","September 2009","July 3, 2009","December 13, 2011","August 26, 2015","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00932477"
393,"NCT00932022","Trospium Chloride XR in Obese Female Patients With Overactive Bladder",,"Completed","Has Results","Obesity|Overactive Bladder|Incontinence","Drug: Trospium Chloride, Extended Release (XR)|Other: placebo","Percent Change From Baseline in Urinary Urgency Incontinence (UUI)|Percent Change From Baseline in Urgency Severity Associated With Toilet Voids|Percent Change From Baseline in Voided Volume|Percent Change From Baseline in Over Active Bladder (OAB)-Symptom Composite Score|Percent Change From Baseline in Percentage of Patients Continent","Allergan","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","127","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MA-SXR-09-003|Sanctura XR obesity OAB Trial","July 2009","December 2011","December 2011","July 2, 2009","January 21, 2013","January 21, 2013","La Mesa, California, United States",,"https://ClinicalTrials.gov/show/NCT00932022"
394,"NCT00915525","Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",,"Completed","Has Results","Overactive Bladder|Urinary Incontinence","Biological: botulinum toxin Type A","Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes|Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)|Percentage of Patients With a Positive Response on the 4-Point TBS|Change From Study Baseline in the Daily Average Number of Micturition Episodes|Change From Study Baseline in the Urinary Incontinence-Specific Quality of Life (I-QOL) Questionnaire Total Summary Score|Change From Study Baseline in the I-QOL Questionnaire Total Summary Score|Change From Study Baseline in the King's Health Questionnaire (KHQ) Role Limitations Domain|Change From Study Baseline in the KHQ Role Limitations Domain|Change From Study Baseline in the KHQ Social Limitations Domain|Change From Study Baseline in Daily Frequency of Urgency Episodes","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","829","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-096","February 1, 2010","August 5, 2014","August 5, 2014","June 8, 2009","December 18, 2015","April 30, 2019","Newport Beach, California, United States|Gent, Belgium|Victoria, British Columbia, Canada|Prague, Czechia|Tubingen, Germany|Warsaw, Poland|Moscow, Russian Federation|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00915525"
395,"NCT00910845","Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",,"Completed","Has Results","Overactive Bladder","Biological: onabotulinumtoxinA|Drug: normal saline","Change From Baseline in Number of Daily Episodes of Urinary Incontinence|Change From Baseline in Number of Daily Micturition Episodes|Change From Baseline in Volume Voided Per Micturition","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","557","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-095","September 2009","July 2011","July 2011","June 1, 2009","March 5, 2013","March 5, 2013","Newport Beach, California, United States|Victoria, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00910845"
396,"NCT00910520","Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",,"Completed","Has Results","Overactive Bladder","Biological: onabotulinumtoxinA|Drug: normal saline","Change From Baseline in Number of Daily Episodes of Urinary Incontinence|Change From Baseline in Number of Daily Micturition Episodes|Change From Baseline in Volume Voided Per Micturition","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","548","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-520","September 2009","August 2011","August 2011","June 1, 2009","March 5, 2013","March 5, 2013","Laguna Hills, California, United States|Gent, Belgium|Prague, Czech Republic|Tubingen, Germany|Warsaw, Poland|Moscow, Russian Federation|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00910520"
397,"NCT00907426","Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin",,"Completed","Has Results","Hypotrichosis","Drug: Bimatoprost 0.03% solution|Drug: Vehicle solution","Percentage of Treatment Responders at Month 4|Change From Baseline in Upper Eyelash Length at Month 4|Change From Baseline in Average Progressive Upper Eyelash Thickness at Month 4|Change From Baseline in Upper Eyelash Darkness at Month 4","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","368","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-038","August 2009","November 2010","May 2011","May 22, 2009","September 19, 2012","September 19, 2012","San Diego, California, United States|London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00907426"
398,"NCT00894517","A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia",,"Completed","Has Results","Benign Prostatic Hyperplasia","Biological: Botulinum Toxin Type A|Drug: Placebo (saline)","Percent Change in Total Sperm Count Per Ejaculate|Change From Baseline in Log Transformed Sperm Concentration|Change From Baseline in Ejaculatory Volume|Change From Baseline in Total Sperm Motility|Change From Baseline in Normal Sperm Morphology","Allergan","Male","45 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-091","August 2009","June 2012","August 2012","May 7, 2009","September 30, 2013","September 30, 2013","Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00894517"
399,"NCT00884585","Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis",,"Completed","Has Results","Atopic Conjunctivitis","Drug: Cyclosporine Vehicle|Drug: Cyclosporine 0.010%","Percentage of Treatment Responders|Percentage of Punctate Corneal Staining Responders|Percentage of Patients With an Improvement in the Composite Symptom Score|Percentage of Patients With an Improvement in the Punctate Corneal Staining Score","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192371-016","May 2009","October 2010","July 2011","April 21, 2009","November 5, 2012","November 5, 2012","Bakersfield, California, United States|Randwick, New South Wales, Australia|Ottawa, Ontario, Canada|Prague, Czech Republic|Dijon, Burgundy, France|Munich, Bavaria, Germany|Bangalore, Karnataka, India|Tel Aviv, Israel|Rome, Italy|Wellington, New Zealand|Valladolid, Spain|Newcastle-upon-tyne, Tyne and Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00884585"
400,"NCT00876447","A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis",,"Completed","Has Results","Overactive Bladder","Biological: Botulinum Toxin Type A 300U|Biological: Botulinum Toxin Type A 200U","Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes|Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score|Change From Study Baseline in Volume Per Void","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","397","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-094","January 1, 2009","June 12, 2013","September 4, 2013","April 6, 2009","June 13, 2014","May 1, 2019","Middlebury, Connecticut, United States|Randwick, Australia|Innsbruck, Austria|Ghent, Belgium|Rio de Janeiro, Brazil|Victoria, British Columbia, Canada|Ostrava, Czechia|Salouel, France|Kiel, Germany|Florence, Italy|Amsterdam, Netherlands|Epsom, New Zealand|Poznan, Poland|Porto, Portugal|Moscow, Russian Federation|Singapore, Singapore|Presov, Slovakia|Pretoria, South Africa|Tenerife, Spain|Hualien, Taiwan|Kiev, Ukraine|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00876447"
401,"NCT00874887","A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms",,"Completed","Has Results","Anti-biotic Resistance","Drug: moxifloxacin 0.5% HCI ophthalmic solution|Drug: gatifloxacin ophthalmic solution 0.3%","Percentage of Subjects With Strain Resistance of the Conjunctiva as Determined by Minimum Inhibitory Concentration (MIC) at Day 14|Mutant Prevention Concentration (MPC) of the Conjunctiva at Day 14|Minimum Inhibitory Concentration 50 (MIC50) at Day 14|Minimum Inhibitory Concentration 90 (MIC90) at Day 14|Minimum Inhibitory Concentration (MIC) Range at Day 14","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 4","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","GMA-ZYM-08-001","March 2009","September 2009","October 2009","April 3, 2009","December 19, 2011","December 19, 2011","Minneapolis, Minnesota, United States|Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00874887"
402,"NCT00863551","Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial",,"Completed","Has Results","Elderly|Pharmacokinetics|Overactive Bladder","Drug: Trospium Chloride","Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5|Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose|Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose|Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose|Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose","Allergan","All","65 Years to 75 Years   (Older Adult)","Phase 4","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-SXR-09-001|SMART Trial","April 2009","August 2009","August 2009","March 18, 2009","December 19, 2011","February 26, 2016","Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00863551"
403,"NCT00856414","Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines",,"Completed","Has Results","Skin Aging","Biological: botulinum toxin Type A","The First Visit Onset of Efficacy as Measured by Physician Assessment|The First Visit Onset of Efficacy as Measured by Subject Assessment|Average Subject Assessment Score in Improvement of Appearance of Frown Lines|Change From Baseline in Patient Satisfaction as Measured by Facial Line Outcome (FLO) Questionnaire Score|Percentage of Patients Reporting Self-Perception of Age (SPA)","Allergan","Female","35 Years to 55 Years   (Adult)","Phase 4","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-BTX-0806","March 2009","April 2009","April 2009","March 5, 2009","December 12, 2011","January 29, 2019","West Palm Beach, Florida, United States|Livonia, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00856414"
404,"NCT00836017","CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy",,"Completed","Has Results","Cervical Dystonia","Other: No Intervention","Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score|Percentage of Participants With Cervical Dystonia (CD) Severity Mild|Percentage of Participants With Improvement in Clinicians Global Impression of Change|Percentage of Participants With Improvement in the Patient Global Impression of Change|Pain Numeric Rating Scale Score","Allergan","All","Child, Adult, Older Adult",,"1046","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MedAff BTX-0718","January 2009","August 2013","August 2013","February 4, 2009","July 17, 2014","July 17, 2014","Springfield, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00836017"
405,"NCT00835198","Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone; Tretinoin|Drug: Tretinoin","Change From Baseline in Inflammatory Lesion Counts (Papules, Pustules and Nodules) at Week 12|Change From Baseline in Investigator Global Assessment at Week 12|Change From Baseline in Overall Disease Severity at Week 12|Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-ACZ0801","December 2008","August 2009","August 2009","February 3, 2009","October 31, 2011","October 31, 2011","Strongsville, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00835198"
406,"NCT00834210","Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone|Drug: Tazarotene","Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12|Change From Baseline in Investigator Global Assessment at Week 12|Change From Baseline in Overall Disease Severity at Week 12|Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-ACZ0802","December 2008","September 2009","September 2009","February 3, 2009","October 31, 2011","October 31, 2011","Fremont, California, United States",,"https://ClinicalTrials.gov/show/NCT00834210"
407,"NCT00834171","A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin",,"Completed","Has Results","Ocular Hypertension","Drug: Loteprednol etabonate ophthalmic suspension 0.5%|Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).","Mean Elevated Intraocular Pressure (IOP) During Treatment","Allergan","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","MA-RES-08-003","January 2009","December 2009","December 2009","February 3, 2009","September 26, 2011","September 26, 2011","Maclean, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00834171"
408,"NCT00833235","A Natural History Study of Patients With Dry Eye",,"Completed","No Results Available","Dry Eye","Other: Artificial Tears","Percentage of Patients with Progression of Dry Eye Disease|Change from Baseline in Ocular Surface Disease Index© (OSDI©) Score|Percentage of Patients with an Increase in Blurred Vision|Change from Baseline in Schirmer's Test|Change from Baseline in Conjunctival Staining Score on a 6-Point Scale|Change from Baseline in Corneal Staining Score on a 6-Point Scale","Allergan","All","40 Years and older   (Adult, Older Adult)",,"284","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MA-RES-08-001","February 1, 2009","March 6, 2017","March 6, 2017","February 2, 2009",,"July 25, 2017","Jones Eye Institute, Little Rock, Arkansas, United States|North Valley Eye Medical Group, Inc., Mission Hills, California, United States|Milauskas Eye Institute, Rancho Mirage, California, United States|Eye Center of Northern Colorado, Fort Collins, Colorado, United States|Cape Coral Eye Center, PA, Cape Coral, Florida, United States|The Eye Institute of West Florida, Largo, Florida, United States|The Wilmer Eye Institute Johns Hopkins Hospital, Baltimore, Maryland, United States|Minnesota Eye Consultants, P.A., Bloomington, Minnesota, United States|Mulqueeny Eye Centers, Creve Coeur, Missouri, United States|Mercy Eye Specilaists, Springfield, Missouri, United States|Cleveland Eye Clinic, Brecksville, Ohio, United States|Ophthalmic Partners Bala, Cynwyd, Pennsylvania, United States|Hazleton Eye Specialists, Township, Pennsylvania, United States|Vanderbilt Eye Institute, Nashville, Tennessee, United States|Alkek Eye Center, Department of Ophthalmology, Houston, Texas, United States|The Eye Clinic of Texas/ dba Texas Clinical Eye Research Center, League City, Texas, United States|See Clearly Vision Group, McLean, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00833235"
409,"NCT00829049","Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris",,"Terminated","Has Results","Acne Vulgaris","Drug: Tazarotene Cream 0.1%|Drug: Adapalene","Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12|Percentage of Patients With >= 1 Grade Improvement in the Investigator Global Assessment at Week 16|Percentage of Patients With >= 2 Grade Improvement in the Overall Disease Severity Score at Week 12|Median Percent Change From Baseline in Inflammatory Lesion Counts (Papules/Pustules, Nodules) at Week 16","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-TAZ0702","October 2007","October 2008","October 2008","January 26, 2009","September 12, 2012","September 12, 2012","Fremont, California, United States",,"https://ClinicalTrials.gov/show/NCT00829049"
410,"NCT00827255","Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%",,"Completed","Has Results","Dry Eye Disease","Drug: Cyclosporine Ophthalmic Emulsion 0.05%","Percentage of Patients With Complete Clearing of Corneal Staining at Month 12|Schirmer's Test at Month 12","Allergan","All","16 Years and older   (Child, Adult, Older Adult)",,"35","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","MA-RES-08-002","January 2009","June 2009","October 2009","January 22, 2009","July 18, 2012","April 25, 2019","Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00827255"
411,"NCT00822055","Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy","Change from baseline in mean IOP|Patient tolerability/comfort measured by Likert scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","COM0501","May 2005","November 2006","November 2006","January 14, 2009",,"January 14, 2009","Barrie, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00822055"
412,"NCT00811850","Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow",,"Completed","Has Results","Glaucoma","Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|Drug: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution","Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery|Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery|Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery|Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery|Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery|Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery|Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery|Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery","Allergan","All","30 Years and older   (Adult, Older Adult)","Phase 4","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-COM-08-009","December 2008","December 2009","December 2009","December 19, 2008","August 1, 2012","April 24, 2019","Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00811850"
413,"NCT00811564","An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|Drug: latanoprost 0.005%","Intraocular Pressure (IOP) at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-COM-08-008","December 2008","January 2010","January 2010","December 19, 2008","September 21, 2011","September 21, 2011","Slingerlands, New York, United States",,"https://ClinicalTrials.gov/show/NCT00811564"
414,"NCT00809848","Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma",,"Completed","Has Results","Ocular Hypertension|Glaucoma","Drug: AGN-210669 ophthalmic solution, 0.075%|Drug: AGN-210669 ophthalmic solution, 0.05%|Drug: AGN-210669 ophthalmic solution, 0.025%|Drug: bimatoprost ophthalmic solution 0.03%|Drug: AGN-210669 vehicle ophthalmic solution","Change From Baseline in Average Eye Intraocular Pressure (IOP)|Percentage of Patients With ≥ 20% Reduction From Baseline in Diurnal IOP","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","210669-003","February 2009","May 2009","May 2009","December 17, 2008","October 18, 2013","October 18, 2013","Artesia, California, United States",,"https://ClinicalTrials.gov/show/NCT00809848"
415,"NCT00799227","Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema",,"Completed","Has Results","Diabetic Macular Edema|Vitrectomy","Drug: Dexamethasone","Change From Baseline in Central Retinal Thickness in the Study Eye|Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients With at Least 10 Letters of Improvement in BCVA From Baseline in the Study Eye|Percentage of Patients With Fluorescein Leakage as Measured by Fluorescein Angiography (FA) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206207-018","January 1, 2009","December 1, 2009","December 1, 2009","November 27, 2008","August 4, 2014","April 23, 2019","Charlotte, North Carolina, United States|Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT00799227"
416,"NCT00791323","Efficacy of Ketorolac 0.4% in Prostaglandin Suppression",,"Completed","Has Results","Inflammation","Drug: Ketorolac 0.4%|Drug: Lubricating Eye Drop","Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","MA-ACU-08-001","November 2008","August 2009","August 2009","November 14, 2008","September 23, 2011","September 23, 2011","Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00791323"
417,"NCT00775411","Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)",,"Completed","Has Results","Choroidal Neovascularization|Age-Related Maculopathy","Drug: dexamethasone|Biological: ranibizumab","Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4|Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 26|Percentage of Participants With Fluorescein Leakage Improved, Unchanged and Worsened From Baseline as Assessed by Fluorescein Angiography at Week 26","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206207-019","November 2008","November 2009","April 2010","October 20, 2008","September 3, 2012","September 3, 2012","San Antonio, Texas, United States|Sydney, New South Wales, Australia|Manila, Philippines",,"https://ClinicalTrials.gov/show/NCT00775411"
418,"NCT00761592","Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm",,"Completed","Has Results","Blepharospasm","Biological: Botulinum Toxin Type A 900kDa|Biological: Botulinum Toxin Type A 150kDa","Change From Baseline to Week 4 in Blepharospasm Disability Index|Change From Baseline to Week 8 in Blepharospasm Disability Index|Change From Baseline to Week 4 and Week 8 in Total Jankovic Rating Scale (JRS) (Severity and Frequency Measured on a Scale of 0-4)|Changes From Baseline to Week 4 and Week 8 in Patient Global Assessment (PGA) Score|Duration of Action","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALLBL001","July 2006","January 2008","January 2008","September 29, 2008","July 9, 2009","November 19, 2013","Bonn, Germany|Wiesbaden, Germany|Zwickau, Germany",,"https://ClinicalTrials.gov/show/NCT00761592"
419,"NCT00761202","Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms",,"Completed","Has Results","Dry Eye Syndromes","Drug: A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Drug: Sodium hyaluronate","Conjunctival Staining by Lissamine Green|Corneal Staining by Fluorescein|Conjunctival Hyperaemia|Ocular Comfort and Ocular Symptoms on Visual Analogue Scale|Daily Eyedrop Usage|Lipid Layer Pattern Assessment","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","AGN/OPH/DE/002","August 2007","June 2008","June 2008","September 29, 2008","February 4, 2010","November 19, 2013","London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00761202"
420,"NCT00756678","Efficacy and Acceptability of Two Lubricant Eye Drops",,"Completed","Has Results","Dry Eye Syndromes","Drug: Lubricant Eye Drops (Optive™)|Drug: Lubricating Eye Drops (blink® Tears)","Mean Frequency of Eye Drop Use Over 1 Week|Change From Baseline in Dry Eye Disease Comfort Assessment Score on Day 16|Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16|Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 16","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-OPT-08-001","September 2008","August 2009","August 2009","September 22, 2008","October 31, 2011","October 31, 2011","Chevy Chase, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00756678"
421,"NCT00735449","Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|Drug: timolol maleate 0.5%|Drug: latanoprost 0.005%","Mean Intraocular Pressure (IOP) at 10 AM at Week 12|Mean Intraocular Pressure (IOP) at 10 AM at Week 6|Mean Intraocular Pressure (IOP) at 8 AM at Week 12|Mean Intraocular Pressure (IOP) at 8 AM at Week 6|Number of Subjects With Adverse Events","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-COM-07-XTC","July 2008","December 2009","December 2009","August 15, 2008","November 24, 2011","April 23, 2019","Newark, New Jersey, United States|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00735449"
422,"NCT00717418","Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease",,"Completed","Has Results","Keratoconjunctivitis Sicca","Drug: cyclosporine ophthalmic emulsion 0.05%, artificial tears","Ocular Surface Disease Index (OSDI) Total Score at Baseline","Allergan","All","Child, Adult, Older Adult",,"781","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R.E.S.T.O.R.E.","September 2004","August 2006","August 2008","July 17, 2008","January 12, 2012","January 12, 2012","Wilson, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00717418"
423,"NCT00716742","Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)",,"Completed","Has Results","Open-Angle Glaucoma|Ocular Hypertension","Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%","Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year","Allergan","All","18 Years and older   (Adult, Older Adult)",,"1099","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro2","September 2004","September 2007","September 2009","July 16, 2008","January 6, 2012","January 6, 2012","Murfreesboro, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00716742"
424,"NCT00693485","Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy",,"Completed","Has Results","Glaucoma, Open-Angle","Drug: 400 ug Brimonidine Implant|Drug: 200 ug Brimonidine Implant|Drug: Sham (no implant)","Percentage of Patients With a Visual Field Improvement in the Study Eye|Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","190342-030D","September 2008","January 2011","August 2011","June 9, 2008","April 24, 2013","April 24, 2013","Artesia, California, United States|Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00693485"
425,"NCT00693420","Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence",,"Completed","Has Results","Eyelashes","Drug: Bimatoprost 0.03% sterile solution|Drug: vehicle sterile solution","Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16|Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 20 (Post-treatment)|Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16|Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)|Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16|Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)|Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16|Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-032","April 2007","October 2007","December 2007","June 9, 2008","May 12, 2009","October 30, 2013","San Diego, California, United States|Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00693420"
426,"NCT00691197","Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear",,"Completed","Has Results","Ametropia","Device: Carboxymethylcellulose sodium and Glycerin|Device: Carboxymethylcellulose sodium","Best Corrected Visual Acuity|Corneal Staining","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","246","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG9689-002","March 2008","October 2008","October 2008","June 5, 2008","December 10, 2009","July 22, 2015","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00691197"
427,"NCT00661479","An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa",,"Completed","Has Results","Retinitis Pigmentosa","Drug: 400 µg Brimonidine Tartrate Implant|Drug: 200 µg Brimonidine Tartrate Implant|Drug: 100 µg Brimonidine Tartrate Implant|Other: Sham (no implant)","Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in Contrast Sensitivity in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","190342-028D","July 2008","December 2009","May 2010","April 18, 2008","April 24, 2013","April 24, 2013","Arlington, Texas, United States|Paris, France|Tubingen, Germany|Coimbra, Portugal",,"https://ClinicalTrials.gov/show/NCT00661479"
428,"NCT00658619","Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)",,"Completed","Has Results","Macular Degeneration","Drug: 400 µg Brimonidine Tartrate Implant|Drug: 200 µg Brimonidine Tartrate Implant|Other: Sham (no implant)","Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye|Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in Contrast Sensitivity in the Study Eye|Change From Baseline in Reading Speed in the Study Eye","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","190342-032D","May 1, 2008","June 1, 2010","April 8, 2011","April 15, 2008","April 26, 2013","August 21, 2018","Abilene, Texas, United States|Sydney, New South Wales, Australia|Karlsruhe, Germany|Udine, Italy|Seoul, Korea, Republic of|Makati City, Philippines|Coimbra, Portugal",,"https://ClinicalTrials.gov/show/NCT00658619"
429,"NCT00652496","Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.01% ophthalmic solution|Drug: Bimatoprost 0.015% formulation 1 ophthalmic solution|Drug: Bimatoprost 0.015% formulation 2 ophthalmic solution|Drug: Bimatoprost 0.02% ophthalmic solution|Drug: Bimatoprost 0.03% ophthalmic solution","Intraocular pressure (IOP)|Patient Comfort|Patient Satisfaction|Treatment Preference","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-030","January 2005","May 2005","May 2005","April 3, 2008",,"April 3, 2008","Wenatchee, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00652496"
430,"NCT00652483","Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Brimonidine ophthalmic solution 0.1%|Drug: Brimonidine ophthalmic solution 0.2%","Intraocular pressure (IOP)|IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","433","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","190342-021","May 2003","December 2003","September 2004","April 3, 2008",,"April 3, 2008","Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00652483"
431,"NCT00652106","Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|Drug: Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Drug: Brimonidine 0.2% ophthalmic solution","Intraocular pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","432","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","190342-019T","June 2003","March 2004","March 2004","April 3, 2008",,"April 3, 2008","El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00652106"
432,"NCT00651859","Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.01% Ophthalmic Solution|Drug: Bimatoprost 0.03% Ophthalmic Solution|Drug: Bimatoprost Vehicle Ophthalmic Solution","Intraocular pressure (IOP)|IOP","Allergan","All","20 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-024","November 2002","January 2004","January 2004","April 3, 2008",,"April 3, 2008","San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00651859"
433,"NCT00651729","Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity",,"Completed","No Results Available","Stroke|Muscle Spasticity","Biological: Botulinum Toxin Type A","Adverse events|Spasticity as measured by the Ashworth scale","Allergan","All","21 Years and older   (Adult, Older Adult)","Phase 2","279","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-056","April 2003","December 2004","December 2004","April 3, 2008",,"May 28, 2008","Indianapolis, Indiana, United States|Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00651729"
434,"NCT00651690","Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment",,"Completed","No Results Available","Stroke|Muscle Spasticity","Biological: Botulinum Toxin Type A|Biological: Placebo","Seven functional tasks (nail filing, hand cleaning, holding a water bottle, brushing teeth, holding a small fruit, holding a medium fruit, and holding a large fruit)|Spasticity of the upper-limb flexors as measured by the Ashworth Scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-065","March 2004","May 2005","May 2005","April 3, 2008",,"May 28, 2008","Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00651690"
435,"NCT00651612","Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Drug: Concurrent brimonidine 0.2% and 0.5% timolol","Adverse Events","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","604","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","190342-024T","November 2005","January 2007","January 2007","April 3, 2008",,"April 3, 2008","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT00651612"
436,"NCT00651586","Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers",,"Completed","No Results Available","Acute Bacterial Corneal Ulcers|Bacterial Keratitis","Drug: Gatifloxacin 0.3% ophthalmic solution|Drug: Ciprofloxacin 0.3% ophthalmic solution","Complete re-epithelialization of the corneal ulcer|Investigator's evaluation of clinical efficacy|Patient reported outcomes|Microbiological Cure","Allergan","All","8 Years and older   (Child, Adult, Older Adult)","Phase 2","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","198782-002","October 2003","April 2005","April 2005","April 3, 2008",,"July 29, 2008","Galveston, Texas, United States|Madurai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00651586"
437,"NCT00621933","Surveillance of Ocular Surface Flora (SURFACE)",,"Completed","Has Results","Cataract",,"Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid|Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva|Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Eyelid|Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva","Allergan","All","50 Years and older   (Adult, Older Adult)",,"399","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MA-Zymar-08-001","December 2007","October 2008","November 2008","February 22, 2008","July 18, 2012","April 26, 2019","Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00621933"
438,"NCT00611403","Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients",,"Completed","Has Results","Dry Eye Syndromes","Drug: Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Drug: Artificial Tears REFRESH ENDURA®","Percentage of Patients With Clinical Success at Month 6|Change From Baseline in Keratocyte Density in the Anterior Flap of the Eyes at Month 6|Change From Baseline in Goblet Cell Density of the Eyes at Month 6","Allergan","All","21 Years to 50 Years   (Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192371-014","December 2007","December 2008","June 2009","February 8, 2008","December 20, 2011","December 20, 2011","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00611403"
439,"NCT00575016","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",,"Terminated","Has Results","Overactive Bladder","Biological: Normal saline (Placebo); botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (50U); botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (100U); botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (200U)","Change From Baseline in Number of Weekly Episodes of Urinary Incontinence|Change From Baseline in Maximum Cystometric Capacity (MCC)|Change From Baseline in Maximum Detrusor Pressure (MDP)","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-518","December 2007","February 2010","July 2010","December 17, 2007","October 17, 2011","October 2, 2015","Cairo, Egypt|Thessaloniki, Greece|Ahmadabad, India|Beirut, Lebanon|Belgrade, Serbia|Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT00575016"
440,"NCT00564681","Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia",,"Completed","Has Results","Cervical Dystonia","Biological: botulinum toxin type A|Biological: botulinum toxin type A Formulation 2|Drug: Normal Saline","Change From Baseline in Observed Total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Score at Week 4 of Treatment Cycle 1|Physician's Global Assessment of Response to Treatment at Week 4 of Treatment Cycle 1|Patient's Global Assessment of Response to Treatment at Week 4 of Treatment Cycle 1|Change From Baseline in Pain as Evaluated With the TWSTRS Pain Subscale at Week 4 of Treatment Cycle 1|Duration of Treatment Effect for Treatment Responders","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-090","December 2007","December 2008","December 2009","November 28, 2007","December 11, 2012","January 5, 2016","Winston-Salem, North Carolina, United States|Halifax, Nova Scotia, Canada|Prague, Czech Republic|Berlin, Germany|Budapest, Hungary|Mumbai, India|Manila, Philippines|Warsaw, Poland|Moscow, Russian Federation|Belgrade, Serbia|Singapore, Singapore|Spisska Nova, Slovakia|Cape Town, South Africa|Tainan, Taiwan|Bangkok, Thailand|Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00564681"
441,"NCT00549783","BOTOX® Economic Spasticity Trial (BEST)",,"Completed","Has Results","Muscle Spasticity","Biological: Botulinum Toxin Type A 900kD|Biological: Placebo","Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24|Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Functional Goal at Week 12|Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Functional Goal at Week 52|Patient Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Functional Goal at Week 12|Patient Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Functional Goal at Week 24|Patient Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Functional Goal at Week 52|Activities of Daily Living Quality of Life (QOL) Score at Week 12|Activities of Daily Living Quality of Life (QOL) Score at Week 24|Activities of Daily Living Quality of Life (QOL) Score at Week 52|Direct Costs for Canada|Direct Costs for Germany|Direct Costs for Sweden|Direct Costs for the United Kingdom","Allergan","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AGN/HO/SPA/001-191622","October 2007","January 2010","July 2010","October 26, 2007","August 22, 2012","August 22, 2012","Edmonton, Alberta, Canada|Beelitz, Germany|Uppsala, Sweden|Burslem, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00549783"
442,"NCT00544713","Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery",,"Completed","Has Results","Dry Eye Syndrome","Drug: Carboxymethylcellulose and Glycerin based artificial tear|Drug: Carboxymethylcellulose","Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90|Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90|Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90|Best Corrected Visual Acuity (BCVA) Status at Day 90|Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90|Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90|Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90|Change From Baseline of the Worse Eye in Schirmer's Test at Day 90|Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90|Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90|Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90|Change From Baseline in Study Product Usage at Day 90","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AG9818-001","September 2007","June 2008","June 2008","October 16, 2007","December 14, 2011","December 14, 2011","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00544713"
443,"NCT00541242","Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Ocular Hypertension|Glaucoma","Drug: bimatoprost 0.03% eye drops|Drug: latanoprost 0.005% eye drops","Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12|Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","586","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-034","December 2007","August 2008","August 2008","October 10, 2007","October 27, 2011","October 27, 2011","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT00541242"
444,"NCT00539526","Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues",,"Completed","Has Results","Open Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.03%|Drug: travoprost 0.004%|Drug: latanoprost 0.005% eye drops","Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3|Change From Baseline in Corneal Staining With Fluorescein at Month 3|Change From Baseline in Tear Break-Up Time (TBUT) at Month 3","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-LUM-07-003","September 2007","July 2008","September 2008","October 4, 2007","October 31, 2011","April 24, 2019","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00539526"
445,"NCT00538304","A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost eye drops|Drug: placebo","Change From Baseline in Mean Peak Macroscopic Conjunctival Hyperemia at Month 1|Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye at Month 1|Change From Baseline in Mean Intraocular Pressure (IOP) at Month 1|Percentage of Physicians Who Were Very or Extremely Willing to Continue Patient on Drug, if Drug Were Marketed at Month 1|Percentage of Patients Who Were Very or Extremely Willing to Use This Glaucoma Medication at Month 1|Percentage of Patients Who Reported No Change in the Appearance of Their Eyes Since the Beginning of the Study at Month 1","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-035","November 2007","May 2008","May 2008","October 2, 2007","October 27, 2011","April 23, 2019","Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00538304"
446,"NCT00535938","MDs on Botox Utility (MOBILITY)",,"Completed","Has Results","Blepharospasm|Torticollis|Strabismus|Muscle Spasticity","Other: botulinum toxin type A","Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cervical Dystonia|Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Blepharospasm|Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Hyperhidrosis|Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cerebral Palsy|Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Adult Focal Spasticity|Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Facial Nerve Disorder|Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With ""Other"" Disorders|BOTOX® Dose in Patients With Cervical Dystonia|BOTOX® Dose in Patients With Blepharospasm|BOTOX® Dose in Patients With Hyperhidrosis|BOTOX® Dose in Patients With Adult Focal Spasticity|BOTOX® Dose in Patients With Cerebral Palsy|BOTOX® Dose in Patients With Facial Nerve Disorder|BOTOX® Dose in Patients With ""Other"" Disorders|Concurrent Procedure Resource Utilization Patterns|Concurrent Surgical Procedure Resource Utilization Patterns","Allergan","All","14 Years and older   (Child, Adult, Older Adult)",,"1372","Industry","Observational","Time Perspective: Prospective","AGN/MMC B00705","September 2007","September 2013","September 2013","September 27, 2007","September 10, 2014","September 10, 2014","Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00535938"
447,"NCT00533351","Safety and Efficacy of AGN201781 in Neuropathic Pain",,"Terminated","Has Results","Neuralgia","Drug: AGN201781|Drug: placebo","Change From Baseline in Daily Pain Score at Week 2|Change From Baseline in Subject Global Impression of Change Score at Week 2","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201781-504","March 2008","June 2008","June 2008","September 21, 2007","January 19, 2012","February 24, 2016","St. Leonards, New South Wales, Australia|Kiel, Germany",,"https://ClinicalTrials.gov/show/NCT00533351"
448,"NCT00528541","Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia",,"Completed","Has Results","Spasmodic Torticollis","Biological: botulinum toxin type A","Dysphagia Incidence Over 10 Weeks|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4|Physician Assessment of Cervical Dystonia Severity at Week 4|Global Assessment of Benefit by Physician at Week 4|Global Assessment of Benefit by Patient at Week 4|Patient Assessment of Need for Retreatment at Week 4|Patient Visual Analog Assessment of Pain at Week 4|Physician Comparison of Benefit to Previous Injections at Week 10|Patient Comparison of Benefit to Previous Injections at Week 10","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MedAff-BTX-0616","September 2007","September 2009","September 2009","September 12, 2007","December 16, 2011","December 16, 2011","Adelaide, South Australia, Australia|Zagreb, Croatia|Rome, Italy|Krakow, Poland|Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00528541"
449,"NCT00524264","A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery",,"Completed","Has Results","Cataract Extraction|Pain|Inflammation","Drug: ketorolac","Resolution of Post Operative Inflammation|Ocular Pain|Mean Pupil Area","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191578-005","October 2007","April 2008","April 2008","September 3, 2007","October 1, 2009","October 1, 2009","Artesia, California, United States",,"https://ClinicalTrials.gov/show/NCT00524264"
450,"NCT00521456","A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery",,"Completed","Has Results","Cataract Extraction","Drug: ketorolac eye drops","Resolution of Post Operative Inflammation|Ocular Pain|Mean Pupil Area","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","263","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191578-006","October 2007","March 2008","March 2008","August 27, 2007","October 1, 2009","October 1, 2009","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00521456"
451,"NCT00518089","A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis",,"Completed","Has Results","Bacterial Conjunctivitis","Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops","Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6|Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6|Percentage of Patients With Microbiological Cure Up to Day 6|Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6|Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6","Allergan","All","1 Year and older   (Child, Adult, Older Adult)","Phase 3","859","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","198782-005","February 2008","January 2009","January 2009","August 20, 2007","November 30, 2011","April 23, 2019","Downey, California, United States|Rajajinagar, Bangalore, India",,"https://ClinicalTrials.gov/show/NCT00518089"
452,"NCT00514852","Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye",,"Completed","Has Results","Dry Eye Syndrome","Drug: Carboxymethylcellulose and Glycerin based artificial tear|Drug: Carboxymethylcellulose","Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score|Change From Baseline at Day 30 in Schirmer Test, With Anesthesia|Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein|Patient Acceptability Score (Dryness) at Day 30|Patient Acceptability Score (Vision) at Day 30|Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein|Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein|Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score","Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AG9818-002","October 2007","January 2008","January 2008","August 10, 2007","December 15, 2009","December 15, 2009","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00514852"
453,"NCT00511706","Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)",,"Completed","Has Results","Choroidal Neovascularization|Age-Related Maculopathy","Drug: dexamethasone|Biological: ranibizumab|Other: sham","Injection Free Interval|Change From Baseline in the Best Corrected Visual Acuity (BCVA) at Week 25|Change From Baseline in the Mean Central Retinal Subfield Thickness at Week 25 as Assessed by Optical Coherence Tomography (OCT) in the Study Eye|Change From Screening in the Area of Leakage From Choroidal Neovascularization (CNV) at Week 25 as Assessed by Fluorescein Angiography in the Study Eye","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","206207-016","November 1, 2007","March 1, 2009","March 1, 2009","August 6, 2007","September 3, 2012","April 25, 2019","Boynton Beach, Florida, United States|Parramatta, New South Wales, Australia|Paris, France|Tel Aviv, Israel|Milano, Italy|Seoul, Korea, Republic of|Auckland, New Zealand|Coimbra, Portugal|Southampton, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00511706"
454,"NCT00509873","A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis",,"Completed","Has Results","Bacterial Conjunctivitis","Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops","Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6|Percentage of Patients With Microbiological Cure at Day 6|Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6|Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6","Allergan","All","1 Year and older   (Child, Adult, Older Adult)","Phase 3","578","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","198782-004","August 2007","June 2008","June 2008","August 1, 2007","November 30, 2011","November 30, 2011","Gretna, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00509873"
455,"NCT00487214","Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma",,"Completed","No Results Available","Glaucoma, Open-Angle",,,"Allergan","All","18 Years and older   (Adult, Older Adult)",,"361","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MEDNET2001","June 2002","February 2003","February 2003","June 15, 2007",,"June 1, 2011",,,"https://ClinicalTrials.gov/show/NCT00487214"
456,"NCT00464685","Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema",,"Completed","Has Results","Diabetic Macular Edema","Drug: Dexamethasone|Drug: Sham injection|Procedure: Laser Photocoagulation","Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye|Change From Baseline in BCVA in the Study Eye|Change From Baseline in Central Subfield Retinal Thickness in the Study Eye|Change From Baseline in the Focal Leakage Area in the Study Eye|Time to Retreatment in the Study Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","206207-012","May 1, 2007","February 8, 2010","February 8, 2010","April 24, 2007","August 4, 2014","April 24, 2019","Artesia, California, United States|Victoria, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00464685"
457,"NCT00464438","A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis",,"Completed","Has Results","Bacterial Conjunctivitis","Drug: gatifloxacin|Drug: moxifloxacin 0.5% eye drops","Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7|Percentage of Patients With Microbiological Improvement|Percentage of Patients With Improvement in Ocular Signs for Lid Erythema|Percentage of Patients With Improvement in Ocular Signs for Conjunctival Discharge at Day 7","Allergan","All","up to 31 Days   (Child)","Phase 4","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","198782-003","June 2007","September 2008","September 2008","April 23, 2007","September 21, 2011","September 21, 2011","Sacramento, California, United States|Whitby, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00464438"
458,"NCT00461292","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",,"Completed","Has Results","Overactive Bladder","Biological: botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (300U)|Other: Normal saline (Placebo); botulinum toxin Type A (200U)|Other: Normal saline (Placebo); botulinum toxin Type A (300U)","Change From Baseline in Number of Weekly Episodes of Urinary Incontinence|Change From Baseline in Maximum Cystometric Capacity (MCC)|Change From Baseline in Maximum Detrusor Pressure (MDP)|Change From Baseline in Total Score on Incontinence Quality of Life (I-QOL) Questionnaire","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","275","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-516","May 2007","March 2010","April 2010","April 17, 2007","October 17, 2011","October 2, 2015","Middlebury, Connecticut, United States|Rio de Janeiro, Brazil|Victoria, British Columbia, Canada|Salouel, France|Milan, Italy|Amsterdam, Netherlands|Porto, Portugal|Singapore, Singapore|Pretoria, South Africa|Tenerife, Spain|Hualien, Taiwan|Scunthorpe, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00461292"
459,"NCT00457795","24-hour IOP-lowering Effect of Brimonidine 0.1%",,"Completed","Has Results","Open-angle Glaucoma|Ocular Hypertension","Drug: brimonidine 0.1% (Alphagan® P)","Intraocular Pressure (IOP) for a 24-Hour Period at Week 4|Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4|Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4|Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4","Allergan","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-080806-2","December 2006","February 2009","February 2009","April 9, 2007","November 24, 2011","November 24, 2011","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00457795"
460,"NCT00445705","Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome",,"Terminated","Has Results","Fibromyalgia","Drug: placebo|Drug: AGN 203818","Change From Baseline in Mean Daily-Average-Pain Score at Week 4|Change From Baseline in the Short Form Brief Pain Inventory (SF-BPI) Average Pain Score at Week 4|Change From Baseline in the Fibromyalgia Impact Questionnaire (FIQ) Total Score of Physical Impairment at Week 4|Patient Global Impression of Change (PGIC) for Fibromyalgia Syndrome Status at Week 4","Allergan","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","203818-503","March 2007","January 2008","January 2008","March 9, 2007","January 20, 2012","September 7, 2015","Canton, Ohio, United States|Geneva, Switzerland|Stanmore, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00445705"
461,"NCT00443274","Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms","BIFS","Active, not recruiting","No Results Available","Breast Implant","Other: NBIR Placeholder|Device: 410 Arm|Device: BIFs","Risk rates of adverse events of high clinical interest (eg, cancers, neurological diseases, connective tissue diseases) assessed by the investigator|Risk rates of common complications of breast surgery (eg, capsular contracture, implant rupture/deflation) assessed by the subject and investigator|Re-operations","Allergan","Female","18 Years and older   (Adult, Older Adult)",,"56460","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BIFS001|CMO-EPI-PLS-0536","November 1, 2006","April 18, 2030","June 1, 2030","March 5, 2007",,"November 13, 2019","Core and Associates, Birmingham, Alabama, United States|Michael S. Beckenstein, M.D., Birmingham, Alabama, United States|Birmingham Plastic Surgery Clinic, Birmingham, Alabama, United States|Eich Plastic Surgery, Birmingham, Alabama, United States|Hedden Plastic Surgery, Birmingham, Alabama, United States|Premier Plastic Surgery, PC, Birmingham, Alabama, United States|Dr L. Dwight Baker, Dothan, Alabama, United States|Feagin & Owen, MD, PC, Dothan, Alabama, United States|The Rumley Center PC, Gadsden, Alabama, United States|McCullough Plastic Surgery Center, Gulf Shores, Alabama, United States|William E. Alison Jr., MD, Huntsville, Alabama, United States|Randy Proffitt, MD, FACS, Mobile, Alabama, United States|Karl B. Hiatt, MD, Montgomery, Alabama, United States|Plastic Surgery Associates of Montgomery, Montgomery, Alabama, United States|Cosmetic Surgical Art Center, Chandler, Arizona, United States|Maffi Plastic Surgery, Paradise Valley, Arizona, United States|Shapiro Aesthetic Plastic Surgery, Paradise Valley, Arizona, United States|Cosmetic Surgery Institute, Phoenix, Arizona, United States|Larry Leverett, MD, Phoenix, Arizona, United States|Sumer L. Daiza, MD, Phoenix, Arizona, United States|Patti A. Flint, MD, Scottsdale, Arizona, United States|Admire Plastic Surgery, Scottsdale, Arizona, United States|Wesley G. Wilson, MD, Scottsdale, Arizona, United States|Arizona Center for Aesthetic Plastic Surgery, Scottsdale, Arizona, United States|John J. Corey, MD, Scottsdale, Arizona, United States|Sean T. Lille, M.D., PC, Scottsdale, Arizona, United States|Affiliated Plastic Surgeons, Scottsdale, Arizona, United States|Bryan Gawley, M.D., Scottsdale, Arizona, United States|Deborah White, MD, Scottsdale, Arizona, United States|James Nachbar, M.D., Scottsdale, Arizona, United States|The Shaw Center, Scottsdale, Arizona, United States|Christopher Maloney, M.D., Tucson, Arizona, United States|Perfection Plastic Surgery, Tucson, Arizona, United States|Maxwell Aesthetics, Tucson, Arizona, United States|Aesthetic Plastic Surgery, LLC, Little Rock, Arkansas, United States|George Sun, MD, Arcadia, California, United States|Jane S. Weston, MD, Atherton, California, United States|Steven K. Struck, MD, Atherton, California, United States|Bruce B. Kadz, MD, Beverly Hills, California, United States|Cassileth Plastic Surgery, Beverly Hills, California, United States|Francis Sheng, M.D., Beverly Hills, California, United States|Jay Orringer, M.D., Beverly Hills, California, United States|Lawrence Koplin, M.D., Beverly Hills, California, United States|Linda Li, MD, Beverly Hills, California, United States|Lisa B. Cassileth, MD, Beverly Hills, California, United States|Marc Mani, MD, Beverly Hills, California, United States|Robert M. Rey, MD, Beverly Hills, California, United States|Rodeo Drive Plastic Surgery, Beverly Hills, California, United States|Beverly Hills Cosmetic Surgical Group, Beverly Hills, California, United States|Gary S. Takowsky, MD, Beverly Hills, California, United States|SK Plastic Surgery, Beverly Hills, California, United States|Brent Moelleken, MD, FACS, Beverly Hills, California, United States|D. Garth Fisher, MD, Beverly Hills, California, United States|J. Timothy Katzen, M.D., Beverly Hills, California, United States|Mark Berman, MD, Beverly Hills, California, United States|Spalding Outpatient Surgery Center, Beverly Hills, California, United States|Frederic H. Corbin, MD, Brea, California, United States|George Orloff, MD, Burbank, California, United States|Lorne K. Rosenfield, M.D., Burlingame, California, United States|R. Laurence Berkowitz, MD, Campbell, California, United States|Regina L. Rosenthal, MD, Campbell, California, United States|CosmetiCare, Corona Del Mar, California, United States|Robert W. Kessler, MD, Corona Del Mar, California, United States|Kyoung C. Kim, MD, Costa Mesa, California, United States|Culver City Surgical Center, Culver City, California, United States|Aesthetic & Reconstructive Plastic Surgery Medical Associates, Inc., Danville, California, United States|Ranch & Coast Plastic Surgery, Del Mar, California, United States|Steve Laverson, MD, Encinitas, California, United States|Genevieve MacDonald, MD, Encino, California, United States|Regency Surgery Center, Encino, California, United States|Nuance Cosmetic Surgery, Folsom, California, United States|Plastic Surgery Associates of Folsom, Folsom, California, United States|Institute of Cosmetic Surgery, Fountain Valley, California, United States|Fremont Plastic Surgery, Fremont, California, United States|John A. Romano, MD, Fremont, California, United States|Aesthetic Plastic Surgery Pavilion, Fresno, California, United States|Catherine Riolo, MD, Fresno, California, United States|Kenty U. Sian, M.D., Fresno, California, United States|Andrew J. Matthews, MD, Gilroy, California, United States|Allan W. Perry Jr, MD, Glendale, California, United States|Plastic Surgery Specialists, Greenbrae, California, United States|California Aesthetic Center, Huntington Beach, California, United States|Victoria Tran, MD, Huntington Beach, California, United States|Newport Coast Cosmetic Institute, Huntington Beach, California, United States|Andrew D. Smith, MD, Irvine, California, United States|Mehrdad Mark Mofid, MD, La Jolla, California, United States|Robert Shumway, MD, La Jolla, California, United States|Scott R. Miller, MD, La Jolla, California, United States|La Mesa Surgical Center, La Mesa, California, United States|Tom Pousti, MD, La Mesa, California, United States|Mission Plastic Surgery, Ladera Ranch, California, United States|Aesthetic Plastic Surgical Institute, Inc., Laguna Beach, California, United States|Michael J. Watanabe, MD, Laguna Hills, California, United States|Cynthia M. Goodman, M.D., Larkspur, California, United States|Image Plastic Surgery, Long Beach, California, United States|Mary A. Powers, M.D., Long Beach, California, United States|Pearlman D. Hicks, Jr., MD, Long Beach, California, United States|Susan E. Downey, M.D., Los Angeles, California, United States|Wave Plastic Surgery & Laser Center, Inc., Los Angeles, California, United States|Jeffrey Rosenberg, MD, Los Angeles, California, United States|Plastic Surgery Center, Los Angeles, California, United States|Geoffrey R. Keyes, MD, Los Angeles, California, United States|Dan Yamini, MD, Los Angeles, California, United States|Mossi Salibian, M.D., Los Angeles, California, United States|Sunset Cosmetic Surgery, Los Angeles, California, United States|David A. Stoker, MD, Marina Del Rey, California, United States|Marina Plastic Surgery, Marina Del Rey, California, United States|Pueblo Nuevo Surgery Center, Modesto, California, United States|Theodore E. Staahl, M.D., F.A.S.C., INC., Modesto, California, United States|David S. Goldberg, M.D., Monterey, California, United States|Thomas E. Zewert, M.D., Monterey, California, United States|Pearl Plastic Surgery Center, Mountain View, California, United States|Robert M. Lowen, M.D., INC., Mountain View, California, United States|Renuance Surgery Center, Murrieta, California, United States|Boris Ackerman, M.D., Newport Beach, California, United States|Cosmeticare, Newport Beach, California, United States|Cosmetic, Plastic and Reconstructive Surgery, Newport Beach, California, United States|Edward J. Domanskis, MD, Newport Beach, California, United States|Finesse Aesthetic & Plastic Surgery, Newport Beach, California, United States|H. Jae Chun, MD, Newport Beach, California, United States|Hisham M. Seify, MD, Newport Beach, California, United States|Jed H. Horowitz, MD, Newport Beach, California, United States|Jon Grazer MD, MPH, Inc, Newport Beach, California, United States|Joseph T. Cruise, MD, Newport Beach, California, United States|Lavinia K. Chong, MD, Newport Beach, California, United States|Michael Elam M.D. Cosmetic Surgery, Newport Beach, California, United States|Newport Beach Plastic Surgery Center, Newport Beach, California, United States|Orange Coast Surgical Center, Newport Beach, California, United States|Orange County Plastic Surgery, Newport Beach, California, United States|Pacific Center for Plastic Surgery, Newport Beach, California, United States|Semira Bayati Plastic and Reconstructive Surgery, Newport Beach, California, United States|Tenley K. Lawton, MD, Newport Beach, California, United States|Terry J. Dubrow, MD, Newport Beach, California, United States|The Center for Aesthetic Plastic Surgery, Newport Beach, California, United States|Katharine Nitta, M.D., Newport Beach, California, United States|Renaissance, Newport Beach, California, United States|Ka Ming Li, MD, Ontario, California, United States|Troy J. Andreasen, M.D., Ontario, California, United States|Andres Taleisnik, MD, Orange, California, United States|Daniel Reichner, MD, Orange, California, United States|Daryl K. Hoffman, MD, Palo Alto, California, United States|Stanford Plastic & Reconstructive Surgery, Palo Alto, California, United States|Seung Kim, MD, Palo Alto, California, United States|Stewart P. Wang, MD, Pasadena, California, United States|Arvin Taneja, MD, Pasadena, California, United States|Kevin Ruhge, M.D., Pasadena, California, United States|Pasadena Cosmetic Surgery, Pasadena, California, United States|Taylor Plastic Surgery Center, Pasadena, California, United States|The Plastic Surgery Center, Pleasanton, California, United States|Beverly Hills Physicians, Rancho Cucamonga, California, United States|Inland Cosmetic Surgery, Rancho Cucamonga, California, United States|Plastic Surgery Associates of Redding, Redding, California, United States|Norbert Collins, M.D., Redlands, California, United States|Todd C. Rau, M.D., Redlands, California, United States|Plastic Surgery Specialists, Riverside, California, United States|Robert A Hardesty, MD, Riverside, California, United States|Chrysalis Cosmetics, Sacramento, California, United States|Salinas Plastic Surgery, Salinas, California, United States|Salinas Valley Ambulatory Surgery Center, Salinas, California, United States|Diana M. Breister-Ghosh, MD, San Diego, California, United States|Sassan Alavi, M.D., San Diego, California, United States|Barry S. Handler, M.D., San Diego, California, United States|Jonathan S. Wilensky, MD, San Diego, California, United States|Robert Kearney, M.D., San Diego, California, United States|Ron Soltero, MD, San Diego, California, United States|Belladerma, San Diego, California, United States|Douglas W. Reavie, MD, San Diego, California, United States|Roy Kim, M.D., San Francisco, California, United States|Randall Weil, MD, San Francisco, California, United States|Kenneth Bermudez, MD, San Francisco, California, United States|Craig N. Creasman, MD, San Jose, California, United States|Plastic & Reconstructive Surgery Assoc. Inc., San Jose, California, United States|Samaritan Plastic Surgery Center, San Jose, California, United States|Wally Hosn, MD, San Luis Obispo, California, United States|Frank Piro, MD, San Mateo, California, United States|Michael C. Glafkides, M.D., San Mateo, California, United States|Plastic Surgery Associates, San Mateo, California, United States|Ghada Afifi, M.D., Santa Ana, California, United States|Santa Monica Institute of Laser and Aesthetic Surgery, Santa Monica, California, United States|Telesos Plastic Surgery, South Pasadena, California, United States|Plastic Surgery Center of Stockton, Stockton, California, United States|Advanced Institution for Plastic Surgery, Temecula, California, United States|Charles Chalekson, M.D., Templeton, California, United States|Beverly Hills Physicians, Thousand Oaks, California, United States|Kryger Institute of Plastic Surgery, AMC, Thousand Oaks, California, United States|Todd M. Gerlach, MD, Torrance, California, United States|Association of South Bay Plastic Surgeons, Torrance, California, United States|Michael R. Arnstein, MD, Torrance, California, United States|Palos Verdes Plastic Surgery Medical Center, Inc., Torrance, California, United States|Edward H. Park, MD, Upland, California, United States|Valencia Plastic Surgery, Valencia, California, United States|Robert G. Aycock, M.D., F.A.C.S., Walnut Creek, California, United States|Joseph A. Mele, III, M.D., INC., Walnut Creek, California, United States|Michael R. Schwartz, MD, FACS, Westlake Village, California, United States|Tuan H. Nguyen, DO, Westminster, California, United States|John B. Fisher, MD, Yorba Linda, California, United States|Boulder Plastic Surgery, Boulder, Colorado, United States|Douglas Raskin, MD, Colorado Springs, Colorado, United States|Center for Plastic Surgery, Colorado Springs, Colorado, United States|Audobon Medical Campus, Colorado Springs, Colorado, United States|Greg Liebscher MD, Colorado Springs, Colorado, United States|Center for Cosmetic Surgery, Golden, Colorado, United States|Advanced Cosmetic and Plastic Surgery, Danbury, Connecticut, United States|Harold E. Beam, MD, Glastonbury, Connecticut, United States|Keith J. Attkiss, MD, LLC, Greenwich, Connecticut, United States|Wilfred Brown, MD, Middlebury, Connecticut, United States|Esana, New Haven, Connecticut, United States|Pomperaug Plastic Surgery, Southbury, Connecticut, United States|Davinci Plastic Surgery, Washington, District of Columbia, United States|Ronald S. Perlman, MD, Washington, District of Columbia, United States|Andrew P. Amunategui, M.D., Aventura, Florida, United States|Fabio A. Castro, MD, Aventura, Florida, United States|Lee A. Gibstein, MD, Bay Harbor Islands, Florida, United States|Tal T. Roudner, MD, Coral Gables, Florida, United States|Sergio M. Zamora, MD, Daytona Beach, Florida, United States|The Aesthetics Institute, Fort Lauderdale, Florida, United States|Marc S. Schneider MD, PA, Fort Myers, Florida, United States|Wittenborn Plastic Surgery, Fort Myers, Florida, United States|Center for Plastic and Reconstructive Surgery, Gainesville, Florida, United States|UF Health Springhill/Plastic and Reconstructive Surgery, Gainesville, Florida, United States|UF Health, College of Medicine, Gainesville, Florida, United States|David Y. Globerman, MD, Hollywood, Florida, United States|James Stern, MD, Hollywood, Florida, United States|R. Dean Glassman, MD, Jacksonville, Florida, United States|Coastal Cosmetic Center, Jacksonville, Florida, United States|Contemporary Plastic Surgery, Jacksonville, Florida, United States|Jacksonville Plastic Surgery, Jacksonville, Florida, United States|First Coast Plastic Surgery, PA, Jacksonville, Florida, United States|Allure Institute for Plastic Surgery, Jupiter, Florida, United States|Doran Stark, MD, Lakeland, Florida, United States|Cosmetic and Reconstructive Plastic Surgery, Loxahatchee Groves, Florida, United States|Itzhak Nir, MD, Loxahatchee Groves, Florida, United States|Aesthetic Plastic Surgery Center, Melbourne, Florida, United States|Brevard Plastic Surgery, Melbourne, Florida, United States|Cory J. Lawler, M.D., Melbourne, Florida, United States|Gary Rosenbaum, M.D., Miami Beach, Florida, United States|Miami Beach Cosmetic, Miami Beach, Florida, United States|Phillip R. Craft, MD, Miami, Florida, United States|Brandon E. Kallman, MD, Miami, Florida, United States|The Maercks Institute, Miami, Florida, United States|Brad P. Herman, MD, Miami, Florida, United States|Joel Levin, MD, Miami, Florida, United States|Miami Plastic Surgery, Miami, Florida, United States|Aesthetic Plastic Surgery and Med Spa of Naples, Naples, Florida, United States|Gardner Plastic Surgery, Naples, Florida, United States|Riverchase Dermatology, Naples, Florida, United States|Stanley P. Gulin, M.D., Naples, Florida, United States|Naples Cosmetic Surgery Center, Naples, Florida, United States|Ocala Plastic Surgery, Ocala, Florida, United States|Paddock Park Surgery Center, Ocala, Florida, United States|Orlando Plastic Surgery Center, LLC, Orlando, Florida, United States|Gardens Plastic Surgery, Palm Beach Gardens, Florida, United States|Mark Pinsky, M.D., Palm Beach Gardens, Florida, United States|Dr Richard V. Cashio, Jr., Palm Coast, Florida, United States|Plastic Surgery Center, Panama City, Florida, United States|Gulf Coast Plastic Surgery, Pensacola, Florida, United States|Jocelyn E. Leveque, MD, Pensacola, Florida, United States|Take Shape Plastic Surgery, Plantation, Florida, United States|Daniel M. Calloway, MD, Ponte Vedra Beach, Florida, United States|Ponte Vedra Plastic Surgery, Ponte Vedra Beach, Florida, United States|AJG Aesthetics, Saint Petersburg, Florida, United States|William W. Adams, MD, Saint Petersburg, Florida, United States|Holcomb/Kreithen Plastic Surgery and MedSpa, Sarasota, Florida, United States|Diaco Institute of Plastic Surgery, Tampa, Florida, United States|Henry A. Redmon, MD, Tampa, Florida, United States|Tampa Palms Plastic Surgery, Tampa, Florida, United States|Tamy M. Faierman, M.D., P.A., Weston, Florida, United States|Weston Cosmetic Surgery Center, Weston, Florida, United States|Clifford P. Clark, III, MD, Winter Park, Florida, United States|D. Scott Rotatori, M.D., P.A., Winter Park, Florida, United States|Arthur J. DeBaise, MD, Winter Park, Florida, United States|The Bougainvillea Clinique, Winter Park, Florida, United States|Randal H. Rudderman, MD, Alpharetta, Georgia, United States|Swan Center for Plastic Surgery, Alpharetta, Georgia, United States|The Moore Center for Plastic Surgery, Athens, Georgia, United States|Peachtree Plastic Surgery, Atlanta, Georgia, United States|APC Plastic Surgery, Atlanta, Georgia, United States|Joseph M. Woods IV, MD, LLC, Atlanta, Georgia, United States|Kavali Plastic Surgery, Atlanta, Georgia, United States|Vinings Surgery Center, Atlanta, Georgia, United States|Atlanta Plastic Surgery, Atlanta, Georgia, United States|Plastic & Reconstr Surgery, Atlanta, Georgia, United States|Plastic Surgery Center of Atlanta, Atlanta, Georgia, United States|Summit Plastic Surgery, Brunswick, Georgia, United States|Jain Plastic Surgery, P.C., Columbus, Georgia, United States|Atlantic Center for Plastic & Cosmetic Surgery, Duluth, Georgia, United States|Southern Plastic Surgery, P.C., Duluth, Georgia, United States|Prima Center for Plastic Surgery, Duluth, Georgia, United States|Marietta Plastic Surgery, Marietta, Georgia, United States|North Atlanta Plastic Surgery, Roswell, Georgia, United States|Coastal Empire Plastic Surgery, Savannah, Georgia, United States|Southern Crescent Plastic Surgery, Stockbridge, Georgia, United States|G. Courtney Houston, MD, Thomasville, Georgia, United States|Jeffrey T. Healy, MD, 'Aiea, Hawaii, United States|K. Dieffenbach, M.D., 'Aiea, Hawaii, United States|Clyde Ishii Jr., M.D,, Honolulu, Hawaii, United States|Honolulu Plastic Surgeon, Honolulu, Hawaii, United States|Shim Ching, MD, Honolulu, Hawaii, United States|Athena Clinic, Honolulu, Hawaii, United States|Mark D. Wigod Plastic Surgery, Meridian, Idaho, United States|Jeffrey S. Poulter, MD, Bloomington, Illinois, United States|Advanced Aesthetics Surgery & Laser Center, Champaign, Illinois, United States|Kenneth L. Stein, MD, Chicago, Illinois, United States|John Cook, MD, Chicago, Illinois, United States|The Geldner Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Gregory Wiener, Chicago, Illinois, United States|Lawrence Iteld Plastic Surgery, Chicago, Illinois, United States|Center for Cosmetic Medicine, LTD, Decatur, Illinois, United States|DuPage Medical Group, Downers Grove, Illinois, United States|Plastic Surgery Associates, Moline, Illinois, United States|DuPage Plastic Surgery, Naperville, Illinois, United States|Michael A Epstein, MD, Northbrook, Illinois, United States|Face & Body Plastic Surgery, Oak Brook, Illinois, United States|Dreyfuss and Gelman Plastic Surgery, Orland Park, Illinois, United States|William N. Georgis, MD, Rockford, Illinois, United States|Turkle and Associates, Carmel, Indiana, United States|Cosmetic and Plastic Surgery of Northwest Indiana, Hobart, Indiana, United States|Perkins Van Natta Center, Indianapolis, Indiana, United States|Indiana Plastic Surgery, Munster, Indiana, United States|John Vander Zee, M.D., Cedar Rapids, Iowa, United States|Iowa Plastic Surgery, Davenport, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|Avalon Plastic Surgery Center, Waterloo, Iowa, United States|Des Moines Plastic Surgery, West Des Moines, Iowa, United States|Kenneth Fischer, MD, Manhattan, Kansas, United States|Premier Plastic Surgery, Olathe, Kansas, United States|Juan C. Nosti, MD, Shawnee Mission, Kansas, United States|Center for Plastic Surgery PA, Topeka, Kansas, United States|Poggi Plastic Surgery, Wichita, Kansas, United States|Wichita Clinic, Wichita, Kansas, United States|Aesthetic and Plastic Surgery PA, Wichita, Kansas, United States|Calobrace Plastic Surgery Center, Louisville, Kentucky, United States|Kenneth L. Odinet, MD, Lafayette, Louisiana, United States|West Jefferson Physicians Center, Marrero, Louisiana, United States|Kamran Khoobehi, MD, Metairie, Louisiana, United States|Surgical Associates, Metairie, Louisiana, United States|Placstic and Reconstructive Surgery, Mickel Plastic Surgery, Monroe, Louisiana, United States|Highland Clinic, Shreveport, Louisiana, United States|Western Avenue Day Surgery Center, South Portland, Maine, United States|Western Avenue Day Surgery, South Portland, Maine, United States|Dean P. Kane, MD, FACS, PA, Baltimore, Maryland, United States|George T. Grace, MD Surgery Center, Catonsville, Maryland, United States|Allegany Plastic Surgery, Cumberland, Maryland, United States|Plastic Surgery One, Frederick, Maryland, United States|Plastic Surgery Institute of Washington, North Bethesda, Maryland, United States|The Plastic Surgery Institute of Washington, North Bethesda, Maryland, United States|Surgery Center of Potomac, Rockville, Maryland, United States|Ricardo L. Rodriguez, MD, Timonium, Maryland, United States|Christine Hamori, MD, PC, Duxbury, Massachusetts, United States|Sheldon J. Sevinor, MD, Lynn, Massachusetts, United States|Joseph A. Russo, MD, Newton, Massachusetts, United States|Cynthia M. Poulos, MD, Northborough, Massachusetts, United States|Aesthetic Plastic Surgery Ctr, Springfield, Massachusetts, United States|Michigan Center for Cosmetic Surgery, Ann Arbor, Michigan, United States|Somerset Research Center, Birmingham, Michigan, United States|Amae Plastic Surgery, Bloomfield Hills, Michigan, United States|Bloomfield Laser and Cosmetic Surgery Center, Bloomfield Hills, Michigan, United States|Bengtson Center for Aesthetics & Plastic Surgery, Grand Rapids, Michigan, United States|Hand and Plastic Surgery Centre, P.L.C., Grand Rapids, Michigan, United States|Plastic Surgery Associates, Grand Rapids, Michigan, United States|Plastic Surgery Arts of West Michigan, Holland, Michigan, United States|Argyle Plastic & Reconstructive Surgery, Jackson, Michigan, United States|Plastic Surgery Inst. of Michigan, Midland, Michigan, United States|Plastic Surgery Arts & Spa, Rochester Hills, Michigan, United States|Arno Weiss, Jr., MD, Saginaw, Michigan, United States|M.D.P.C, Saginaw, Michigan, United States|Ronald C. Barry, MD, Saginaw, Michigan, United States|Raj K. Gupta, MD, Taylor, Michigan, United States|Gryskiewicz Twin Cities Cosmetic Surgery, Burnsville, Minnesota, United States|Midsota Plastic Surgeons, Saint Cloud, Minnesota, United States|Ness Plastic Surgery, Wayzata, Minnesota, United States|Das Plastic Surgery, Flowood, Mississippi, United States|The Runnels Clinic, Flowood, Mississippi, United States|Meridian Plastic Surgery, Meridian, Mississippi, United States|Accent Plastic & Reconstructive Surgery, Tupelo, Mississippi, United States|North Mississippi Plastic Surgery, Tupelo, Mississippi, United States|Tupelo Plastic Surgery, Tupelo, Mississippi, United States|St. Louis Cosmetic Surgery, Chesterfield, Missouri, United States|Richard L. Kofkoff, MD, PC, Chesterfield, Missouri, United States|Robert A. Young, MD, Chesterfield, Missouri, United States|John J. Seaberg, III, MD, Columbia, Missouri, United States|Summit Plastic Surgery, Lee's Summit, Missouri, United States|Plastic Surgery Center, Saint Joseph, Missouri, United States|Paul Rottler, M.D., PC, Saint Louis, Missouri, United States|BodyAesthetic Plastic Surgery, Saint Louis, Missouri, United States|Parkcrest Plastic Surgery, Saint Louis, Missouri, United States|Terence M. Myckatyn, M.D., Saint Louis, Missouri, United States|Terence M. Myckatyn, MD, Saint Louis, Missouri, United States|William G. Hart, Jr., MD, Saint Louis, Missouri, United States|Renaissance Plastic Surgery, Saint Peters, Missouri, United States|Billings Plastic Surgery, Billings, Montana, United States|Aesthetic Surgical Images, Omaha, Nebraska, United States|Anson & Higgins Plastic Surgery Assoc., Las Vegas, Nevada, United States|Michael C. Edwards, MD, FACS, Las Vegas, Nevada, United States|Brian J. Parker, MD, Las Vegas, Nevada, United States|Herte Center for Cosmetic Surgery, Las Vegas, Nevada, United States|Stephen M. Miller, M.D., P.C., Las Vegas, Nevada, United States|The Weiland Group, Las Vegas, Nevada, United States|Center for Plastic Surgery, Reno, Nevada, United States|Atlantic Plastic Surgery, Portsmouth, New Hampshire, United States|Richard L. Zeff, M.D., P.A., Stratham, New Hampshire, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Anthony G. Berlet, MD, Cedar Grove, New Jersey, United States|Delaware Valley Plastic Surgery, PA, Cherry Hill, New Jersey, United States|Louis M. Iorio, MD, Colts Neck, New Jersey, United States|Contemporary Plastic Surgery, East Brunswick, New Jersey, United States|Anthony S. Lombardi, Jr., M.D., Eatontown, New Jersey, United States|The Peer Group, Florham Park, New Jersey, United States|Plastic Surgery Plus, Freehold, New Jersey, United States|The Plastic Surgery Group, Montclair, New Jersey, United States|Brian S. Glatt, MD, Morristown, New Jersey, United States|Robert Zubowski, M.D., Paramus, New Jersey, United States|Allure Plastic Surgery, LLC, Red Bank, New Jersey, United States|Caroline A. Glicksman, MD, Sea Girt, New Jersey, United States|Beverly Friedlander, MD, Short Hills, New Jersey, United States|Farrokh Shafaie, M.D., Summit, New Jersey, United States|Summit Plastic Surgery, Summit, New Jersey, United States|Michael J. Conn, MD, Teaneck, New Jersey, United States|Personal Enhancement Center, Toms River, New Jersey, United States|Advanced Aesthetics Plastic Surgery Center, Verona, New Jersey, United States|Bhupesh Vasisht, MD, Voorhees, New Jersey, United States|New Mexico Plastic Surgery, Albuquerque, New Mexico, United States|Suffolk Plastic Surgeons, PC, East Setauket, New York, United States|CNY Cosmetic & Reconstructive Surgery, Fayetteville, New York, United States|Denis F. Branson, MD, Fayetteville, New York, United States|Aristocrat Plastic Surgery, Great Neck, New York, United States|Plastic & Reconstructive Surgery, Mount Kisco, New York, United States|Michael A. Kalvert, MD, New City, New York, United States|A. Eric Sadeh, MD, PC, New York, New York, United States|Luis Cenedese, M.D., New York, New York, United States|William Samson, MD, New York, New York, United States|David P. Rapaport, MD, New York, New York, United States|Jennifer L. Walden, MD, New York, New York, United States|Lenox Hill Plastic Surgery, New York, New York, United States|Park East Ambulatory Surgical Unit, P.C., New York, New York, United States|Bryan G. Forley, M.D., P.C., New York, New York, United States|Museum Mile Surgery Center, New York, New York, United States|Nina S. Naidu, M.D., New York, New York, United States|Paul R. Weiss, MD, New York, New York, United States|The Reed Center, New York, New York, United States|David J. Friedman M.D., P.C., New York, New York, United States|Mia Talmor, MD, New York, New York, United States|Townhouse 114, New York, New York, United States|Vega Plastic Surgery & Medspa, Pittsford, New York, United States|Lindsay House Surgery, Rochester, New York, United States|Stephen Evangelisti M.D., Rochester, New York, United States|Plastic Surgery Group of Rochester LLC, Rochester, New York, United States|Saratoga Springs Plastic Surgery PC, Saratoga Springs, New York, United States|Dr. Fox & Schingo Plastic Surgery, Schenectady, New York, United States|Keith Berman MD, Staten Island, New York, United States|John W. Decorato, MD, Staten Island, New York, United States|Alfred T. Culliford, IV, MD, Staten Island, New York, United States|Allure Plastic Surgery, Staten Island, New York, United States|Mark D. Epstein MD, Stony Brook, New York, United States|Philip A. Falcone, MD, FACS, Syracuse, New York, United States|Community General Hospital, Syracuse, New York, United States|Amherst Cosmetic Surgery, Williamsville, New York, United States|David Funt MD, Woodmere, New York, United States|Charlotte Plastic Surgery Center, Charlotte, North Carolina, United States|Charlotte Plastic Surgery, Charlotte, North Carolina, United States|Graper Cosmetic Surgery, Charlotte, North Carolina, United States|Faces Plastic Surgery, PA, Durham, North Carolina, United States|Care Plastic Surgery, Durham, North Carolina, United States|Southeastern Plastic Surgery, PC, Gastonia, North Carolina, United States|Stillwater Plastic Surgery, Huntersville, North Carolina, United States|The Hunstad Center, Huntersville, North Carolina, United States|Wilmington Plastic Surgery, Wilmington, North Carolina, United States|Wake Forest University School of Medicine - Plastic & Reconstructive Surgery, Winston-Salem, North Carolina, United States|Akron Plastic Surgeons, Inc., Akron, Ohio, United States|J. Vicente Poblete, MD, FACS, Avon, Ohio, United States|Beachwood Plastic Surgery and Medical Spa, Beachwood, Ohio, United States|Robert D. Lewis, MD, Canfield, Ohio, United States|Christopher Reeder, D.O., F.A.C.O.S., Centerville, Ohio, United States|Allison Lied Plastic Surgery, Cincinnati, Ohio, United States|Kurtis W. Martin, MD, Cincinnati, Ohio, United States|Columbus Institute of Plastic Surgery, Columbus, Ohio, United States|Advanced Aesthetic and Laser Surgery, Columbus, Ohio, United States|John Flory, MD, Dublin, Ohio, United States|Arrowhead Plastic Surgeons, Maumee, Ohio, United States|Reconstructive & Aesthetic Surgeons, Inc., Toledo, Ohio, United States|Artisan Surgery Center, Toledo, Ohio, United States|Frank Barone, MD Inc., Toledo, Ohio, United States|Gary C. Hill, MD, Edmond, Oklahoma, United States|Cosmetic Surgery Affiliates, LLC, Oklahoma City, Oklahoma, United States|Gonce Cosmetic Surgery Center, Oklahoma City, Oklahoma, United States|Jones Plastic Surgery, Oklahoma City, Oklahoma, United States|Robert A. Hein, MD, Oklahoma City, Oklahoma, United States|Shadid Plastic Surgery Associates, Oklahoma City, Oklahoma, United States|Lisa D. Taylor, MD, Oklahoma City, Oklahoma, United States|E. Bradley Garber, M.D., P.C., Tulsa, Oklahoma, United States|Oklahoma Cosmetic Surgery Center @ Tulsa Surgical Arts, Tulsa, Oklahoma, United States|Robert Quinn, MD, Bend, Oregon, United States|The Leffel Center, Bend, Oregon, United States|Aesthetic Plastic Surgery, Eugene, Oregon, United States|Jewell Plastic Surgery Center, Eugene, Oregon, United States|Adams House Surgery Center, Portland, Oregon, United States|Michael F. Bohley, M.D., Portland, Oregon, United States|Ronald V. DeMars, M.D., Portland, Oregon, United States|The Waldorf Center, Portland, Oregon, United States|Connall Cosmetic Surgery, Tualatin, Oregon, United States|Blair County Plastic Surgery, Altoona, Pennsylvania, United States|David A. Silberman MD, Doylestown, Pennsylvania, United States|Stratis-Gayner Plastic Surgery, Harrisburg, Pennsylvania, United States|Lancaster Plastic Surgery Ltd., Lancaster, Pennsylvania, United States|Ernest Normington M.D., Lewisburg, Pennsylvania, United States|Hospital of the University of Pennsylvania, Penn Plastic Surgery, Philadelphia, Pennsylvania, United States|Hurwitz Center for Plastic Surgery, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Denis F. Branson, MD, Pittsburgh, Pennsylvania, United States|Robert W. Bragdon, MD, Pittsburgh, Pennsylvania, United States|Premier Plastic Surgery, Wexford, Pennsylvania, United States|Berks Plastic Surgery, Wyomissing, Pennsylvania, United States|Northeast Institute of Plastic Surgery, Warwick, Rhode Island, United States|Plastic Surgery Consultants, LLC, Columbia, South Carolina, United States|Healing Waters at Palmetto Health, Columbia, South Carolina, United States|Advanced Cosmetic Surgery, Greenville, South Carolina, United States|Lowcountry Plastic Surgery Center, Mount Pleasant, South Carolina, United States|Low Country Plastic Surgery, Okatie, South Carolina, United States|Carolina Plastic Surgery, Spartanburg, South Carolina, United States|Fleming Plastic Surgery, Brentwood, Tennessee, United States|Associates in Plastic & Reconstructive Surgery, Chattanooga, Tennessee, United States|Chattanooga Plastic Surgery, Chattanooga, Tennessee, United States|Wolf River Plastic Surgery, P.C., Germantown, Tennessee, United States|Plastic Surgery Clinic of Jackson, Jackson, Tennessee, United States|Aesthetic Plastic Surgery Associates, Knoxville, Tennessee, United States|The Breazeale Clinic, Knoxville, Tennessee, United States|Dean Kleto, MD, Knoxville, Tennessee, United States|Steven J. Smith, MD, Knoxville, Tennessee, United States|Cosmetic Surgery Specialists, Memphis, Tennessee, United States|The Lett Center, Mount Juliet, Tennessee, United States|Middle TN Plastic Surgery, Murfreesboro, Tennessee, United States|Alexander G. Nein, MS, MD, FACS, Nashville, Tennessee, United States|Lois Wagstrom, M.D., PC, Nashville, Tennessee, United States|Plastic Surgery Center of Nashville, Nashville, Tennessee, United States|Nashville Cosmetic Surgery Center, Nashville, Tennessee, United States|Maxwell Aesthetics, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|North Texas Plastic & Reconstructive Surgery, Allen, Texas, United States|Mary Ann D. Piskun, MD, Amarillo, Texas, United States|Meridian Surgery Center, Austin, Texas, United States|Malcolm Rude, MD, PA, College Station, Texas, United States|Mark A. Deuber, MD, Dallas, Texas, United States|David M. Godat, M.D., Dallas, Texas, United States|Highland Park Plastic Surgery, Dallas, Texas, United States|David E. Martin, MD Plastic Surgery, Dallas, Texas, United States|Jeffery K. Krueger MD, Dallas, Texas, United States|Patrick L. Hodges, M.D., Dallas, Texas, United States|USA Plastic Surgery, Dallas, Texas, United States|Plastic Surgery Center Of Dallas, Dallas, Texas, United States|Warren J. Katz MD Associated, Dallas, Texas, United States|David E. Morales, M.D., Dallas, Texas, United States|William M. Carpenter, M.D., Dallas, Texas, United States|Rios Center for Plastic Surgery, Edinburg, Texas, United States|Cosmetic Surgery & Laser Center of El Paso, El Paso, Texas, United States|El Paso Cosmetic Surgery, El Paso, Texas, United States|Southwest Plastic Surgery, El Paso, Texas, United States|Southwest Plastic Surgery, El Paso, Texas, United States|Danielle LeBlanc, MD, Fort Worth, Texas, United States|Dennis Schuster, MD, Fort Worth, Texas, United States|Emily McLaughlin, MD, Fort Worth, Texas, United States|Fort Worth Surgery Center, Clear Fork Surgery Center, Medical Centre Surgical Hospital, Fort Worth, Texas, United States|Jonathan B. Heistein, MD, Fort Worth, Texas, United States|Louis L. Strock, MD, Fort Worth, Texas, United States|Patrick Chen, MD, F.A.C.S., Fort Worth, Texas, United States|Kirby Plastic Surgery, Fort Worth, Texas, United States|Christine Stiles, MD, Frisco, Texas, United States|Georgetown Plastic Surgery, Georgetown, Texas, United States|Bruce K. Smith, MD, Houston, Texas, United States|Lisa D. Santos, MD, Houston, Texas, United States|The Aesthetic Center for Plastic Surgery, Houston, Texas, United States|ACPS, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Azita Madjidi, M.D., Houston, Texas, United States|Basu Plastic Surgery, Houston, Texas, United States|Craig S. Rock, MD, Houston, Texas, United States|Houston Center for Plastic Surgery, PA, Houston, Texas, United States|Neal R. Reisman, MD, Houston, Texas, United States|David D. Davila, DO, Houston, Texas, United States|Camille G. Cash, MD, Houston, Texas, United States|Hill Country Surgery Center, Kerrville, Texas, United States|Avila Plastic Surgery, Mission, Texas, United States|Cosmetic Surgery Associates of Texas, Plano, Texas, United States|West Plano Plastic Surgery Center, Plano, Texas, United States|Robert J. Schwartz, MD, Richardson, Texas, United States|Regional Plastic Surgery, Richardson, Texas, United States|Regional Plastic Surgery Center, Rockwall, Texas, United States|The Thompson Center for Plastic Surgery, Round Rock, Texas, United States|Advanced Concepts in Plastic Surgery, San Antonio, Texas, United States|Scott & White Clinic, Temple, Texas, United States|McHugh Plastic Surgery, The Woodlands, Texas, United States|Rivela Plastic Surgery, The Woodlands, Texas, United States|Daniel S. Sellers, MD, Bountiful, Utah, United States|Premier Plastic Surgery, Bountiful, Utah, United States|David S. Motoki, M.D., P.C., Draper, Utah, United States|Jed R. Bindrup, M.D., Draper, Utah, United States|Richard H. Fryer, M.D., Draper, Utah, United States|Steven H. Warnock, MD, Draper, Utah, United States|Aesthetica Plastic Surgery, Lindon, Utah, United States|M. Kirk Moore, MD, Midvale, Utah, United States|Alpine Plastic & Reconstructive Surgery, Ogden, Utah, United States|Brzowski Plastic Surgery, Ogden, Utah, United States|Charles Pledger, MD, Provo, Utah, United States|James M. Clayton, MD, Provo, Utah, United States|The Center for Advanced Plastic Surgery, Saint George, Utah, United States|Bryce D. Allred, MD, West Jordan, Utah, United States|Victoria Plastic Surgery Center, Fairfax, Virginia, United States|Parva Plastic Surgery, Leesburg, Virginia, United States|Gloria Duda, M.D., P.C., McLean, Virginia, United States|National Center for Plastic Surgery, McLean, Virginia, United States|Plastic Surgery Center of Hampton Roads, Newport News, Virginia, United States|Hague Center, Norfolk, Virginia, United States|Austin-Weston Center, Reston, Virginia, United States|Plastic Surgery at Ridgewood Hill, Salem, Virginia, United States|Anna Drzewiecki Plastic Surgery, Virginia Beach, Virginia, United States|Renaissance Center, Bellevue, Washington, United States|James H. Blackburn, MD, Bellingham, Washington, United States|Plastic Surgery Bellingham, Bellingham, Washington, United States|Yarrow Bay Plastic Surgery, Kirkland, Washington, United States|Remington Plastic Surgery, Kirkland, Washington, United States|Richard A. Baxter, Mountlake Terrace, Washington, United States|Foley Plastic Surgery Center, Olympia, Washington, United States|Puyallup Ambulatory Surgicenter, Puyallup, Washington, United States|Mary Lee Peters, MD, Seattle, Washington, United States|Downey Plastic Surgery, Seattle, Washington, United States|Alfonso Oliva, MD, Spokane, Washington, United States|Spokane Plastic Surgeons, Spokane, Washington, United States|Peace Health Medical Group, Plastic Surgery, Vancouver, Washington, United States|Cynthia D. Gray, MD, Vancouver, Washington, United States|Ultimate Plastic and Reconstructive Surgery, Huntington, West Virginia, United States|Center for Aesthetics & Plastic Surgery, Neenah, Wisconsin, United States|Cosmetic and Plastic Surgery Specialists, Wauwatosa, Wisconsin, United States|Banff Plastic Surgery, Banff, Alberta, Canada|The Centre for Personal Surgery, Burlington, Ontario, Canada|Sean Rice, M.D., North York, Ontario, Canada|The Center for Plastic and Esthetic Surgery, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00443274"
462,"NCT00441766","Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain",,"Terminated","Has Results","Irritable Bowel Syndrome","Drug: AGN 203818|Drug: placebo","Change From Baseline in Mean Highest-Average-Pain Score at Week 4|Percentage of Patients Who Rated Their Condition as Improved on the Subject Global Impression of Change (SGIC) at Week 4|Percentage of Patients Who Experienced Adequate Relief of Irritable Bowel Syndrome (IBS) Pain (AR-IBS) at Week 4|Change From Baseline in Frequency of Bowel Movements at Week 4 Using the Bristol Stool Scale (BSS)","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 2","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","203818-008","March 2007","February 2008","February 2008","March 1, 2007","January 20, 2012","January 20, 2012","Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00441766"
463,"NCT00440141","Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops","IOP|Tolerability","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-AP01","July 2006","March 2007","March 2007","February 26, 2007",,"January 2, 2008","Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00440141"
464,"NCT00440011","Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost 0.03% eye drops|Drug: travoprost 0.004% eye drops","Intraocular Pressure (IOP)|Tolerability - Conjunctival Hyperemia","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-LUM01","August 2006","October 2007","October 2007","February 26, 2007","September 26, 2008","April 25, 2019","San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00440011"
465,"NCT00439140","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",,"Terminated","Has Results","Overactive Bladder","Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo)","Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in FEV1/FVC Ratio|Change From Baseline in the Number of Urinary Incontinence Episodes|Change From Baseline in the Maximum (Amplitude) Detrusor Pressure (MDP)|Change From Baseline in Maximum Cystometric Capacity (MCC)","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-082","June 2007","December 2012","December 2012","February 23, 2007","January 24, 2014","January 24, 2014","Philadelphia, Pennsylvania, United States|Herston, Queensland, Australia|Victoria, British Columbia, Canada|Chennai, India",,"https://ClinicalTrials.gov/show/NCT00439140"
466,"NCT00432341","Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia",,"Terminated","Has Results","Spasmodic Torticollis","Biological: botulinum toxin type A","Duration of Treatment Benefit|Toronto Western Spasmodic Torticollis Rating Scale Duration Target Score (TDTS) at Week 4|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4|Global Assessment of Benefit by Patient at Week 4|Global Assessment of Benefit by Physician at Week 4|Physician Assessment of Cervical Dystonia Severity at Week 4|Physician Comparison of Benefit to Previous Injections at Week 20|Patient Comparison of Benefit to Previous Injections at Week 20|Patient Visual Analog Assessment of Pain at Week 4|Patient Assessment of Need for Retreatment at Week 4","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MedAff-BTX-0615","June 2007","March 2009","June 2009","February 7, 2007","December 16, 2011","December 16, 2011","Buenos Aires, Argentina|Parkville, Victoria, Australia|New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00432341"
467,"NCT00395057","A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration",,"Terminated","Has Results","Choroid Neovascularization|Age-Related Macular Degeneration","Drug: AGN 211745|Drug: Ranibizumab 500µg","Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3|Lesion Size as Assessed by Fluorescein Angiography (FA) and Photography at Month 3|Foveal Thickness as Assessed by Optical Coherence Tomography (OCT) at Month 3|Visual Functioning Questionnaire (VFQ) at Month 3|Time to Treatment With Standard of Care at Month 6","Allergan","All","50 Years and older   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","211745-001","January 2007","October 2008","February 2009","November 2, 2006","December 13, 2011","September 7, 2015","Houston, Texas, United States|Sydney, New South Wales, Australia|Makati, Philippines",,"https://ClinicalTrials.gov/show/NCT00395057"
468,"NCT00381719","Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy",,"Completed","No Results Available","Diabetic Neuropathy, Painful","Drug: AGN 203818|Drug: placebo capsule","Reduction in Daily Pain Score|Changes in sleep interference score|Beck depression inventory|Quality of Life questionnaires","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","203818-004","October 2006","November 2007","November 2007","September 28, 2006",,"January 7, 2008","Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00381719"
469,"NCT00380783","Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis",,"Terminated","No Results Available","Cystitis, Interstitial","Drug: AGN 203818","Reduction in daily pain scores","Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","203818-005","October 2006","March 2007","March 2007","September 26, 2006",,"May 30, 2011","Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT00380783"
470,"NCT00363714","A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",,"Completed","No Results Available","Age-Related Macular Degeneration|Choroidal Neovascularization","Drug: AGN211745","Adverse Events|Visual Acuity using the Diabetic Retinopathy Study chart|IOP|OCT|Fluorescein Angiography (FA)","Allergan|Sirna Therapeutics Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIRNA 0401|AGN211745","November 2004","April 2007","April 2007","August 15, 2006",,"August 18, 2008","Baltimore, Maryland, United States|Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00363714"
471,"NCT00343187","A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash",,"Terminated","No Results Available","Rash|Non-small-Cell Lung Cancer","Drug: ACZONE (dapsone) Gel, 5%|Drug: Vehicle Control","Safety: Adverse events; laboratory parameters; Vital signs; Pharmacokinetics|Efficacy: Lesion counts; Plaque area; % of FSA affected; Erythema Score; Pruritus VAS Score; CTCAE v3.0 Grade for rash; Proportion of subjects who have rash on the face that worsens to specific category.","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ACZ EGFR 01","June 2006","July 2007","July 2007","June 22, 2006",,"May 30, 2011","Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00343187"
472,"NCT00333996","A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis",,"Terminated","No Results Available","Anterior Uveitis","Drug: Dexamethasone","Anterior Chamber Cell","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","206207-015","May 2006","March 2007","March 2007","June 6, 2006",,"May 30, 2011","Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00333996"
473,"NCT00333814","A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis",,"Completed","Has Results","Intermediate Uveitis|Posterior Uveitis","Drug: Dexamethasone|Drug: dexamethasone|Drug: Sham injection","Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206207-014","May 2006","December 2008","April 2009","June 6, 2006","April 14, 2011","April 14, 2011","Dallas, Texas, United States|Sydney, Australia|Vienna, Austria|São Paulo, São Paulo/SP, Brazil|Montreal, Quebec, Canada|Prague, Czech Republic|Paris, France|Heidelberg, Germany|Holargos, Greece|Hyderabad, India|Petah Tikva, Israel|Seoul, Korea, Republic of|Gdansk, Poland|Coimbra, Portugal|Johannesburg, South Africa|Madrid, Spain|Lausanne, Switzerland|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00333814"
474,"NCT00332540","Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: bimatoprost/timolol fixed combination","IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","520","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192024-018T","August 2001","August 2003","August 2003","June 1, 2006",,"May 30, 2011","Rochester, New York, United States|Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00332540"
475,"NCT00332436","Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: brimonidine/timolol fixed combination","IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","586","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","190342-013T","December 1999","November 2001","November 2001","June 1, 2006",,"May 30, 2011","Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00332436"
476,"NCT00332384","Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: brimonidine/timolol fixed combination","IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","573","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","190342-012T","January 2000","November 2001","November 2001","June 1, 2006",,"May 30, 2011","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT00332384"
477,"NCT00332345","Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: brimonidine/timolol fixed combination","IOP","Allergan","All","21 Years and older   (Adult, Older Adult)","Phase 2","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","190342-011T","July 1999","August 1999","August 1999","June 1, 2006",,"May 30, 2011","Artesia, California, United States",,"https://ClinicalTrials.gov/show/NCT00332345"
478,"NCT00332072","Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: bimatoprost/timolol fixed combination","IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","541","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192024-021T","August 2001","August 2003","August 2003","June 1, 2006",,"May 30, 2011","Ogden, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00332072"
479,"NCT00332059","Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: bimatoprost/timolol fixed combination","IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","445","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192024-026T","May 2003","September 2004","September 2004","June 1, 2006",,"May 30, 2011","Bel Air, Maryland, United States|Vienna, Austria|Montreal, Quebec, Canada|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00332059"
480,"NCT00325715","AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers",,"Completed","No Results Available","Peptic Ulcer","Drug: AGN 201904|Drug: esomeprazole","Stomach or upper intestinal erosions","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","201904-006","April 2006","August 2006","August 2006","May 15, 2006",,"June 2, 2011","Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00325715"
481,"NCT00311376","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",,"Completed","Has Results","Overactive Bladder","Biological: botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (300U)|Other: Normal Saline (Placebo); botulinum toxin Type A (200U)|Other: Normal Saline (Placebo); botulinum toxin Type A (300U)","Change From Baseline in Number of Weekly Episodes of Urinary Incontinence|Change From Baseline in Maximum Cystometric Capacity (MCC)|Change From Baseline in Maximum Detrusor Pressure (MDP)|Change From Baseline in Total Score on Incontinence Quality of Life (I-QOL) Questionnaire","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","416","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-515","August 2006","May 2010","May 2010","April 6, 2006","October 17, 2011","December 4, 2015","Royal Oak, Michigan, United States|Randwick, New South Wales, Australia|Innsbruck, Austria|Gent, Belgium|Sherbrooke, Canada|Ostrava, Czech Republic|Garches, France|Halle (Saale), Germany|Christchurch, New Zealand|Wroclaw, Poland|Moscow, Russian Federation|Martin, Slovakia|Lviv, Ukraine|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00311376"
482,"NCT00300443","Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: bimatoprost","Lowering intraocular pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192024-031","December 2005","June 2007","June 2007","March 9, 2006",,"May 30, 2011","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT00300443"
483,"NCT00284518","Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia",,"Completed","Has Results","Benign Prostatic Hyperplasia","Biological: botulinum toxin Type A|Drug: normal saline","Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12|Change From Baseline in International Prostate Symptom Score (IPSS) at Week 72|Change From Baseline in Peak Urine Flow Rate|Change From Baseline in Total Prostate Volume|Change From Baseline in Transitional Zone Prostate Volume|Change From Baseline in Post-Void Residual","Allergan","Male","50 Years and older   (Adult, Older Adult)","Phase 2","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-517","December 2005","May 2009","May 2010","February 1, 2006","December 17, 2012","December 17, 2012","Murdoch, Australia|Vienna, Austria|Victoria, British Columbia, Canada|Olomouc, Czech Republic|Paris Cedex 13, France|Braunschweig, Germany|Perugia, Italy|Seoul, Korea, Republic of|Martin, Slovakia|Taipei, Taiwan|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00284518"
484,"NCT00249782","A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.",,"Completed","No Results Available","Rosacea","Drug: Vehicle control, 2x/day|Drug: ACZONE (dapsone) Gel, 5%, 2x/day|Drug: ACZONE (dapsone) Gel, 5%, 1x/day|Drug: MetroGel® (metronidazole gel), 1.0% 1x/day|Drug: ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)","Efficacy: Percent change and change from baseline in inflammatory lesion counts;|""Success"" rate, defined as proportion of subjects with a score of 0 or 1 and at least a 2 point improvement from baseline on the IGA scale;|Erythema & telangiectasia scores;|Lesion counts over time|Safety: Adverse events and concomitant medications; Local symptom scores; Hematology and chemistry laboratory parameters; Vital signs|Other: Plasma dapsone concentrations","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","ACZ ROS 01","November 2005","May 2006","May 2006","November 7, 2005",,"May 30, 2011","Radiant Research, Birmingham, Alabama, United States|Radiant Research, Tucson, Arizona, United States|East Bay Dermatology Medical Group, Inc., Fremont, California, United States|Therapeutics Clinical Research, San Diego, California, United States|Clincial Research Specialists, Inc., Santa Monica, California, United States|Cherry Creek Research, Inc, Denver, Colorado, United States|The Savin Center, PC, New Haven, Connecticut, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Tampa Bay Medical Research, Clearwater, Florida, United States|FXM Research, Miami, Florida, United States|University Clinical Research, Inc., Pembroke Pines, Florida, United States|MedaPhase, Inc., Newnan, Georgia, United States|Welborn Clinic, Evansville, Indiana, United States|Dermatology Clinical Trials Unit Washington University, St. Louis, Missouri, United States|Skin Specialists, PC, Omaha, Nebraska, United States|Academic Dermatology Associates, Albuquerque, New Mexico, United States|Dermatology Consulting Services, High Point, North Carolina, United States|University Dermatology Consultants, Inc., Cincinnati, Ohio, United States|Dermatology Research Associates Inc., Cincinnati, Ohio, United States|Northwest Dermatology and Research Center, Portland, Oregon, United States|Oregon Medical Research Center, Portland, Oregon, United States|Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States|Dermatology Research Association, Inc., Nashville, Tennessee, United States|DermResearch, Inc., Austin, Texas, United States|J&S Studies Inc., Bryan, Texas, United States|Madison Skin & Research, Inc., Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00249782"
485,"NCT00243711","A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop",,"Completed","No Results Available","Dry Eye","Drug: Carboxymethylcellulose sodium and Glycerin","Dry Eye Symptoms|Ocular surface damage, tear stability, tear production","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AG9689-001","September 2005","April 2006","April 2006","October 25, 2005",,"May 30, 2011","Warrensburg, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00243711"
486,"NCT00243542","Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency",,"Completed","No Results Available","Acne Vulgaris","Drug: ACZONE Gel, 5%|Drug: Vehicle","The within-subject between treatment period differences in change from baseline to the 2nd week of each treatment period and change from baseline to the end of each treatment period will be summarized based upon various lab parameters.|The safety evaluable data set will be used, and each variable will be summarized using descriptive statistics.|Analyses of clinical lab values, AEs, vitals, and concomitant meds will be performed on all subjects who received treatment.|Acne Lesions: Tabular summaries of total lesion counts will be provided by appropriate descriptive statistics.","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","ACZ ACN 01","November 2005","October 2006","October 2006","October 24, 2005",,"May 30, 2011","Radiant Research, Inc., Birmingham, Alabama, United States|Therapeutics Clinical Research, San Diego, California, United States|Department of Dermatology, University of California, San Francisco, San Francisco, California, United States|Dermatology Associates, PC at the Washington Hospital Center, Washington, District of Columbia, United States|Howard University Hospital Department of Dermatology, Washington, District of Columbia, United States|FXM Research, Miami, Florida, United States|University Clinical Research, Inc, Pembroke Pines, Florida, United States|MedaPhase, Inc., Newnan, Georgia, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Washington University Dermatology Clinical Trials Unit, St. Louis, Missouri, United States|Skin Specialists, PC, Omaha, Nebraska, United States|Department of Dermatology SUNY Downstate Medical Center, Brooklyn, New York, United States|Columbia University Medical Center Department of Dermatology, New York, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Universtiy Dermatology Consultants, Inc., Cincinnati, Ohio, United States|Paddington Testing Clinic, Philadelphia, Pennsylvania, United States|Society Hill Dermatology, Philadelphia, Pennsylvania, United States|Okatie Research Center, LLC, Beaufort, South Carolina, United States|Dermatology Associates of Knoxville, Knoxville, Tennessee, United States|Dermatology Research Associates, Nashville, Tennessee, United States|DermResearch, Inc., Austin, Texas, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|J&S Studies, Inc., Bryan, Texas, United States|Research Across America, Dallas, Texas, United States|Suzanne Bruce and Associates, PA, Houston, Texas, United States|The Education and Research Foundation, Inc., Lynchburg, Virginia, United States|Virginia Clinical Research, Norfolk, Virginia, United States|Advanced Healthcare, SC, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00243542"
487,"NCT00168480","A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis",,"Completed","No Results Available","Hyperhidrosis","Biological: Botulinum Toxin Type A","Assessment of axillary sweat production|Patient reported health outcome measures","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","424","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-513","November 2003","April 2007","April 2007","September 15, 2005",,"September 29, 2008","Portland, Oregon, United States|Pinneberg, Germany|Goteborg, Sweden|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00168480"
488,"NCT00168454","A Research Study for Patients With Overactive Bladder",,"Completed","Has Results","Overactive Bladder|Urinary Incontinence","Biological: botulinum toxin Type A|Drug: Placebo","Change in Number of Urinary Urge Incontinence Episodes|Change in Number of Micturitions|Change in Number of Nocturia Episodes|Maximum Cystometric Capacity (MCC) by Urodynamic Measurements|Incontinence Quality of Life Instrument (I-QOL)","Allergan","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","313","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-077","July 2005","January 2008","June 2008","September 15, 2005","February 11, 2010","November 6, 2013","Pittsburgh, Pennsylvania, United States|Ghent, Belgium|Victoria, British Columbia, Canada|Berlin, Germany|Warsaw, Poland|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00168454"
489,"NCT00168441","A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia",,"Completed","No Results Available","Postherpetic Neuralgia","Drug: Botulinum Toxin Type A","Pain score|Various Quality of Life questionnaires|Reduction in area of pain/allodynia","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","117","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","191622-066","June 2004","June 2005","June 2005","September 15, 2005",,"May 30, 2011",,,"https://ClinicalTrials.gov/show/NCT00168441"
490,"NCT00168428","A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches",,"Completed","Has Results","Migraine Disorders","Biological: Botulinum Toxin Type A|Other: placebo (saline)","Change in Frequency of Headache Days|Change in Total Cumulative Hours of Headache Occurring on Headache Days|Change in Frequency of Moderate/Severe Headache Days|Change in Frequency of Migraine/Probable Migraine Headache Days|Change in Frequency of Headache Episodes|Percentage of Patients With Severe HIT-6 Impact Category Scores","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","705","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-080","March 2006","December 2007","August 2008","September 15, 2005","December 7, 2010","November 18, 2013","Walnut Creek, California, United States|Calgary, Alberta, Canada|Zagreb, Croatia|Essen, Germany|Zurich, Switzerland|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00168428"
491,"NCT00168415","A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis",,"Completed","No Results Available","Hyperhidrosis","Biological: Botulinum Toxin Type A","Subject's assessment of the severity of hyperhidrosis using the HDS Scale|Measurement of axillary sweat production","Allergan","All","12 Years to 17 Years   (Child)","Phase 4","144","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-075","August 2005","June 2007","June 2007","September 15, 2005",,"September 29, 2008","Portland, Oregon, United States|Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00168415"
492,"NCT00168402","A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis",,"Completed","No Results Available","Hyperhidrosis","Drug: Botulinum Toxin Type A","Subject's assessment of the severity of hyperhidrosis|Measurement of axillary sweat production","Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","193","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191622-046","February 2002","October 2005","October 2005","September 15, 2005",,"May 30, 2011",,,"https://ClinicalTrials.gov/show/NCT00168402"
493,"NCT00168389","A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema",,"Completed","Has Results","Diabetic Macular Edema","Drug: Dexamethasone|Other: Sham","Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye|Average Change From Baseline in BCVA in the Study Eye|Change From Baseline in BCVA in the Study Eye|Percentage of Patients With a BCVA Improvement of ≥10 Letters From Baseline in the Study Eye|Average Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)|10th Percentile for Time to BCVA Improvement of ≥15 Letters From Baseline in the Study Eye|Percentage of Patients With BCVA Improvement of ≥15 Letters From Baseline in the Study Eye at 3-month Intervals","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206207-010","February 2005","June 2012","June 2012","September 15, 2005","August 4, 2014","August 4, 2014","Inglewood, California, United States|Westmead, New South Wales, Australia|Toronto, Ontario, Canada|Prague, Czech Republic|Hamburg, Germany|Tel Aviv, Israel|Rockwell Center, Makati, Philippines|Coimbra, Portugal|Cape Town, South Africa|Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00168389"
494,"NCT00168363","Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: brimonidine","lowering of intraocular pressure","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","190342-022","January 2005","August 2006","August 2006","September 15, 2005",,"May 30, 2011",,,"https://ClinicalTrials.gov/show/NCT00168363"
495,"NCT00168350","Memantine in Patients With Chronic Glaucoma",,"Completed","No Results Available","Open-Angle Glaucoma","Drug: memantine","Progression of glaucoma","Allergan","All","18 Years to 82 Years   (Adult, Older Adult)","Phase 3","1179","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192944-005","March 2000","September 2006","September 2006","September 15, 2005",,"November 4, 2010",,,"https://ClinicalTrials.gov/show/NCT00168350"
496,"NCT00168337","A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema",,"Completed","Has Results","Diabetic Macular Edema","Drug: Dexamethasone|Other: Sham","Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye|Average Change From Baseline in BCVA in the Study Eye|Change From Baseline in BCVA in the Study Eye|Percentage of Patients With a BCVA Improvement of ≥10 Letters From Baseline in the Study Eye|Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206207-011","May 2005","May 2012","May 2012","September 15, 2005","August 4, 2014","August 4, 2014","Artesia, California, United States|Sao Paulo, Brazil|Mississauga, Ontario, Canada|Bogota, Colombia|Dijon, France|Budapest, Hungary|New Delhi, India|Milano, Italy|Seoul, Korea, Republic of|Auckland, New Zealand|Warszawa, Poland|Singapore, Singapore|Taipei, Taiwan|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00168337"
497,"NCT00168324","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion",,"Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Drug: 700 µg Dexamethasone|Drug: 350 µg Dexamethasone|Other: Sham Injection","Cumulative Response Rate of 15 or More Letter Improvement|Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in Retinal Thickness in the Study Eye|Percentage of Patients With a Change From Baseline in BCVA by Category","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","599","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206207-008","October 1, 2004","March 1, 2008","October 1, 2008","September 15, 2005","August 26, 2009","April 23, 2019","Los Angeles, California, United States|Sydney, Australia|Graz, Austria|Halifax, Nova Scotia, Canada|Brno, Czechia|Creteil, France|Karlsruhe, Germany|Rehovot, Israel|Tabacalera, Mexico|Makati, Philippines|Coimbra, Portugal|Arcadia, South Africa|Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00168324"
498,"NCT00168298","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion",,"Completed","Has Results","Macular Edema|Retinal Vein Occlusion","Drug: 700 µg Dexamethasone|Drug: 350 µg Dexamethasone|Other: Sham Injection","Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change From Baseline in Retinal Thickness in the Study Eye|Percentage of Patients With a Change From Baseline in BCVA by Category","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","668","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206207-009","November 1, 2004","March 1, 2008","September 5, 2008","September 15, 2005","August 26, 2009","April 23, 2019","Houston, Texas, United States|Sao Paulo, Brazil|Mississauga, Ontario, Canada|Bogota, Colombia|Kowloon, Hong Kong|Tamil Nadu, India|Udine, Italy|Seoul, Korea, Republic of|Auckland, New Zealand|Poznan, Poland|Singapore, Singapore|Alicante, Spain|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00168298"
499,"NCT00156910","A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches",,"Completed","Has Results","Migraine Disorders","Biological: Botulinum Toxin Type A|Other: Placebo (saline)","Change in Frequency of Headache Episodes|Change in Frequency of Headache Days|Change in Frequency of Acute Headache Pain Medication Intakes|Change in Frequency of Migraine/Probable Migraine Headache Days|Change in Frequency of Migraine/Probable Migraine Headache Episodes","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","679","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-079","February 2006","November 2007","July 2008","September 12, 2005","December 7, 2010","November 18, 2013","Seattle, Washington, United States|Markham, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00156910"
500,"NCT00152048","Evaluation of Eflornithine on Facial and Forearm Skin",,"Completed","No Results Available","Hirsutism","Drug: Eflornithine hydrochloride","Change in facial skin thickness measured by ultrasound at 24 weeks|Skin biopsies|Histology and histochemistry in the dermis|Physician Global Assessment|Subject Self-Assessment Questionnaire","Allergan","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SPD488-401|2004-000726-78","November 30, 2004",,"October 31, 2005","September 9, 2005",,"October 30, 2019",,,"https://ClinicalTrials.gov/show/NCT00152048"
501,"NCT00151541","A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%",,"Completed","No Results Available","Acne Vulgaris","Drug: Dapsone Topical Gel + adapalene gel 0.1%|Drug: Dapsone Topical Gel + benzoyl peroxide gel 4%|Drug: Dapsone Topical Gel + vehicle control","The primary efficacy endpoint will be mean percent reduction in inflammatory lesion counts.|Additional efficacy endpoints will be the mean percent reduction from Baseline in non-inflammatory and total lesion counts, as well as the proportion of subjects who achieve success (none/minimal) on a 5-point Global Acne Assessment Score.|Safety endpoints will include treatment-emergent and treatment related adverse events. An additional safety endpoint will be the local adverse reaction assessment.","Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","DAP0407","February 2005","July 2005","July 2005","September 9, 2005",,"May 30, 2011",,,"https://ClinicalTrials.gov/show/NCT00151541"
502,"NCT00141882","Memantine in Patients With Chronic Glaucoma",,"Completed","No Results Available","Open-Angle Glaucoma","Drug: memantine","Progression of glaucoma","Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192944-004","March 1999","January 2006","August 2006","September 2, 2005",,"November 4, 2010",,,"https://ClinicalTrials.gov/show/NCT00141882"
503,"NCT01629134","Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips",,"Completed","Has Results","Lip Augmentation","Device: Crosslinked hyaluronic acid gel","Subject Rating of the Natural Look and Feel of the Lips|Injector Rating of the Natural Look and Feel of the Lips|Bruising of the Lips|Swelling of the Lips|Ease of Injection|Malleability of Product|Need for Massage|Return to Social Engagement|Comparative Rating With Previous Treatment|Rating of Injection Discomfort","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)",,"62","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/MED/FIL/019","June 2012","December 2012","December 2012","June 27, 2012","May 14, 2013","October 13, 2014","Dusseldorf, North Rhine-Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT01629134"
504,"NCT01579305","Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-L® for Lip Volume Enhancement",,"Completed","Has Results","Lip Volume Enhancement","Device: Juvéderm® Volbella with Lidocaine|Device: Restylane-L®","Month 3 Overall Lip Fullness Scale Responder Rate Based on Independent Central Reviewer's Assessment","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","S15L-003","April 2012","June 2013","January 2014","April 17, 2012","August 5, 2014","January 17, 2019","Cannes, France|Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01579305"
505,"NCT01559064","The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face",,"Completed","Has Results","Age-related Volume Deficit in the Mid-face","Device: Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)","Subject Experience Measured by Patient Satisfaction Questionnaire","Allergan Medical|Allergan","All","30 Years and older   (Adult, Older Adult)",,"115","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAF/AGN/MED/FIL/017","February 2012","August 2012","August 2012","March 21, 2012","June 10, 2013","October 13, 2014","Aalst, Belgium|Koln, North Rhine-Westphalia, Germany|Naarden, Netherlands|Mere Green, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01559064"
506,"NCT00076687","Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function",,"Completed","Has Results","Stroke|Muscle Spasticity|Motor Neuron Disease","Biological: botulinum toxin Type A|Drug: saline","Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Volume (FEV1)|Change From Baseline in FEV1/FVC Ratio|Change From Baseline in Ashworth Scale","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","191622-057","October 2003","August 2009","August 2009","February 26, 2004","October 3, 2011","October 3, 2011","Miami, Florida, United States|Prague, Czech Republic|Szeged, Hungary|Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT00076687"
507,"NCT01176773","Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancement",,"Completed","Has Results","Lip Enhancement","Device: hyaluronic acid gel","Investigator Assessment of the Subject's Overall Lip Fullness on the 4-point Lip Fullness Scale|Investigator Assessment of Perioral Line Severity Using the Perioral Line Severity Scale|Investigator Assessment of Oral Commissures Using the Oral Commissures Severity Scale|Subject Assessment of Appearance and Feel of the Lips Using the Look and Feel Scale|Number of Subjects Who Attain Their Lip Treatment Goal|Adverse Events","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","62","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","S15-002","August 2010","May 2011","January 2012","August 6, 2010","July 12, 2012","October 13, 2014","Belfast, United Kingdom|Cheadle, United Kingdom|Halesowen, United Kingdom|Sutton Coldfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01176773"
508,"NCT00948246","European Union (EU) Post-Market Study on Easyband®",,"Completed","Has Results","Morbid Obesity","Device: Easyband®","Feasibility and Ease of Implantation|% Excess Weight Loss|Change in BMI|Change in Weight","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)",,"112","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CIP10088","April 2009","October 2011","December 2011","July 29, 2009","November 26, 2012","October 13, 2014","Brussels, Belgium|Peschiera, Italy|Nieuwegein, Netherlands|Cheshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00948246"
509,"NCT00035906","Research Study in Patients With Persistent Macular Edema",,"Completed","No Results Available","Diabetes|Macular Edema|Diabetic Retinopathy|Retinal Disease|Uveitis, Posterior","Drug: DEX PS DDS®",,"Allergan|Oculex Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","DC-103-06-03","October 2001","August 2004","August 2004","May 7, 2002",,"May 30, 2011","Oculex Pharmaceuticals, Sunnyvale, California, United States",,"https://ClinicalTrials.gov/show/NCT00035906"
510,"NCT00850889","Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nasolabial Folds",,"Completed","Has Results","Nasolabial Folds","Device: Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Device: A gel of hyaluronic acid (concentration of 20 mg/mL)","Procedural Pain Score|Comparative Pain|Investigator Assessment of Improvement Since Baseline in Nasolabial Fold (NLF) Severity|Subject Assessment of Improvement From Baseline in Nasolabial Fold (NLF) Severity","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","MA-JULIDO-0801","November 2008","November 2008","November 2008","February 25, 2009","April 21, 2011","January 9, 2019","Niagara Falls, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00850889"
511,"NCT00025818","Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome",,"Completed","No Results Available","Keratoconjunctivitis Sicca|Sjogren's Syndrome|Lupus Erythematosus, Systemic|Arthritis, Rheumatoid|Scleroderma, Systemic","Drug: Ophthalmic Emulsion",,"Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","192371-011-01","May 2001","March 2003","March 2003","October 29, 2001",,"May 30, 2011","Eyecare of La Jolla, La Jolla, California, United States|UCLA, Los Angeles, California, United States|Opticare, Waterbury, Connecticut, United States|Brandon Eye Clinic, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|UIC Eye Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Hunkleler Eye Center, Overland Park, Kansas, United States|D'Ambrosio Eye Care, Leominster, Massachusetts, United States|Great Lakes Eye Institute, Saginaw, Michigan, United States|Cornea Consultants of Albany, Albany, New York, United States|Dr. Freedman's Office, Brooklyn, New York, United States|Dr. Wittpen's Office, Stony Brook, New York, United States|The Cole Eye Institute, Cleveland, Ohio, United States|Northwest Cornea, Portland, Oregon, United States|Corona Research, El Paso, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00025818"
512,"NCT00691327","Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants",,"Completed","Has Results","Breast Reconstruction","Device: Natrelle(TM) Silicone-Filled Breast Implants","Local Complications|Satisfaction With Breast Implants as Determined by Patients and Physicians on a 5-point Scale","Allergan Medical|Allergan","Female","Child, Adult, Older Adult","Not Applicable","84329","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","910044","December 1997","December 2012","December 2012","June 5, 2008","February 12, 2014","October 13, 2014","Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00691327"
513,"NCT00690339","Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study",,"Completed","Has Results","Breast Augmentation|Breast Reconstruction|Revision of Augmentation or Reconstruction","Device: Style 410 Silicone-Filled Breast Implants","Local Complications|Satisfaction With Breast Implants as Determined by Patients and Physicians on a 5-point Scale.","Allergan Medical|Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","941","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","00201","February 2001","December 2012","December 2012","June 4, 2008","February 4, 2014","October 13, 2014","Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00690339"
514,"NCT00689871","Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants",,"Completed","Has Results","Breast Augmentation|Breast Reconstruction|Revision of Augmentation or Reconstruction","Device: Natrelle(TM) Silicone-Filled Breast Implants","Local Complications|Satisfaction With Breast Implants as Determined by Patients and Physicians on a 5-point Scale","Allergan Medical|Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","715","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","020056","January 1999","December 2010","August 2011","June 4, 2008","January 23, 2012","October 13, 2014","Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00689871"
515,"NCT00653861","Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine",,"Completed","Has Results","Nasolabial Folds","Device: JUVÉDERM™ Injectable Gel with Lidocaine|Device: JUVÉDERM™ Injectable Gel","Procedural Pain Score|Comparative Pain|Nasolabial Fold (NLF) Severity","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","JULIDO-001","April 2008","June 2008","July 2008","April 7, 2008","December 30, 2009","October 13, 2014","Mt. Kisco, New York, United States",,"https://ClinicalTrials.gov/show/NCT00653861"
516,"NCT00534339","EasyBand GOAL Trial",,"Withdrawn","No Results Available","Morbid Obesity","Device: Easyband (Telemetrically adjustable gastric banding device)","Percent excess weight loss (%EWL)","Allergan Medical|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10042","December 2010","April 2012","February 2016","September 24, 2007",,"October 7, 2014","USA, California, United States|Canada, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00534339"
517,"NCT01737853","Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",,"Completed","No Results Available","Glaucoma Primary Open Angle","Drug: Ganforti|Drug: Krytantek","IOP (Intraocular Pressure)|Adverse Events","Allergan S.A. DE C.V..","All","Child, Adult, Older Adult",,"90","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","ALLE-GANFORT-001-4-2011","February 2011","February 2011","June 2012","November 30, 2012",,"November 30, 2012","Asociación Para Evitar La Ceguera en México, Mexico City, DF, Mexico|Instituto Oftalmológico Conde de Valencian, Mexico City, DF, Mexico|Global Galucoma Institute, Guadalajara, Jalisco, Mexico|Hospital de Nuestra Señora de la Luz, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT01737853"
518,"NCT03855865","Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)",,"Withdrawn","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Vortioxetine|Drug: Placebo","Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at the End of the Double Blind Treatment Period (DBTP) (end of Week 6)|Change from Baseline in MADRS Total Score at Day 1 Post-first Dose of Treatment","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-31|2018‐000063‐88","July 1, 2019","December 31, 2020","December 31, 2020","February 27, 2019",,"July 19, 2019",,,"https://ClinicalTrials.gov/show/NCT03855865"
519,"NCT03814733","Assessment of Effect of Rapastinel on Driving Performance",,"Completed","No Results Available","Driving Performance","Drug: Rapastinel|Drug: Alprazolam|Drug: Ketamine|Drug: Rapastinel Matched Placebo|Drug: Alprazolam Matched Placebo|Drug: Ketamine Matched Placebo","Simulated driving performance as measured by SDLP using the CRCDS-MiniSim for rapastinel compared with placebo and positive control (alprazolam)|simulated driving performance as measured by SDLP using the CRCDS-MiniSim for rapastinel compared with a clinical comparator (ketamine)|Karolinska Sleepiness Scale (KSS)|Self-perceived safety to drive (""Right now do you feel safe to drive?)|Visual Analog Scale to assess participant's motivation and self-appraisal of their driving performance|CogScreen SDC Test|Proportion of abnormal lane exceedance events|Average Speed (mph)|Total collisions|Number of exceeded cornering speed threshold events|Divided attention: average number of correct responses|Divided attention: average number of errors|Divided attention: average reaction time|Rapastinel blood plasma concentration|Adverse Events|Proportion of abnormal electrocardiograms|Columbia-Suicide Severity Rating Scale","Naurex, Inc, an affiliate of Allergan plc","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","RAP-PK-18","November 5, 2018","March 29, 2019","April 3, 2019","January 24, 2019",,"July 11, 2019","Collaborative Neuroscience Network, San Clemente, California, United States|Algorithme Pharma, Aurora, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03814733"
520,"NCT03799900","Assessment of Abuse Potential of Rapastinel in Humans",,"Completed","No Results Available","Human Abuse Potential","Drug: Rapastinel|Drug: Ketamine|Drug: Placebo","Maximum effect (Emax) for ""At this Moment"" Drug Liking visual analog scale (VAS).|Maximum effect (Emax)|Minimum effect (Emin)|Time to Emax (TEmax)|Time to Emin (TEmin)|Time averaged area under the effect curve (TA_AUE)|Maximum plasma drug concentration (Cmax)|Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration (AUClast)|Adverse events|Proportion of abnormal electrocardiograms|Columbia-Suicide Severity Rating Scale","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","RAP-PK-12","November 1, 2018","March 24, 2019","March 29, 2019","January 10, 2019",,"May 16, 2019","Vince and Associates Clinical Research Inc, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03799900"
521,"NCT03726658","AGN-241751 in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: AGN-241751|Drug: Placebo","Part A: To evaluate the efficacy at 1 day post the initial single oral dose of AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD)|Part B: To evaluate the efficacy at Day 7 of AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD) dosed twice daily (BID)|Part A: To evaluate the efficacy at Day 8 and Day15 of AGN-241751 administered orally once daily and at Day 22 (7 days after completion of AGN-241751 dosing) compared with placebo in participants with MDD|Part B: To evaluate the efficacy on Day 2, Day 11, Day 14, Day 18, and Day 21 (7 days after completion of dosing) after BID administration of AGN-241751 compared with placebo in participants with MDD dosed BID","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","223","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3125-104-002","November 8, 2018","October 23, 2019","October 23, 2019","October 31, 2018",,"December 13, 2019","Alea Research, Phoenix, Arizona, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Hassman Research Institute, Berlin, New Jersey, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03726658"
522,"NCT03675776","Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change from Baseline on Montgomery-Asberg Depression Rating Scale (MADRS) total score at end of double-blind treatment (end of week 6).|Change from Baseline in MADRS total score at 1 Day after first dose of treatment","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-30|2018-000060-29","October 30, 2018","July 11, 2019","July 11, 2019","September 18, 2018",,"July 19, 2019","Bugát Pál Hospital, Clinexpert, Gyongyos, Hungary|Himorogi Psychiatric Institute, Ichigayatamachi, Japan|Kishiro Mental Clinic, Kawasaki-shi, Japan|Tatsuta Clinic, Kobe-shi, Japan|Medical corporation Sato-Kai Yuge Hospital, Kumamoto-shi, Japan|Sagaarashiyama-Tanaka Clinic, Kyoto-shi, Japan|Senzoku psychosomatic Medicine Clinic, Meguro-ku, Japan|Higashi Sapporo Mental Clinic, Sapporo-shi, Japan|Sangenjaya Neurology- Psychosomatic Clinic, Setagaya-ku, Japan|Yoyogi Mental Clinic, Shibuya-ku, Japan|Maynds Tower Mental Clinic, Shibuya-ku, Japan|Himeno Tomomi Clinic, Shinagawa-ku, Japan|Shinjuku Research Park Clinic, Shinjuku-ku, Japan|Ohwa Mental Clinic, Toshima-ku, Japan|Okehazama Hospital Fujita Kokoro Care Center, Toyoake-city, Japan|Yokohama Onoecho Clinic, Yokohama-shi, Japan|Centrum Medyczne Luxmed Sp.z o.o., Lublin, Poland|Federal State Budgetary Research Institution ""Mental Health Science Center"", Moscow, Russian Federation|Yaroslavl Regional Psychiatric Hospital, Yaroslavl, Russian Federation|MENTUM, s.r.o., Bratislava, Slovakia|Vavrusova Consulting s.r.o. Neštátna Psychiatrická ambulancia, Bratislava, Slovakia|Liptovská nemocnica s poliklinikou MUDr. Ivana Stodolu Liptovský Mikuláš, Liptovsky Mikulas, Slovakia|Psycholine s.r.o., Rimavska Sobota, Slovakia",,"https://ClinicalTrials.gov/show/NCT03675776"
523,"NCT03668600","Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: Rapastinel","Count of participants experiencing one or more Treatment emergent adverse events (TEAs)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAP-MD-99","August 23, 2018","July 3, 2019","July 3, 2019","September 12, 2018",,"July 19, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Pharmacology Research Institute, Encino, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|CITrials, Riverside, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|David A. Medina, MD, Orlando, Florida, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|University of Kansas School of Medicine Clinical Trial Unit, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|Coastal Research Associates, South Weymouth, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Patient Priority Clinical Sites, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network LLC, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Austin, Texas, United States|Houston Clinical Trials, Bellaire, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Inc, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03668600"
524,"NCT03614156","Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Time to First Relapse During the 52 Weeks of the Double-Blind Treatment Period (DBTP)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-33|2018-000064-28","August 2, 2018","July 11, 2019","July 11, 2019","August 3, 2018",,"July 19, 2019","Alea Research, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|California Pharmaceutical Research Institute, Anaheim, California, United States|Synergy Research San Diego, National City, California, United States|Excell Research Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|California Neuroscience Research Medical Group,Inc., Sherman Oaks, California, United States|Viking Clinical Research Ltd., Temecula, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Research Centers of America, Hollywood, Florida, United States|Clinical NeuroscienceSolutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Iris Research, Inc., Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|CBH Health, Gaithersburg, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Bugát Pál Hospital, Clinexpert, Gyongyos, Hungary|Medical corporation Sato-Kai Yuge Hospital, Kumamoto-shi, Japan|Sagaarashiyama-Tanaka Clinic, Kyoto-shi, Japan|Sangenjaya Neurology- Psychosomatic Clinic, Setagaya-ku, Japan|Yoyogi Mental Clinic, Shibuya-ku, Japan|Maynds Tower Mental Clinic, Shibuya-ku, Japan|Ohwa Mental Clinic, Toshima-ku, Japan|Centrum Medyczne Luxmed Sp.z o.o., Lublin, Poland|MENTUM, s.r.o., Bratislava Mestská Časť Ružinov, Slovakia|VAVRUŠOVÁ CONSULTING s.r.o., Psychiatrická ambulancia, Bratislava, Slovakia|Liptovská nemocnica s poliklinikou MUDr. Ivana Stodolu Liptovský Mikuláš, Liptovský Mikuláš, Slovakia|PsychoLine s.r.o., Psychiatrická ambulancia, Rimavská Sobota, Slovakia",,"https://ClinicalTrials.gov/show/NCT03614156"
525,"NCT03560518","Study of Rapastinel as Monotherapy in Patients With MDD",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change from Baseline on Montgomery-Asberg Depression Rating Scale (MADRS) total score at end of treatment (end of Week 6)|Change from Baseline total score at day1 post-first dose of treatment","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","439","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-32","June 15, 2018","July 8, 2019","July 8, 2019","June 18, 2018",,"July 19, 2019","Alea Research, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|California Pharmaceutical Research Institute, Inc., Anaheim, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Synergy Research San Diego, National City, California, United States|Excell Research Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|California Neuroscience Research Medical Group,Inc., Sherman Oaks, California, United States|Viking Clinical Research Ltd., Temecula, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Iris Research, Inc., Smyrna, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|CBH Health, LLC, Gaithersburg, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03560518"
526,"NCT03352453","A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change from baseline in Montgomery-Asberg Depression Rating Scale) MADRS Total Score|Change from Baseline in Sheehan - Suicidality Tracking Scale (S-STS) Total Score","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-20","December 5, 2017","June 17, 2019","June 17, 2019","November 24, 2017",,"July 19, 2019","The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, Birmingham, Alabama, United States|Collaborative NeuroScience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Asclepes Research Centers, Panorama City, California, United States|Institute of Living, Hartford, Connecticut, United States|Innovative Clinical Research, Inc, Hialeah, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Atlanta Center for Medical Research (ACMR), Atlanta, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|CBH Health, Gaithersburg, Maryland, United States|Altea Research Institute, Las Vegas, Nevada, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States|Carilion Medical Center, a Virginia Nonprofit Corporation, Roanoke, Virginia, United States|Department of Veterans Affairs Salem VA Medical Center, Salem, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03352453"
527,"NCT03002077","Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Rapastinel","Safety and Tolerability of Rapastinel assessed by Examining the Frequency and Severity of Adverse Events (AE)|Change from Baseline in Brief Psychiatric Rating Scale Positive Symptoms Subscale (BPRS+)|Change from Baseline in the Clinician Administered Dissociative States Scale (CADSS)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","617","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAP-MD-06","February 3, 2017","December 6, 2018","December 6, 2018","December 23, 2016",,"February 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Research Partners; LLC., Oakland, California, United States|Excell Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|University of California, Irvine, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Anderson Clinical Research, Redlands, California, United States|CITrials, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|PCSD Feighner Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc.,, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|Innova Clinical Trials Inc., Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Millenia Psychiatry & Research, Inc, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|The University of South Florida Board of Trustees, A public Body Corporate, for University of South Florida, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Iris Research, Smyrna, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|J Gary Booker, MD APMC, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|CBH Health, Rockville, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Altea Research, Las Vegas, Nevada, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Pharmaceutical Research Associates Inc, Marlton, New Jersey, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, Inc, Brooklyn, New York, United States|Bioscience Research, Mount Kisco, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Carolina Clinical Trials, Inc., Charleston, North Carolina, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|Patient Priority Clinical Site, LLC, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Lindner Center of Hope, Mason, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, LLC, Bellaire, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Wood, The Woodlands, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States|Psychiatric Alliance of the Blue Ridge, Inc., Charlottesville, Virginia, United States|NorthWest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Eastside Therapeutic Resource, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03002077"
528,"NCT02951988","A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo-matching Rapastinel","Time to First Relapse during the First 52 Weeks of the Double-Blind Treatment Period|Time to First Relapse during the Entire Double-Blind Treatment Period","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","604","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-04","November 13, 2016","February 22, 2019","February 22, 2019","November 1, 2016",,"April 23, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|University of Arizona Department of Psychiatry, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Research Partners; LLC., Oakland, California, United States|Excell Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Anderson Clinical Research, Redlands, California, United States|CITrials, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|PCSD Feighner Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc.,, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|Innova Clinical Trials Inc., Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Sarkis Clinical Trials, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Millenia Psychiatry & Research, Inc, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|The University of South Florida Board of Trustees, A public Body Corporate, for University of South Florida, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|IRIS Research, Smyrna, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|J Gary Booker, MD APMC, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|CBH Health, Rockville, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Altea Research, Las Vegas, Nevada, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Pharmaceutical Research Associates Inc, Marlton, New Jersey, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, Inc, Brooklyn, New York, United States|Bioscience Research, Mount Kisco, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|Patient Priority Clinical Site, LLC, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Lindner Center of Hope, Mason, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, LLC, Bellaire, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Wood, The Woodlands, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States|Psychiatric Alliance of the Blue Ridge, Inc, Charlottesville, Virginia, United States|NorthWest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Eastside Therapeutic Resource, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02951988"
529,"NCT02943577","A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study|Change From Baseline in MADRS Total Score|Change From Baseline to Day 21 in MADRS Total Score for the Placebo Non-responders of mITT Population|Change From Baseline to Day 8 in MADRS Total Score for the Placebo Non-responders of mITT Population","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","429","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-03","November 2, 2016","October 26, 2018","November 21, 2018","October 24, 2016","November 13, 2019","November 13, 2019","Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Innova Clinical Trials Inc., Miami, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|The University of South Florida Board of Trustees, A public Body Corporate, for University of South Florida, Tampa, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, Inc, Brooklyn, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Houston Clinical Trials, LLC, Bellaire, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States|Psychiatric Alliance of the Blue Ridge, Inc., Charlottesville, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02943577/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02943577/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02943577"
530,"NCT02943564","A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study|Change From Baseline in MADRS Total Score","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","658","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-02","November 1, 2016","December 12, 2018","December 18, 2018","October 24, 2016","December 27, 2019","December 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Department of Psychiatry, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|ProScience Research Group, Culver City, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Pacific Research Partners; LLC., Oakland, California, United States|CITrials, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|PCSD Feighner Research, San Diego, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Sarkis Clinical Trials, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Millenia Psychiatry & Research, Inc, Orlando, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|IRIS Research, Smyrna, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|J Gary Booker, MD APMC, Shreveport, Louisiana, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|CBH Health, Rockville, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, Olivette, Missouri, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Pharmaceutical Research Associates Inc, Marlton, New Jersey, United States|The Medical Research Network, LLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Patient Priority Clinical Site, LLC, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Lindner Center of Hope, Mason, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|Community Clinical Research, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Family Psychiatry of The Wood, The Woodlands, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Eastside Therapeutic Resource, Everett, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02943564/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02943564/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02943564"
531,"NCT02932943","A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial|Change From Baseline in MADRS Total Score|Change From Baseline to Day 21 in MADRS Total Score for the Placebo Non-responders of mITT Population|Change From Baseline to Day 8 in MADRS Total Score for the Placebo Non-responders of mITT Population","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-01","October 15, 2016","September 21, 2018","November 8, 2018","October 13, 2016","October 11, 2019","October 11, 2019","Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Excell Research, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc.,, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Altea Research, Las Vegas, Nevada, United States|Bioscience Research, Mount Kisco, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|NorthWest Clinical Research Center, Bellevue, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02932943/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02932943/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02932943"
532,"NCT02366364","Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers","NRX-1074","Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: NRX-1074 375 mg|Drug: NRX-1074 500 mg|Drug: NRX-1074 750 mg","Number of participants with adverse events as a measure of safety and tolerability|Plasma pharmacokinetics Cmax|Plasma pharmacokinetics - Tmax","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX1074-C-102","February 2015","April 2015","April 2015","February 19, 2015",,"February 22, 2016","Chicago Research Center, Inc., Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02366364"
533,"NCT02192099","Open Label Extension for GLYX13-C-202, NCT01684163",,"Terminated","Has Results","Major Depressive Disorder","Drug: Rapastinel (225 mg/450 mg IV administration)","The Number of Participants Who Experience an Adverse Event Over the Course of the Study.","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GLYX13-C-203","September 8, 2014","November 8, 2018","November 8, 2018","July 16, 2014","November 27, 2019","November 27, 2019","Office of Psychiatric Research, Birmingham, Alabama, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Chicago Research Center, Chicago, Illinois, United States|University of Kansas School of Medicine Clinical Trial Unit, Wichita, Kansas, United States|PharmaSite Research, Inc., Baltimore, Maryland, United States|Boston Clinical Trials Inc., Roslindale, Massachusetts, United States|Woodlands Professional Princeton Medical Institute Building, Princeton, New Jersey, United States|Finger Lake Clinical Research, Rochester, New York, United States|Lindner Center of HOPE, Mason, Ohio, United States|PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02192099/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02192099/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02192099"
534,"NCT02067793","Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: NRX-1074 1 mg|Drug: Placebo|Drug: NRX-1074 5 mg|Drug: NRX-1074 10 mg","To evaluate the mean change from baseline in Hamilton Depression Rating Scale 17 (HDRS-17) score for each NRX-1074 dose group versus the placebo group's mean change|Change in Brief Psychiatric Rating Scale positive symptoms (BPRS+) scale|Change in Clinician Administered Dissociative States Scale (CADSS)|Change in Columbia-Suicide Severity Rating Scale (C-SSRS)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX1074-C-201","March 2014","February 2015","February 2015","February 20, 2014",,"March 17, 2016","Pacific Research Partners, Oakland, California, United States|Psychiatric Medicine Associates, Skokie, Illinois, United States|University of Kansas School of Medicine Clinical Trial Unit, Wichita, Kansas, United States|Boston Clinical Trials, Inc., Roslindale, Massachusetts, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|Mount Sinai School of Medicine, Elmsford, New York, United States|New York State Psychiatric Institute, New York, New York, United States|Lindner Center of HOPE, Mason, Ohio, United States|Research Strategies Memphis, Memphis, Tennessee, United States|Research Across America, Dallas, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02067793"
535,"NCT01856556","Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers",,"Completed","No Results Available","Healthy","Drug: NRX-1074|Drug: Placebo","Observed and laboratory-confirmed safety|Plasma concentration of parent drug will be assessed over time to estimate duration of pharmacodynamics in future efficacy trials. Plasma concentration and pharmacokinetics will be related in time to observed side effects.","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 55 Years   (Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NRX1074-C-101","May 2013","November 2014","November 2014","May 17, 2013",,"January 26, 2016","Lotus Clinical Research, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT01856556"
536,"NCT02685033","Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis",,"Completed","Has Results","Osteomyelitis","Drug: Dalbavancin|Drug: Comparator","Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population|Percentage of Participants With Clinical Response at Day 365 in the CE Population|Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population|Percentage of Participants With Clinical Improvement at Day 21 in the CE Population|Percentage of Participants With Clinical Response at Day 42 in the mITT Population|Percentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population|Percentage of Participant With Clinical Response at Day 180 in the mITT Population|Percentage of Participants With Clinical Response at Day 180 in the CE Population|Percentage of Participants With Clinical Response at Day 365 in the mITT Population|Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population|Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population","Durata Therapeutics Inc., an affiliate of Allergan plc","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAL-MD-04","March 15, 2016","December 12, 2017","December 12, 2017","February 18, 2016","January 4, 2019","January 4, 2019","Allergan Investigative Site 001, Cherkasy, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02685033/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02685033/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02685033"
537,"NCT01684163","Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants",,"Completed","No Results Available","Major Depressive Disorder","Drug: GLYX-13 5 mg/kg|Drug: GLYX-13 10 mg/kg|Drug: Placebo","Change in Hamilton Depression Rating Scale Score|Clinical Global Impression of Change","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GLYX13-C-202","November 2012","April 2014","June 2014","September 12, 2012",,"March 17, 2016","University of Alabama Office of Psychiatric Clinical Research, Birmingham, Alabama, United States|Pharmacology Research Institute, Encino, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Evanston Premier Healthcare Research, LLC, Northbrook, Illinois, United States|Indiana University Health Neuroscience Center, Indianapolis, Indiana, United States|University of Kansas, Wichita, Kansas, United States|PharmaSite Research , Inc., Baltimore, Maryland, United States|Bostin Clinical Trials, Inc., Roslindale, Massachusetts, United States|CRI Lifetree, Marlton, New Jersey, United States|Global Medical Institutes LLC, Princeton, New Jersey, United States|Clinilabs, Inc., New York, New York, United States|Michael R Liebowitz MD, New York, New York, United States|Finger Lake Clinical Research, Rochester, New York, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|CRI Lifetree, Phildadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center of Dallas, Dallas, Texas, United States|CRI Lifetree, Salt Lake City, Utah, United States|Summit Research Network, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01684163"
538,"NCT02860065","CPC-201 Alzheimer's Disease Type Dementia: PET Study",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: CPC-201|Other: Positron emission tomography (PET)","Donepezil Maximum tolerated dose (MTD) change on imaging","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-15","September 30, 2016","June 30, 2017","June 30, 2017","August 9, 2016",,"August 9, 2017","Henry Ford Health System--West Bloomfield Hospital, West Bloomfield Township, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02860065"
539,"NCT02269644","A P3 Comparator Trial in Community Acquired Bacterial Pneumonia",,"Withdrawn","No Results Available","Community Acquired Pneumonia","Drug: Dalbavancin|Drug: Linezolid|Drug: Linezolid Placebo|Drug: Azithromycin","Treatment Response of CABP Symptoms|Efficacy of dalbavancin to the comparator regimen|Safety Analysis","Durata Therapeutics Inc., an affiliate of Allergan plc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DUR001-305|2014-002683-32","November 2015","November 2016","December 2016","October 21, 2014",,"January 22, 2016","Mercury Street Medical Group, Butte, Montana, United States",,"https://ClinicalTrials.gov/show/NCT02269644"
540,"NCT02127970","Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",,"Completed","Has Results","Abscess|Wound Infection|Surgical Site Infection|Cellulitis","Drug: Dalbavancin|Drug: Dalbavancin-matching Placebo","Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug|Percentage of Participants by Clinical Status at End of Treatment (EOT) and Final Visit (FV)","Durata Therapeutics Inc., an affiliate of Allergan plc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","698","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DUR001-303","April 18, 2014","March 11, 2015","March 11, 2015","May 1, 2014","August 14, 2018","September 28, 2018","110, Montgomery, Alabama, United States|103, Anaheim, California, United States|117, Long Beach, California, United States|106, Long Beach, California, United States|118, Modesto, California, United States|104, San Diego, California, United States|113, San Diego, California, United States|115, San Diego, California, United States|116, San Diego, California, United States|108, Stockton, California, United States|105, Sylmar, California, United States|112, Washington, District of Columbia, United States|107, Orlando, Florida, United States|120, Saint Cloud, Florida, United States|114, Augusta, Georgia, United States|122, Columbus, Georgia, United States|125, Savannah, Georgia, United States|119, Eunice, Louisiana, United States|101, Springfield, Massachusetts, United States|109, Detroit, Michigan, United States|121, Butte, Montana, United States|123, Omaha, Nebraska, United States|111, Toledo, Ohio, United States|126, Franklin, Tennessee, United States|127, Smyrna, Tennessee, United States|802, Sofia, Bulgaria|800, Sofia, Bulgaria|801, Sofia, Bulgaria|200, Zagreb, Croatia|201, Zagreb, Croatia|253, Tallinn, Estonia|252, Tallinn, Estonia|251, Tartu, Estonia|302, Kutaisi, Georgia|303, Tbilisi, Georgia|300, Tbilisi, Georgia|301, Tbilisi, Georgia|352, Debrecen, Hungary|353, Kaposvar, Hungary|354, Pecs, Hungary|351, Szeged, Hungary|402, Daugavpils, Latvia|401, Liepaja, Latvia|403, Rezekne, Latvia|400, Riga, Latvia|404, Riga, Latvia|501, Cluj-Napoca, Cluj County, Romania|502, Bucharest, Romania|500, Bucharest, Romania|503, Bucharest, Romania|555, Vsevolozhsk, Leningrad Region, Russian Federation|557, Irkutsk, Russian Federation|552, Moscow, Russian Federation|554, Moscow, Russian Federation|553, Novosibirsk, Russian Federation|551, St. Petersburg, Russian Federation|556, Tomsk, Russian Federation|600, Belgrade, Serbia|601, Belgrade, Serbia|603, Nis, Serbia|602, Novi Sad, Serbia|756, Breyten, South Africa|760, Cape Town, South Africa|752, Dundee, South Africa|755, Johannesburg, South Africa|751, Middleburg, South Africa|758, Port Elizabeth, South Africa|757, Pretoria, South Africa|753, Pretoria, South Africa|759, Pretoria, South Africa|754, Worcester, South Africa|700, Cherkasy, Ukraine|704, Dnipropetrovsk, Ukraine|706, Ivano-Frankivsk, Ukraine|701, Ivano-Frankivsk, Ukraine|705, Kharkiv, Ukraine|703, Lviv, Ukraine|702, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT02127970"
541,"NCT02549196","A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type","CPC-12","Completed","Has Results","Dementia of Alzheimer's Type","Drug: Donepezil|Drug: Solifenacin","Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort|Number of Participants With TEAEs Leading to Study Drug Discontinuation","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CPC-001-12","October 7, 2015","September 28, 2017","September 28, 2017","September 15, 2015","March 5, 2019","March 5, 2019","Quantum Laboratories, Deerfield Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|PMG Research, Winston-Salem, North Carolina, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02549196/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02549196/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02549196"
542,"NCT01234558","Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: GLYX-13","Change in depression score|Change in BPRS+","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GLYX13-C201","May 2011","June 2012","July 2012","November 4, 2010",,"September 12, 2012","Mulitple, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01234558"
543,"NCT01946568","A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.",,"Completed","No Results Available","Bacterial Infections.","Drug: Dalbavancin","To characterize the pharmacokinetics in pediatric patients by measuring AUC 0-inf of dalbavancin.|To characterize the pharmacokinetics in pediatric patients by measuring Cmax of dalbavancin.|To characterize the pharmacokinetics in pediatric patients by measuring AUC0-last of dalbavancin.|To characterize the pharmacokinetics in pediatric patients by measuring AUC0-t of dalbavancin.|To characterize the pharmacokinetics in pediatric patients by measuring Tmax of dalbavancin.|To characterize the pharmacokinetics in pediatric patients by measuring t1/2 of dalbavancin.|To evaluate the safety of a single dose of dalbavancin which will be measured by adverse event monitoring.|To evaluate the safety of a single dose of dalbavancin which will be measured by clinical laboratories (hematology and serum chemistry).|To evaluate the safety of a single dose of dalbavancin which will be measured by blood pressure and pulse rate.","Durata Therapeutics Inc., an affiliate of Allergan plc","All","3 Months to 11 Years   (Child)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","DUR001-106","June 2013","April 2015","April 2015","September 19, 2013",,"June 23, 2015","University Arkansas Medical Center, Little Rock, Arkansas, United States|University of California, San Diego, San Diego, California, United States|Connecicut Children's Hospital, Hartford, Connecticut, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Columbia University, New York, New York, United States|Duke Medical Center, Durham, North Carolina, United States|Pediatric Pharmacology, Toledo, Ohio, United States|Texas Children's Hospital - Clinical Care Center, Houston, Texas, United States|Tallin's Children Hospital Pediatric Clinic, Tallinn, Estonia|Tartu University Hospital Anesthesiology & Intensive Care, Tartu, Estonia",,"https://ClinicalTrials.gov/show/NCT01946568"
544,"NCT02434666","Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07",,"Completed","No Results Available","Dementia of the Alzheimer's Type","Drug: CPC-201","safety and tolerability of the maximum tolerated dose (MTD) of CPC-201 (adverse events)|safety and tolerability of CPC-201 20mg/day (adverse events)","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-10","January 8, 2015","October 18, 2016","November 22, 2016","May 5, 2015",,"September 20, 2017","Miami Jewish Health Systems, Miami, Florida, United States|Quantum Laboratories, Inc. Memory Disorder Center, Pompano Beach, Florida, United States|Premiere Research Institute Neuroscience, West Palm Beach, Florida, United States|IU School of Medicine IU Health Neuroscience Center, Indianapolis, Indiana, United States|Giles Cromwell, MD, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02434666"
545,"NCT01014650","Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers",,"Completed","No Results Available","Healthy","Drug: GLYX-13|Drug: IV normal saline","Observed and laboratory-confirmed safety|Plasma concentration of parent drug will be assessed over time to estimate duration of pharmacodynamics in future efficacy trials. Plasma concentration and pharmacokinetics will be related in time to observed side effects.","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 55 Years   (Adult)","Phase 1","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GLYX13-C-101","November 2009","October 2015","October 2015","November 17, 2009",,"February 22, 2016","Lotus Clinical Research, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT01014650"
546,"NCT02185053","A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia",,"Completed","No Results Available","Alzheimer's Disease","Drug: CPC-201","Donepezil Maximum tolerated dose (MTD) change","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-07","July 2014","July 2016","July 2016","July 9, 2014",,"July 26, 2016","CPC1, West Palm Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02185053"
547,"NCT01431339","Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",,"Completed","Has Results","Abscess|Wound Infection|Surgical Site Infection|Cellulitis","Drug: IV Dalbavancin|Drug: Vancomycin/Linezolid","Early Clinical Efficacy|Clinical Status|>= 20% Reduction in Lesion Area","Durata Therapeutics Inc., an affiliate of Allergan plc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","739","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DUR001-302","July 2011","November 2012","December 2012","September 9, 2011","February 12, 2014","February 12, 2014","Durata Clinical Site, Montgomery, Alabama, United States|Durata Clinical Site, Anaheim, California, United States|Durata Clinical Site, Buena Park, California, United States|Durata Study Site, Chula Vista, California, United States|Durata Clinical Site, Long Beach, California, United States|Durata Study Site, Los Angeles, California, United States|Durata Study Site, Norwalk, California, United States|Durata Study Site, Oxnard, California, United States|Durata Study SIte, San Diego, California, United States|Durata Study Site, Stockton, California, United States|Durata Clinical Site, Boyton Beach, Florida, United States|Durata Clinical Site, Ft. Meyers, Florida, United States|Durata Clinical Site, Miami, Florida, United States|Durata Study Site, Orlando, Florida, United States|Durata Clinical Site, St. Cloud, Florida, United States|Durata Clinical Site, Augusta, Georgia, United States|Durata Study Site, Columbus, Georgia, United States|Durata Clinical Site, Chicago, Illinois, United States|Durata Study Site, Baton Rouge, Louisiana, United States|Durata Study Site, New Orleans, Louisiana, United States|Durata Study Site, Shreveport, Louisiana, United States|Durata Study Site, Zachary, Louisiana, United States|Durata Study Site, Las Vegas, Nevada, United States|Durata Study Site, Springfield, Ohio, United States|Durata Study Site, Philadelphia, Pennsylvania, United States|Durata Study Site, Austin, Texas, United States|Durata Clinical Site, Austin, Texas, United States|Durata Clinical Site, Houston, Texas, United States|Durata Study Site, Richmond, Texas, United States|Durata Study Site, Middleton, Wisconsin, United States|Durata Study Site, Pleven, Bulgaria|Durata Study Site, Plovdiv, Bulgaria|Durata Study Site, Sevlievo, Bulgaria|Durata Study Site, Sofia, Bulgaria|Durata Study Site, Sofia, Bulgaria|Durata Study Site, Sofia, Bulgaria|Durata Study Site, Sofia, Bulgaria|Durata Study Site, Kohtla-Jarve, Estonia|Durata Clinical Site, Kohtla-Jarve, Estonia|Durata Clinical Site, Tallinn, Estonia|Durata Clinical Site, Tallinn, Estonia|Durata Study Site, Tartu, Estonia|Durata Study Site, Budapest, Hungary|Durata Clinical Site, Budapest, Hungary|Durata Study Site, Debrecen, Hungary|Durata Clinical Site, Kaposvar, Hungary|Durata Clinical SIte, Pecs, Hungary|Durata Clinical Site, Szeged, Hungary|Durata Study Site, Veszprem, Hungary|Durata Clinical Site, Haifa, Israel|Durata Study Site, Jerusalem, Israel|Durata Clinical Site, Kfar Saba, Israel|Durata Study Site, Petach Tikva, Israel|Durata Clinical Site, Petah-Tiqva, Israel|Durata Clinical Site, Ramat-Gan, Israel|Durata Study Site, Tel Aviv, Israel|Durata Clinical Site, Jung Gu, Daegu, Korea, Republic of|Durata Clinical Site, Ansan, Korea, Republic of|Durata Study Site, Daejeon, Korea, Republic of|Durata Study Site, Gwangju, Korea, Republic of|Durata Clinical Site, Incheon, Korea, Republic of|Durata Clinical Site, Kangwon-do, Korea, Republic of|Durata Study Site, Seoul, Korea, Republic of|Durata Clinical Site, Seoul, Korea, Republic of|Durata Study Site, Seoul, Korea, Republic of|Durata Study Site, Seoul, Korea, Republic of|Durata Clinical Site, Seoul, Korea, Republic of|Durata Study Site, Seoul, Korea, Republic of|Durata Clinical Site, Seoul, Korea, Republic of|Durata Clinical Site, Daugavpils, Latvia|Durata Clinical Site, Liepaja, Latvia|Durata Study Site, Rezekne, Latvia|Durata Study Site, Riga, Latvia|Durata Clinical Site, Riga, Latvia|Durata Clinical Site, Ventspils, Latvia|Durata Clinical Site, Kaunas, Lithuania|Durata Clinical Site, Kauno m. sav, Lithuania|Durata Clinical Site, Klaipėda, Lithuania|Durata Clinical Trial, Vilnius, Lithuania|Durata Clinical Site, Šiauliai, Lithuania|Durata Study Site, Bucharest, Romania|Durata Clinical Site, Bucharest, Romania|Durata Study Site, Bucharest, Romania|Durata Clinical Trial, Bucharest, Romania|Durata Study Site, Bucharest, Romania|Durata Clinical Site, Burcharest, Romania|Durata Study Site, Cluj-Napoca, Romania|Durata Study Site, Constanta, Romania|Durata Study Site, Targu Mures, Romania|Durata Clinical Site, Timisoara, Romania|Durata Clinical Site, Vsevolozhsk, Leningrad Region, Russian Federation|Durata Study Site, Vsevolozhsk, Leningrad, Russian Federation|Durata Study Site, Moscow, Russian Federation|Durata Clinical Site, Moscow, Russian Federation|Durata Study Site, Petrozavodsk, Russian Federation|Durata Clinical Site, Smolensk, Russian Federation|Durata Clinical Site, St. Petersburg, Russian Federation|Durata Study Site, Tomsk, Russian Federation|Durata Clinical Site, Tver, Russian Federation|Durata Clinical Site, Volgograd, Russian Federation|Durata Clinical Site, Yaroslavl, Russian Federation|Durata Clinical Site, Banska Bystrica, Slovakia|Durata Clinical Site, Levice, Slovakia|Durata Clinical Site, Nitra, Slovakia|Durata Clinical Site, Svidnik, Slovakia|Durata Study Site, KwaZulu, Durban, South Africa|Durata Study Site, KwaZulu-Natal, Ladysmieth, South Africa|Durata Study Site, Mpumalanga, Middleburg, South Africa|Durata Study Site, Mpekweni, Paarl, South Africa|Durata Study Site, Western Cape, Paarl, South Africa|Durata Clinical Site, Gauteng, Pretoria, South Africa|Durata Study Site, Gauteng, Soweto, South Africa|Durata Study Site, Johannesburg, South Africa|Durata Study Site, Port Elizabeth, South Africa|Durata Study Site, Port Elizabeth, South Africa|Durata Clinical Site, Pretoria, South Africa|Durata Study Site, Thabazimbi, South Africa|Durata Study Site, Tainan, Fukien, Taiwan|Durata Study Site, Kaohsiung, Taiwan|Durata Study Site, Kaohsiung, Taiwan|Durata Clinical Site, Taichung City, Taiwan|Durata Clinical Site, Taipai, Taiwan|Durata Study Site, Taipei, Taiwan|Durata Study Site, Yung Kang City, Taiwan|Durata Study Site, Cherkasy, Ukraine|Durata Study Site, Dnipropetrovsk, Ukraine|Durata Study Site, Donetsk, Ukraine|Durata Clinical Site, Ivano-Frankivsk, Ukraine|Durata Study Site, Ivano-Frankivsk, Ukraine|Durata Study Site, Ivano-Frankivsk, Ukraine|Durata Study Site, Kharkiv, Ukraine|Durata Clinical Site, Kyiv, Ukraine|Durata Study Site, Kyiv, Ukraine|Durata Study Site, Lviv, Ukraine|Durata Study Site, Lviv, Ukraine|Durata Study Site, Uzhhorod, Ukraine|Durata Study Site, Zaporizhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01431339"
548,"NCT01339091","Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",,"Completed","Has Results","Abscess|Wound Infection|Surgical Site Infection|Cellulitis","Drug: Dalbavancin|Drug: Vancomycin / Linezolid","Early Clinical Efficacy|>= 20% Reduction in Lesion Area|Clinical Status","Durata Therapeutics Inc., an affiliate of Allergan plc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","573","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DUR001-301","March 2011","September 2012","November 2012","April 20, 2011","December 25, 2013","January 31, 2014","Durata Study Site, Anaheim, California, United States|Durata Study Site, Azusa, California, United States|Durata Study Site, Bellflower, California, United States|Durata Study Site, Buena Park, California, United States|Durata Study Site, Carmel, California, United States|Durata Study Site, Chula Vista, California, United States|Durata Study Site, Covina, California, United States|Durata Study Site, Fountain Valley, California, United States|Durata Study Site, La Mesa, California, United States|Durata Study Site, Long Beach, California, United States|Durata Study Site, Los Alamitos, California, United States|Durata Study Site, Los Angeles, California, United States|Durata Study Site, Oceanside, California, United States|Durata Study Site, Palm Desert, California, United States|Durata Study Site, Pasadena, California, United States|Durata Study Site, Sacramento, California, United States|Durata Study Site, San Diego, California, United States|Durata Study Site, Santa Ana, California, United States|Durata Study Site, Sylmar, California, United States|Durata Study Site, Torrance, California, United States|Durata Study Site, Upland, California, United States|Durata Study Site, Whittier, California, United States|Durata Study Site, Miami, Florida, United States|Durata Study Site, Miami, Florida, United States|Durata Study Site, Orlando, Florida, United States|Durata Study Site, St. Cloud, Florida, United States|Durata Study Site, Tampa, Florida, United States|Durata Study Site, Columbus, Georgia, United States|Durata Study Site, Savannah, Georgia, United States|Durata Study Site, Idaho Falls, Idaho, United States|Durata Study Site, Pocatello, Idaho, United States|Durata Study Site, Moline, Illinois, United States|Durata Study Site, Rock Island, Illinois, United States|Durata Study Site, Baton Rouge, Louisiana, United States|Durata Study Site, Lafayette, Louisiana, United States|Durata Clinical Site, New Orleans, Louisiana, United States|Durata Study Site, Opelousas, Louisiana, United States|Durata Study Site, Detroit, Michigan, United States|Durata Study Site, Minneapolis, Minnesota, United States|Durata Study Site, Las Vegas, Nevada, United States|Durata Study Site, Somers Point, New Jersey, United States|Durata Study Site, Bronx, New York, United States|Durata Study Site, Buffalo, New York, United States|Durata Study Site, Lake Success, New York, United States|Durata Study Site, New Hyde Park, New York, United States|Durata Study Site, Staten Island, New York, United States|Durata Study Site, Winston Salem, North Carolina, United States|Durata Study Site, Winston-Salem, North Carolina, United States|Durata Study Site, Columbus, Ohio, United States|Durata Study Site, Lima, Ohio, United States|Durata Study Site, Toledo, Ohio, United States|Durata Study Site, Pittsburgh, Pennsylvania, United States|Durata Study Site, Houston, Texas, United States|Durata Study Site, Houston, Texas, United States|Durata Study Site, Madison, Wisconsin, United States|Durata Study Site, Middleton, Wisconsin, United States|Durata Study Site, Winnipeg, Manitoba, Canada|Durata Study Site, Trois-Rivieres, Quebec, Canada|Durata Study Site, Dubrovnik, Croatia|Durata Clinical Site, Slavonski Brod, Croatia|Durata Study Site, Zagreb, Croatia|Durata Study Site, Zagreb, Croatia|Durata Clinical Site, Tbilisi, Georgia|Durata Study Site, Bochum, Germany|Durata Study Site, Munster, Germany|Durata Study Site, Krakow, Poland|Durata Study Site, Legionowo, Poland|Durata Study Site, Warszawa, Poland|Durata Study Site, Wroclaw, Poland|Durata Study Site, Kharkiv, Ukraine, Russian Federation|Durata Study Site, Kyiv city, Ukraine, Russian Federation|Durata Study Site, Ekaterinburg, Russian Federation|Durata Study Site, Moscow, Russian Federation|Durata Clinical Site, Moscow, Russian Federation|Durata Study Site, Moscow, Russian Federation|Durata Study Site, Perm, Russian Federation|Durata Study Site, Saratov, Russian Federation|Durata Study Site, Smolensk, Russian Federation|Durata Study Site, St. Petersburg, Russian Federation|Durata Study Site, St. Petersburg, Russian Federation|Durata Study Site, St. Petersburg, Russian Federation|Durata Study Site, St. Petersburg, Russian Federation|Durata Clinical Site, St. Petersburg, Russian Federation|Durata Study Site, Tomsk, Russian Federation|Durata Study Site, Cherkasy, Ukraine|Durata Study Site, Ivano-Frankivsk, Ukraine|Durata Study Site, Kharkiv, Ukraine|Durata Study Site, Kyiv, Ukraine|Durata Study Site, Kyiv, Ukraine|Durata Study Site, Uzhgorod, Ukraine|Durata Study Site, Zaporizhzhya, Ukraine|Durata Study Site, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT01339091"
549,"NCT04126031","Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.","NOOR","Recruiting","No Results Available","Gram-negative Bacterial Infection","Drug: Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Drug: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3","Part A: Ceftazidime and avibactam plasma concentrations by nominal sampling time using appropriate descriptive statistics, eg, number, mean, standard deviation (SD), minimum, median, maximum, geometric mean, and coefficient of variation|Part B: Number of subjects with adverse events (AEs) and Serious Adverse Events (SAEs)|Part B: Number of deaths reported for study subjects|Part B: Number of subjects discontinued due to adverse events (AEs)|Part B: Number of subjects with clinically significant abnormal laboratory results|Part A: Number of subjects with adverse events (AEs) and Serious Adverse Events (SAEs)|Part A: Number of deaths reported for study subjects|Part A: Number of subjects discontinued due to adverse events (AEs)|Part A: Number of subjects with clinically significant abnormal laboratory results|Part B: Ceftazidime and avibactam plasma concentrations by nominal sampling time using appropriate descriptive statistics, eg, number, mean, standard deviation (SD), minimum, median, maximum, geometric mean, and coefficient of variation|Part B efficacy assessment: All-cause mortality|Part B efficacy assessment: Clinical outcome assessed as proportion of subjects meeting the criteria for clinical cure, clinical improvement, clinical failure, or indeterminate at End-of-IV, End-of-Treatment, Test-of-Cure, and Late Follow-up Visits|Part B efficacy assessment: Cure defined as clinical improvement and no need for further antibacterial treatment, 7 to 14 days after end of treatment|Part B efficacy assessment: Microbiological eradication 7 to 14 days after end of treatment|Part B efficacy assessment: Emergent infections","Pfizer|Allergan","All","up to 88 Days   (Child)","Phase 2","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","C3591024|2018-002800-16","March 10, 2020","December 18, 2021","December 18, 2021","October 14, 2019",,"January 7, 2020","CTSC Clinical Research Center, Sacramento, California, United States|UC Davis Health, Sacramento, California, United States|UC Davis Outpatient Clinic Glassrock Building, Sacramento, California, United States|University of California Davis Health, Investigational Drug Services, Sacramento, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|Tufts Medical Center, IDS Pharmacy, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Duke University Investigational Drug Services, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04126031"
550,"NCT04089722","Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the ""Bra Strap Fat"" Region",,"Recruiting","No Results Available","Brassiere Strap Fat (BSF)|Bra Strap Fat (BSF)","Drug: Deoxycholic Acid","Reduction of Anterior/Posterior Axilla Fat","Juva Skin & Laser Center|Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","60E56","July 26, 2019","June 11, 2020","June 11, 2020","September 13, 2019",,"September 13, 2019","JUVA Skin & Laser Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04089722"
551,"NCT04040621","Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia",,"Recruiting","No Results Available","Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia","Drug: Ceftazidime-avibactam","Area under the plasma concentration curve|Area under the plasma concentration time profile from time 0 to infinity|Area under the plasma concentration time profile from time 0 to the last quantifiable concentration|Maximum plasma concentration|Time of last quantifiable plasma concentration|Time for Cmax|Terminal elimination half life|Clearance|Volume of distribution at steady state|Volume of distribution during terminal phase|Plasma concentration will be summarized using descriptive statistics, eg, number, mean, SD, minimum, median, maximum, geometric mean, and coefficient of variation.|Number of subjects with adverse Events (AE) and Serious Adverse Events (SAEs)|Number of subjects with clinically significant abnormal laboratory results|Number of subjects with clinically significant abnormal vital signs|Number of deaths reported for study subjects|Number of subjects discontinued due to AEs|Number of subjects with abnormal findings from physical examinations performed","Pfizer|Allergan","All","3 Months to 17 Years   (Child)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","C3591025|2018-002841-12|EMBA","March 3, 2020","May 25, 2021","May 25, 2021","August 1, 2019",,"January 7, 2020","Rady Children's Hospital San Diego, San Diego, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Yale New Haven Hospital, Department of Pharmacy Services, New Haven, Connecticut, United States|Yale Center for Clinical Investigation Church Street Research Unit (CSRU), New Haven, Connecticut, United States|University of New Mexico Health Sciences Center Hospital Inpatient Pharmacy 4N, Albuquerque, New Mexico, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|UNM Clinical & Translational Sciences Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT04040621"
552,"NCT04038125","Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME","ICOD","Not yet recruiting","No Results Available","Diabetic Macular Edema|Diabetic Retinopathy|Retinal Ischemia","Drug: Ozurdex Drug Implant Product","Evaluate re perfusion following Ozurdex use.","Retina Macula Specialists of Miami, LLC|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCH-0-012-019","August 15, 2019","February 2020","February 2021","July 30, 2019",,"July 30, 2019","Retina Macula Specialists of Miami, LLC, North Miami Beach, Florida, United States|Retina Macula Specialists of Miami, LLC, South Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04038125"
553,"NCT03923478","ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis",,"Recruiting","No Results Available","Ulcerative Colitis Chronic Mild|Ulcerative Colitis Chronic Moderate","Drug: ABI-M201|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events|Incidence of Treatment-Emergent Laboratory Abnormalities|Clinical Remission|Endoscopic Improvement","Assembly Biosciences|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ABI-M201-101","June 24, 2019","June 2021","December 2021","April 22, 2019",,"November 29, 2019","(Investigator site), Oakland, California, United States|(Investigator Site), San Carlos, California, United States|(Investigator Site), Decatur, Georgia, United States|(Investigator Site), Shreveport, Louisiana, United States|(Investigator Site), Rockville, Maryland, United States|(Investigator Site), Chesterfield, Michigan, United States|(Investigator Site), Ypsilanti, Michigan, United States|(Investigator Site), Plymouth, Minnesota, United States|(Investigator Site), Rochester, Minnesota, United States|(Investigator Site), Beavercreek, Ohio, United States|(Investigator Site), Jackson, Tennessee, United States|(Investigator Site), Houston, Texas, United States|(Investigator Site), Ogden, Utah, United States|(Investigator Site), Bellevue, Washington, United States|(Investigator Site), Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03923478"
554,"NCT03832179","Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","STAMP","Recruiting","No Results Available","Diabetic Macular Edema|Cataract","Drug: Bevacizumab|Drug: Ranibizumab|Drug: Aflibercept|Drug: Ozurdex","Comparison of central foveal thickness outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy|Visual acuity outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy","Bay Area Retina Associates|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STAMP","November 15, 2018","June 1, 2020","October 30, 2020","February 6, 2019",,"January 18, 2020","Bay Area Retina Associates, Walnut Creek, California, United States",,"https://ClinicalTrials.gov/show/NCT03832179"
555,"NCT03726788","Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis","TOXART","Not yet recruiting","No Results Available","Joint Diseases|Knee|Therapeutics|Magnetic Resonance Imaging","Drug: Botulinum Toxin Type A 100U|Drug: Botulinum Toxin Type A 200U|Drug: Triamcinolone Hexacetonide Inj Susp 20 MG/ML","Assesment of vascularization by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) according to the % Area Under the Curve (AUC) of perfusion value|Pain analysis by the visual analogue scale (VAS)|Joint amplitude measured by goniometry|Western Ontario McMaster University Osteoarthritis (WOMAC) Index|Two minutes walk|Frequency of consumption of analgesics|Amount of consumption of analgesics","Lille Catholic University|Allergan","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","105","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RC-P0037","September 2019","November 2021","April 2022","October 31, 2018",,"May 21, 2019","Lille Catholic University, Lille, France",,"https://ClinicalTrials.gov/show/NCT03726788"
556,"NCT03719885","TrueTear in Sjogren's Disease Patients",,"Recruiting","No Results Available","Dry Eye Syndromes|Sjogren's Syndrome","Device: TrueTear Intranasal Tear Neurostimulator","Schirmer testing|Visual acuity|Slit Lamp exam|Number of adverse events","University of Pennsylvania|Allergan","All","22 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","830076","November 1, 2018","July 25, 2019","July 22, 2020","October 25, 2018",,"September 13, 2019","Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03719885/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03719885"
557,"NCT03701919","Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy",,"Enrolling by invitation","No Results Available","Bariatric Surgery|Postoperative Nausea and Vomiting","Drug: Botulinum toxin pyloroplasty|Drug: Normal saline pyloric injection","Use of rescue antiemetics|Patient satisfaction survey|Subjective experience of nausea|Number of episodes of vomiting|30 day readmission rate|Hospital length of stay","Albany Medical College|Allergan","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","104","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5090","January 7, 2019","April 1, 2020","April 1, 2020","October 10, 2018",,"January 10, 2019","Albany Medical Center, Albany, New York, United States",,"https://ClinicalTrials.gov/show/NCT03701919"
558,"NCT03637348","Effect of TrueTear Corneal Surface Imaging",,"Completed","No Results Available","Cataract|Myopia","Device: TrueTear","Surface asymmetry index (SAI) assessed with corneal topography|Surface regularity index (SRI) assessed with corneal topography","Price Vision Group|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2018-008","August 13, 2018","July 8, 2019","July 8, 2019","August 20, 2018",,"July 12, 2019","Price Vision Group, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03637348"
559,"NCT03631368","Treatment of Hypertrophic Scars With Intradermal Botox",,"Recruiting","No Results Available","Hypertrophic Scar","Drug: Botox","Improvement of hypertrophic scars based on the Subject and Observer Scar Assessment Scale","Roy G. Geronemus, M.D.|Allergan|Laser and Skin Surgery Center of New York","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LSSC-BOTOXSCAR-2018","October 1, 2018","May 31, 2019","May 31, 2019","August 15, 2018",,"September 26, 2018","Laser & Skin Surgery Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03631368"
560,"NCT03616262","""Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome""",,"Recruiting","No Results Available","Complex Regional Pain Syndrome","Drug: Botox + Lidocaine|Drug: Lidocaine alone","Reduction in the VAS score will be the primary outcome measure.|Quality of Life as a measure of function with pain.|Disability|Thermography|Goniometry|Algometry|Modified VAS Score|Electrical Impedence Myography","VA Connecticut Healthcare System|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VACHS","July 2016","December 2019","December 2019","August 6, 2018",,"August 6, 2018","VA Connecticut Healthcare System, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03616262"
561,"NCT03580044","Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria",,"Not yet recruiting","No Results Available","Serious Bacterial Infection","Combination Product: ATM-AVI|Drug: BAT","Proportion of subjects with clinical cure in the microbiological Intent-To-Treat (micro-ITT) analysis set|Proportion of subjects with clinical cure in the Microbiologically Evaluable (ME) analysis set|Proportion of subjects with clinical cure in the micro-ITT and ME analysis sets|Proportion of subjects with a favorable per subject microbiological response in the micro ITT and ME analysis sets|Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets|Proportion of subjects who died on or before 28 days in the Intent-To-Treat (ITT) and micro-ITT analysis sets|Incidence and severity of adverse events|Incidence of abnormalities in physical examination|Incidence of vital sign abnormalities|Incidence of ECG abnormalities|Incidence of clinical laboratory abnormalities","Pfizer|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C3601009|2017-004544-38|ASSEMBLE","July 27, 2020","November 23, 2021","December 10, 2021","July 9, 2018",,"December 17, 2019","Harbor-UCLA Medical Center, Torrance, California, United States|LA BioMed at Harbor-UCLA Medical Center, Torrance, California, United States|Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|La BioMed at Harbor-UCLA Medical Center, Torrance, California, United States|Artemis Hospital, Gurugram, Haryana, India|Government medical College, Kozhikode, Kerala, India|Deenanath Mangeshkar Hospital And Research Centre, Pune, Maharashtra, India|SR Kalla Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Apollo Hospitals Enterprise Limited, Chennai, Tamil NADU, India|Victoria Hospital, Bangalore Medical College and Research Institute, Bangalore, India|Spitalul Clinic de Boli Infectioase si Tropicale ""Dr. Victor Babes"", Bucuresti, Romania|Spitalul Clinic de Boli Infectioase Cluj Napoca, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase ""Sf. Parascheva"" Iasi, Iasi, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Spitalul Clinic Judetean de Urgenta ""Pius Brinzeu"", Timisoara, Romania|SBHI of the city of Moscow ""N.I.Pirogov City Clinical Hospital # 1"", Moscow, Russian Federation|GBUZ of Novosibirsk region ""City clinical hospital #2"", Novosibirsk, Russian Federation|Regional State Budgetary Healthcare Institution ""Clinical Emergency Hospital"", Smolensk, Russian Federation|FSBEI of HE ""Smolensk State Medical University"" of the Ministry of Health of the RF, Smolensk, Russian Federation|FSBEI of HE ""Smolensk State Medical University"" of the Ministry of Health of the Russian Federation, Smolensk, Russian Federation|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03580044"
562,"NCT03544593","The Volumetric Analysis of Fat Grafting",,"Recruiting","No Results Available","Autologous Fat Grafting","Device: Revolve System","Graft retention|Volume of adipose harvested (mL)|Volume of adipocyte injected (mL)|Operating room time (harvesting, processing, and reinjection time) (min)|Standardized before and after photos","Hunstad Kortesis Bharti Cosmetic Sugrery|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","11-01-2017","January 4, 2018","March 2019","March 2019","June 4, 2018",,"June 4, 2018","Kelly Costin, Huntersville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03544593"
563,"NCT03543566","Bladder Antimuscarinic Medication and Accidental Bowel Leakage","BAMA","Completed","No Results Available","Urinary Incontinence, Urge|Fecal Incontinence",,"change in FI symptom severity|post-treatment change in FI frequency","University of Alabama at Birmingham|Allergan","Female","18 Years and older   (Adult, Older Adult)",,"32","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-300000103","May 21, 2018","January 18, 2019","January 18, 2019","June 1, 2018",,"January 22, 2019","UAB Kirklin Clinic, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03543566"
564,"NCT03517540","Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)","TANDEM","Recruiting","No Results Available","Non-alcoholic Steatohepatitis (NASH)","Drug: Tropifexor (LJN452)|Drug: Cenicriviroc (CVC)","Number of participants with Adverse Events|Proportion of participants who have at least a one point improvement in fibrosis|Proportion of participants with resolution of steatohepatitis","Novartis Pharmaceuticals|Allergan|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLJC242A2201J|2017-004208-24|LJC242A2201J","September 11, 2018","July 28, 2020","September 2, 2020","May 7, 2018",,"July 18, 2019","Novartis Investigative Site, Chandler, Arizona, United States|Novartis Investigative Site, North Little Rock, Arkansas, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Pasadena, California, United States|Novartis Investigative Site, Rialto, California, United States|Novartis Investigative Site, Palmetto Bay, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Shreveport, Louisiana, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Morehead City, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Hermitage, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Murray, Utah, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Prague, Czechia|Novartis Investigative Site, Prague, Czechia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Vila Real, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Stavropol, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom|Novartis Investigative Site, Aberdeen, United Kingdom|Novartis Investigative Site, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03517540"
565,"NCT03489265","Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence","ELXDFI","Withdrawn","No Results Available","Fecal Incontinence|Accidental Bowel Leakage|Anal Incontinence|Diarrhea|Urge Incontinence","Drug: Eluxadoline 100 mg|Other: Placebo","Run-in days per week with fecal incontinence|Treatment Period 1 days per week with fecal incontinence|Treatment Period 2 days per week with fecal incontinence|Follow-up days per week with fecal incontinence|Days per week with loperamide (escape medication)|Days per week patient described bowel movements as 6 or 7 on the Bristol Stool Scale|Days per week patient reported strong urge sensations|Fecal Incontinence Severity Score (FISS) over time|Fecal Incontinence Quality of Life Scale Score for Lifestyle (FIQOL-Lifestyle)|Fecal Incontinence Quality of Life Scale Score for Coping/Behavior (FIQOL-Coping/Behavior)|Fecal Incontinence Quality of Life Scale Score for Depression/Self-Perception (FIQOL-Depression/Self-Perception)|Fecal Incontinence Quality of Life Scale Score for Embarrassment (FIQOL-Embarrassment)|Brief Symptom Inventory-18 Anxiety Score (BSI-Anxiety)|Brief Symptom Inventory-18 Depression Score (BSI-Depression)|Preference for study drug vs. loperamide|Preference for eluxadoline or placebo","University of North Carolina, Chapel Hill|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17-1561|895","April 2019","September 2019","March 2020","April 5, 2018",,"July 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03489265"
566,"NCT03469258","Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma",,"Recruiting","No Results Available","Pancreatic Cancer","Drug: Pancrelipase","Effect of pancreatic enzyme replacement therapy on the completion rate of adjuvant chemotherapy and radiation after surgery for early stage pancreatic cancer|Initiation rate of adjuvant treatment for resected pancreatic cancer|Subject adherence to pancreatic enzyme replacement therapy as determined by pill count|Subject adherence to pancreatic enzyme replacement therapy during surgery and adjuvant treatment for early stage pancreatic cancer|Measure serum albumin levels before and after surgery and adjuvant treatment for early stage pancreatic cancer|Measure body weight before and after surgery and adjuvant treatment for early stage pancreatic cancer|Evaluate quality of life before and after surgery and adjuvant treatment for early stage pancreatic cancer using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire|Monitor the incidence and severity of complications after surgery for early stage pancreatic cancer|Measure grip strength before and after surgery and adjuvant treatment for early-stage pancreatic cancer","Dana-Farber Cancer Institute|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17-450","April 13, 2018","December 31, 2020","December 31, 2023","March 19, 2018",,"March 7, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03469258"
567,"NCT03456349","Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care",,"Completed","No Results Available","Alzheimer's Disease","Drug: HTL0018318|Drug: Placebo","Treatment emergent adverse events (TEAEs), Safety and Tolerability","Heptares Therapeutics Limited|Allergan","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HTL0018318-202|2017-000649-34","November 10, 2017","July 16, 2018","July 16, 2018","March 7, 2018",,"July 20, 2018","Syneos, Prague, Czechia|Syneos, Warsaw, Poland|Syneos, Bratislava, Slovakia|Syneos, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03456349"
568,"NCT03380624","Tear Lipid Layer Thickness With Emollient Eye Drops",,"Completed","No Results Available","Dry Eye Syndromes","Drug: Refresh Optive|Drug: Refresh Optimum OMEGA 3","Lipid Layer Thickness","Ohio State University|Allergan","All","30 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2016H0354","March 1, 2017","June 30, 2018","June 30, 2018","December 21, 2017",,"May 23, 2019","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03380624"
569,"NCT03373162","Functional Effects of Botox on the Brain Using MRS and fMRI",,"Completed","Has Results","Healthy","Drug: onabotulinumtoxinA","Glutamate + Glutamine (Glx)/Creatine Ratio as Measured by MRS in the Brainstem Pre and Post-Botox|Change From Baseline in Functional MRI Mean Blood Oxygen Level Dependent (BOLD) Response in the Amygdala|Number of Participants With Structural Brain Volume Change Following Botox Injections","University of California, Irvine|Allergan","Female","30 Years to 40 Years   (Adult)","Phase 4","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017-3377","September 30, 2017","November 1, 2017","November 1, 2017","December 14, 2017","April 26, 2019","April 26, 2019","University of California, Irvine, Irvine, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03373162/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03373162/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03373162"
570,"NCT03367429","The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination",,"Recruiting","No Results Available","Stroke|Muscle Spasticity","Drug: Botox","Botulinum Toxin Muscle Effect (BTME) Volume of Abnormal Voxels per MRI Slice in Muscles after Research Injections|Change in Botulinum Toxin Muscle Effect (BTME) Volume of Abnormal Voxels per MRI Slice in Muscles after Clinical Injections","Weill Medical College of Cornell University|Allergan","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 4","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1708018456","June 15, 2018","October 2020","October 2020","December 8, 2017",,"June 20, 2019","NewYork Presbyterian Hospital - Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03367429"
571,"NCT03341780","Standard Amblyopia Therapy in Adult Amblyopes",,"Completed","No Results Available","Amblyopia","Procedure: amblyopia therapy","visual acuity","Southern California College of Optometry|Allergan","All","18 Years and older   (Adult, Older Adult)",,"9","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SoutherCCO","December 16, 2014","October 24, 2016","October 24, 2016","November 14, 2017",,"November 17, 2017",,,"https://ClinicalTrials.gov/show/NCT03341780"
572,"NCT03250988","Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility",,"Completed","No Results Available","Spasticity, Muscle|Muscular Diseases|Musculoskeletal Disease|Muscle Hypertonia|Muscle Spasticity|Neuromuscular Manifestations|Signs and Symptoms|Nervous System Diseases|Neurologic Manifestations","Diagnostic Test: Neurological Examination","Prevalence of comorbid spasticity and urinary incontinence in a long-term care facility|Quality of life in residents of a long-term care facility|Physical and mental well-being in residents of a long-term care facility|Perceived disability in residents of a long-term care facility","Vanderbilt University Medical Center|Allergan","All","18 Years and older   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","170963","January 30, 2018","August 1, 2018","August 1, 2018","August 16, 2017",,"October 9, 2018","Tennessee State Veterans' Homes, Murfreesboro, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03250988"
573,"NCT03249311","Levomilnacipran in Healthy Males",,"Recruiting","No Results Available","None (i.e. Healthy Volunteers)","Drug: Levomilnacipran|Drug: Duloxetine|Drug: Placebos","Primary End Point|Secondary End Points","University of Ottawa|Allergan","Male","18 Years to 40 Years   (Adult)","Phase 4","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","REB2017004","March 2, 2018","December 31, 2019","January 31, 2020","August 15, 2017",,"April 17, 2019","Institute of Mental Health Research, Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03249311"
574,"NCT03244228","A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878",,"Completed","No Results Available","Healthy","Drug: HTL0016878|Drug: Placebo - Concentrate","Treatment emergent adverse events (TEAEs)|Physical examinations|vital signs (Heart Rate and Blood pressure)|Laboratory safety assessment|ECG|Columbia- suicide severity rating scale (C-SSRS)|Maximum plasma concentration (Cmax) of HTL0016878|Time to Maximum plasma concentration (Tmax) of HTL0016878|Area under the curve of HTL0016878|Half-life (t1/2) of HTL0016878|Amount excreted in urine (Ae) of HTL0016878|Fraction of dose eliminated unchanged on urine (fe/F) of HTL0016878","Heptares Therapeutics Limited|Allergan","All","Child, Adult, Older Adult","Phase 1","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HTL0016878-101|2017-001385-26|16-028","August 25, 2017","September 23, 2019","September 23, 2019","August 9, 2017",,"November 29, 2019","Hammersmith Medicines Research, London, Hammersmith, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03244228"
575,"NCT03243864","Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis",,"Recruiting","No Results Available","Renal Failure|Bacterial Infections|Critical Illness","Drug: Ceftazidime-avibactam","Ceftazidime plasma concentrations|Avibactam plasma concentrations|Ceftazidime effluent concentrations|Avibactam effluent concentrations|Maximum plasma concentration (Cmax)|Number of participants with adverse effects as a measure of safety|Minimum plasma concentration (Cmin)|Half-life (t1/2)|Clearance (Cl)|AUC 0 to 8 hours|Sieving Coefficient","Temple University|Allergan","All","18 Years and older   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","866","March 13, 2017","March 21, 2020","October 21, 2020","August 9, 2017",,"April 10, 2019","Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03243864"
576,"NCT03241563","Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat",,"Completed","No Results Available","Fat Reduction","Drug: Sodium Deoxycholate|Drug: Triamcinolone","Evaluation of Efficacy of Kybella with Triamcinolone in the Reduction of Submental Fat|Evaluation of Safety of Kybella with Triamcinolone for Reduction of Submental Fat","Goldman, Butterwick, Fitzpatrick and Groff|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ATX-TRIAM-2016","April 2016","February 2017","February 2017","August 7, 2017",,"August 7, 2017","Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc., San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03241563"
577,"NCT03211390","Using Telemedicine to Improve Spasticity Diagnosis Rates",,"Completed","No Results Available","Spasticity, Muscle|Muscular Diseases|Musculoskeletal Disease|Muscle Hypertonia|Muscle Spasticity|Neuromuscular Manifestations|Signs and Symptoms|Nervous System Diseases|Neurologic Manifestations","Diagnostic Test: Neurological Examination|Diagnostic Test: Teleneurological Examination","Sensitivity of Teleneurology|Specificity of Teleneurology|Spasticity Diagnosis","Vanderbilt University Medical Center|Allergan","All","18 Years and older   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","170703","January 30, 2018","August 1, 2018","August 1, 2018","July 7, 2017",,"October 9, 2018","Tennessee State Veterans' Homes, Murfreesboro, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03211390"
578,"NCT03097835","Evaluation of Skin Quality Improvement",,"Completed","No Results Available","Skin Quality","Drug: Hyper-Diluted Botox|Drug: Topical anesthesia|Other: 0.9% saline solution","Percent Improvement in Skin Quality|Patient and Investigator Reported Outcomes","Steve Yoelin M.D. Medical Associates, Inc.|Allergan","All","35 Years to 55 Years   (Adult)","Phase 2","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HDB101","February 12, 2018","July 12, 2018","July 26, 2018","March 31, 2017",,"February 22, 2019","Steve Yoelin MD & Associates, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03097835"
579,"NCT03065582","The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biological Effects",,"Unknown status","No Results Available","Pigmentation","Other: Topical Product A|Other: Topical Product B|Other: Topical Product C|Other: Control","diffuse reflectance spectroscopy|photography|investigator's global assessment score|Diffuse reflectance spectroscopy|Investigator's global assessment score|Photography|Investigator global assessment score|Biological effects","Henry Ford Health System|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB # 9695","June 2015","June 2017",,"February 28, 2017",,"February 28, 2017","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03065582"
580,"NCT02959970","Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris",,"Completed","No Results Available","Acne Vulgaris","Drug: dapsone gel","Number of Participants with Treatment-Emergent Adverse Events|Trough Plasma Concentration of Dapsone|Peak Plasma Concentration of Dapsone|Patient-Rated Assessment of Stinging/Burning using a 4-Point Scale|Investigator-Rated Assessment of Dryness using a 4-Point Scale|Investigator-Rated Assessment of Scaling using a 4-Point Scale|Investigator-Rated Assessment of Erythema using a 4-Point Scale","Almirall, S.A.|Allergan","All","9 Years to 11 Years   (Child)","Phase 4","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1679-401-006","October 31, 2016","February 8, 2018","February 8, 2018","November 9, 2016",,"December 4, 2018","Kirklin Clinic, Birmingham, Alabama, United States|Center for Dermatology Clinical Research, Fremont, California, United States|Quest Dermatology Research, Northridge, California, United States|Southern California Dermatology, Santa Ana, California, United States|Redwood Family Dermatology, Santa Rosa, California, United States|Center for Clinical and Cosmetic Research, Aventura, Florida, United States|Baumann Cosmetic and Research Institute, Miami Beach, Florida, United States|Dermresearch, PLLC, Louisville, Kentucky, United States|Hamzavi Dermatology, Fort Gratiot, Michigan, United States|Saint Louis University Dermatology, Saint Louis, Missouri, United States|Skin Specialists, PC, Omaha, Nebraska, United States|Skin Specialty Dermatology, New York, New York, United States|Health Sciences/Department of Dermatology, Winston-Salem, North Carolina, United States|KGL Skin Study Center, Broomall, Pennsylvania, United States|Department of Dermatology, UPCII, Hershey, Pennsylvania, United States|Arlington Research Center, Inc., Arlington, Texas, United States|DermResearch, LLC, Austin, Texas, United States|University of Texas Medical School at Houston, Houston, Texas, United States|Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States|Premier Clinical Research, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02959970"
581,"NCT02871440","A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye",,"Completed","No Results Available","Dry Eye Syndromes","Drug: Omega 3|Drug: Optive Advanced|Drug: Optive","Tear evaporation rate|Tear break-up time|Subjective ocular comfort","The University of New South Wales|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","57","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","SOVS2016-040","September 19, 2016","September 18, 2017","September 18, 2017","August 18, 2016",,"August 2, 2018",,,"https://ClinicalTrials.gov/show/NCT02871440"
582,"NCT02830776","Topical Bimatoprost for Chemical Blepharoplasty",,"Unknown status","No Results Available","Dermatochalasis","Drug: bimatoprost 0.03% ophthalmic solution","Graded improvement in dermatochalasis|Improved patient satisfaction","Tulane University|Allergan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","833277-1","November 2016","April 30, 2017","June 30, 2017","July 13, 2016",,"May 2, 2017","Tulane Department of Dermatology, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02830776"
583,"NCT02792803","A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma",,"Unknown status","No Results Available","POAG|Primary Open Angle Glaucoma|Ocular Hypertension","Drug: Xalatan|Drug: Apo-Latanoprost|Drug: Co-Latanoprost","Intraocular Pressure|Ocular Hyperemia","Dr. David Yan|Allergan|DBYAN Medicine Professional Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Pro00012759","September 2015","April 2017","September 2017","June 8, 2016",,"July 26, 2017","Opthalmis Diagnostic Services, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02792803"
584,"NCT02684084","Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema","COLLIDE","Terminated","No Results Available","Diabetic Macular Edema","Drug: Ozurdex|Drug: Lucentis","Comparison of mean change from baseline ETDRS BCVA letters|Mean change in Central Subfield Thickness (CST)|Number of re-injections|Re-injection interval|Proportion of eyes with 15- and 10-ETDRS letters gained/lost|Proportion of study eyes with Proliferative Diabetic Retinopathy (PDR) at study completion","North Toronto Eye Care Laser and Eye Specialists|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","5","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT-CAN-EYE-0399","November 2015","November 2016","December 2016","February 17, 2016",,"August 20, 2018","Toronto Retina Institue, Toronto, Ontario, Canada|North Toronto Eye Care Laser and Eye Specialists, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02684084"
585,"NCT02639052","Itch Relieving Effect of Botox: a Study in Healthy Subjects",,"Completed","Has Results","Pruritus","Drug: Botox|Drug: Saline","Itch by VAS Itch Intensity at Baseline (Visit 1)|Itch by VAS Itch Intensity at 1 Week (Visit 2)|Itch by VAS Itch Intensity at 1 Month (Visit 3)|Itch by VAS Itch Intensity at 3 Months (Visit 4)|Change in Heat Pain Relief by VAS Pain Intensity Reporting After 1 Week, 1 Month, and 3 Months After Treatment","Temple University|Allergan","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","23230|126938","February 2016","July 2016","January 2017","December 24, 2015","April 27, 2017","April 27, 2017",,,"https://ClinicalTrials.gov/show/NCT02639052"
586,"NCT02623829","Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)",,"Completed","No Results Available","Post-operative Excessive Scarring","Drug: Botulinum Toxin|Drug: Saline","Manchester Scar Scale (MSS) score difference|modified Manchester Scar Scale (mMSS) score difference","Icahn School of Medicine at Mount Sinai|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GCO 15-1093","December 1, 2015","March 1, 2019","March 1, 2019","December 8, 2015",,"April 22, 2019","Icahn School of Medicine at Mount Sinia, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02623829"
587,"NCT02555982","Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor","Btx-HT","Recruiting","No Results Available","Essential Head Tremor","Drug: BOTOX ® 200 Unités|Drug: Placebo","clinical state improvement of patients evaluated by the Clinical Global Impression of Change (CGI)|% of responders defined with CGI|The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)|The Essential Tremor Embarrassment Assessment (ETEA)|The Quality of life in Essential Tremor (QUEST)|tremor frequency measured by accelerometer|mean peak amplitude measured by accelerometer|distance traveled measured by accelerometer","University Hospital, Clermont-Ferrand|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU-0245|2015-000162-59","June 27, 2016","September 2020","June 2021","September 22, 2015",,"September 18, 2019","Centre Hospitalier Pays D'Aix, Aix-en-Provence, France|CHU d'Amiens, Amiens, France|Hôpital Jean Minjoz, Besançon, France|Hôpital Haut-Levêque, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|Hôpital R Salendro, Lille, France|Hôpital neurologique, Lyon, France|Hôpital de la Timone, Marseille, France|CHU Gui de Chauliac, Montpellier, France|CH Narbonne, Narbonne, France|Hôpital Caremeau, Nîmes, France|AP-HP, Paris, France|Fondation Rothschild, Paris, France|CH F. Mittérand, Pau, France|CHU de Poitiers, Poitiers, France|Hôpital de Hautepierre, Strasbourg, France|CHU de Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02555982"
588,"NCT02471651","Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema","DIME","Completed","Has Results","Diabetic Macular Edema","Drug: Dexamethasone intravitreal implant (0.7 mg)|Drug: Intravitreal anti-VEGF injection","Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months|Mean Change in Standardized Best-corrected Visual Acuity (BCVA) Between Baseline and 9 Months|Total Number of Treatments in Each Arm Between Baseline and 9 Months","California Retina Consultants|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRC2015-02","June 2015","October 24, 2018","October 24, 2018","June 15, 2015","February 19, 2019","February 19, 2019","California Retina Consultants, Bakersfield, California, United States|California Retina Consultants, Oxnard, California, United States|California Retina Consultants, Santa Barbara, California, United States|California Retina Consultants, Santa Maria, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02471651/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02471651"
589,"NCT02471105","Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml","SPORTII","Unknown status","No Results Available","Ocular Hypertension|Glaucoma","Drug: Preserved Bimatoprost 0.01%|Drug: Tafluprost Unit Dose Preservative Free 15microgram/ml","the difference in mean IOP values between the 2 groups|the difference in IOP values between the groups in change from baseline IOP|the difference in mean IOP between the 2 groups|the difference in IOP between the 2 groups at each timepoints","Universitaire Ziekenhuizen Leuven|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","67","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","S57304","September 2015","May 2017","December 2017","June 15, 2015",,"May 12, 2016","Hommer Ophthalmology Institute, Vienna, Austria|UZ Leuven, Leuven, Vlaams Brabant, Belgium|San Paolo Hospital, Milan, Italy|Bietti Foundation, Rome, Italy|Clinical Research Centre Momorial A. de Rotschild, Geneve, Switzerland|Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, United Kingdom|Western Eye Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02471105"
590,"NCT02459951","Improving Holding Function of the Hemiplegic Hand",,"Completed","Has Results","Stroke","Other: clenched fist","Geometric Ratios of Log-transformed Transit Time|Fraction of Successful Holds for Each Evaluation Session|Ratio of Successful Holds","Nathaniel Mayer|Allergan|Albert Einstein Healthcare Network","All","35 Years to 80 Years   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","4729FBD","July 2015","January 31, 2017","April 30, 2017","June 2, 2015","July 1, 2019","July 18, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02459951/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02459951"
591,"NCT02448043","Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure",,"Completed","Has Results","Nail Growth Cessation|Intraocular Pressure","Drug: Bimatoprost 0.01%|Other: Placebo: saline","Change From Baseline in Nail Length of Hands|Change From Baseline in Nail Length of Digits|Intraocular Pressure at 30 Days of Treatment|Nail Brittleness at 30 Days of Treatment|Number of Days Until the First Nail Chipped|Change in Skin Pigmentation on Hands|Change in Hirsutism on Hands","Northwestern University|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STU00200526","June 4, 2015","May 6, 2016","May 6, 2016","May 19, 2015","December 13, 2019","December 13, 2019","David J. Palmer, MD, Glenview, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02448043"
592,"NCT02413346","A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Sarecycline","Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)","Almirall, S.A.|Allergan","All","9 Years and older   (Child, Adult, Older Adult)","Phase 3","490","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC1403","March 20, 2015","August 26, 2016","August 26, 2016","April 9, 2015","May 4, 2018","February 1, 2019","Actavis Investigational Study Site #206, Mobile, Alabama, United States|Actavis Investigational Study Site #236, Hot Springs, Arkansas, United States|Actavis Investigational Study Site #245, Carlsbad, California, United States|Actavis Investigational Study Site #129, Encino, California, United States|Actavis Investigational Study Site #209, Fremont, California, United States|Actavis Investigational Study Site #147, Sacramento, California, United States|Actavis Investigational Study Site #150, San Diego, California, United States|Actavis Investigational Study Site #125, San Diego, California, United States|Actavis Investigational Study Site #204, San Diego, California, United States|Actavis Investigational Study Site #222, Denver, Colorado, United States|Actavis Investigational Study Site #148, Wheat Ridge, Colorado, United States|Actavis Investigational Study Site #226, Clearwater, Florida, United States|Actavis Investigational Study Site #238, Jupiter, Florida, United States|Actavis Investigational Study Site #249, Miami, Florida, United States|Actavis Investigational Study Site #145, Miami, Florida, United States|Actavis Investigational Study Site #211, Miramar, Florida, United States|Actavis Investigation Study Site # 140, North Miami Beach, Florida, United States|Actavis Investigational Study Site #151, Orange, Florida, United States|Actavis Investigational Study Site #203, Tampa, Florida, United States|Actavis Investigational Study Site #242, Snellville, Georgia, United States|Actavis Investigational Study Site #124, Boise, Idaho, United States|Actavis Investigational Study Site #106, Chicago, Illinois, United States|Actavis Investigational Study Site #113, South Bend, Indiana, United States|Actavis Investigational Study Site #213, Louisville, Kentucky, United States|Actavis Investigational Study Site #217, Rockville, Maryland, United States|Actavis Investigational Study Site #251, Clarkston, Michigan, United States|Actavis Investigational Study Site #235, Clinton Township, Michigan, United States|Actavis Investigational Study Site #227, Fort Gratiot, Michigan, United States|Actavis Investigational Study Site #111, Warren, Michigan, United States|Actavis Investigational Study Site #221, Fridley, Minnesota, United States|Actavis Investigational Study Site #231, Omaha, Nebraska, United States|Actavis Investigational Study Site #146, New York, New York, United States|Actavis Investigational Study Site #208, New York, New York, United States|Actavis Investigational Study Site #240, Rochester, New York, United States|Actavis Investigational Study Site #230, Stony Brook, New York, United States|Actavis Investigational Study Site #229, Raleigh, North Carolina, United States|Actavis Investigational Study Site #149, Gresham, Oregon, United States|Actavis Investigational Study Site #257, Philadelphia, Pennsylvania, United States|Actavis Investigational Study Site #225, Goodlettsville, Tennessee, United States|Actavis Investigational Study Site #128, Knoxville, Tennessee, United States|Actavis Investigational Study Site #216, Knoxville, Tennessee, United States|Actavis Investigational Study Site #109, Nashville, Tennessee, United States|Actavis Investigational Study Site #223, Arlington, Texas, United States|Actavis Investigational Study Site #252, Arlington, Texas, United States|Actavis Investigational Study Site #220, College Station, Texas, United States|Actavis Investigational Study Site #104, Dallas, Texas, United States|Actavis Investigational Study Site #142, Houston, Texas, United States|Actavis Investigational Study Site #105, Houston, Texas, United States|Actavis Investigational Study Site #201, Katy, Texas, United States|Actavis Investigational Study Site #223, Pflugerville, Texas, United States|Actavis Investigational Study Site #101, Plano, Texas, United States|Actavis Investigational Study Site #207, San Antonio, Texas, United States|Actavis Investigational Study Site #212, West Jordan, Utah, United States|Actavis Investigational Study Site #244, Norfolk, Virginia, United States|Actavis Investigational Study Site #144, Spokane, Washington, United States|Actavis Investigational Study Site #233, Walla Walla, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02413346"
593,"NCT02399657","Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema",,"Unknown status","No Results Available","Diabetes Mellitus|Macular Edema|Retinal Exudates and Deposits","Drug: Intravitreal dexamethasone 0.7mg implant","The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center)|The average change in ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity|The Ratio of eyes with central macular thickness under 290 micrometer in OCT (optical coherence tomography)|The Ratio of eyes showing reduced perifoveal capillary leakage in fluorescein angiography|The average change in number of microaneurysm in macula|The progression rate of cataract|Number of eyes having increased intraocular pressure","Inje University|Allergan","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 4","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EXTINCT","February 2015","December 2016","December 2016","March 26, 2015",,"April 6, 2015","Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Dong-A University hospital, Busan, Korea, Republic of|Pusan national university hospital, Busan, Korea, Republic of|Inje University Haeundae Paik hospital, Busan, Korea, Republic of|Inje University Busan Paik hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02399657"
594,"NCT02335905","Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children",,"Active, not recruiting","No Results Available","Hematogenously Acquired Staphylococcus Aureus Osteomyelitis|Bone Infection|Osteomyelitis","Drug: Ceftaroline Fosamil","Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), deaths and discontinuations due to adverse events (AEs)|Clinical response at the conclusion of IV ceftaroline|Clinical outcome at the completion of total therapy (IV ceftaroline plus oral antibiotics)|Clinical outcome during the one year follow-up period after end of antibiotic treatment|Proportion of participants with plasma levels of Ceftaroline that exceeds 1 μg/mL for over 60% of a dosing interval","Baylor College of Medicine|Allergan","All","1 Year to 17 Years   (Child)","Phase 1|Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-35130|TEF-IT-43/IIT-2017-10048","January 2015","February 2020","June 30, 2020","January 12, 2015",,"November 27, 2019","Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02335905"
595,"NCT02334683","Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia",,"Recruiting","No Results Available","Spasticity|Focal Dystonia|Tremor, Limb","Device: Electrical stimulation|Device: Ultrasound","Change in Patient Global Impression of Change|Change in Visual Analog scale|Change in muscle strength","Icahn School of Medicine at Mount Sinai|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","GCO 14-1113|#86127","December 2014","August 2020","August 2020","January 8, 2015",,"November 27, 2019","Ninds, Nih, Bethesda, Maryland, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02334683"
596,"NCT02330016","Juvederm Voluma® XC for the Treatment of Hypoplastic Chin","VolumaChin","Unknown status","No Results Available","Mandibular Hypoplasia","Device: Voluma XC","Primary outcome will be a change in the facial angle as measured by a blinded facial image analysis technician.|Evaluation of the patient's self image using the satisfaction with lower face and jawline, satisfaction of chin, and appraisal of area under chin modules of the FACE-Q questionnaire.","Kenneth Beer|Allergan|Beer, Kenneth R., M.D., PA","All","22 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VolumaChin-001","December 2014","August 2015","October 2015","January 1, 2015",,"June 18, 2015","Kenneth R. Beer, M.D., PA, West Palm Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02330016"
597,"NCT02322866","Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",,"Completed","Has Results","Acne Vulgaris","Drug: Sarecycline|Drug: Placebo","Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12|Percentage of Participants With Investigator's Global Assessment (IGA) Scale Success at Week 12|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3|Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9|Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6|Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3","Almirall, S.A.|Allergan","All","9 Years to 45 Years   (Child, Adult)","Phase 3","1034","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SC1402","December 3, 2014","January 12, 2017","January 12, 2017","December 23, 2014","May 7, 2018","February 1, 2019","Warner Chilcott Research Site (Site #206), Mobile, Alabama, United States|Warner Chilcott Research Site (Site #236), Hot Springs, Arkansas, United States|Warner Chilcott Research Site (Site #245), Carlsbad, California, United States|Warner Chilcott Research Site (Site #234), Encinitas, California, United States|Warner Chilcott Research Site (Site #209), Fremont, California, United States|Warner Chilcott Research Site (Site #215), Oceanside, California, United States|Warner Chilcott Research Site (Site #204), San Diego, California, United States|Warner Chilcott Research Site (Site #254), San Diego, California, United States|Warner Chilcott Research Site (Site #257), Santa Ana, California, United States|Warner Chilcott Research Site (Site #243), Santa Monica, California, United States|Warner Chilcott Research Site (Site #222), Denver, Colorado, United States|Warner Chilcott Research Site (Site #237), Aventura, Florida, United States|Warner Chilcott Research Site (Site #226), Clearwater, Florida, United States|Warner Chilcott Research Site (Site #238), Jupiter, Florida, United States|Warner Chilcott Research Site (Site #255), Lauderdale Lakes, Florida, United States|Warner Chilcott Research Site (Site #249), Miami, Florida, United States|Warner Chilcott Research Site (Site #202), Miami, Florida, United States|Warner Chilcott Research Site (Site #211), Miramar, Florida, United States|Warner Chilcott Research Site (Site #247), Ocala, Florida, United States|Warner Chilcott Research Site (Site #241), Orlando, Florida, United States|Warner Chilcott Research Site (Site #228), Pinellas Park, Florida, United States|Warner Chilcott Research Site (Site #203), Tampa, Florida, United States|Warner Chilcott Research Site (Site #242), Snellville, Georgia, United States|Warner Chilcott Research Site (Site #210), Champaign, Illinois, United States|Warner Chilcott Research Site (Site #213), Louisville, Kentucky, United States|Warner Chilcott Research Site (Site #217), Rockville, Maryland, United States|Warner Chilcott Research Site (Site #248), Watertown, Massachusetts, United States|Warner Chilcott Research Site (Site #205), Bay City, Michigan, United States|Warner Chilcott Research Site (Site #251), Clarkston, Michigan, United States|Warner Chilcott Research Site (Site #235), Clinton Township, Michigan, United States|Warner Chilcott Research Site (Site #227), Fort Gratiot, Michigan, United States|Warner Chilcott Research Site (Site #221), Fridley, Minnesota, United States|Warner Chilcott Research Site (Site #231), Omaha, Nebraska, United States|Warner Chilcott Research Site (Site #253), Newington, New Hampshire, United States|Warner Chilcott Research Site (Site #239), Albuquerque, New Mexico, United States|Warner Chilcott Research Site (Site #208), New York, New York, United States|Warner Chilcott Research Site (Site #240), Rochester, New York, United States|Warner Chilcott Research Site (Site #230), Stony Brook, New York, United States|Warner Chilcott Research Site (Site #229), Raleigh, North Carolina, United States|Warner Chilcott Research Site (Site #250), Wilmington, North Carolina, United States|Warner Chilcott Research Site (Site #218), Beachwood, Ohio, United States|Warner Chilcott Research Site (Site #256), Philadelphia, Pennsylvania, United States|Warner Chilcott Research Site (Site #214), Warwick, Rhode Island, United States|Warner Chilcott Research Site (Site #219), Fountain Inn, South Carolina, United States|Warner Chilcott Research Site (Site #225), Goodlettsville, Tennessee, United States|Warner Chilcott Research Site (Site #216), Knoxville, Tennessee, United States|Warner Chilcott Research Site (Site #252), Arlington, Texas, United States|Warner Chilcott Research Site (Site #220), College Station, Texas, United States|Warner Chilcott Research Site (Site #201), Katy, Texas, United States|Warner Chilcott Research Site (Site #223), Pflugerville, Texas, United States|Warner Chilcott Research Site (Site #207), San Antonio, Texas, United States|Warner Chilcott Research Site (Site #224), Webster, Texas, United States|Warner Chilcott Research Site (Site #212), West Jordan, Utah, United States|Warner Chilcott Research Site (Site #244), Norfolk, Virginia, United States|Warner Chilcott Research Site (Site #246), Seattle, Washington, United States|Warner Chilcott Research Site (Site #233), Walla Walla, Washington, United States|Warner Chilcott Research Site (Site #232), Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02322866"
598,"NCT02320149","Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",,"Completed","Has Results","Acne Vulgaris","Drug: Sarecycline|Drug: Placebo","Absolute Change in Facial Inflammatory Lesion Counts at Week 12|Percentage of Participants With Investigator Global Assement (IGA) Success at Week 12|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6|Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3|Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9|Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6|Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3|Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12|Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9|Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6|Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3|Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12|Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9|Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6|Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3","Almirall, S.A.|Allergan","All","9 Years to 45 Years   (Child, Adult)","Phase 3","968","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SC1401","December 18, 2014","February 1, 2017","February 1, 2017","December 19, 2014","May 17, 2018","February 15, 2019","Warner Chilcott Research Site (Site #155), Beverly Hills, California, United States|Warner Chilcott Research Site (Site #129), Encino, California, United States|Warner Chilcott Research Site (Site #150), La Mesa, California, United States|Warner Chilcott Research Site (Site #136), Los Angeles, California, United States|Warner Chilcott Research Site (Site #147), Sacramento, California, United States|Warner Chilcott Research Site (Site #123), San Diego, California, United States|Warner Chilcott Research Site (Site #125), San Diego, California, United States|Warner Chilcott Research Site (Site #139), Santa Rosa, California, United States|Warner Chilcott Research Site (Site #157), Tustin, California, United States|Warner Chilcott Research Site (Site #122), Denver, Colorado, United States|Warner Chilcott Research Site (Site #148), Wheat Ridge, Colorado, United States|Warner Chilcott Research Site (Site #133), New Haven, Connecticut, United States|Warner Chilcott Research Site (Site #130), Boca Raton, Florida, United States|Warner Chilcott Research Site (Site #152), Boynton Beach, Florida, United States|Warner Chilcott Research Site (Site #102), Miami, Florida, United States|Warner Chilcott Research Site (Site #145), Miami, Florida, United States|Warner Chilcott Research Site (Site #140), North Miami Beach, Florida, United States|Warner Chilcott Research Site (Site #151), Orange Park, Florida, United States|Warner Chilcott Research Site (Site #108), Sanford, Florida, United States|Warner Chilcott Research Site (Site #110), West Palm Beach, Florida, United States|Warner Chilcott Research Site (Site #154), Atlanta, Georgia, United States|Warner Chilcott Research Site (Site #120), Augusta, Georgia, United States|Warner Chilcott Research Site (Site #124), Boise, Idaho, United States|Warner Chilcott Research Site (Site #106), Chicago, Illinois, United States|Warner Chilcott Research Site (Site #112), Plainfield, Indiana, United States|Warner Chilcott Research Site (Site #113), South Bend, Indiana, United States|Warner Chilcott Research Site (Site #117), Louisville, Kentucky, United States|Warner Chilcott Research Site (Site #135), Lake Charles, Louisiana, United States|Warner Chilcott Research Site (Site #153), Metairie, Louisiana, United States|Warner Chilcott Research Site (Site #137), Detroit, Michigan, United States|Warner Chilcott Research Site (Site #111), Warren, Michigan, United States|Warner Chilcott Research Site (Site #119), Saint Louis, Missouri, United States|Warner Chilcott Research Site (Site #138), Omaha, Nebraska, United States|Warner Chilcott Research Site (Site #103), Henderson, Nevada, United States|Warner Chilcott Research Site (Site #127), Verona, New Jersey, United States|Warner Chilcott Research Site (Site #146), New York, New York, United States|Warner Chilcott Research Site (Site #132), New York, New York, United States|Warner Chilcott Research Site (Site #134), Smithtown, New York, United States|Warner Chilcott Research Site (Site #107), High Point, North Carolina, United States|Warner Chilcott Research Site (Site #126), Cincinnati, Ohio, United States|Warner Chilcott Research Site (Site #143), Warren, Ohio, United States|Warner Chilcott Research Site (Site #149), Gresham, Oregon, United States|Warner Chilcott Research Site (Site #131), Portland, Oregon, United States|Warner Chilcott Research Site (Site #114), Greer, South Carolina, United States|Warner Chilcott Research Site (Site #128), Knoxville, Tennessee, United States|Warner Chilcott Research Site (Site #109), Nashville, Tennessee, United States|Warner Chilcott Research Site (Site #116), Austin, Texas, United States|Warner Chilcott Research Site (Site #104), Dallas, Texas, United States|Warner Chilcott Research Site (Site #115), El Paso, Texas, United States|Warner Chilcott Research Site (Site #142), Houston, Texas, United States|Warner Chilcott Research Site (Site #105), Houston, Texas, United States|Warner Chilcott Research Site (Site #101), Plano, Texas, United States|Warner Chilcott Research Site (Site #118), San Antonio, Texas, United States|Warner Chilcott Research Site (Site #156), Layton, Utah, United States|Warner Chilcott Research Site (Site #141), Salt Lake City, Utah, United States|Warner Chilcott Research Site (Site #121), Charlottesville, Virginia, United States|Warner Chilcott Research Site (Site #144), Spokane, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02320149/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02320149/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02320149"
599,"NCT02297100","Intravesicular Onabotulinumtoxin A in Interstitial Cystitis",,"Completed","Has Results","Interstitial Cystitis","Drug: Onabotulinumtoxin A|Procedure: injections upper aspect of trigone of urinary bladder|Procedure: injections on posterior bladder wall excluding the trigone","The Primary Outcome Will be Assessing the Measurement of Subjective Patient Pain Using the O'Leary-Sant Symptom and Problem Indexes.|The Primary Outcome Will be Assessing the Measurement of Subjective Patient Pain Using the Pelvic Pain and Urinary Urgency Frequency (PUF) Questionnaire|Change in Patient Performance in Uroflowmetry.","Wake Forest University Health Sciences|Allergan","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","27","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00026734","December 2014","January 10, 2018","January 10, 2018","November 21, 2014","May 22, 2018","September 5, 2018","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02297100/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02297100"
600,"NCT02293798","Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold",,"Completed","Has Results","Mastopexy","Device: silk surgical scaffold","Number of Participants With Areolar Dilation of up to 6mm at 12 Months","Mark Mofid MD|Allergan|Mofid, Mehrdad Mark, M.D.","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","820","August 2014","June 2016","June 2016","November 18, 2014","September 10, 2019","September 10, 2019","La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02293798"
601,"NCT02252744","Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis",,"Completed","Has Results","Dry Eye Syndromes|Rheumatoid Arthritis","Other: No intervention","Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease","Western University of Health Sciences|Allergan","All","18 Years and older   (Adult, Older Adult)",,"286","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","WesternU-12irb027","November 2012","June 2014","December 2014","September 30, 2014","February 3, 2016","February 3, 2016",,,"https://ClinicalTrials.gov/show/NCT02252744"
602,"NCT02199964","The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface","CsA","Completed","No Results Available","Dry Eye","Drug: Cyclosporin 0.05% emulsion|Drug: Endura, Refresh artificial tears","Corneal fluorescein staining|eye irritation symptoms","Baylor College of Medicine|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H-33276","March 2014","December 2015","December 2015","July 25, 2014",,"July 20, 2016","Alkek Eye Center, Dept of Ophthalmology, Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02199964"
603,"NCT02173405","Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain","BotoxMPP","Unknown status","No Results Available","Myofascial Pain Syndromes|Myofascial Trigger Point Pain|Trigger Point Pain, Myofascial","Drug: OnabotulinumtoxinA|Drug: Placebo","efficacy|Duration of effect|quality of life|bladder/bowel/sexual functions|complications of therapy","University Hospitals Cleveland Medical Center|Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UHCMC IRB 04-13-45|IIT #578","August 2014","September 2015","September 2016","June 25, 2014",,"June 11, 2015","University Case Medical Center, Cleveland, Ohio, United States|University Hospitals Landerbrook Health Center, Urology, Mayfield Heights, Ohio, United States|University Hospitals Westlake Health Center, Urology, Westlake, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02173405"
604,"NCT02167035","Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Combigan Two Times Daily (BID)|Drug: Simbrinza Three Times Daily (TID)","Intraocular Pressure|Ocular Symptom and Tolerability Questionaire","Cornerstone Health Care, PA|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","43","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","TEP001","August 2014","March 2018","March 2018","June 18, 2014","October 24, 2018","October 24, 2018","Cornerstone Health Care, High Point, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02167035/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02167035/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02167035"
605,"NCT02165111","Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome",,"Completed","Has Results","Scleroderma|Raynaud's Syndrome","Drug: Onabotulinumtoxin A|Drug: sterile saline solution","Change in Digital Blood Flow From Pre- to Post-injection.|Rate of Change in Raynaud's Phenomenon Symptoms Measured With the Raynaud's Condition Score.|Number of Ulcers as Measure of Digital Ulcer Healing|Assessment of Raynaud's Symptoms Severity Using the Quick-DASH Score.|Assessment of Raynaud's Symptom Severity Using the McCabe Cold Sensitivity Score.|Assessment of Raynaud's Symptom Severity Using the VAS for Pain.","Johns Hopkins University|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA_00087346","January 2015","September 2015","September 2015","June 17, 2014","December 22, 2016","December 22, 2016","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02165111"
606,"NCT02138461","Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops",,"Completed","Has Results","Glaucoma",,"Tolerability of Medications as Measured by the COMTOL Validated Instrument","MDbackline, LLC|Allergan","All","18 Years and older   (Adult, Older Adult)",,"211","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","JH-ALG-MDB-1301","October 2013","September 2014","September 2014","May 14, 2014","September 25, 2014","September 25, 2014","Harvard Eye Associates, Laguna Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT02138461"
607,"NCT02117752","Dermal Tolerability of Dapsone Gel in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: dapsone gel|Drug: dapsone gel vehicle|Drug: sodium lauryl sulfate|Drug: Normal saline","Mean Cumulative Irritation Index During Induction Phase|Incidence of Sensitization Reactions During Challenge Phase","Almirall, S.A.|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","237","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","225678-009","April 2014","July 2014","July 2014","April 21, 2014",,"October 9, 2018","Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02117752"
608,"NCT02117739","Photoallergy Potential of Dapsone Gel in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: dapsone gel|Drug: dapsone gel vehicle","Photoallergic (Sensitizing) Potential Using a Visual Scale","Almirall, S.A.|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","58","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","225678-011","April 2014","July 2014","July 2014","April 21, 2014",,"October 9, 2018","Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02117739"
609,"NCT02108483","Phototoxicity Test of Dapsone Gel in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: dapsone gel|Drug: dapsone gel vehicle","Phototoxicity Irritation Potential Using a Visual Scale","Almirall, S.A.|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","225678-010","April 2014","May 2014","May 2014","April 9, 2014",,"October 9, 2018","Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02108483"
610,"NCT02070302","BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome",,"Completed","Has Results","Carpal Tunnel Syndrome","Drug: Botulinum Toxin Type A|Drug: Placebo","Change From Baseline Levine Symptom Severity Scale Status at Weeks 6, 12,18.|Change From Baseline Levine Function Severity Scale Status at Weeks 6, 12,18.|Change From Baseline in Median Nerve Compression on Neuromuscular Ultrasound at Week 6, Week 12, and Week 18.|Change From Baseline Electrodiagnostics Distal Sensory Median Nerve Latency at Week 6, Week 12, and Week 18.|Change From Baseline Electrodiagnostics Motor Median Nerve Latency at Week 6, Week 12, and Week 18.|Change From Baseline Jamar Pinch (Unrelated Dominant Hand - Mean Value of All Repetitions/Positions) at Weeks 6, 12,18.","Benjamin Sucher|Allergan|Arizona Arthritis & Rheumatology Research, PLLC.","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","85700","October 2014","February 2016","February 2016","February 25, 2014","September 27, 2017","September 27, 2017","Arizona Arthritis & Rheumatology, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02070302"
611,"NCT02058836","Botulinum Toxin for the Management of Chronic Orchialgia",,"Completed","Has Results","Chronic Testicular Pain","Drug: Botox Injection|Procedure: Normal saline injection","Visual Analog Scale for Pain Score|Quality of Life Questionnaire Score|Units of Analgesics Used for Testicular Pain","Wake Forest University Health Sciences|Allergan","Male","Child, Adult, Older Adult","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00023188","November 2014","October 18, 2016","October 18, 2016","February 10, 2014","January 23, 2018","September 5, 2018","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02058836"
612,"NCT02049476","Study of the Effectiveness of Ozurdex for the Control of Uveitis",,"Completed","Has Results","Uveitis, Intermediate|Uveitis, Posterior","Drug: Dexamethasone pellet","Number of Participants With Absence of Intraocular Inflammation at 6 Months|Number of Participants With Absence of Intraocular Inflammation at 12 Months","Johns Hopkins University|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00088146","January 2014","June 30, 2018","June 30, 2018","January 30, 2014","July 5, 2019","July 5, 2019","The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02049476/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02049476"
613,"NCT02037425","Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine",,"Completed","Has Results","Chronic Migraine","Drug: onabotulinumtoxinA","Subject Global Impression of Change|Duration of onabotulinumtoxinA Over 3 Injection Cycles in Groups A, B, and C|Headache Days|Migraine Disability Assessment Scale (MIDAS)|Social Readjustment Rating Scale (SRRS)|Physician Global Impression of Change (PGIC)|Beck Depression Inventory II (BDI-II)|State-Trait Anxiety Inventory (STAI)|Sleep Quality Question|Acute Medication Usage|Consistency of Response to onbotulinumtoxinA Over Three Injection Cycles|Duration of onabotulinumtoxinA Over 3 Injection Cycles","Cady, Roger, M.D.|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-002AL","April 2014","September 2015","September 2015","January 16, 2014","March 8, 2016","August 11, 2016","Clinvest/A Division of Banyan Group, Inc., Springfield, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02037425"
614,"NCT02036541","AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma",,"Completed","Has Results","Glaucoma|Glaucoma, Open Angle","Device: AqueSys XEN 45 Glaucoma Implant","Proportion of Subjects Achieving a 20% or Greater Reduction in IOP From Baseline on the Same or Less Number of Medications|Mean Change in IOP From Baseline","AqueSys, Inc.|Allergan","All","45 Years and older   (Adult, Older Adult)","Not Applicable","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P13-001","January 2013","February 2016","August 2016","January 15, 2014","June 1, 2017","June 1, 2017","George R. Reiss, MD PC, Glendale, Arizona, United States|Vold Vision, Fayetteville, Arkansas, United States|Montebello Eye Center, Montebello, California, United States|San Diego Eye Care Center, Oceanside, California, United States|Palo Alto Eye Group, Palo Alto, California, United States|Eye Center of Northern Colorado, Fort Collins, Colorado, United States|Stiles Eyecare Excellence & Glaucoma Institute, Overland Park, Kansas, United States|Washington University in St. Louis, Department of Ophthalmology, Saint Louis, Missouri, United States|New York Eye and Ear Infirmary, New York, New York, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|R and R Eye Research, LLC, San Antonio, Texas, United States|Spokane Eye Clinic, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02036541"
615,"NCT02036424","Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema",,"Completed","Has Results","Diabetic Macular Edema","Drug: Ozurdex|Drug: Bevacizumab","Mean Visual Acuity Change|Change in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) From Baseline to Month Seven","Raj K. Maturi, MD|Allergan|Maturi, Raj K., M.D., P.C.","All","18 Years and older   (Adult, Older Adult)","Phase 4","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","OA 003","January 2014","August 2015","August 2015","January 15, 2014","November 3, 2015","December 1, 2015","Raj K Maturi MD PC, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02036424"
616,"NCT02004067","Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease",,"Completed","No Results Available","Primary Sjogren Syndrome|Secondary Sjogren Syndrome|Aqueous Deficient Dry Eye Disease|Evaporative Dry Eye Disease","Drug: Restasis|Drug: Refresh Endura","Ocular surface inflammation","Federal University of São Paulo|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAAE: 17821013.0.0000.5505","January 2013","August 2016","August 2016","December 6, 2013",,"February 16, 2017","Departamento de Oftalmologia da Escola Paulista de Medicina - UNIFESP, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02004067"
617,"NCT01974323","Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone Gel|Drug: Dapsone Gel Vehicle","Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)|Change From Baseline in Inflammatory Facial Lesion Counts|Change From Baseline in Noninflammatory Facial Lesion Counts|Change From Baseline in Total Lesion Counts|Percentage Change From Baseline in Total Lesion Counts|Percentage of Patients Reporting ""Very Good"" or ""Excellent"" on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)|Change From Baseline in the 9-Item ASIS Sign Domain Score|Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale|Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale","Almirall, S.A.|Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","2238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","225678-007","November 2013","October 2014","October 2014","November 1, 2013","February 6, 2017","October 9, 2018","Beverly Hills, California, United States|Aventura, Florida, United States|Windsor, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01974323"
618,"NCT01974141","A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: Dapsone Gel|Drug: Dapsone Gel Vehicle","Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)|Change From Baseline in Inflammatory Facial Lesion Counts|Change From Baseline in Noninflammatory Facial Lesion Counts|Change From Baseline in Total Lesion Counts|Percentage Change From Baseline in Total Lesion Counts|Percentage of Patients Reporting ""Very Good"" or ""Excellent"" on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)|Change From Baseline in the 9-Item ASIS Sign Domain Score|Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale|Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale","Almirall, S.A.|Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","2102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","225678-006","November 2013","October 2014","October 2014","November 1, 2013","February 6, 2017","October 9, 2018","Encino, California, United States|North Bay, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01974141"
619,"NCT01964105","3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery",,"Completed","Has Results","Hypomastia|Primary Breast Augmentation","Device: 3D Imaging","Breast Q Augmentation Module","Washington University School of Medicine|Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","201210065","November 2012","May 16, 2017","May 16, 2017","October 17, 2013","December 26, 2017","December 26, 2017","West County Plastic Surgeons of Washington University, Saint Louis, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01964105/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01964105/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01964105/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01964105"
620,"NCT01945892","Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome",,"Completed","No Results Available","Macular Edema|Visual Acuity","Drug: Ozurdex","Visual acuity|Retinal Thickness|Intraocular pressure","Ludwig-Maximilians - University of Munich|Allergan","All","18 Years to 90 Years   (Adult, Older Adult)",,"23","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","MAF/ISS/OPH/RET/011","November 2011","June 2013","July 2013","September 19, 2013",,"September 19, 2013","Dept. of Ophthalmology, LMU Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT01945892"
621,"NCT01920945","OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study",,"Terminated","No Results Available","New Daily Persistent Headache","Drug: OnabotulinumtoxinA","change from baseline in frequency of headache days","St. Luke's-Roosevelt Hospital Center|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALLERGAN-13-002","September 2014","October 2016","October 2016","August 12, 2013",,"October 26, 2016","Roosevelt Hospital Headache Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01920945"
622,"NCT01911377","Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS",,"Terminated","No Results Available","Neuropathic Pain|Allodynia","Drug: Botulinum Toxin Type A|Drug: Normal Saline for Injection","Brief Pain Inventory|Neuropathic Pain Symptom Inventory|The Hospital Anxiety and Depression Scale|Daily Sleep Interference Scale|Clinician Global Impression Scale|Patient's Global Impression Scale","University of Manitoba|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Botox 2013","October 2013","May 2015","August 2015","July 30, 2013",,"October 2, 2015","WRHA Health Sciences Centre Rehabilitation Hospital, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01911377"
623,"NCT01905137","Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain",,"Active, not recruiting","No Results Available","Myofascial Pelvic Pain","Drug: Intervention-Botulinum Toxin Type A|Drug: placebo","To evaluate the change in patient-reported pelvic pain following pelvic floor injections of 200 units of Botox compared with 20cc of normal saline.|To evaluate the change in patient-reported pelvic pain following Botox injections in conjunction with pelvic floor physical therapy compared to saline injections with physical therapy.","Boston Urogynecology Associates|Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","015-2013","July 2013","March 9, 2018","June 2019","July 23, 2013",,"April 12, 2019","Boston Urogynecology Associates, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01905137"
624,"NCT01891487","Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows",,"Completed","No Results Available","Hypotrichosis","Drug: Track A|Drug: Track B","One grade improvement at week 16, 24 and 36 as based on the IGEA|Grade improvement based on IEA4 at week 16, 24 and 36","ATS Clinical Research|Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","33","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ATSBROW-001","May 2013","September 2014","January 2015","July 3, 2013",,"January 14, 2015","Ava MD, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT01891487"
625,"NCT01870440","TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema",,"Completed","No Results Available","Macular Edema|Uveitis","Drug: Ozurdex Intravitreal Injection (0.7 mg)","Best Corrected Visual Acuity (using Early Treatment Diabetic Retinopathy Study Protocal)|Central Subfoveal Retinal Thickness|Best Corrected Visual Acuity","Northern California Retina Vitreous Associates|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCRVA-2013-Ozurdex-16.2","May 2013","February 2015","February 2015","June 6, 2013",,"March 11, 2015","Northern California Retina Vitreous Associates, Mountain View, California, United States",,"https://ClinicalTrials.gov/show/NCT01870440"
626,"NCT01826812","Impairment of Reading Ability in Dry Eye Patients",,"Completed","Has Results","Dry Eye Syndromes","Other: 30 minutes sustained reading|Other: Dry eye exam","Sustained Silent Reading Speed|Change in Total Ocular Staining Score (OSS)|Change in Tear Osmolarity|Change in Visual Acuity|Cytokines","Johns Hopkins University|Allergan","All","50 Years and older   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NA_00082755","April 2013","November 2015","November 2015","April 9, 2013","March 24, 2016","February 15, 2018","The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01826812"
627,"NCT01821573","Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients","FOLOTOX","Completed","No Results Available","COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO","Drug: botulinum toxin type A|Drug: injection of NaCl 0.9%","Measure of the maximal length of the muscles treated by Botulinum|The maximal strength measure|Inter-segmental coordination measure|Measure of joint torque at knee and ankle level.","Assistance Publique - Hôpitaux de Paris|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P110136 / AOM11223|2012-001203-21","July 2013","September 5, 2017","May 23, 2019","April 1, 2013",,"May 30, 2019","Service de médecine physique et réadaptation CHU de Brest, Brest, Bretagne, France|Nicolas Roche, Garches, Hauts-de-Seine, France|Centre de rééducation de l'ADAPT Montargis, Amilly, Loiret, France",,"https://ClinicalTrials.gov/show/NCT01821573"
628,"NCT01804517","Impact of a Nurse for Migraine Management: the IMPACT Project","IMPACT","Completed","No Results Available","Migraine Without Aura|Migraine With Aura|Chronic Migraine",,"Hit-6 score change|Frequency of moderate and severe headache days|Frequency of headache days|Chronic headache status|Medication overuse|Acute medication intake|Efficacy of acute treatment|Response rate to prophylactics|Short Form 12 score|Visits to the emergency department|Severe adverse effects from treatments|Phone calls returned|Patient satisfaction|Phone call return delay|Global improvement","Notre-Dame Hospital, Montreal, Quebec, Canada|Allergan","All","18 Years and older   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","IMPACT","February 2013","November 2015","November 2015","March 5, 2013",,"December 8, 2016","Hôpital Notre-Dame, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01804517"
629,"NCT01790685","Ozurdex for Retinal Vein Occlusion Study (ORVO Study)","ORVO","Completed","Has Results","Retinal Vein Occlusion","Drug: dexamethasone implant","Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex","Johns Hopkins University|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00079951","February 2013","December 2014","December 2014","February 13, 2013","April 3, 2015","April 22, 2015","Wilmer Eye Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01790685"
630,"NCT01787669","Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema","SwitchDMO","Completed","No Results Available","Diabetes|Diabetic Macular Oedema|Diabetic Macular Edema|Diabetic Retinopathy","Drug: Avastin (Bevacizumab)|Drug: Ozurdex (dexamethasone)","Proportion of eyes that have central macular thickness <300 microns 6 months after switching|Mean change in central macular thickness (CMT) as measured by OCT.","University of Sydney|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SwitchDMO","June 2013","January 2017","October 2017","February 8, 2013",,"November 13, 2018","Sydney Eye Hospital, Sydney, New South Wales, Australia|Centre for Eye Research Australia (Royal Victorian Eye & Ear Hospital), Melbourne, Victoria, Australia|Lions Eye Institute, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01787669"
631,"NCT01751373","Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A",,"Completed","No Results Available","Stroke|Muscle Spasticity","Behavioral: Optimal muscle activation therapy|Behavioral: Standard Therapy","Amplitude and timing of electromyographic signals (EMG)|Motor Evoked Potential amplitude|Goal Attainment Scale|Modified Ashworth Scale|Modified Tardieu Scale|Frequency and amplitude of electroencephalographic (EEG) activity","Sunnybrook Health Sciences Centre|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ALSRIIIT-01","May 2011","November 2014","November 2014","December 18, 2012",,"May 20, 2015","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01751373"
632,"NCT01741246","Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging",,"Completed","No Results Available","Migraine|Chronic Migraine",,"Pattern of brain metabolism using positron emission tomography(PET).|Changes of resting state brain networks using magnetic resonance imaging (MRI)","University of California, San Francisco|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)",,"78","Other|Industry","Observational","Time Perspective: Prospective","1107004","September 2011","June 2015","June 2015","December 4, 2012",,"June 30, 2015","UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01741246"
633,"NCT01700387","A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency",,"Completed","Has Results","Chronic Migraine","Drug: onabotulinumtoxinA|Drug: Topiramate|Drug: Placebo","Subject Attrition Post Randomization|Subject Global Impression of Change (SGIC)|Physician Global Impression of Change (PGIC)|Subject's Mental Efficiency Workload Test (MEWT) Overall Performance Index (PI) Score at Visits 2-6 to Measure Cognitive Efficiency|Subject's Controlled Oral Word Association Test (COWAT) Scores at Visits 2-6 to Measure Cognitive Efficiency|Change in Number of Headache Days Reported in 30-day Baseline Period vs. Treatment Period Months 1-12|Subject's Headache Impact Test (HIT-6) Scores at Visits 2-6 to Measure Effect of Headache in Subject's Life|MEWT Score for Simple Reaction Time Sub-test at Visits 2-6 to Measure Mental Efficiency|MEWT Score for Running Memory Continuous Performance Task Sub-test at Visits 2-6 to Measure Mental Efficiency|MEWT Scores for Matching to Sample Sub-test at Visit 2-6 to Measure Mental Efficiency|MEWT Scores for Mathematical Processing Sub-test at Visits 2-6 to Measure Mental Efficiency|Subject Estimation of Compliance With Daily Topiramate|Pharmacoeconomic Estimates on Number of Patients Needed to Treat (Randomize) to Have One Successful Patient at 3, 6, 9, and 12 Months.|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Subject's Migraine Specific Quality of Life Questionnaire (MSQ) Scores at Baseline, 3, 6, 9 and 12 Months to Measure Subject's Quality of Life","Cady, Roger, M.D.|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12-001AL|71403","October 2012","August 2014","August 2014","October 4, 2012","October 13, 2014","February 22, 2018","Clinvest/A Division of Banyan Group, Inc., Springfield, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01700387"
634,"NCT01682460","Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients","IVES","Completed","Has Results","Glaucoma|Dry Eyes","Drug: Refresh Tears Lubricant Eye Drops (Allergan)","Ocular Surface Staining|Tear Break up Time With Fluorescein|Ocular Surface Disease Index (OSDI) Score","University of Waterloo|Allergan","All","17 Years and older   (Child, Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18262","August 2012","April 2013","April 2013","September 11, 2012","July 3, 2014","June 5, 2017","Centre for Contact Lens Research, University of Waterloo, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01682460"
635,"NCT01679015","Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes",,"Completed","No Results Available","Dry Eyes|Allergic Conjunctivitis",,"Prevalence of dry eye in an allergic population presenting to a high volume optometry practice|Prevalence of allergic patients with moderate to severe ocular signs and symptoms","Schwartz Laser Eye Center|Allergan","All","18 Years and older   (Adult, Older Adult)",,"250","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AL-001","August 2012","February 2014","February 2014","September 5, 2012",,"June 3, 2016","Schwartz Laser Eye Center, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01679015"
636,"NCT01673191","A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus",,"Completed","Has Results","Macular Edema|Diabetes Mellitus","Drug: Dexamethasone intravitreal implant|Drug: Steroid plus NSAID eye drop combination therapy","Mean Change in Best Corrected Visual Acuity|Mean Change in Central Retinal Thickness|Mean Change in Intraocular Pressure","Retinal Consultants of Arizona|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCA2012","November 2012","December 2014","December 2014","August 27, 2012","April 5, 2017","April 5, 2017","Retinal Consultants of Arizona, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01673191"
637,"NCT01629433","Onabotulinumtoxina Intradetrusorial Injections and NGF Expression","Onab/A-NGF","Completed","No Results Available","Overactive Detrusor|Detrusor Hyperreflexia of Bladder",,"to investigate onab/A- induced changes on gene expression of NGF, TRPV1, TrkA and p75 in bladder wall tissue of patients with neurogenic and idiopathic DO.|To evaluate urodynamic improvements|To investigate urodynamic improvements.","University Of Perugia|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)",,"25","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","onabotulinumatoxin and NGF","January 2009","June 2011","March 2012","June 27, 2012",,"June 27, 2012","University of Perugia, Dept. of Urology and Andrology, Perugia, Italy",,"https://ClinicalTrials.gov/show/NCT01629433"
638,"NCT01628549","Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: 50 mg P005672-HCl|Drug: Placebo|Drug: 100 mg P005672-HCl","The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit|The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit|The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit|The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit|The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit|The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit|The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12","Almirall, S.A.|Allergan","All","12 Years to 45 Years   (Child, Adult)","Phase 2","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PR-10411","June 30, 2012","November 16, 2012","January 31, 2013","June 26, 2012","January 8, 2019","February 1, 2019","Warner Chilcott Investigational Site, Mobile, Alabama, United States|Warner Chilcott Investigational Site, Tucson, Arizona, United States|Warner Chilcott Investigational Site, Hot Springs, Arkansas, United States|Warner Chilcott Investigational Site, Los Angeles, California, United States|Warner Chilcott Investigational Site, San Diego, California, United States|Warner Chilcott Investigational Site, Santa Monica, California, United States|Warner Chilcott Investigational Site, Clearwater, Florida, United States|Warner Chilcott Investigational Site, Coral Gables, Florida, United States|Warner Chilcott Investigational Site, Gainesville, Florida, United States|Warner Chilcott Investigational Site, Miami, Florida, United States|Warner Chilcott Investigational Site, Miramar, Florida, United States|Warner Chilcott Investigational Site, Pinellas Park, Florida, United States|Warner Chilcott Investigational Site, Arlington Heights, Illinois, United States|Warner Chilcott Investigational Site, Chicago, Illinois, United States|Warner Chilcott Investigational Site, Granger, Indiana, United States|Warner Chilcott Investigational Site, Indianapolis, Indiana, United States|Warner Chilcott Investigational Site, Louisville, Kentucky, United States|Warner Chilcott Investigational Site, Boston, Massachusetts, United States|Warner Chilcott Investigational Site, Fridley, Minnesota, United States|Warner Chilcott Investigational Site, Saint Louis, Missouri, United States|Warner Chilcott Investigational Site, Berlin, New Jersey, United States|Warner Chilcott Investigational Site, Albuquerque, New Mexico, United States|Warner Chilcott Investigational Site, Rochester, New York, United States|Warner Chilcott Investigational Site, Rochester, New York, United States|Warner Chilcott Investigational Site, Charlotte, North Carolina, United States|Warner Chilcott Investigational Site, Salisbury, North Carolina, United States|Warner Chilcott Investigational Site, Wilmington, North Carolina, United States|Warner Chilcott Investigational Site, Cincinnati, Ohio, United States|Warner Chilcott Investigational Site, Portland, Oregon, United States|Warner Chilcott Investigational Site, Philadelphia, Pennsylvania, United States|Warner Chilcott Investigational Site, Greer, South Carolina, United States|Warner Chilcott Investigational Site, Arlington, Texas, United States|Warner Chilcott Investigational Site, Austin, Texas, United States|Warner Chilcott Investigational Site, Houston, Texas, United States|Warner Chilcott Investigational Site, Plano, Texas, United States|Warner Chilcott Investigational Site, San Antonio, Texas, United States|Warner Chilcott Investigational Site, Sandy, Utah, United States|Warner Chilcott Investigational Site, Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01628549"
639,"NCT01613716","Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)","OPERA","Completed","Has Results","Diabetic Macular Edema|Epiretinal Membrane","Drug: Ozurdex","Central Retinal Thickness|Visual Acuity","The Cleveland Clinic|Allergan","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","115200","July 2012","December 2016","February 2017","June 7, 2012","May 16, 2018","May 16, 2018","Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01613716"
640,"NCT01591746","Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction",,"Completed","Has Results","Breast Cancer|Pain, Postoperative|BRCA1 Mutation|BRCA2 Mutation|Breast Diseases|Neoplasms","Drug: Botulinum Toxin Type A|Drug: Placebo","Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale|Physical Well-Being Using the BREAST-Q, Reconstruction Module|Initial Intraoperative Fill Volume in Milliliters (mL)|Number of Tissue Expansion Visits|Total Volume of Tissue Expansion|Rate of Reconstruction Failure","Mayo Clinic|Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 3","131","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","11-001687","August 2012","July 18, 2017","July 18, 2017","May 4, 2012","October 10, 2019","October 10, 2019","Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01591746/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01591746"
641,"NCT01589471","The Value of Botox-A for Management of Low Anterior Resection Syndrome",,"Completed","No Results Available","Low Anterior Resection Syndrome|Rectal Cancer","Drug: intra-rectal Botulinum toxin A injection","Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score|Efficacy of intra-rectal Botox-A injection on anorectal function as documented with a visual scale for tenesmus and completeness of stool evacuation|Efficacy of intra-rectal Botox-A injection on quality of life as documented with EORTC-QlQ standardized questionnaires|Efficacy of intra-rectal Botox-A injection as documented with a patient medicine calender|Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized anorectal manometry readings|Long term efficacy of intra-rectal Botox-A injection on anorectal function as documented with Wexner score, EORTC-QLQ questionnaire and visual scale|Safety of intra-rectal Botox-A injections as documented with adverse events monitoring","Centre hospitalier de l'Université de Montréal (CHUM)|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE 11.088","May 2012","October 2015","November 2015","May 2, 2012",,"February 12, 2018","Centre Hospitalier Universitaire de Montréal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01589471"
642,"NCT01571232","Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema",,"Completed","Has Results","Diabetic Macular Edema|Non-proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy","Drug: dexamethasone intravitreal implant|Drug: intravitreal bevacizumab","The Change in Visual Acuity (Number of ETDRS Letters).|The Change in Central Foveal Thickness (Microns on High Resolution OCT).|The Change in Macular Leakage on Fluorescein Angiography From Baseline|The Change in Mean Macular Sensitivity on Microperimetry From Baseline|The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.","Retina Macula Institute|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIT-406","April 2012","February 2014","March 2015","April 5, 2012","May 31, 2017","May 31, 2017","Retina Macula Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01571232"
643,"NCT01564732","Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding",,"Terminated","Has Results","Morbid Obesity","Device: Standard-LAGB|Device: Plicated-LAGB","Weight Loss|Quality of Life|Quantitative Change in Hypertension|Quantitative Change in Diabetes|Quantitative Change in Hyperlipidemia|Quantitative Change in Hypertriglyceridemia","Dana Portenier, MD|Allergan|Duke University","All","18 Years to 60 Years   (Adult)","Not Applicable","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Pro00033638","September 2013","April 2015","April 2015","March 28, 2012","June 1, 2016","July 1, 2016","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01564732"
644,"NCT01543061","Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints",,"Completed","No Results Available","Contact Lens Related Dry Eye Syndrome","Device: OPTIVEtm Plus|Procedure: No treatment|Device: Blink Contacts® Eye Drops","Tear Break up Time|Conjunctival staining measurement|Tear film evaporation rate|Ocular Surface Disease Index questionnaire|Comfort, vision and ocular symptoms questionnaire|Post wear contact lens deposition and lipid uptake assessment","Optometric Technology Group Ltd|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AG9965-006 ID 11-19","February 2012","September 2012","December 2012","March 2, 2012",,"September 27, 2013","OTG Research & Consultancy, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01543061"
645,"NCT01489904","Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy",,"Unknown status","No Results Available","Sialorrhea|Cerebral Palsy","Biological: BOTULINUM NEUROTOXIN TYPE-A","Asses drool quantification pre and post-infiltration in submandibular and parotid glands with BoNT-A|Asses at what period of time after infiltration occurs the maximum response in decreased drooling, and whether Botulinum toxin-A reduce the volume of drooling without altering the swallowing function.","Hospital Vall d'Hebron|Allergan","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-021691-28","November 2011","November 2011","November 2012","December 12, 2011",,"October 30, 2012","CEIC Hospital Vall d Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01489904"
646,"NCT01471054","Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma",,"Terminated","Has Results","Macular Edema|Cystoid Macular Edema|Uveal Melanoma|Radiation Maculopathy|Radiation Retinopathy","Drug: Ozurdex|Drug: Bevacizumab","Number of Participants for Whom Study Eye Showed >=2 Lines of Improvement in Best-corrected Visual Acuity|Change in Central Subfield Retinal Thickness|Development of Glaucoma|Development of Cataract|Development of Retinal Detachment|Development of Vitreous Hemorrhage","Arman Mashayekhi|Allergan|Wills Eye","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Wills IRB# 11-089","April 2014","July 2015","July 2015","November 11, 2011","January 10, 2019","September 3, 2019","Ocular Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01471054"
647,"NCT01469221","Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)",,"Terminated","Has Results","Bladder Cancer","Drug: Apaziquone|Drug: Placebo","Time to Recurrence|2-Year Recurrence Rate","Spectrum Pharmaceuticals, Inc|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPI-1012|2011-003517-42","January 2012","April 2013","April 2013","November 10, 2011","December 15, 2017","December 15, 2017","Tower Research Institute, Los Angeles, California, United States|Department of Urology, University of Miami Miller School of Medicine, Miami, Florida, United States|Somerset Urological Associates, PA, Somerville, New Jersey, United States|Associated Medical Professionals of New York, PLLC, Oneida, New York, United States|Male and Female Urology, Staten Island, New York, United States|Associated Medical Professionals of New York, PLLC, Syracuse, New York, United States|Alliance Urology Specialists, Greensboro, North Carolina, United States|Nemocnice Jablonec nad Nisou, Urologické oddělení, Jablonec nad Nisou, Czechia|Fakultní Thomayerova nemocnice s poliklinikou Urologické oddělení, Prague, Czechia|Szpital Miejski im. Prof. E. Michałowskiego, Katowice, Poland|CenterMed Kraków sp z o.o., Kraków, Poland|Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie, Oddział Urologii i Onkologii Urologicznej, Lublin, Poland|Nieubliczny Zakład Opieki Zdrowotnej Europejskie Centrum Zdrowia Otwock im. Fryderyka Chopina Nieubliczny Zakład Opieki Zdrowotnej, Otwock, Poland|Niepubliczny Zakład Opieki Zdrowotnej Pabianickie Centrum Medyczne, Pabianice, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej, Wojewódzki Szpital Specjalistyczny nr 3, Rybnik, Poland|Wojewódzki Szpital Specjalistyczny W Siedlcach, Siedlce, Poland|Pomorska Akademia Medyczna, Szczecin, Poland|Wojewódzki Szpital Specjalistyczny im Janusza Korczaka, Słupsk, Poland|Centrum Medycznego Kształcenia Podyplomowego, Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego, Warszawa, Poland|Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON, Warszawa, Poland|Szpital Bielański im. ks. J. Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej, Warszawa, Poland|Szpital Kliniczny Dzieciątka Jezus - Centrum Leczenia Obrażeń, Warszawa, Poland|Międzyleski Szpital Specjalistyczny w Warszawie Oddział Urologii, Warszawa, Poland|Wojewódzki Szpital Specjalistyczny we Wrocławiu, Ośrodek Badawczo Rozwojowy, Wrocław, Poland|Niepubliczny Zakład Opieki Zdrowotnej-Centrum Medyczne Szpital Świętej Rodziny sp z o.o., Łódź, Poland|Univerzitná nemocnica L. Pasteura Košice Univerzitná nemocnica L. Pasteura Košice, Košice, Slovakia|Univerzitná nemocnica Martin Urologická klinika, Martin, Slovakia|Fakultná nemocnica s poliklinikou J. A. Reimana Prešov Urologická klinika, Prešov, Slovakia|Fakultná nemocnica s poliklinikou Žilina Urologické oddelenie, Žilina, Slovakia",,"https://ClinicalTrials.gov/show/NCT01469221"
648,"NCT01450787","Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics",,"Terminated","Has Results","Dry Eyes",,"Conjunctival Staining Score|Tear Film Osmolarity","COA Research Foundation, INC|Allergan","All","40 Years and older   (Adult, Older Adult)",,"63","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","000322","January 2012","June 2012","June 2012","October 12, 2011","September 30, 2013","September 30, 2013","Columbus Ophthalmalogy Associates, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01450787"
649,"NCT01449682","Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.",,"Completed","Has Results","Retinal Vein Occlusion|Macular Edema","Drug: Ozurdex","Macular Function Using Microperimetry|Macular Function Using Multi-focal ERG|To Determine if There is a Change in Visual Acuity (Number of ETDRS Letters) at 48 Weeks Compared to Baseline Values for Both the PRN and Q16weeks Treatment Groups|To Determine if There is a Change in Central Foveal Thickness (Microns on High Resolution OCT) at 48 Weeks Compared to Baseline Values for Both the PRN and Q16weeks Treatment Groups","Retina Macula Institute|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IIT-287","October 2011","July 2012","February 2013","October 10, 2011","May 31, 2017","May 31, 2017","Retina Macula Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01449682"
650,"NCT01441895","Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser",,"Unknown status","No Results Available","Cataract|Dry Eye",,"Change in Corneal Sensitivity Testing|Ocular Surface Disease Index (OSDI)|Subject Dry Eye Questionnaire|Artificial Tear Use|Corneal and Conjunctival Staining|Tear Break Up Time (TBUT) with Biomicroscopy|Best Corrected Visual Acuity (BCVA)|Intraocular Pressure (IOP)","Ophthalmic Consultants of Long Island|Allergan","All","18 Years and older   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AGN02-FEMTO","September 2011","December 2016","December 2016","September 28, 2011",,"April 25, 2016","Ophthlamic Consultants of Long Island - Rockville Centre, Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT01441895"
651,"NCT01422161","Study of Botulinum Toxin and Recovery of Hand Function After Stroke",,"Completed","Has Results","Stroke With Hemiparesis","Drug: Botulinum Toxin commonly known as BOTOX®|Drug: Placebo","Time Taken to Form a Stable Grasp Pre-Treatment|Time Taken to Form a Stable Grasp Post Treatment|Measure of Upper Limb Motor Impairment Measured by Fugl Meyer Scale|Disability Measured by Modified Rankin Scale Score Post-Treatment|Motor Impairment Measured by the Fugl-Meyer Scale Post-Treatment|Disability Measured by Modified Rankin Scale Score Pre-Treatment","NYU Langone Health|Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","10-01126","April 2010","October 2015","October 2015","August 23, 2011","May 31, 2019","June 20, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01422161"
652,"NCT01421719","Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease",,"Completed","Has Results","Parkinson's Disease|Neurogenic Bladder|Urinary Incontinence|Clostridium Botulinum Toxin Adverse Reaction","Drug: Cystoscopic injection of Botox into the urinary bladder","Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment.|Number of Incontinence Episodes Per Day","Stanford University|Allergan","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","000124","February 2009","May 2011","July 2011","August 23, 2011","March 10, 2017","March 10, 2017","Stanford University Hospital and Clinics, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01421719"
653,"NCT01410565","Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer",,"Terminated","Has Results","Bladder Cancer","Drug: Apaziquone|Drug: Placebo","Time to Recurrence|Recurrence Rate at 24 Months|Participants With Treatment Emergent Adverse Events (TEAEs)","Spectrum Pharmaceuticals, Inc|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPI-1011","July 2011","March 2014","March 2014","August 5, 2011","December 13, 2016","December 13, 2016","Valley Urologic Associates, Glendale, Arizona, United States|Precision Trials, LLC, Phoenix, Arizona, United States|South Orange County Medical Research Center, Laguna Woods, California, United States|The Urology Center of Colorado, Denver, Colorado, United States|Connecticut Clinical Research Center, Middlebury, Connecticut, United States|Urology Enterprises, Marietta, Georgia, United States|North Idaho Urology, Coeur d'Alene, Idaho, United States|Idaho Urologic Institute, P.A., Meridian, Idaho, United States|Northeast Indiana Research, LLC, Ft. Wayne, Indiana, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Regional Urology, LLC, Shreveport, Louisiana, United States|Anne Arundel Urology, Annapolis, Maryland, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Five Valleys Urology, Missoula, Montana, United States|Delaware Valley Urology, LLC - Voorhees, Voorhees, New Jersey, United States|Delaware Valley Urology, LLC-Westampton, Westampton, New Jersey, United States|University Urology Associates, New York, New York, United States|Urology Associates of Rochester, LLC, Rochester, New York, United States|TriState Urologic Services PSC, Inc., Cincinnati, Ohio, United States|Urologic Consultants of Southeastern Pennsylvania, LLP, Bala Cynwyd, Pennsylvania, United States|Urology Health Specialists, Bryn Mawr, Pennsylvania, United States|Urological Associates of Lancaster, Lancaster, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates of South Texas, McAllen, Texas, United States|Urology of Virginia, PC, Virginia Beach, Virginia, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, United States|Integrity Medical Research, LLC, Mountlake Terrace, Washington, United States|G. Steinhoff Clinical Research Pacific Urologic Research, Victoria, British Columbia, Canada|Queen Elizabeth II Health Science Center, Halifax, Nova Scotia, Canada|The Male/Female Health and Research Centre - Royal Court Medical Centre, Barrie, Ontario, Canada|Brantford Urology Research, Brantford, Ontario, Canada|G. Kenneth Jansz Medicine Professional Corporation, Burlington, Ontario, Canada|Urology Resource Centre, Burlington, Ontario, Canada|Kingston General Hospital / Queen's University, Kingston, Ontario, Canada|Urology Associates, Urologic Medical Research, Kitchener, Ontario, Canada|Mor Urology, Inc., Newmarket, Ontario, Canada|Office of Bernard Goldfarb, North Bay, Ontario, Canada|Stanley Flax Medical Professional Corporation, North York, Ontario, Canada|The Fe/Male Health Centre, Oakville, Ontario, Canada|Urotec, Oshawa, Ontario, Canada|Urology/Male Infertility, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network Princess Margaret Hospital, Toronto, Ontario, Canada|Centre universitaire de sante McGill, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01410565"
654,"NCT01410201","Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane","OZURDEX2","Terminated","No Results Available","Epiretinal Membrane|Macular Edema","Drug: Dexamethasone Intravitreal Implant","Changes in best corrected visual acuity|Incidence of persistent macular edema on Central OCT thickness in treatment (PPV + MP + DEX) versus non-treatment (PPV + MP) groups","Barnes Retina Institute|Allergan","All","Child, Adult, Older Adult","Not Applicable","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OZURDEX ERM","August 2011","January 2016","January 2016","August 5, 2011",,"July 27, 2016","St. Lukes Hospital, Chesterfield, Missouri, United States|St. Louis Eye Surgery and Laser Center, St. Louis, Missouri, United States|The Retina Institute, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01410201"
655,"NCT01390961","Comparison of Tolerability Between Two Allergy Drops",,"Unknown status","No Results Available","Allergic Conjunctivitis","Drug: alacaftadine and naphazoline HCl & pheniramine maleate","Tolerability","Hom, Milton M., OD, FAAO|Allergan","All","18 Months and older   (Child, Adult, Older Adult)","Phase 4","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IIT-000256","August 2011","December 2011","January 2012","July 11, 2011",,"July 11, 2011","Milton M. Hom, OD, FAAO., Azusa, California, United States",,"https://ClinicalTrials.gov/show/NCT01390961"
656,"NCT01387906","Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo",,"Completed","No Results Available","Hypotrichosis","Drug: topical bimatoprost","Efficacy of Latisse applied to the lateral and medial eyebrow","Kenneth Beer|Allergan|Beer, Kenneth R., M.D., PA","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Latisse2010","March 2011","March 2012","June 2012","July 6, 2011",,"June 15, 2012","Kenneth R. Beer, M.D. ,PA, West Palm Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01387906"
657,"NCT01384851","Efficacy of the Chronic Application of Tear Formulations",,"Unknown status","No Results Available","Dry Eye","Drug: Next Generation Emulsion|Drug: Refresh Dry Eye Therapy|Drug: Refresh Contacts","Tear Film Evaporation|Interferometry|Tear Film Osmolarity|Non-invasive tear break up time|Tear sampling and bio-marker analysis","Glasgow Caledonian University|Allergan","All","18 Years to 79 Years   (Adult, Older Adult)","Not Applicable","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AG9965-004","July 2011","November 2011","November 2011","June 29, 2011",,"July 1, 2011","Glasgow Caledonian University, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01384851"
658,"NCT01352546","Botox Injection for Treatment of Vaginismus",,"Completed","Has Results","Vaginismus","Biological: BOTOX","Ability to Achieve Pain Free Intercourse.","Plastic Surgery Professional Association|Allergan","Female","20 Years to 40 Years   (Adult)","Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTX-PV-01","August 2010","December 2012","December 2012","May 12, 2011","August 7, 2017","August 7, 2017","Plastic Surgery Professional Association, Manchester, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT01352546"
659,"NCT01339936","Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers",,"Completed","Has Results","Dry Eye Syndrome","Device: Carboxymethylcellulose sodium, glycerin and polysorbate 80","Tear Film Evaporation Rate|Tear Break Up Time|Ocular Surface Disease Index Score","Optometric Technology Group Ltd|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AG9965-005 ID 10-12","March 2011","August 2011","May 2012","April 21, 2011","November 28, 2013","November 28, 2013","OTG Research & Consultancy, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01339936"
660,"NCT01335126","Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artificial Tears",,"Unknown status","No Results Available","Dry Eye","Other: Emulsion type artificial tear","Tolerability Questionnaire|Acceptability Questionnaire|Tear Break Up Time","Hom, Milton M., OD, FAAO|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","AG9965-007","March 2011","October 2011","November 2011","April 14, 2011",,"April 14, 2011",,,"https://ClinicalTrials.gov/show/NCT01335126"
661,"NCT01323829","EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction","BTXA EMG","Completed","No Results Available","High Tone Pelvic Floor Dysfunction","Other: EMG Guidance of Injection","To evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD.","Pelvic and Sexual Health Institute|Allergan","Female","18 Years to 79 Years   (Adult, Older Adult)","Not Applicable","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTXA EMG","November 2010","July 2013","December 2013","March 28, 2011",,"May 5, 2014","Pelvic and Sexual Health Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01323829"
662,"NCT01321424","Diurnal Variation in Tear Osmolarity",,"Completed","No Results Available","Dry Eye Disease",,"The measured difference in Tear Osmolarity during the course of the day to support clinical diagnosis and differentiate between aqueous-deficiency and meibomian gland disease.|Ocular Improvement","Ophthalmic Consultants of Long Island|Allergan","All","18 Years and older   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","ALRGN01","March 2011","February 2016","March 2016","March 23, 2011",,"April 25, 2016","Ophthalmic Consultants of Connecticut, Fairfield, Connecticut, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Ophthalmic Consultants of Long Island, Manhasset, New York, United States|Ophthalmic Consultants of Long Island, Port Jefferson, New York, United States|Ophthalmic Consultants of Long Island, Rockville Centre, New York, United States|Ophthalmic Consultants of Long Island, Valley Stream, New York, United States",,"https://ClinicalTrials.gov/show/NCT01321424"
663,"NCT01297634","Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle",,"Completed","No Results Available","Wrinkles","Drug: Botulinum Toxin Type-A (day 0)","Treatment Area|Complete Treatment Phase","Ivo Pitanguy Institute|Allergan","Female","30 Years to 60 Years   (Adult)","Phase 4","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","191622|396936|CEP001/11","May 2011","November 2011","November 2011","February 17, 2011",,"November 23, 2011","Ivo Pitanguy Institute, Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT01297634"
664,"NCT01284478","Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery",,"Completed","No Results Available","Pseudophakic Cystoid Macular Edema,|Diabetic Macular Edema","Drug: Dexamethasone Implant","BEST CORRECTED VISUAL ACUITY (ETDRS)|RETINAL THICKNESS MEASURED BY SPECTRAL DOMAIN OPTICAL TOMOGRAPHY","Northern California Retina Vitreous Associates|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCRVA-2011-Ozurdex-16-1","January 2011","October 2012","October 2012","January 27, 2011",,"October 4, 2012","Northern California Retina Vitreous Associates, Mountain View, California, United States",,"https://ClinicalTrials.gov/show/NCT01284478"
665,"NCT01282411","Anatomic Outcomes Following Ozurdex Injections",,"Completed","No Results Available","Retinal Vein Occlusions",,,"Barnes Retina Institute|Allergan","All","21 Years and older   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2010.006","February 2010","May 2011","July 2011","January 25, 2011",,"July 27, 2016","Barnes Retina Institute, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01282411"
666,"NCT01273727","Ozurdex for Macular Edema Post Membrane Peeling",,"Completed","No Results Available","Epiretinal Membrane|Cellophane Maculopathy|Macular Edema|Retinal Edema","Drug: Dexamethasone|Drug: dexamethasone","mean best corrected visual acuity as measured by Snellen visual acuity compared to enrollment|mean decrease in area and or volume of central foveal thickness as measured by OCT compared to enrollment","Retina Specialists, PC|Allergan","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3433-001","June 2010","April 2014","April 2014","January 10, 2011",,"May 13, 2015","Retina Specialists PC, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01273727"
667,"NCT01272414","Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction",,"Withdrawn","No Results Available","Graves Ophthalmopathy","Drug: Botulinum Toxin Type A|Drug: Saline injection","Reduction in upper lid retraction (in mm)|Subjective improvement in lid retraction related dry eye symptoms|Subjective improvement in lid retraction related cosmesis","University of Toronto|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","10-0261-A","January 2011","January 2012","February 2012","January 7, 2011",,"June 3, 2015","Mount Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01272414"
668,"NCT01269801","Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds","JUVE_BTX","Completed","Has Results","Wrinkles","Drug: onabotulinumtoxinA|Drug: JUVÉDERM","Efficacy","AboutSkin Dermatology and DermSurgery, PC|Allergan","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 4","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JUVE_BTX-09-01","January 2011","September 2011","February 2012","January 4, 2011","December 16, 2014","December 16, 2014","About Skin Dermatology, Englewood, Colorado, United States|Niagara Falls Dermantology and Skin Care Center, Niagara Falls, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01269801"
669,"NCT01227226","Tear Osmolarity Over Time With Artificial Tears",,"Unknown status","No Results Available","Dry Eye","Drug: Artificial tears","Tear osmolarity","Hom, Milton M., OD, FAAO|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","06","October 2010","March 2011","March 2011","October 25, 2010",,"February 7, 2011","Milton M. Hom, OD, FAAO., Azusa, California, United States",,"https://ClinicalTrials.gov/show/NCT01227226"
670,"NCT01225341","Botulinum Toxin A for Herpes Labialis",,"Completed","No Results Available","Herpes Labialis","Drug: onabotulinumtoxinA|Other: Bacteriostatic normal saline","Efficacy|Measurement of Lesion Size|Pain Assessment|Symptom Evaluation","DeNova Research|Allergan","All","18 Years to 64 Years   (Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","HSV-BOT-01-09","August 2010","May 2014","June 2014","October 21, 2010",,"February 12, 2015","DeNova Research, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01225341"
671,"NCT01218737","Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation",,"Completed","No Results Available","Ocular Infection and Inflammation","Drug: 0.3% gatifloxacin and 1.0% prednisolone acetate association|Drug: isolated 0.3% gatifloxacin and 1.0% prednisolone acetate","Percentage of eyes with absence of signs/symptoms of ocular infection/inflammation after surgery.","Federal University of São Paulo|Allergan","All","18 Years to 60 Years   (Adult)","Phase 3","101","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG9890X-001","January 2009","June 2009","June 2009","October 11, 2010",,"March 21, 2018","Federal University of Sao Paulo - Dept of Ophthalmology, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01218737"
672,"NCT01206244","Diurnal Variation of Tear Meniscus and Tear Osmolarity",,"Completed","No Results Available","Dry Eye",,"Variations in tear osmolarity and tear meniscus volume in patients with dry eyes and in healthy control subjects over an 8-hr daytime period.","University of Miami|Allergan","All","18 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","UM20100465","September 2010","September 2011","September 2011","September 21, 2010",,"June 13, 2013","Bascom Palmer Eye Institute, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01206244"
673,"NCT01193231","A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing",,"Completed","No Results Available","Must be PRK Candidate",,"Time to re-epithelialization|Time to zero pain|Occurence of enhancments","Durrie Vision|Allergan","All","18 Years to 39 Years   (Adult)",,"10","Other|Industry","Observational","Time Perspective: Prospective","ACVL-001","August 2010","March 2011","April 2011","September 1, 2010",,"February 14, 2012","Durrie Vision, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01193231"
674,"NCT01177358","Botox in the Healing of Surgical Wounds of the Neck",,"Unknown status","No Results Available","Scar","Drug: Botulinum Toxin Type A|Drug: Normal Saline","Vancouver Scar Scale|Patient and Observer Scar Assessment Scale","Nova Scotia Health Authority|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BTX-001","September 2011","January 2015","July 2015","August 9, 2010",,"September 16, 2014","Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT01177358"
675,"NCT01162668","Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employees",,"Completed","No Results Available","Obesity",,"Weight loss|Body mass index (BMI)|ecomonic outcomes|Systolic blood pressure|Diastolic blood pressure|Medication use|quality of life|Work productivity","University of Mississippi Medical Center|Allergan","All","18 Years and older   (Adult, Older Adult)",,"165","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","41165","April 2010","June 2014","June 2014","July 14, 2010",,"May 15, 2018","Central Mississippi Medical Center Comprehensive Weight Management Program, Jackson, Mississippi, United States|Oxford Bariatric, Oxford, Mississippi, United States|Oxford Surgical & Bariatric Clinic,LLC., Oxford, Mississippi, United States|South Mississippi Surgical Weight Loss Center, Pascagoula, Mississippi, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT01162668/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT01162668/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01162668"
676,"NCT01129583","Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness",,"Completed","Has Results","Post Traumatic Stiffness","Drug: Botulinum Toxin Type A|Drug: Saline","Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire|Elbow Range of Motion|Broberg Morrey Composite Elbow Function Score","Columbia University|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAA8392","November 2003","September 2009","May 2010","May 24, 2010","May 2, 2011","March 27, 2015","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01129583"
677,"NCT01071096","Calcitonin Gene-related Peptide Levels in Chronic Migraine",,"Completed","Has Results","Chronic Migraine","Drug: OnabotulinumtoxinA|Drug: Saline","Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7.|Change in Number of Headache Days Per Month From Baseline to Month 1 (M1), Month 1 to Month 2 (M2), and Month 2 to Month 3 (M3).|Inter-ictal (Baseline) Levels of Saliva Calcitonin Gene-related Peptide (CGRP)|Saliva CGRP Levels for OnabotulinumtoxinA Responders (Reduction of Headache Days Greater Than 30%) vs. Non-responders and Saline|Changes Between Inter-ictal (Baseline) Levels Between Responders and Non-responders","Cady, Roger, M.D.|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10-001AL","June 2010","June 2011","June 2011","February 19, 2010","February 17, 2012","February 12, 2013","Clinvest, Springfield, Missouri, United States|Island Neurological Associates, P.C., Plainview, New York, United States",,"https://ClinicalTrials.gov/show/NCT01071096"
678,"NCT01064830","Topical Cyclosporine Suspension for the Treatment of Brittle Nails",,"Completed","Has Results","Brittle Nail Syndrome","Drug: topical cyclosporine ophthalmic suspension 0.05%|Drug: vehicle","• Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails.|Patients Assessment of Satisfaction With Length of Fingernails","University of North Carolina, Chapel Hill|Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","09-1141","February 2010","August 2011","August 2011","February 8, 2010","December 3, 2012","March 13, 2017","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01064830"
679,"NCT01056861","Effects of Botulinum Toxin in Cervical Dystonia",,"Completed","No Results Available","Torticollis|Cervical Dystonia","Drug: Botulinum Toxin A","Evidence of Cortical organizational changes with botulinum toxin treatment in patients with torticollis utilizing magnetoencephalography|Tsui Torticollis Rating scale","Henry Ford Health System|Allergan","All","18 Years to 90 Years   (Adult, Older Adult)",,"7","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","5307|08-0124","January 2010","July 2014","July 2014","January 26, 2010",,"April 17, 2015","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01056861"
680,"NCT01026077","The Savella Pregnancy Registry","SPR","Recruiting","No Results Available","Fibromyalgia",,"The primary objective is to estimate the prevalence of major congenital anomalies among off-springs of women exposed to Savella during pregnancy.|Estimate the prevalence of spontaneous abortions, stillbirths, induced abortions, minor congenital anomalies, and adverse pregnancy outcomes.","Syneos Health|Allergan","Female","18 Years and older   (Adult, Older Adult)",,"350","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MLN-MD-30","November 2009","December 2019","December 2019","December 4, 2009",,"April 5, 2019","Syneos Health, Wilmington, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01026077"
681,"NCT01023724","A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)",,"Completed","Has Results","Post Operative Anterior Chamber Inflammation (Flare)","Drug: Ketorolac Tromethamine 0.45%|Drug: Bromfenac 0.09%","Anterior Chamber Inflammation (Flare)","Bucci Laser Vision Institute|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-11-06 1","December 2009","January 2010","February 2010","December 2, 2009","August 26, 2011","August 26, 2011","Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01023724"
682,"NCT01021761","A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification",,"Completed","Has Results","Cataracts","Drug: Ketorolac Tromethamine|Drug: Bromfenac|Drug: nepafenac","Aqueous PGE2 Inhibition","Frank A. Bucci, Jr., M.D.|Allergan|Bucci Laser Vision Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2009 0199","October 2009","December 2009","January 2010","November 30, 2009","August 26, 2011","August 31, 2011",,,"https://ClinicalTrials.gov/show/NCT01021761"
683,"NCT01013077","The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability",,"Completed","No Results Available","Dry Eye Syndrome","Drug: Optive|Drug: Soothe|Drug: New Emulsion","contrast sensitivity|aberrometry|reading ability|dry eye questionnaire|slit lamp exam","Southern California College of Optometry|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","09-11","November 2009","March 2011","August 2011","November 13, 2009",,"July 3, 2012","Southern California College of Optometry, Fullerton, California, United States",,"https://ClinicalTrials.gov/show/NCT01013077"
684,"NCT01004042","Evaluation of Quality of Life and Self-steem After Botox® in Depressed and Non-depressed Patients",,"Completed","No Results Available","Depression|Quality of Life","Drug: Botulinum Toxin Type A - BOTOX","WHOQOL BREF|Rosenberg Self-Esteem Scale|Beck Depression Inventory","Brazilan Center for Studies in Dermatology|Allergan","Female","25 Years to 60 Years   (Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-CBED09-02|Version 2.0: 10/07/2009","October 2009","March 2010","April 2010","October 29, 2009",,"February 29, 2012","Brazilian Center for Studies in Dermatology, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT01004042"
685,"NCT01001806","A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification",,"Completed","Has Results","Cataracts","Drug: Ketorolac Tromethamine 0.45%|Drug: bromfenac 0.09%|Drug: nepafenac 0.1%","Peak Aqueous Penetration","Frank A. Bucci, Jr., M.D.|Allergan|Bucci Laser Vision Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2009-0199","October 2009","December 2009","January 2010","October 27, 2009","August 26, 2011","October 3, 2011","Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01001806"
686,"NCT00986427","Restasis for Treatment of Brittle Nails",,"Completed","Has Results","Brittle Nails","Drug: Restasis (cyclosporine ophthalmic emulsion) 0.05%|Drug: Refresh® Dry Eye therapy","Change From Baseline in the Physician's Global Assessment (PGA) of Target Fingernails #1 and #2|Change From Baseline in Quality of Life (QOL) Related to Nail Disease|Growth of the Treated and Untreated Nail in the Previous 4 Weeks|Number of Subjects Achieving Improvement in the Physician's Global Improvement Assessment (PGIA)","Julian M. Mackay-Wiggan|Allergan|Columbia University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","AAAD9927|Res-01-2009","July 2009","July 2010","December 2012","September 30, 2009","August 20, 2013","August 20, 2013","Columbia University Medical Center Department of Dermatology, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00986427"
687,"NCT00945295","Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity",,"Completed","Has Results","Upper Limb Spasticity","Drug: Botulinum toxin type A, BoNT-A|Other: Rehabilitation Therapy","The Maximum Change in Fugl-Meyer Upper Extremity Score From the Baseline Exam to Any Post Injection Visit in Each Treatment Arm. Comparison of the Difference Scores Between the Two Groups Will be Considered Significant at p < 0.05.|Length of Time to Meet Re-injection Criteria and the Number of Participants That do Not Meet Re-injection Criteria Prior to Completion of the Study.","JoAnn Harnar|Allergan|Biomedical Research Institute of New Mexico","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allergan-100808","January 2009","May 2012","May 2012","July 24, 2009","November 1, 2013","November 1, 2013","New Mexico VA Health Care System, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT00945295"
688,"NCT00908050","Study of the Safety and Efficacy of Botox in Bruxism",,"Unknown status","No Results Available","Bruxism","Drug: Botulinum toxin type A","Age and maximum masseter voluntary contractions (MVC)","Baylor College of Medicine|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H-22737","April 2009","December 2011","July 2012","May 25, 2009",,"June 27, 2011","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00908050"
689,"NCT00900666","Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury",,"Terminated","Has Results","Stiff Knee Gait|Brain Injuries","Drug: placebo|Drug: botulinum toxin A (BTX-A)","Mean Peak Knee Flexion During Swing Phase of Gait|Gait Function (Based on 6-Minute Walk)","Mary Free Bed Rehabilitation Hospital|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","19","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MFB2008.08","January 2009","June 2011","December 2011","May 13, 2009","June 24, 2013","June 24, 2013","Mary Free Bed Rehabilitation Hospital, Grand Rapids, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00900666"
690,"NCT00895063","Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia",,"Terminated","No Results Available","Spasmodic Dysphonia|Dystonia","Behavioral: Vocal Exercise","Self-rating of vocal function","NYU Langone Health|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BOTOXEX","December 2007","May 2013","May 2013","May 7, 2009",,"March 3, 2016","Private Practice of Dr. Andrew Blitzer, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00895063"
691,"NCT00856999","Botox Cosmetic and the Young Patient With Glabellar Furrows",,"Completed","Has Results","Glabellar Furrows","Drug: Botox","Reduction of the Facial Wrinkle Scale|Patient Assessed Frown-line Improvement","Oregon Health and Science University|Allergan","Female","30 Years to 50 Years   (Adult)","Phase 4","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGNR-08-0093","February 8, 2005","November 17, 2010","November 17, 2010","March 6, 2009","July 23, 2019","July 23, 2019",,,"https://ClinicalTrials.gov/show/NCT00856999"
692,"NCT00850733","516-BOTOX Urinary Incontinence Detrusor",,"Completed","No Results Available","Urinary Incontinence|Urinary Bladder, Overactive",,,"Veterans Medical Research Foundation|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)",,,"Other|Industry","Observational",,"071304|VMRF Project #07366","August 2008","September 2009","September 2009","February 25, 2009",,"September 17, 2009",,,"https://ClinicalTrials.gov/show/NCT00850733"
693,"NCT00850421","Pilot Study of BOTOX for Migraine Headaches",,"Terminated","Has Results","Migraine Headache","Drug: Botulinum Toxin Type A","To Determine Whether Resource Utilization is Decreased in Subjects Treated With BOTOX Injections for Episodic Migraine Headache.|To Determine Whether Quality of Life is Improved in Subjects Treated With BOTOX Injections for Episodic Migraine Headache.|To Assess the Effect of BOTX Injections on the Frequency and Intensity of Migraine Episodes in Subjects With Episodic Migraine Headache.","HealthPartners Institute|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01837-04-C","April 2004","April 2010","April 2010","February 25, 2009","September 18, 2013","September 26, 2018","Park Nicollet Health Services, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00850421"
694,"NCT00824811","Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel",,"Withdrawn","No Results Available","Epiphora","Drug: Cyclosporine Eye Drops (Restasis)|Drug: Lubricant Eye Drops (Refresh Endura™)|Drug: Fluorometholone Eye Drops (FML Forte®)","Patient Epiphora Grade Scores","M.D. Anderson Cancer Center|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2007-0757","June 2009",,,"January 19, 2009",,"August 2, 2012",,,"https://ClinicalTrials.gov/show/NCT00824811"
695,"NCT00822523","Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies",,"Completed","Has Results","Muscle Strength|Botulinum Toxins, Type A","Drug: Botulinum Toxin, Type A|Drug: Saline","Change in Measured Force (Change From Baseline) (Using Strain Gauges) of Dorsiflexion of Digits 2 and 3 (""Force of EDB"") After vs. Before Botulinum Toxin Injection Into EDB|Stability of Baseline Measurements of Force|Difference in Force From Day 14 to Day 21|Number of Participants With Serious Adverse Effects to onabotulinumtoxinA (Botulinum Type A Neurotoxin)|Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Root Mean Squared With 1000 ms Window).|Percent Change of the Surface Electromyogram (SEMG) MRV-500 From EDB After vs. Before Botulinum Toxin Injection Into EDB.|Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Root Mean Squared With 500 ms Window).|Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Root Mean Squared With 200 ms Window).|Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 1000 ms Window).|Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 500 ms Window).|Correlation in Percent Change of the CMAP (With Standard Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 200 ms Window).|Correlation in Percent Change of the CMAP (With ""Inactive"" Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Root Mean Squared With 1000 ms Window).|Correlation in Percent Change of the CMAP (With ""Inactive"" Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Root Mean Squared With 500 ms Window).|Correlation in Percent Change of the CMAP (With ""Inactive"" Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Root Mean Squared With 200 ms Window).|Correlation in Percent Change of the CMAP (With ""Inactive"" Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 1000 ms Window).|Correlation in Percent Change of the CMAP (With ""Inactive"" Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 500 ms Window).|Correlation in Percent Change of the CMAP (With ""Inactive"" Reference Electrode Location) From EDB After vs. Before Botulinum Toxin Injection Into EDB vs. Percent Change Surface Electromyography (as Measured by Mean Rectified Voltage With 200 ms Window).","Loma Linda University|Allergan","All","18 Years to 54 Years   (Adult)","Not Applicable","13","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","58360","January 2009","March 2009","July 2015","January 14, 2009","August 31, 2016","September 5, 2018","Electromyography Laboratory, Loma Linda University Medical Center, Loma Linda, California, United States|Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT00822523"
696,"NCT00822081","Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|Drug: dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.","Change from baseline in mean IOP.|Patient tolerability/comfort measured by Likert scale.","Bp Consulting, Inc|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","COM0501","January 2005","April 2006","April 2006","January 14, 2009",,"January 14, 2009","Barrie, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00822081"
697,"NCT00816517","Use of Botulinum Toxin to Treat Psoriasis",,"Completed","No Results Available","Psoriasis Vulgaris","Biological: injection of botulinum toxin type A.","psoriasis scoring scale|3mm skin biopsy.","University of Minnesota|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0808M45282","January 2009","June 2015","December 2015","January 1, 2009",,"April 4, 2016","Univerisity of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00816517"
698,"NCT00812838","H-22411: BOTOX® for Peyronie's Disease",,"Unknown status","No Results Available","Peyronie's Disease","Drug: 100 units of Botulinum Toxin Type A|Other: Preservative free normal saline","Change in penile curvature|Improvements in penile blood flow|Reduction in penile plaque size as seen on ultrasound|Changes in IIEF (International Index of Erectile Function) scores","Mohit Khera|Allergan|Baylor College of Medicine","Male","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-07-40-04","February 2009","July 2017","January 2018","December 22, 2008",,"November 9, 2016","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00812838"
699,"NCT00773253","Botox for Cervical Dystonia Following EMG Mapping",,"Completed","Has Results","Cervical Dystonia","Drug: Botulinum toxin A","Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)|Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale","University of California, San Francisco|Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allergan cervical dystonia","April 2008","October 2010","January 2011","October 16, 2008","October 13, 2011","October 13, 2011","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00773253"
700,"NCT00706940","Tear Dynamics After Restasis Treatment in Dry Eye Patients",,"Completed","No Results Available","Dry Eye",,"Increase in tear volume after the 3-month treatment and returned to baseline during 6-month follow-up after discontinuation of study treatment.|Tear meniscus volume after treatment","University of Miami|Allergan","All","18 Years to 90 Years   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20080340","August 2011","December 31, 2016","December 31, 2016","June 30, 2008",,"April 25, 2017","Bascom Palmer Eye Institute, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00706940"
701,"NCT00704275","Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes",,"Unknown status","No Results Available","Dry Eye","Drug: 0.05% cyclosporin eye drop","Corneal and conjunctival staining score|Schirmer 1 score","Chulalongkorn University|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","391/48","June 2007","July 2008","October 2008","June 24, 2008",,"June 24, 2008","OPD Chulalongkorn University Hospital, Bangkok, Thailand|OPD Chulalongkorn University Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00704275"
702,"NCT00669474","Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.",,"Terminated","No Results Available","Essential Axillary Hyperhidrosis","Procedure: Suction curettage|Drug: Treatment with Botox","Effectiviness and duration of effect of both treatments|Adverse events of both treatments","University Hospital, Ghent|Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008/219","June 2009","August 2011","August 2011","April 30, 2008",,"June 4, 2015","University Hospital Ghent, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT00669474"
703,"NCT00661089","Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity",,"Completed","Has Results","Post-stroke Shoulder Pain and Spasticity","Drug: Botulinum Toxin Type A - OnabotulinumtoxinA|Drug: Placebo (Saline)","Change in Pain Rating From Baseline to Four Weeks|Change in Disability Assessment Scale for Hygiene|Time to Don a Pull Over Shirt|Ability to Perform Hygiene Rating","Shirley Ryan AbilityLab|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0335-006","September 2003","March 2009","February 2010","April 18, 2008","February 6, 2012","November 20, 2017","Rehabilitation Institute of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00661089"
704,"NCT00648986","Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails",,"Completed","No Results Available","Brittle Nails","Drug: Tazorac","The primary endpoint was the change in the Physician's Global Improvement Assessment (PGIA) of the 2 target nails. The PGIA score reflects the comparison of photographs taken at baseline to the nails at 12 weeks, 24 weeks, and 36 weeks.|Physician's Global Assessment (PGA) measures the severity of brittle nail symptoms.|Physician ratings of the roughness, raggedness, and peeling of the target nails.|A VapoMeter measures the Transonychial Water Loss (TOWL) on both target nails.|Subject reporting provides the subjects' assessments of their nail breakage.|Subject reporting provides the subjects' satisfaction with the product.","Columbia University|Allergan","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAA5735|TAZ11-2003","August 2005","December 2006","December 2006","April 1, 2008",,"July 2, 2014","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00648986"
705,"NCT00621335","A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt","CICOM1010","Completed","No Results Available","Open Angle Glaucoma|Ocular Hypertension",,"Comparison of the tolerability and effectiveness of Combigan and Cosopt in the treatment of open angle glaucoma or ocular hypertension","DBYAN Medicine Professional Corporation|Allergan","All","40 Years to 90 Years   (Adult, Older Adult)",,"64","Other|Industry","Observational","Time Perspective: Prospective","CICOM 1010","March 2007","February 2008","February 2008","February 22, 2008",,"February 25, 2013","Ophthalmic Consultants Centres, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00621335"
706,"NCT00580502","Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Body Mass Index (BMI) Between 30-40 kg/m2","LBMI","Completed","Has Results","Obesity","Device: LAP-BAND® Adjustable Gastric Band (LAGB®)","To Determine Percent of Excess Weight Loss (%EWL) After Laparoscopic Adjustable Gastric Banding Surgery|Level of LDL (Bad Cholesterol) After Laparoscopic Adjustable Gastric Band Surgery|Level of Triglycerides (Bad Cholesterol) After Laparoscopic Adjustable Gastric Band Surgery|Level of HbA1c (Blood Test for Diabetes) After Laparoscopic Adjustable Gastric Band Surgery","NYU Langone Health|Allergan","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H # 10686|10686|G030190","March 2004","September 2012","September 2012","December 24, 2007","March 23, 2015","March 23, 2015",,,"https://ClinicalTrials.gov/show/NCT00580502"
707,"NCT00567788","Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study",,"Unknown status","No Results Available","Glaucoma, Angle-Closure","Drug: Latanoprost-Bimatoprost|Drug: Bimatoporost-Latanoprost","The primary endpoint is defined as IOP reduction from baseline measurement (week 0) to the measurement at week 6 at each treatment period.|Incidence of side effects of each medication.","Singapore National Eye Centre|Allergan","All","40 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R353/11/2004|SQGL08","July 2006",,"July 2008","December 5, 2007",,"December 5, 2007","Singapore National Eye Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00567788"
708,"NCT00565201","Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients","Botox/Rehab","Completed","No Results Available","Stroke","Drug: Botox and rehab|Drug: Placebo and rehab","Wolf Motor Function Test|Arm Motor Ability Test|Stroke Impact Scale|Modified Ashworth Scale|Upper Extremity range of motion measurements|Caregiver questionnaire","Emory University|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00002727","October 2007","December 2009","December 2011","November 29, 2007",,"August 13, 2013","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00565201"
709,"NCT00529386","Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)",,"Terminated","Has Results","Prostatitis|Chronic Pain Syndrome","Drug: Botox","GRA","Queen's University|Allergan","Male","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BOTOX-CP","January 2006","September 2009","December 2009","September 14, 2007","March 11, 2019","March 25, 2019","Centre for Advanced Urological Research, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00529386"
710,"NCT00496964","Botox for Non-surgical Lateral Release in Patellofemoral Pain",,"Terminated","Has Results","Patellofemoral Pain Syndrome","Drug: Botulinum toxin A + exercise|Drug: Placebo","Visual Analog Scale Pain Ratings (VAS)|Change in Anterior Knee Pain Scale.|Functional Index Questionnaire|Lower Extremity Functional Scale|Maximal Knee Extensor Force During Concentric and Isometric Contractions|Knee Extensor Fatigue|Muscle Activation During Maximal Contractions and Fatigue Contractions","Virginia Commonwealth University|Allergan","All","18 Years to 40 Years   (Adult)","Phase 3","5","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PT_PMR_3700","May 2005","June 2008","June 2008","July 6, 2007","May 18, 2011","October 23, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00496964"
711,"NCT00479596","This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.","BTX0621","Unknown status","No Results Available","Overactive Bladder","Drug: Botox","Safety and efficacy of BOTOX to placebo (saline) in the treatment of OAB secondary to BPO.|Patient satisfaction to intradetrussor injection of Botox versus placebo.","Urological Sciences Research Foundation|Allergan","Male","40 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BTX0621","January 2007",,"May 2007","May 28, 2007",,"May 30, 2007","Urological Sciences Research Foundation, Culver City, California, United States",,"https://ClinicalTrials.gov/show/NCT00479596"
712,"NCT00477802","Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease",,"Terminated","No Results Available","Parkinson Disease","Biological: Botulinum Toxin Type A|Biological: Placebo","the change in the ""on"" time with LID 1 month and 3 months after injected compared to baseline scores. A reduction of 40% in the mean ""on"" time with LID in the Botox® group compared to the placebo group will be considered significant.|changes in: the duration, severity, and pain of LID using the UPDRS Part IV, physician and patient Clinical Global Impression [CGI] of change, Schwab & England score, Abnormal Involuntary Movement Scale, 4-point modified dyskinesia rating scale (Goetz)","University of Cincinnati|Allergan","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 4","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06122801","May 2007","November 2008","December 2008","May 24, 2007",,"February 16, 2009","University Neurology - Movement Disorders Clinic, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00477802"
713,"NCT00464373","Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome","BTX-URO-01","Terminated","No Results Available","Chronic Prostatitis With Chronic Pelvic Pain Syndrome|Prostatitis","Drug: Botulinum Toxin Type A|Drug: Placebo","NIH-CPSI Total Score|NIH-CPSI Subscales|Standardized questions for the assessment of the treatment outcome|International prostate symptom score (I-PSS)","Daniel Stephan Engeler|Allergan|Cantonal Hospital of St. Gallen","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BTX-URO-01|EKSG 06/056","April 2007","May 2013","June 2013","April 23, 2007",,"February 3, 2014","Department of Urology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT00464373"
714,"NCT00462449","Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity","Botox + FES","Completed","Has Results","Upper Extremity Spasticity|Stroke|Acquired Brain Injury","Device: Functional Electrical Stimulation (FES) through the Ness H200","Change From Baseline in Arm Function Based on Motor Activities Log (MAL-O)|Change From Baseline in Dexterous Hand Function as Measured by the Action Research Arm Test (ARAT)|Change From Baseline in Self-performance in Activities of Daily Living Assessed With the (MAL - Self Report)","University of Pittsburgh|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0611012","November 2007","January 2010","January 2010","April 19, 2007","June 20, 2014","June 20, 2014","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00462449"
715,"NCT00444886","Treatment of Thoracic Outlet Syndrome (TOS) With Botox",,"Completed","No Results Available","Thoracic Outlet Syndrome","Drug: Botulinum Toxin Type A injection (BOTOX)","Pain as measured on Visual Analog Scale (VAS) at 6 weeks, 3 months and 6 months post-intervention|Paresthesias as measured on VAS|Function as measured with Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, SF-36, number of days lost from work","University of British Columbia|Allergan","All","19 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H06-03355|Data not known","May 2007","February 2011","February 2011","March 8, 2007",,"February 10, 2011","GF Strong Rehabilitation Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00444886"
716,"NCT00430196","BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity",,"Completed","No Results Available","Upper Limb Spasticity","Drug: BOTOX®|Drug: Zanaflex®","wrist Modified Ashworth Score|Disability Assessment Scale|Modified Frenchay Assessment|Walking Speed|Contralateral Grip Strength|Contralateral Finger Tap|Epworth Sleepiness Scale|Cognitive Evaluations Questionnaire|Discontinuation|Titration schedule of oral study medication between treatment groups","Icahn School of Medicine at Mount Sinai|Allergan","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","135","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","GCO # 02-0510","December 2003",,"September 2006","February 1, 2007",,"February 1, 2007",,,"https://ClinicalTrials.gov/show/NCT00430196"
717,"NCT00405431","Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?",,"Completed","No Results Available","Glaucoma","Drug: Restasis|Drug: Endura (artificial tears)","intraocular pressure|ocular inflammation","Wills Eye|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","43","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB #03-598","March 2004","June 2005","November 2007","November 30, 2006",,"November 22, 2016","Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00405431"
718,"NCT00395759","The Visual Effect of an Investigational Artificial Tear in the Tear Layer.",,"Completed","No Results Available","Dry Eye Disease","Drug: Optiva artificial tear by Allergan","Contrast sensitivity and optical aberrations before daily artificial tear use and at 1 and 2 weeks after daily use|Dry eye questionnaire before and at 1 and 2 weeks after artificial tear use|Slit lamp exam before and at 1 and 2 weeks after artificial tear use","Southern California College of Optometry|Allergan","All","18 Years to 40 Years   (Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Supportive Care","SCCO2-2233","September 2005",,"September 2007","November 3, 2006",,"October 23, 2007","Southern California College of Optometry, Fullerton, California, United States",,"https://ClinicalTrials.gov/show/NCT00395759"
719,"NCT00352807","Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients",,"Completed","No Results Available","Cataract","Drug: Brimonidine Purite","Bioanalysis of brimonidine concentrations.","Indiana University School of Medicine|Allergan|Indiana University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0501-45","February 2005",,"December 2005","July 17, 2006",,"October 17, 2007","University Hospital, Indianapolis, Indiana, United States|Veterans Affairs Medical Center, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States|Iu Eye at Carmel, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00352807"
720,"NCT00348335","Efficacy of Topical Cyclosporin for Ocular Rosacea",,"Completed","No Results Available","Rosacea","Drug: Cyclosporine 0.05%|Drug: Ocular lubricant","hyperemia","Ophthalmic Consultants of Long Island|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","32,133","June 2006","September 2007","September 2007","July 4, 2006",,"July 29, 2011","2500 Rte 347 Bldg 24, StonyBrook, New York, United States",,"https://ClinicalTrials.gov/show/NCT00348335"
721,"NCT00347828","Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose",,"Unknown status","No Results Available","Eye Infection|Infection","Drug: Moxifloxacin ophthalmic solution 0.5%|Drug: Gatifloxacin ophthalmic solution 0.3%","Evidence of growth and number of colonies of bacteria on chocolate agar prior to antibiotic administration, t=0 hrs|Evidence of growth and number of colonies of bacteria on blood agar prior to antibiotic administration, t=0 hrs|Evidence of growth and number of colonies of bacteria on chocolate agar post-antibiotic administration, t=1 hr|Evidence of growth and number of colonies of bacteria on blood agar post-antibiotic administration, t=1 hr","Ophthalmic Consultants of Boston|Allergan","All","25 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","Allergan/Z101","June 2006",,"June 2006","July 4, 2006",,"July 4, 2006","Ophthalmic Consultants of Boston, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00347828"
722,"NCT00347204","Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK",,"Completed","No Results Available","Myopia|Hyperopia","Drug: ketorolac (Acular LS)|Drug: Nepafenac (Nevanac)","Prevention of postoperative discomfort on postoperative days 1 to 5 after PRK|Best-corrected Visual acuity at all study visits|Degree of corneal haze at all study visits|Time to epithelial closure in each eye after PRK","Center For Excellence In Eye Care|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","5225","January 2006",,"June 2006","July 4, 2006",,"July 4, 2006",,,"https://ClinicalTrials.gov/show/NCT00347204"
723,"NCT00336349","A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Neuropathic Foot Pain",,"Completed","No Results Available","Diabetes Mellitus|Neuropathic Pain","Drug: Botulinum Toxin Type A","VAS of pain|SF36 for life quality|sleep quality|blood flow of feet","Taipei Medical University Hospital|Allergan","All","30 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","TMUH20060504","June 2006","December 2007","December 2007","June 13, 2006",,"July 26, 2011","Chaur-Jong Hu, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00336349"
724,"NCT00282958","The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain",,"Completed","No Results Available","Subacute Cervical Pain|Subacute Upper Back Pain","Drug: Botulinum Toxin type a (Botox)","NDI, VAS, SF-36","Palo Alto Veterans Institute for Research|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable",,"Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","DAT0014","February 2003",,"July 2006","January 27, 2006",,"March 5, 2015",,,"https://ClinicalTrials.gov/show/NCT00282958"
725,"NCT00250952","Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection Affects Its Overall Effect and Duration.",,"Completed","No Results Available","Skin Wrinkling","Drug: Botox Cosmetic™","Using the per visit photographs, the effect of Botox was measured separately for each treatment site (right and left crow's feet at maximum smile) for all visits.|Using the per visit photographs, the remaining effect of Botox treatment was measured separately for each treatment site (right and left crow's feet at maximum smile) for the 30, 60, and 90 day follow up visits.","Carruthers Dermatology Centre|Allergan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","CCR-001","February 2005",,"June 2005","November 9, 2005",,"November 9, 2005","Skin Care Physicians of Chestnut Hill, Chestnut Hill, Massachusetts, United States|Carruthers Dermatology Centre, Inc., Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00250952"
726,"NCT00241215","Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome",,"Completed","No Results Available","Cervicobrachial Neuralgia|Myofascial Pain Syndromes","Drug: Botulinum toxin serotype A","Numerical pain rating|Brief Pain Inventory|Neck Disability Index|Cervical range of motion|Number of trigger points|Postural exam|Pain Diary and medications use|Short Form (SF)-36","University of California, Los Angeles|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","UCLA#03-03-061-03A","June 2003","November 2005",,"October 18, 2005",,"June 21, 2016","UCLA Pain Management Center, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT00241215"
727,"NCT00199589","Treatment of Spastic Equinovarus Foot After Stroke",,"Completed","No Results Available","Spastic Equinovarus","Drug: Botulinic toxin (Botox)","Plantar contact during walking|Gait velocity|Barthel index|MIF|Autosatisfaction by EVA|Asworth scale|Ankle range of motion","University Hospital, Limoges|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I01014","October 2002",,"December 2007","September 20, 2005",,"December 30, 2008","Département de Médecine Physique et de Réadaptation, Bordeaux, France|Département de Médecine Physique et de Réadaptation, CHU Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT00199589"
728,"NCT00178646","Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity",,"Completed","No Results Available","Stroke|Brain Injuries|Spasticity","Drug: Botox","Ashworth Scale|Range of Motion","The University of Texas Health Science Center, Houston|Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","33","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-01-103","January 2002","March 2010","March 2010","September 15, 2005",,"January 9, 2014","Kessler Institute for Rehabiliation, West Orange, New Jersey, United States|Memorial Hermann Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00178646"
729,"NCT03969537","Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections",,"Enrolling by invitation","No Results Available","Cervical Dystonia|Telemedicine","Other: Telemedicine follow-up visit","Patient Satisfaction with Telehealth","Vanderbilt University Medical Center|Allergan Foundation","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","190232","April 1, 2019","October 1, 2020","October 1, 2020","May 31, 2019",,"May 31, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03969537"
730,"NCT02016612","Seri Surgical Scaffold Support of the Lower Pole of the Breast","SeriSupport","Completed","Has Results","Recurrent Ptosis of the Breast","Device: Seri Surgical Scaffold","Nipple to Fold Measurement on Stretch|Percent Breast Tissue Above Nipple","Bengtson Center|Allergan Medical","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","76","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","007","October 2013","November 2015","November 30, 2016","December 20, 2013","February 13, 2018","February 13, 2018","Bengtson Center for Aesthetics and Plastic Surgery, Grand Rapids, Michigan, United States|Center for Aesthetics and Plastic Surgery, Grand Rapids, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02016612"
731,"NCT00442312","Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy",,"Unknown status","No Results Available","Glaucoma","Drug: Combigan Ophthalmic Solutiom","The change of IntraOcular Pressure From baseline to week 12|The change of IntraOcular Pressure on week 8.|The change of IntraOcular Pressure on week 12","Genovate Biotechnology Co., Ltd.,|Allergan Medical","All","20 Years and older   (Adult, Older Adult)","Phase 4","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","COM 003","May 2006",,"November 2006","March 1, 2007",,"March 1, 2007","Allergan, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00442312"
732,"NCT03931785","A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome",,"Active, not recruiting","No Results Available","Irritable Bowel Syndrome With Diarrhea (IBS-D)","Drug: MD-7246|Drug: Placebo","Change from Baseline in Abdominal Pain at its Worst at Each Week on a Numerical Rating Scale (NRS)|Proportion of 6/12 Week Abdominal Pain 30% Change Responders","Ironwood Pharmaceuticals, Inc.|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MCP-103-205","May 1, 2019","September 2020","September 2020","April 30, 2019",,"January 10, 2020","Clinical Research Associates, Huntsville, Alabama, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|GW Research, Inc., Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Diagnamics Inc., Encinitas, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Paragon Rx Clinical, Garden Grove, California, United States|Grossmont Center For Clinical Research, La Mesa, California, United States|Facey Medical Foundation, Mission Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|Precision Research Institute, San Diego, California, United States|Paragon Rx Clinical, Inc. - Santa Ana, Santa Ana, California, United States|UNISON Clinical Trials, Sherman Oaks, California, United States|Millennium Clinical Trials, Thousand Oaks, California, United States|Advanced Rx Clinical Research, Westminster, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Connecticut Clinical Research Institute, Bristol, Connecticut, United States|Chase Medical Research of Greater New Haven LLC, Hamden, Connecticut, United States|The Chappel Group Research, LLC, Kissimmee, Florida, United States|San Marcus Research Clinic Inc, Miami Lakes, Florida, United States|Well Pharma Medical Research Corporation, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Research Institute of Central Florida, LLC, Winter Park, Florida, United States|Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Rockford Gastroenterology Associates LTD, Rockford, Illinois, United States|Clinical Trials Management LLC, Metairie, Louisiana, United States|Clinical Trials of America -- LA LLC, West Monroe, Louisiana, United States|Meritus Center For Clinical Research, Hagerstown, Maryland, United States|Meridian Clinical Research, Rockville, Maryland, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|New England Center For Clinical Research Inc PrimaCare Research, LLC, Fall River, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Galen Research, Chesterfield, Missouri, United States|Bozeman Health Deaconess Hospital, Bozeman, Montana, United States|Barrett Clinic, P.C. - BTC - PPDS, La Vista, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Healthwise Medical Associates, Brooklyn, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Carolina Digestive Health Associates, Charlotte, North Carolina, United States|Carolina Digestive Health Associates, Concord, North Carolina, United States|Peters Medical Research, LLC, High Point, North Carolina, United States|Clinical Trials of America-NC, LLC, Mount Airy, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Progressive Medicine of the Triad, LLC, Winston-Salem, North Carolina, United States|Lillestol Research, Fargo, North Dakota, United States|Hometown Urgent Care and Research, Cincinnati, Ohio, United States|Hightop Medical Research Center, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Remington Davis Inc, Columbus, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Central Sooner Research, Norman, Oklahoma, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists, Inc., Oklahoma City, Oklahoma, United States|Oregon Center For Clinical Investigations Inc, Salem, Oregon, United States|Partners In Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Partners, Lincoln, Rhode Island, United States|Mountain View Clinical Research Inc, Greer, South Carolina, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|MW Clinical Research Center, Beaumont, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Quality Research Inc, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|New River Valley Research Institute, Christiansburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03931785"
733,"NCT03848143","Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain",,"Recruiting","No Results Available","Neuropathic Pain","Drug: onabotulinum toxin A","Pain Intensity","Isabel Moreno Hay|Allergan Sales, LLC|University of Kentucky","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","45231|IIT-10247","September 11, 2019","August 2020","June 2021","February 20, 2019",,"September 26, 2019","Orofacial Pain Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03848143"
734,"NCT03661697","Combination Versus Laser Treatment Only",,"Completed","No Results Available","Photoaging","Device: Skin Care Regimen plus Lytera 2.0 and Laser Therapy|Device: Basic Skin Care Regimen Only and Laser Therapy|Other: Lytera plus Laser","Change in aesthetics|Change in skin tone","University of Miami|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","14","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20171006","October 10, 2018","March 7, 2019","March 7, 2019","September 7, 2018",,"January 18, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03661697"
735,"NCT03573908","A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation",,"Active, not recruiting","No Results Available","Irritable Bowel Syndrome Characterized by Constipation","Drug: Linaclotide|Drug: Placebo","Change from Baseline in Abdominal Score (abdominal bloating, abdominal discomfort, and abdominal pain) at Each Week|Change from Baseline in 12-week Abdominal Score|Number of 6/12 Week Abdominal Score Responder|Change From Baseline in Abdominal Score at Each Week (Time Course Analysis)","Ironwood Pharmaceuticals, Inc.|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MCP-103-312","June 20, 2018","April 2019","June 2019","June 29, 2018",,"January 14, 2019","Clinical Research Associates, Huntsville, Alabama, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Adobe Clinical Research, LLC, Tucson, Arizona, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|GW Research, Inc., Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Diagnamics, Inc., Encinitas, California, United States|MD Studies, Inc., Fountain Valley, California, United States|Paragon Rx Clinical, Inc. - Garden Grove, Garden Grove, California, United States|Grossmont Center For Clinical Research, La Mesa, California, United States|Facey Medical Foundation, Mission Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|Precision Research Institute, San Diego, California, United States|Paragon Rx Clinical, Inc.- Santa Ana, Santa Ana, California, United States|Millennium Clinical Trials, Thousand Oaks, California, United States|St. Joseph Heritage Healthcare, Yorba Linda, California, United States|Connecticut Clinical Research Institute, Bristol, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|The Chappel Group Research, Kissimmee, Florida, United States|San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|Jesscan Medical Research, Miami, Florida, United States|Well Pharma Medical Research Corporation, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States|Precision Clinical Research, Sunrise, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Research Institute of Central Florida, LLC, Winter Park, Florida, United States|Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|Delta Research Partners, LLC, Monroe, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Alan A. Rosen, MD, PA, Baltimore, Maryland, United States|Meritus Center For Clinical Research, Hagerstown, Maryland, United States|Boston Clinical Trials, Inc., Boston, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Gastroenterology Associates of West Michigan, Wyoming, Michigan, United States|Gastrointestinal Associates PA, Flowood, Mississippi, United States|St. Louis Center For Clinical Research, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital, Bozeman, Montana, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Healthwise Medical Associates, Brooklyn, New York, United States|Long Island Gastrointestinal Research Group, LLP, Great Neck, New York, United States|Carolina Digestive Health Associates, Charlotte, North Carolina, United States|Carolina Digestive Health Associates, Concord, North Carolina, United States|Cumberland Research Associates, Fayetteville, North Carolina, United States|Peters Medical Research, LLC, High Point, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Clinical Trials of America - North Carolina, LLC, Winston-Salem, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Lillestol Research, Fargo, North Dakota, United States|Hightop Medical Research Center, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Remington Davis, Inc., Columbus, Ohio, United States|Dayton Gastroenterology, Inc., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Great Lakes Gastroenterology Research, LLC, Mentor, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Partners In Clinical Research, Cumberland, Rhode Island, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|MW Clinical Research Center, Beaumont, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Quality Research, Inc., San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|New River Valley Research Institute, Christiansburg, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03573908"
736,"NCT03332342","Closed Eye Neutrophils in Dry Eye Disease",,"Completed","No Results Available","Dry Eye|Ocular Inflammation","Other: Eye wash","Comfort assessment using the dry eye questionnaire|Comfort assessment using the ocular surface disease index|Repeatability of diagnostic in measuring leukocyte count|Repeatability of diagnostic in measuring leukocyte phenotype","University of Alabama at Birmingham|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","153","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","000517538","November 8, 2017","December 12, 2018","May 14, 2019","November 6, 2017",,"May 17, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03332342"
737,"NCT03180593","Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH","BVreduce","Completed","No Results Available","Hypertension Complicated|Hypertrophy, Left Ventricular|Blood Pressure","Drug: Valsartan 80 mg","LVH reduction at 4 weeks.|24hr-ABPM measurement Change from baseline in mean 24 hour ABPM SBP|LVH reduction at 8 weeks.|24hr-Systolic ABPM measurement|24hr- DBP ABPM measurements|Office Blood Pressure measurements","Trinity Hypertension & Metabolic Research Institute|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","BYS-IT-78","February 7, 2017","January 25, 2018","January 25, 2018","June 8, 2017",,"April 11, 2018","Trinity Hypertension & Metabolic Research Institute, Carrollton, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03180593"
738,"NCT02392026","Safety and Tolerability of Metronidazole Gel 1.3%",,"Completed","No Results Available","Vaginosis, Bacterial","Drug: Metronidazole Gel","Number of subjects with treatment-emergent adverse events (AEs), serious AEs, treatment-related AEs and AEs leading to study discontinuation after Metronidazole Vaginal Gel is administered in post-menarcheal, adolescent females with bacterial vaginosis.|Number of subjects reporting presence of daily vaginal discharge and/or odor following single dose administration of Metronidazole Vaginal Gel 1.3%assessment of the presence of vaginal discharge and odor following single dose administration.","Insud Pharma|Allergan Sales, LLC","Female","12 Years to 17 Years   (Child)","Phase 4","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MG1401","August 11, 2015","October 31, 2016","November 30, 2016","March 18, 2015",,"October 24, 2019","Allergan Research Site #318, Long Beach, California, United States|Allergan Research Site #324, Paramount, California, United States|Allergan Research Site #315, Bardstown, Kentucky, United States|Allergan Research Site #314, New Orleans, Louisiana, United States|Allergan Research Site #319, Columbus, Ohio, United States|Allergan Research Site #322, Dayton, Ohio, United States|Allergan Research Site #321, Memphis, Tennessee, United States|Allergan Research Site #316, Irving, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02392026"
739,"NCT01744158","Exploring Hypertonia in Children With Cerebral Palsy","HypE-CP","Unknown status","No Results Available","Cerebral Palsy.","Other: No intervention applicable","Hypertonia Assessment Tool-Discriminate (HAT-D)|Barry-Albright Dystonia scale|Modified Ashworth Scale","Women's and Children's Hospital, Australia|Allergan Australia Pty Ltd","All","2 Years to 18 Years   (Child, Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","REC2202/8/12","March 2011","October 2013","January 2014","December 6, 2012",,"December 6, 2012","Women's and Children's Hospital, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01744158"
740,"NCT03724292","An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers",,"Completed","No Results Available","Psoriasis","Drug: Placebo|Drug: VTP-43742","Number of participants with treatment-emergent adverse events (TEAEs) in the healthy volunteer (Part 1) group|Maximum plasma concentration (Cmax) in the healthy volunteer (Part 1) group|Time to maximum plasma concentrations (tmax) in the healthy volunteer (Part 1) group|The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration (AUCt) in the healthy volunteer (Part 1) group|Half life (t½) in the healthy volunteer (Part 1) group","Vitae Pharmaceuticals Inc., an Allergan affiliate|Vitae Pharmaceuticals, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VTP-43742-002-1","August 1, 2015","March 8, 2016","March 8, 2016","October 30, 2018",,"October 30, 2018","Healthy Volunteer Site 1, Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03724292"
741,"NCT02555709","An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients",,"Completed","No Results Available","Psoriasis","Drug: VTP-43742|Drug: Placebo 1|Drug: Placebo 2","safety data, including AEs, laboratory evaluations, ECG results, and vital signs assessments, will be listed by subject and summarized by dose and time point|Maximum plasma concentration (Cmax) will be summarized using descriptive statistics by visit and dose level|Time to maximum plasma concentrations (tmax) will be summarized using descriptive statistics by visit and dose level|The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration (AUCt) will be summarized using descriptive statistics by visit and dose level|The area under the plasma concentration versus time curve, from time 0 to infinity (by extrapolation) (AUC∞) will be summarized using descriptive statistics by visit and dose level|Half life (t½) will be summarized using descriptive statistics by visit and dose level|Percent change from baseline in total PASI will be summarized using descriptive statistics by visit and dose level","Vitae Pharmaceuticals Inc., an Allergan affiliate|Vitae Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VTP-43742-002","August 2015","March 2016","March 2016","September 21, 2015",,"October 30, 2018","Patient Site 5, Rogers, Arkansas, United States|Patient Site 1, Miami, Florida, United States|Patient Site 8, Tampa, Florida, United States|Patient 12, Tampa, Florida, United States|Patient Site 13, Carmel, Indiana, United States|Patient Site 4, Plainfield, Indiana, United States|Healthy Volunteer Site 1, Fair Lawn, New Jersey, United States|Patient Site 2, New York, New York, United States|Patient Site 9, High Point, North Carolina, United States|Patient Site 6, College Station, Texas, United States|Patient Site 3, Dallas, Texas, United States|Patient Site 10, Houston, Texas, United States|Patient Site 11, Houston, Texas, United States|Patient Site 7, Webster, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02555709"
742,"NCT02603458","NRX-1074 in Early Course Schizophrenia",,"Withdrawn","No Results Available","Schizophrenia","Drug: NRX-1074|Drug: Placebo","Brief Psychiatric Rating Scale (BPRS) total score|Change in total score of Brief Psychiatric Rating Scale (BPRS) from baseline to Day 28|Change in total score of Clinical Assessment Interview for Negative Symptoms (CAINS) from baseline to day 28|Total score of MATRICS Consensus Cognitive Battery|Logical Memory Test of the Wechsler Memory Scale III","NYU Langone Health|Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 50 Years   (Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S14-01975",,"August 2020",,"November 11, 2015",,"February 5, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|New York University Langone Medical Center/ Bellevue Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02603458"
743,"NCT02446314","An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults",,"Completed","Has Results","Cognitive Decline","Dietary Supplement: Placebo|Dietary Supplement: Wild Blueberry Powder - 450mg|Dietary Supplement: Wild Blueberry Powder - 900 mg|Dietary Supplement: Wild Blueberry extract 100mg","Proportion of Words Correctly Recognised.|Total Number of Correct Sequences Recalled|Combined Z Score of Delayed Words Recalled, Words Recognised, and Pictures Recognised.|Combined Z Score of Mean Reaction Time Scores for Incongruent Attention Network and Stroop Task Trials.|Combined Z Score of Proportion of Immediate Words Recalled, Number of Correct Serial 3 and Serial 7 Subtractions, Sternberg Task Coefficent of the Line|Systolic Blood Pressure|Diastolic Blood Pressure|Heart Rate|Positive Affect Score|Negative Affect Score","University of Reading|Naurex, Inc, an affiliate of Allergan plc","All","65 Years to 80 Years   (Older Adult)","Not Applicable","122","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","RDG-001","May 2015","November 2016","July 2017","May 18, 2015","August 8, 2019","August 8, 2019","University of Reading, Reading, Berkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02446314"
744,"NCT04067856","Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery",,"Not yet recruiting","No Results Available","Diabetic Macular Edema|Cataract","Drug: Bevacizumab Injection","Final visual acuity|Final optical coherence tomography central macular thickness|Total number of intravitreal injections over study period","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Allergan|Doheny Image Reading Center","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","22361-01","October 2019","May 2020","November 2020","August 28, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04067856"
745,"NCT03584958","Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries",,"Enrolling by invitation","No Results Available","Glaucoma|Ocular Hypertension",,"Biometry prediction accuracy|Post-operative corneal curvature","Wills Eye|Allergan|The American Society of Cataract and Refractive Surgery Foundation","All","18 Years and older   (Adult, Older Adult)",,"150","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-689E","August 1, 2018","December 31, 2019","June 15, 2020","July 12, 2018",,"June 10, 2019","Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03584958"
746,"NCT03361176","Kybella With Triamcinolone",,"Completed","Has Results","Adiposity","Drug: Injectable sodium deoxycholate|Combination Product: Injectable sodium deoxycholate with Triamcinolone acetate","Change in Clinician-Reported Submental Fat Rating Scale|Change in Clinician-Reported Submental Laxity Rating Scale|Subject Satisfaction Rating Scale","Goldman, Butterwick, Fitzpatrick and Groff|Allergan|Maryland Laser Skin and Vein Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Kybelladose-2017-02","March 26, 2018","October 12, 2018","December 18, 2018","December 4, 2017","May 9, 2019","May 9, 2019","West Dermatology Research Center, San Diego, California, United States|Maryland Dermatology Laser, Skin and Vein Institute, Hunt Valley, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03361176/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03361176"
747,"NCT01879449","Prevalence of Spasticity in Veterans Living in a Long-term Care Facility",,"Completed","No Results Available","Spasticity",,"Spasticity diagnosis|Spasticity treatment awareness and preferences survey","Vanderbilt University|Allergan|Merz North America, Inc.","All","18 Years and older   (Adult, Older Adult)",,"54","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","110470VU|VUMC38674-R|VUMC35131-R","February 2013","May 2014","May 2014","June 17, 2013",,"January 26, 2016","Tennessee State Veterans Home, Murfreesboro, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01879449"
748,"NCT03372941","Hospital Avoidance Strategies for ABSSSI",,"Recruiting","No Results Available","Skin Infection","Drug: Dalbavancin","Healthcare utilization related to ABSSSI|Healthcare cost related to ABSSSI management|Clinical response|Clinical success|Overall patient satisfaction based on standardized measures|Patient satisfaction specific to ABSSSI care|Patient safety|Quality of life measured using RAND SF-36 Survey","Washington University School of Medicine|Barnes-Jewish Hospital|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201709136","March 4, 2019","March 4, 2020","June 4, 2020","December 14, 2017",,"March 5, 2019","Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03372941"
749,"NCT03223298","Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles",,"Recruiting","No Results Available","Pain, Head|Pain Syndrome|Temporomandibular Disorder|Myofascial Pain Syndrome|Myofascial Pain","Drug: Botulinum toxin type A|Drug: 0.9% Sodium Chloride Injection","Comparison in Jaw Pain as reported by patient on Visual Analog Scale|Change in Jaw Function as measured by Jaw Function Limitation Scale|Change in Jaw Function as measured by Maximum interincisal opening|Change in objectively assessed quality of life as measured by Short Form 36","Weill Medical College of Cornell University|New York Presbyterian Hospital|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","110","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1607017383","August 31, 2018","June 30, 2020","December 31, 2020","July 21, 2017",,"September 30, 2019","University of Illinois at Chicago, Chicago, Illinois, United States|Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03223298"
750,"NCT01262339","BTX-A Treatment for Palmar Hyperhidrosis",,"Terminated","Has Results","Primary Focal Hyperhidrosis of the Hands","Drug: BTX-A","Evaluate the Efficacy of Botulinum Toxin A (BTX-A) in the Treatment of Primary Palmar Hyperhidrosis Delivered Via Iontophoresis.","University of Wisconsin, Madison|Allergan|Mattioli","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-2009-0193","November 2010","April 2012","November 2012","December 17, 2010","January 26, 2015","January 26, 2015","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01262339"
751,"NCT02029677","Appetite Suppression / Hormone Study Control Group",,"Active, not recruiting","No Results Available","Morbid Obesity|Bariatric Surgery Patient",,"Hormonal Mechanism of Action for Weight Loss","Oregon Weight Loss Surgery, LLC|Legacy Health System|Allergan","All","18 Years to 69 Years   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","FWA00001280","September 2008","January 2020","January 2020","January 8, 2014",,"March 13, 2019","Oregon Weight Loss Surgery, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02029677"
752,"NCT01780636","Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome",,"Unknown status","No Results Available","Non-relaxing Puborectalis Syndrome","Drug: botulinum toxin","Change in symptoms based on scores using the PAC-SYM and Wexner Constipation questionnaires.|Change in pressures on anal manometry","University of California, Irvine|American Urogynecologic Society|Allergan","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALLERGAN-72570","January 2013","January 2014","July 2014","January 31, 2013",,"January 31, 2013","University of California, Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT01780636"
753,"NCT01701518","A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes",,"Unknown status","No Results Available","Epiretinal Membrane|Macular Edema","Drug: Ozurdex","Best corrected visual acuity|Best corrected visual acuity at 1,4 and 6 months|Retinal thickness and volume|Intraocular pressure (IOP)|Cataract progression (if applicable)","Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto|Allergan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OZ123","October 2012","March 2016","December 2016","October 5, 2012",,"January 5, 2016","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01701518"
754,"NCT00211718","Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain",,"Unknown status","No Results Available","Arthritis|Shoulder Pain","Drug: intra-articular botulinum toxin type a",": Primary Outcomes:|Change in Pain Score|Change in Joint Function|Patient Global Assessment|Secondary Outcomes:|Pain Relief|Change in Health Status Quality of Life-SF36|Change in Disease specific Health Related QOL-WOOS|Function improvement - Range of Motion, SPADI, Simple Shoulder tes|Physican Assessment of Pain and Global Assessment of Improvement|Safety Measure,","Minneapolis Veterans Affairs Medical Center|Allergan|Minnesota Veterans Medical Research and Education Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","U.S. Fed|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IRB Protocol Number 03404B","July 2004",,"June 2007","September 21, 2005",,"November 3, 2005","Minneapolis VAMC, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00211718"
755,"NCT00211679","Intra-articularInjection of Botulinum Toxin Type",,"Unknown status","No Results Available","Arthritis|Pain","Drug: Botulinum Toxin Type A","Change in Pain Score|Change in Joint Function|Patient Global Assessment|Pain Relief|Change in Health Status Quality of Life-SF36|Change in Disease specific Health Related QOL-WOMAC|Function improvement by Timed Stands Test and Range of Motion|Physican Assessment of Pain and Global Assessment of Improvement|Safety Measure,","Minneapolis Veterans Affairs Medical Center|Allergan|Minnesota Veterans Medical Research and Education Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","U.S. Fed|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","Protocol Number 03393B","June 2004",,"June 2007","September 21, 2005",,"September 21, 2005","Minneapolis VAMC, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00211679"
756,"NCT00179114","Vanderbilt University Spasticity Management Program Evaluation Plan",,"Completed","No Results Available","Spasticity","Drug: Botulinum Toxin Type A|Drug: Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)","Total time (in seconds) spent by caregivers to complete a defined care area task at one year followup.|Categorical rating by blinded, independent reviewer of baseline and one-year care area task videos.|Range of motion score for each care area goal, assigned by physical therapist and compared at baseline vs. one-year followup.|Differences in the number of hospital admissions 12 months pre- and 12 months post-program.|Differences in costs associated with caregiving 12 months pre- and 12 months post-treatment.|Difference in Physician's global assessment of spasticity at baseline and one-year followup.","Vanderbilt University|Allergan|Medtronic","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMPEP-9.1","August 2002",,"February 2006","September 15, 2005",,"August 20, 2007","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00179114"
757,"NCT00367133","Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema","IVT","Completed","Has Results","Diabetic Macular Edema","Procedure: Standard of Care Group|Drug: 1mg triamcinolone acetonide|Drug: 4mg triamcinolone acetonide","Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.|Median Change in Visual Acuity Baseline to 2 Years|Distribution of Change in Visual Acuity Baseline to 2 Years|Central Subfield Thickness at 2 Years|Mean Change in Central Subfield Thickness Baseline to 2 Years|Median Change in Central Subfield Thickness Baseline to 2 Years|Overall Central Subfield Thickening Decreased by >=50% Baseline to 2 Years|Central Subfield Thickness < 250 Microns at 2 Years|Change in Visual Acuity From Baseline to 3 Years|Distribution of Visual Acuity Change Baseline to 3 Years|Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years|Change in Central Subfield Thickness on OCT Baseline to 3 Years|Percentage of Eyes With a Change in Central Subfield Thickness on OCT <250 Microns From Baseline to 3 Years","Jaeb Center for Health Research|National Eye Institute (NEI)|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","840","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NEI-105|U10EY018817-03|U10EY014229-07|U10EY014231-09","July 2004","May 2008","October 2008","August 22, 2006","July 9, 2010","August 26, 2016","Jones Eye Institute/University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|SCPMG Regional Offices - Kaiser Permanente, Baldwin Park, California, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|University of California, Irvine, Irvine, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|Doheny Eye Institute, Los Angeles, California, United States|Jules Stein Eye Institute, Los Angeles, California, United States|Southern California Desert Retina Consultants, MC, Palm Springs, California, United States|West Coast Retina Medical Group, Inc., San Francisco, California, United States|Orange County Retina Medical Group, Santa Ana, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Eldorado Retina Associates, P.C., Louisville, Colorado, United States|Connecticut Retina Consultants, New Haven, Connecticut, United States|Connecticut Retina Consultants, New Haven, Connecticut, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Retina Group of Florida, Ft. Lauderdale, Florida, United States|Central Florida Retina Institute, Lakeland, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|International Eye Center, Tampa, Florida, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Retina Consultants of Hawaii, Inc., Aiea, Hawaii, United States|Retina Associates of Hawaii, Inc., Honolulu, Hawaii, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois Retina Associates, Joliet, Illinois, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Maine Vitreoretinal Consultants, Bangor, Maine, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Ophthalmological Institute at Johns Hopkins, Baltimore, Maryland, United States|The Retina Group of Washington, Greenbelt, Maryland, United States|Retina Consultants of Delmarva, P.A., Salisbury, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kresge Eye Institute, Detroit, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Associated Retinal Consultants, Grand Rapids, Michigan, United States|Vision Research Foundation, Royal Oak, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|St. Louis University Eye Institute, St. Louis, Missouri, United States|Barnes Retina Institute, St. Louis, Missouri, United States|Delaware Valley Retina Associates, Lawrenceville, New Jersey, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|University of Rochester, Rochester, New York, United States|Retina Consultants, PLLC, Slingerlands, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|University of North Carolina, Dept. of Ophthalmology, Chapel Hill, North Carolina, United States|Charlotte Eye Ear Nose and Throat Assoc, PA, Charlotte, North Carolina, United States|Horizon Eye Care, PA, Charlotte, North Carolina, United States|Wake Forest University Eye Center, Winston-Salem, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|OSU Eye Physicians and Surgeons, LLC., Dublin, Ohio, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Penn State College of Medicine, Hershey, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Retina Consultants, Providence, Rhode Island, United States|Palmetto Retina Center, Columbia, South Carolina, United States|Carolina Retina Center, Columbia, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|West Texas Retina Consultants P.A., Abilene, Texas, United States|Texas Retina Associates, Arlington, Texas, United States|Retina Research Center, Austin, Texas, United States|Texas Retina Associates, Dallas, Texas, United States|University of Texas Medical Branch, Dept of Ophthalmology and Visual Sciences, Galveston, Texas, United States|Charles A. Garcia, PA & Associates, Houston, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Rocky Mountain Retina Consultants, Salt Lake City, Utah, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin-Madison, Dept. of Ophthalmology, Madison, Wisconsin, United States|Medical College of Wiconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00367133"
758,"NCT00320281","Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.",,"Completed","Has Results","Spinal Cord Injury|Pain","Drug: botulinum toxin A|Other: placebo","Numerical Rating Scale-NRS|Brief Pain Inventory-SF|Short-Form McGill Pain Questionnaire|Modified Leeds Neuropathic Symptoms and Signs Scale|Beck Depression Inventory|Cervical Range of Motion Measurements|Patient Global Outcome Ratings|Respiratory Function Measures|Rehabilitation Interference Scale (RIS)","Craig Hospital|The Craig H. Neilsen Foundation|Allergan","All","15 Years and older   (Child, Adult, Older Adult)","Phase 4","19","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2691","April 2006","August 2008","August 2008","May 3, 2006","July 29, 2013","July 29, 2013","Craig Hospital, Englewood, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00320281"
759,"NCT00105027","The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study","SCORE","Completed","Has Results","Macular Edema, Cystoid|Retinal Vein Occlusion","Other: Standard Care|Drug: intravitreal triamcinolone injection","The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit|Changes From Baseline in Best-corrected ETDRS Visual Acuity Score|Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography|Adverse Ocular Outcomes","The Emmes Company, LLC|National Eye Institute (NEI)|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","682","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEI-99|5U10EY014351-05|5U10EY014404|5U10EY014352","October 2004","February 2009","February 2009","March 4, 2005","January 19, 2011","July 2, 2018","University of Wisconsin, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT00105027/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT00105027/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT00105027"
760,"NCT03508921","Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection",,"Recruiting","No Results Available","Overactive Bladder|Urinary Tract Infections","Procedure: Periprocedural Antibiotics|Drug: Extended Antibiotics|Procedure: Injection of OnabotulinumtoxinA (BTX-A)","Post procedural- urinary tract infection|Urinary retention|Recurrent urinary tract infection","Vanderbilt University Medical Center|The Allergan Foundation|Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction","All","18 Years and older   (Adult, Older Adult)","Phase 4","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","00011112222","July 1, 2018","June 1, 2020","September 1, 2020","April 26, 2018",,"August 26, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03508921/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03508921"
761,"NCT03347747","Facial Asymmetrical Clinical Evaluation Study","FACE","Unknown status","No Results Available","Loss of Facial Adipose Tissue","Other: Study Photography + Personal & Medical History Collection","Study Photos and Questionnaire Data Processing","McDaniel Institute of Anti-Aging Research|Allergan|Merz Aesthetics Inc.|ThermiGen, LLC","All","45 Years to 80 Years   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","FCLVOL-2017","June 9, 2017","June 30, 2018","July 31, 2018","November 20, 2017",,"November 20, 2017","McDaniel Institute of Anti-Aging Research, Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03347747"
762,"NCT02342223","Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy",,"Completed","Has Results","HIV Facial Lipoatrophy","Device: Voluma","Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS) by Prinicple Investigator|Percentage of Participants With Device or Procedure Related Adverse Events|Number of Participants Achieving Grade 1 in the Carruthers Lipoatrophy Severity Scale (CLSS)|Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS) by Participants|Subject Satisfaction Questionnaire (SSQ)|Dermatology Life Quality Index (DLQI)","Jared Jagdeo, MD, MS|Allergan|VA Northern California Health Care System|East Bay Institute for Research and Education","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","U.S. Fed|Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allergan-97727","February 2015","May 2016","May 2016","January 19, 2015","January 16, 2017","January 16, 2017","Sacramento VA Medical Center, Mather, California, United States",,"https://ClinicalTrials.gov/show/NCT02342223"
763,"NCT01945866","Phase II Combination Steroid and Anti-VEGF for Persistent DME",,"Completed","Has Results","Diabetic Macular Edema","Drug: intravitreal ranibizumab 0.3 mg|Drug: dexamethasone intravitreal implant|Procedure: Sham injection","Mean Change in Visual Acuity Letter Score|At 24 Weeks After Randomization, Number of Eyes With at Least 10 and at Least 15 Letter Gain (Increase) or Loss (Decrease) in E-ETDRS Letter Score Visual Acuity.|Visual Acuity Area Under the Curve (AUC) Between Randomization and 24 Weeks|Mean Change in OCT CSF Thickness, Adjusted for Thickness at Time of Randomization|Number of Eyes With ≥1 and ≥2 logOCT Step Gain or Loss in CSF Thickness|Eyes With OCT CSF Thickness < the Gender-specific Spectral Domain OCT Equivalent of 250 Microns on Zeiss Stratus|OCT CSF Thickness Area Under the Curve Between Randomization and 24 Weeks","Jaeb Center for Health Research|Allergan|Genentech, Inc.|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","129","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DRCR.net Protocol U|EY14231|EY23207|EY18817","February 2014","June 5, 2017","June 5, 2017","September 19, 2013","September 25, 2018","September 25, 2018","Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|Northern California Retina Vitreous Associates, Mountain View, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Retinal Consultants Medical Group, Inc., Sacramento, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Retina Group of New England, New London, Connecticut, United States|New England Retina Associates, Norwich, Connecticut, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville, Florida, United States|Central Florida Retina Institute, Lakeland, Florida, United States|Ocala Eye Retina Consultants, Ocala, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|National Eye Institute/National Institutes of Health, Bethesda, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Retina Vitreous Center, Grand Blanc, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|The Retina Institute, Saint Louis, Missouri, United States|The Institute of Ophthalmology and Visual Science (IOVS), Newark, New Jersey, United States|MaculaCare, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Charlotte Eye Ear Nose and Throat Assoc, PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Associates of Utah, P.C., Salt Lake City, Utah, United States|Virginia Retina Center, Leesburg, Virginia, United States|Retina Institute of Virginia, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Spokane Eye Clinic, Spokane, Washington, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01945866/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01945866/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01945866"
764,"NCT02910921","Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit","Migraine Alert","Completed","No Results Available","Migraine Disorders|Headache Disorders, Primary|Headache Disorders|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases",,"AUC of individual prediction models using cross validation data on environmental and physiological variables.|AUC of individual prediction models using post prediction data on environmental and physiological variables.","Second Opinion Health|Mayo Clinic|University of Southern California|Allergan","All","18 Years and older   (Adult, Older Adult)",,"19","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-005803","November 2016","July 2018","July 31, 2018","September 22, 2016",,"August 6, 2018","Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02910921"
765,"NCT00444600","Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema","LRT for DME","Completed","Has Results","Diabetic Retinopathy|Diabetic Macular Edema","Drug: Triamcinolone Acetonide + laser|Drug: Ranibizumab + laser|Drug: Sham injection + laser|Drug: Ranibizumab + deferred laser","Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity|Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline|Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema|Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score|Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness|Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity|Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator|Change in Retinal Thickening of Central Subfield on Optical Coherence Tomography From Baseline to 1 Year|Number of Injections in First Year|Number of Laser Treatments Received Prior to the 1 Year Visit|Percentage of Eyes Receiving Laser at the 48 Week Visit (%)|Mean Optical Coherence Tomography Retinal Volume at 1 Year|Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year","Jaeb Center for Health Research|National Eye Institute (NEI)|Allergan|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","691","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NEI-133|U10EY018817-03|U10EY014229-07|U10EY014231-09","March 2007","December 2009","February 2014","March 8, 2007","July 12, 2011","October 7, 2019","Sall Research Medical Center, Artesia, California, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|University of California, Irvine, Irvine, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|Southern California Desert Retina Consultants, MC, Palm Springs, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Retina Vitreous Consultants, Fort Lauderdale, Florida, United States|Retina Consultants of Southwest Florida, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville, Florida, United States|Central Florida Retina Institute, Lakeland, Florida, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Illinois Retina Associates, Joliet, Illinois, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Retina Consultants of Delmarva, P.A., Salisbury, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Eyesight Ophthalmic Services, PA, Portsmouth, New Hampshire, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|University of North Carolina, Dept of Ophthalmology, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Wake Forest University Eye Center, Winston-Salem, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Penn State College of Medicine, Hershey, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Retina Consultants, Providence, Rhode Island, United States|Palmetto Retina Center, Columbia, South Carolina, United States|Carolina Retina Center, Columbia, South Carolina, United States|Southeastern Retina Associates, PC, Kingsport, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|West Texas Retina Consultants P.A., Abilene, Texas, United States|Retina Research Center, Austin, Texas, United States|Texas Retina Associates, Dallas, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Vitreoretinal Consultants, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00444600"
766,"NCT00445003","Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy","LRTforDME+PRP","Completed","Has Results","Proliferative Diabetic Retinopathy|Diabetic Macular Edema","Drug: Ranibizumab|Drug: Triamcinolone Acetonide|Behavioral: Sham injection|Procedure: Focal/grid laser","Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks|Additional Treatments for Diabetic Macular Edema|Change in Optical Coherence Tomography Central Subfield Thickness|Total Optical Coherence Tomography Retinal Volume|Change in Visual Acuity From Baseline|Eyes With Anti-vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema|Number of Eyes With Additional Number of Treatments for Diabetic Macular Edema|Change in Optical Coherence Tomography Retinal Volume","Jaeb Center for Health Research|National Eye Institute (NEI)|Genentech, Inc.|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","333","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NEI-134|U10EY018817-03|U10EY014229-07|U10EY014231-09","March 2007","October 2009","July 2010","March 8, 2007","July 13, 2011","August 26, 2016","Sall Research Medical Center, Artesia, California, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|University of California, Irvine, Irvine, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|Southern California Desert Retina Consultants, MC, Palm Springs, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Eldorado Retina Associates, P.C., Louisville, Colorado, United States|Retina Consultants of Southwest Florida, Fort Myers, Florida, United States|Retina Vitreous Consultants, Ft. Lauderdale, Florida, United States|Central Florida Retina Institute, Lakeland, Florida, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|Illinois Retina Associates, Joliet, Illinois, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Maine Vitreoretinal Consultants, Bangor, Maine, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Ophthalmological Institute at Johns Hopkins, Baltimore, Maryland, United States|Retina Consultants of Delmarva, P.A., Salisbury, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Retina Center, PA, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Eyesight Ophthalmic Services, PA, Portsmouth, New Hampshire, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|University of North Carolina, Dept of Ophthalmology, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Horizon Eye Care, PA, Charlotte, North Carolina, United States|Wake Forest University Eye Center, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|OSU Eye Physicians and Surgeons, LLC., Dublin, Ohio, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Penn State College of Medicine, Hershey, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Retina Consultants, Providence, Rhode Island, United States|Palmetto Retina Center, Columbia, South Carolina, United States|Carolina Retina Center, Columbia, South Carolina, United States|Southeastern Retina Associates, PC, Kingsport, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|West Texas Retina Consultants P.A., Abilene, Texas, United States|Texas Retina Associates, Arlington, Texas, United States|Retina Research Center, Austin, Texas, United States|Texas Retina Associates, Dallas, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Vitreoretinal Consultants, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Virginia Retina Center, Leesburg, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00445003"
767,"NCT02344511","Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","AHOM","Withdrawn","No Results Available","Osteomyelitis","Drug: Dalbavancin|Drug: cefazolin, nafcillin, oxacillin or vancomycin","Number of patients with clinical improvement at Day 8|Number of clinical responders|Average reduction in C-reactive Protein (CRP) relative to the highest value|Number of clinical responders by pathogen|Number of Participants with Adverse Events","Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)|Durata Therapeutics Inc., an affiliate of Allergan plc","All","2 Years to 16 Years   (Child)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DUR001-304","March 2016","October 2018","April 2019","January 26, 2015",,"September 23, 2016",,,"https://ClinicalTrials.gov/show/NCT02344511"
768,"NCT01373424","The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias","DCP","Active, not recruiting","No Results Available","Dystonia",,"Observational","Hyder A. Jinnah, MD, PhD|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|Allergan|Dystonia Study Group|Emory University","All","18 Years and older   (Adult, Older Adult)",,"3165","Other|NIH|Industry","Observational","Observational Model: Other|Time Perspective: Other","IRB00046266|U54TR001456|RDCRN#6301|U54NS065701","January 2011","December 1, 2019","December 1, 2019","June 15, 2011",,"September 11, 2019","University of Alabama, Birmingham, Birmingham, Alabama, United States|Mayo Clinic, Arizona, Scottsdale, Arizona, United States|Parkinson's and Movement Disorders Institute, Fountain Valley, California, United States|University of California, San Diego, La Jolla, California, United States|University of Colorado, Denver, Denver, Colorado, United States|University of Florida, Gainesville, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|National Institutes of Health, Bethesda, Maryland, United States|Parkinson's and Movement Disorders Center of Maryland, Elkridge, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Wake Forest, Winston-Salem, North Carolina, United States|Sanford Health - Fargo, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Pennsylvania, Parkinson's Disease and Movement Disorders Center, Philadelphia, Pennsylvania, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas, Southwestern, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|University of Texas, Houston, Texas, United States|James Madison University, Harrisonburg, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Westmead, Australia|University of Alberta, Edmonton, Alberta, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Hopital de la Salpetriere, Paris, France|University Hospital of Schleswig-Holstein, Luebeck, Germany|University of Rome, Rome, Italy|University College London Institute of Neurology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01373424"
769,"NCT03518034","A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","TRAVERSE","Recruiting","No Results Available","Hypogonadism|Cardiovascular Diseases","Drug: Testosterone|Drug: Placebo","Time to Major Adverse Cardiac Event (MACE)|Assessing cardiovascular safety|Assessing prostate safety","AbbVie|Acerus Pharmaceuticals Corporation|Allergan Sales, LLC|Endo Pharmaceuticals|Upsher-Smith Laboratories","Male","45 Years to 80 Years   (Adult, Older Adult)","Phase 4","6000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-100","May 3, 2018","June 30, 2022","June 30, 2022","May 8, 2018",,"January 13, 2020","Wright Clinical Research, LLC /ID# 210864, Alabaster, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 202982, Birmingham, Alabama, United States|Cahaba Research, Inc. /ID# 167928, Birmingham, Alabama, United States|Atlanta VAMC /ID# 170318, Decatur, Alabama, United States|G & L Research, LLC /ID# 170365, Foley, Alabama, United States|Fundamental Research /ID# 170504, Gulf Shores, Alabama, United States|Urology Centers of Alabama /ID# 206197, Homewood, Alabama, United States|Longwood Research /ID# 201754, Huntsville, Alabama, United States|Medical Affiliated Research Center, Inc. /ID# 170569, Huntsville, Alabama, United States|Mostellar Medical Center /ID# 170329, Irvington, Alabama, United States|Terence T. Hart, MD /ID# 201561, Tuscumbia, Alabama, United States|Alaska Urological Institute /ID# 167894, Anchorage, Alaska, United States|East Valley Family Physicians /ID# 170530, Chandler, Arizona, United States|Fountain Hills Family Practice P.C /ID# 170419, Fountain Hills, Arizona, United States|Horizon Clinical Research Asoc /ID# 202937, Gilbert, Arizona, United States|Lenzmeier Family Medicine /ID# 202945, Glendale, Arizona, United States|Desert Clinical Rsch, LLC /ID# 170428, Mesa, Arizona, United States|Phoenix Medical Group, PC /ID# 170516, Peoria, Arizona, United States|Phoenix VA Healthcare /ID# 202962, Phoenix, Arizona, United States|Elite Clinical Studies, LLC /ID# 168058, Phoenix, Arizona, United States|Family Practice Specialists /ID# 167859, Phoenix, Arizona, United States|Central Phoenix Medical Clinic /ID# 170333, Phoenix, Arizona, United States|Tatum Highlands Medical Assoc /ID# 208277, Phoenix, Arizona, United States|Fiel Family & Sports Medicine /ID# 203034, Tempe, Arizona, United States|Quality of Life Medical & Research Center /ID# 167915, Tucson, Arizona, United States|Arizona Research Assoc /ID# 170421, Tucson, Arizona, United States|Veterans Affairs (VA) Health Care System - Tucson /ID# 167600, Tucson, Arizona, United States|Verde Valley Medical Center /ID# 202955, Tucson, Arizona, United States|Eclipse Clinical Research /ID# 170381, Tucson, Arizona, United States|B.G. Clinical Research Center, LLC /ID# 170461, Little Rock, Arkansas, United States|Preferred Research Partners In /ID# 170539, Little Rock, Arkansas, United States|Applied Research Center of Arkansas /ID# 170487, Little Rock, Arkansas, United States|Pacific Oaks Medical Group /ID# 170540, Beverly Hills, California, United States|TriWest Research Associates /ID# 170498, El Cajon, California, United States|Diagnamics Inc. /ID# 205836, Encinitas, California, United States|Cedars-Sinai Medical Group (MGOE) /ID# 170383, Encino, California, United States|St. Jude Hospital Yorba Linda /ID# 170437, Fullerton, California, United States|Arizona Internal Medicine Specialists, LLC- Glendale /ID# 203011, Glendale, California, United States|Allied Clinical Research /ID# 170519, Gold River, California, United States|Marvel Clinical Research, LLC /ID# 170324, Huntington Beach, California, United States|Irvine Center for Clinical Research /ID# 170368, Irvine, California, United States|Clinical Trials Research /ID# 210862, Lincoln, California, United States|Torrance Clinical Research Institute, Inc. /ID# 170307, Lomita, California, United States|VA Long Beach Healthcare System /ID# 170374, Long Beach, California, United States|Tower Urology /ID# 170330, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System /ID# 167948, Los Angeles, California, United States|Facey Medical Foundation /ID# 203004, Mission Hills, California, United States|Catalina Research Institute, LLC /ID# 170501, Montclair, California, United States|NewportNativeMD, Inc. /ID# 168110, Newport Beach, California, United States|Translational Res Group, Inc. /ID# 168115, North Hollywood, California, United States|Valley Clinical Trials, Inc /ID# 201587, Northridge, California, United States|Amicis Research /Id# 170587, Northridge, California, United States|Diabetes Associates Medical Gr /ID# 170499, Orange, California, United States|Desert Oasis Healthcare Medica /ID# 170841, Palm Springs, California, United States|Saviers Medical Group /ID# 170327, Port Hueneme, California, United States|Center for Clinical Trials of Sacramento, Inc. /ID# 168108, Sacramento, California, United States|Integrated Research Center, Inc. /ID# 170391, San Diego, California, United States|Ritchken & First MD's /ID# 201341, San Diego, California, United States|San Diego Sexual Medicine /ID# 170457, San Diego, California, United States|San Diego Clinical Trials /ID# 170468, San Diego, California, United States|Comprehensive Oncology Centre - Vratsa EOOD /ID# 168252, San Diego, California, United States|West Coast Research LLC /ID# 167903, San Ramon, California, United States|Syrentis Clinical Research /ID# 168056, Santa Ana, California, United States|Care Access Research, Santa Clarita /ID# 167916, Santa Clarita, California, United States|Encompass Clinical Research /ID# 202203, Spring Valley, California, United States|Stanford University /ID# 167595, Stanford, California, United States|St. Joseph's Medical Associate /ID# 170424, Stockton, California, United States|Olive View UCLA Medical Center /ID# 206131, Sylmar, California, United States|Millennium Clinical Trials /ID# 210695, Thousand Oaks, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center /ID# 170400, Torrance, California, United States|Bayview Research Group LLC /ID# 203036, Valley Village, California, United States|Anthony Mills, MD, Inc. /ID# 170571, West Hollywood, California, United States|Lynn Institute of Denver /ID# 170312, Aurora, Colorado, United States|Colorado Springs Family Practice /ID# 168231, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies /ID# 170477, Colorado Springs, Colorado, United States|Urology Associates, P.C. /ID# 170484, Englewood, Colorado, United States|Foothills Urology /ID# 170406, Golden, Colorado, United States|New West Physicians /ID# 203032, Golden, Colorado, United States|Complete Family Care Research /ID# 170371, Northglenn, Colorado, United States|Aventura Heart Center /ID# 170354, Aventura, Florida, United States|MB Clinical Research /ID# 202970, Boca Raton, Florida, United States|Imagine Research of Palm Beach County /ID# 212140, Boynton Beach, Florida, United States|Helix Biomedics, LLC /ID# 202310, Boynton Beach, Florida, United States|Meridien Research Inc. - Brooksville /ID# 170556, Brooksville, Florida, United States|Innovative Research /ID# 170360, Clearwater, Florida, United States|Tampa Bay Medical Res, Inc /ID# 170512, Clearwater, Florida, United States|ALL Medical Research /ID# 170493, Cooper City, Florida, United States|Century Clinical Research, Inc /ID# 167597, Daytona Beach, Florida, United States|Seidman Clinical Trials,Delray /ID# 170418, Delray Beach, Florida, United States|S&W Clinical Research /ID# 170311, Fort Lauderdale, Florida, United States|Invesclinic, U.S., LLC /ID# 202553, Fort Lauderdale, Florida, United States|Office of Sam N. Lerman, MD /ID# 170373, Fort Lauderdale, Florida, United States|University of Florida - Hull Rd /ID# 170518, Gainesville, Florida, United States|Malcom Randall VAMC /ID# 170645, Gainesville, Florida, United States|International Research Associates, LLC - Hialeah /ID# 170543, Hialeah, Florida, United States|Indago Research and Health Cen /ID# 170420, Hialeah, Florida, United States|The University of Florida Heal /ID# 170450, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research /ID# 170446, Jacksonville, Florida, United States|Solutions Through Adv Rch /ID# 201590, Jacksonville, Florida, United States|Care Partners Clinical Researc /ID# 202520, Jacksonville, Florida, United States|Care Research center Inc. /ID# 167924, Kendall, Florida, United States|Meridien Research /ID# 170370, Kenneth City, Florida, United States|Meridien Research /ID# 167846, Lakeland, Florida, United States|South Florida Wellness & Clinic /ID# 170510, Margate, Florida, United States|Panax Clinical Research /ID# 170525, Miami, Florida, United States|Veritas Research, Corp. /ID# 202975, Miami, Florida, United States|Pharmax Research Clinic /ID# 170403, Miami, Florida, United States|APF Research, LLC. /ID# 170412, Miami, Florida, United States|Well Pharma Med Res Corp /ID# 170337, Miami, Florida, United States|Floridian Research Institute LLC /ID# 167882, Miami, Florida, United States|Advanced Pharma CR, LLC /ID# 167840, Miami, Florida, United States|Applemed Research Inc. /ID# 170364, Miami, Florida, United States|Future Care Solution LLc /ID# 170361, Miami, Florida, United States|New Horizon Research Center /ID# 170574, Miami, Florida, United States|Office of Francisco G Miranda, /ID# 203184, Miami, Florida, United States|International Research Associates, LLC /ID# 170563, Miami, Florida, United States|Bravo Health Care Center /ID# 202201, North Bay Village, Florida, United States|Harmony Clinical Research, Inc. /ID# 201816, North Miami Beach, Florida, United States|Endocrine Associates of Florida, P.A. /ID# 167839, Ocoee, Florida, United States|Sensible Healthcare /ID# 170402, Ocoee, Florida, United States|Omega Research Consultants /ID# 170340, Orlando, Florida, United States|IMIC Inc. /ID# 167899, Palmetto Bay, Florida, United States|South Broward Research /ID# 170480, Pembroke Pines, Florida, United States|DBC Research USA /ID# 170332, Pembroke Pines, Florida, United States|South Florida Research Solutio /ID# 167972, Pembroke Pines, Florida, United States|DBC Research USA Corporation /ID# 170435, Pembroke Pines, Florida, United States|Synexus Clinical Research US, Inc /ID# 209955, Pinellas Park, Florida, United States|Synexus Clinical Research US, Inc /ID# 210249, Pinellas Park, Florida, United States|DMI Research, Inc. /ID# 170893, Pinellas Park, Florida, United States|Clinical Research Center FL /ID# 202979, Pompano Beach, Florida, United States|St. Johns Center /ID# 212654, Ponte Vedra, Florida, United States|Charlotte Heart & Vascular Institute /ID# 202965, Port Charlotte, Florida, United States|Health Awareness, Inc. /ID# 170507, Port Saint Lucie, Florida, United States|Prof Health Care of Pinellas /ID# 167895, Saint Petersburg, Florida, United States|Advance Medical Research /ID# 170532, Saint Petersburg, Florida, United States|Precision Clinical Research /ID# 170469, Sunrise, Florida, United States|Meridien Research Inc. - Tampa /ID# 170377, Tampa, Florida, United States|Winter Park Urology Center/Charter Research /ID# 210542, Winter Park, Florida, United States|Atlanta Vascular Research Foundation - Atlanta Clinical Research Centers /ID# 170894, Atlanta, Georgia, United States|Masters of Clinical Research, Inc. /ID# 167950, Augusta, Georgia, United States|Endocrine Consustants Research /ID# 168147, Columbus, Georgia, United States|Physicians Research Associates, LLC /ID# 170313, Lawrenceville, Georgia, United States|Atlanta Center for Clinical Research /ID# 202984, Roswell, Georgia, United States|Meridian Clinical Research, LLC /ID# 167854, Savannah, Georgia, United States|Meridian Clinical Research, LLC /ID# 170548, Savannah, Georgia, United States|Herman Clinical Research, LLC /ID# 170474, Suwanee, Georgia, United States|North Georgia Clin Res /ID# 170467, Woodstock, Georgia, United States|East-West Medical Research Institute /ID# 202959, Honolulu, Hawaii, United States|Institute of Arthritis Researc /ID# 170495, Idaho Falls, Idaho, United States|Solaris Clinical Research /ID# 202936, Meridian, Idaho, United States|Biofortis, Inc. /ID# 167856, Addison, Illinois, United States|Synexus Clinical Research US, Inc /ID# 209956, Chicago, Illinois, United States|Chicago Clinical Research Institute, Inc /ID# 203190, Chicago, Illinois, United States|Loretto Hospital.Affnity Clinical Research Institute /ID# 207262, Chicago, Illinois, United States|Midwest Endocrinology /ID# 202992, Crystal Lake, Illinois, United States|Pharmakon Inc /ID# 206149, Evergreen Park, Illinois, United States|Clinical Investigation Specialists, Inc. /ID# 170631, Gurnee, Illinois, United States|Edward Hines Jr. VA Hospital /ID# 167944, Hines, Illinois, United States|Koch Family Medicine SC /ID# 202205, Morton, Illinois, United States|Affinity Clinical Research /ID# 202552, Oak Brook, Illinois, United States|American Health Network of IN /ID# 170359, Avon, Indiana, United States|American Health Network of IN /ID# 170483, Avon, Indiana, United States|Investigators Research Group, LLC /ID# 170557, Brownsburg, Indiana, United States|Investigative Clinical Research of Indiana, LLC /ID# 170473, Elwood, Indiana, United States|Deaconess Clinic Downtown /ID# 167855, Evansville, Indiana, United States|Clinical Research Advantage, Inc. /ID# 170656, Evansville, Indiana, United States|MediSphere Medical Research Center /ID# 170317, Evansville, Indiana, United States|Richard L. Roudebush VA Medical Center /ID# 203020, Indianapolis, Indiana, United States|Urology of Indiana /ID# 203469, Indianapolis, Indiana, United States|First Urology,PSC /ID# 167719, Jeffersonville, Indiana, United States|LaPorte County Institute for Clinical Research, Inc. /ID# 170331, Michigan City, Indiana, United States|American Health Network of Ind /ID# 170578, Muncie, Indiana, United States|West Broadway Clinic /ID# 202204, Council Bluffs, Iowa, United States|IA Diabetes & Endo Res Ctr /ID# 170462, West Des Moines, Iowa, United States|The Iowa Clinic, PC /ID# 202986, West Des Moines, Iowa, United States|Heartland Research Associates, LLC /ID# 203031, Augusta, Kansas, United States|PRN Professional Research Network of Kansas, LLC /ID# 170415, Wichita, Kansas, United States|Drs. Borders, Hood, and Assoc /ID# 170536, Lexington, Kentucky, United States|The Research Grp of Lexington /ID# 202900, Lexington, Kentucky, United States|University of Louisville /ID# 170607, Louisville, Kentucky, United States|Research Integrity, LLC /ID# 168264, Owensboro, Kentucky, United States|Alexandria Cardiology Clinic /ID# 170463, Alexandria, Louisiana, United States|Centex Studies, Inc - Lake Charles /ID# 170416, Lake Charles, Louisiana, United States|Tandem Clinical Research, LLC /ID# 206203, Marrero, Louisiana, United States|Tulane School of Medicine /ID# 170472, New Orleans, Louisiana, United States|Chesapeake Urology Associates /ID# 211874, Baltimore, Maryland, United States|Maryland Cardiovascular Specialists /ID# 168057, Baltimore, Maryland, United States|Johns Hopkins University /ID# 203006, Baltimore, Maryland, United States|Centennial Medical Group /ID# 170568, Elkridge, Maryland, United States|Massachusetts General Hospital /ID# 167969, Boston, Massachusetts, United States|NECCR PrimaCare Research, LLC /ID# 170326, Fall River, Massachusetts, United States|Oakland Medical Research /ID# 170389, Troy, Michigan, United States|Arcturus Healthcare, PLC, Troy /ID# 170431, Troy, Michigan, United States|Olive Branch Family Med Ctr /ID# 170409, Olive Branch, Mississippi, United States|David M. Headley, MD, P.A. /ID# 205428, Port Gibson, Mississippi, United States|West Florissant Internists /ID# 170314, Bridgeton, Missouri, United States|Med Research One /ID# 167923, Florissant, Missouri, United States|Saint Louis University School of Medicine /ID# 170531, Saint Louis, Missouri, United States|Radiant Research, Inc. /ID# 209957, Saint Louis, Missouri, United States|Mercy Clinic Endocrinology, LLC /ID# 170367, Springfield, Missouri, United States|Montana Medical Research /ID# 170579, Missoula, Montana, United States|Skyline Medical Center /ID# 168234, Elkhorn, Nebraska, United States|VA Nebraska-Western Iowa Health Care System /ID# 167892, Omaha, Nebraska, United States|Heartland Clinical Research /ID# 170541, Omaha, Nebraska, United States|Meridian Clinical Research, LLC - Omaha /ID# 167836, Omaha, Nebraska, United States|Clinical Research Advantage, Inc. /ID# 202966, Omaha, Nebraska, United States|McGill Family Practice, P.C. /ID# 170560, Papillion, Nebraska, United States|Synexus Clinical Research US, Inc. /ID# 210232, Henderson, Nevada, United States|Palm Research Center, Inc. /ID# 168224, Las Vegas, Nevada, United States|AB Clinical Trials /ID# 170612, Las Vegas, Nevada, United States|Alas Science Clinical Research /ID# 170352, Las Vegas, Nevada, United States|Clinical Research of So Nevada /ID# 167594, Las Vegas, Nevada, United States|Advanced Biomedical Research of America /ID# 202202, Las Vegas, Nevada, United States|Sheldon Freedman MD, ltd /ID# 170434, Las Vegas, Nevada, United States|Allied Clinical Research /ID# 210859, Reno, Nevada, United States|Internal Medicine Associates /ID# 170538, Bridgeton, New Jersey, United States|Medicor Cardiology /ID# 170436, Bridgewater, New Jersey, United States|Cooper Health System /ID# 170417, Camden, New Jersey, United States|Union Square Medical Associates,PC /ID# 170346, Elizabeth, New Jersey, United States|Amici Clinical Research /ID# 170452, Warren, New Jersey, United States|NM Clin Res & Osteoporosis Center, Inc /ID# 170386, Albuquerque, New Mexico, United States|Albany VA Medical Center /ID# 167862, Albany, New York, United States|James J. Peters VA Medical Center /ID# 202980, Bronx, New York, United States|NY Total Medical Care, PC /ID# 170423, Brooklyn, New York, United States|AccuMed Research Associates /ID# 202200, Garden City, New York, United States|Office of Bruce R. Gilbert, MD /ID# 202963, Great Neck, New York, United States|Synexus Clinical Research US, Inc. /ID# 210293, Jamaica, New York, United States|Mid Hudson Medical Research, PLLC /ID# 170511, New Windsor, New York, United States|Manhattan Medical Research /ID# 167956, New York, New York, United States|DiGiovanna Institute for Medic /ID# 170613, North Massapequa, New York, United States|Premier Medical Group of the Hudson Valley PC /ID# 170456, Poughkeepsie, New York, United States|Endocrine Assc Long Island PC /ID# 170425, Smithtown, New York, United States|Randolph Health Internal Medic /ID# 168227, Asheboro, North Carolina, United States|PMG Research of Charlotte /ID# 202985, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC /ID# 170349, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC /ID# 170634, Charlotte, North Carolina, United States|Rapha Institute for Clinical Research /ID# 170362, Fayetteville, North Carolina, United States|Bland Clinic, PA /ID# 204943, Greensboro, North Carolina, United States|Medication Management, LLC /ID# 205260, Greensboro, North Carolina, United States|Triad Clinical Trials /ID# 170376, Greensboro, North Carolina, United States|OnSite Clinical Solutions, LLC - Charlotte /ID# 170449, Hickory, North Carolina, United States|OnSite Clinical Solutions, LLC - Charlotte /ID# 202968, Hickory, North Carolina, United States|Northstate Clinical Research /ID# 170414, Lenoir, North Carolina, United States|Research Institute of the Caro /ID# 170341, Mooresville, North Carolina, United States|Carteret Medical Group LLC /ID# 170771, Morehead City, North Carolina, United States|Diabetes and Endo Consultants /ID# 201589, Morehead City, North Carolina, United States|Family Medical Associates of Raleigh /ID# 203979, Raleigh, North Carolina, United States|Goshen Medical Center - Vineland /ID# 170342, Whiteville, North Carolina, United States|PMG Research of Wilmington LLC /ID# 170492, Wilmington, North Carolina, United States|Radiant Research, Inc /ID# 202976, Akron, Ohio, United States|New Horizons Clinical Research /ID# 170460, Blue Ash, Ohio, United States|Clinical Research Trials (CRT) /ID# 170533, Canton, Ohio, United States|Diabetes and Endocrinology Associates of Stark County Inc /ID# 170356, Canton, Ohio, United States|Cincinnati Veterans Affairs Medical Center /ID# 170385, Cincinnati, Ohio, United States|Synexus Research Cincinnati /ID# 209958, Cincinnati, Ohio, United States|Rapid Medical Research, INC /ID# 170513, Cleveland, Ohio, United States|Endocrinology Associates, Inc. /ID# 168113, Columbus, Ohio, United States|Synexus Clinical Research US, Inc. /ID# 210234, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center - Department of Urology /ID# 170551, Columbus, Ohio, United States|Aventiv Research, Inc. /ID# 170338, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 168111, Columbus, Ohio, United States|PriMed Clinical Research /ID# 170310, Dayton, Ohio, United States|Dayton VA Medical Center /ID# 168251, Dayton, Ohio, United States|WVVA Healthcare Alliance dba. /ID# 168246, Lewisburg, Ohio, United States|Awasty Research Network, LLC /ID# 210860, Marion, Ohio, United States|Advanced Medical Research, LLC /ID# 170488, Maumee, Ohio, United States|Cardiovascular Research Center, LLC /ID# 203035, Toledo, Ohio, United States|Intend Research /ID# 170581, Norman, Oklahoma, United States|IPS Research Company /ID# 168117, Oklahoma City, Oklahoma, United States|Oklahoma City Clinic /ID# 170497, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute (LHSI) /ID# 202973, Oklahoma City, Oklahoma, United States|Urologic Consultants of Southeastern Pennsylvania /ID# 170351, Bala-Cynwyd, Pennsylvania, United States|Heritage Valley Medical Group /ID# 170387, Beaver, Pennsylvania, United States|AJH/Feasterville Family Health /ID# 168235, Feasterville, Pennsylvania, United States|Indiana-Armstrong Endocrinolgy /ID# 168249, Indiana, Pennsylvania, United States|Richard M Kastelic, MD and Ass /ID# 170382, Johnstown, Pennsylvania, United States|Family Medical Associates /ID# 170396, Levittown, Pennsylvania, United States|Founders Research Corp /ID# 170610, Philadelphia, Pennsylvania, United States|Allegheny Health Network /ID# 210544, Pittsburgh, Pennsylvania, United States|VA Pittsburgh HealthcareSystem /ID# 205837, Pittsburgh, Pennsylvania, United States|SFM Clinical Trials /ID# 168250, Scotland, Pennsylvania, United States|Frontier Clinical Research, LLC - Scottdale /ID# 167864, Scottdale, Pennsylvania, United States|Frontier Clinical Research /ID# 167842, Smithfield, Pennsylvania, United States|Ocean State Clin Rese Part,LLC /ID# 170547, Lincoln, Rhode Island, United States|Synexus Clinical Research US, Inc. /ID# 210228, Anderson, South Carolina, United States|Synexus Clinical Research US, Inc. /ID# 210230, Anderson, South Carolina, United States|Medical Research South, LLC /ID# 203068, Charleston, South Carolina, United States|Synexus Clinical Research US, Inc. /ID# 210237, Greer, South Carolina, United States|DeGarmo Institute of Med Res /ID# 170528, Greer, South Carolina, United States|Self Medical Group - Advanced /ID# 170336, Hodges, South Carolina, United States|Main Street Physician's Care - Waterway /ID# 210441, Little River, South Carolina, United States|PMG Research of Charleston /ID# 170572, Mount Pleasant, South Carolina, United States|Palmetto Institute of Clinical Research, Inc. /ID# 170395, Pelzer, South Carolina, United States|Palmetto Clinical Research /ID# 170524, Summerville, South Carolina, United States|Regional Health - Black Hills Cardiovascular Research /ID# 170576, Rapid City, South Dakota, United States|Holston Medical Group /ID# 170565, Bristol, Tennessee, United States|University Diabetes & Endocrine Consultants /ID# 170392, Chattanooga, Tennessee, United States|Consolidated Medical Practices of Memphis, PLLC /ID# 170328, Collierville, Tennessee, United States|PMG Research of Knoxville /ID# 170393, Jefferson City, Tennessee, United States|Holston Medical Group Clinical /ID# 168165, Kingsport, Tennessee, United States|New Phase Research & Developme /ID# 170526, Knoxville, Tennessee, United States|PMG Research of Knoxville /ID# 170451, Knoxville, Tennessee, United States|PMG Research of Knoxville /ID# 170514, Knoxville, Tennessee, United States|Baptist Memorial Medical Group /ID# 168061, Memphis, Tennessee, United States|Clinical Neuroscience Solution /ID# 170559, Memphis, Tennessee, United States|Methodist Medical Group /ID# 168148, Memphis, Tennessee, United States|University of Tennessee Health /ID# 170321, Memphis, Tennessee, United States|Trinity Clinical Research, LLC /ID# 170369, Tullahoma, Tennessee, United States|Arlington Family Health Pavilion /ID# 170366, Arlington, Texas, United States|Premier Family Physicians /ID# 167946, Austin, Texas, United States|Texas Diabetes and Endocrinology /ID# 170517, Austin, Texas, United States|DiscoveResearch, Inc. /ID# 170320, Beaumont, Texas, United States|Pioneer Research Solutions, Inc. /ID# 168062, Beaumont, Texas, United States|Family Medicine Associates of Texas, PA /ID# 167849, Carrollton, Texas, United States|3rd Coast Research Associates /ID# 203091, Corpus Christi, Texas, United States|Dallas VA Medical Center /ID# 170325, Dallas, Texas, United States|Urology Clinics of North Texas /ID# 203033, Dallas, Texas, United States|North TX Endocrine Ctr /ID# 170552, Dallas, Texas, United States|Radiant Research Dallas /ID# 170319, Dallas, Texas, United States|San Gabriel Clinical Research /ID# 167929, Georgetown, Texas, United States|East Texas Cardiology /ID# 170638, Houston, Texas, United States|PrimeCare Medical Group /ID# 168146, Houston, Texas, United States|Associates in Medicine, P.A. /ID# 170439, Houston, Texas, United States|University of Texas Health /ID# 168239, Houston, Texas, United States|M.E. DeBakey VAMC /ID# 167598, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 170537, Houston, Texas, United States|Discovery MM Services, Inc - Houston - Broadway St /ID# 170558, Houston, Texas, United States|Memorial Clinical Associates R /ID# 170443, Houston, Texas, United States|The Endocrine Center /ID# 170653, Houston, Texas, United States|Texas Center for Drug Development, Inc. /ID# 170404, Houston, Texas, United States|Methodist Urology Associates /ID# 170575, Houston, Texas, United States|Endocrine and Psychiatry Cente /ID# 170520, Houston, Texas, United States|Pioneer Research Solutions, Inc. /ID# 170379, Houston, Texas, United States|Research Trials Wroldwide /ID# 210694, Humble, Texas, United States|Protenium Clinical Research /ID# 170397, Hurst, Texas, United States|Discovery MM Services, Inc - Katy /ID# 202958, Katy, Texas, United States|Texas Cardio Association of Ho /ID# 170494, Kingwood, Texas, United States|FMC Science /ID# 170407, Lampasas, Texas, United States|Centex Studies, Inc /ID# 203019, McAllen, Texas, United States|Discovery MM Services, Inc. /ID# 170562, Missouri City, Texas, United States|Hill Country Medical Assoc /ID# 170444, New Braunfels, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials /ID# 170394, Pflugerville, Texas, United States|ClinRx Research, LLC /ID# 203067, Plano, Texas, United States|Village Health Partners /ID# 170659, Plano, Texas, United States|DeLeon Research /ID# 210861, Plano, Texas, United States|Research Across America /ID# 168229, Plano, Texas, United States|South Texas Cardiovascular Consultants /ID# 203088, San Antonio, Texas, United States|Radiant Research, Inc. /ID# 202947, San Antonio, Texas, United States|Covenant Clinical Research, PA /ID# 170564, San Antonio, Texas, United States|Victorium Clinical Research /ID# 168112, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 200845, San Antonio, Texas, United States|ALM VA Hospital /ID# 167973, San Antonio, Texas, United States|Northeast Endocrinology Associates, PA /ID# 202951, Schertz, Texas, United States|Consano Clinical Research, LLC /ID# 167848, Shavano Park, Texas, United States|Spring Family Practice Associates, PA /ID# 203470, Spring, Texas, United States|Hillcroft Medical Clinic /ID# 170500, Sugar Land, Texas, United States|Northwest Houston Clinical Research PLLC /ID# 168223, Tomball, Texas, United States|Crossroads Clinical Research, /ID# 170372, Victoria, Texas, United States|Hillcrest Clinics /ID# 202961, Waco, Texas, United States|Physicians Research Options, L /ID# 170441, Draper, Utah, United States|Tanner Clinic /ID# 168145, Layton, Utah, United States|Wasatch Peak Family Practice / Synexus Clinical Research US, Inc. /ID# 210175, Layton, Utah, United States|Radiant Research, Inc. /ID# 168248, Murray, Utah, United States|Advanced Research Institute /ID# 170445, Ogden, Utah, United States|Optimum Clinical Research /ID# 170322, Salt Lake City, Utah, United States|VA Salt Lake City Health Care System-George E Wahlen /ID# 167971, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 167596, West Jordan, Utah, United States|Connecticut Clinical Research Center /ID# 207771, Middlebury, Vermont, United States|Burke Internal Medicine & Research /ID# 202981, Burke, Virginia, United States|Seven Corners Medical Center /ID# 170577, Falls Church, Virginia, United States|Manassas Clinical Research Center /ID# 201815, Manassas, Virginia, United States|Virginia Research Center /ID# 170471, Midlothian, Virginia, United States|Health Research of Hampton Roads, Inc. (HRHR) /ID# 204937, Newport News, Virginia, United States|Clinical Research Associates of Tidewater /ID# 170609, Norfolk, Virginia, United States|Clinical Research Partners, LLC - Family Medicine/ Internal Medicine /ID# 170490, Richmond, Virginia, United States|Hunter Holmes McGuire VA Medical Center /ID# 170630, Richmond, Virginia, United States|Salem VA Medical Center /ID# 167925, Salem, Virginia, United States|NW Clinical Research Ctr /ID# 201588, Bellevue, Washington, United States|Sound Medical Research /ID# 202938, Port Orchard, Washington, United States|VA Puget Sound Health Care System /ID# 170555, Seattle, Washington, United States|Universal Research Group, LLC /ID# 170442, Tacoma, Washington, United States|American Health Network - Family Medicine and Specialty Care Services in Greenfi /ID# 202987, Greenfield, Wisconsin, United States|Emanuelli Research & Development Center LLC /ID# 206202, Arecibo, Puerto Rico|Research & Cardiovascular Corp /ID# 170353, Ponce, Puerto Rico|GCM Medical Group /ID# 170466, San Juan, Puerto Rico|Centro de Endocrinologia Alcantara-Gonzalez /ID# 207260, San Juan, Puerto Rico|Advanced Clinical Research /ID# 170553, Toa Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03518034"
770,"NCT01942226","Investigation on Medical Management of Dry Eye Patients",,"Completed","No Results Available","Dry Eye Syndrome",,"Artificial tears utilization patterns|Changes of dry eye symptoms, evaluated by clinicians|Changes of dry eye symptoms, evaluated by patients","National Cheng Kung University|National Taiwan University Hospital|Sun-Huei Tseng Eye Institute|Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan|Allergan Pharmaceuticals Taiwan Co., Ltd.","All","20 Years and older   (Adult, Older Adult)",,"466","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","MODE","August 2013","November 2013","December 2013","September 13, 2013",,"December 9, 2013","Sun-Huei Tseng Eye Institute, Tainan, Taiwan|Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01942226"
771,"NCT00262626","The Canadian Glaucoma Study",,"Terminated","No Results Available","Glaucoma","Drug: Intraocular pressure reduction|Procedure: Argon laser trabeculoplasty|Procedure: Trabeculectomy","Visual field progression|Optic disc progression","Dalhousie University|Canadian National Institute for the Blind|Glaucoma Research Society of Canada|Allergan|Merck Frosst Canada Ltd.|Pfizer","All","Child, Adult, Older Adult","Not Applicable","430","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CGS1","February 1995",,"June 1995","December 7, 2005",,"December 7, 2005","University of British Columbia, Vancouver, British Columbia, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|University of Toronto, Toronto, Ontario, Canada|University of Montreal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00262626"
772,"NCT00145106","Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris",,"Completed","No Results Available","Acne Vulgaris","Drug: Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)","Global improvement from baseline at week 24|Lesion counts at weeks 16, 20 and 24","KGL, Inc.|Milton S. Hershey Medical Center|State University of New York - Downstate Medical Center|Jefferson Medical College of Thomas Jefferson University|NYU Langone Health|Allergan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","189","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","T214","March 2002",,"August 2002","September 5, 2005",,"December 15, 2005","KGL, Inc, Broomall, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00145106"
